

interleukin-8 antagonists, Warner Lambert; interleukin-8 antagonists, LeukoSite	unspecified	cytokine antagonist; NSAID	rheumatoid arthritis; psoriasis; atherosclerosis
anakinra; interleukin-1 receptor antagonist; IL-1ra; interleukin-1 inhibitor; ANTRIL	N2-L-methionylinterleukin 1 receptor antagonist (human isoform x reduced)	Cytokine inhibitor; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; transplant rejection; asthma; septic shock
interleukin-1 receptor ligands, Affymax	unspecified	cytokine inhibitor; NSAID	arthritis; inflammation
SB 242235	unspecified	cytokine inhibitor; NSAID	rheumatoid arthritis
IX 207887	10-methoxy-4H-benzo(4,5)cyclohepta(1,2-b)thiophene-4-yliden)acetic acid	cytokine inhibitor; NSAID	rheumatoid arthritis
ACP	4-[bis(acetyloxy)methyl]-1,2-benzenediol, diacetate	cytokine inhibitor; NSAID	arthritis
interleukin-4; IL-4; SCH 39400; QUADRAKINE	unspecified	cytokine; immunostimulant; NSAID	cancer; viral infection; rheumatoid arthritis
interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSEF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
holmium 166 chitosan; DW 166HC	unspecified	Cytotoxic agent; radiation emission at site of injection	cancer; rheumatoid arthritis
CI 959	5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-benzo[b]thiophene-2-carboxamide sodium salt	degranulation inhibitor; immunosuppressant; NSAID	rhinitis; inflammation; asthma; arthritis

trimetrexate; trimetrexate glucuronate; TMQ; NSC 249008; CI 898; NeuTrexin	5-methyl-6-[[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolin-6-ylidene]amino-2,3-dihydro-2H-pyridine-2-thione	dihydrofolate reductase inhibitor; antifolate; NSAID	cancer; psoriasis; rheumatoid arthritis; pneumocystis
MDAM	N-[4-[2-(2,4-diamino-6-pteridinyloxy)ethyl]benzoyl]-4-methylene-DL-glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma
prinomide; prinomide tromethamine; CGS 10787; CGS 10787B	alpha-cyano-1-methyl-beta-oxopyrrole-2-propionanilide with 2-amino-2-(hydroxymethyl)-1,3-propanediol	DMARD; analgesic; immunosuppressant; NSAID	inflammation; pain; rheumatoid arthritis
actarit; MS 932; MOVER; ORCL	4-(acetylamino)phenylacetic acid	DMARD; immunosuppressant; NSAID	rheumatoid arthritis
rheumatoid arthritis therapy, Xenova; rheumatoid arthritis therapy, Suntory	unspecified	DMARD; NSAID	rheumatoid arthritis
spirogermanium; NSC 192965; SPIRO-32	8,8-diethyl-N,N-dimethyl-2-aza-8-germaspiro[4.5]decan-2-ylpropanamine	DMARD; NSAID	malaria; multiple sclerosis; rheumatoid arthritis; cancer
elastase inhibitors, Cortech	unspecified	elastase inhibitor; proteinase inhibitor; NSAID	arthritis; inflammatory bowel disease; pulmonary obstructive disease
free radical scavenging estrogens, Jenapharm	unspecified	estrogen; free radical scavenger; NSAID	osteoporosis; arthritis; neurological
TBC 2573	unspecified	FGF antagonist; NSAID	restenosis; rheumatoid arthritis; retinopathy
CGP 39565	unspecified	free radical scavenger; DMARD; NSAID	rheumatoid arthritis; arthritis
superoxide dismutase B, manganese complex; Mn-SOD-B	unspecified	free radical scavenger; NSAID	ischemia; arthritis



free radical scavengers, Strathclyde University	unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
SLH 301	unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
superoxide dismutase; superoxide dismutase copper zinc complex; CuZnSOD; OxSODrol	N-acetylsuperoxide dismutase (human clone pS 61-10 copper-zinc subunit protein moiety reduced)	free radical scavenger; NSAID	respiratory disease; ischemia; rheumatoid arthritis; inflammation
superoxide dismutase manganese complex; hMNSOD	unspecified	free radical scavenger; NSAID; immunosuppressant	ischemia; rheumatoid arthritis; inflammation; reperfusion injury
denileukin diftitox; interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion protein; DAB 389-IL-2; LY 335348; DAB389IL2; ONTAK	1-388-toxin (Corneybacterium diphtheriae strain C7), N-L-methionyl-387-L-histidine-388-L-alanine-, (388.fwdarw.2')-protein with 2-133-interleukin 2 (human clone pTIL2-21a)	fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; psoriasis; cancer
immune system modulators, Chiroscience	unspecified	gene	autoimmune disease; rheumatoid arthritis; cancer; HIV infection
glycosidase inhibitor, Oxford GlycoSciences	unspecified	glycosidase inhibitor; NSAID	cancer; rheumatoid arthritis
pentosan polysulfate sodium; SP 54; PZ 68; CARTROPHEN; LASONIL; ELMIRON; LELONG MOUSSE	(1-4)-beta-D-xylan 2,3-bis(hydrogen sulfate), sodium salt	heparinoid; vasodilator; NSAID	arthritis; angina; hyperlipidemia; rheumatoid arthritis; cancer; cystitis
ICE inhibitors, BASF/Parke-Davis	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	endotoxic shock; rheumatoid arthritis; Alzheimer disease

VE 19512	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	rheumatoid arthritis; osteoarthritis; inflammation
VX 740; HMR 3480	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	rheumatoid arthritis; osteoarthritis; inflammation
OM 89; OM 8980; SUBREUM; MODIMMUDAL; MUNOLIXOM	Glycoprotein-rich, endotoxin free E. Coli extract	Immunomodulation	rheumatoid arthritis
thiethazole	2-[1-(1,1-dioxothiethanyl-3)benzimidazolyl-2-thio] acetic acid	immunostimulant; immunosuppressant; antioxidant	cancer; rheumatoid arthritis; infectious disease; transplant rejection
FCE 20696	6H-dibenzo[b,d]pyran-6-carboxylic acid 2-(dimethylamino)ethyl ester hydrochloride	immunostimulant; immunosuppressant; NSAID	viral infection; rheumatoid arthritis
IMREG 1	unspecified	immunostimulant; NSAID; peptide	rheumatoid arthritis; HIV infection
PEPTIMER	unspecified	immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes
esonarimod; KE 298	alpha-[(acetylthio)methyl]-4-methyl-gamma-oxobenzenebutanoic acid	immunosuppressant	rheumatoid arthritis
antisense oligonucleotide, ICAM-1; antisense oligonucleotide, intracellular adhesion molecule-1; ISIS 2302	d[(R)-P-thio](G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A) DNA	immunosuppressant; antisense; oligonucleotide; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease; asthma
apoptosis-inducing antigen, rheumatoid arthritis	unspecified	immunosuppressant; biotechnology; apoptosis inducer; NSAID	rheumatoid arthritis

monocyte colony inhibitory factor-1, Human Genome Sciences	unspecified	immunosuppressant; biotechnology; chemokine	autoimmune disease; rheumatoid arthritis; systemic lupus erythematosus
AI 201	unspecified	immunosuppressant; biotechnology; NSAID	rheumatoid arthritis
AI 202	unspecified	immunosuppressant; biotechnology; peptide; NSAID	rheumatoid arthritis
autoimmune disease-specific MHC blockers, 3 Dimensional Pharmaceuticals	unspecified	immunosuppressant; DMARD; NSAID	rheumatoid arthritis; autoimmune disease
ZYN-LINKER conjugated superantigens	unspecified	immunosuppressant; immunostimulant; NSAID	rheumatoid arthritis; cancer
enlimomab; MAb, intracellular adhesion molecule-1; MAb, ICAM-1; MAb, ICAM; MAb, R65; MAb, CD54; BIRR 0001; BIRR 1	unspecified	immunosuppressant; monoclonal antibody; NSAID	transplant rejection; autoimmune disease; rheumatoid arthritis
MAb, gp39; MAb, arthritis	unspecified	immunosuppressant; monoclonal antibody; NSAID	rheumatoid arthritis
MAb, R73; MAb, rat alpha/beta T cell receptor	unspecified	immunosuppressant; monoclonal antibody; NSAID	transplant rejection; rheumatoid arthritis
priliximab; MAb, humanized CD4; cM-T412; CEN 000029; CENTARA	immunoglobulin G1 (human-mouse monoclonal cm-T412 anti-human antigen CD 4), disulfide with human-mouse monoclonal cm-T412.kappa.-chain, dimer	immunosuppressant; monoclonal antibody; NSAID	multiple sclerosis; autoimmune disease; rheumatoid arthritis
IRA 378	(S)-8-chloro-1,2,3,4-tetrahydro-2-(trifluoromethyl)-6-quinolineacetic acid	immunosuppressant; nitric oxide synthase inhibitor; NSAID	rheumatoid arthritis

BMS 188667; CTLA4Ig	unspecified	immunosuppressant; NSAID	transplant rejection; systemic lupus erythematosus; psoriasis; arthritis; allergy
C-Maf based therapy	unspecified	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis
corticotropin releasing factor binding protein; CRF binding protein; NBI 112	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; inflammation
lenercept; tumor necrosis factor receptor fusion protein; TNF receptor fusion protein; Ro 452081; TENEFUSE	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; asthma; septic shock; multiple sclerosis
autoimmune disease therapy, Molecumetics/Bristol -Myers Squibb	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; multiple sclerosis; systemic lupus erythematosus
CD2 binding agents, Procept	unspecified	immunosuppressant; NSAID	rheumatoid arthritis
CT 2576	unspecified	immunosuppressant; NSAID	HIV infection; rheumatoid arthritis
immunoregulators, AVANT Immunotherapeutics; immunoregulators, Repligen	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma
PG 12	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PG 27	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PG 2946	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3028	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection

PG 3113	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 94	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PIC 060 analogs	unspecified	immunosuppressant; NSAID	psoriasis; dermatitis; diabetes; transplant rejection; rheumatoid arthritis
PIC 101	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; autoimmune disease; transplant rejection
PIC 102	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
PIC 231	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
VX 10393	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
VX 10428	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
laflunimus; HR 325	(Z)-2-cyano-3-cyclopropyl-3-hydroxy-N-[3-methyl-4-(trifluoromethyl)phenyl]-2-propenamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; psoriasis
SCH 24937	1-[6-bromo-5-chloro-3-(2-pyridinyl)-1H-indol-2-yl]-2-(methylsulfinyl)ethanone	immunosuppressant; NSAID	rheumatoid arthritis
KF 20444	10-fluoro-3-(2-fluorophenyl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-b]quinoline-8-carboxylic acid	immunosuppressant; NSAID	rheumatoid arthritis
KB 2683	2-(4-methylphenyl)-4-benzothiazolol acetate	immunosuppressant; NSAID	rheumatoid arthritis; inflammation; autoimmune disease

CI 972	2,6-diamino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; cancer; psoriasis
MX 68	2-[[[4-[2,4-diamino-6-pteridiny]methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl]amino]hexanedioic acid	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease
baohuoside I; icariside II; B-1	3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one	immunosuppressant; NSAID	systemic lupus erythematosus; rheumatoid arthritis
CL 306293	3-amino-2-[1,1'-biphenyl]-4-yl-6-fluoro-4-quinolinecarboxylic acid	immunosuppressant; NSAID	arthritis; HIV infection
amiprilose; amiprilose hydrochloride; THN; SM 1213; KAP 690; THERAFECTIN	3-O-(3-(dimethylamino)propyl)-1,2-O-isopropylidene-alpha-D-glucofuranose hydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; psoriasis
TAK 603	4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1H-1,2,4-triazol-1-ylmethyl)-3-quinolinecarboxylic acid ethyl ester	immunosuppressant; NSAID	rheumatoid arthritis
mizoribine; HE 69; BREDININ	5-hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; kidney disease
TA 383	cis-2-(4-chlorophenyl)-4,5-dihydro-4,5-diphenyl-1H-imidazole monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis

SKF 105685	N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dihydrochloride	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis; HIV infection
AI 200; COLLORAL	trimeric (16-1059)alpha1 (II) collagen	immunosuppressant; NSAID	rheumatoid arthritis
atiprimod; atiprimod dimaleate; SKF 106615	N,N-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine	immunosuppressant; NSAID; macrophage inhibitor	rheumatoid arthritis; autoimmune disease; psoriasis
cladribine; 2-CdA; NSC 105014F; RWJ 26251; LEUSTATIN; LEUSTAT; MYLINAX	2-chloro-2'-deoxyadenosine	immunosuppressant; nucleoside analogue; NSAID	cancer; multiple sclerosis; rheumatoid arthritis
PP 14	unspecified	immunosuppressant; peptide; NSAID	autoimmune disease; rheumatoid arthritis
ZAP inhibitors, Ariad	unspecified	immunosuppressant; protein kinase inhibitor; tyrosine kinase inhibitor; NSAID	transplant rejection; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythematosus; multiple sclerosis
PEGylated p75 TNFR Fc mutein	unspecified	immunosuppressant; TNF inhibitor	rheumatoid arthritis
leflunomide; HWA 486; ARAVA	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	immunosuppressant; tyrosine kinase inhibitor; NSAID; DMARD	rheumatoid arthritis; autoimmune disease
fusion protein, CD5-gelonin; CD5-gelonin T lymphocyte-targeted immunofusion protein; GENIMUNE	unspecified	immunotoxin; NSAID	rheumatoid arthritis; inflammation
alpha d modulator	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	diabetes; atherosclerosis; arthritis; inflammatory bowel disease; respiratory disease

cell adhesion inhibitors, Ligand/Sankyo	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	asthma; rheumatoid arthritis; reperfusion injury
RGD-based angiogenesis antagonists	unspecified	integrin antagonist; NSAID; cell adhesion inhibitor	cancer; rheumatoid arthritis; eye disease
NPC 15669	N-(9H-(2,7-dimethylfluorenyl-9-methoxy)carbonyl)-L-leucine	leukocyte mediator inhibitor; NSAID	arthritis; septic shock; inflammatory bowel disease
CP 105696	(3S-trans)-1-[3-([1,1'-biphenyl]-4-ylmethyl)-3,4-dihydro-4-hydroxy-2H-1-benzopyran-7-yl]cyclopentanecarboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	rheumatoid arthritis
SC 51146	7-[3-[2(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; psoriasis; rheumatoid arthritis; inflammatory bowel disease
NPC 16570	4-[[[2-(9H-fluoren-9-yl)ethoxy]carbonyl]amino]benzoic acid	leumedin; NSAID	rheumatoid arthritis
NPC 17923	4-[[3-[(2,7-dichloro-9H-fluoren-9-yl)oxy]-1-oxopropyl]amino]benzoic acid	leumedin; NSAID	rheumatoid arthritis



tacrolimus; tsukubaenolide; fujimycin; FK 506; (-) )-FK 506; FR 900506; L 679934; PROGRAF; PROTOPIC	[3S- [3R*[E(1S*,3S*,4S*) ],4S*,5R*,8S*,9E,12 R*,14R*,15S*,16R*, 18S*,19S*,26aR*]]- 5,6,8,11,12,13,14,15, 16,17,18,19,24,25,26, 26a-hexadecahydro- 5,19-dihydro xy-3-[2- (4-hydroxy-3- methoxycyclohexyl)- 1-methylethenyl]- 14,16-dimethoxy- 4,10,12,18- tetramethyl-8-(2- propenyl)-15,19- epoxy-3H-pyrido[2,1- c][1,4]oxaazacyclotri co sine- 1,7,20,21(4H,23H)- tetrone	macrolide; immunosuppressant; NSAID; antibiotic	transplant rejection; dermatitis; eye disease; rheumatoid arthritis
matrix metalloproteinase inhibitors, OsteoArthritis; cartilage degrading enzyme inhibitors, OsteoArthritis; CHONDROPROTEC TORS	unspecified	matrix metalloproteinase inhibitor; cicatrizant; proteinase inhibitor; NSAID	arthritis; periodontal disease; skin ulcer; cancer
anti-arthritic matrix metalloproteinase inhibitors	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis
CH 138	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis
CH 263	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis

matrix metalloproteinase inhibitor, State University of New York	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	periodontal disease; kidney disease; cancer; arthritis; osteoporosis
matrix metalloproteinase inhibitors, Bayer	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis
matrix metalloproteinase inhibitors, ProScript	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; arthritis
BE 16627B	N-[N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-seryl]-L-valine	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis
solimastat; BB 3644	(2S,3R)-3-[[1S)-2,2-dimethyl-1-(2-pyridylcarbonyl)propyl]carbonyl]-2-methoxy-5-methylhexanoic acid	matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor	multiple sclerosis; rheumatoid arthritis; inflammatory bowel disease; cancer
bindarit; AF 2838	2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy]-propanoic acid	MCP-1 production inhibitor (reduction of mRNA expression)	rheumatoid arthritis; nephritis
metalloproteinase inhibitors, Syntex	unspecified	metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; arthritis
TNF alpha converting enzyme inhibitors, Immunex; TACE inhibitors, Immunex	unspecified	metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; inflammation
MAB, CD23; GW 353430	unspecified	monoclonal antibody; biotechnology; NSAID	rheumatoid arthritis; asthma
MAB, CD4; 4162W94; BW 4162W94	unspecified	monoclonal antibody; biotechnology; NSAID	rheumatoid arthritis

MAb, chimeric APO1	unspecified	monoclonal antibody; biotechnology; NSAID	rheumatoid arthritis
MAb, interleukin-8; MAb, IL-8; ABX IL8	unspecified	monoclonal antibody; biotechnology; NSAID	respiratory distress syndrome; inflammatory bowel disease; rheumatoid arthritis; inflammation; psoriasis
MAb, tumor necrosis factor; MAb, TNF	unspecified	monoclonal antibody; biotechnology; NSAID	inflammatory bowel disease; rheumatoid arthritis
MAb, Fv, cytokine; CDP 870	unspecified	monoclonal antibody; cytokine inhibitor; immunosuppressant	rheumatoid arthritis; autoimmune disease
MAb, 6G5.1; MAb, autoimmune disease, human, Medarex; MDX CD4	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; rheumatoid arthritis
MAb, T cell receptor; TM 31	unspecified	monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis
MAb, 16H5; MAb, CD4; MAb, rheumatoid arthritis; MAX 16H5	unspecified	monoclonal antibody; NSAID	rheumatoid arthritis
MAb, cytokines; AGT 1	unspecified	monoclonal antibody; NSAID	rheumatoid arthritis
MAb, humanized tumor necrosis factor; MAb, humanized TNF; MAb, CDP571; CDP 571; BAY 103356; B 1351	unspecified	monoclonal antibody; NSAID	septic shock; inflammation; bacterial infection; inflammatory bowel disease; rheumatoid arthritis
MAb, humanized, leukemia; MAb, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	unspecified	monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
MAb, macrophage migration inhibitory factor, Picower Institute for Medical Research	unspecified	monoclonal antibody; NSAID	arthritis; asthma

MAb, VLA-4, humanized; MAb, very late antigen-4, humanized	unspecified	monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
clenoliximab; MAb, CD4; MAb, PRIMATIZED CD4; IDEC 151; SB 217969	immunoglobulin G 4 (human-Macaca monoclonal CE9gamma4PE gamma4-chain anti-human antigen CD4), disulfide with human-Macaca monoclonal CE9gamma4PE kappa-chain, dimer	monoclonal antibody; NSAID	rheumatoid arthritis; psoriasis; asthma
infliximab; MAb, tumor necrosis factor alpha; MAb, TNF-alpha; cA2; TA 650; REMICADE; AVAKINE	immunoglobulin G, anti-(human tumour necrosis factor) (human-mouse monoclonal cA2 heavy chain), disulfide with human-mouse monoclonal cA2 light chain, dimer	monoclonal antibody; NSAID	rheumatoid arthritis; Crohn disease
keliximab; MAb, CD4; MAb, PRIMATIZED CD4; IDEC CE9.1; SB 210396	immunoglobulin G1 (human-Macaca monoclonal CE9.1.gamma.1-chain anti-human antigen CD 4), disulfide with human-Macaca monoclonal CE9.1.lambda.-chain, dimer	monoclonal antibody; NSAID	rheumatoid arthritis; asthma
mercaptoethylguanidine; MEG	(2-mercaptoethyl)-guanidine	nitric oxide synthase inhibitor; COX inhibitor; NSAID	cardiovascular disease; arthritis; colitis
l-arginine; 546C88; BW 546C88	N5-[imino(methylamino)methyl]-L-ornithine	nitric oxide synthase inhibitor; NSAID	septic shock; arthritis; kidney disease
nitric oxide inhibitors, Fisons	unspecified	nitric oxide synthetase inhibitor; NSAID	stroke; rheumatoid arthritis

CPR 3005	Lipid analogue	NSAID	skin disease; eye disease; asthma; rheumatoid arthritis
CPR 3014	Lipid analogue	NSAID	skin disease; eye disease; asthma; rheumatoid arthritis
CPR 3016	Lipid analogue	NSAID	skin disease; eye disease; asthma; rheumatoid arthritis
ZD 2315	unspecified	NSAID	rheumatoid arthritis
collagen, human type II	unspecified	NSAID	rheumatoid arthritis
neutrophil degranulation inhibitor; DGI	unspecified	NSAID	asthma; rheumatoid arthritis
recombinant soluble Fc receptor, rheumatoid arthritis; FcgammaRII	unspecified	NSAID	rheumatoid arthritis
telomere modulators, Geron	unspecified	NSAID	neurodegeneration; atherosclerosis; arthritis
anti-inflammatory agents, Phytera/Tsumura	unspecified	NSAID	rheumatoid arthritis; allergy
antiarthritic agent, Proteus	unspecified	NSAID	rheumatoid arthritis
arthritis therapy, OSI/Hoechst Marion Roussel	unspecified	NSAID	arthritis
arthritis therapy, Sumitomo/CombiChem	unspecified	NSAID	arthritis
autoimmune disease therapy, AMRAD/Kaneka	unspecified	NSAID	diabetes; rheumatoid arthritis
CBF BS2	unspecified	NSAID	rheumatoid arthritis
drug delivery system, GEOMATRIX controlled release diclofenac; diclofenac GEOMATRIX; DICLOFENAC-UNO	unspecified	NSAID	arthritis

drug delivery system, GEOMATRIX controlled release naproxen; naproxen GEOMATRIX	unspecified	NSAID	rheumatoid arthritis
drug delivery system, transdermal flurbiprofen; flurbiprofen transdermal	unspecified	NSAID	arthritis
EN 08	unspecified	NSAID	arthritis
FA 31A	unspecified	NSAID	arthritis
gene discovery, arthritis, LifeSpan	unspecified	NSAID	rheumatoid arthritis
gene discovery, immune system disorders, AlphaGene	unspecified	NSAID	arthritis; asthma; allergy
gene discovery, inflammatory diseases, Ariad/Hoechst Marion Roussel	unspecified	NSAID	inflammation; rheumatoid arthritis
glucocorticoid agonists, Ligand	unspecified	NSAID	inflammation; rheumatoid arthritis; inflammatory bowel disease; asthma
GP 44	unspecified	NSAID	arthritis
GW 92527	unspecified	NSAID	rheumatoid arthritis
HP 466	unspecified	NSAID	arthritis
KP 106	unspecified	NSAID	rheumatoid arthritis
lipophosphoglycan analogue	unspecified	NSAID	rheumatoid arthritis; atherosclerosis; HIV infection
lithium gamma-linolenic acid + eicosapentaenoic acid; EF 5	unspecified	NSAID	rheumatoid arthritis
macrophage migration inhibitory factor inhibitors, Picower Institute for Medical Research	unspecified	NSAID	arthritis; asthma
NBI 116	unspecified	NSAID	multiple sclerosis; rheumatoid arthritis

nitric oxide modulators, Duke University	unspecified	NSAID	hypotension; cancer; rheumatoid arthritis
osteoarthritis therapy, Maxia; rheumatoid arthritis therapy, Maxia	unspecified	NSAID	osteoarthritis; rheumatoid arthritis
PKC-RACK interaction inhibitors, Telik	unspecified	NSAID	arthritis; multiple sclerosis; asthma
protein discovery, rheumatoid arthritis, Oxford GlycoSciences; protein discovery, rheumatoid arthritis, Oxford University	unspecified	NSAID	rheumatoid arthritis
pseudopterosin	unspecified	NSAID	arthritis; asthma; psoriasis
rheumatoid arthritis therapy, Corixa; rheumatoid arthritis therapy, Organon; RA-AnergiX	unspecified	NSAID	rheumatoid arthritis
SC 105	unspecified	NSAID	arthritis
telomerase activators, Geron	unspecified	NSAID	neurodegeneration; atherosclerosis; arthritis
fepradinol; DALGEN; FLEXIDOL	(1)-alpha-(((2-hydroxy-1,1-dimethylethyl)amino)methyl)benzyl alcohol	NSAID	rheumatoid arthritis
CTC 23	(OC-6-22)-diammine[[4,4'-(1,2-ethanediyldinitrilo)bis[2-pentanonato]](2-)-N,N',O,O']cobalt(1+) chloride	NSAID	viral infection; arthritis
U 91502	[3-(1,6-dihydro-1-methyl-6-oxo-4-phenyl-2-pyrimidinyl)propylidene]bisphosphonic acid tetraethyl ester	NSAID	inflammation; arthritis

sulfasalazine; salazosulfapyridine; azulfide; SI 88; AZULFIDINE; SALAZOPYRIN; SLAMA	2-hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid	NSAID	ulcerative colitis; rheumatoid arthritis
seprilose; GW 80126	3-O-heptyl-1,2-O-(1-methylethylidene)-alpha-D-glucofuranose	NSAID	rheumatoid arthritis
amtolmetin guacil; ST 679; MED 15; ARTROMED; EUFANS	N-[[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl]glycine 2-methoxyphenyl ester	NSAID; analgesic	arthritis; rheumatoid arthritis; inflammation; pain
monocyte chemoattractant protein-1 antagonists	unspecified	NSAID; chemokine antagonist	rheumatoid arthritis; atherosclerosis
TNF alpha antagonists, Texas Biotechnology	unspecified	NSAID; cytokine antagonist; apoptosis inhibitor	rheumatoid arthritis
S 2474	unspecified	NSAID; DMARD; COX inhibitor; COX 2 inhibitor; immunosuppressant	rheumatoid arthritis; autoimmune disease
rheumatoid arthritis therapy, Birmingham University	unspecified	NSAID; peptide	rheumatoid arthritis
phospholipase A2 inhibitors, La Jolla	unspecified	NSAID; phospholipase inhibitor	rheumatoid arthritis; inflammatory bowel disease; asthma
ZYN-LINKER conjugated yttrium 90	unspecified	NSAID; radiotherapeutic	arthritis
IPL 423; IZP 96001; BISPAN	unspecified	NSAID; transcription factor regulator	arthritis
nalmefene; nalmetrene; JF 1; INCYSTENE; ARTHENE; FENARC; CERVENE; REVEX	17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma



complement inhibitors, Lidak	unspecified	peptide; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease; reperfusion injury; respiratory distress syndrome; transplant rejection
rheumatoid arthritis therapy, Peptide Therapeutics	unspecified	peptide; NSAID	rheumatoid arthritis
rheumatoid arthritis therapy, Peptide Therapeutics	unspecified	peptide; NSAID	rheumatoid arthritis
TNF peptide antagonist, Tocor	unspecified	peptide; NSAID	rheumatoid arthritis
TNF receptor antagonist, Peptor; TNF receptor antagonist, Teva	unspecified	peptide; NSAID	rheumatoid arthritis; multiple sclerosis
type II collagen analogue	unspecified	peptide; NSAID	rheumatoid arthritis
piclamilast; RP 73401; RPR 73401	3-cyclopentyloxy-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; arthritis
lipocortin; lipomodulin; macrocortin	unspecified	phospholipase inhibitor; NSAID	asthma; arthritis
phospholipase A2 inhibitors, Fisons	unspecified	phospholipase inhibitor; NSAID	asthma; rheumatoid arthritis; psoriasis; inflammatory bowel disease
LM 1228	phosphoric acid mono[2-[(decylsulfonyl)amino]octyl]mono[2-(phenylmethoxy)ethyl] ester	phospholipase inhibitor; NSAID	rheumatoid arthritis

verteporfin; benzoporphyrin derivative; BPD-MA; CL 318952; BPDR; VISUDYNE	trans-18-ethenyl-4,4a- dihydro-3,4- bis(methoxycarbonyl)- 4a,8,14,19- tetramethyl-23H,25H- benzo[b]porphine- 9,13-dipropionic acid monomethyl ester	photosensitizer; NSAID	cancer; psoriasis; arthritis; retinopathy
polyclonal antibody, tumor necrosis factor alpha; immunoglobulin, TNF-alpha lysate; PASSTNF-alpha	unspecified	polyclonal antibody; immunoglobulin; NSAID	rheumatoid arthritis; inflammatory bowel disease
iloprost; ciloprost; ZK 36374; E 1030; SH 401; ILOMED; ENDOPROST; ILOMEDIN; AIPRO	5-[hexahydro-5- hydroxy-4-(3- hydroxy-4-methyl-1- octen-6-ynyl)-2(1H)- pen talenyliene]pentanoic acid	prostanoid; platelet antiaggregant; vasodilator; NSAID	peripheral vascular disease; thrombosis; thrombocytopenia; rheumatoid arthritis
Ro 320432; Ro 32- 0432	(S)-3-[8- [(dimethylamino)met hyl]-6,7,8,9- tetrahydropyrido[1,2- a]indol-10-yl]-4-(1- methyl-1H-indol-3- yl)-1H-pyrrole-2,5- dione	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis
proteinase nexin-1 elastase variant; PN-1 elastase variant	unspecified	proteinase inhibitor; biotechnology; cicatrizant	arthritis; skin ulcer
K 11097	unspecified	proteinase inhibitor; cathepsin S inhibitor; NSAID	rheumatoid arthritis
PS 508	unspecified	proteinase inhibitor; matrix metalloproteinase inhibitor	arthritis; inflammatory bowel disease; periodontal disease
matrix metalloproteinase inhibitor	unspecified	proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	arthritis; cancer; arthritis

BB 2983; GI 245402	unspecified	proteinase inhibitor; matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis; inflammatory bowel disease
cysteine proteinase inhibitor, SynPhar/British Biotech	unspecified	proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis; cancer; osteoarthritis
P 34081	unspecified	proteinase inhibitor; NSAID	arthritis
P 35012	unspecified	proteinase inhibitor; NSAID	arthritis
P 35016	unspecified	proteinase inhibitor; NSAID	arthritis
WY 48989	4-[[2-(7-chloro-2-phenyl-2H-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzo nitrile	proteinase inhibitor; NSAID	arthritis
BABIM	bis(5-amidino-2-benzimidazo)methane	proteinase inhibitor; NSAID	arthritis
peldesine; BCX 34; BCX 34B	2-amino-1,5-dihydro-7-(3-pyridinylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; immunosuppressant; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection; eye disease; dermatitis; HIV infection
CH 799	unspecified	purine nucleoside phosphorylase inhibitor; NSAID	rheumatoid arthritis; inflammatory bowel disease; cancer
purine nucleoside phosphorylase inhibitors, Chiroscience; PNP inhibitors, Chiroscience	unspecified	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection
CI 1000; PD 141955	2-amino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis

mycophenolate mofetil; RS 61443; CellCept	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany 1)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
fenretinide; HPR, 4; 4HPR; RAHA; McN R1967	N-(4-hydroxyphenyl)retinamide	retinoid; NSAID	rheumatoid arthritis; cancer
rheumatoid arthritis therapy	unspecified	SAIK immunomodulation	rheumatoid arthritis
SR 31747	(Z)-N[3-chloro-4-cyclohexylphenyl]-2-propenyl]-N-ethyl-cyclohexanamine hydrochloride	sigma antagonist; immunosuppressant; NSAID	autoimmune disease; arthritis
stromelysin inhibitors, Affymax	unspecified	stromelysin inhibitor; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	arthritis
stromelysin inhibitors, Agouron	unspecified	stromelysin inhibitor; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	cancer; arthritis
drug delivery system, biodegradable micellar paclitaxel; paclitaxel micellar	unspecified	taxane; DMARD; NSAID	rheumatoid arthritis; multiple sclerosis
etanercept; tumor necrosis factor receptor; TNFr; TNR 001; ENBREL	unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease
soluble tumor necrosis factor-a receptor type 1; sTNFR1	unspecified	TNF inhibitor; NSAID	rheumatoid arthritis
CC 1080	unspecified	TNF inhibitor; NSAID	arthritis; cancer; multiple sclerosis

ITF 1779	unspecified	TNF inhibitor; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease
MNX 160	Unspecified	TNF inhibitor; NSAID	rheumatoid arthritis; diabetes; multiple sclerosis
thalidomide; SYNOVIR; THALOMID	N-(2,6-dioxo-3- piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
CC 1069	beta-(3,4- dimethoxyphenyl)- 1,3-dihydro-1,3- dioxo-2H-isoindole- 2-propanamide	TNF modulator; NSAID	cachexia; arthritis; cancer
MHC expression inhibitors, BLSI	unspecified	transcription inhibitor; NSAID	rheumatoid arthritis; systemic lupus erythematosus
SC 106	unspecified	triglyceride; NSAID	rheumatoid arthritis
TCR peptide, rheumatoid arthritis	unspecified	vaccine	rheumatoid arthritis
vaccine, arthritis; vaccine, Vbeta14 T cell receptor; AI 205; IR 205	unspecified	vaccine	rheumatoid arthritis
vaccine, arthritis; vaccine, Vbeta17 T cell receptor; AI 204; IR 204	unspecified	vaccine	rheumatoid arthritis
vaccine, rheumatoid arthritis; IR 501; AI 501	unspecified	vaccine	rheumatoid arthritis
non-ionic surfactant vesicles; NISV	unspecified	vaccine adjuvant; immunosuppressant	rheumatoid arthritis; asthma; inflammation
vaccine, TNF alpha	unspecified	vaccine; cytokine antagonist	rheumatoid arthritis; Crohn disease; cachexia; asthma
MAB, HRFl; vaccine, rheumatoid arthritis	unspecified	vaccine; monoclonal antibody	rheumatoid arthritis
MHC-vaccine, rheumatoid arthritis; AGDR 4/1; AnervaX; RA-AnervaX	unspecified	vaccine; peptide	rheumatoid arthritis

VCAM antagonists, Texas Biotechnology	unspecified	vascular cell adhesion molecule inhibitor; NSAID	atherosclerosis; rheumatoid arthritis; multiple sclerosis
TBC 609	unspecified	vascular cell adhesion molecule inhibitor; NSAID; peptide	atherosclerosis; rheumatoid arthritis; multiple sclerosis
TBC 772	unspecified	vascular cell adhesion molecule inhibitor; NSAID; peptide	atherosclerosis; rheumatoid arthritis; multiple sclerosis
20-epi-1,25 dihydroxyvitamin D <sub>3</sub> ; MC 1288; IE	(1 $\alpha$ ,3 $\beta$ ,5Z,7E,20S)-9,10-secosteroid-5,7,10(19)-triene-1,3,25-triol	vitamin D <sub>3</sub> analogue; immunosuppressant	diabetes; transplant rejection; arthritis
ZD 7349	unspecified	VLA 4 antagonist; integrin antagonist; NSAID; cell adhesion inhibitor	multiple sclerosis; arthritis

Table 39. Current Candidate Therapeutic Interventions for the Treatment of COPD

Product Name	Chemical Name	Action	Indication
3323W	unspecified	5 lipoxygenase inhibitor	asthma
bunaprolast; U 66858	2-butyl-4-methoxy-1-naphthalenol acetate	5 lipoxygenase inhibitor	asthma
BW B70C	N-[3-[3-(4-fluorophenoxy)phenyl]-1-methyl-2-propenyl]-N-hydroxyurea	5 lipoxygenase inhibitor	asthma
CMI 977	unspecified	5 lipoxygenase inhibitor	asthma
docebenone; AA 861	6-(12-hydroxy-5,10-dodecadienyl)-2,3,5-trimethyl-1,4-benzoquinone	5 lipoxygenase inhibitor	asthma; heart failure
drug delivery system, controlled release zileuton; zileuton	unspecified	5 lipoxygenase inhibitor	asthma
FR 110302	2,2-dibutyl-1,2,3,4-tetrahydro-5-(2-quinolinylmethoxy)-1-naphthalenol	5 lipoxygenase inhibitor	asthma

L 691816	5-[3-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]-2,2-dimethylpropyl]-1H-tetrazole	5 lipoxygenase inhibitor	asthma
L 739010	1,6-anhydro-3-C-[6-[[[7-cyano-5-(3-furanyl)-2-naphthalenyl]oxy]methyl]-2-pyridinyl]-2,4-dideoxy-beta-D-threo-hexopyranose	5 lipoxygenase inhibitor	asthma
linazolast; TMK 688; YM 257	4-[5-[[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]amino]-5-oxo-1,3-pentadienyl]-2-methoxyphenylcarbonic acid ethyl ester	5 lipoxygenase inhibitor	asthma; rhinitis
PF 5901	alpha-pentyl-3-(2-quinolinylmethoxy)-benzenemethanol	5 lipoxygenase inhibitor	asthma
R 85355	Unspecified	5 lipoxygenase inhibitor	asthma; psoriasis; inflammatory bowel disease
SB 202235	(S)-N-(2,3-dihydro-6-phenylmethoxy-3-benzofuranyl)urea	5 lipoxygenase inhibitor	asthma
TZI 41127	4-(5-methoxy-3-methyl-1H-indol-2-yl)-2,6-dimethylphenol	5 lipoxygenase inhibitor	asthma
WY 50295; WY 50295 tromet	(S)-alpha-methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid	5 lipoxygenase inhibitor	asthma; rhinitis

ZD 4407	(2S-trans)-1,3-dihydro-1-methyl-5-[[4-(tetrahydro-4-hydroxy-2-methyl-2H-pyran-4-yl)-2-thienyl]thio]-2H-indol-2-one	5 lipoxygenase inhibitor	asthma
CGS 25997	(2S)-(-)-2-[[N-(aminocarbonyl)-N-hydroxyamino]methyl]-7-(4-fluorophenoxy)-1,4-benzodioxan	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
CHF 1909	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma
E 6080	4-[[[(6-hydroxy-4,4,7-trimethyl-2-benzothiazolyl)amino]methyl]benzenesulfonamide monohydrochloride	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
GR 80907	unspecified	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
L 651392	4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one	5 lipoxygenase inhibitor; NSAID	inflammation; bacterial infection; asthma
L 663536; MK 886	1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-alfa,alfa-diethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis
L 699333	2-[2-[1-[(4-chlorophenyl)methyl]-4,5-dihydro-4-methyl-6-[(5-phenyl-2-pyridinyl)methoxy]-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid	5 lipoxygenase inhibitor; NSAID	asthma; inflammation



SC 45662	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis; inflammatory bowel disease
ZD 2138; ICI D2138	6-[[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-2(1H)-quinolinone	5 lipoxygenase inhibitor; NSAID	arthritis; asthma
ZD 7717; ICI D7717	7-[[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenyl]thio]-4-methyl-2H-1,4-benzoxazin-3(4H)-one	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
zileuton; A 64077; ZYFLO	N-(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea	5 lipoxygenase inhibitor; NSAID	inflammation; asthma
GW 328267	unspecified	adenosine agonist; adenosine A2 agonist	asthma
midaglizole; DG 5128	2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine	alpha adrenergic antagonist; alpha2 adrenergic antagonist	asthma; diabetes
melanocortin receptor-1 modulators,	unspecified	analgesic; melanocortin agonist; melanocortin MC1 agonist	asthma; pain; nephritis
LA 351	5H-(1)-benzopyrano(2,3-b)pyridin-5-one	analgesic; NSAID	inflammation; pain; asthma
HP 228	N-acetyl-Nleu-Gln-His-Phe-Arg-Trp-Gly-amide	analgesic; NSAID; peptide; melanocortin agonist	pain; inflammation; asthma; cachexia
L 680833	[S-(R*,S*)]-4-[[[3,3-diethyl-1-[[[1-(4-methylphenyl)butyl]amino]carbonyl]-4-oxo-2-azetidinyloxy]benzenecacetic acid	antibiotic; elastase inhibitor; beta lactam; proteinase inhibitor	emphysema
anti-inflammatory macrolide analogues,	unspecified	antibiotic; macrolide	asthma; inflammation

SB 226882	4-[4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-N-methyl-2-pyrimidinamine	antifungal; MAP kinase inhibitor; signal transduction inhibitor; imidazole	inflammation; asthma; rheumatoid arthritis
antioxidants	unspecified	antioxidant	respiratory distress syndrome; stroke; reperfusion injury; asthma
U 74389F	21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]pregna-1,4,9(11)-triene-3,20-dione monomethanesulfonate	antioxidant	emphysema
synthetic catalytic scavenger analogues; SCS analogues	unspecified	antioxidant; free radical scavenger	stroke; trauma; atherosclerosis; neurodegeneration; asthma
VANTOX	unspecified	antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke
Z 4003	2-[1-[4-(2-methylpropyl)phenyl]ethyl]-4-thiazolidinecarboxylic acid	antioxidant; NSAID	angina; inflammation; emphysema
antisense oligonucleotide, interleukin-5; antisense oligonucleotide, IL-5	unspecified	antisense; oligonucleotide; ,	asthma
D 2522	unspecified	beta adrenergic agonist	asthma
drug delivery system, liposome terbutaline sulfate; terbutaline sulfate liposome	unspecified	beta adrenergic agonist	asthma

nardeterol; SOM 1122	alpha-[[[3-(1H-benzimidazol-1-yl)-1,1-dimethylpropyl]amino]methyl]-2-fluoro-4-hydroxybenzenemethanol	beta adrenergic agonist	asthma
procaterol; procaterol hydrochloride; OPC 2009; CI 888; MEPTIN; PRO-AIR; ONSUKIL; BRON NOVO; PROMAXOL; MASACIN; PROCADIL; PROPULUM	2(1H)-quinolone, 8-hydroxy-5-(1-hydroxy-2-(1-methylethyl)amino)butyl-, monohydrochloride, (R*S*)(+,-)	beta adrenergic agonist	asthma
RP 58802B	alpha-[[[3-(1H-benzimidazol-1-yl)-1-methylpropyl]amino]methyl]-4-hydroxy-3-methoxybenzenemethanol	beta adrenergic agonist	asthma
SL 2021	unspecified	beta adrenergic agonist	asthma
CEDO 20433	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
drug delivery system, liposome salbutamol sulfate; salbutamol sulfate liposome	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
drug delivery system, OROS oral controlled release salbutamol; salbutamol	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
drug delivery system, PULSINCAP salbutamol; salbutamol PULSINCAP	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
drug delivery system, salbutamol sustained release; salbutamol sustained release	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma

drug delivery system, transdermal salbutamol; salbutamol transdermal	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
drug delivery system, transdermal salbutamol; salbutamol transdermal; albuterol transdermal	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
drug delivery system, transdermal TheraDerm-LRS salbutamol; salbutamol TheraDerm-LRS	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
formoterol, (R,R); (R,R)-formoterol	[R-(R*,R*)-(+,-)-N- [2-hydroxy-5-[1- hydroxy-2-[[2-(4- methoxyphenyl)-1-m ethylethyl]amino]ethy l]phenyl]formamide	beta adrenergic agonist; beta2 adrenergic agonist	asthma
formoterol; formoterol; formoterol fumarate; YM 08316; BD 40A; CGP 25827; CGP 25827A; ATOCK; FORADIL; ASMATEC; SINASFIX; LEMOTEC; OXIS	(R*,R*)-(+,-)-N-[2- hydroxy-5-[1- hydroxy-2-[[2-(4- methoxyphenyl)-1- methylethyl]amino]et hyl]phenyl]formamid e	beta adrenergic agonist; beta2 adrenergic agonist	asthma
picumeterol; picumeterol fumarate; GR 114297; GR 114297 X; GR 63411	(-)-(R)-4-amino-3,5- dichloro-alpha-[[[6- [2-(2- pyridinyl)ethoxy]hexy l]amino]methyl]benze nemethanol	beta adrenergic agonist; beta2 adrenergic agonist	asthma
salmeterol, (R)-; (R)- salmeterol	(R)-4-hydroxy- alpha.1-[[[6-(4- phenylbutoxy)hexyl]a mino]methyl-1,3- benzenedimethanol	beta adrenergic agonist; beta2 adrenergic agonist	asthma

bambuterol; BWD 2183; BAMBEC	dimethylcarbamic acid 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-1,3-phenylene ester	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
broxaterol; Z 1170; SUMMAIR	(+,-)-3-bromo-alpha-[(tert-butylamino)methyl]-5-isoxazolemethanol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
etanterol	5-amino-alpha-[(p-hydroxy-alpha-methylphenethyl)amino]methyl]-m-xylene-alpha,alpha'-diol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
LAS 32521	unspecified	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
levosalbutamol; levalbuterol; salbutamol, (R)-; (R)-salbutamol; (R)-albuterol; levalbuterol sulfate; XOPENEX	(R)-alpha'-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
salmeterol + fluticasone; fluticasone + salmeterol; SERETIDE; ADVAIR DISKUS; VIANI	unspecified	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator; corticosteroid	asthma
salmeterol; salmeterol; GR 33343X; SN 408; GR 33343G; SEREVENT	4-hydroxy-alpha.1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma; pulmonary obstructive disease
TA 2005	[R-(R*,R*)]-8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma

SM 11044	[R-(R*,S*)]-1-[3-(3,4-dihydroxyphenyl)-2-[[3-(4-fluorophenyl)propyl]amino]-3-hydroxy-1-oxopropyl]pyrrolidine monohydrobromide	beta adrenergic agonist; beta3 adrenergic agonist; leukotriene antagonist; leukotriene D4 antagonist	asthma
AR C68397AA; AR-C68397AA; ARL 68397	4-hydroxy-7-[2-[[2-[[3-(2-phenylethoxy)propyl]sulfonyl]ethyl]amino]ethyl-2(3H)-benzothiazolone monohydrochloride	beta adrenergic agonist; bronchodilator	asthma; pulmonary obstructive disease; rhinitis
drug delivery system, transdermal controlled release tulobuterol; tulobuterol transdermal; HOKUNALIN TAPE	unspecified	beta adrenergic agonist; bronchodilator	asthma
tulobuterol; HN 078; C 78; HSR 078A; BRELOMAX; BREMAX; ATENOS; BERACHIN; HOKUNALIN	alpha-[(tert-butylamino)methyl]-o-chlorobenzyl alcohol	beta adrenergic agonist; bronchodilator	asthma
drug delivery system, HALO salbutamol; salbutamol HALO	unspecified	beta2 adrenergic agonist; beta adrenergic agonist	asthma
allergy immunogen, migis epsilon	unspecified	,	allergy; asthma
allergy therapy, E coli enterotoxin B subunit-antigen fusion protein	unspecified	,	rhinitis; asthma
DNase, second generation	unspecified	,	bronchitis; cystic fibrosis
emoctakin; interleukin-8	unspecified	,	asthma
fusion protein, IL-10	unspecified	,	asthma; inflammatory bowel disease

secretory leukocyte proteinase inhibitor, truncated; TEI 7361	unspecified		respiratory distress syndrome; emphysema
antisense oligonucleotide, adenosine A1 receptor; antisense oligonucleotide, asthma; EPI 2010; E 2010;	unspecified	;; antisense; oligonucleotide; mRNA translation inhibitor	asthma
interleukin-4 receptor; IL-4r;	unspecified	;; cytokine antagonist	inflammation; asthma
soluble interleukin-5 receptor alpha; IL-5Ra	unspecified	;; cytokine antagonist	asthma
interleukin-1 receptor; IL-1r; HJ 1306	unspecified	;; cytokine inhibitor; immunosuppressant	asthma
anakinra; interleukin-1 receptor antagonist; IL-1ra; interleukin-1 inhibitor; ANTRIL	N2-L-methionylinterleukin 1 receptor antagonist (human isoform x reduced)	;; cytokine inhibitor; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; transplant rejection; asthma; septic shock
interleukin-12; IL-12; natural killer stimulatory factor; NKSF; edodekin alfa; Ro 247472; Ro 24-7472	unspecified	;; cytokine; immunostimulant	asthma
deoxyribose deoxyribose; deoxyribonuclease; DNase; PULMOZYME	deoxyribonuclease, (human clone 18-1 protein moiety)	;; deoxyribonuclease; enzyme	cystic fibrosis; bronchitis; pulmonary obstructive disease; systemic lupus erythematosus
enkephalinase	unspecified	;; enkephalinase; enzyme	asthma; eye disease
platelet-activating factor acetylhydrolase; PAF-AH; SUN Y7016; PAFASE	unspecified	;; hydrolase	respiratory distress syndrome; asthma; inflammatory bowel disease
IgE receptors, soluble, CorBec	unspecified	;; immunosuppressant	asthma

antisense oligonucleotide, ICAM-1; antisense oligonucleotide, intracellular adhesion molecule-1; ISIS 2302	d[(R)-P-thio](G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A) DNA	;; immunosuppressant; antisense; oligonucleotide; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease; asthma
lenercept; tumor necrosis factor receptor fusion protein; TNF receptor fusion protein; Ro 452081; TENEFUSE	unspecified	;; immunosuppressant; NSAID	rheumatoid arthritis; asthma; septic shock; multiple sclerosis
MAB, AL 901; MAB, IgE; AL 901; CGP 51901; IGE 025A	unspecified	;; monoclonal antibody	allergy; rhinitis; asthma
MAB, CD23; MAB, PRIMATIZED CD23	unspecified	;; monoclonal antibody	asthma; allergy; rhinitis
MAB, IgE; MAB, E25	unspecified	;; monoclonal antibody	asthma; allergy; rhinitis
MAB, interleukin-4; SB 240683	unspecified	;; monoclonal antibody	asthma
MAB, interleukin-5; MAB, IL-5; SCH 55700; CDP 835	unspecified	;; monoclonal antibody; immunosuppressant	asthma
clenoliximab; MAB, CD4; MAB, PRIMATIZED CD4; IDEC 151; SB 217969	immunoglobulin G 4 (human-Macaca monoclonal CE9gamma4PE gamma4-chain anti-human antigen CD4), disulfide with human-Macaca monoclonal CE9gamma4PE kappa-chain, dimer	;; monoclonal antibody; NSAID	rheumatoid arthritis; psoriasis; asthma
keliximab; MAB, CD4; MAB, PRIMATIZED CD4; IDEC CE9.1; SB 210396	immunoglobulin G1 (human-Macaca monoclonal CE9.1.gamma.1-chain anti-human antigen CD 4), disulfide with human-Macaca monoclonal CE9.1.lambda.-chain, dimer	;; monoclonal antibody; NSAID	rheumatoid arthritis; asthma



MAb, macrophage migration inhibitory factor,	unspecified	,; monoclonal antibody; NSAID	arthritis; asthma
MAb, VLA-4, humanized; MAb, very late antigen-4, humanized	unspecified	,; monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
neutrophil degranulation inhibitor; DGI	unspecified	,; NSAID	asthma; rheumatoid arthritis
RecepTox-Fce	unspecified	,; peptide; fusion toxin	asthma; allergy
lipocortin; lipomodulin; macrocortin	unspecified	,; phospholipase inhibitor; NSAID	asthma; arthritis
eglin C	unspecified	,; proteinase inhibitor	septic shock; emphysema
EPI-HNE-1	unspecified	,; proteinase inhibitor	cystic fibrosis; emphysema
alpha-1-antitrypsin; TgAAT; BAY 105233	unspecified	,; proteinase inhibitor; elastase inhibitor	emphysema; cystic fibrosis; genetic disorder
LEX 043	unspecified	,; proteinase inhibitor; serine proteinase inhibitor	inflammation; asthma
neutral endopeptidase; NEP	unspecified	,; proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
ribozymes, asthma	unspecified	,; ribozyme; oligonucleotide	asthma
secretory leukocyte proteinase inhibitor; serine leukocyte proteinase inhibitor; SLPI; serine proteinase inhibitor; SPI; SLPI	unspecified	,; serine proteinase inhibitor; proteinase inhibitor	asthma
vaccine, TNF alpha	unspecified	,; vaccine; cytokine antagonist	rheumatoid arthritis; Crohn disease; cachexia; asthma
bradykinin2 antagonists,	unspecified	bradykinin antagonist	asthma

NOVA 567; NPC 567	N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalaninebradykinin	bradykinin antagonist; cicatrizant; peptide; NSAID	asthma; skin ulcer; inflammation
icatibant; icatibant acetate; HOE 140	D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolincarbonyl-L-(2alpha,3abeta,7abeta)-octahydro-1H-indole-2-carbonyl-L-arginine	bradykinin antagonist; NSAID	asthma; inflammation; rhinitis; osteoarthritis
NPC 17731	N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-(trans-4-propoxy-D-proline)-8-[L-(2alpha,3abeta,7abeta)-octahydro-1H-indole-2-carboxylic acid]-bradykinin	bradykinin antagonist; NSAID	inflammation; septic shock; asthma
FR 173657	(E)-3-[6-(acetylamino)-3-pyridinyl]-N-[2-[[2,4-dichloro-3-[(2-methyl-8-quinolinyl)oxy]methyl]phenyl]methylamino]-2-oxoethyl-2-propenamide	bradykinin antagonist; NSAID; analgesic	asthma; inflammation; pain
dametralast; LA 2851	7-methylpyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine	bronchodilator	asthma
F 3121	1,4-dihydro-3-amino-4-oxo-1-((3-trifluoromethyl)phenyl)pyridazine	bronchodilator	asthma
HOE 058A	unspecified	bronchodilator	asthma

KF 15570	imidazo(4,5-c)quinolinc-4-one	bronchodilator	asthma
KF 17625	5-phcnyl-(3H)-imidazo(4,5-c) (1,8)-naphthyridin-4-(5H)-one	bronchodilator	asthma
LM 3339	2-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)pyridine 1-oxide	bronchodilator	asthma
PF 904	1-ethyl-6-methyl-1H-pyrazino[2,3-c][1,2,6]thiadiazin-4-amine 2,2-dioxide	bronchodilator	asthma
RU 32210	unspecified	bronchodilator	asthma
S 123701	unspecified	bronchodilator	asthma
SC 109	unspecified	bronchodilator	asthma; pulmonary fibrosis
SDZ MKS492	(R)-8-[[1-(3,4-dimethoxyphenyl)-2-hydroxyethyl]amino]-3,7-dihydro-7-(2-methoxyethyl)-1,3-dimethyl-1H-purine-2,6-dione	bronchodilator	asthma
LY 150310	1-(1,2,3,4-tetrahydro-1-naphthalenyl)-1H-imidazole mononitrate	bronchodilator; imidazole	asthma
fenspiride; KSP 193; PNEUMORAL; ESPIRAN	8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one	bronchodilator; NSAID	inflammation; asthma
Ro 251553; Ro 25-1553	N-acetyl-His-Ser-Asp-Ala-Val-Phe-Thr-Glu-Asn-Tyr-Thr-Lys-Leu-Arg-Lys-Gln-NLeu-Ala-Ala-Lys-Lys-Tyr-Leu-Asn-Asp-Leu-Lys-Lys-Gly-Gly-Thr-amide, cyclic (25->21)-peptide	bronchodilator; VIP agonist	asthma

CD 349	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-(nitrooxy)propyl 3-(nitrooxy)propyl ester	calcium antagonist; bronchodilator	hypertension; asthma; angina
RWJ 22108	4-(2-chloro-6-fluorophenyl)-1,4,6,7,8,9-hexahydro-2-methylthiopyrino[3,2-b]pyridine-3-carboxylic acid 5,5-dioxide 2-[methyl(phenylmethyl)amino]ethyl ester	calcium antagonist; bronchodilator	asthma
MDL 27399	N-[1-[N-[N-(4-methoxy-1,4-dioxobutyl)-L-alanyl]-L-alanyl]-L-prolyl]-L-phenylalanine methyl ester	cathepsin G inhibitor; proteinase inhibitor	emphysema
VLA4 integrin antagonist	unspecified	cell adhesion inhibitor; integrin antagonist; VLA 4 antagonist; NSAID	asthma; rheumatoid arthritis; multiple sclerosis
CCR3 inhibitors	unspecified	chemokine antagonist	asthma
chloride channel blocker	unspecified	chloride channel blocker	asthma; pulmonary obstructive disease
AQRA 721	N-1-azabicyclo[2.2.2]oct-3-yl-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepine-11-carboxamide	cholinergic antagonist; bronchodilator	asthma
DAC 5889; DAC 6150	6-oxo-3-phenyl-3-piperidinecarboxylic acid 1-azabicyclo[2.2.2]oct-3-yl ester	cholinergic antagonist; muscarinic antagonist; muscarinic M1 antagonist; bronchodilator	asthma

rispenzepine; ulvenzepine; DF 594	6,11-dihydro-11-[(1-methyl-3-piperidinyl)carbonyl]-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one	cholinergic antagonist; muscarinic antagonist; muscarinic M1 antagonist; muscarinic M3 antagonist; antispasmodic; bronchodilator	asthma; bronchitis
revatropate; UK 112166	(R)-3-quinuclidyl-(2S)-2-hydroxymethyl-4-(R)-methylsulfinyl-2-phenylbutyrate	cholinergic antagonist; muscarinic M3 antagonist; muscarinic antagonist	asthma; pulmonary obstructive disease
chymase inhibitors,	unspecified	chymase inhibitor; NSAID	asthma; inflammation; rhinitis
CMI 903	unspecified	complement inhibitor	asthma
anti-inflammatory corticosteroids	unspecified	corticosteroid	psoriasis; asthma
budesonide; budesonide propionate; S 1320; PREFERID; PULMICORT; RHINOCORT; ENTOCORT; NARICORT; INFLAMMIDE; BETACTIN; ELTAIR; HORACORT; RHINOCORT AQUA	(11beta,16alpha)-16,17-[butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione	corticosteroid	asthma; skin disease; inflammation; rhinitis; ulcerative colitis; Crohn disease
butixocort propionate; JO 1222	(11beta)-11-hydroxy-17-(1-oxobutoxy)-21-[(1-oxopropyl)thio]]pregn-4-ene-3,20-dione	corticosteroid	inflammation; asthma; inflammatory bowel disease

CGP 13774; KSR 592	(+)-methyl 9alpha-chloro- 6alpha-fluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-p ropionyloxy-androsta-1,4-diene-17beta-carboxylate	corticosteroid	asthma; rhinitis
ciclesonide; BY 9010; BTR 15	[11beta,16alfa (R)]-16,17-[(cyclohexylmethylen e)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-diene-3,20-dione	corticosteroid	asthma
D 5272	unspecified	corticosteroid	asthma
D 5519	unspecified	corticosteroid	asthma
deflazacort; azacort; L 5458; MDL 458; AZACORTID; CALCORT; LANTADIN; DEFLAN; FLANTADIN; DEZACOR; ZAMENE; ROSILIN; DEFLAMON; PRANDIN	(11beta,16beta)-21-(acetyloxy)-11-hydroxy-2'-methyl-5'H-pregna-1,4-die no[17,16-d]oxazole-3,20-dione	corticosteroid	rheumatoid arthritis; skin disease; asthma
drug delivery system, corticosteroid binding globulin; corticosteroid binding globulin; ALX 25	unspecified	corticosteroid	inflammation; asthma
drug delivery system, LDS microemulsion anti-asthma steroids; anti-asthma steroids LDS microemulsion	unspecified	corticosteroid	asthma

drug delivery system, liposome beclometasone dipropionate; beclometasone dipropionate, liposome	unspecified	corticosteroid	asthma
drug delivery system, liposome rofleponide; rofleponide liposome; rofleponide palmitate	[(6alpha,11beta,16alpha(R)) 16,17-[[butylidenebis(oxy)]6,9-difluoro-11,21-dihydroxypregn-4-ene-3,20-dione	corticosteroid	asthma; rhinitis
fluticasone propionate; fluticasone; CCI 18781; SN 410; SN 411MD; FLOVENT; FLIXONASE; FLIXOTIDE; FLONASE; FLUTIVATE; FLUTIDE NASAL; CUTIVATE; RONTILONA; TRIALONA; FLUNASE	((6alpha,11beta,16alpha,17alpha)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-androsta-1,4-diene-17-carbothioic acid, S-(fluoromethyl) ester	corticosteroid	dermatitis; rhinitis; asthma; pulmonary obstructive disease; skin disease
GW 215864	unspecified	corticosteroid	asthma
GW 250495	unspecified	corticosteroid	asthma
icometasone enbutate; icometasone enbutate; icometasone acetate; isomethasone acetate; CL 09	(11beta,16alpha)-21-(acetyloxy)-9-chloro-11-hydroxy-16-methyl-17-(1-oxobutoxy)pregna-1,4-diene-3,20-dione	corticosteroid	asthma; skin disease
mometasone furoate; mometasone; S 2640; SCH 32088; ELOCOM; ELOCON; FULMETA; ECURAL; ERMIL; NASONEX; ASMANEX	(11beta,16alpha)-9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-pregna-1,4-diene-3,20-dione	corticosteroid	dermatitis; asthma; rhinitis; psoriasis; pruritis

rofleponide; D 5522	[6alpha,11beta,16alpha(R)] 16,17-[butylidenebis(oxy)]6,9-difluoro-11,21-dihydroxypregn-4-ene-3,20-dione	corticosteroid	asthma
ST 126; TO 199	unspecified	corticosteroid	asthma
RPR 106541	[6alpha,11beta,16alpha(R),17beta]-16,17-[butylidenebis(oxy)]-6,9-difluoro-11-hydroxy-17-(methylthio)androst-4-en-3-one	corticosteroid; glucocorticoid	asthma
methylprednisolone suleptanate; U 67590A; PROMEDROL	(6alpha,11beta)-11,17-dihydroxy-6-methyl-21-[[8-[methyl(2-sulfoethyl)amino]-1,8-dioxooctyl]oxy]pregna-1,4-diene-3,20-dione monosodium salt	corticosteroid; immunosuppressant	inflammation; asthma; anaphylactic shock; transplant rejection
tepoxalin; RWJ 20485; ORF 20485	5-(4-chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide	COX inhibitor; 5-lipoxygenase inhibitor; NSAID	asthma; inflammation; inflammatory bowel disease
BAY 169996	unspecified	cytokine antagonist	asthma
cytokine trap,	unspecified	cytokine antagonist	cancer; asthma; rheumatoid arthritis; allergy
IL-4 antagonists, Pharmacopeia; IL-4 antagonists	unspecified	cytokine antagonist	asthma
interleukin-4 signal transduction antagonists	unspecified	cytokine antagonist	asthma
interleukin-5 inhibitor	unspecified	cytokine antagonist	asthma
interleukin-4 receptor inhibitors	unspecified	cytokine inhibitor	asthma; diabetes
interleukin-1 inhibitors,	unspecified	cytokine inhibitor; NSAID	inflammation; asthma; inflammatory bowel disease



JTE 711	unspecified	cytokine synthesis inhibitor	dermatitis; asthma; rhinitis
amlexanox; amoxanox; CHX 3673; AA 673; SOLFA; ELICS; APHTHASOL	2-amino-7-(1-methylethyl)-5-oxo-5H-[1]-benzopyrano[2,3-b]pyridine-3-carboxylic acid	degranulation inhibitor	asthma; psoriasis; rhinitis; mucositis; conjunctivitis; allergy
asobamast; Z 1819	2-ethoxyethyl[4-(3-methyl-5-isoxazolyl)-2-thiazolyl]oxamate	degranulation inhibitor	asthma
azelastine; A 5610; W 2979M; E 0659; AZEPTIN; ALLERGODIL; ASTELIN; RADETHAZIN; AFLUONA; AFLUON; AZEPIT; AZECOF; AZERUNART CHOS H; BIFERTIN	4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone	degranulation inhibitor	asthma; rhinitis; skin disease; conjunctivitis
BN 50601	2-[4-(1,1-dimethylethyl)phenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[3,4-b]pyridin-7-ol	degranulation inhibitor	asthma
CGP 25875	unspecified	degranulation inhibitor	asthma
cromoglicate lisetil; AKY 953; KY 556; N 556	2-[[2-(ethoxycarbonyl)-4-oxo-4H-1-benzopyran-5-yl]oxy]-1-[[[2-(ethoxycarbonyl)-4-oxo-4H-1-benzopyran-5-yl]oxy]methyl]ethyl ester, L-lysine dihydrochloride	degranulation inhibitor	asthma; rhinitis; dermatitis; allergy

drug delivery system, oral cromolyn sodium; cromolyn sodium oral delivery system	unspecified	degranulation inhibitor	asthma; allergy; eye disease
nedocromil; FPL 59002; FPL 59002KP; TILADE; TILARIN; TILAVIST; TILAD; NEDREL; DISVEN; IRTEN	9-ethyl-6,9-dihydro- 4,6-dioxo-10-propyl- 4H-pyrano[3,2- g]quinoline-2,8- dicarboxylic acid	degranulation inhibitor	asthma; eye disease; skin disease; rhinitis
pemirolast; pemirolast potassium; BMY 26517; DE 068; BL 5617; PEMILASTON; ALLEGYSAL	9-methyl-3-(1H- tetrazol-5-yl)-4H- pyrido[1,2- a]pyrimidin-4-one	degranulation inhibitor	asthma; conjunctivitis; rhinitis; dermatitis; restenosis
picumast; picumast dihydrochloride; BM 15100	7-[3-[4-(4- chlorobenzyl)-1- piperazinyl]propoxy]- 3,4-dimethylcoumarin	degranulation inhibitor	rhinitis; asthma
quinotolast; quinotolast sodium; FK 021; FR 71021; ASLOCK	4-oxo-1-phenoxy-N- 1H-tetrazol-5-yl-4H- quinolizine-3- carboxamide	degranulation inhibitor	asthma; rhinitis; dermatitis
sulochrin	unspecified	degranulation inhibitor	asthma
suplatast tosilate; IPD 1151T; MPD; IPD	dimethyl-2-[4-(3- ethoxy-2- hydroxypropoxy)phen- ylcarbamoyl]ethylsulf- onium-p-toluene sulfonate	degranulation inhibitor	dermatitis; asthma; allergy; rhinitis
tazanolast; WP 833; TAZANOL; TAZALEST	oxo[[3-(1H-tetrazol- 5- yl)phenyl]amino]aceti- c acid, butyl ester	degranulation inhibitor	asthma; rhinitis
tetrazolast meglumine; tetrazolast; MDL 26024GO	4-(1H-tetrazol-5- yl)tetrazolo[1,5- a]quinoline with 1- deoxy-1- (methylamino)-D- glucitol	degranulation inhibitor	asthma

CI 959	5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-benzo[b]thiophene-2-carboxamide sodium salt	degranulation inhibitor; immunosuppressant; NSAID	rhinitis; inflammation; asthma; arthritis
AP 414	unspecified	degranulation inhibitor; tyrosine kinase inhibitor	asthma; allergy
MDAM	N-[4-[2-(2,4-diamino-6-pteridiny)ethyl]benzoyl]-4-methylene-DL-glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma
ALP 231	unspecified	elastase inhibitor; proteinase inhibitor	emphysema
ALP 242	unspecified	elastase inhibitor; proteinase inhibitor	asthma; emphysema; psoriasis
DF 1283	tert-butyl (7S) 3-(acetoxymethyl)-7-[(N-benzyloxycarbonyl-L-valyl)amino]-5,5-dioxide-5-thia-1-azabicyclo[4.2.0]oct-2-8-one-2-carboxylate	elastase inhibitor; proteinase inhibitor	emphysema; cystic fibrosis; bronchitis
FK 706	N-[4-[[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-L-prolinamide monosodium salt	elastase inhibitor; proteinase inhibitor	emphysema
FR 134043	unspecified	elastase inhibitor; proteinase inhibitor	emphysema
FR 901277	unspecified	elastase inhibitor; proteinase inhibitor	emphysema

MDL 27324	(S)-N-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-L-alanyl-L-alanyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-L-prolinamide.	elastase inhibitor; proteinase inhibitor	emphysema
TEI 5624	(S)-4-[[[4-chlorophenyl]sulfonyl]amino]-5-[[5-methyl-2-[(1-methylethyl)amino]-4-oxo-4H-3,1-benzoxazin-7-yl]amino]-5-oxopentanoic acid	elastase inhibitor; proteinase inhibitor	emphysema
TEI 6344	(S)-6-amino-2-[[[4-chlorophenyl]sulfonyl]amino]-N-[5-methyl-2-[(1-methylethyl)amino]-4-oxo-4H-3,1-benzoxazin-7-yl]hexanamide	elastase inhibitor; proteinase inhibitor	emphysema
TEI 8362	unspecified	elastase inhibitor; proteinase inhibitor	emphysema; respiratory distress syndrome
SR 26831	5-[(2-chlorophenyl)methyl]-2-(2,2-dimethyl-1-oxopropoxy)-4,5,6,7-tetrahydro-5-hydroxythieno[3,2-c]pyridinium	elastase inhibitor; proteinase inhibitor; NSAID	inflammation; emphysema
BQ 153	cyclo(3-sulfo-D-alanyl-L-prolyl-D-valyl-L-leucyl-D-tryptophyl)	endothelin A antagonist; endothelin antagonist	asthma
endothelin antagonist	unspecified	endothelin antagonist	kidney disease; ischemia; inflammatory bowel disease; asthma

BW 443C	L-tyrosyl-D-arginylglycyl-4-nitro-L-phenylalanyl-L-prolinamide diacetate (salt)	enkephalinase inhibitor; analgesic	asthma; pain; cough
BAY x 1005	(R)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)benzeneacetic acid	FLAP antagonist	asthma
VML 530; ABT 080	unspecified	FLAP antagonist	asthma
VB 5122	unspecified	free radical scavenger; xanthine oxidase inhibitor	inflammation; asthma
beta-glucan antagonist	unspecified	glucan antagonist	conjunctivitis; asthma; psoriasis; ulcerative colitis
nitrocinonide	6alpha,9-difluoro-11beta,16alpha,17-trihydroxy-3-oxoandrost-1,4-diene-17beta-carboxylic acid, ester with ethyl(S)-1-hydroxyethyl carbonate, cyclic(R)-16,17-acetal with butyraldehyde	glucocorticoid	asthma
glucocorticoids,	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation; asthma; autoimmune disease
methylhistamine, R-alpha; BP 2.94	unspecified	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 49648	(2S-trans)-4-(2-methyl-3-pyrrolidinyl)-1H-imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 50971	(3R-trans)-4-(4-methyl-3-pyrrolidinyl)-1H-imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
HQL 79	4-(diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]piperidine	histamine antagonist; 5HT antagonist	allergy; asthma

asthma therapy	unspecified	histamine antagonist; histamine H1 antagonist	asthma
DF 1111301	1-(2-ethoxyethyl)- N,N-dimethyl-1H- benzimidazole-2- ethanamine dihydrochloride	histamine antagonist; histamine H1 antagonist	allergy; asthma
ebastine; LAS W090; LAS 90; EBASTEL; KESTINE; EVASTEL	1-[4-(1,1- dimethylethyl)phenyl]- 4-[4- (diphenylmethoxy)-1- piperidinyl]-1- butanone	histamine antagonist; histamine H1 antagonist	allergy; rhinitis; asthma
epinastine; WAL 801; WAL 801CL; ALESION	9,13b-dihydro-1H- dibenz[c,f]imidazo[1, 5-a]azepin-3-amine	histamine antagonist; histamine H1 antagonist	allergy; asthma; psoriasis; rhinitis
F 9505A	unspecified	histamine antagonist; histamine H1 antagonist	asthma
mizolastine; SL 850324; MKC 431; MIZOLLEN; ZOLIM; MISTAMINE	2-[[1-[1-[(4- fluorophenyl)methyl]- 1H-benzimidazol-2- yl]-4-piperidinyl] methylamino]-4(1H)- pyrimidinone	histamine antagonist; histamine H1 antagonist	asthma; allergy; rhinitis
olopatadine; olopatadine hydrochloride; KW 4679; ALO 4943A; PATANOL	(Z)-11-[3- (dimethylamino)prop ylidene]-6,11- dihydro-dibenz[b,e] oxepin-2-acetic acid	histamine antagonist; histamine H1 antagonist	allergy; rhinitis; asthma; conjunctivitis
selenotifen; BN 52256	4,9-dihydro-4-(1- methyl-4- piperidinylidene)- 10H- benzo[4,5]cyclohepta [1,2-b]selenophen-10- one	histamine antagonist; histamine H1 antagonist	eye disease; asthma; arrhythmia; rhinitis
ZCR 2060	2-[2-[4- (diphenylmethyl)-1- piperazinyl]ethoxy]be nzoic acid maleate	histamine antagonist; histamine H1 antagonist	asthma; allergy

FCC 13	3,4,10,14b-tetrahydrodibenzo[c,f]pyranzino[1,2-a]azepine-2(1H)carboxamide	histamine antagonist; histamine H1 antagonist; 5HT antagonist	asthma
mequitamium iodide; LG 30435	1-methyl-3-(10H-phenothiazin-10-ylmethyl)-1-azoniabicyclo[2.2.2]octane iodide	histamine antagonist; histamine H1 antagonist; muscarinic antagonist; cholinergic antagonist	asthma; rhinitis
KY 234	1-[3-(4-benzhydryl-1-piperazinyl)propyl]-3-(1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylic acid	histamine antagonist; histamine H1 antagonist; thromboxane synthetase inhibitor	asthma
pibaxizine; UCB 20028; UCB J028; J028; J 028	[2-[2-[4-(diphenylmethylene)piperidinyl]ethoxy]ethoxy]acetic acid	histamine antagonist; histamine H2 antagonist	irritable bowel syndrome; asthma
KC 11425	5,6-dihydro-2-methyl-8-(2-methylpropyl)-1-[2-[4-(4-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4H-pyrrolo[3,2,1-ij]quinoline	histamine antagonist; PAF antagonist	asthma; allergy
KC 11404	4-n-butyl-5,6-dihydro-8-hydroxy-2-methyl-1-[2-[4-(4-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4H-pyrrolo[3,2,1-ij]quinoline	histamine antagonist; PAF antagonist; 5 lipoxygenase inhibitor	asthma; allergy
dehydroepiandrosterone sulfate; DHEAS; PB 005	unspecified	hormone; vaccine adjuvant; corticosteroid	inflammation; infectious disease; asthma
pentigetide; IgE pentapeptide human; pentapeptide DSDPR; TA 521; PENTYDE	N2-[1-N-(N-L-alpha-aspartyl-L-seryl)-L-[alpha-aspartyl]-L-prolyl]-L-arginine	immunoglobulin	conjunctivitis; asthma; rhinitis
SRL 172	unspecified	immunostimulant	tuberculosis; cancer; asthma; bacterial infection; leprosy; rhinitis

asthma/allergy therapy,	unspecified	immunosuppressant	asthma; allergy
D 22557	unspecified	immunosuppressant	allergy; asthma
D 7193	unspecified	immunosuppressant	asthma
IgE receptor inhibitors,	unspecified	immunosuppressant	asthma
immunology/inflammation therapy	unspecified	immunosuppressant	inflammation; autoimmune disease; asthma
immunosuppressant	unspecified	immunosuppressant	asthma
immunosuppressants,	unspecified	immunosuppressant	autoimmune disease; asthma
LCB 2183	Unspecified	immunosuppressant	rhinitis; dermatitis; asthma
oxeclosporin; SDZ IMM 125; IMM 125	2-[O-(2-hydroxyethyl)-D-serine]-cyclosporin A	immunosuppressant	asthma
T cell modulators,	unspecified	immunosuppressant	asthma; rhinitis; conjunctivitis; allergy
CBP 1011	unspecified	immunosuppressant; corticosteroid	autoimmune disease; systemic lupus erythematosus; asthma
D 22558	unspecified	immunosuppressant; cytokine inhibitor	asthma; allergy
immunoregulators,	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma
phellodendrine; OB 5	(7S-cis)-5,8,13,13a-tetrahydro-2,11-dihydroxy-3,10-dimethoxy-7-methyl-6H-dibenzo[a,g]quinolizinium	immunosuppressant; NSAID	transplant rejection; inflammation; viral infection; asthma; kidney disease
alphaE beta7 antagonists,	unspecified	integrin antagonist; cell adhesion inhibitor	asthma; psoriasis; inflammatory bowel disease
cell adhesion inhibitors,	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	asthma; rheumatoid arthritis; reperfusion injury



TBC 1269	3',3'''-(1,6-hexanediyl)bis[6'-(alpha-D-mannopyranosyloxy)-[1,1'-biphenyl]-3-acetic acid	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation; asthma
VLA-4 antagonist,	unspecified	integrin antagonist; VLA 4 antagonist	asthma
VLA-4 antagonists, inflammatory diseases; BIO 1211	N-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-leucyl-L-alpha-aspartyl-L-valyl-L-proline	integrin antagonist; VLA 4 antagonist	asthma; multiple sclerosis
VLA4 antagonists	unspecified	integrin antagonist; VLA 4 antagonist; cell adhesion inhibitor	asthma; inflammatory bowel disease
BW A137C	N-hydroxy-N-[[4-(phenylmethoxy)phenyl]methyl]acetamide	leukotriene antagonist	asthma
BW A797C	acetamide, n-hydroxy-n-(3-(5,6,7,8-tetrahydro-2-naphthalenyl)-2-propenyl)-	leukotriene antagonist	asthma
CL 891301	unspecified	leukotriene antagonist	asthma
CS 615	unspecified	leukotriene antagonist	asthma
FK 011	unspecified	leukotriene antagonist	asthma
LF 60361	unspecified	leukotriene antagonist	asthma
RP 12525	unspecified	leukotriene antagonist	asthma
zafirlukast; 204219; ICI 204219; ACCOLATE; VANTICON	[3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamic acid, cyclopentyl ester	leukotriene antagonist	asthma; rhinitis
BIIL 284	unspecified	leukotriene antagonist; leukotriene B4 antagonist	asthma; pulmonary obstructive disease

pranlukast; dolukast; ONO 1078; RS 411; ONON; ULTAIR	N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide	leukotriene antagonist; leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene E4 antagonist	asthma; rhinitis
leukotriene D4 antagonists	unspecified	leukotriene antagonist; leukotriene D4 antagonist	asthma
LY 290154	(E)-7-chloro-2-[2-[3-[4-(1H-tetrazol-5-yl)-1-[7-(1H-tetrazol-5-ylmethoxy)-1H-indol-1-yl]butyl]phenyl]ethenyl]quinoline	leukotriene antagonist; leukotriene D4 antagonist	asthma
RG 14524	unspecified	leukotriene antagonist; leukotriene D4 antagonist	asthma
RS 601	4-[5,5,6,6,6-pentafluoro-1-[[4-(4-fluorophenyl)sulfonyl]amino]hexyl]benzenebutanoic acid	leukotriene antagonist; leukotriene D4 antagonist; thromboxane antagonist	asthma
YM 158; YM 57158	N-[5-[3-[(4-chlorophenyl)sulfonyl]propyl]-2-(1H-tetrazol-5-ylmethoxy)phenyl]-3-[[4-(1,1-dimethylethyl)-2-thiazolyl]methoxy]-benzamide	leukotriene antagonist; leukotriene D4 antagonist; thromboxane antagonist	asthma; rhinitis
ZD 3523; ICI D3523	unspecified	leukotriene antagonist; NSAID	asthma; inflammation

LY 292728	7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo-9H-xanthene-4-propanoic acid disodium salt	leukotriene B4 antagonist; leukotriene antagonist	asthma
ontazolast; BIRM 270	(S)-N-[2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazoline	leukotriene B4 antagonist; leukotriene antagonist	asthma
RP 69698	5-(1,1-dimethyl-5-((4,6-diphenyl-2-pyridyl)oxy)pentyl)-1H-tetrazole	leukotriene B4 antagonist; leukotriene antagonist	asthma; emphysema
RG 14893	4-(2-(methyl(2-phenethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; inflammation
SC 51146	7-[3-[2(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; psoriasis; rheumatoid arthritis; inflammatory bowel disease
BAY x 7195	[S-(Z)]-4-[[1-(2-carboxyethyl)-4-[4-(4-phenoxybutoxy)phenyl]-2-butenyl]thio]benzoic acid	leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene antagonist	asthma
cinalukast; Ro 245913	(E)-4-(3-(2-(4-cyclobutyl-2-thiazolyl)ethenyl)phenylamino)-2,2-diethyl-4-oxobutanoic acid	leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene antagonist	asthma

pirodomast; SCH 37224	4-hydroxy-1-phenyl- 3-(1-pyrrolidinyl)- 1,8-naphthyridin- 2(1H)-one	leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	rhinitis; asthma
CGP 44044A	(1R,2S)-1-hydroxy-1- (3-trifluoromethyl- phenyl)-8-(4-acetyl-3- hydroxy-2-propyl- phenoxy)-octa- 3(E),5(Z)-dien-2-yl-7- thio-4-oxo-4H-1- benzopyran-2- carboxylic acid sodium salt	leukotriene D4 antagonist; leukotriene antagonist	asthma
DS 4574	6-(2- cyclohexylethyl)- [1,3,4]thiadiazolo[3,2- a]-1,2,3-triazolo[4,5- d]pyrimidin-9(1H)- one	leukotriene D4 antagonist; leukotriene antagonist	gastrointestinal ulcer; asthma
LY 203647	1-[2-hydroxy-3- propyl-4-[4-[2-[4- (1H-tetrazol-5- yl)butyl]-2H-tetrazol- 5- yl]butoxy]phenyl]etha- none	leukotriene D4 antagonist; leukotriene antagonist	hypertension; asthma
LY 287192	(E)-2-[[5-[3-[2-(7- chloro-2- quinolinyl)ethenyl]ph enyl]-2H-tetrazol-1-2- yl]methyl]-5- fluorobenzoic acid sodium salt	leukotriene D4 antagonist; leukotriene antagonist	asthma
LY 290324	(E)-7-chloro-2-[2-[3- [[7-[2-(1H-tetrazol-5- yl)ethyl]-1H-indol-1- yl]methyl]phenyl]ethe nyl]quinoline hydrochloride	leukotriene D4 antagonist; leukotriene antagonist	asthma

montelukast; montelukast sodium; MK 476; MK 0476; SINGULAIR	[R-(E)]- 1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropanecarboxylic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
NZ 107	4-bromo-5-[[[(3-ethoxy-4-methoxyphenyl)methyl]amino]-3(2H)-pyridazinone	leukotriene D4 antagonist; leukotriene antagonist	asthma
pobilukast; pobilukast edamine; SKF 104353; SKF 104353Z2; SKF 104353Q	[R-(R*,S*)]-beta-[(2-carboxyethylthio)-alpha-hydroxy-2-(8-phenyloctyl)benzenepropanoic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma; rhinitis
RG 12525	2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]quinoline	leukotriene D4 antagonist; leukotriene antagonist	asthma
ritolukast; WY 48252	1,1,1-trifluoro-alpha-2-quinolylmethanesulfonamides	leukotriene D4 antagonist; leukotriene antagonist	asthma
SKF 106203	(S)-beta[(2-carboxyethylthio)-2-(8-phenyloctyl)benzenepropanoic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
verlukast; MK 679; L 660711; MK 571; L 668019	[R-(E)]-3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]thio]methyl]thio]propanoic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma

YM 16638	[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]acetic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
CGP 44826	2-ethenyloxy-N-[4-(5-cyclopentyl-carbonylamino-1-methylindol-3-ylmethyl)-3-methoxy-benzoyl]benzenesulfonylamide	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
FPL 55712	7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid monosodium salt	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
irialukast; CGP 45715A	(1R,2S)-1-hydroxy-1-(3-(trifluoromethylphenyl))-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-deca-3(E),5(Z)-diene-2-yl-7-thio-4-oxo-4H-1-benzopyran-2-carboxylic acid sodium salt	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
MDL 43291	(4a.alpha,7Z,8.beta,8a.beta)-[(octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio]acetic acid	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
sulukast; LY 170680	5-(3-(2(R)-(carboxyethylthio)-1(S)-hydroxypentadeca-3(E),5(Z)-dienyl)phenyl)-1H-tetrazole	leukotriene E4 antagonist; leukotriene D4 antagonist; leukotriene antagonist	asthma

BAY y 1015	unspecified	leukotriene synthesis inhibitor	asthma
MAB, interleukin-5; MAB, IL-5; SB 240563	unspecified	monoclonal antibody;	asthma
MAbs, CCR3	unspecified	monoclonal antibody; ; chemokine antagonist	asthma
MAB, CD4; HumaT4	unspecified	monoclonal antibody; ; immunosuppressant	psoriasis; asthma; rheumatoid arthritis; irritable bowel syndrome; transplant rejection; allergy
MAB, CD23; GW 353430	unspecified	monoclonal antibody; ; NSAID	rheumatoid arthritis; asthma
J 104135	unspecified	muscarinic antagonist; muscarinic M3 antagonist; cholinergic antagonist	urinary incontinence; pulmonary obstructive disease; asthma
FK 888	trans-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-propyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide	neurokinin antagonist	asthma; migraine
lanepitant; LY 303870	(R)-N-[2-acetyl[(2-methoxyphenyl)methyl]amino]-1-(1H-indol-3-ylmethyl)ethyl]-[1,4'-bipiperidine]-1'-acetamide	neurokinin antagonist; analgesic; neurokinin 1 antagonist	asthma; pain; migraine
L 733060	(2S-cis)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID	inflammation; pain; asthma
saredutant; SR 48968	(S)-N-[4-(4-acetylamino-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl]-N-methyl-benzamide	neurokinin antagonist; analgesic; neurokinin 2 antagonist	asthma; pain; urinary incontinence

MEN 10376	unspecified	neurokinin antagonist; bronchodilator; neurokinin 2 antagonist	asthma; anxiety
CP 99994	(2S-cis)-N-[(2-methoxyphenyl)methyl]-2-phenyl-3-piperidinamine	neurokinin antagonist; neurokinin 1 antagonist; analgesic	asthma; pain
nolpitantium besilate; SR 140333.	(S) 1-[2-[3-(3,4-dichlorophenyl)-1-[[3-(1-methylethoxy)phenyl]acetyl]-3-piperidinyl]ethyl]-4-phenyl-1-azoniabicyclo[2.2.2]octane	neurokinin antagonist; neurokinin 1 antagonist; NSAID	asthma; inflammation
NKP 608C	unspecified	neurokinin antagonist; neurokinin 1 antagonist; substance P antagonist	bronchitis
ZD 7944	unspecified	neurokinin antagonist; neurokinin 2 antagonist	asthma
SR 144190	(R)-4-benzoyl-2-(3,4-difluorophenyl)-2-[2-[4-[[[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]ethyl]morpholine	neurokinin antagonist; neurokinin 2 antagonist; analgesic	asthma; urinary incontinence; asthma; pain



FK 224; FR 115224	N-[N2-[N-[N-[N-[alfa,beta-didehydro-N-methyl-N-[N-[1-oxo-3-(2-pentylphenyl)propyl]-L-threonyl]tyrosyl]-L-leucyl]-D-phenylalanyl]-L-allothreonyl]-L-asparaginy]-L-serine epsilon-lactone	neurokinin antagonist; neurokinin 2 antagonist; NSAID	asthma; inflammation
NS 2073	unspecified	nitric oxide activator; NSAID	inflammation; glaucoma; gastrointestinal ulcer; asthma
NCX 1005	(11beta,16alpha)-9-fluoro-11,17-dihydroxy-16-methyl-21-[4-(nitrooxy)-1-oxobutoxyl]pregna-1,4-diene-3,20-dione	nitric oxide donor	asthma; inflammatory bowel disease
andolast; CR 2039	N-4-(5-tetrazolyl)-phenyl-4-(5-tetrazolyl)-benzamide	NSAID	asthma; inflammation; allergy
anti-inflammatory agent,	unspecified	NSAID	inflammation; asthma
bamaquimast; F 10126; L 0042	3-[3-[[[(methylamino)carbonyl]oxy]propyl]-1-propyl-2(1H)-quinoxalinone	NSAID	asthma
BTS 71321	N-[1-(4-chlorophenyl)-1-methylethyl]-1H-imidazole-1-propanamine	NSAID	asthma
CD40 receptor signalling pathway inhibitor, CD40 receptor signalling pathway inhibitor,	unspecified	NSAID	allergy; asthma; inflammation
chemokine receptor modulators	unspecified	NSAID	inflammation; asthma; atherosclerosis

contignasterol; IZP 94005	(3alpha,4beta,5alpha,6alpha,7beta,14beta,22S)-22,29-epoxy-3,4,6,7,29-pentahydroxystigmastan-15-one	NSAID	asthma; respiratory disease
glucocorticoid agonists	unspecified	NSAID	inflammation; rheumatoid arthritis; inflammatory bowel disease; asthma
interleukin modulators,	unspecified	NSAID	inflammation; asthma
IPL 576092	unspecified	NSAID	asthma; respiratory disease
limazocic; SA 3443	(R)-hexahydro-7,7-dimethyl-6-oxo-1,2,5-dithiazocine-4-carboxylic acid	NSAID	liver disease; inflammation; emphysema; drug overdose
macrophage migration inhibitory factor inhibitors	unspecified	NSAID	arthritis; asthma
PKC-RACK interaction inhibitors	unspecified	NSAID	arthritis; multiple sclerosis; asthma
PNU 142731; PNU 142731A	1-[(2,4-di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indol-9-yl)acetyl]pyrrolidine mono hydrochloride	NSAID	asthma
pseudopterosin	unspecified	NSAID	arthritis; asthma; psoriasis
tioxamast; F 1865	[[4-(4-methoxyphenyl)-2-thiazolyl]amino]oxoacetic acid ethyl ester	NSAID	asthma; inflammation; skin disease
Z 1957	ethyl N-((3-methyl-5-isoxazolyl)-2-thiazolyl) oxamate	NSAID	asthma; inflammation
VX 745	unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation; neurological; heart failure; Crohn disease; asthma
NCX 1004	unspecified	NSAID; nitric oxide donor	asthma

phospholipase A2 inhibitors	unspecified	NSAID; phospholipase inhibitor	rheumatoid arthritis; inflammatory bowel disease; asthma
INKP 300	unspecified	NSAID; signal transduction inhibitor	asthma
D 7003	unspecified	nucleoside	bronchitis
oligonucleotide, asthma	unspecified	oligonucleotide; ; immunostimulant	asthma
sulfated oligosaccharide	unspecified	oligosaccharide	asthma
bepafant; WEB 2170	4-[[6-(2-chlorophenyl)-8,9-dihydro-1-methyl-4H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazpin-8-yl]carbonyl]morpholine	PAF antagonist	asthma; rhinitis
E 6123	(S)-(+)-6-(2-chlorophenyl)-3-cyclopropanecarbonyl-8,11-dimethyl,2,3,4,5-tetrahydro-8H-pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine	PAF antagonist	asthma
foropafant; SR 27417	N,N-dimethyl-N'-(3-pyridinylmethyl)-N'-[4-[2,4,6-tris(1-methylethyl)phenyl]-2-thiazolyl]-1,2-ethanediamine	PAF antagonist	asthma
ginkgolide A,B,C; BN 52063	(1alpha,7beta)-1,7-dihydroxyginkgolide A mixt with ginkgolide A and (1beta)-1-hydroxyginkgolide A	PAF antagonist	asthma; rhinitis; thrombocytopenia

israpafant; Y 24180; PAFNOI	4-(2-chlorophenyl)- 6,9-dimethyl-2-[2-[4- (2- methylpropyl)phenyl] ethyl]-6H-thieno[3,2- f][1,2,4]triazolo[4,3- a][1,4]diazepine.	PAF antagonist	asthma
L 680573; MK 287	(2S-trans)-2-[[3- methoxy-2-propoxy- 5-[tetrahydro-5- (3,4,5- trimethoxyphenyl)-2- furanyl]phenyl]sulfonyl]ethanol	PAF antagonist	asthma; septic shock
Ro 191400	unspecified	PAF antagonist	asthma
Ro 193704; Ro 19- 3704	(R)-3-[4-[2- [(methoxycarbonyl)oxy]-3- [[[(octadecylamino)carbonyl]oxy]propoxy]butyl]thiazolium iodide	PAF antagonist	asthma
Ro 240238; Ro 24- 0238; Ro 244376	[R-(E,E)]-5-(4- methoxyphenyl)-N- [1-methyl-4-(3- pyridinyl)butyl]-2,4- decadienamide	PAF antagonist	asthma
roceapafant; BN 50730	6-(2-chlorophenyl)- 7,10-dihydro-N-(4- methoxyphenyl)-1- methyl-4H- pyrido[4',3':4,5]thieno [3,2- f][1,2,4]triazolo[4,3- a][1,4]diazepine- 9(8H)-carbothioamide	PAF antagonist	hypotension; cytoprotectant; asthma
tulopafant; RP 59227	(+)-N-(3- benzoylphenyl)-3-(3- pyridinyl)-1H,3H- pyrrolo[1,2- c]thiazole-7- carboxamide	PAF antagonist	asthma

YM 461; YM 46A	1-(3-phenylpropyl)-4-[[2-(3-pyridinyl)-4-thiazolidinyl]carbonyl]piperazine (E)-2-butenedioate (1:1)	PAF antagonist	asthma; pulmonary obstructive disease
SCH 37370	1-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine	PAF antagonist; histamine antagonist; histamine H1 antagonist	asthma; rhinitis
CMI 392	trans-2-[5-(N'-methyl-N'-hydroxyureidylmethyl)-3-methoxy-4-p-chlorophenylthioethoxyphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran	PAF antagonist; leukotriene antagonist	psoriasis; dermatitis; asthma
BN 52111	1-(6-((2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy)-6-oxohexyl)-pyridinium bromide	PAF antagonist; NSAID	asthma; inflammation
BN 52115	1-[6-[(2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy]-6-oxohexyl]quinolinium bromide	PAF antagonist; NSAID	asthma; inflammation
SM 10661	cis-(+,-)-3,5-dimethyl-2-(3-pyridinyl)-4-thiazolidinone monohydrochloride	PAF antagonist; NSAID	endotoxic shock; inflammation; asthma
tetrahydrocarbazole	4-(2-chlorophenyl)-9-methyl-2-[3-(1,2,3,4-tetrahydro-9H-carbazol-9-yl)-1-propynyl]-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist; NSAID	inflammation; asthma

tiapafant; PCA 4248	1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid methyl 2-(phenylthio)ethyl ester	PAF antagonist; NSAID	asthma; inflammation
UR 10324	2-(2-acetyl-3,11-dioxo-4,10-dioxo-7-thia-2,12-diazanonacos-1-yl)-1-ethylpyridinium chloride	PAF antagonist; NSAID	inflammation; asthma
UR 12460	4-[[[(diphenylmethyl)amino]acetyl]-alpha-(2-methyl-3-pyridinyl)-1-piperazineacetonitrile	PAF antagonist; NSAID	inflammation; asthma
UR 12510	unspecified	PAF antagonist; NSAID	inflammation; asthma
UR 12519	unspecified	PAF antagonist; NSAID	inflammation; asthma
UR 12551	unspecified	PAF antagonist; NSAID	inflammation; asthma
AH 21132	cis N-(4-(1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo(c)(1,6)naphthyridin-6-yl)phenyl)-acetamide (Z)-2-butenedioate (1:2)	PAF antagonist; phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
apafant; WEB 2086; WEB 2086BS	4-[3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo [4,3-a][1,4]diazepin-2-yl]-1-oxopropyl morpholine	PAF antagonist; platelet antiaggregant	asthma; rhinitis; pancreatitis
dacopafant; RP 48740	(3R)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide	PAF antagonist; platelet antiaggregant	asthma; thrombosis

F 1850	unspecified	PAF antagonist; platelet antiaggregant	thrombosis; asthma
ginkgolide B; BN 52021	hexacyclic trilactone	PAF antagonist; platelet antiaggregant	thrombosis; dermatitis; asthma; multiple sclerosis; septic shock
L 659989	trans-(+,-)-tetrahydro- 2-[3-methoxy-5- (methylsulfonyl)-4- propoxyphenyl]-5- (3,4,5- trimethoxyphenyl)furan	PAF antagonist; platelet antiaggregant	asthma; thrombosis
R 74654	3-(6-(0-(2R,2S)-(3- heptadecylcarbamoyl oxytetrahydropyran- 2-yl)met hyl)phosphonoxy)hex ylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis
R 74717	3-(5-(0-(2S,3S)-(3- heptadecylcarbamoyl thiotetrahydropyran-2- yl)me thyl)phosphonoxy)pe ntylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis
Ro 244736; Ro 24- 4736	5-[3-[4-(2- chlorophenyl)-9- methyl-6H- thieno[3,2- f][1,2,4]triazolo [4,3- a][1,4]diazepin-2-yl]- 2-propynyl]-6(5H)- phenanthridinone	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock
SDZ 64412; SDZ 64- 412	2,3-dihydro-5-[4-[2- (3,4,5- trimethoxyphenyl)eth yl]phenyl]imidazo[2,1- a]isoquinoline monohydrochloride	PAF antagonist; platelet antiaggregant	asthma; thrombosis

SR 27388	4-[2-[[2-(dimethylamino)ethyl](3-pyridinylmethyl)amino]-4-thiazolyl]-2,6-bis(1,1-dimethylethyl)phenol	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock
UK 74505	4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]-5-[(2-pyridinylamino)carbonyl]-3-pyridinecarboxylic acid ethyl ester	PAF antagonist; platelet antiaggregant	thrombosis; asthma
UR 12670	4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]-1-(1-oxo-3,3-diphenylpropyl)-piperidine	PAF antagonist; platelet antiaggregant	kidney disease; ischemia; asthma; pancreatitis
WEB 2347	6-(2-chlorophenyl)-8,9-dihydro-1-methyl-N,N-dipropyl-4H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-8-carboxamide	PAF antagonist; platelet antiaggregant	asthma; anaphylactic shock; thrombosis
YM 264	1-(3-methyl-3-phenylbutyl)-4-[[2-(3-pyridinyl)-4-thiazolidinyl]carbonyl]piperazine (E)-2-butenedioate (1:1)	PAF antagonist; platelet antiaggregant	thrombosis; asthma
SDZ 64619	(+,-)-2-[6-methoxy-2-(methylsulfonyl)-3,9-dioxo-4,8-dioxo-2,10-diazaoctacosan-1-yl]-1-methylpyridinium iodide	PAF antagonist; platelet antiaggregant; bronchodilator	thrombosis; asthma
asthma therapy	unspecified	peptide	asthma



cathepsin S inhibitors, Peptimmune	unspecified	peptide; proteinase inhibitor; cathepsin S inhibitor	asthma
BY 244	unspecified	phosphodiesterase inhibitor	asthma
BY 343	unspecified	phosphodiesterase inhibitor	asthma
phosphodiesterase inhibitor	unspecified	phosphodiesterase inhibitor	asthma
roflumilast; BY 217	3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide	phosphodiesterase inhibitor	asthma
KF 19514	1,5-dihydro-5-phenyl-4H-imidazo[4,5-c][1,8]naphthyridin-4-one	phosphodiesterase inhibitor; bronchodilator	asthma
KP 885	unspecified	phosphodiesterase inhibitor; bronchodilator	asthma
P 1432	3-(cyclopropylmethyl)-xanthine	phosphodiesterase inhibitor; bronchodilator	asthma
WY 123641; PDA 641	unspecified	phosphodiesterase inhibitor; bronchodilator	asthma
arofylline; LAS 31025	3-(4-chlorophenyl)-3,7-dihydro-1-propyl-1H-purine-2,6-dione	phosphodiesterase inhibitor; bronchodilator; NSAID	asthma; inflammation
LAS 31396	unspecified	phosphodiesterase inhibitor; bronchodilator; NSAID	asthma; inflammation
tolafentrine; BY 4070	(-)-4-(cis-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl)-p-toluenesulfonamide	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma

zardaverine; B 84290	6-(4-(difluoromethoxy)-3-methoxyphenyl)-3(2H)-pyridazinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
AWD 12281	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
BAY 198004	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
CP 220629; CP 220,629	1-cyclopentyl-3-ethyl-1,4,5,6-tetrahydro-6-(2-methylphenyl)-7H-pyrazolo[3,4-c]pyridin-7-one	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
DWP 205297	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
PDE-4 inhibitors	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
YM 976	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
CDP 840	(R)-4-[2-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-phenylethyl]pyridine	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; inflammation
filaminast; WAY PDA 641	1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethanone, (E)-O-(aminocarbonyl)oxime	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma

LAS 32688	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
phosphodiesterase inhibitors	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
piclamilast; RP 73401; RPR 73401	3-cyclopentyloxy-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; arthritis
SB 207499; ARIFLO	cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylic acid	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; pulmonary obstructive disease
D 4418	N-(3,5-dichloro-4-pyridinyl)-8-methoxy-5-quinolinecarboxamide	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; immunosuppressant; bronchodilator	asthma
D 22888	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; phosphodiesterase V inhibitor; bronchodilator	asthma
SKF 96231	2-(2-propoxyphenyl)-6-purinone	phosphodiesterase inhibitor; phosphodiesterase V inhibitor; bronchodilator	asthma
doxofylline; ABC 12/3; DO 309; MAXIVENT; ANSIMAR	7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione	phosphodiesterase inhibitor; xanthine	asthma

CI 1018	(R)-N-(3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-4-pyridinecarboxamide	phosphodiesterase IV inhibitor	asthma
phospholipase A2 inhibitors	Unspecified	phospholipase inhibitor; NSAID	asthma; rheumatoid arthritis; psoriasis; inflammatory bowel disease
cyclic polyamine analogue	unspecified	polyamine analogue; NSAID	Crohn disease; asthma; inflammation
BILX 1; RS 91309	unspecified	potassium channel activator	asthma
BRL 55834	(3S,4R)-3,4-dihydro-2,2-dimethyl-4-(2-oxopiperidin-1-yl)-6-pentafluoroethyl-2H-1-benzopyran-3-ol	potassium channel activator; bronchodilator	asthma
CL 891902	unspecified	potassium channel activator; bronchodilator	asthma; hypertension
emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease
potassium channel activator	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
Ro 316930	2,2-dimethyl-4-(2-pyridinyl)-2H-1-benzopyran-6-carbonitrile N4-oxide	potassium channel activator; bronchodilator	hypertension; asthma
RP 66471	1S,2R-trans-2-benzoyloxy-1-(pyrid-3-yl)cyclohexane-(N-methyl)-carbthioamide	potassium channel activator; bronchodilator	asthma

SCA 40	6-bromo-8-(methylamino)-imidazo[1,2-a]pyrazine-2-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
SDZ PCO400	(3S-trans)-2,4-dihydro-3-hydroxy-2,2-dimethyl-4-[(3-oxo-1-cyclopenten-1-yl)oxy]-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	asthma
SR 47063	4-(2-cyanoimino-1,2-dihydropyrid-1-yl)-6-nitro-2,2-dimethyl-2H-1-benzopyran	potassium channel activator; bronchodilator	heart ischemia; asthma
symakalim; EMD 57283	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; coronary artery disease; asthma
UR 8225	1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence
UR 8308	1,2-dihydro-2,2-dimethyl-4-(N-oxide-2-pyridyl)-1-oxonaphthalen-6-carbonitrile	potassium channel activator; bronchodilator	asthma
UR 8328	1,2-dihydro-2,2-dimethyl-4-(N-oxide-2-pyridyl)-6-pentafluoroethylnaphtalen-1-one	potassium channel activator; bronchodilator	asthma
YM 934	3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-2H-1,4-benzoxazine N-oxide	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence

bimakalim; EMD 52692; SR 44866	2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; vasodilator; bronchodilator	coronary artery disease; asthma; peripheral vascular disease
rilmakalim; HOE 234	(3S,4R)-3-hydroxy-2,2-dimethyl-4-(3-oxo-1-pyrrolidinyl)-6-phenylsulfonylchroman hemihydrate	potassium channel activator; vasodilator; bronchodilator	asthma
potassium channel modulators	unspecified	potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes
NS 1619	1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one	potassium channel modulator; bronchodilator	stroke; asthma
protein kinase activators	unspecified	protein kinase activator; protein kinase A activator	asthma; thrombosis
allergy therapy	unspecified	protein kinase inhibitor	allergy; asthma
Y 27632	[4(R)-trans]-4-(1-aminoethyl)-N-4-pyridinylcyclohexane carboxamide	protein kinase inhibitor	hypertension; asthma; cancer
Syk inhibitors	unspecified	protein kinase inhibitor; tyrosine kinase inhibitor	asthma; allergy
Der p I inhibitor	unspecified	proteinase inhibitor	asthma
midesteine; MR 889	2-thiophenecarbothioic acid, S-ester with (+,-)-2-mercapto-N-(tetrahydro-2-oxo-3-thienyl)propionamide	proteinase inhibitor	emphysema
alpha-1-antitrypsin	unspecified	proteinase inhibitor; ,	emphysema
alpha-1-antitrypsin	unspecified	proteinase inhibitor; ,	asthma; emphysema; cystic fibrosis; dermatitis; psoriasis

MDL 101146	N-[4-(4-morpholinylcarbonyl)benzoyl]-L-valyl-N-[3,3,4,4,4-pentafluoro-1-(1-methylethyl)-2-oxobutyl]-L-prolinamide	proteinase inhibitor; neutrophil elastase inhibitor	bronchitis
mycophenolate mofetil; mycophenolate mofetil hydrochloride; RS 61443; RS-61443-190;	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany l)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
NO-SOD mimetics, NitroMed; nitrosylated superoxide dismutase mimetics	unspecified	SOD mimetic; nitric oxide donor	asthma; respiratory distress syndrome; ischemia; reperfusion injury
CGP 49823	(2R-trans)-1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-N-(4-quinolinylmethyl)-4-piperidinamine	substance P antagonist	anxiety; asthma
FR 113680	N-acetyl-L-threonyl-1-formyl-D-tryptophyl-N-methyl-N-(phenylmethyl)-L-phenylalaninamide	substance P antagonist	asthma
WS 9326A	unspecified	substance P antagonist	asthma
dapitant; RPR 100893	[3aS-[2(R*),3aalpha,4beta,7aalpha]]-octahydro-4-(2-methoxyphenyl)-2-[2-(2-methoxyphenyl)-1-oxopropyl]-7,7-diphenyl-1H-isoindol-4-ol	substance P antagonist; NSAID	asthma; inflammation; migraine
MEN.10627	unspecified	tachykinin antagonist; antispasmodic	irritable bowel syndrome; asthma

nepadutant; MEN 11420	Cyclo[3-amino-L-alanyl-L-leucyl-N-[2-(acetyl amino)-2-deoxy-beta-D-glucopyranosyl]-L-asparaginyL-L-alpha-aspartyl-L-tryptophyl-L-phenylalanyl], cyclic (4->1)-peptide	tachykinin antagonist; antispasmodic	asthma; irritable bowel syndrome
seratrovast; scrabenast; AA 2414; A 73001; ABT 001; BRONICA	(+,-)-zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-benzeneheptanoic acid	thromboxane antagonist	asthma; rhinitis
SKF 88046	N,N'-bis[7-93-chlorobenzene aminosulfonyl)-1,2,3,4-tetrahydroisoquinolyl]disulfonylimide	thromboxane antagonist	asthma
domitroban; S 1452; S 145; ANBOXAN	(+,-)-[1alpha,2alpha(Z),3beta,4alpha]-7-[3-[(phenylsulfonyl)amino]bicyclo[2.2.1]hept-2-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	asthma; rhinitis; thrombosis
ICI 185282	[2alpha,4alpha,5alpha(Z)]-7-[4-(2-hydroxyphenyl)-2-(trifluoromethyl)-1,3-dioxan-5-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
ICI 192605	[2alpha,4alpha,5alpha(Z)]-6-[2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-4-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
KT 2962; KT 2-962	3-[4-[(4-chlorophenyl)sulfonyl]amino]butyl]-6-(1-methylethyl)-1-azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis



L 670596	(-)-6,8-difluoro-2,3,4,9-tetrahydro-9-[[4-(methylsulfonyl)phenyl]methyl]-1H-carbazole-1-acetic acid	thromboxane antagonist; platelet antiaggregant	asthma; thrombosis
ON 579	4-(2-(4-chlorophenylsulfonylamino)ethylthio)-2,6-difluorophenoxyacetic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
ONO 8809	[1S-[1 $\alpha$ ,2 $\alpha$ (Z),3 $\beta$ ,4 $\alpha$ ]]-6-[3-[[[(4-bromophenyl)sulfonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-5-hexenoic acid decyl ester	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
ramatroban; BAY u 3405; EN 13774	(R)-3-[[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid	thromboxane antagonist; platelet antiaggregant	asthma; rhinitis
SQ 33961	[1S-(exo,exo)]-2-[[3-[4-[[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
KDI 792; FK 070; FR 12170	[2S-[2 $\alpha$ , (Z),4 $\beta$ ]]-6-[4-[[[(4-chlorophenyl)sulfonyl]amino]-1-(3-pyridinylmethyl)-2-pyrrolidinyl]-5-hexenoic acid	thromboxane antagonist; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma

E 6700	(E)-alpha-[(4-methoxy-2,5-dimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene]-3-pyridineheptanoic acid	thromboxane synthetase inhibitor	asthma
F 1322	N-[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]-3-hydroxy-5-(3-pyridinylmethoxy)-2-naphthalenecarboxamide	thromboxane synthetase inhibitor	asthma
KK 505	2-ethyl-4-(3-pyridyl)-1(2H)-phthalazinone	thromboxane synthetase inhibitor; bronchodilator	asthma
KK 562	2-methyl-4-(5-thiazolyl)-1(2H)-phthalazinone	thromboxane synthetase inhibitor; bronchodilator	asthma
imitrodast; CS 518; RS 5186	4,5-dihydro-2-(1H-imidazol-1-ylmethyl)-benzo[b]thiophene-6-carboxylic acid sodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	asthma
nafagrel; DP 1904	5,6,7,8-tetrahydro-6-(1H-imidazol-1-ylmethyl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; angina; asthma; restenosis
ozagrel; ozagrel sodium; OKY 046; DOMENAN; CATACLOT; XANBON; VEGA	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	stroke; thrombosis; asthma; cough
Y 20811	4-(hydroxy(5-(1H-imidazol-1-yl)-2-methylphenyl)methyl)-3,5-dimethyl-benzoic acid, monosodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; asthma; stroke

ZT 386	unspecified	thromboxane synthetase inhibitor; thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
tumor necrosis factor inhibitors	unspecified	TNF inhibitor; NSAID	inflammation; asthma; inflammatory bowel disease
NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	asthma; inflammation; restenosis
BAY 358535; BAY 35-8535; BAY 171998; BAY 17-1998	unspecified	tryptase inhibitor	asthma
BAY 443428	unspecified	tryptase inhibitor	asthma
oral tryptase inhibitors,	unspecified	tryptase inhibitor	inflammatory bowel disease; asthma; psoriasis
tryptase inhibitors	unspecified	tryptase inhibitor	asthma
tryptase inhibitors	unspecified	tryptase inhibitor; NSAID	asthma; inflammation; rhinitis; inflammatory bowel disease; psoriasis
APC 366	N2-[(1-hydroxy-2-naphthalenyl)carbonyl]-L-arginyl-L-prolinamide monohydrochloride	tryptase inhibitor; peptide	asthma
allergy/asthma therapy,	unspecified	Unspecified	asthma; allergy
antiasthma agent	unspecified	unspecified	asthma
AP 0341	5-amino-3-(4-chlorophenyl)-N-methyl-1H-1,2,4-triazole-1-carbothioamide	unspecified	asthma
APO 77	unspecified	unspecified	asthma
ARL 68475; FPL 68475	unspecified	unspecified	asthma
asthma therapy	unspecified	unspecified	asthma
asthma therapy	unspecified	unspecified	asthma
asthma therapy	unspecified	unspecified	asthma

asthma therapy	unspecified	unspecified	asthma
asthma therapy	unspecified	unspecified	asthma
asthma/allergy therapy.	unspecified	unspecified	asthma; allergy
batebulast; batebulast hydrochloride; NCO 650	trans-4-guanidinomethylcyclohexanecarboxylic acid p-tert-butyl-phenyl ester hydrochloride	unspecified	asthma
CCR3 receptor modulators	unspecified	unspecified	asthma
CL 296141	unspecified	unspecified	asthma
CPR 3005	unspecified	unspecified	skin disease; eye disease; asthma; rheumatoid arthritis
CPR 3014	unspecified	unspecified	skin disease; eye disease; asthma; rheumatoid arthritis
CPR 3016	unspecified	unspecified	skin disease; eye disease; asthma; rheumatoid arthritis
CPR 7011	L-alpha-dipalmitoyl-sn-glycero-3-phosphocholine	unspecified	bronchitis; cystic fibrosis; rhinitis; asthma
CT 1441	unspecified	unspecified	asthma; allergy
D 20783	unspecified	unspecified	asthma; rhinitis
D 21247	unspecified	unspecified	asthma; rhinitis
D 24241	unspecified	unspecified	asthma; allergy
D 43787	unspecified	unspecified	asthma; allergy
D 4396	unspecified	unspecified	asthma
DF 1012	endo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide	unspecified	cough; bronchitis
drug delivery system, transdermal ketotifen; ketotifen	unspecified	unspecified	asthma
endothelium-associated disease therapy	unspecified	unspecified	stroke; asthma

erdosteine; dithiosteine; RV 144; P 144; KW 9144; EDIREL; TUSSOL	[[2-oxo-2- [(tetrahydro-2-oxo-3- thienyl)amino]ethyl]t thio]acetic acid	unspecified	bronchitis
FPL 68164	unspecified	unspecified	asthma
IgE regulators	unspecified	unspecified	asthma; allergy
INS 365	unspecified	unspecified	cystic fibrosis; bronchitis; eye disease
ion channel modulators,	unspecified	unspecified	arrhythmia; asthma
KCA 757	4-[6-acetyl-3-[3-[(4- acetyl-3-hydroxy-2- propylphenyl)thio]pro poxy]-2- propylphenoxy]butan oic acid	unspecified	asthma
KP 136; AL 136	8-hexyloxy-3-(1H- tetrazol-5-yl)-2H-1- benzopyran-2-one	unspecified	asthma
KSU 2178	unspecified	unspecified	dermatitis; asthma
L 0066; F 11105	unspecified	unspecified	asthma
LAS 30813	unspecified	unspecified	asthma; allergy
LDP 977	unspecified	unspecified	asthma
mast cell activation inhibitors	unspecified	unspecified	asthma; rhinitis
MDL 105212	(R)-1-[2-[3-(3,4- dichlorophenyl)-1- (3,4,5- trimethoxybenzoyl)- 3-pyrrolidinyl]ethyl]- 4-phenyl-4- piperidinecarboxamid e	unspecified	asthma
NIP 502	4-chloro-5-[[[(3- ethoxy-4- methoxyphenyl)meth yl]amino]-3(2H)- pyridazinone	unspecified	asthma
osthole; osthol	7-methoxy-8-(3- methyl-2-butenyl)- 2H-1-benzopyran-2- one	unspecified	asthma

repirinast; BAY u 2372; MY 5116; ROMET	isopentyl 5,6-dihydro- 7,8-dimethyl-4,5- dioxo-4H-pyrano[3,2- c]quinolinc-2- carboxylate	unspecified	asthma
SCA 8801	6-bromo 8- (methylamino)- imidazo[1,2- a]pyrazine-2- carbonitrile	unspecified	asthma
scopinast; KA 398	7-[3-[4-[bis(4- fluorophenyl)hydroxy methyl]-1- piperidinyl]propoxy]- 6-methoxy-2H-1- benzopyran-2-one	unspecified	asthma; allergy
TA 270	N-[1,2-dihydro-4- hydroxy-1-methyl-3- (octyloxy)-2-oxo-7- quinolinyl]-3-(4- hydroxy-3,5- dimethoxyphenyl)-2- propenamide	unspecified	asthma; rhinitis
TAK 661	unspecified	unspecified	dermatitis; asthma
tetrahydrocorynanthei n	17-methoxycorynan- 16-carboxylic acid methyl ester	unspecified	asthma; allergy
Th2 modulators	unspecified	unspecified	asthma; dermatitis
thymosin beta 4; Tbeta4	Thymosin beta 4 (rat clone pROS2 precursor)	unspecified	septic shock; respiratory distress syndrome; asthma
TO 190	unspecified	unspecified	asthma
tranilast; MK 341; AINTERU; BESSARAL; CLANIST; LIZAMONT; RIZALAST; SYNBERNIA; TEIBLOCK; RIZABEN	2-[[3-(3,4- dimethoxyphenyl)-1- oxo-2- propenyl]amino]benz oic acid	unspecified	asthma; allergy; conjunctivitis; rhinitis; restenosis

U 75412E	(16alpha)-21-[4-[3-(ethylamino)-2-pyridinyl]-1-piperazinyl]-16-methylpregna-1,4,9(11)-triene-3,20-dione (2Z)-2-butenedioate (1:1)	unspecified	asthma
doqualast; SM 857	11-oxo-11H-pyrido[2,1-b]quinazoline-2-carboxylic acid	uricosuric	asthma; gout
vaccine, asthma	unspecified	vaccine	asthma
vaccine, asthma, Proteus International	unspecified	vaccine	asthma
nonionic surfactant vesicles; NISV	unspecified	vaccine adjuvant; immunosuppressant	rheumatoid arthritis; asthma; inflammation
colforsin dapropate; NKH 477; ADEHL	N,N-dimethyl-beta-alanine (3R,4aS,5S,6S,6aS,10S,10aR,10bS)-5-(acetyloxy)-3-ethenyldodecahydro-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-1H-naphtho[2,1-b]pyran-6-yl ester	vasodilator; bronchodilator	heart failure; asthma; musculoskeletal disorder
ibudilast; KC 404; KETAS; AIVYNAL; EYEVYNIL	3-isobutyl-2-isopropylpyrazolo-(1,5alpha)-pyridine	vasodilator; PAF antagonist	asthma; eye disease
VLA-4 inhibitors, Epimmune	unspecified	VLA 4 antagonist; integrin antagonist; cell adhesion inhibitor	asthma
isbufylline	7-isobutyltheophylline	xanthine	asthma
MX 2120	7-(2,2-dimethyl)propyl-1-methylxanthine	xanthine	asthma
nestifylline; ABC 99	7-(1,3-dithiolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione	xanthine	asthma

MPX	3,7-dihydro-1-methyl-3-(1-methylethyl)-1H-purine-2,6-dione	xanthine; bronchodilator	asthma
-----	--	--------------------------	--------

Table 40. Current Candidate Therapeutic Interventions for the Treatment of Autoimmune Disorders

Product Name	Chemical Name	Action	Indication
brequinar; brequinar sodium; DUP 785; NSC 368390	6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic acid	antimetabolite; immunosuppressant	cancer; autoimmune disease; transplant rejection
ENZYOX	unspecified	antioxidant	autoimmune disease
antisense oligonucleotide, autoimmune disease	unspecified	antisense; oligonucleotide; immunosuppressant	autoimmune disease
apoptosis modulators	unspecified	apoptosis inhibitor; apoptosis inducer	cancer; autoimmune disease; neurodegeneration
complement inhibitor,	unspecified	complement inhibitor; proteinase inhibitor; serine proteinase inhibitor; immunosuppressant	autoimmune disease
interferon gamma antagonists,	unspecified	cytokine antagonist; immunosuppressant	autoimmune disease
interleukin-12 signal transduction antagonists	unspecified	cytokine antagonist; immunosuppressant; NSAID	autoimmune disease; transplant rejection; rheumatoid arthritis
uromodulin	unspecified	cytokine inhibitor; immunosuppressant	autoimmune disease
SelCIDs	unspecified	cytokine inhibitor; NSAID; immunosuppressant; TNF inhibitor; phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	autoimmune disease; inflammation



interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSIF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
superoxide dismutase variants; SOD	unspecified	free radical scavenger; NSAID; immunosuppressant	inflammation; autoimmune disease; reperfusion injury
interleukin-4 diphtheria toxin chimeric protein; IL-4 diphtheria toxin chimeric protein; IL-4 fusion protein	unspecified	fusion toxin; immunosuppressant	autoimmune disease; transplant rejection; cancer; HIV infection
glucocorticoids	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation; asthma; autoimmune disease
castanospermine	[1S- (1alpha,6beta,7alpha, 8beta,8abeta)]- octahydro-1,6,7,8- indolizine tetrol	glycosidase inhibitor; immunosuppressant	autoimmune disease; viral infection
growth and differentiation factor 3; GDF 3	unspecified	growth factor; differentiation inducer; immunosuppressant	transplant rejection; autoimmune disease
MDL 28842	(Z)-9-(5-deoxy-5- fluoro-beta-D-threo- pent-4-enofuranosyl- 9H-purin-6-one	homocysteine hydrolase inhibitor; immunosuppressant	malaria; autoimmune disease
Hsp70 modulators, autoimmune disease	unspecified	HSP70 inhibition	autoimmune disease
cetraric acid	9-(ethoxymethyl)-4- formyl-3,8- dihydroxy-1,6- dimethyl-11-oxo- 11H- dibenzo[b,e][1,4]diox epin-7-carboxylic acid	immunostimulant	autoimmune disease
immunostimulants	unspecified	immunostimulant	cancer; autoimmune disease

lymphocyte activation inhibitors	unspecified	immunostimulant	autoimmune disease; transplant rejection
T cell modulators,	unspecified	immunostimulant; immunosuppressant	infectious disease; autoimmune disease
B7 molecules; B7-1; B7-2	unspecified	immunosuppressant	autoimmune disease; transplant rejection
cholera toxin subunit B-antigen conjugate	unspecified	immunosuppressant	autoimmune disease
Fc receptors, soluble,	unspecified	immunosuppressant	autoimmune disease
interferon receptor type 1; IFNAR2	unspecified	immunosuppressant	autoimmune disease
MAB, CD45RB	unspecified	immunosuppressant	transplant rejection; autoimmune disease
MAB, humanized B7.1	unspecified	immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MAB, humanized B7.2	unspecified	immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MEDI 507	unspecified	immunosuppressant	autoimmune disease; transplant rejection; psoriasis
PEPTIMER	unspecified	immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes
RG 1046	unspecified	immunosuppressant	autoimmune disease; transplant rejection
T cell antigen receptor technology; TCR technology	unspecified	immunosuppressant	research tool; autoimmune disease
autoimmune disease therapy	unspecified	immunosuppressant	autoimmune disease
bactobolamine	[3S-(3alpha,4alpha,4beta,5beta,6alpha)]-4-amino-3-(dichloromethyl)-3,4,4a,5,6,7-hexahydro-5,6,8-trihydroxy-3-methyl-1H-2-benzopyran-1-one	immunosuppressant	autoimmune disease
BTS 63155	unspecified	immunosuppressant	autoimmune disease

calcineurin inhibitor	unspecified	immunosuppressant	autoimmune disease; neurological
CT 2544	unspecified	immunosuppressant	autoimmune disease; transplant rejection
drug delivery system, LDS microemulsion ciclosporin; ciclosporin LDS microemulsion	unspecified	immunosuppressant	autoimmune disease; transplant rejection
drug delivery system, microemulsion ciclosporin; ciclosporin microemulsion; SANDIMMUN NEORAL; SANDIMMUN OPTORAL; NEORAL; NEORAL- SANDIMMUN	unspecified	immunosuppressant	autoimmune disease; transplant rejection
FR 901459	4-L-leucine-7-L- threonine-10-L- leucine-cyclosporin A	immunosuppressant	autoimmune disease
FTY 720	2-amino-2-[2-(4- octylphenyl)ethyl]- 1,3-propanediol hydrochloride	immunosuppressant	transplant rejection; autoimmune disease
glycophospholipid, Graves' disease	unspecified	immunosuppressant	autoimmune disease
immunology/inflamm ation therapy	unspecified	immunosuppressant	inflammation; autoimmune disease; asthma
immunophilins,	unspecified	immunosuppressant	autoimmune disease
immunoregulators,	unspecified	immunosuppressant	autoimmune disease
immunoregulatory colostrum isolate	unspecified	immunosuppressant	autoimmune disease
immunosuppressant	unspecified	immunosuppressant	autoimmune disease; transplant rejection
immunosuppressants,	unspecified	immunosuppressant	autoimmune disease; asthma
immunosuppressants	unspecified	immunosuppressant	transplant rejection; autoimmune disease
immunosuppressants,	unspecified	immunosuppressant	autoimmune disease; transplant rejection

immunosuppressants,	unspecified	immunosuppressant	autoimmune disease
immunosuppressants,	unspecified	immunosuppressant	autoimmune disease
immunosuppressants, ZAP70	unspecified	immunosuppressant	autoimmune disease
interferon gamma inhibitor	unspecified	immunosuppressant	septic shock; autoimmune disease
interleukin-2 receptor ligand	unspecified	immunosuppressant	transplant rejection; autoimmune disease
ion channel modulators,	unspecified	immunosuppressant	cardiovascular disease; neurological; autoimmune disease
IR 1116	Unspecified	immunosuppressant	autoimmune disease
leptin antagonists	unspecified	immunosuppressant	autoimmune disease; transplant rejection
LF 150195	unspecified	immunosuppressant	autoimmune disease
LZ 8	unspecified	immunosuppressant	autoimmune disease
microcolins	unspecified	immunosuppressant	autoimmune disease
myriocin; thermozymocidin; ISP-I	[2S- (2R*,3S*,4S*,6E)]-2- amino-3,4-dihydroxy- 2-(hydroxymethyl)- 14-oxo-6-eicosenoic acid	immunosuppressant	autoimmune disease; transplant rejection
PRO 2844	(OC-6-22)- pentaammine(4- methylpyridine)ruthen ium(3+) trichloride	immunosuppressant	psoriasis; autoimmune disease; transplant rejection
prodigiosin 25-C; prodigiosin	4-methoxy-5-[(5- methyl-4-pentyl-2H- pyrrol-2- ylidene)methyl]-2,2'- bi-1H-pyrrole	immunosuppressant	autoimmune disease
rapamycin analoguc	unspecified	immunosuppressant	autoimmune disease
Rh toleragens	unspecified	immunosuppressant	autoimmune disease
SKF 106610	2-[3-(1- piperidiny)propyl]- 8,8-dipropyl-2- azaspiro[4.5]decane dihydrochloride	immunosuppressant	autoimmune disease
SM 8849	4-[1-(2-fluoro-4- biphenyl)ethyl]-2- methylaminothiazole	immunosuppressant	autoimmune disease
Stat4/Stat6 blockers	unspecified	immunosuppressant	autoimmune disease; allergy

TOK 8801	5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)imidazo[2,1-b]thiazole-2-carboxamide	immunosuppressant	autoimmune disease
trescrimus; LF 80299; LF 299	[4-[(3-aminopropyl)amino]butyl]carbamic acid 2-[[6-[(aminoiminomethyl)amino]hexyl]amino]-2-oxoethyl ester	immunosuppressant	autoimmune disease
VE 19613	unspecified	immunosuppressant	autoimmune disease
VX 497	unspecified	immunosuppressant	psoriasis; autoimmune disease; viral infection; hepatitis
XENOJECT	unspecified	immunosuppressant	cancer; autoimmune disease
aldose reductase inhibitors	unspecified	immunosuppressant; aldose reductase inhibitor; NSAID	autoimmune disease; allergy; inflammation
MAb, gp39; BMS 202448	unspecified	immunosuppressant; biotechnology	autoimmune disease
monocyte colony inhibitory factor-1	unspecified	immunosuppressant; biotechnology; chemokine	autoimmune disease; rheumatoid arthritis; systemic lupus erythematosus
chemokine receptor antagonists	unspecified	immunosuppressant; chemokine antagonist; cytokine antagonist	autoimmune disease
CBP 1011	unspecified	immunosuppressant; corticosteroid	autoimmune disease; systemic lupus erythematosus; asthma
CBP 2011	unspecified	immunosuppressant; corticosteroid	autoimmune disease; thrombocytopenia
CBP 2012	unspecified	immunosuppressant; corticosteroid	autoimmune disease; thrombocytopenia
autoimmune disease-specific MHC blockers	unspecified	immunosuppressant; DMARD; NSAID	rheumatoid arthritis; autoimmune disease

Bcl-x gamma-based therapy,	unspecified	immunosuppressant; gene; apoptosis inducer	autoimmune disease
protein A-based immune modulator	unspecified	immunosuppressant; immunostimulant	autoimmune disease; cancer
signal transduction modulators	unspecified	immunosuppressant; immunostimulant; NSAID	autoimmune disease; cancer; inflammation
MAB, H65 humanized Fab'	unspecified	immunosuppressant; monoclonal antibody	autoimmune disease
MAB, human interleukin-6 receptor; MAB, human IL-6 receptor; hPM-1; MRA	unspecified	immunosuppressant; monoclonal antibody	autoimmune disease; cancer
MAB, UCHL1; MAB, CD45RO	unspecified	immunosuppressant; monoclonal antibody	autoimmune disease
MAB, CD3-immunotoxin	unspecified	immunosuppressant; monoclonal antibody; biotechnology; immunotoxin	transplant rejection; autoimmune disease
enlimomab; MAB, intracellular adhesion molecule-1; MAB, ICAM-1; MAB, ICAM; MAB, R65; MAB, CD54; BIRR 0001; BIRR 1	unspecified	immunosuppressant; monoclonal antibody; NSAID	transplant rejection; autoimmune disease; rheumatoid arthritis
MAB, MHC class II; CDP 855	unspecified	immunosuppressant; monoclonal antibody; NSAID	autoimmune disease; systemic lupus erythematosus
priliximab; MAB, humanized CD4; cM-T412; CEN 000029;	immunoglobulin G1 (human-mouse monoclonal cm-T412 anti-human antigen CD 4), disulfide with human-mouse monoclonal cm-T412.kappa.-chain, dimer	immunosuppressant; monoclonal antibody; NSAID	multiple sclerosis; autoimmune disease; rheumatoid arthritis
C-Maf based therapy	unspecified	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis

leukocyte function associated antigen 3 T cell inhibitor protein; LFA3TIP; LFA3TIP; AMEVIVE	unspecified	immunosuppressant; NSAID	inflammation; autoimmune disease; psoriasis
OX40-based immunotherapy	unspecified	immunosuppressant; NSAID	inflammation; autoimmune disease
inflammation therapy,	unspecified	immunosuppressant; NSAID	inflammatory bowel disease; inflammation; autoimmune disease
KB 2683	2-(4-methylphenyl)-4-benzothiazolol acetate	immunosuppressant; NSAID	rheumatoid arthritis; inflammation; autoimmune disease
MX 68	2-[[[4-[2,4-diamino-6-pteridiny]methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl]amino]hexanedioic acid	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease
PIC 101	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; autoimmune disease; transplant rejection
PIC 102	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
PIC 231	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
SKF 105685	N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dihydrochloride	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis; HIV infection
atiprimod; atiprimod dimaleate; SKF 106615	N,N-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine	immunosuppressant; NSAID; macrophage inhibitor	rheumatoid arthritis; autoimmune disease; psoriasis
calcineurin inhibitory peptides	unspecified	immunosuppressant; peptide	autoimmune disease
immunosuppressant peptides	unspecified	immunosuppressant; peptide	transplant rejection; autoimmune disease
T cell peptide	unspecified	immunosuppressant; peptide	autoimmune disease; cancer; bacterial infection

PP 14	unspecified	immunosuppressant; peptide; NSAID	autoimmune disease; rheumatoid arthritis
potassium channel blocker	unspecified	immunosuppressant; potassium channel blocker	autoimmune disease; allergy; inflammation
autoimmune disease therapy	unspecified	immunosuppressant; proteinase inhibitor	autoimmune disease
leflunomide; HWA 486; ARAVA	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	immunosuppressant; tyrosine kinase inhibitor; NSAID; DMARD	rheumatoid arthritis; autoimmune disease
MAb, ICAM-3; MAb, intracellular adhesion molecule-3; MAb, ICAM-R; ICM3	unspecified	integrin antagonist; biotechnology; cell adhesion inhibitor; immunosuppressant; monoclonal antibody	autoimmune disease; psoriasis
MAb, L-selectin, humanized; SMART anti-L-selectin; HuDREG 200	unspecified	integrin antagonist; biotechnology; monoclonal antibody; cell adhesion inhibitor; immunosuppressant; L selectin antagonist	trauma; respiratory distress syndrome; autoimmune disease; reperfusion injury
microcolin A	N-(2,4-dimethyl-1-oxooctyl)-N-methylleucyl-N-[1-[[2-[(2,5-dihydro-2-methyl-5-oxo-1H-pyrrol-1-yl)carbonyl]-4-hydroxy-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-N-methylthreoninamide, 23-acetate	lipopeptide; immunosuppressant	autoimmune disease



sirolimus; rapamycin; NSC 226080; AY 22989; RAPAMUNE	(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacycloheptriacontine-1,5,11,28,29(4H,6H,31H)-pentone	macrolide; immunosuppressant; antibiotic	transplant rejection; autoimmune disease; restenosis
MAB, red blood cell D antigen; MAB, rhesus D; AM 101	unspecified	monoclonal antibody; biotechnology; immunosuppressant	autoimmune disease
MAB, interleukin-12; MAB, IL-12; J695; C17.15	unspecified	monoclonal antibody; cytokine antagonist; immunosuppressant	autoimmune disease
MAB, Fv, cytokine; CDP 870	unspecified	monoclonal antibody; cytokine inhibitor; immunosuppressant	rheumatoid arthritis; autoimmune disease
MAB, humanized CD3; MAB, SMART CD3; HuM291	unspecified	monoclonal antibody; immunosuppressant	transplant rejection; autoimmune disease; psoriasis
daclizumab; dacliximab; MAB, Tac; MAB, humanized Tac; MAB, SMART Tac; Ro 247375; ZENAPAX	immunoglobulin G1 (human-mouse monoclonal clone 1H4 gamma chain anti-human antigen Tac), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection; cancer; autoimmune disease; eye disease

MAB, 6G5.1; MAB, autoimmune disease, human, Medarex; MDX CD4	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; rheumatoid arthritis
MAB, alpha-tubulin	unspecified	monoclonal antibody; immunosuppressant	cancer; autoimmune disease; diagnosis
MAB, autoimmune disease; MAB, MHC II	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAB, CD45RB	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, Fc antagonist; MDX 33	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; thrombocytopenia
MAB, gp39; MAB, CD40L; IDEC 131	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection; systemic lupus erythematosus
MAB, H57597	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAB, inflammation therapy,	unspecified	monoclonal antibody; immunosuppressant	inflammation; autoimmune disease
MAB, L0-CD2a; BTI 322	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, MHC II-CD4; 14-CD4	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; graft versus host disease
MAB, migis-mIgG; Mab, B cell	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAB, RhCA 61-76; MAB, anti-AChR alpha subunit; TCM 240	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAbs, B cells; migis	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; cancer
MAB, MHC class II	unspecified	monoclonal antibody; immunosuppressant; NSAID	autoimmune disease; transplant rejection; graft versus host disease; cancer
S 2474	unspecified	NSAID; DMARD; COX inhibitor; COX 2 inhibitor; immunosuppressant	rheumatoid arthritis; autoimmune disease
immunosuppressive, ANUTECH	unspecified	peptide; immunosuppressant	autoimmune disease

inflammation therapy, BTG; autoimmune disease therapy, BTG	unspecified	peptide; immunosuppressant	inflammation; autoimmune disease
complement inhibitors,	unspecified	peptide; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease; reperfusion injury; respiratory distress syndrome; transplant rejection
polyclonal antibody, idiopathic thrombocytopenic purpura; polyclonal antibody, ITP; MelGAM	unspecified	polyclonal antibody; immunoglobulin	autoimmune disease
polyclonal antibody, immune thrombocytopenic purpura; polyclonal antibody, ITP; Rho(D) immune globulin; WinRho SD; WinRho SDF	unspecified	polyclonal antibody; immunosuppressant; immunoglobulin	autoimmune disease; HIV infection
ANK 102	Unspecified	polysaccharide; immunosuppressant	autoimmune disease
cathepsin S inhibitors,	unspecified	proteinase inhibitor; cathepsin S inhibitor; NSAID; immunosuppressant	inflammation; autoimmune disease
SR 31747	(Z)-N[3-chloro-4-cyclohexylphenyl)-2-propenyl]-N-ethyl-cyclohexanamine hydrochloride	sigma antagonist; immunosuppressant; NSAID	autoimmune disease; arthritis
signal transduction inhibitor, SUGEN/ArQule	unspecified	signal transduction inhibitor; immunosuppressant	cancer; diabetes; neurological; autoimmune disease
SP 100030	Unspecified	signal transduction inhibitor; NSAID; immunosuppressant	inflammation; autoimmune disease

tumor necrosis factor binding protein; TBP-1; TBP	unspecified	TNF inhibitor; immunosuppressant	autoimmune disease; reperfusion injury; inflammation; septic shock
etanercept; tumor necrosis factor receptor; TNFr; TNR 001;	unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease
transcription factor inhibitors	unspecified	transcription factor regulator	inflammation; autoimmune disease
NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	inflammation; ischemia; cancer; autoimmune disease
AP-1 inhibitor, JNK inhibitor	unspecified	transcription factor regulator; NSAID; immunosuppressant	inflammation; autoimmune disease; cancer
SC 114	unspecified	triglyceride; immunosuppressant	autoimmune disease; transplant rejection
AP 251	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
p56 lck inhibitors	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
ZAP70 inhibitors	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
Tolerogen, autoimmune disease	unspecified	unspecified	autoimmune disease
Vaccine, gene-based, autoimmune disease	unspecified	vaccine; gene therapy	autoimmune disease; inflammation
vaccine, gene-based, autoimmune disease;	unspecified	vaccine; gene therapy; immunosuppressant	autoimmune disease

Table 41. Current Candidate Therapeutic Interventions for the Treatment of Systemic Lupus Erythematosus

Product Name	Chemical Name	Action	Indication
prasterone; dehydroepiandrosterone; DHEA; GL 701; NBI 106; PB 007; ASTENILE; DEANDROS; DIANDRON	(3beta)-3-hydroxyandrost-5-en-17-one	androgen; vaccine adjuvant; hormone replacement therapy; corticosteroid	systemic lupus erythematosus; hormone deficiency; Alzheimer disease; reperfusion injury; ischemia

FasdeltaTM	unspecified	apoptosis inhibitor	HIV infection
MAb, C5; MAb, complement C5; 5G1.1	unspecified	complement inhibitor; monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus
RP 54745	4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinoliny)-3H-1,2-dithiol-3-one	cytokine antagonist; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; psoriasis
interleukin-1 receptor; IL-1r; HJ 1306	unspecified	cytokine inhibitor; immunosuppressant	asthma
ScICIDs	unspecified	cytokine inhibitor; NSAID; immunosuppressant; TNF inhibitor; phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	autoimmune disease; inflammation
dornase alfa; deoxyribonuclease; DNase; PULMOZYME	deoxyribonuclease, (human clone 18-1 protein moiety)	deoxyribonuclease; enzyme	cystic fibrosis; bronchitis; pulmonary obstructive disease; systemic lupus erythematosus
actarit; MS 932; MOVER; ORCL	4-(acetylamino)phenylacetic acid	DMARD; immunosuppressant; NSAID	rheumatoid arthritis
gene therapy, transforming growth factor beta	unspecified	gene therapy; NSAID	rheumatoid arthritis
glucocorticoids, Ligand	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation; asthma; autoimmune disease
gallium nitrate; NSC 15200; CALSTAT; GANITE	gallium nitrate nonahydrate	hypocalcemic; nitric oxide synthase inhibitor	hypercalcemia; cancer
gecsporin; ciclosporin G; cyclosporin G; ciclosporin, (NVA)2-; cyclosporin, (NVA)2-; OG 37325	7-L-norvaline cyclosporin A	immunostimulant	transplant rejection

recombinant alpha3 collagen chain; BST 3003	unspecified	immunosuppressant	kidney disease; systemic lupus erythematosus
drug delivery system, microemulsion ciclosporin; ciclosporin microemulsion; SANDIMMUN NEORAL; SANDIMMUN OPTORAL; NEORAL; NEORAL-SANDIMMUN	unspecified	immunosuppressant	autoimmune disease; transplant rejection
fluasterone	unspecified	immunosuppressant	cancer; diabetes; systemic lupus erythematosus
immunosuppressant	unspecified	immunosuppressant	autoimmune disease; transplant rejection
LJP 394	unspecified	immunosuppressant	systemic lupus erythematosus
VX 497	unspecified	immunosuppressant	psoriasis; autoimmune disease; viral infection; hepatitis
SM 8849	4-[1-(2-fluoro-4-biphenyl)ethyl]-2-methylaminothiazole	immunosuppressant	autoimmune disease
monocyte colony inhibitory factor-1	unspecified	immunosuppressant; biotechnology; chemokine	autoimmune disease; rheumatoid arthritis; systemic lupus erythematosus
CBP 1011	unspecified	immunosuppressant; corticosteroid	autoimmune disease; systemic lupus erythematosus; asthma
MAB, MHC class II; CDP 855	unspecified	immunosuppressant; monoclonal antibody; NSAID	autoimmune disease; systemic lupus erythematosus
BMS 188667; CTLA4Ig	unspecified	immunosuppressant; NSAID	transplant rejection; systemic lupus erythematosus; psoriasis; arthritis; allergy

MAb, CD40 ligand; 5C8; ANTOVA	unspecified	immunosuppressant; NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
autoimmune disease therapy	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; multiple sclerosis; systemic lupus erythematosus
PG 2946	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3028	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3113	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
MX 68	2-[[[4-[2,4-diamino- 6-pteridiny]methyl]- 3,4-dihydro-2H-1,4- benzothiazin-7- yl]carbonyl]amino]he xanedioic acid	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease
baohuoside 1; icaraside II; B-1	3-[(6-deoxy-alpha-L- mannopyranosyl)oxy]- 5,7-dihydroxy-2-(4- methoxyphenyl)-8-(3- methyl-2-butenyl)- 4H-1-benzopyran-4- one	immunosuppressant; NSAID	systemic lupus erythematosus; rheumatoid arthritis
SKF 105685	N,N-dimethyl-8,8- dipropyl-2- azaspiro[4,5]decane- 2-propanamine dihydrochloride	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis; HIV infection
ZAP inhibitors	unspecified	immunosuppressant; protein kinase inhibitor; tyrosine kinase inhibitor; NSAID	transplant rejection; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythematosus; multiple sclerosis

sirolimus; rapamycin; NSC 226080; AY 22989; RAPAMUNE	(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[[[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacycloheptriacontine-1,5,11,28,29(4H,6H,31H)-pentone	macrolide; immunosuppressant; antibiotic	transplant rejection; autoimmune disease; restenosis
bindarit; AF 2838	2-methyl-2-[[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy]-propanoic acid	MCP-1 production inhibition; mRNA expression inhibition	rheumatoid arthritis; nephritis
MAb, 1C7; passive immunotherapy, systemic lupus erythematosus	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus
MAb, Fc antagonist; MDX 33	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; thrombocytopenia
MAb, gamma interferon, humanized; SMART anti-gamma interferon	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus; multiple sclerosis
MAb, gp39; MAb, CD40L; IDEC 131	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection; systemic lupus erythematosus
MAb, H57597	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAb, interleukin-10; MAb, IL-10	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus
MAb, migis-mIgG; Mab, B cell	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease



MAbs, B cells; migis	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; cancer
zolimomab aritox; MAb, H65 RTA; MAb, bone marrow-ricin A conjugate; CD5-T lymphocyte immunotoxin; MAb, CD5; XMMLY H65 RTA; XOMAZYME H65; XOMAZYME CD5+; ORTHOZYME CD5+; CD5 Plus	unspecified	monoclonal antibody; immunotoxin; immunosuppressant	transplant rejection
MAb, cytokines; AGT 1	unspecified	monoclonal antibody; NSAID	rheumatoid arthritis
MAb, VLA-4, humanized; MAb, very late antigen-4, humanized	unspecified	monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
MAb, B7; MAb, PRIMATIZED B7; IDEC 114	unspecified	monoclonal antibody; NSAID; immunosuppressant	systemic lupus erythematosus; inflammation; transplant rejection; psoriasis
MER W8020	Unspecified	peptide; analgesic; NSAID	inflammation; pain
inflammation therapy, autoimmune disease therapy	unspecified	peptide; immunosuppressant	inflammation; autoimmune disease
complement inhibitors	unspecified	peptide; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease; reperfusion injury; respiratory distress syndrome; transplant rejection
polyclonal antibodies, HIV, anti-70K	unspecified	polyclonal antibody; immunoglobulin	HIV infection

nafamostat; nafamostat mesylate; nafamostat mesilate; FUT 175; FUTHAN TORII; FUTHAN BANYU	6-amidino-2-naphthyl p-guanidinobenzoate	proteinase inhibitor; platelet antiaggregant	thrombosis; pancreatitis; allergy; anaphylactic shock
mycophenolate mofetil; RS 61443	(E)-6-(1,3-dihydro-4- hydroxy-6-methoxy- 7-methyl-3-oxo-5- isobenzofurany l)-4- methyl-4-hexenoic acid 2-(4- morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
rolafagrel; FCE 22178	5,6-dihydro-7-(1H- imidazol-1-yl)-2- naphthalenecarboxyli c acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; kidney disease
thalidomide; SYNOVIR; THALOMID	N-(2,6-dioxo-3- piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
MHC expression inhibitors, BLSI	unspecified	transcription inhibitor; NSAID	rheumatoid arthritis; systemic lupus erythematosus
AP 251	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
vaccine, systemic lupus erythematosus	unspecified	vaccine	systemic lupus erythematosus
MAb, 3E10; vaccine, nephritis	unspecified	vaccine; monoclonal antibody	nephritis

Table 42. Current Candidate Therapeutic Interventions for the Treatment of Immunosuppression

Product Name	Chemical Name	Action	Indication
--------------	---------------	--------	------------

depsidomycin; antibiotic MI 951- 65F2	N-[docosahydro-7- methyl-14-(1- methylethyl)-11,23- bis(2-methylpropyl)- 5,9,12,15,21,24- hexaoxo-7H,17H- dipyridazino[6,1- c:6',1'- i][1,4,7,10,13,16]oxa pentaazacyclonadec in-8-yl]-2- (formylamino)-3- methylpentanamide	antibiotic; immunosuppressant; peptide	bacterial infection
brequinar; brequinar sodium; DUP 785; NSC 368390	6-fluoro-2-(2'- fluoro[1,1'-biphenyl]- 4-yl)-3-methyl-4- quinolinecarboxylic acid	antimetabolite; immunosuppressant	cancer; autoimmune disease; transplant rejection
antisense oligonucleotide, interleukin-1; antisense oligonucleotide, IL-1	unspecified	antisense; immunosuppressant; oligonucleotide; NSAID	inflammation
antisense oligonucleotide, NF- kappaB p65 subunit	unspecified	antisense; oligonucleotide; biotechnology; immunosuppressant	Crohn disease
antisense oligonucleotide, autoimmune disease	unspecified	antisense; oligonucleotide; immunosuppressant	autoimmune disease
antisense oligonucleotide, graft versus host disease	unspecified	antisense; oligonucleotide; immunosuppressant; apoptosis inducer	transplant rejection
apoptosis inhibitors, Oxford Asymmetry/LXR Biotechnology	unspecified	apoptosis inducer	cancer; cardiac therapy; transplant rejection; gastrointestinal disorder

L-selectin antagonist, NeXstar	unspecified	aptamer; oligonucleotide; integrin antagonist; L selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation
P-selectin antagonist, NeXstar	unspecified	aptamer; oligonucleotide; integrin antagonist; P selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation
gene therapy, tumor necrosis factor receptor	unspecified	biotechnology; gene therapy; TNF inhibitor; immunosuppressant; NSAID	rheumatoid arthritis
growth and differentiation factor 3; GDF 3	unspecified	biotechnology; growth factor; differentiation inducer; immunosuppressant	transplant rejection; autoimmune disease
growth and differentiation factor- 1; GDF-1	unspecified	biotechnology; growth factor; neurotrophic factor	neurodegeneration
MAB, human interleukin-6 receptor; MAb, human IL-6 receptor; hPM-1; MRA	unspecified	biotechnology; immunosuppressant; monoclonal antibody	autoimmune disease; cancer
LFA-1 alpha subunit; leukocyte function associated antigen-1 alpha subunit; leukocyte cell surface adhesion receptor molecule	unspecified	biotechnology; nosuppressant; NSAID	inflammation

enlimomab; MAb, intracellular adhesion molecule-1; MAb, ICAM-1; MAb, ICAM; MAb, R65; MAb, CD54; BIRR 0001; BIRR 1	unspecified	biotechnology;; monoclonal antibody; NSAID	transplant rejection; autoimmune disease; rheumatoid arthritis
OX40-based immunotherapy, Cantab	unspecified	biotechnology;; NSAID	inflammation; autoimmune disease
casein kinase inhibitors, ICOS	unspecified	casein kinase inhibitor; immunosuppressant; NSAID	inflammation; cancer
ICE inhibitor, IDUN	unspecified	caspase inhibitor; apoptosis inhibitor; IL-1 beta converting enzyme inhibitor; immunosuppressant	transplant rejection; septic shock; rheumatoid arthritis; inflammatory bowel disease; diabetes
cell therapy, FCRx	unspecified	cell therapy; immunosuppressant	transplant rejection
MAb, C5; MAb, complement C5; 5G1.1	unspecified	complement inhibitor; monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus
complement inhibitor, BioCryst/3 Dimensional Pharmaceuticals	unspecified	complement inhibitor; proteinase inhibitor; serine proteinase inhibitor; immunosuppressant	autoimmune disease
methylprednisolone suleptanate; U 67590A; PROMEDROL	(6alpha,11beta)-11,17-dihydroxy-6-methyl-21-[[8-[methyl(2-sulfoethyl)amino]-1,8-dioxooctyl]oxy]pregna-1,4-diene-3,20-dione monosodium salt	corticosteroid; immunosuppressant	inflammation; asthma; anaphylactic shock; transplant rejection
ORG 6632	21-chloro-9alpha-fluoro-11beta-hydroxy-16alpha,17alpha-dimethylpregna-1,4-diene-3,20-dione	corticosteroid; immunosuppressant	cancer; rheumatoid arthritis

gene therapy, soluble TNF receptor; gene therapy, corneal transplant rejection	unspecified	cytokine antagonist	transplant rejection
interferon gamma antagonists, Pharmacopeia; interferon gamma antagonists, Regeneron	unspecified	cytokine antagonist; immunosuppressant	autoimmune disease
interleukin-12 signal transduction antagonists, Ligand	unspecified	cytokine antagonist; immunosuppressant; NSAID	autoimmune disease; transplant rejection; rheumatoid arthritis
RP 54745	4-chloro-5-(3,4- dihydro-1-methyl- 2(1H)-isoquinoliny)- 3H-1,2-dithiol-3-one	cytokine antagonist; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; psoriasis
interleukin-8 receptor; IL-8r	unspecified	cytokine antagonist; NSAID; immunosuppressant	allergy; inflammation; transplant rejection
interleukin-1 receptor; IL-1r; HJ 1306	unspecified	cytokine inhibitor; immunosuppressant	asthma
uromodulin	unspecified	cytokine inhibitor; immunosuppressant	autoimmune disease
anakinra; interleukin- 1 receptor antagonist; IL-1ra; interleukin-1 inhibitor; ANTRIL	N2-L- methionylinterleukin 1 receptor antagonist (human isoform x reduced)	cytokine inhibitor; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; transplant rejection; asthma; septic shock
interleukin-7 receptor; IL-7r	unspecified	cytokine inhibitor; NSAID; immunosuppressant	allergy; inflammation; transplant rejection
Sc1CIDs	unspecified	cytokine inhibitor; NSAID; immunosuppressant; TNF inhibitor; phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	autoimmune disease; inflammation

interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSIF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
CI 959	5-methoxy-3-(1- methylethoxy)-N-1H- tetrazol-5-yl- benzo[b]thiophene-2- carboxamide sodium salt	degranulation inhibitor; immunosuppressant; NSAID	rhinitis; inflammation; asthma; arthritis
MDAM	N-[4-[2-(2,4-diamino- 6- pteridiny]ethyl]benzo yl]-4-methylene-DL- glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma
prinomide; prinomide tromethamine; CGS 10787; CGS 10787B	alpha-cyano-1- methyl-beta- oxopyrrole-2- propionanilide with 2- amino- 2- (hydroxymethyl)-1,3- propanediol	DMARD; analgesic; immunosuppressant; NSAID	inflammation; pain; rheumatoid arthritis
actarit; MS 932; MOVER; ORCL	4- (acetylamino)phenyla cetic acid	DMARD; immunosuppressant; NSAID	rheumatoid arthritis
superoxide dismutase manganese complex; hMNSOD	unspecified	free radical scavenger; NSAID; immunosuppressant	ischemia; rheumatoid arthritis; inflammation; reperfusion injury
superoxide dismutase variants; SOD	unspecified	free radical scavenger; NSAID; immunosuppressant	inflammation; autoimmune disease; reperfusion injury
interleukin-4 diphtheria toxin chimeric protein; IL-4 diphtheria toxin chimeric protein; IL-4 fusion protein	unspecified	fusion toxin; immunosuppressant	autoimmune disease; transplant rejection; cancer; HIV infection
gene therapy, transplant rejection	unspecified	gene therapy; biotechnology; immunosuppressant	transplant rejection

gene cytokines therapy	unspecified	gene therapy; cytokine; immunosuppressant	autoimmune disease; rheumatoid arthritis; diabetes; multiple sclerosis
gene expression regulation technology,	unspecified	gene therapy; genomics; immunosuppressant	delivery system; drug design technology; graft versus host disease; transplant rejection
herpes simplex thymidine kinase; gene therapy, HS-tk	unspecified	gene therapy; immunosuppressant	transplant rejection
herpes simplex thymidine kinase; gene therapy, HS tk; gene therapy, graft versus host disease	unspecified	gene therapy; immunosuppressant	transplant rejection
glucocorticoids, Hoechst Marion Roussel	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation
glucocorticoids, Ligand	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation; asthma; autoimmune disease
castanospermine	[1S-(1alpha,6beta,7alpha,8beta,8abeta)]-octahydro-1,6,7,8-indolizine tetrol	glycosidase inhibitor; immunosuppressant	autoimmune disease; viral infection
MDL 28842	(Z)-9-(5-deoxy-5-fluoro-beta-D-threo-pent-4-enofuranosyl-9H-purin-6-one	homocysteine hydrolase inhibitor; immunosuppressant	malaria; autoimmune disease
lymphocyte activation inhibitors, Celltech	unspecified	immunostimulant	autoimmune disease; transplant rejection
geclosporin; ciclosporin G; ciclosporin G; ciclosporin, (NVA)2-; ciclosporin, (NVA)2-; OG 37325	7-L-norvaline ciclosporin A	immunostimulant	transplant rejection



RM 06	N-[N-[[[5-(1,6-dihydro-6-oxo-9H-purin-9-yl)pentyl]oxy]carbonyl]-L-leucyl]-L-methionine	immunostimulant	cancer; transplant rejection
T cell modulators, ArQule; T cell modulators, T Cell Sciences	unspecified	immunostimulant; immunosuppressant	infectious disease; autoimmune disease
thiethazole	2-[1-(1,1-dioxothiethanyl-3)benzimidazolyl-2-thio] acetic acid	immunostimulant; immunosuppressant; antioxidant	cancer; rheumatoid arthritis; infectious disease; transplant rejection
FCE 20696	6H-dibenzo[b,d]pyran-6-carboxylic acid 2-(dimethylamino)ethyl ester hydrochloride	immunostimulant; immunosuppressant; NSAID	viral infection; rheumatoid arthritis
thymidine kinase; gene therapy, HS-tk	unspecified	immunosuppressant	transplant rejection; eye disease
AI 101	unspecified	immunosuppressant	multiple sclerosis
AI 301	unspecified	immunosuppressant	eye disease
B7 molecules; B7-1; B7-2	unspecified	immunosuppressant	autoimmune disease; transplant rejection
cholera toxin subunit B-antigen conjugate	unspecified	immunosuppressant	autoimmune disease
Fc receptors, soluble, InKine	unspecified	immunosuppressant	autoimmune disease
galactin L-14-1; immunomodulatory lectin-1; IML-1	unspecified	immunosuppressant	transplant rejection; multiple sclerosis
IgE receptors, soluble, CorBec	unspecified	immunosuppressant	asthma
interferon receptor type 1; IFNAR2	unspecified	immunosuppressant	autoimmune disease
MAb, CD45RB	unspecified	immunosuppressant	transplant rejection; autoimmune disease
MAb, humanized B7.1	unspecified	immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MAb, humanized B7.2	unspecified	immunosuppressant	psoriasis; transplant rejection; autoimmune disease

MEDI 507	unspecified	immunosuppressant	autoimmune disease; transplant rejection; psoriasis
OX40-IgG fusion protein	unspecified	immunosuppressant	inflammatory bowel disease
PEPTIMER	unspecified	immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes
recombinant alpha3 collagen chain; BST 3002	unspecified	immunosuppressant	kidney disease
recombinant alpha3 collagen chain; BST 3003	unspecified	immunosuppressant	kidney disease; systemic lupus erythematosus
RG 1046	unspecified	immunosuppressant	autoimmune disease; transplant rejection
T cell antigen receptor technology; TCAR technology	unspecified	immunosuppressant	research tool; autoimmune disease
AI 100; MYLORAL	unspecified	immunosuppressant	multiple sclerosis
AI 102	unspecified	immunosuppressant	multiple sclerosis
AI 300	unspecified	immunosuppressant	eye disease
asthma/allergy therapy, Rigel	unspecified	immunosuppressant	asthma; allergy
autoimmune disease therapy, Genome Pharmaceuticals	unspecified	immunosuppressant	autoimmune disease
BCH 1200	unspecified	immunosuppressant	HIV infection
BTS 63155	unspecified	immunosuppressant	autoimmune disease
calcineurin inhibitor, Agouron	unspecified	immunosuppressant	autoimmune disease; neurological
CI 0694; SULFASIM	unspecified	immunosuppressant	HIV infection
CT 2544	unspecified	immunosuppressant	autoimmune disease; transplant rejection
CT 3578	unspecified	immunosuppressant	transplant rejection
cytomuline	unspecified	immunosuppressant	transplant rejection
D 22557	unspecified	immunosuppressant	allergy; asthma
D 7193	unspecified	immunosuppressant	asthma
D5; PM 92114	unspecified	immunosuppressant	cancer
drug delivery system, CYTOPORTER ciclosporin	unspecified	immunosuppressant	transplant rejection

drug delivery system, HILT, ciclosporin; ciclosporin, HILT, psoriasis; CYCLOPS	unspecified	immunosuppressant	psoriasis
drug delivery system, LDS microemulsion ciclosporin; ciclosporin LDS microemulsion	unspecified	immunosuppressant	autoimmune disease; transplant rejection
drug delivery system, liposome ciclosporin; ciclosporin liposome	unspecified	immunosuppressant	transplant rejection
drug delivery system, liposome ciclosporin; ciclosporin liposome; LipoSPOR	unspecified	immunosuppressant	psoriasis
drug delivery system, microemulsion ciclosporin; ciclosporin microemulsion; SANDIMMUN NEORAL; SANDIMMUN OPTORAL; NEORAL; NEORAL- SANDIMMUN	unspecified	immunosuppressant	autoimmune disease; transplant rejection
fluasterone	unspecified	immunosuppressant	cancer; diabetes; systemic lupus erythematosus
gene discovery, autoimmune disease, deCODE genetics	unspecified	immunosuppressant	autoimmune disease
gliotoxin	unspecified	immunosuppressant	transplant rejection
glycophospholipid, Graves' disease, City of Hope	unspecified	immunosuppressant	autoimmune disease
IgE receptor inhibitors, InKine	unspecified	immunosuppressant	asthma
immunology/inflamm ation therapy, Rigel	unspecified	immunosuppressant	inflammation; autoimmune disease; asthma

immunophilins, Vertex; immunophilins, Chugai	unspecified	immunosuppressant	autoimmune disease
immunoregulators, T Cell Sciences; immunoregulators, MYCOsearch	unspecified	immunosuppressant	autoimmune disease
immunoregulatory colostrum isolate	unspecified	immunosuppressant	autoimmune disease
immunosuppressant, Hollis Eden	unspecified	immunosuppressant	autoimmune disease; transplant rejection
immunosuppressant, Rhone-Poulenc Rorer	unspecified	immunosuppressant	asthma
immunosuppressants, Agouron	unspecified	immunosuppressant	autoimmune disease; asthma
immunosuppressants, AstraZeneca; immunosuppressants, University of California	unspecified	immunosuppressant	transplant rejection; autoimmune disease
immunosuppressants, Kinetix	Unspecified	immunosuppressant	autoimmune disease; transplant rejection
immunosuppressants, Millennium	unspecified	immunosuppressant	autoimmune disease
immunosuppressants, Nanodesign	unspecified	immunosuppressant	autoimmune disease
immunosuppressants, ZAP70, Roche; immunosuppressants, ZAP70, BioFocus	unspecified	immunosuppressant	autoimmune disease
insulin-dependent diabetes therapy, Procept	unspecified	immunosuppressant	diabetes
interferon gamma inhibitor, PharmaGenics	unspecified	immunosuppressant	septic shock; autoimmune disease
interleukin-2 receptor ligand, Affymax	unspecified	immunosuppressant	transplant rejection; autoimmune disease
ion channel modulators, ArQule; ion channel modulators, ICAgen	unspecified	immunosuppressant	cardiovascular disease; neurological; autoimmune disease

leptin antagonists, Imperial College	unspecified	immunosuppressant	autoimmune disease; transplant rejection
LF 150195	unspecified	immunosuppressant	autoimmune disease
LJP 394	unspecified	immunosuppressant	systemic lupus erythematosus
LJP 920	unspecified	immunosuppressant	transplant rejection
LZ 8	unspecified	immunosuppressant	autoimmune disease
microcolins	unspecified	immunosuppressant	autoimmune disease
NE 501	unspecified	immunosuppressant	transplant rejection
promedulan; TERICIMUS	unspecified	immunosuppressant	cancer
rapamycin analogue, Reading University	unspecified	immunosuppressant	autoimmune disease
Rh toleragens	unspecified	immunosuppressant	autoimmune disease
RWJ 60475	unspecified	immunosuppressant	transplant rejection
spiperone analogues, Arcturus	unspecified	immunosuppressant	skin disease
Stat4/Stat6 blockers, Tularik	unspecified	immunosuppressant	autoimmune disease; allergy
T cell modulators, Fisons	unspecified	immunosuppressant	asthma; rhinitis; conjunctivitis; allergy
VE 19613	unspecified	immunosuppressant	autoimmune disease
VX 10367	unspecified	immunosuppressant	transplant rejection
VX 497	unspecified	immunosuppressant	psoriasis; autoimmune disease; viral infection; hepatitis
Xe 9	unspecified	immunosuppressant	transplant rejection
XENOJECT	unspecified	immunosuppressant	cancer; autoimmune disease
ZAP 70 modulators, Pharmacoepia	unspecified	immunosuppressant	transplant rejection
oxamisole; PR 879317A	(+,-)-2,3,5,6,7,8- hexahydro-8,8- dimethoxy-2-phenyl- imidazo(1,2-a)- pyridine	immunosuppressant	viral infection

gusperimus; gusperimus hydrochloride; deoxyspergualin, 15-; desoxyspergualin; DSG; NKT 01; NSC 356894; BMS 181173; BMY 42215- 1; SPANIDIN; SUPANIDIN	(+,-)-7- [(aminoiminomethyl) amino]-N-[2-[[4-[(3- aminopropyl)amino]b utyl]amino]-1- hydroxy-2- oxoethyl]heptanamide	immunosuppressant	transplant rejection; multiple sclerosis; cancer
FR 901483	(2 alpha,5 beta, 6 beta, 7 beta, 8 beta, 10a beta)-octahydro- 5-[(4- methoxyphenyl)meth yl]-2-(methylamino)- 1H-7,10a- methanopyrrolo[1,2- a]azocine-6,8-diol, 8- (dihydrogen phosphate)	immunosuppressant	transplant rejection
PRO 1556	(OC-6-11)- hexakis(1H- imidazole- kappaN3)ruthenium(2 +) dichloride	immunosuppressant	transplant rejection
PRO 2844	(OC-6-22)- pentaammine(4- methylpyridine)ruthen ium(3+) trichloride	immunosuppressant	psoriasis; autoimmune disease; transplant rejection
myriocin; thermozymocidin; ISP-I	[2S- (2R*,3S*,4S*,6E)]-2- amino-3,4-dihydroxy- 2-(hydroxymethyl)- 14-oxo-6-eicosenoic acid	immunosuppressant	autoimmune disease; transplant rejection

bactobolamine	[3S-(3alpha,4alpha,4abeta,5beta,6alpha)]-4-amino-3-(dichloromethyl)-3,4,4a,5,6,7-hexahydro-5,6,8-trihydroxy-3-methyl-1H-2-benzopyran-1-one	immunosuppressant	autoimmune disease
discodermolide	[3S-(3alpha,4beta,5beta,6alpha(2R*,3Z,5R*,6R*,7S*,8Z,11R*,12S*,13S*,14S*,15R*,16E))] -6-[14-[(aminocarbonyl)oxy]-2,6,12-trihydroxy-5,7,9,11,13,15-hexamethyl-3,8,16,18-nonadecatetracnyl]tetrahydro-4-hydroxy-3,5-dimethyl-2H-pyran-2-one	immunosuppressant	transplant rejection
tresperimus; LF 80299; LF 299	[4-[(3-aminopropyl)amino]butyl]carbamic acid 2-[[6-[(aminoiminomethyl)amino]hexyl]amino]-2-oxoethyl ester	immunosuppressant	autoimmune disease
SKF 106610	2-[3-(1-piperidinyl)propyl]-8,8-dipropyl-2-azaspiro[4.5]decane dihydrochloride	immunosuppressant	autoimmune disease
oxeclosporin; SDZ IMM 125; IMM 125	2-[O-(2-hydroxyethyl)-D-serine]-cyclosporin A	immunosuppressant	asthma
FTY 720	2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride	immunosuppressant	transplant rejection; autoimmune disease

HMR 1715	2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-6-heptynamide	immunosuppressant	transplant rejection
SM 8849	4-[1-(2-fluoro-4-biphenyl)ethyl]-2-methylaminothiazole	immunosuppressant	autoimmune disease
SDZ RAD	42-O-(2-hydroxyethyl)rapamycin	immunosuppressant	transplant rejection
dinaline; GOE 1734; NSC 328786; AAPBA	4-amino-N-(2-aminophenyl)benzamide	immunosuppressant	cancer
FR 901459	4-L-leucine-7-L-threonine-10-L-leucine-cyclosporin A	immunosuppressant	autoimmune disease
prodigiosin 25-C; prodigiosin	4-methoxy-5-[(5-methyl-4-pentyl-2H-pyrrol-2-ylidene)methyl]-2,2'-bi-1H-pyrrole	immunosuppressant	autoimmune disease
TOK 8801	5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)imidazo[2,1-b]thiazole-2-carboxamide	immunosuppressant	autoimmune disease
esonarimod; KE 298	alpha-[(acetylthio)methyl]-4-methyl-gamma-oxobenzenebutanoic acid	immunosuppressant	rheumatoid arthritis
HMR 1279	alpha-cyano-N-(4-cyanophenyl)-beta-oxocyclopropanepropionamide	immunosuppressant	transplant rejection
dehydrodidemnin B; DDB	N-[1-(1,2-dioxopropyl)-L-prolyl]didemnin A	immunosuppressant	viral infection; cancer
YM 13650	propanedioic acid, mono(3-imidazo[2,1-b]benzothiazol-2-ylphenyl) ester	immunosuppressant	transplant rejection
IR 1116	Unspecified	immunosuppressant	autoimmune disease
LCB 2183	Unspecified	immunosuppressant	rhinitis; dermatitis; asthma



aldose reductase inhibitors, Washington Research Foundation	unspecified	immunosuppressant; aldose reductase inhibitor; NSAID	autoimmune disease; allergy; inflammation
rapamycin analogues	unspecified	immunosuppressant; antifungal	transplant rejection; mycosis
antisense oligonucleotide, ICAM-1; antisense oligonucleotide, intracellular adhesion molecule-1; ISIS 2302	d[(R)-P-thio](G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A) DNA	immunosuppressant; antisense; oligonucleotide; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease; asthma
antibody-mediated stroke inhibitor	unspecified	immunosuppressant; biotechnology	gynecological; stroke; thrombosis; myocardial infarction
lymphocyte activation gene 3 protein; LAG 3 protein	unspecified	immunosuppressant; biotechnology	transplant rejection; multiple sclerosis
MAb, gp39; BMS 202448	unspecified	immunosuppressant; biotechnology	autoimmune disease
MAb, interleukin-2 receptor; MAb, IL-2R	unspecified	immunosuppressant; biotechnology	transplant rejection
apoptosis-inducing antigen, diabetes; IG 2; IG2	unspecified	immunosuppressant; biotechnology; apoptosis inducer	diabetes
MP 4	unspecified	immunosuppressant; biotechnology; apoptosis inducer	multiple sclerosis
apoptosis-inducing antigen, rheumatoid arthritis	unspecified	immunosuppressant; biotechnology; apoptosis inducer; NSAID	rheumatoid arthritis
monocyte colony inhibitory factor-1, Human Genome Sciences	unspecified	immunosuppressant; biotechnology; chemokine	autoimmune disease; rheumatoid arthritis; systemic lupus erythematosus
AI 401	unspecified	immunosuppressant; biotechnology; hormone	diabetes
AI 201	unspecified	immunosuppressant; biotechnology; NSAID	rheumatoid arthritis

AI 402	unspecified	immunosuppressant; biotechnology; peptide	diabetes
AI 502	unspecified	immunosuppressant; biotechnology; peptide	transplant rejection
ATP 012; TP 12	unspecified	immunosuppressant; biotechnology; peptide	multiple sclerosis
AI 202	unspecified	immunosuppressant; biotechnology; peptide; NSAID	rheumatoid arthritis
chemokine receptor antagonists, ICOS	unspecified	immunosuppressant; chemokine antagonist; cytokine antagonist	autoimmune disease
soluble complement receptor type 1; sCR1; TP 10; TP 10HD; BRL 55730; YM 55730	unspecified	immunosuppressant; complement inhibitor	respiratory distress syndrome; heart ischemia; transplant rejection
CBP 1011	unspecified	immunosuppressant; corticosteroid	autoimmune disease; systemic lupus erythematosus; asthma
CBP 2011	unspecified	immunosuppressant; corticosteroid	autoimmune disease; thrombocytopenia
CBP 2012	unspecified	immunosuppressant; corticosteroid	autoimmune disease; thrombocytopenia
D 22558	unspecified	immunosuppressant; cytokine inhibitor	asthma; allergy
autoimmune disease- specific MHC blockers, 3 Dimensional Pharmaceuticals	unspecified	immunosuppressant; DMARD; NSAID	rheumatoid arthritis; autoimmune disease
Bcl-x gamma-based therapy, Boston Life Sciences; autoimmune disease therapy, Boston Life Sciences	unspecified	immunosuppressant; gene; apoptosis inducer	autoimmune disease

polyclonal antibody; rabbit antithymocyte; immunoglobulin; rabbit antithymocyte; rabbit antithymocyte immunoglobulin; THYMOGLOBULIN	unspecified	immunosuppressant; immunoglobulin; polyclonal antibody	transplant rejection; aplastic anemia
protein A-based immune modulator	unspecified	immunosuppressant; immunostimulant	autoimmune disease; cancer
ZYN-LINKER conjugated superantigens	unspecified	immunosuppressant; immunostimulant; NSAID	rheumatoid arthritis; cancer
signal transduction modulators, National Jewish Center for Immunology and Respiratory Medicine	unspecified	immunosuppressant; immunostimulant; NSAID	autoimmune disease; cancer; inflammation
SDZ 281240	unspecified	immunosuppressant; macrolide; antibiotic	psoriasis
MAb, 33B3.1; MAb, anti-interleukin-2 receptor	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAb, B7.1; MAb, M24; M 24	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAb, CD3 humanized	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAb, H65 humanized Fab'	unspecified	immunosuppressant; monoclonal antibody	autoimmune disease
MAb, T10B9; T10B9.1A-31; MEDI 500	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAb, UCHL1; MAb, CD45RO	unspecified	immunosuppressant; monoclonal antibody	autoimmune disease
MAbs, organ transplantation; TOLERIMAB	unspecified	immunosuppressant; monoclonal antibody	transplant rejection

inolimomab; MAb, IL-2 receptor CD25; MAb, interleukin-2 receptor CD25; BT 563; LEUKOTAC	immunoglobulin G 1 (mouse monoclonal B-B10.gamma.-chain anti-human interleukin 2 receptor.alpha.-chain), disulfide with mouse monoclonal B-B10.kappa.-chain, dimer	immunosuppressant; monoclonal antibody	transplant rejection
MAb, BC3	unspecified	immunosuppressant; monoclonal antibody; biotechnology	transplant rejection
MAb, CD3-immunotoxin	unspecified	immunosuppressant; monoclonal antibody; biotechnology; immunotoxin	transplant rejection; autoimmune disease
MAb, gp39; MAb, arthritis	unspecified	immunosuppressant; monoclonal antibody; NSAID	rheumatoid arthritis
MAb, MHC class II; CDP 855	unspecified	immunosuppressant; monoclonal antibody; NSAID	autoimmune disease; systemic lupus erythematosus
MAb, R73; MAb, rat alpha/beta T cell receptor	unspecified	immunosuppressant; monoclonal antibody; NSAID	transplant rejection; rheumatoid arthritis
priliximab; MAb, humanized CD4; cM-T412; CEN 000029; CENTARA	immunoglobulin G1 (human-mouse monoclonal cm-T412 anti-human antigen CD 4), disulfide with human-mouse monoclonal cm-T412.kappa.-chain, dimer	immunosuppressant; monoclonal antibody; NSAID	multiple sclerosis; autoimmune disease; rheumatoid arthritis
IRA 378	(S)-8-chloro-1,2,3,4-tetrahydro-2-(trifluoromethyl)-6-quinolineacetic acid	immunosuppressant; nitric oxide synthase inhibitor; NSAID	rheumatoid arthritis
BMS 188667; CTLA4Ig	unspecified	immunosuppressant; NSAID	transplant rejection; systemic lupus erythematosus; psoriasis; arthritis; allergy

C-Maf based therapy	unspecified	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis
corticotropin releasing factor binding protein; CRF binding protein; NBI 112	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; inflammation
E 21R	unspecified	immunosuppressant; NSAID	cancer; inflammation; allergy
lenercept; tumor necrosis factor receptor fusion protein; TNF receptor fusion protein; Ro 452081; TENEFUSE	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; asthma; septic shock; multiple sclerosis
leukocyte function associated antigen 3 T cell inhibitor protein; LFA3TIP; LFA3TIP; AMEVIVE	unspecified	immunosuppressant; NSAID	inflammation; autoimmune disease; psoriasis
MAb, CD40 ligand; 5C8; ANTOVA	unspecified	immunosuppressant; NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
autoimmune disease therapy, Molecumetics/Bristol -Myers Squibb	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; multiple sclerosis; systemic lupus erythematosus
BN 58705	unspecified	immunosuppressant; NSAID	septic shock; inflammation
BW 91Y78	unspecified	immunosuppressant; NSAID	inflammation
CD2 binding agents, Procept	unspecified	immunosuppressant; NSAID	rheumatoid arthritis
CD4 inhibitors, Procept; CD4 inhibitors, Novartis	unspecified	immunosuppressant; NSAID	inflammation
CT 2576	unspecified	immunosuppressant; NSAID	HIV infection; rheumatoid arthritis
immunoregulators, AVANT Immunotherapeutics; immunoregulators, Repligen	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma

inflammation therapy, Genzyme/LeukoSite	unspecified	immunosuppressant; NSAID	inflammatory bowel disease; inflammation; autoimmune disease
PG 12	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PG 27	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PG 2946	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3028	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3113	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 94	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PIC 060 analogs	unspecified	immunosuppressant; NSAID	psoriasis; dermatitis; diabetes; transplant rejection; rheumatoid arthritis
PIC 101	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; autoimmune disease; transplant rejection
PIC 102	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
PIC 231	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
Ro 236457	unspecified	immunosuppressant; NSAID	inflammation
VX 10393	Unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
VX 10428	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes

phellodendrine; OB 5	(7S-cis)-5,8,13,13a-tetrahydro-2,11-dihydroxy-3,10-dimethoxy-7-methyl-6H-dibenzo[a,g]quinolizinium	immunosuppressant; NSAID	transplant rejection; inflammation; viral infection; asthma; kidney disease
TEI 1338	(E)-N-(2-methoxycarbonylphenyl)-8-(2-naphthyl)-5,6-trans-5,6-methano-7-octenamide	immunosuppressant; NSAID	allergy; inflammation
laflunimus; HR 325	(Z)-2-cyano-3-cyclopropyl-3-hydroxy-N-[3-methyl-4-(trifluoromethyl)phenyl]-2-propenamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; psoriasis
TEI 3332	[(6,7-dihydroxy-2-naphthalenyl)thio]acetic acid methyl ester	immunosuppressant; NSAID	allergy; inflammation
SCH 24937	1-[6-bromo-5-chloro-3-(2-pyridinyl)-1H-indol-2-yl]-2-(methylsulfinyl)ethanone	immunosuppressant; NSAID	rheumatoid arthritis
KF 20444	10-fluoro-3-(2-fluorophenyl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-b]quinoline-8-carboxylic acid	immunosuppressant; NSAID	rheumatoid arthritis
KB 2683	2-(4-methylphenyl)-4-benzothiazolol acetate	immunosuppressant; NSAID	rheumatoid arthritis; inflammation; autoimmune disease
CI 972	2,6-diamino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; cancer; psoriasis

MX 68	2-[[[4-[2,4-diamino-6-pteridiny]methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl]amino]hexanedioic acid	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease
albifylline; HWA 138	3,7-dihydro-1-(5-hydroxy-5-methylhexyl)-3-methyl-1H-purine-2,6-dione	immunosuppressant; NSAID	septic shock; inflammation
baohuoside I; icariside II; B-1	3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one	immunosuppressant; NSAID	systemic lupus erythematosus; rheumatoid arthritis
CL 306293	3-amino-2-[1,1'-biphenyl]-4-yl-6-fluoro-4-quinolinecarboxylic acid	immunosuppressant; NSAID	arthritis; HIV infection
amiprilose; amiprilose hydrochloride; THN; SM 1213; KAP 690; THERAFECTIN	3-O-(3-(dimethylamino)propyl)-1,2-O-isopropylidene-alpha-D-glucofuranose hydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; psoriasis
TAK 603	4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1H-1,2,4-triazol-1-ylmethyl)-3-quinolinecarboxylic acid ethyl ester	immunosuppressant; NSAID	rheumatoid arthritis
mizoribine; HE 69; BREDININ	5-hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; kidney disease
TA 383	cis-2-(4-chlorophenyl)-4,5-dihydro-4,5-diphenyl-1H-imidazole monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis



SKF 105685	N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dihydrochloride	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis; HIV infection
AI 200; COLLORAL	trimeric (16-1059)alpha1 (II) collagen	immunosuppressant; NSAID	rheumatoid arthritis
atiprimod; atiprimod dimaleate; SKF 106615	N,N-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine	immunosuppressant; NSAID; macrophage inhibitor	rheumatoid arthritis; autoimmune disease; psoriasis
celastrol	unspecified	immunosuppressant; NSAID; terpene	inflammation
CD45 inhibitors, Ontogen	unspecified	immunosuppressant; NSAID; tyrosine phosphatase inhibitor	transplant rejection; inflammation
cladribine; 2-CdA; NSC 105014F; RWJ 26251; LEUSTATIN; LEUSTAT; MYLINAX	2-chloro-2'-deoxyadenosine	immunosuppressant; nucleoside analogue; NSAID	cancer; multiple sclerosis; rheumatoid arthritis
calcineurin inhibitory peptides, Oregon Health Sciences University	unspecified	immunosuppressant; peptide	autoimmune disease
human leukocyte antigen-derived protein; HLA-derived protein; ALLOTRAP 2702	unspecified	immunosuppressant; peptide	transplant rejection
immunosuppressant peptides, SangStat; immunosuppressant peptides, Syntem	unspecified	immunosuppressant; peptide	transplant rejection; autoimmune disease
T cell peptide, University of Illinois	unspecified	immunosuppressant; peptide	autoimmune disease; cancer; bacterial infection
PP 14	unspecified	immunosuppressant; peptide; NSAID	autoimmune disease; rheumatoid arthritis
potassium channel blocker, Merck & Co	unspecified	immunosuppressant; potassium channel blocker	autoimmune disease; allergy; inflammation

ZAP inhibitors, Ariad	unspecified	immunosuppressant; protein kinase inhibitor; tyrosine kinase inhibitor; NSAID	transplant rejection; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythematosus; multiple sclerosis
autoimmune disease therapy, Peptimmune	unspecified	immunosuppressant; proteinase inhibitor	autoimmune disease
PEGylated p75 TNFR Fc mutein	unspecified	immunosuppressant; TNF inhibitor	rheumatoid arthritis
lclunomide; HWA 486; ARAVA	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	immunosuppressant; tyrosine kinase inhibitor; NSAID; DMARD	rheumatoid arthritis; autoimmune disease
alpha4 beta7 antagonists, LeukoSite/Warner Lambert	unspecified	integrin antagonist; alpha4 beta7 integrin antagonist; cell adhesion inhibitor	Crohn disease; inflammatory bowel disease
CDP 850	unspecified	integrin antagonist; biotechnology; cell adhesion inhibitor; immunosuppressant; monoclonal antibody; E selectin antagonist	cancer
MAb, ICAM-3; MAb, intracellular adhesion molecule-3; MAb, ICAM-R; ICM3	unspecified	integrin antagonist; biotechnology; cell adhesion inhibitor; immunosuppressant; monoclonal antibody	autoimmune disease; psoriasis
MAb, B11; MAb, E-selectin; MAb, endothelium leukocyte adhesion molecule	unspecified	integrin antagonist; biotechnology; immunosuppressant; monoclonal antibody; E selectin antagonist; cell adhesion inhibitor; NSAID	inflammation
MAb, L-selectin, humanized; SMART anti-L-selectin; HuDREG 200	unspecified	integrin antagonist; biotechnology; monoclonal antibody; cell adhesion inhibitor; immunosuppressant; L selectin antagonist	trauma; respiratory distress syndrome; autoimmune disease; reperfusion injury

GM 1676	unspecified	integrin antagonist; cell adhesion inhibitor; immunosuppressant; NSAID	inflammation
selectin antagonists, Oxford GlycoSciences	unspecified	integrin antagonist; P selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation
low molecular weight selectin inhibitors, Kanebo/Ontogen	Unspecified	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation; allergy
TBC 427	unspecified	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor	ischemia; psoriasis; respiratory distress syndrome; transplant rejection; reperfusion injury
TBC 1269	3',3'''-(1,6- hexanediyl)bis[6'- (alpha-D- mannopyranosyloxy)- [1,1'-biphenyl]-3- acetic acid	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation; asthma
interferon, modified, Tanox	unspecified	interferon; biotechnology; immunosuppressant	cancer
microcolin A	N-(2,4-dimethyl-1- oxooctyl)-N- methylleucyl-N-[1- [[2-[(2,5-dihydro-2- methyl-5-oxo-1H- pyrrol-1-yl)carbonyl]- 4-hydroxy-1- pyrrolidinyl]carbonyl]- 2-methylpropyl]-N- methylthreoninamide, 23-acetate	lipopeptide; immunosuppressant	autoimmune disease
drug delivery system, NanoCrystal sirolimus; sirolimus NanoCrystal	unspecified	macrolide; antibiotic; immunosuppressant	transplant rejection

sirolimus; rapamycin; NSC 226080; AY 22989; RAPAMUNE	(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacycloheptriacontine-1,5,11,28,29(4H,6H,31H)-pentone	macrolide; immunosuppressant; antibiotic	transplant rejection; autoimmune disease; restenosis
tacrolimus; tsukubaenolide; fujimycin; FK 506; (-)-FK 506; FR 900506; L 679934; PROGRAF; PROTÓPIC	[3S-[3R*[E(1S*,3S*,4S*),4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone	macrolide; immunosuppressant; NSAID; antibiotic	transplant rejection; dermatitis; eye disease; rheumatoid arthritis
MAb, red blood cell D antigen; MAb, rhesus D; AM 101	unspecified	monoclonal antibody; biotechnology; immunosuppressant	autoimmune disease

MAB, interleukin-12; MAB, IL-12; J695; C17.15	unspecified	monoclonal antibody; cytokine antagonist; immunosuppressant	autoimmune disease
MAB, Fv, cytokine; CDP 870	unspecified	monoclonal antibody; cytokine inhibitor; immunosuppressant	rheumatoid arthritis; autoimmune disease
MAB 2E1; MAB, effector cell proteinase receptor-1	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, 1C7; passive immunotherapy, systemic lupus erythematosus	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus
MAB, 6G5.1; MAB, autoimmune disease, human, Medarex; MDX CD4	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; rheumatoid arthritis
MAB, alpha-tubulin	unspecified	monoclonal antibody; immunosuppressant	cancer; autoimmune disease; diagnosis
MAB, autoimmune disease; MAB, MHC II	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAB, BMA 031	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, CD11a; hu 1124	unspecified	monoclonal antibody; immunosuppressant	psoriasis; transplant rejection
MAB, CD45; LM CD45	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, CD45RB	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, CD7; SDZ CHH 380	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, Fc antagonist; MDX 33	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; thrombocytopenia
MAB, gamma interferon, humanized; SMART anti-gamma interferon	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus; multiple sclerosis
MAB, gp39; MAB, CD40L; IDEC 131	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection; systemic lupus erythematosus
MAB, H57597	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease

MAB, humanized CD3; MAb, SMART CD3; HuM291	unspecified	monoclonal antibody; immunosuppressant	transplant rejection; autoimmune disease; psoriasis
MAB, inflammation therapy, LeukoSite/MorphoSy	unspecified	monoclonal antibody; immunosuppressant	inflammation; autoimmune disease
MAB, interleukin-10; MAB, IL-10	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus
MAB, interleukin-5; MAB, IL-5; SCH 55700; CDP 835	unspecified	monoclonal antibody; immunosuppressant	asthma
MAB, L0-CD2a; BTI 322	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, major histocompatibility complex I; F(ab') <sub>2</sub> , MHC I	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, MHC II-CD4; 14-CD4	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; graft versus host disease
MAB, MHCII-CD8	unspecified	monoclonal antibody; immunosuppressant	transplant rejection; graft versus host disease
MAB, migis-mIgG; Mab, B cell	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAB, RhCA 61-76; MAB, anti-AChR alpha subunit; TCM 240	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAB, T cell antigen receptor; ATM 027; TM 27	unspecified	monoclonal antibody; immunosuppressant	multiple sclerosis
MAB, T cell antigen receptor; TM 29	unspecified	monoclonal antibody; immunosuppressant	cancer; Crohn disease
MAB, transplant rejection; CBL1; ABX CBL	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAbs, B cells; migis	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; cancer

daclizumab; dacliximab; MAb, Tac; MAb, humanized Tac; MAb, SMART Tac; Ro 247375; ZENAPAX	immunoglobulin G1 (human-mouse monoclonal clone 1H4 gamma chain anti-human antigen Tac), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection; cancer; autoimmune disease; eye disease
odulimomab; MAb, LFA-1 alpha subunit	immunoglobulin G1, anti-(human CD11 (antigen).alpha.- chain)(mouse monoclonal 25.3.gamma.1-chain), disulfide with mouse monoclonal 25. 3 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection
basiliximab; SDZ CHI621; CHI 621; SIMULECT	Immunoglobulin G1, anti-(human interleukin 2 receptor) (human-mouse monoclonal CHI621 .gamma.1- chain),disulfide with human-mouse mo noclonal CHI621 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection
MAb, CD6 blocked ricin; MAb, T12-bR; ONCOLYSIN CD6	unspecified	monoclonal antibody; immunosuppressant; immunotoxin	transplant rejection
MAb, MHC class II	unspecified	monoclonal antibody; immunosuppressant; NSAID	autoimmune disease; transplant rejection; graft versus host disease; cancer
MAb, T cell receptor; TM 31	unspecified	monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis
MAb, CD5- momordin; immunotoxin CD5- momordin; ITF 1532	unspecified	monoclonal antibody; immunotoxin; immunosuppressant	cancer; transplant rejection

zolimomab aritox; MAb, H65 RTA; MAb, bone marrow- ricin A conjugate; CD5-T lymphocyte immunotoxin; MAb, CD5; XMMLY H65 RTA; XOMAZYME H65; XOMAZYME CD5+; ORTHOZYME CD5+; CD5 Plus	unspecified	monoclonal antibody; immunotoxin; immunosuppressant	transplant rejection
MAb, humanized, leukemia; MAb, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	unspecified	monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
MAb, B7; MAb, PRIMATIZED B7; IDEC 114	unspecified	monoclonal antibody; NSAID; immunosuppressant	systemic lupus erythematosus; inflammation; transplant rejection; psoriasis
neuroimmunophilins, KOSAN	unspecified	neurotrophic factor	neurodegeneration
NOX 100	unspecified	nitric oxide scavenger	diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 51	unspecified	nitric oxide scavenger	diabetes; cancer; cardiovascular disease; transplant rejection; septic shock
NOX 101	Unspecified	nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
S 2474	unspecified	NSAID; DMARD; COX inhibitor; COX 2 inhibitor; immunosuppressant	rheumatoid arthritis; autoimmune disease
immune system modulators, OSI	unspecified	NSAID; immunosuppressant	inflammation
NE 0501	unspecified	oligosaccharide	transplant rejection



opioid antagonists, NIH	unspecified	opiate antagonist; peptide; immunosuppressant	addiction; alcoholism; obesity; transplant rejection
recombinant PSGL 1, Genetics Institute; PSGL 1	unspecified	P selectin antagonist; E selectin antagonist; L selectin antagonist; selectin antagonist; NSAID	inflammation; transplant rejection; ischemia; reperfusion injury
AH 21132	cis N-(4-(1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo(c)(1,6)naphthyridin-6-yl)phenyl)-acetamide (Z)-2-butenedioate (1:2)	PAF antagonist; phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
immunosuppressive, ANUTECH	unspecified	peptide; immunosuppressant	autoimmune disease
inflammation therapy, BTG; autoimmune disease therapy, BTG	unspecified	peptide; immunosuppressant	inflammation; autoimmune disease
rD-mPGPtide	unspecified	peptide; immunosuppressant	transplant rejection; multiple sclerosis
transplantation therapy, SangStat	unspecified	peptide; immunosuppressant	transplant rejection
CD4 peptide antagonist, Tocor	unspecified	peptide; immunosuppressant; NSAID	inflammation
complement inhibitors, Lidak	unspecified	peptide; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease; reperfusion injury; respiratory distress syndrome; transplant rejection
D 4418	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; immunosuppressant; bronchodilator	asthma

B669	3-(cyclohexylimino)-3,5-dihydro-N,5-diphenyl-2-phenazinamine	phospholipase activator; immunosuppressant; NSAID	inflammation
polyclonal antibody, tumor necrosis factor alpha; polyclonal antibody, TNFalpha; CytoTAB	unspecified	polyclonal antibody; immunoglobulin; immunosuppressant	septic shock; malaria; restenosis; Crohn disease; graft versus host disease
polyclonal antibody, immune thrombocytopenic purpura; polyclonal antibody, ITP; Rho(D) immune globulin; WinRho SD; WinRho SDF	unspecified	polyclonal antibody; immunosuppressant; immunoglobulin	autoimmune disease; HIV infection
polysaccharide A immunomodulator	unspecified	polysaccharide; immunosuppressant	surgery
ANK 102	Unspecified	polysaccharide; immunosuppressant	autoimmune disease
SPC 100270	unspecified	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant	ischemia; transplant rejection; reperfusion injury
Ro 320432; Ro 32-0432	(S)-3-[8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis

MLR 52; (+)-MLR-52	[9S-(9alpha,10beta,11alpha,12alpha,13alpha)]-2,3,10,11,12,13-hexahydro-11,12-dihydroxy-10-methoxy-9-methyl-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-1m]pyrrolo[3,4-j][1,7]benzodiazonin-1-one	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant	cancer
cathepsin S inhibitors, Axys/Rhone-Poulenc Rorer	unspecified	proteinase inhibitor; cathepsin S inhibitor; NSAID; immunosuppressant	inflammation; autoimmune disease
aloxistatin; trexostatine; EP 4S3; E 64d; E 64; EST	[S-[2alpha,3beta(R*)]]-3-[[[3-methyl-1-[(3-methylbutyl)amino]carbonyl]butyl]amino]carbonyl]oxiranecarboxylic acid ethyl ester	proteinase inhibitor; immunosuppressant	muscular dystrophy
peldesine; BCX 34; BCX 34B	2-amino-1,5-dihydro-7-(3-pyridinylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; immunosuppressant; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection; eye disease; dermatitis; HIV infection
purine nucleoside phosphorylase inhibitors, Chiroscience; PNP inhibitors, Chiroscience	unspecified	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection
mycophenolate mofetil; RS 61443; CellCept	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus

ribozymes, organ transplantation	unspecified	ribozyme; oligonucleotide; immunosuppressant	transplant rejection
SR 31747	(Z)-N[3-chloro-4-cyclohexylphenyl]-2-propenyl]-N-ethyl-cyclohexanamine hydrochloride	sigma antagonist; immunosuppressant; NSAID	autoimmune disease; arthritis
signal transduction inhibitor, SUGEN/ArQule	unspecified	signal transduction inhibitor; immunosuppressant	cancer; diabetes; neurological; autoimmune disease
SP 100030	Unspecified	signal transduction inhibitor; NSAID; immunosuppressant	inflammation; autoimmune disease
ABT 281; A 86281	unspecified	Tacrolimus-like; no immunosuppression	psoriasis
CGS 12970	3-methyl-2-(3-pyridinyl)-1H-indole-1-octanoic acid	thromboxane synthase inhibitor; immunosuppressant	transplant rejection
pirmagrel; CGS 13080	imidazo(1,5-a)pyridine-5-hexanoic acid	thromboxane synthetase inhibitor; immunosuppressant	transplant rejection
tumor necrosis factor binding protein; TBP-1; TBP	unspecified	TNF inhibitor; immunosuppressant	autoimmune disease; reperfusion injury; inflammation; septic shock
etanercept; tumor necrosis factor receptor; TNFr; TNR 001; ENBREL	unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease
thalidomide; SYNOVIR; THALOMID	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection
AP-1 inhibitor, Signal; JNK inhibitor, Signal	unspecified	transcription factor regulator; NSAID; immunosuppressant	inflammation; autoimmune disease; cancer
SC 114	unspecified	triglyceride; immunosuppressant	autoimmune disease; transplant rejection

AP 251	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
p56 lck inhibitors, Celltech	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
ZAP70 inhibitors, Celltech	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
immunosuppressant, Xcyte Therapies	unspecified	Unspecified	psoriasis
LSL 90202	L-lysine monoeicosapentaenoate (1:1)	unspecified	kidney disease
non-ionic surfactant vesicles; NISV	unspecified	vaccine adjuvant; immunosuppressant	rheumatoid arthritis; asthma; inflammation
vaccine, gene-based, autoimmune disease; GENEVAX	unspecified	vaccine; gene therapy; immunosuppressant	autoimmune disease
20-epi-1,25 dihydroxyvitamin D3; MC 1288; IE	(1alpha,3beta,5Z,7E,20S)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D3 analogue; immunosuppressant	diabetes; transplant rejection; arthritis

Table 43. Current Candidate Therapeutic Interventions for the Treatment of Transplant Rejection

Product Name	Chemical Name	Action	Indication
brequinar; brequinar sodium; DUP 785; NSC 368390	6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic acid	antimetabolite; immunosuppressant	cancer; autoimmune disease; transplant rejection
antisense oligonucleotide, graft versus host disease	unspecified	antisense; oligonucleotide; immunosuppressant; apoptosis inducer	transplant rejection
apoptosis inhibitors	unspecified	apoptosis inducer	cancer; cardiac therapy; transplant rejection; gastrointestinal disorder

ICE inhibitor, IDUN	unspecified	caspase inhibitor; apoptosis inhibitor; IL-1 beta converting enzyme inhibitor; immunosuppressant	transplant rejection; septic shock; rheumatoid arthritis; inflammatory bowel disease; diabetes
APT 070; APT 070C; APT070C	unspecified	complement inhibitor; immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
methylprednisolone suleptanate; U 67590A; PROMEDROL	(6alpha,11beta)-11,17- dihydroxy-6-methyl- 21-[[8-[methyl(2- sulfoethyl)amino]- 1,8- dioxooctyl]oxy]pregn- a-1,4-diene-3,20- dione monosodium salt	corticosteroid; immunosuppressant	inflammation; asthma; anaphylactic shock; transplant rejection
gene therapy, soluble TNF receptor; gene therapy, corneal transplant rejection	unspecified	cytokine antagonist	transplant rejection
interleukin-12 signal transduction antagonists, Ligand	unspecified	cytokine antagonist; immunosuppressant; NSAID	autoimmune disease; transplant rejection; rheumatoid arthritis
interleukin-8 receptor; IL-8r	unspecified	cytokine antagonist; NSAID; immunosuppressant	allergy; inflammation; transplant rejection
anakinra; interleukin- 1 receptor antagonist; IL-1ra; interleukin-1 inhibitor; ANTRIL	N2-L- methionylinterleukin 1 receptor antagonist (human isoform x reduced)	cytokine inhibitor; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; transplant rejection; asthma; septic shock
interleukin-7 receptor; IL-7r	unspecified	cytokine inhibitor; NSAID; immunosuppressant	allergy; inflammation; transplant rejection
MDAM	N-[4-[2-(2,4-diamino- 6- pteridiny)ethyl]benzo- yl]-4-methylene-DL- glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma

interleukin-4 diphtheria toxin chimeric protein; IL-4 diphtheria toxin chimeric protein; IL-4 fusion protein	unspecified	fusion toxin; immunosuppressant	autoimmune disease; transplant rejection; cancer; HIV infection
growth and differentiation factor 3; GDF 3	unspecified	growth factor; differentiation inducer; immunosuppressant	transplant rejection; autoimmune disease
lymphocyte activation inhibitors, Celltech	unspecified	immunostimulant	autoimmune disease; transplant rejection
geclosporin; ciclosporin G; cyclosporin G; ciclosporin, (NVA)2-; cyclosporin, (NVA)2-; OG 37325	7-L-norvaline cyclosporin A	immunostimulant	transplant rejection
RM 06	N-[N-[[[5-(1,6- dihydro-6-oxo-9H- purin-9- yl)pentyl]oxy]carbonyl]-L-leucyl]-L-methionine	immunostimulant	cancer; transplant rejection
thiethazole	2-[1-(1,1- dioxothiethanyl- 3)benzimidazolyl-2- thio] acetic acid	immunostimulant; immunosuppressant; antioxidant	cancer; rheumatoid arthritis; infectious disease; transplant rejection
T-cell modulators	unspecified	Immunosuppressant	transplant rejection
B7 molecules; B7-1; B7-2	unspecified	immunosuppressant	autoimmune disease; transplant rejection
galaptin L-14-1; immunomodulatory lectin-1; IML-1	unspecified	immunosuppressant	transplant rejection; multiple sclerosis
MAb, CD45RB	unspecified	immunosuppressant	transplant rejection; autoimmune disease
MAb, humanized B7.1	unspecified	immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MAb, humanized B7.2	unspecified	immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MEDI 507	unspecified	immunosuppressant	autoimmune disease; transplant rejection; psoriasis

RG 1046	unspecified	immunosuppressant	autoimmune disease; transplant rejection
CT 2544	unspecified	immunosuppressant	autoimmune disease; transplant rejection
CT 3578	unspecified	immunosuppressant	transplant rejection
cytomuline	unspecified	immunosuppressant	transplant rejection
drug delivery system, CYTOPORTER ciclosporin	unspecified	immunosuppressant	transplant rejection
drug delivery system, LDS microemulsion ciclosporin; ciclosporin LDS microemulsion	unspecified	immunosuppressant	autoimmune disease; transplant rejection
drug delivery system, liposome ciclosporin; ciclosporin liposome	unspecified	immunosuppressant	transplant rejection
drug delivery system, microemulsion ciclosporin; ciclosporin microemulsion; SANDIMMUN NEORAL; SANDIMMUN OPTORAL; NEORAL; NEORAL- SANDIMMUN	unspecified	immunosuppressant	autoimmune disease; transplant rejection
gliotoxin	unspecified	immunosuppressant	transplant rejection
immunosuppressant, Hollis Eden	unspecified	immunosuppressant	autoimmune disease; transplant rejection
immunosuppressants, AstraZeneca; immunosuppressants, University of California	unspecified	immunosuppressant	transplant rejection; autoimmune disease
immunosuppressants, Fujisawa/Hoechst Marion Roussel	unspecified	immunosuppressant	transplant rejection
immunosuppressants, Kinetix	unspecified	immunosuppressant	autoimmune disease; transplant rejection
interleukin-2 receptor ligand, Affymax	unspecified	immunosuppressant	transplant rejection; autoimmune disease
ISAtx 247	unspecified	immunosuppressant	transplant rejection



leptin antagonists, Imperial College	unspecified	immunosuppressant	autoimmune disease; transplant rejection
LJP 920	unspecified	immunosuppressant	transplant rejection
NE 501	unspecified	immunosuppressant	transplant rejection
RWJ 60475	unspecified	immunosuppressant	transplant rejection
VX 10367	unspecified	immunosuppressant	transplant rejection
Xe 9	unspecified	immunosuppressant	transplant rejection
ZAP 70 modulators, Pharmacopeia	unspecified	immunosuppressant	transplant rejection
gusperimus; gusperimus hydrochloride; deoxyspergualin, 15-; desoxyspergualin; DSG; NKT 01; NSC 356894; BMS 181173; BMY 42215- 1; SPANIDIN; SUPANIDIN	(+,-)-7 [(aminoiminomethyl) amino]-N-[2-[[4-[(3- aminopropyl)amino]b utyl]amino]-1- hydroxy-2- oxoethyl]heptanamide	immunosuppressant	transplant rejection; multiple sclerosis; cancer
FR 901483	(2 alpha,5 beta, 6 beta, 7 beta, 8 beta, 10a beta)-octahydro- 5-[(4- methoxyphenyl)meth yl]-2-(methylamino)- 1H-7,10a- methanopyrrolo[1,2- a]azocine-6,8-diol, 8- (dihydrogen phosphate)	immunosuppressant	transplant rejection
PRO 1556	(OC-6-11)- hexakis(1H- imidazole- kappaN3)ruthenium(2 +) dichloride	immunosuppressant	transplant rejection
PRO 2844	(OC-6-22)- pentaammine(4- methylpyridine)ruthen ium(3+) trichloride	immunosuppressant	psoriasis; autoimmune disease; transplant rejection
myriocin; thermozymocidin; ISP-I	[2S- (2R*,3S*,4S*,6E)]-2- amino-3,4-dihydroxy- 2-(hydroxymethyl)- 14-oxo-6-eicosenoic acid	immunosuppressant	autoimmune disease; transplant rejection

discodermolide	[3S-[3 $\alpha$ ,4 $\beta$ ,5 $\beta$ ,6 $\alpha$ ,7 $\alpha$ (2R*,3Z,5R*,6R*,7S*,8Z,11R*,12S*,13S*,14S*,15R*,16E)]]-6-[14-[(aminocarbonyl)oxy]-2,6,12-trihydroxy-5,7,9,11,13,15-hexamethyl-3,8,16,18-nonadecatetraenyl]tetrahydro-4-hydroxy-3,5-dimethyl-2H-pyran-2-one	immunosuppressant	transplant rejection
FTY 720	2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride	immunosuppressant	transplant rejection; autoimmune disease
HMR 1715	2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-6-heptynamide	immunosuppressant	transplant rejection
RAD 001; SDZ RAD	42-O-(2-hydroxyethyl)rapamycin	immunosuppressant	transplant rejection
HMR 1279	alpha-cyano-N-(4-cyanophenyl)-beta-oxocyclopropanepropionamide	immunosuppressant	transplant rejection
YM 13650	propanedioic acid, mono(3-imidazo[2,1-b]benzothiazol-2-ylphenyl) ester	immunosuppressant	transplant rejection
rapamycin analogues	unspecified	immunosuppressant; antifungal	transplant rejection; mycosis
lymphocyte activation gene 3 protein; LAG 3 protein	unspecified	immunosuppressant; biotechnology	transplant rejection; multiple sclerosis
MAb, interleukin-2 receptor; MAb, IL-2R	unspecified	immunosuppressant; biotechnology	transplant rejection
AI 502	unspecified	immunosuppressant; biotechnology; peptide	transplant rejection

soluble complement receptor type 1; sCR1; TP 10; TP 10HD; BRL 55730; YM 55730	unspecified	immunosuppressant; complement inhibitor	respiratory distress syndrome; heart ischemia; transplant rejection
polyclonal antibody, rabbit antithymocyte; immunoglobulin, rabbit antithymocyte; rabbit antithymocyte immunoglobulin; THYMOGLOBULIN	unspecified	immunosuppressant; immunoglobulin; polyclonal antibody	transplant rejection; aplastic anemia
MAB, 33B3.1; MAB, anti-interleukin-2 receptor	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAB, B7.1; MAB, M24; M 24	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAB, CD3 humanized	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAB, T10B9; T10B9.1A-31; MEDI 500	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAbs, organ transplantation; TOLERIMAB	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
inolimomab; MAB, IL-2 receptor CD25; MAB, interleukin-2 receptor CD25; BT 563; LEUKOTAC	immunoglobulin G 1 (mouse monoclonal B-B10.gamma.-chain anti-human interleukin 2 receptor.alpha.-chain), disulfide with mouse monoclonal B-B10.kappa.-chain, dimer	immunosuppressant; monoclonal antibody	transplant rejection
MAB, BC3	unspecified	immunosuppressant; monoclonal antibody; biotechnology	transplant rejection
MAB, CD3-immunotoxin	unspecified	immunosuppressant; monoclonal antibody; biotechnology; immunotoxin	transplant rejection; autoimmune disease

enlimomab; MAb, intracellular adhesion molecule-1; MAb, ICAM-1; MAb, ICAM; MAb, R65; MAb, CD54; BIRR 0001; BIRR 1	unspecified	immunosuppressant; monoclonal antibody; NSAID	transplant rejection; autoimmune disease; rheumatoid arthritis
MAb, R73; MAb, rat alpha/beta T cell receptor	unspecified	immunosuppressant; monoclonal antibody; NSAID	transplant rejection; rheumatoid arthritis
BMS 188667; CTLA4Ig	unspecified	immunosuppressant; NSAID	transplant rejection; systemic lupus erythematosus; psoriasis; arthritis; allergy
immunoregulators, AVANT Immunotherapeutics; immunoregulators, Repligen	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma
PG 12	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PG 27	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PG 2946	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3028	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3113	Unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 94	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PIC 060 analogs	unspecified	immunosuppressant; NSAID	psoriasis; dermatitis; diabetes; transplant rejection; rheumatoid arthritis
PIC 101	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; autoimmune disease; transplant rejection

PIC 102	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
PIC 231	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
VX 10393	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
VX 10428	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
phellodendrine; OB 5	(7S-cis)-5,8,13,13a-tetrahydro-2,11-dihydroxy-3,10-dimethoxy-7-methyl-6H-dibenzo[a,g]quinolizinium	immunosuppressant; NSAID	transplant rejection; inflammation; viral infection; asthma; kidney disease
laflunimus; HR 325	(Z)-2-cyano-3-cyclopropyl-3-hydroxy-N-[3-methyl-4-(trifluoromethyl)phenyl]-2-propenamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; psoriasis
mizoribine; HE 69; BREDININ	5-hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; kidney disease
CD45 inhibitors, Ontogen	unspecified	immunosuppressant; NSAID; tyrosine phosphatase inhibitor	transplant rejection; inflammation
human leukocyte antigen-derived protein; HLA-derived protein; ALLOTRAP 2702	unspecified	immunosuppressant; peptide	transplant rejection
immunosuppressant peptides, SangStat; immunosuppressant peptides, Syntem	unspecified	immunosuppressant; peptide	transplant rejection; autoimmune disease

ZAP inhibitors, Ariad	unspecified	immunosuppressant; protein kinase inhibitor; tyrosine kinase inhibitor; NSAID	transplant rejection; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythematosus; multiple sclerosis
TBC 427	unspecified	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor	ischemia; psoriasis; respiratory distress syndrome; transplant rejection; reperfusion injury
drug delivery system, NanoCrystal sirolimus; sirolimus NanoCrystal	unspecified	macrolide; antibiotic; immunosuppressant	transplant rejection
sirolimus; rapamycin; NSC 226080; AY 22989; RAPAMUNE	(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacycloheptatriacontine-1,5,11,28,29(4H,6H,31H)-pentone	macrolide; immunosuppressant; antibiotic	transplant rejection; autoimmune disease; restenosis

tacrolimus; tsukubaenolide; fujimycin; FK 506; (-)-FK 506; FR 900506; L 679934; PROGRAF; PROTOPIC	[3S-[3R*[E(1S*,3S*,4S*),4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone	macrolide; immunosuppressant; NSAID; antibiotic	transplant rejection; dermatitis; eye disease; rheumatoid arthritis
MAb 2E1; MAb, effector cell proteinase receptor-1	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, 64G12; Mab, interferon receptor type-1; 64G12	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, BMA 031	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, CD11a; hu 1124	unspecified	monoclonal antibody; immunosuppressant	psoriasis; transplant rejection
MAB, CD45; LM CD45	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, CD45RB	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, CD7; SDZ CHH 380	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, gp39; MAB, CD40L; IDEC 131	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection; systemic lupus erythematosus
MAB, humanized CD3; MAB, SMART CD3; HuM291	unspecified	monoclonal antibody; immunosuppressant	transplant rejection; autoimmune disease; psoriasis

MAB, L0-CD2a; BTI 322	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, major histocompatibility complex I; F(ab') <sub>2</sub> , MHC I	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, MHCII-CD8	unspecified	monoclonal antibody; immunosuppressant	transplant rejection; graft versus host disease
MAB, transplant rejection; CBL1; ABX CBL	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, CD4; HumaT4	unspecified	monoclonal antibody; immunosuppressant	psoriasis; asthma; rheumatoid arthritis; irritable bowel syndrome; transplant rejection; allergy
daclizumab; dacliximab; MAb, Tac; MAb, humanized Tac; MAb, SMART Tac; Ro 247375; ZENAPAX	immunoglobulin G1 (human-mouse monoclonal clone 1H4 gamma chain anti-human antigen Tac), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection; cancer; autoimmune disease; eye disease
odulimomab; MAb, LFA-1 alpha subunit; ANTILFA	immunoglobulin G1, anti-(human CD11 (antigen).alpha.-chain)(mouse monoclonal 25.3.gamma.1-chain), disulfide with mouse monoclonal 25.3 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection



basiliximab; SDZ CHI621; CHI 621; SIMULECT	Immunoglobulin G1, anti-(human interleukin 2 receptor) (human-mouse monoclonal CHI621 .gamma.1- chain),disulfide with human-mouse mo noclonal CHI621 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection
MAB, CD6 blocked ricin; MAb, T12-bR; ONCOLYSIN CD6	unspecified	monoclonal antibody; immunosuppressant; immunotoxin	transplant rejection
MAB, MHC class II	unspecified	monoclonal antibody; immunosuppressant; NSAID	autoimmune disease; transplant rejection; graft versus host disease; cancer
MAB, CD5- momordin; immunotoxin CD5- momordin; ITF 1532	unspecified	monoclonal antibody; immunotoxin; immunosuppressant	cancer; transplant rejection
zolimomab aritox; MAb, H65 RTA; MAb, bone marrow- ricin A conjugate; CD5-T lymphocyte immunotoxin; MAb, CD5; XMMLY H65 RTA; XOMAZYME H65; XOMAZYME CD5+; ORTHOZYME CD5+; CD5 Plus	unspecified	monoclonal antibody; immunotoxin; immunosuppressant	transplant rejection
MAB, humanized, leukemia; MAb, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	unspecified	monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
MAB, B7; MAb, PRIMATIZED B7; IDEDEC 114	unspecified	monoclonal antibody; NSAID; immunosuppressant	systemic lupus erythematosus; inflammation; transplant rejection; psoriasis

NOX 100	unspecified	nitric oxide scavenger	diabetes; cancer; trauma; transplant rejection; septic shock; hemorrhagic shock
NOX 51	unspecified	nitric oxide scavenger	diabetes; cancer; hemorrhagic shock; transplant rejection; septic shock
NOX 101	Unspecified	nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; hemorrhagic shock
NE 0501	unspecified	oligosaccharide	transplant rejection
opioid antagonists, NIH	unspecified	opiate antagonist; peptide; immunosuppressant	drug addiction; alcoholism; obesity; transplant rejection
recombinant PSGL 1, Genetics Institute; PSGL 1	unspecified	P selectin antagonist; E selectin antagonist; L selectin antagonist; selectin antagonist; NSAID	inflammation; transplant rejection; ischemia; reperfusion injury
rD-mPGPtide	unspecified	peptide; immunosuppressant	transplant rejection; multiple sclerosis
transplantation therapy, SangStat	unspecified	peptide; immunosuppressant	transplant rejection
complement inhibitors, Lidak	unspecified	peptide; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease; reperfusion injury; respiratory distress syndrome; transplant rejection
SPC 100270	unspecified	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant	ischemia; transplant rejection; reperfusion injury

Ro 320432; Ro 32-0432	(S)-3-[8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis
peldesine; BCX 34; BCX 34B	2-amino-1,5-dihydro-7-(3-pyridinylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; immunosuppressant; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection; eye disease; dermatitis; HIV infection
purine nucleoside phosphorylase inhibitors, Chiroscience; PNP inhibitors, Chiroscience	unspecified	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection
mycophenolate mofetil; mycophenolate mofetil hydrochloride; RS 61443; RS-61443-190; CellCept	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
ribozymes, organ transplantation	unspecified	ribozyme; oligonucleotide; immunosuppressant	transplant rejection
CGS 12970	3-methyl-2-(3-pyridinyl)-1H-indole-1-octanoic acid	thromboxane synthase inhibitor; immunosuppressant	transplant rejection
pirimagrel; CGS 13080	imidazo(1,5-a)pyridine-5-hexanoic acid	thromboxane synthetase inhibitor; immunosuppressant	transplant rejection
thalidomide; SYNOVIR; THALOMID	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease

thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection
SC 114	unspecified	triglyceride; immunosuppressant	autoimmune disease; transplant rejection
20-epi-1,25 dihydroxyvitamin D <sub>3</sub> ; MC 1288; IE	(1 $\alpha$ ,3 $\beta$ ,5Z,7E,20S)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D <sub>3</sub> analogue; immunosuppressant	diabetes; transplant rejection; arthritis

Table 44. Current Candidate Therapeutic Interventions for the Treatment of Pain Related to Inflammation

Product Name	Chemical Name	Action	Indication
anti-inflammatory	4,5-dihydro-3-(1-pyrrolyl)-1-(3-trifluoromethylphenyl)-1H pyrazole	15 lipoxygenase, cyclooxygenase, and thromboxane synthetase inhibitor	inflammation
CO 1828	4-methoxy-2-(3-phenyl-2-propynyl)phenol	5 lipoxygenase and cyclooxygenase inhibitor	inflammation
darbufelone; CI 1004	(Z)-2-amino-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-4(5H)-thiazolone	5 lipoxygenase inhibitor; COX inhibitor; COX 2 inhibitor; NSAID	inflammation
P 8892	2-[2-(ethylhydroxyamino)ethyl]dibenz[b,e]oxepin-11(6H)-one	5 lipoxygenase inhibitor; COX inhibitor; NSAID	inflammation
CI 986	2-hydroxy-N,N,N-trimethylethanaminium salt with 5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1,3,4-thiadiazole-2(3H)-thione (1:1)	5 lipoxygenase inhibitor; COX inhibitor; NSAID	inflammation

P 8977	3-(6,11-dihydro-11-oxo-dibenz[b,e]oxepin-2-yl)-N-methylpropanamide	5 lipoxygenase inhibitor; COX inhibitor; NSAID	inflammation
CI 987	5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylidene]-2,4-thiazolidinedione	5 lipoxygenase inhibitor; COX inhibitor; NSAID	inflammation
BIL 226XX	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation
CGS 23885	unspecified	5 lipoxygenase inhibitor; NSAID	psoriasis; inflammation
CGS 24891	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation
CHF 1909	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma
GR 80907	unspecified	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
lagunamycin	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation
SC 45662	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis; inflammatory bowel disease
DUP 654	(2-phenylmethyl)-1-naphthalenol	5 lipoxygenase inhibitor; NSAID	psoriasis; inflammation
CGS 25997	(2S)-(-)-2-[[N-(aminocarbonyl)-N-hydroxyamino]methyl]-7-(4-fluorophenoxy)-1,4-benzodioxan	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
A 121798	(E)-1-methyl-6-[[[3-(tetrahydro-4-methoxy-2-methyl-2H-pyran-4-yl)-2-propenyl]oxy]methyl]-2(1H)-quinolinone	5 lipoxygenase inhibitor; NSAID	inflammation
enofelast; BIL 239X	(E)-4-[2-(4-fluorophenyl)ethenyl]-2,6-dimethylphenol	5 lipoxygenase inhibitor; NSAID	inflammation

T 0757; T 757	(E)-N-(4-hydroxy-3,5-dimethylphenyl)-3,7-dimethyl-2,6-octadienamide	5 lipoxygenase inhibitor; NSAID	inflammation
L 663536; MK 886	1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethylthio)-alfa,alfa-diethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis
SCH 40120	10-(3-chlorophenyl)-6,8,9,10-tetrahydrobenzo[b][1,8]naphthyridin-5(7H)-one	5 lipoxygenase inhibitor; NSAID	inflammation; psoriasis
ICI 211965	2-[1-methoxy-1-[3-(2-naphthalenylmethoxy)phenyl]propyl]thiazole	5 lipoxygenase inhibitor; NSAID	inflammation
L 699333	2-[2-[1-[(4-chlorophenyl)methyl]-4,5-dihydro-4-methyl-6-[(5-phenyl-2-pyridinyl)methoxy]-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
carbázomycin C	3,6-dimethoxy-1,2-dimethyl-9H-carbazol-4-ol	5 lipoxygenase inhibitor; NSAID	inflammation
carbázomycin B	3-methoxy-1,2-dimethyl-9H-carbazol-4-ol	5 lipoxygenase inhibitor; NSAID	inflammation
E 6080	4-[[[6-hydroxy-4,4,7-trimethyl-2-benzothiazolyl)amino]methyl]benzenesulfonamide monohydrochloride	5 lipoxygenase inhibitor; NSAID	asthma; inflammation

L 651392	4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one	5 lipoxygenase inhibitor; NSAID	inflammation; bacterial infection; asthma
ZD 7717; ICI D7717	7-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenyl]thio]-4-methyl-2H-1,4-benzoxazin-3(4H)-one	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
zileuton; A 64077; ABBOTT 64077; ZYFLO	N-(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea	5 lipoxygenase inhibitor; NSAID	inflammation; asthma
T 0799; T 799	N-(4-hydroxy-3,5-dimethylphenyl)-3-thiophenecarboxamide	5 lipoxygenase inhibitor; NSAID	inflammation
A 69412	N-[1-(3-furanyl)ethyl]-N-hydroxyurea	5 lipoxygenase inhibitor; NSAID	inflammation
A 78773; A 79175	N-[3-[5-(4-fluorophenoxy)-2-furanyl]-1-methyl-2-propynyl]-N-hydroxyurea	5 lipoxygenase inhibitor; NSAID	allergy; inflammation
atreleuton; atreluton; ABT 761; A 85761.0; ABT 85761	N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxy-urea	5 lipoxygenase inhibitor; NSAID	inflammation
A 72694; ABT72694	N-2,2-dimethyl-3((1-(4-chlorophenylmethyl)-3-(1,1-dimethylethylthio)-5-(1-methylethyl)indol-2-yl))-propyl-n-hydrourea	5 lipoxygenase inhibitor; NSAID	inflammation
lipoxygenase inhibitor	N-hydroxy-N-[1-(2-phenyl-5-benzofuranyl)ethyl]urea	5 lipoxygenase inhibitor; NSAID	inflammation

lurosetron; lurosetron mesylate; GR 87442; GR 87442N; GR 87442X	6-fluoro-2,3,4,5-tetrahydro-5-methyl-2-[(5-methylimidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one	5HT antagonist; 5HT3 antagonist; NSAID	inflammation; emesis
AAL 13	2-[4-(3-chloropropyl)-1-piperazinyl]quinoline	5HT reuptake inhibitor; analgesic; NSAID	inflammation; pain
AKI 1	unspecified	adenosine regulating agent; NSAID	inflammation; arthritis
AKI 2	unspecified	adenosine regulating agent; NSAID	inflammation; arthritis
GP 1515	1-(5-amino-5-deoxy-beta-D-ribofuranosyl)-3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-amine	adenosine regulating agent; NSAID	inflammation
drug delivery system, hydrogel diclofenac; diclofenac hydrogel; DICLOFENAC HYCORE-R	unspecified	analgesic; NSAID	pain; inflammation
drug delivery system, OSAT diclofenac; diclofenac sustained release	unspecified	analgesic; NSAID	pain; inflammation
drug delivery system, OSAT ibuprofen; ibuprofen sustained release	unspecified	analgesic; NSAID	pain; rheumatoid arthritis; osteoarthritis; inflammation
drug delivery system, sustained release microsphere flurbiprofen; flurbiprofen, sustained release	unspecified	analgesic; NSAID	pain; inflammation
TZI 41078	unspecified	analgesic; NSAID	inflammation; pain
RP 67580	(3aR-cis)-octahydro-2-[1-imino-2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-4H-isoindol-4-one	analgesic; NSAID	pain; inflammation



HU 239	(6aR-trans)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid	analgesic; NSAID	inflammation; pain
proglumetacin; protacine; CR 604; IMPETIN; PROXIL; PROXATIL; AFLOXAN; TOLINDOL; BRUXEL; MIRIDACIN	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-[4-[3-[[4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl]oxy]propyl]-1-piperazinyl]ethyl ester, (+,-)-	analgesic; NSAID	inflammation; pain
FA 401	1-(4-fluorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid carboxymethyl ester	analgesic; NSAID	pain; inflammation
BN 50370	1,3-dihydro-3,6-dimethyl-7-hydroxy-furo(3,4)pyridine hydrochloride	analgesic; NSAID	inflammation; pain
flurbiprofen axetil; LFP 83; ROPION; LIPFEN	2-fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid, 1-(acetyloxy)ethyl ester	analgesic; NSAID	pain; inflammation
analgesic	3-methyl-5-oxobenzo(b)thieno(2,3-d)thiazolo(3,2-a)pyrimidine-2-carboxylic acid ethyl ester	analgesic; NSAID	pain; inflammation; gastrointestinal ulcer
DTA	4'-methyl-[1,1':3',1''-terphenyl]-5'-acetic acid	analgesic; NSAID	inflammation; pain
diaveridine; EGIS 5645	5-[(3,4-dimethoxyphenyl)methyl]-2,4-pyrimidinediamine	analgesic; NSAID	inflammation; pain

LA 351	5H-(1)-benzopyrano(2,3-b)pyridin-5-one	analgesic; NSAID	inflammation; pain; asthma
M 5011; T 3788	alpha-2-[4-(3-methylthienyl)phenyl]propionic acid	analgesic; NSAID	inflammation; pain
2-halopyridines	unspecified	analgesic; NSAID	inflammation; pain; insomnia
HCT 3012	unspecified	analgesic; NSAID; nitric oxide donor	pain; inflammation
HP 228	N-acetyl-Nleu-Gln-His-Phe-Arg-Trp-Gly-amide	analgesic; NSAID; peptide; melanocortin agonist	pain; inflammation; asthma; cachexia
heparanase inhibitors	unspecified	angiogenesis inhibitor; NSAID	cancer; inflammation
XMP 300	unspecified	angiogenesis inhibitor; peptide	inflammation; cancer
AGN 190383	4-[1-(acetyloxy)tridecyl]-5-hydroxy-2(5H)-furanone	Antagonist prior to 5-lipoxygenase and cyclooxygenase	inflammation
loteprednol + tobramycin; tobramycin + loteprednol	unspecified	antibiotic	inflammation; bacterial infection
anti-inflammatory macrolide analogues, KOSAN	unspecified	antibiotic; macrolide	asthma; inflammation
drug delivery system, ATRIGEL sustained release sanguinarine chloride; sanguinarine chloride ATRIGEL	unspecified	antibiotic; NSAID; antifungal	bacterial infection; mycosis; inflammation; periodontal disease
SB 226882	4-[4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-N-methyl-2-pyrimidinamine	antifungal; MAP kinase inhibitor; signal transduction inhibitor; imidazole	inflammation; asthma; rheumatoid arthritis
aminoimidazole carboxamide ribonucleotide formyltransferase inhibitors, AICART inhibitors	unspecified	antifungal; ribonucleotide formyltransferase inhibitor; NSAID; imidazole	cancer; inflammation

drug delivery system, anti-inflammatory;	intraocular biodegradable polymer	anti-inflammatory intraocular	inflammation
ibuprofen piconol; U 75630; BE 100; OU 75630; STADERM; VESICUM	alpha-methyl-4-(2-methylpropyl)benzeneacetic acid 2-pyridinylmethyl ester	Antiinflammatory with ibuprofen mechanism, topical cream	inflammation
EN 07	Medicinal herbal extract	Antiinflammatory; dermatologic antiinflammatory	inflammation
nitroxide antioxidant	unspecified	antioxidant; free radical scavenger; NSAID	respiratory distress syndrome; inflammation; cancer; reperfusion injury
antioxidants	unspecified	antioxidant; NSAID	inflammation; atherosclerosis
antioxidants	unspecified	antioxidant; NSAID	skin disease; inflammation; cancer
naphterpin; CL 190Y2	(4aS-cis)-3,4a,5,12b-tetrahydro-8,10-dihydroxy-2,5,5,9-tetramethyl-4H-benzo[d]naphtho[2,3-b]pyran-7,12-dione	antioxidant; NSAID	diabetes; cardiovascular disease; cancer; inflammation
boldine	(S)-5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-4H-dibenzo[de,g]quinoline-2,9-diol	antioxidant; NSAID	inflammation
AD 0261	2-[[3-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]propyl]amino]-4-methylphenol	antioxidant; NSAID	inflammation; allergy; skin disease
Z 4003	2-[1-[4-(2-methylpropyl)phenyl]ethyl]-4-thiazolidinecarboxylic acid	antioxidant; NSAID	angina; inflammation; emphysema
antisense oligonucleotide, IL-1 receptor (type 1)	unspecified	antisense; biotechnology; oligonucleotide; NSAID	inflammation

antisense oligonucleotide, interleukin-1; antisense oligonucleotide, IL-1	unspecified	antisense; immunosuppressant; oligonucleotide; NSAID	inflammation
antisense oligonucleotide, B7-1	unspecified	antisense; oligonucleotide; biotechnology; NSAID	inflammation
antisense oligonucleotide, B7-2	unspecified	antisense; oligonucleotide; biotechnology; NSAID	inflammation
antisense oligonucleotide, ELAM; ISIS 4730	unspecified	antisense; oligonucleotide; NSAID	inflammation
antisense oligonucleotide, PECAM-1	unspecified	antisense; oligonucleotide; NSAID	inflammation
antisense oligonucleotides, VCAM-1	unspecified	antisense; oligonucleotide; NSAID	inflammation
drug delivery system, antisense oligonucleotide, ICAM-1; antisense oligonucleotide, ICAM-1 delivery system; Oligo TCS	unspecified	antisense; oligonucleotide; NSAID	inflammation
drug delivery system, oral, antisense oligonucleotide, TNF-alpha; antisense oligonucleotide, TNF-alpha delivery system	unspecified	antisense; oligonucleotide; NSAID	inflammation
anti-inflammatory aptamers	unspecified	aptamer; NSAID	inflammation
L-selectin antagonist	unspecified	aptamer; oligonucleotide; integrin antagonist; L selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation

P-selectin antagonist	unspecified	aptamer; oligonucleotide; integrin antagonist; P selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation
neutrophil elastase inhibitor, NeXstar	unspecified	aptamer; oligonucleotide; NSAID; elastase inhibitor; proteinase inhibitor	inflammation; respiratory disease
bradykinin antagonists	unspecified	bradykinin antagonist; analgesic; NSAID	pain; inflammation; septic shock
NOVA 567; NPC 567	N2-D-arginyl-3- (trans-4-hydroxy-L- proline)-7-D- phenylalaninebradyki nin	bradykinin antagonist; cicatrizant; peptide; NSAID	asthma; skin ulcer; inflammation
bradykinin antagonist/mu agonist	unspecified	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	inflammation; pain; migraine
CP 0880; CP 880	N-[[3-[[1-oxo-3-[4- [(1- oxopropyl)phenylami no]-1-(2- phenylethyl)-3- piperidinyl]propyl]am ino]phenyl]acetyl]- beta-alanyl-D-arginyl- L-arginyl-L-prolyl- (4R)-4-hydroxy-L- prolylglycyl-3-(2- thienyl)-L-alanyl-L- seryl-(3R)-1,2,3,4- tetrahydro-3- isoquinolinecarbonyl- N-cyclohexylglycyl- L-arginine	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	inflammation; pain
CP 0364	unspecified	bradykinin antagonist; NSAID	hypertension; inflammation
CP 0494	unspecified	bradykinin antagonist; NSAID	septic shock; inflammation

FR 172357	unspecified	bradykinin antagonist; NSAID	inflammation
non-peptide bradykinin antagonist	unspecified	bradykinin antagonist; NSAID	inflammation
icatibant; icatibant acetate; HOE 140	D-arginyl-L-arginyl- L-prolyl-trans-4- hydroxy-L- prolyl-glycyl-3-(2- thienyl)-L-alanyl-L- seryl-D-1,2,3,4- tetrahydro-3- isoquinolincarbonyl- L- (2 $\alpha$ ,3 $\beta$ ,7 $\beta$ )- octahydro-1H-indole- 2-carbonyl-L-arginine	bradykinin antagonist; NSAID	asthma; inflammation; rhinitis; osteoarthritis
NPC 17731	N <sup>2</sup> -D-arginyl-3- (trans-4-hydroxy-L- proline)-7-(trans-4- propoxy-D-proline)- 8-[L- (2 $\alpha$ ,3 $\beta$ ,7 $\beta$ )- octahydro-1H- indole-2-carboxylic acid]-bradykinin	bradykinin antagonist; NSAID	inflammation; septic shock; asthma
FR 173657	(E)-3-[6- (acetylamino)-3- pyridinyl]-N-[2-[[2,4- dichloro-3-[[[(2- methyl-8- quinolinyl)oxy]methyl- phenyl]methylamino ]-2-oxoethyl-2- propenamide	bradykinin antagonist; NSAID; analgesic	asthma; inflammation; pain
CP 9430	unspecified	bradykinin antagonist; NSAID; peptide	inflammation

CP 0597	D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-(3R)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-N-cyclohexylglycyl-L-arginine	bradykinin antagonist; NSAID; peptide	inflammation
fenspiride; KSP 193; PNEUMORAL; ESPIRAN	8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one	bronchodilator; NSAID	inflammation; asthma
C5A antagonists, SKF 96365	unspecified	C5A antagonists	inflammation
SKF 96365	1-[2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]-1H-imidazole	calcium antagonist; NSAID	inflammation
NE 28345	(Z)-4-hydroxy-3-methoxy-N-9-octadecenylbenzeneacetamide	capsaicin analogue; NSAID	inflammation
casein kinase inhibitors	unspecified	casein kinase inhibitor; immunosuppressant; NSAID	inflammation; cancer
CD11b/CD18 inhibitors, Corvas; CORLEUKIN	unspecified	CD11b/CD18 receptor inhibitor; NSAID	inflammation
atrinositol; PP 56	D-myo-inositol 1,2,6-tris(dihydrogen phosphate)	chelating agent; NSAID	inflammation; hyperlipidemia
chemoattractant antagonists	unspecified	chemokine antagonist	inflammation
chemokine antagonists	unspecified	chemokine antagonist	inflammation
CHEMOTIDES	unspecified	chemokine antagonist; NSAID	inflammation
chymase inhibitors, Alys	unspecified	chymase inhibitor; NSAID	asthma; inflammation; rhinitis
MDS 004	unspecified	cicatrizant; NSAID	skin ulcer; inflammation

malotilate; NND 105; NKK 105; DA 3857; KANTEC; KANTECS; TRACTAL	1,3-dithiol-2-ylidenepropanedioic acid bis(1-methylethyl) ester	cicatrizant; NSAID	liver disease; inflammation; skin ulcer
collagenase inhibitors	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis; inflammation
complement factor inhibitors	unspecified	Complement factor inhibitors	inflammation; respiratory distress syndrome
CMI CAB2	unspecified	complement inhibitor; biotechnology; NSAID	inflammation; respiratory distress syndrome
inflammation therapy, complement regulatory protein	unspecified	complement inhibitor; biotechnology; NSAID	inflammation
MAB, C5 single chain; MAB, complement C5; 5G1.1-SC	unspecified	complement inhibitor; monoclonal antibody; NSAID	inflammation; myocardial infarction; stroke; ischemia
sCR1sLex; TP 20	unspecified	complement inhibitor; neutrophil adhesion inhibitor; NSAID	respiratory distress syndrome; inflammation
TP 16	unspecified	complement inhibitor; NSAID	inflammation
kallikrein inhibitors	unspecified	complement inhibitor; NSAID	inflammation
TK 9C	unspecified	complement inhibitor; NSAID	inflammation
CSK 802	unspecified	corticosteroid	inflammation
DM V; DM 5	unspecified	corticosteroid	inflammation
ORG 7258	unspecified	corticosteroid	inflammation
P16CM analogues	unspecified	corticosteroid	inflammation
butixocort propionate; JO 1222	(11beta)-11-hydroxy-17-(1-oxobutoxy)-21-[(1-oxopropyl)thio]]pregn-4-ene-3,20-dione	corticosteroid	inflammation; asthma; inflammatory bowel disease



budesonide; budesonide propionate; S 1320; PREFERID; PULMICORT; RHINOCORT; ENTOCORT; NARICORT; INFLAMMIDE; BETACTIN; ELTAIR; HORACORT; RHINOCORT AQUA	(11beta,16alpha)- 16,17- [butylidenebis(oxy)]- 11,21- dihydroxypregna-1,4- diene-3,20-dione	corticosteroid	asthma; skin disease; inflammation; rhinitis; ulcerative colitis; Crohn disease
rimexolone; trimexolone; ORG 6216; RIMEXEL; VEXOL	(11beta,16alpha,17beta)- 11-hydroxy-16,17- dimethyl-17-(1- oxopropyl)androsta- 1,4-diene-3-one	corticosteroid	rheumatoid arthritis; inflammation; eye disease
prednisolone analogue	(11beta,16beta)- 11,21-dihydroxy- 3,20-dioxo-4'H- pregna-1,4- dieno[16,17- d]isoxazole-3'- carboxylic acid	corticosteroid	inflammation
amelometasone; TS 410; CS 830; REONA	(11beta,16beta)-9- fluoro-11-hydroxy- 21-methoxy-16- methyl-17-(1- oxopropoxy)pregna- 1,4-diene-3,20-dione	corticosteroid	inflammation
tipredane; SQ 27239	(11beta,17alpha)-17- (ethylthio)-9-fluoro- 11-hydroxy-17- (methylthio)androsta- 1,4-diene-3-one	corticosteroid	inflammation; psoriasis

clobetasone butyrate; clobetasone; DE 049; CCI 5537; GR 2/1214; SN 203; CLOBETRON; EUMOVATE; EUMOVATE N; KINDABATE; KINDALONE; BUTIDEX	(16beta)-21-chloro-9- fluoro-16-methyl-17- (1-oxobutoxy)pregna- 1,4-diene-3,11,20- trione	corticosteroid	eye disease; inflammation
16-epiestriol; epiestriol	(16beta,17.beta)estra- 1,3,5(10)-triene- 3,16,17-triol	corticosteroid	inflammation
ulobetasol propionate; halobetasol propionate; CGP 14458; BMY 30056; ULTRAVATE	(6alpha,11beta,16beta)- 21-chloro-6,9- difluoro-11-hydroxy- 16-methyl-17-(1- oxopropoxy)-pregna- 1,4-diene-3,20-dione	corticosteroid	skin disease; inflammation; psoriasis
methylprednisolone aceponate; MPA; SH 440; ZK 91588; ADVANTAN	(6alpha,11beta)-21- (acetyloxy)-11- hydroxy-6-methyl-17- (1-oxopropoxy)pr egna-1,4-diene-3,20- dione	corticosteroid	inflammation
P16CM	16alpha- methoxycarbonylpred nisolone	corticosteroid	inflammation
halopredone; THS 20; THS 201; F2; HALOART; HALOART S	17alpha,21-diacetoxy- 2-bromo-6beta,9alpha- difluoro-11beta- hydroxy-1,4- pregnadiene-3,20- dione	corticosteroid	inflammation
prednisolone analogue	21-(acetyloxy)-11- hydroxy-3,20-dioxo- 4'H-pregna-1,4- dieno[16,17-d ]isoxazole-3'- carboxylic acid ethyl ester	corticosteroid	inflammation

compound 3Ae	21-ethylthio-6alpha,9alpha-difluoro-11beta-hydroxy-16alpha,17alpha-isopropylidenedioxy-1,4-pregnadiene-3,20-dione	corticosteroid	inflammation; skin disease
methylprednisolone suleptanate; U 67590A; PROMEDROL	(6alpha,11beta)-11,17-dihydroxy-6-methyl-21-[[8-[methyl(2-sulfoethyl)amino]-1,8-dioxooctyl]oxy]pregna-1,4-diene-3,20-dione monosodium salt	corticosteroid; immunosuppressant	inflammation; asthma; anaphylactic shock; transplant rejection
BIL 93BS; BIL 0093BS	unspecified	COX inhibitor; 5 lipoxigenase inhibitor; NSAID	inflammation
anti-inflammatory	1,2-dihydro-1-oxo-N-2-thiazolylpyrrolo[3,2,1-kl]phenothiazine-2-carboxamide	COX inhibitor; 5 lipoxigenase inhibitor; NSAID	inflammation
E 5110	3-[[3,5-bis-(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-1-methoxy-2-pyrrolidinone	COX inhibitor; 5 lipoxigenase inhibitor; NSAID	inflammation
tepoxalin; RWJ 20485; ORF 20485	5-(4-chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide	COX inhibitor; 5 lipoxigenase inhibitor; NSAID	asthma; inflammation; inflammatory bowel disease
LY 178002	5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-4-thiazolidinone	COX inhibitor; 5 lipoxigenase inhibitor; NSAID	inflammation; ischemia
ML 3000	6-(4-chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl-1H-pyrrolizine-5-acetic acid	COX inhibitor; 5 lipoxigenase inhibitor; NSAID	inflammation

meloxicam; UH AC62; UH AC26XX; MOBIC; MOBICOX; MOBEC; MOVALIS; MOVATEC	4-hydroxy-2-methyl- N-(5-methyl-2- thiazolyl)-2H-1,2- benzothiazine-3-car boxamide 1,1-dioxide	COX inhibitor; analgesic; COX 2 inhibitor; NSAID	rheumatoid arthritis; inflammation; pain; osteoarthritis
D 1367	unspecified	COX inhibitor; analgesic; NSAID	pain; inflammation
AHR 10037	2-amino-3-(4- chlorobenzoyl)benzen eacetamide	COX inhibitor; analgesic; NSAID	inflammation; pain
T 614	N-[3-(formylamino)- 4-oxo-6-phenoxy-4H- 1-benzopyran-7-yl]- methanesulfonamide	COX inhibitor; analgesic; NSAID; DMARD	inflammation; pain
cyclooxygenase inhibitor, Oxis	unspecified	COX inhibitor; antioxidant; NSAID	inflammation
BF 389; biofor 389	4-[[3,5-bis(1,1- dimethylethyl)-4- hydroxyphenyl]methy lene]dihydro-2- methyl-2H-1,2- oxazin-3(4H)-one	COX inhibitor; COX 2 inhibitor; 5 lipooxygenase inhibitor; NSAID	inflammation
RWJ 63556	N-[5-[(4- fluorophenoxy)-2- thienyl]methansulfon amide	COX inhibitor; COX 2 inhibitor; 5 lipooxygenase inhibitor; NSAID	inflammation
CT 3	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	pain; inflammation
L 748731	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation
MK 663	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
JTE 522	4-(4-cyclohexyl-2- methyl-5-oxazolyl)-2- fluorobenzenesulfona mide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
rofecoxib; MK 966; VIOXX	4-[4- (methylsulfonyl)phen yl]-3-phenyl-2(5H)- furanone	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; rheumatoid arthritis; osteoarthritis; pain; Alzheimer disease

NS 398	N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
L 745337	N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	pain; inflammation
L 752860	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
COX 2 inhibitors	unspecified	COX inhibitor; COX 2 inhibitor; NSAID	inflammation
L 761066	(R)-1-[(4-bromophenyl)methyl]-5-methoxy-beta,2-dimethyl-1H-indole-3-butanoic acid	COX inhibitor; COX 2 inhibitor; NSAID	inflammation
L 768277	5-[4-(methylsulfonyl)phenyl]-6-phenylthiazolo[3,2-b][1,2,4]triazole	COX inhibitor; COX 2 inhibitor; NSAID	inflammation
BIRL 790	6-chloro-4-[(1-methylethyl)sulfonyl]-2-(phenylmethyl)-1,3(2H,4H)-isoquinolinedione	COX inhibitor; COX 2 inhibitor; NSAID	inflammation
COX 2 inhibitors	unspecified	COX inhibitor; COX 2 inhibitor; NSAID; analgesic	inflammation; osteoarthritis; pain
CGP 31081	unspecified	COX inhibitor; NSAID	inflammation
lornoxicam; chlortenoxicam; Ro 139297; TS 110; CTX; SAFEM; XEFO; LORCAM	6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazin e-3-carboxamide 1,1-dioxide	COX inhibitor; NSAID; analgesic	inflammation; pain
COX 2 inhibitors, SALVAT	unspecified	COX inhibitor; NSAID; COX 2 inhibitor	inflammation

trifenagrel; BW 325U	2-[2-(4,5-diphenyl-1H-imidazole-2-yl)phenoxy]-N,N-dimethylethanamine	COX inhibitor; platelet antiaggregant; NSAID	inflammation; thrombosis
nimesulide; R 805; NIM 03; MESULID; AULIN; NIMED; AINEX; NISULID; ESKAFLAM; SCAFLAN; OXETIAN; ANTIFLOXIL; ARLAGIN	N-(4-nitro-2-phenoxyphenyl)methanesulfonamide	COX inhibitor; prostaglandin synthetase inhibitor; COX 2 inhibitor; NSAID	inflammation
interleukin-4 receptor; IL-4r; NUVANCE	unspecified	cytokine antagonist	inflammation; asthma
DoB 0041	unspecified	cytokine antagonist; biotechnology; NSAID	inflammation
DoB 0039	unspecified	cytokine antagonist; NSAID	inflammation
interleukin-1 antagonist; IRAP	unspecified	cytokine antagonist; NSAID	inflammation
interferon antagonists; interferon antagonists	unspecified	cytokine antagonist; NSAID	inflammation
interleukin-1 antagonist	unspecified	cytokine antagonist; NSAID	inflammation
interleukin-6 antagonist	unspecified	cytokine antagonist; NSAID	cachexia; inflammation
interleukin-8 receptor; IL-8r	unspecified	cytokine antagonist; NSAID; immunosuppressant	allergy; inflammation; transplant rejection
E 5090	(Z)-3-[4-(acetyloxy)-5-ethyl-3-methoxy-1-naphthalenyl]-2-methyl-2-propenoic acid	cytokine inhibitor; analgesic; NSAID	inflammation; pain
interleukin-8 inactivating proteinase; CT 8	unspecified	cytokine inhibitor; biotechnology; NSAID	respiratory disease; inflammation
interleukin-1 inhibitor; IL-1 inhibitor; SEPTANIL	unspecified	cytokine inhibitor; NSAID	inflammation; septic shock
CGP 47969A	unspecified	cytokine inhibitor; NSAID	inflammation

immunomodulatory cytokine modulator	unspecified	cytokine inhibitor; NSAID	inflammation
interleukin-1 inhibitors	unspecified	cytokine inhibitor; NSAID	inflammation; asthma; inflammatory bowel disease
interleukin-1 receptor ligands	unspecified	cytokine inhibitor; NSAID	arthritis; inflammation
interleukin-8 inhibitors	unspecified	cytokine inhibitor; NSAID	inflammation; cardiovascular disease
interleukin-7 receptor; IL-7r	unspecified	cytokine inhibitor; NSAID; immunosuppressant	allergy; inflammation; transplant rejection
SeICIDs	unspecified	cytokine inhibitor; NSAID; immunosuppressant; TNF inhibitor; phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	autoimmune disease; inflammation
cytokine regulators	unspecified	cytokine synthesis inhibitor; NSAID	inflammation; pigmentation disorder
JTE 607	unspecified	cytokine synthesis inhibitor; NSAID	inflammation
SKF 104351	2-(4-fluorophenyl)- 6,7-dihydro-3-(4- pyridinyl)-5H- pyrrolo[1,2- a]imidazole	cytokine synthesis inhibitor; NSAID	inflammation
SKF 86002	6-(4-fluorophenyl)- 2,3-dihydro-5-(4- pyridinyl)imidazo[2,1- b]thiazole	cytokine synthesis inhibitor; NSAID	inflammation
SKF 105809	6,7-dihydro-2-[4- (methylsulfinyl)phenyl]- 3-(4-pyridinyl)-5H- pyrrolo[1,2- a]imidazole	cytokine synthesis inhibitor; NSAID	inflammation
BMY 30094	N- hydroxybenzenenona- namide	cytokine synthesis inhibitor; NSAID	inflammation; psoriasis

CI 959	5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-benzo[b]thiophene-2-carboxamide sodium salt	degranulation inhibitor; immunosuppressant; NSAID	rhinitis; inflammation; asthma; arthritis
eclazolast; RG 2871; REV 2871; RHC 2871	2-ethoxyethyl-5-chloro-2-benzoxazolecarboxylate	degranulation inhibitor; NSAID	inflammation
prinomide; prinomide tromethamine; CGS 10787; CGS 10787B	alpha-cyano-1-methyl-beta-oxopyrrole-2-propionanilide with 2-amino-2-(hydroxymethyl)-1,3-propanediol	DMARD; analgesic; immunosuppressant; NSAID	inflammation; pain; rheumatoid arthritis
LY 243062	D-1-isopropyl-6-n-propyl-8-beta-methylthiomethylergoline	dopamine agonist; dopamine D2 agonist; NSAID	inflammation
MAb, E-selectin	unspecified	E selectin antagonist; monoclonal antibody; NSAID	inflammation
neutrophil elastase/matrix metalloproteinase inhibitor	unspecified	elastase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	inflammation
SR 26831	5-[(2-chlorophenyl)methyl]-2-(2,2-dimethyl-1-oxopropoxy)-4,5,6,7-tetrahydro-5-hydroxythieno[3,2-c]pyridinium	elastase inhibitor; proteinase inhibitor; NSAID	inflammation; emphysema
superoxide dismutase manganese complex; Mn-SOD	unspecified	free radical scavenger; NSAID	respiratory disease; inflammation
superoxide dismutase, modified; SI 3501	unspecified	free radical scavenger; NSAID	inflammation



superoxide dismutase; copper zinc complex; CuZnSOD; OxSODrol	N-acetylsuperoxide dismutase (human clone pS 61-10 copper-zinc subunit protein moiety reduced)	free radical scavenger; NSAID	respiratory disease; ischemia; rheumatoid arthritis; inflammation
OPC 15161; NF 1616904	6-(1H-indol-3- ylmethyl)-5-methoxy- 3-(2-methylpropyl)-2- (1H)-pyrazinone, 4- oxide	free radical scavenger; NSAID	inflammation; kidney disease
superoxide dismutase manganese complex; hMNSOD	unspecified	free radical scavenger; NSAID; immunosuppressant	ischemia; rheumatoid arthritis; inflammation; reperfusion injury
superoxide dismutase variants; SOD	unspecified	free radical scavenger; NSAID; immunosuppressant	inflammation; autoimmune disease; reperfusion injury
VB 5122	unspecified	free radical scavenger; xanthine oxidase inhibitor	inflammation; asthma
mipragoside; AGF 44	[R-[R*,S*-(E)]]-N- [1-[[[O-[N-acetyl-1- (1-methylethyl)-alfa- neuraminosyl]-(2-3)- O-[O-beta-D- galactopyranosyl-(1- 3)-2-(acetylamino)-2- deoxy-beta-D- galactopyranosyl-(1- 4)-O-beta-D- galactopyranosyl-(1- 4)-beta-D- glucopyranosyl]oxy] methyl]-2-hydroxy-3- heptadecenyl]octadec anamide	ganglioside analogue; analgesic; NSAID	inflammation; pain
gene therapy, glucocorticomimetic receptor; gene therapy, asthma	unspecified	gene therapy; NSAID	inflammation; asthma
inflammatory disease therapy, IL-1Hy273	unspecified	gene; biotechnology	inflammation

genetic suppressor elements, inflammation	unspecified	Genetic suppression of inflammation	inflammation
glucocorticoids	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation
glucocorticoids	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation; asthma; autoimmune disease
loteprednol etabonate; loteprednol; P 5604; HGP 1; CDDD 5604; LOTEMAX; ALREX; LENOXIN	(11beta,17alpha)-17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid chloromethyl ester	glucocorticoid; NSAID	inflammation; conjunctivitis; rhinitis
MY 1250	5,6-dihydro-7,8-dimethyl-4,5-dioxo-4H-pyrano[3,2-c]quinoline-2-carboxylic acid	histamine antagonist; histamine H1 antagonist; NSAID	inflammation; allergy
CP 331; CP 6	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-[[2-oxo-2-[[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]ethyl]thio]ethyl ester	histamine antagonist; histamine H2 antagonist; analgesic; NSAID	inflammation; pain
dehydroepiandrosterone sulfate; DHEAS; PB 005	unspecified	hormone; vaccine adjuvant; corticosteroid	inflammation; infectious disease; asthma
ICE inhibitors	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	inflammation
interleukin-1 beta converting enzyme inhibitors, ICE inhibitors	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	inflammation
interleukin-1 converting enzyme inhibitor; ICE-1 inhibitor	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	inflammation; inflammatory bowel disease

VE 19512	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	rheumatoid arthritis; osteoarthritis; inflammation
VX 740; HMR 3480	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	rheumatoid arthritis; osteoarthritis; inflammation
GYKI 66114	N-(ethoxycarbonyl)-L-alanyl-L-tyrosyl-L-valyl-N-[(1S)-2-carboxy-1-formylethyl]-L-alaninamide	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID; peptide	inflammation
GYKI 66115	N-(ethoxycarbonyl)-L-alanyl-L-tyrosyl-L-valyl-N-[(1S)-2-carboxy-1-formylethyl]glycinamide	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID; peptide	inflammation
clotrimazole + mometasone; mometasone + clotrimazole; SCH 458	unspecified	imidazole; corticosteroid; antifungal	mycosis; inflammation
anti-inflammatory agents	Unspecified bacterial proteins	Immunomodulation	inflammation
acemannan; CARN 1000; CARN 750; CARRASYN; ALIMINASE; VORALEX; CARRAVEX	(1->4),(1->6)-alpha-D-galacto-beta-D-mannan acetate	immunostimulant; cicatrizant	inflammatory bowel disease; skin ulcer; inflammation; cancer
immunology/inflammation therapy, Rigel	unspecified	immunosuppressant	inflammation; autoimmune disease; asthma
aldose reductase inhibitors	unspecified	immunosuppressant; aldose reductase inhibitor; NSAID	autoimmune disease; allergy; inflammation
signal transduction modulators	unspecified	immunosuppressant; immunostimulant; NSAID	autoimmune disease; cancer; inflammation

corticotropin releasing factor binding protein; CRF binding protein; NBI 112	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; inflammation
E 21R	unspecified	immunosuppressant; NSAID	cancer; inflammation; allergy
leukocyte function associated antigen 3 T cell inhibitor protein; LFA3TIP; LFA3TIP; AMEVIVE	unspecified	immunosuppressant; NSAID	inflammation; autoimmune disease; psoriasis
LFA-1 alpha subunit; leukocyte function associated antigen-1 alpha subunit; leukocyte cell surface adhesion receptor molecule	unspecified	immunosuppressant; NSAID	inflammation
MAb, CD40 ligand; 5C8; ANTOVA	unspecified	immunosuppressant; NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
OX40-based immunotherapy, Cantab	unspecified	immunosuppressant; NSAID	inflammation; autoimmune disease
BN 58705	unspecified	immunosuppressant; NSAID	septic shock; inflammation
BW 91Y78	unspecified	immunosuppressant; NSAID	inflammation
CD4 inhibitors	unspecified	immunosuppressant; NSAID	inflammation
inflammation therapy	unspecified	immunosuppressant; NSAID	inflammatory bowel disease; inflammation; autoimmune disease
Ro 236457	unspecified	immunosuppressant; NSAID	inflammation
phellodendrine; OB 5	(7S-cis)-5,8,13,13a-tetrahydro-2,11-dihydroxy-3,10-dimethoxy-7-methyl-6H-dibenzo[a,g]quinolizinium	immunosuppressant; NSAID	transplant rejection; inflammation; viral infection; asthma; kidney disease

TEI 1338	(E)-N-(2-methoxycarbonylphenyl)-8-(2-naphthyl)-5,6-trans-5,6-methano-7-octenamide	immunosuppressant; NSAID	allergy; inflammation
TEI 3332	[(6,7-dihydroxy-2-naphthalenyl)thio]acetic acid methyl ester	immunosuppressant; NSAID	allergy; inflammation
KB 2683	2-(4-methylphenyl)-4-benzothiazolol acetate	immunosuppressant; NSAID	rheumatoid arthritis; inflammation; autoimmune disease
albifylline; HWA 138	3,7-dihydro-1-(5-hydroxy-5-methylhexyl)-3-methyl-1H-purine-2,6-dione	immunosuppressant; NSAID	septic shock; inflammation
celastrol	unspecified	immunosuppressant; NSAID; terpene	inflammation
CD45 inhibitors	unspecified	immunosuppressant; NSAID; tyrosine phosphatase inhibitor	transplant rejection; inflammation
potassium channel blocker	unspecified	immunosuppressant; potassium channel blocker	autoimmune disease; allergy; inflammation
fusion protein, CD5-gelonin; CD5-gelonin T lymphocyte-targeted immunofusion protein; GENIMUNE	unspecified	immunotoxin; NSAID	rheumatoid arthritis; inflammation
MAB, B11; MAB, E-selectin; MAB, endothelium leukocyte adhesion molecule	unspecified	integrin antagonist; biotechnology; immunosuppressant; monoclonal antibody; E selectin antagonist; cell adhesion inhibitor; NSAID	inflammation
MAB, selectin; CY 1788; CY 1787	Unspecified	integrin antagonist; biotechnology; monoclonal antibody; E selectin antagonist; cell adhesion inhibitor; NSAID	inflammation; septic shock; rhinitis

MAB, L-selectin, human	unspecified	integrin antagonist; biotechnology; monoclonal antibody; L selectin antagonist; cell adhesion inhibitor; NSAID	inflammation; anaphylactic shock
GM 1676	unspecified	integrin antagonist; cell adhesion inhibitor; immunosuppressant; NSAID	inflammation
neutrophil inhibitory factor; NIF; CORLEUKIN NIF	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	reperfusion injury; inflammation; stroke
anti-inflammatory agents	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; cancer
cell adhesion antagonist, cell adhesion antagonist,	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation
cell adhesion inhibitor	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; allergy
cell adhesion inhibitor	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	cancer; inflammation
drug delivery system, STEALTH cell adhesion inhibitors	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	cancer; inflammation
E-selectin inhibitors	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation
GM 1606	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation
GM 1925	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation
GM 1986	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation

GM 1998	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; respiratory distress syndrome; heart ischemia; reperfusion injury
GM 2296	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; respiratory distress syndrome
GM 7050	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; cancer
VCAM-1 inhibitors	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation
cell adhesion inhibitors	unspecified	integrin antagonist; cell adhesion inhibitor; selectin antagonist; NSAID	inflammation
L-selectin inhibitors	unspecified	integrin antagonist; L selectin antagonist; cell adhesion inhibitor; NSAID	inflammation
NE 1704	unspecified	integrin antagonist; oligosaccharide; E selectin antagonist; cell adhesion inhibitor; NSAID	inflammation
P-selectin inhibitors	unspecified	integrin antagonist; P selectin antagonist; cell adhesion inhibitor; NSAID	inflammation
selectin antagonists	unspecified	integrin antagonist; P selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation
CEN 100	unspecified	integrin antagonist; peptide; P selectin antagonist; cell adhesion inhibitor; NSAID	ischemia; inflammation; reperfusion injury

low molecular weight selectin inhibitors	unspecified	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation; allergy
TBC 1269	3',3'''-(1,6- hexanediyl)bis[6'- (alpha-D- mannopyranosyloxy)- [1,1'-biphenyl]-3- acetic acid	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation; asthma
EPI KAL2	unspecified	kallikrein inhibitor; biotechnology	inflammation
PKSI 527	[1(S)-trans]-4-[[2- [[[4- (aminomethyl)cyclohexyl]carbonyl]amino]- 1-oxo-3- phenylpropyl]amino] benzeneacetic acid monohydrochloride	kallikrein inhibitor; NSAID	septic shock; inflammation; thrombosis
leukocyte adhesion inhibitors	unspecified	leukocyte adhesion inhibitor; NSAID	inflammation; cardiac therapy
moxilubant; CGS 25019; CGS 25019C	4-[5-[4- (aminoiminomethyl)phenoxy]pentyl]oxy]- 3-methoxy-N,N- bis(1- methylethyl)benzamide	leukotriene antagonist; leukotriene B4 antagonist; NSAID	inflammation
ZD 3523; ICI D3523	unspecified	leukotriene antagonist; NSAID	asthma; inflammation
RP 66153	unspecified	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation



WF 11605	(1S,1R,4aS,6aR,8R,9R,10aS,12aS)-9-acetoxy-2-((R)-1,2dimethylpropyl)-8-(beta-D-glucopyranosyl)oxy-1,2,3,4,4a,5,6,6a,7,8,9,10,10a,11,12,12a-hexadecahydro-2,4a,7,7,10a,12a,hexamethyl-3-oxochrysene-1-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	hepatitis; inflammation; psoriasis
SB 201993	(E)-3-[[[6-(2-carboxyethenyl)-5-[[8-(4-methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	psoriasis; inflammation
SB 201146	(E)-3-[6-[[[(3-aminophenyl)sulfinyl]methyl]-3-[[8-(4-methoxyphenyl)octyl]oxy]-2-pyridinyl]-2-propenoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation
ticolubant; SB 209247	(E)-3-[6-[[[2,6-dichlorophenyl]thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation; psoriasis
LY 255283	1-[5-ethyl-2-hydroxy-4-[[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]ethanone	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation
PF 10042	1-[5-hydroxy-5-[8-(1-hydroxy-2-phenylethyl)-2-dibenzofuranyl]-1-oxopentyl]pyrrolidine	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation

RP 64966	2-((4-(5-(3-phenylpropyl)-2-thienyl)butyl)oxy)acetic acid (sodium salt)	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation; psoriasis; inflammatory bowel disease
RG 14893	4-(2-(methyl(2-phenethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; inflammation
LY 213024	5-(3-carboxybenzoyl)-2-(decyloxy)benzenepropanoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation
SC 50605	7-[3-[2(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	psoriasis; inflammation
LY 264086	7-carboxy-3-(decyloxy)-9-oxo-9H-xanthene-4-propanoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation
LY 210073	Unspecified	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation
WAY 121006 trom	3-fluoro-4'-(2-quinolinylmethoxy)-[1,1'-biphenyl]-4-acetic acid	leukotriene B4 antagonist; leukotriene D4 antagonist; leukotriene antagonist; NSAID	inflammation
macrophage chemotaxin inhibitor	unspecified	macrophage inhibitor; NSAID	inflammation; cardiovascular disease
S 3304	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor	cancer; inflammation

CH 104	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; inflammation
CH 715	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; inflammation
PI 88	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	inflammation; cancer
PGE 2946979	3-[(hydroxyamino)carbonyl]-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinecarboxylic acid phenylmethyl ester	metalloproteinase inhibitor; proteinase inhibitor	inflammation; cancer
TNF alpha converting enzyme inhibitors, TACE inhibitors	unspecified	metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; inflammation
MAb, inflammation	unspecified	monoclonal antibody	inflammation
MAb, interleukin-8; MAb, IL-8; ABX IL8	unspecified	monoclonal antibody; biotechnology; NSAID	respiratory distress syndrome; inflammatory bowel disease; rheumatoid arthritis; inflammation; psoriasis
MAb, inflammation therapy, LeukoSite/MorphoSys	unspecified	monoclonal antibody; immunosuppressant	inflammation; autoimmune disease
MAb, cadherin	unspecified	monoclonal antibody; NSAID	inflammation
MAb, CD11a	unspecified	monoclonal antibody; NSAID	inflammation
MAb, CD11b; MAb, m60.1; m60.1; LY 303932	unspecified	monoclonal antibody; NSAID	inflammation; heart ischemia; reperfusion injury
MAb, CD11b	unspecified	monoclonal antibody; NSAID	inflammation

MAB, CD18	unspecified	monoclonal antibody; NSAID	inflammation
MAB, CD18, humanized; SMART anti-CD18	unspecified	monoclonal antibody; NSAID	inflammation
MAB, humanized tumor necrosis factor; MAB, humanized TNF; MAB, CDP571; CDP 571; BAY 103356; B 1351	unspecified	monoclonal antibody; NSAID	septic shock; inflammation; bacterial infection; inflammatory bowel disease; rheumatoid arthritis
MAB, interferon alfa; MAB, IFN-alfa	unspecified	monoclonal antibody; NSAID	inflammation
MAB, interleukin-8, Medarex	unspecified	monoclonal antibody; NSAID	inflammation
MAB, T cells; MAB, rheumatoid arthritis	unspecified	monoclonal antibody; NSAID	inflammation
MAB, tumor necrosis factor-alpha, human; D2E7; LU 200134	unspecified	monoclonal antibody; NSAID	inflammation
MAB, VLA-4, humanized; MAB, very late antigen-4, humanized	unspecified	monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
MAB, monocyte chemoattractant protein-1 receptor; MAbs, MCP-1 receptor	unspecified	monoclonal antibody; NSAID; chemokine antagonist	inflammation
MAB, B7; MAB, PRIMATIZED B7; IDEC 114	unspecified	monoclonal antibody; NSAID; immunosuppressant	systemic lupus erythematosus; inflammation; transplant rejection; psoriasis
leishmania lipophosphoglycan	leishmania lipophosphoglycan	Monocyte recruitment blockade	inflammation; restenosis
antisense oligonucleotide, interleukin-1 beta; antisense oligonucleotide, IL-1 beta	unspecified	mRNA translation inhibitor; antisense; oligonucleotide	inflammation

L 733060	(2S-cis)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID	inflammation; pain; asthma
CP 96345	(2S,3S)-cis-2-(diphenylmethyl)-N-[[2-(methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID; substance P antagonist	inflammation; pruritis; pain
neurokinin antagonists	unspecified	neurokinin antagonist; analgesic; NSAID	pain; inflammation
nolpitantium besilate; SR 140333	(S) 1-[2-[3-(3,4-dichlorophenyl)-1-[[3-(1-methylethoxy)phenyl]acetate]-3-piperidinyl]ethyl]-4-phenyl-1-azoniabicyclo[2.2.2]octane	neurokinin antagonist; neurokinin 1 antagonist; NSAID	asthma; inflammation
L 737488	(S)-N-[4-[3,5-bis(trifluoromethyl)phenyl]-1-(1H-indol-3-ylmethyl)-2-oxobutyl]-1-azabicyclo[2.2.2]octane-4-carboxamide monohydrochloride	neurokinin antagonist; neurokinin 1 antagonist; NSAID	inflammation
FK 224; FR 115224	N-[N2-[N-[N-[N-[alfa,beta-didehydro-N-methyl-N-[N-[1-oxo-3-(2-pentylphenyl)propyl]-L-threonyl]tyrosyl]-L-leucyl]-D-phenylalanyl]-L-allothreonyl]-L-asparaginy]-L-serine epsilon-lactone	neurokinin antagonist; neurokinin 2 antagonist; NSAID	asthma; inflammation

NS 2073	unspecified	nitric oxide activator; NSAID	inflammation; glaucoma; gastrointestinal ulcer; asthma
NS 2028	unspecified	nitric oxide inhibitor; NSAID	inflammation
NOS inhibitor	unspecified	nitric oxide synthase inhibitor; NSAID	neurological; inflammation
inflammatory disease therapy,	unspecified	NSAID	inflammation
compinact A	unspecified	NSAID	inflammation
compinact C	unspecified	NSAID	inflammation
GELIN	unspecified	NSAID	inflammation
TSG 6	unspecified	NSAID	inflammation
acute inflammation therapy	unspecified	NSAID	inflammation
adenosine kinase inhibitors, inflammation	unspecified	NSAID	inflammation
anchoring protein modulators	unspecified	NSAID	inflammation
anti-inflammatory agent	unspecified	NSAID	inflammation; asthma
anti-inflammatory agents	unspecified	NSAID	inflammation
anti-inflammatory agents	unspecified	NSAID	inflammation
anti-inflammatory agents	unspecified	NSAID	inflammation
anti-inflammatory agents	unspecified	NSAID	inflammation
anti-inflammatory agents	unspecified	NSAID	inflammation
anti-inflammatory, Pharmacopeia; anti- inflammatory	unspecified	NSAID	inflammation
anti-inflammatory, anti-inflammatory	unspecified	NSAID	inflammation
anti-inflammatory, transcription factors	unspecified	NSAID	inflammation
anti-inflammatory	unspecified	NSAID	inflammation
APC 1024	unspecified	NSAID	inflammation

APC 1070	unspecified	NSAID	inflammation
APC 1132	unspecified	NSAID	inflammation
APC 1134	unspecified	NSAID	inflammation
APC 1390	unspecified	NSAID	inflammation
bradykinin receptor modulators, Pharmacopeia	unspecified	NSAID	inflammation
C5a inhibitors	unspecified	NSAID	inflammation; cardiovascular disease
CD40 receptor signalling pathway inhibitor; CD40 receptor signalling pathway inhibitor	unspecified	NSAID	allergy; asthma; inflammation
cell adhesion molecules intracellular inhibitors	unspecified	NSAID	cancer; inflammation
chemokine receptor modulators	unspecified	NSAID	inflammation; asthma; atherosclerosis
CPH 82; REUMACON; COMIHOG	unspecified	NSAID	inflammation; Alzheimer disease
D 20207	unspecified	NSAID	inflammation; respiratory disease
diclofenac digolil; F 5402M	unspecified	NSAID	inflammation
drug delivery system, diclofenac; diclofenac PULSINCAP	unspecified	NSAID	inflammation
drug delivery system, DIFFUCAP diclofenac; diclofenac DIFFUCAP; DICLOMAX	unspecified	NSAID	inflammation
drug delivery system, diclofenac; diclofenac; ISV 205	unspecified	NSAID	glaucoma; inflammation
drug delivery system, GEOMATRIX controlled release ketoprofen; ketoprofen GEOMATRIX	unspecified	NSAID	inflammation

drug delivery system, NSAIDs; ENTEROTEC	unspecified	NSAID	inflammation
drug delivery system, submicron emulsion diclofenac; diclofenac SME	unspecified	NSAID	inflammation
drug discovery	unspecified	NSAID	inflammation; diabetes; cardiovascular disease; neurological; cancer; infectious disease
EN 03	unspecified	NSAID	inflammation
G-protein antagonist	unspecified	NSAID	inflammation; cardiovascular disease; neurological
G-protein therapy	unspecified	NSAID	inflammation; cardiovascular disease; cancer
gene discovery, inflammatory diseases	unspecified	NSAID	inflammation; rheumatoid arthritis
gene discovery, oxidative stress pathways	unspecified	NSAID	neurological; inflammation
glucocorticoid agonists	unspecified	NSAID	inflammation; rheumatoid arthritis; inflammatory bowel disease; asthma
GM 7072	unspecified	NSAID	inflammation
ICAM-1 inhibitors, intracellular adhesion molecule-1 inhibitors	unspecified	NSAID	inflammation
ICR 18	unspecified	NSAID	inflammation
IL-8 receptor modulators	unspecified	NSAID	inflammation
inflammatory disease therapy	unspecified	NSAID	inflammation
interleukin modulators	unspecified	NSAID	inflammation; asthma
interleukin-8 receptor antagonists	unspecified	NSAID	inflammation
IPL 576; IZP 94005	unspecified	NSAID	psoriasis; allergy; inflammation



kinase modulators	unspecified	NSAID	cancer; inflammation
leucomyzin	unspecified	NSAID	inflammation; hyperlipidemia
LG 21101	unspecified	NSAID	inflammation; multiple sclerosis
major histocompatibility complex II, ligand, MHC II ligand	unspecified	NSAID	allergy; inflammation
MN 10021	unspecified	NSAID	inflammation
p38 kinase modulators	unspecified	NSAID	inflammation
PG CC8	unspecified	NSAID	eye disease; inflammation
phosphosugar anti-inflammatory agent	unspecified	NSAID	inflammation
sialophorin chimeric molecules	unspecified	NSAID	inflammation
signal transduction modulators	unspecified	NSAID	cancer; inflammation; neurological
SR 129	unspecified	NSAID	inflammation
SR 318B; SR 318	unspecified	NSAID	inflammation
synthetic glycosaminoglycans	unspecified	NSAID	inflammation; cancer; neuropathy
TNF alpha proteinase inhibitor; TAPI	unspecified	NSAID	inflammation
white blood cell migration inhibitors	unspecified	NSAID	inflammation; multiple sclerosis
ketoprofen, (R)-; (R)-ketoprofen	(R)-3-benzoyl-alpha-methylbenzeneacetic acid	NSAID	inflammation
limazocic; SA 3443	(R)-hexahydro-7,7-dimethyl-6-oxo-1,2,5-dithiazocine-4-carboxylic acid	NSAID	liver disease; inflammation; emphysema; intoxication
dexketoprofen; ketoprofen, (S)-; (S)-ketoprofen	(S)-3-benzoyl-alpha-methylbenzeneacetic acid	NSAID	inflammation
tioxamast; F 1865	[[4-(4-methoxyphenyl)-2-thiazolyl]amino]oxoacetic acid ethyl ester	NSAID	asthma; inflammation; skin disease

U 91502	[3-(1,6-dihydro-1-methyl-6-oxo-4-phenyl-2-pyrimidinyl)propylidene]bisphosphonic acid tetraethyl ester	NSAID	inflammation; arthritis
AO 1535	[R-[R*,S*-(E)]]-N-[1-[(beta-D-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecenyl]-3-pyridinecarboxamide	NSAID	skin disease; inflammation
DUP 983	1-(4-(4-pyridyl)phenyl)-1-(4-fluorophenyl)-2-imidazolyl-1-ethanol	NSAID	inflammation
acemetacin; TV 1322; TVX 1322; K 708; BAY F 4975; ANAGEL; FLAMARION; MOSTANOL; OLDAN; RANTUDIL; RANTUDAL; RUCATEN; SPORTIX; TILUR	1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid ester with glycolic acid	NSAID	inflammation
tropesin; indometacin tropine ester; tropine indometacinate; VUFB 12018; REPANIDAL	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-carboxy-2-phenylethyl ester	NSAID	inflammation
indometacin farnesil; indomethacin farnesyl; IM-F; E 0710; E 710; INFREE	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid, 3,7,11-trimethyl-2,6,10-dodecatrienyl ester	NSAID	inflammation
anti-inflammatory	1-(4-chlorophenyl)-1,3-dihydro-3,3-dimethyl-2H-pyrrolo(2,3-b)pyridine-2-one	NSAID	inflammation

tebufelone; NE 11740	1-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-5-hexyn-1-one	NSAID	inflammation
bermoprofen; AD 1590; DIBENON	10,11-dihydro- $\alpha$ ,8-dimethyl-11-oxodibenz[b,f]oxepin-2-acetic acid	NSAID	inflammation
zaltoprofen; CN 100; ZC 102; SOLETON; PEON	10,11-dihydro- $\alpha$ -methyl-10-oxodibenzo[b,f]thiepin-2-acetic acid	NSAID	inflammation; respiratory disease
YT 1	2-phenyl-4(1H)-quinolone	NSAID	inflammation
lonazolac; SNK 874; ARTHROAKUT; IRRITREN	3-(4-chlorophenyl)-1-phenyl-1H-pyrazole-4-acetic acid	NSAID	inflammation
HWA 131	3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-7H-thiazolo[3,2-b][1,2,4]triazin-7-one	NSAID	inflammation
KF 18280	3-benzyl-5-phenyl-3H-imidazo(4,5-c)(1,8)naphthyridine-4(5H)-one	NSAID	inflammation
piroxicam cinnamate; SPA A510; SPA S510; CINNOXICAM; SINARTROL	3-phenyl-propenoic acid, 2-methyl-3-[(2-pyridinylamino)-carbonyl]-2 H-1,2-benzothiazin-4-yl ester, S,S-dioxide	NSAID	inflammation
eltenac; B 78820	4-(2,6-dichloroanilino)-3-thiopheneacetic acid	NSAID	inflammation
oxaprozin; WY 21743; DAYPRO; ACTIRIN; DURAPRO; DURAPROX; DAXPROZIN	4,5-diphenyl-2-oxazolepropanoic acid	NSAID	inflammation
anti-inflammatory	4-[(2-aminoethyl)amino]-1-(2-thienyl)-1-butanone	NSAID	inflammation

ximoprofen; XIFAM	4-[3-(hydroxyimino)cyclohexyl]-alpha-methylbenzencacetic acid	NSAID	inflammation
FK 3311	4'acetyl-2'-[2,4-difluorophenoxy]methanesulfonanilide	NSAID	inflammation
tenoxicam; Ro 12 0068; LIMAN; MITROTIL; TILCOTIL	4-hydroxy-2-methyl-N-2-pyridyl-2H-thieno[2,3-c]-1,2-thiazine-3-carboxamide 1,1-dioxide	NSAID	inflammation
anti-inflammatory	4-propylthio-o-anisidine	NSAID	inflammation
DUP 697	5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]thiophene	NSAID	inflammation
PD 144795	5-methoxy-3-(1-methylethoxy)-benzo[b]thiophene-2-carboxamide 1-oxide	NSAID	inflammation
droxicam; E 3128; OMBOLAN; FERPAN; DROGELON; PRECAM; DROBENAM; DROXAR	5-methyl-3-(2-pyridyl)-2H,5H-1,3-oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione-6,6-dioxide	NSAID	inflammation
decasilate	8-(2-phenylethyl)-1-oxa-diazaspiro[4.5]decan-2-one compound with 2-thiophenecarboxylic acid (1:1)	NSAID	allergy; inflammation
ibuprofen guaiacol; methoxybutropate; metoxybutropate; AF 2259; BENFLOGIN; BELEP	alpha-methyl-4-(2-methylpropyl)benzeneacetic acid 2-methoxyphenyl ester	NSAID	inflammation

amproxicam; CP 65703; FLUCAM; NACYL	ethyl 1-[[2-methyl-3-[(2-pyridinylamino)carbonyl]-2H-1,2-benzothiazin-4-yl]oxy] ethyl ester S,S-dioxide carbonic acid	NSAID	inflammation
Z 1957	ethyl N-((3-methyl-5-isoxazolyl)-2-thiazolyl) oxamate	NSAID	asthma; inflammation
adelmidrol; LG 21301	N,N'-bis(2-hydroxyethyl)nonane diamide	NSAID	inflammation; acne
andolast; CR 2039	N-4-(5-tetrazolyl)-phenyl-4-(5-tetrazolyl)-benzamide	NSAID	asthma; inflammation; allergy
salnacedin; G 201; SCY	N-acetyl-L-cysteine 2-hydroxybenzoate	NSAID	inflammation; skin disease
diclofenac potassium; CGP 45840B; CATAFLAM; CATAFLAN; DICLOFEN; VOLTAREN	potassium (o-(2,6-dichloroanilino)-phenyl)acetate	NSAID	inflammation; migraine; surgery
glucocorticoid receptor agonists,	unspecified	NSAID, glucocorticoid agonists	inflammation
CHF 2003	unspecified	NSAID; analgesic	pain; inflammation
drug delivery system, HIT diclofenac; diclofenac HIT; HYAL AT2101; HYAL CT1101; HYAL AV2201; HYAL AT1201; HYANALGESE; HYANALGESE-D; SOLARASE; ORALEASE	unspecified	NSAID; analgesic	pain; cancer; inflammation; skin disease; mucositis
drug delivery system, HIT ibuprofen; ibuprofen HIT; HYAL AT2102	unspecified	NSAID; analgesic	inflammation; pain

drug delivery system, HIT piroxicam; piroxicam HIT; HYAL AT2103	unspecified	NSAID; analgesic	inflammation; pain
drug delivery system, IPDAS ketoprofen; ketoprofen IPDAS; KETELAN	unspecified	NSAID; analgesic	inflammation; pain
drug delivery system, naproxen; naproxen, sustained release; IPDAS naproxen; NAPROLEN; NAPRELAN	unspecified	NSAID; analgesic	inflammation; pain
drug delivery system, oral transmucosal piroxicam; piroxicam oral transmucosal	unspecified	NSAID; analgesic	inflammation; pain
drug delivery system, transdermal diclofenac	unspecified	NSAID; analgesic	pain; inflammation
drug delivery system, transdermal fenoprofen; fenoprofen transdermal	unspecified	NSAID; analgesic	pain; inflammation
drug delivery system, transdermal flurbiprofen	unspecified	NSAID; analgesic	pain; inflammation
drug delivery system, transdermal ketoprofen	unspecified	NSAID; analgesic	inflammation; pain
drug delivery system, transdermal piroxicam; piroxicam transdermal	unspecified	NSAID; analgesic	pain; inflammation
polyunsaturated fatty acids, PUFA	unspecified	NSAID; analgesic	inflammation; pain
tilnoprofen arbamel; Y 23023	(+/-)-alpha-2-methyl- 5H- [1]benzopyran[2,3- b]pyridine-7-acetic acid, 2- (dimethylamino)-2- oxoethyl ester	NSAID; analgesic	inflammation; pain

dexketoprofen trometamol; LM 1158; TRIS; D 1158; ENANTYUM; QUIRALAM; KETESSE	(S)-3-benzoyl-alpha- methylbenzeneacetic acid cpd with 2- amino-2- (hydroxymethyl)-1,3- propanediol (1:1)	NSAID; analgesic	pain; inflammation
florifenine; FI 2522	2-(1- pyrrolidinyl)ethyl-N- [7-(trifluoromethyl)- 4- quinolyl]anthranilate	NSAID; analgesic	inflammation; pain
aceclofenac; YT 919; AIRTAL; GERBIN; FALCOL; BRISTAFLAM; PRESERVEX; BIOFENAC; BARRACAN	2-[(2,6- dichlorophenyl)amino ]benzeneacetic acid, carboxymethyl ester	NSAID; analgesic	pain; inflammation
bromfenac; bromfenac sodium; AHR 10282; DURACT	2-amino-3-(4- bromobenzoyl)benzen eacetic acid	NSAID; analgesic	inflammation; pain
mofezolac; N 22; DISOPAIN	3,4-bis(4- methoxyphenyl)-5- isoxazoleacetic acid	NSAID; analgesic	inflammation; pain
nabumetone; BRL 14777; RELIFEN; RELIFEX; LISTRAN; PRODAG; BALMOX; NABUMETON; RELAFEN	4-(6-methoxy-2- naphthyl)-2-butanone	NSAID; analgesic	pain; inflammation
piroxicam betadex; piroxicam cyclodextrin; CHF 1194; BREXIN; BREXINE; BREXIDOL; CYCLADOL; BREXICAM; BREXINIL	4-hydroxy-2-methyl- N-(2-pyridinyl)-2H- 1,2-benzothiazine-3- carboxamide 1,1- dioxide compound with beta- cyclodextrin	NSAID; analgesic	pain; inflammation

HAI 105	6,11-dihydro-2-methoxy-alpha-methyl-11-oxodibenz[b,e]oxepin-3-acetic acid	NSAID; analgesic	pain; inflammation
tifurac; RS 82917; RS 82917030	7-[4-(methylthio)benzoyl]-5-benzofuranacetic acid	NSAID; analgesic	inflammation; pain
pelubiprofen; CS 670; RS 2131	alpha-methyl-4-[(2-oxocyclohexyllidene)methyl]benzeneacetic acid	NSAID; analgesic	inflammation; pain
HN 3392	N-(4-(4-methoxyphenyl)-5-phenylthiazolyl)	NSAID; analgesic	inflammation; pain
amtolmetin guacil; STN 679; MED 15; ARTROMED; EUFANS	N-[[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl]glycine 2-methoxyphenyl ester	NSAID; analgesic	arthritis; rheumatoid arthritis; inflammation; pain
flosulide; ZK 38997; CGP 28238; CGS 28238; SH 459	N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide	NSAID; analgesic	inflammation; pain
olvanil; oluvanil; NE 19550	N-vanillyloleamide	NSAID; analgesic	pain; inflammation; viral infection
AF 150	N,N,-dimethyl-N-[2-[2-[4-(2-methylpropyl)phenyl]-1-oxopropoxy]ethyl]-1-octanaminium bromide	NSAID; antibacterial	bacterial infection; inflammation
PS 519	unspecified	NSAID; anti-ischemic; proteinase inhibitor	inflammation; stroke
apoptosis modulators	unspecified	NSAID; apoptosis inhibitor; apoptosis inducer; caspase inhibitor	cancer; neuropathy; inflammation
CCR1 antagonists	unspecified	NSAID; chemokine antagonist	inflammation



CCR5 antagonists	unspecified	NSAID; chemokine antagonist	HIV infection; inflammation
CXCR3 antagonists	unspecified	NSAID; chemokine antagonist	inflammation
neurotactin blockers	unspecified	NSAID; chemokine antagonist; gene	multiple sclerosis; inflammation
complement C3a receptor modulators	unspecified	NSAID; complement inhibitor	inflammation
etodolac; RAK 591; AY 24236; NIH 9918; RAK 593; RAK 592; HYPEN; LODINE; ULTRADOL; ARFLOGIN; TEDOLAN; ETANAL; ANTILAK; EDINE; LODIO; OSTELUC	1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid	NSAID; COX inhibitor; COX 2 inhibitor	inflammation
immune system modulators,	unspecified	NSAID; immunosuppressant	inflammation
MKK3 modulators	unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation
MKK4 modulators	unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation; neurodegeneration
VX 745	unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation; neurological; heart failure; Crohn disease; asthma
isalsteine; TF 914	(+,-)-N-(2-((2-methyl-4-oxo-1,3-benzodioxan-2-yl)thio)propionyl)glycine	NSAID; mucolytic	respiratory disease; inflammation
NCX 284	unspecified	NSAID; nitric oxide donor	inflammation
nitrosylated nonsteroidal anti-inflammatory agent; NO-NSAIDs	unspecified	NSAID; nitric oxide donor	inflammation

ITF 1697	Unspecified	NSAID; peptide	septic shock; inflammation; heart ischemia; inflammatory bowel disease
misoprostol + diclofenac; diclofenac + misoprostol; ARTHROTEC	unspecified	NSAID; prostaglandin	inflammation
proteasome inhibitors, inflammation	unspecified	NSAID; transcription factor regulator	inflammation; cancer
recombinant PSGL 1, PSGL 1	unspecified	P selectin antagonist; E selectin antagonist; L selectin antagonist; selectin antagonist; NSAID	inflammation; transplant rejection; ischemia; reperfusion injury
BN 54068	unspecified	PAF antagonist; NSAID	inflammation
UR 12510	unspecified	PAF antagonist; NSAID	inflammation; asthma
UR 12519	unspecified	PAF antagonist; NSAID	inflammation; asthma
UR 12551	unspecified	PAF antagonist; NSAID	inflammation; asthma
BN 52111	1-(6-((2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy)-6-oxohexyl)-pyridinium bromide	PAF antagonist; NSAID	asthma; inflammation
tiapafant; PCA 4248	1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid methyl 2-(phenylthio)ethyl ester	PAF antagonist; NSAID	asthma; inflammation
BN 52115	1-[6-[(2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy]-6-oxohexyl]quinolinium bromide	PAF antagonist; NSAID	asthma; inflammation

UR 10324	2-(2-acetyl-3,11-dioxo-4,10-dioxo-7-thia-2,12-diazanonacos-1-yl)-1-ethylpyridinium chloride	PAF antagonist; NSAID	inflammation; asthma
tetrahydrocarbazole	4-(2-chlorophenyl)-9-methyl-2-[3-(1,2,3,4-tetrahydro-9H-carbazol-9-yl)-1-propynyl]-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist; NSAID	inflammation; asthma
UR 12460	4-[[[(diphenylmethyl)amino]acetyl]-alpha-(2-methyl-3-pyridinyl)-1-piperazineacetonitrile	PAF antagonist; NSAID	inflammation; asthma
SM 10661	cis-(+,-)-3,5-dimethyl-2-(3-pyridinyl)-4-thiazolidinone monohydrochloride	PAF antagonist; NSAID	endotoxic shock; inflammation; asthma
CV 6209	2-(2-acetyl-6-methoxy-3,9-dioxo-4,8-dioxo-2,10-diazaoctacos-1-yl)-1-ethylpyridinium chloride	PAF antagonist; platelet antiaggregant; NSAID	thrombosis; inflammation
UR 11353	2-[[[acetyl[[[tetrahydro-5-(octadecyloxy)-3-furanyl]methoxy]carbonyl]amino]methyl]-1-ethylpyridinium chloride	PAF antagonist; platelet antiaggregant; NSAID	thrombosis; inflammation
urokinase receptor antagonists	unspecified	peptide	cancer; inflammation
MER W8020	Unspecified	peptide; analgesic; NSAID	inflammation; pain
inflammation therapy, autoimmune disease therapy,	Unspecified	peptide; immunosuppressant	inflammation; autoimmune disease

CD4 peptide antagonist,	unspecified	peptide; immunosuppressant; NSAID	inflammation
cytochrome b558 derived peptide, anti-inflammatory peptide	unspecified	peptide; NSAID	inflammation
CEN 294	unspecified	peptide; NSAID	inflammation; ischemia; reperfusion injury
corticotropin releasing factor analogue, CRF analogue	unspecified	peptide; NSAID	inflammation
inflammation therapy	unspecified	peptide; NSAID	inflammation
mystixins	unspecified	peptide; NSAID	inflammation
LAS 31396	unspecified	phosphodiesterase inhibitor; bronchodilator; NSAID	asthma; inflammation
arofylline; LAS 31025	3-(4-chlorophenyl)-3,7-dihydro-1-propyl-1H-purine-2,6-dione	phosphodiesterase inhibitor; bronchodilator; NSAID	asthma; inflammation
CDP 840	(R)-4-[2-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-phenylethyl]pyridine	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; inflammation
phosphodiesterase IV inhibitor	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; NSAID	inflammation
B669	3-(cyclohexylimino)-3,5-dihydro-N,5-diphenyl-2-phenazinamine	phospholipase activator; immunosuppressant; NSAID	inflammation
phospholipase C inhibitors	unspecified	phospholipase inhibitor; NSAID	inflammation
WAY 121520	1-[(4-chlorophenyl)methyl]-2-methyl-5-(2-quinolinylmethoxy)-1H-indole-3-acetic acid	phospholipase inhibitor; NSAID	inflammation

BMS 188184	3-[(1Z,2Z)-3-carboxy-2-methyl-1-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)methylene]-2-propenyl]benzoic acid	phospholipase inhibitor; NSAID	psoriasis; dermatitis; inflammation
YM 26734	4-(3,5-didodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyphenyl)chroman	phospholipase inhibitor; NSAID	inflammation
YM 265671; YM 26567-1	trans-(+)-1-[3-[3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxyphenyl]-1-dodecanone	phospholipase inhibitor; NSAID	inflammation
U 73122	1-[6-[[[(17 beta)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]	phospholipase inhibitor; platelet antiaggregant; NSAID	inflammation; thrombosis
plasminogen activator inhibitor; PAI-2	unspecified	plasminogen activator inhibitor; cicatrizant	cancer; inflammation; skin ulcer
drug delivery system, MICROPUMP oral controlled release aspirin; aspirin MICROPUMP; ASACARD	unspecified	platelet antiaggregant; thromboxane synthetase inhibitor; analgesic; NSAID	thrombosis; pain; inflammation
cyclic polyamine analogue	unspecified	polyamine analogue; NSAID	Crohn disease; asthma; inflammation
anti-inflammatory agents	unspecified	protein kinase inhibitor; cytokine inhibitor; TNF inhibitor	inflammation
Ro 318830	unspecified	protein kinase inhibitor; protein kinase C inhibitor; NSAID	inflammation

SPC 100840	unspecified	protein kinase inhibitor; protein kinase C inhibitor; NSAID	ischemia; psoriasis; cancer; inflammation; reperfusion injury
UCN 01; UCN 1; KW 2401	(3 $\alpha$ ,9 $\beta$ ,10 $\alpha$ ,11 $\alpha$ ,13 $\beta$ )-(+)-2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one	protein kinase inhibitor; protein kinase C inhibitor; NSAID	cancer; inflammation; allergy
balanol; (-)-balanol; azepinostatin; ophiocordin	(3R-trans)-4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxybenzoic acid 1-[hexahydro-3-[(4-hydroxybenzoyl)amino]-1H-azepin-4-yl] ester	protein kinase inhibitor; protein kinase C inhibitor; NSAID	cancer; inflammation; psoriasis
GF 109203X; Go 6850	3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione	protein kinase inhibitor; protein kinase C inhibitor; NSAID	inflammation
LEX 028	unspecified	proteinase inhibitor; cathepsin G inhibitor; NSAID	inflammation
cathepsin S inhibitors	unspecified	proteinase inhibitor; cathepsin S inhibitor; NSAID; immunosuppressant	inflammation; autoimmune disease
APC 1403	unspecified	proteinase inhibitor; NSAID	inflammation
LEX 026	unspecified	proteinase inhibitor; serine proteinase inhibitor	thrombosis; inflammation

LEX 043	unspecified	proteinase inhibitor; serine proteinase inhibitor	inflammation; asthma
BCX 1170	unspecified	proteinase inhibitor; serine proteinase inhibitor; complement inhibitor; NSAID	cardiovascular disease; inflammation
neutral endopeptidase; NEP	unspecified	proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
anti-inflammatory	unspecified	rac inhibitor; RAS inhibitor; signal transduction inhibitor; NSAID	inflammation
secretory cell inhibitors, CAMR	unspecified	secretory cell inhibitors	allergy; inflammation; respiratory disease
BCX 1470	unspecified	serine proteinase inhibitor; complement inhibitor; NSAID; proteinase inhibitor	cardiovascular disease; inflammation
complement inhibitors	unspecified	serine proteinase inhibitor; NSAID; complement inhibitor; proteinase inhibitor	inflammation; myocardial infarction; reperfusion injury; respiratory distress syndrome
p-38-2 inhibitor	unspecified	signal transduction inhibitor; NSAID	inflammation; ischemia
SP 100030	Unspecified	signal transduction inhibitor; NSAID; immunosuppressant	inflammation; autoimmune disease
dapitant; RPR 100893	[3aS-[2(R*),3aalpha,4beta,7aalpha]]-octahydro-4-(2-methoxyphenyl)-2-[2-(2-methoxyphenyl)-1-oxopropyl]-7,7-diphenyl-1H-isoindol-4-ol	substance P antagonist; NSAID	asthma; inflammation; migraine
screening technology, cox-2 gene suppression	unspecified	target based screening; biotechnology	drug design technology; inflammation; cancer

TGF beta antagonists; transforming growth factor beta antagonists	unspecified	TGF beta antagonist; cicatrizant	cancer; viral infection; inflammation; skin ulcer
thrombospondin inhibitor	unspecified	thrombospondin inhibitor; peptide; NSAID	inflammation; cancer; sickle cell anemia
tumor necrosis factor binding protein; TBP-1; TBP	unspecified	TNF inhibitor; immunosuppressant	autoimmune disease; reperfusion injury; inflammation; septic shock
tumor necrosis factor binding protein; TNFbp	unspecified	TNF inhibitor; NSAID	septic shock; inflammation
tumor necrosis factor inhibitors	unspecified	TNF inhibitor; NSAID	inflammation; asthma; inflammatory bowel disease
tumor necrosis factor receptor inhibitors	unspecified	TNF inhibitor; NSAID	septic shock; inflammation
A 802715	3,7-dihydro-1-(5-hydroxy-5-methylhexyl)-3-methyl-7-propyl-1H-purine-2,6-dione	TNF inhibitor; NSAID	inflammation; septic shock
peptide T; natural; peptide T	N-[N-[N2-[N-[N-(N-L-alanyl-L-seryl)-L-threonyl]-L-threonyl]-L-threonyl]-L-asparaginy]-L-tyrosyl]-L-threonine	TNF inhibitor; peptide; NSAID	HIV infection; psoriasis; inflammation
transcription factor inhibitors	unspecified	transcription factor regulator	inflammation; autoimmune disease
NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	asthma; inflammation; restenosis
NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	inflammation; ischemia; cancer; autoimmune disease
AP-1 inhibitor; JNK inhibitor	unspecified	transcription factor regulator; NSAID; immunosuppressant	inflammation; autoimmune disease; cancer



ademetionine; FO 1561; GUMBARAL; DONAMET; TRANSMETIL; CERITAN; ERGEN; TWIN; SAMY R	(3S)-5'-[(3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine hydroxide inner salt	transmethylator; NSAID	inflammation; cognitive defect; cholestasis
tryptase inhibitors	unspecified	tryptase inhibitor; NSAID	asthma; inflammation; rhinitis; inflammatory bowel disease; psoriasis
UBC inhibitors; ubiquitin conjugating enzyme inhibitors	unspecified	ubiquitin conjugating enzyme inhibitor; NSAID	cancer; inflammation
non-ionic surfactant vesicles; NISV	unspecified	vaccine adjuvant; immunosuppressant	rheumatoid arthritis; asthma; inflammation
vaccine, gene-based, autoimmune disease	unspecified	vaccine; gene therapy	autoimmune disease; inflammation

Table 45. Current Candidate Therapeutic Interventions for the Treatment of Psoriasis

Product Name	Chemical Name	Action	Indication
masoprocol; CHX 100; ACTINEX	(R*,S*)-4,4'-(2,3-dimethyl-1,4-butanediyl)bis-1,2-benzenediol	5 lipoxygenase inhibitor	skin disease; cancer; psoriasis
WY 47288	2-[(1-naphthalenyloxy)methyl]quinoline	5 lipoxygenase inhibitor	psoriasis
enazadrem; enazadrem phosphate; CP 70490; CP 7049009	4,6-dimethyl-2-[(6-phenylhexyl)amino]-5-pyrimidinol	5 lipoxygenase inhibitor	psoriasis
lonapalene; RS 43179	6-chloro-2,3-dimethoxy-1,4-naphthalenediol diacetate	5 lipoxygenase inhibitor	psoriasis
R 85355	Unspecified	5 lipoxygenase inhibitor	asthma; psoriasis; inflammatory bowel disease
BW 4C; BW A4C; BW 4C86	N-(3-phenoxy-phenyl-2-propenyl)acetohydroxamic acid	5 lipoxygenase inhibitor; chelating agent; NSAID	arthritis; psoriasis

CGS 23885	unspecified	5 lipoxygenase inhibitor; NSAID	psoriasis; inflammation
SC 45662	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis; inflammatory bowel disease
DUP 654	(2-phenylmethyl)-1-naphthalenol	5 lipoxygenase inhibitor; NSAID	psoriasis; inflammation
L 663536; MK 886	1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-alpha,alpha-diethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis
SCH 40120	10-(3-chlorophenyl)-6,8,9,10-tetrahydrobenzo[b][1,8]naphthyridin-5(7H)-one	5 lipoxygenase inhibitor; NSAID	inflammation; psoriasis
AE 941; NEOVASTAT; NEORETNA; PSOVASCAR; ARTHROVAS	unspecified	angiogenesis inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; eye disease; retinopathy
glycopine; glucosaminylmuramyl dipeptide; GMDP; LICOPID; LIKOPID	N2-[N-[N-acetyl-4-O-[2-(acetyl-amino)-2-deoxy-beta-D-glucopyranosyl]muramoyl]-L-alanyl]-D-alpha-glutamine	antibiotic; vaccine adjuvant; immunostimulant; glycopeptide	psoriasis; cancer; leukopenia; septic shock; infectious disease; eye disease
liarozole; liarozole hydrochloride; liarozole fumarate; R 75251; R 85246; LIAZAL	5-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-1H-benzimidazole	antifungal; androgen synthesis inhibitor; imidazole	cancer; psoriasis
taxoids	unspecified	Antihyperproliferative agent	psoriasis
drug delivery system, psoriasis therapy, P 37	unspecified	Antikeratinocyte activity	psoriasis

drug delivery system, fluorouracil; fluorouracil Therapeutic Implant; MPI 5003	unspecified	antimetabolite	cancer; psoriasis; viral infection
drug delivery system, topical methotrexate; methotrexate topical	unspecified	antimetabolite	psoriasis
ZYN-LINKER conjugated methotrexate	unspecified	antimetabolite; NSAID	cancer; rheumatoid arthritis; psoriasis
drug delivery system, stabilized lipid dithranol; dithranol stabilized lipid; MICANOL	unspecified	Antimitotic	psoriasis
TV 2801	Anthralin derivative	antimitotic	psoriasis
TV 2802	Anthralin derivative	antimitotic	psoriasis
trimethylangelicin; TMA; 4,4',6'-trimethylangelicin; 4,6,4'-trimethylangelicin	4,6,9-trimethyl-2H-furo[2,3-h]-1-benzopyran-2-one	Antiproliferative agent	psoriasis
topical antiproliferative agents	unspecified	antiproliferative agent	psoriasis
SDZ LAP977	5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxybenzoic acid methyl ester	antiproliferative agent	psoriasis
maxacalcitol; 22-oxacalcitriol; oxacalcitriol; OCT; MC 1275	[1S-[1 $\alpha$ (R*),3 $\beta$ ,4E(1S*,3R*,5Z),7 $\alpha$ ]]-4-methylene-5-[2-octahydro-1-[1-(3-hydroxy-3-methylbutoxy)ethyl]-7 $\alpha$ -methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol	antiproliferative agent; vitamin D3 analogue	hyperparathyroidism; psoriasis
drug delivery system, NOVASOME topical anthralin; anthralin, topical NOVASOME	unspecified	Antimitotic; DNA synthesis inhibition; topical agent	psoriasis

E2F inhibitors	unspecified	apoptosis inducer; antiproliferative agent	cancer; psoriasis; viral infection; restenosis
thrombopoietin; platelet factor 4; PF4; endostatin B; REPLISTATIN	unspecified	biotechnology	heparin neutralization; psoriasis; HIV infection; cancer; diabetes
senescence derived inhibitor 1; Sdi 1	unspecified	biotechnology; cyclin dependent kinase inhibitor	cancer; psoriasis; eye disease; cancer
oncostatin M; tumor necrosis factor; TNF; PAC 4D	3-157-tumor necrosis factor (human)	biotechnology; cytokine	cancer; psoriasis
interleukin-8 receptor; IL-8r	unspecified	biotechnology; cytokine antagonist; NSAID	psoriasis; rheumatoid arthritis; respiratory distress syndrome; septic shock
interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSIF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	biotechnology; cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
epidermal growth factor diphtheria toxin chimeric protein; EGF diphtheria toxin chimeric protein; EGF fusion protein; DAB 389-EGF; DAB 389-EGF	unspecified	biotechnology; fusion toxin	cancer; restenosis; psoriasis
denileukin diftitox; interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion protein; DAB 389-IL- 2; LY 335348; DAB389IL2; ONTAK	1-388-toxin (Corneybacterium diphtheriae strain C7), N-L-methionyl- 387-L-histidine-388- L-alanine-, (388.fwdarw.2')- protein with 2-133- interleukin 2 (human clone pTIL2-21a)	biotechnology; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; psoriasis; cancer

polyethylene glycol transforming growth factor beta2; PEG-TGF beta2; transforming growth factor beta2 macrogol	unspecified	biotechnology; growth factor	osteoporosis; psoriasis; eye disease
MAB, humanized B7.1	unspecified	biotechnology; immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MAB, humanized B7.2	unspecified	biotechnology; immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MEDI 507	unspecified	biotechnology; immunosuppressant	autoimmune disease; transplant rejection; psoriasis
antisense oligonucleotide, ICAM-1; antisense oligonucleotide, intracellular adhesion molecule-1; ISIS 2302	d[(R)-P-thio](G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A) DNA	biotechnology; immunosuppressant; antisense; oligonucleotide; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease; asthma
BMS 188667; CTLA4Ig	unspecified	biotechnology; immunosuppressant; NSAID	transplant rejection; systemic lupus erythematosus; psoriasis; arthritis; allergy
leukocyte function associated antigen 3 T cell inhibitor protein; LFA3TIP; LFA3TIP; AMEVIVE	unspecified	biotechnology; immunosuppressant; NSAID	inflammation; autoimmune disease; psoriasis
MAB, CD11a; hu 1124	unspecified	biotechnology; monoclonal antibody; immunosuppressant	psoriasis; transplant rejection
MAB, humanized CD3; MAB, SMART CD3; HuM291	unspecified	biotechnology; monoclonal antibody; immunosuppressant	transplant rejection; autoimmune disease; psoriasis

clenoliximab; MAb, CD4; MAb, PRIMATIZED CD4; IDEC 151; SB 217969	immunoglobulin G 4 (human-Macaca monoclonal CE9gamma4PE gamma4-chain anti-human antigen CD4), disulfide with human-Macaca monoclonal CE9gamma4PE kappa-chain, dimer	biotechnology; monoclonal antibody; NSAID	rheumatoid arthritis; psoriasis; asthma
MAb, B7; MAb, PRIMATIZED B7; IDEC 114	unspecified	biotechnology; monoclonal antibody; NSAID; immunosuppressant	systemic lupus erythematosus; inflammation; transplant rejection; psoriasis
MAb, idiotypic GD2; vaccine, cancer; cancer vaccine	unspecified	biotechnology; monoclonal antibody; vaccine	cancer; psoriasis
oligonucleotides, psoriasis	unspecified	biotechnology; oligonucleotide	psoriasis
oligonucleotides,	unspecified	biotechnology; oligonucleotide; ribozyme	cancer; psoriasis
vaccine, psoriasis; vaccine, T cell receptor; IR 502	unspecified	biotechnology; vaccine	psoriasis
CDF inhibitor	unspecified	CDF inhibition; inhibition of cdc25C	cancer; psoriasis
SPC 101210	unspecified	ceramide	psoriasis
SPC 103600	unspecified	ceramide regulator	psoriasis
differentiation-inducing compounds	unspecified	Control of cell differentiation	cancer; psoriasis; restenosis
AGN 191743	unspecified	corticosteroid	psoriasis
anti-inflammatory corticosteroids	unspecified	corticosteroid	psoriasis; asthma
auranofin + betamethasone dipropionate; betamethasone dipropionate + auranofin	unspecified	corticosteroid	psoriasis

drug delivery system, betamethasone ViaFoam mousse; betamethasone ViaFoam mousse; BETAMOUSSE; LUXIQ	unspecified	corticosteroid	psoriasis; dermatitis
drug delivery system, clobetasol ViaFoam mousse; clobetasol ViaFoam mousse; OLUX	unspecified	corticosteroid	psoriasis
drug delivery system, liposome clobetasol; clobetasol liposome; LipoFORT	unspecified	corticosteroid	psoriasis
drug delivery system, topical DermaStick betamethasone dipropionate; betamethasone propionate DermaStick; DermaStick	unspecified	corticosteroid	psoriasis
mometasone furoate + salicylic acid; COMBISOR	unspecified	corticosteroid	psoriasis
prednicarbate; HOE 777; S 770777; DERMATOP; PREDNITOP	(11beta)-17- [(ethoxycarbonyl)oxy ]-11-hydroxy-21-(1- oxopropoxy)-pregna- 1,4-diene-3,20-dione	corticosteroid	psoriasis
mometasone furoate; mometasone; S 2640; SCH 32088; ELOCOM; ELOCON; FULMETA; ECURAL; ERMIL; NASONEX; ASMANEX	(11beta,16alpha)- 9,21-dichloro-17-[(2- furanylcarbonyl)oxy]- 11-hydroxy-16- methyl-pregna-1,4- diene-3,20-dione	corticosteroid	dermatitis; asthma; rhinitis; psoriasis; pruritis

tipredane; SQ 27239	(11beta,17alpha)-17-(ethylthio)-9-fluoro-11-hydroxy-17-(methylthio)androsta-1,4-diene-3-one	corticosteroid	inflammation; psoriasis
halobetasol propionate; CGP 14458; BMY 30056; ULTRAVATE	(6alpha,11beta,16beta)-21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-pregna-1,4-diene-3,20-dione	corticosteroid	skin disease; inflammation; psoriasis
FPL 62064	N-(4-methoxyphenyl)-1-phenyl-1H-pyrazole-3-amine	COX inhibitor; 5 lipoxygenase inhibitor	inflammatory bowel disease; psoriasis
RU 46057	2-[1,2-bis(1-oxopropoxy)ethyl]-4-hydroxy-N-2-thiazolyl-8-(trifluoromethyl)-3-quinolinecarboxamide	COX inhibitor; 5 lipoxygenase inhibitor; NSAID	arthritis; psoriasis
RP 54745	4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-3H-1,2-dithiol-3-one	cytokine antagonist; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; psoriasis
interleukin-8 antagonists	unspecified	cytokine antagonist; NSAID	rheumatoid arthritis; psoriasis; atherosclerosis
ETH 615	4-[[[(3-fluorophenyl)methyl][4-(2-quinolinylmethoxy)phenyl]amino]methyl]benzoic acid	cytokine synthesis inhibitor	psoriasis
BMY 30094	N-hydroxybenzenenonamide	cytokine synthesis inhibitor; NSAID	inflammation; psoriasis
amlexanox; amoxanox; CHX 3673; AA 673; SOLFA; ELICS; APHTHASOL	2-amino-7-(1-methylethyl)-5-oxo-5H-[1]-benzopyrano[2,3-b]pyridine-3-carboxylic acid	degranulation inhibitor	asthma; psoriasis; rhinitis; mucositis; conjunctivitis; allergy



alitretinoin; LGD 1057; LG 1057; LGN 1057; ALRT 1057; NSC 659772; PANRETIN	9-cis-retinoic acid	differentiation inducer; retinoid agonist; RAR agonist; RXR agonist	cancer; psoriasis
psoriasis therapy	unspecified	dihydrofolate reductase inhibitor	psoriasis
dihydrofolate reductase inhibitor, psoriasis	unspecified	dihydrofolate reductase inhibitor; antifolate	psoriasis
trimetrexate; trimetrexate glucuronate; TMQ; NSC 249008; CI 898	5-methyl-6-[[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolin-2-ylidene	dihydrofolate reductase inhibitor; antifolate; NSAID	cancer; psoriasis; rheumatoid arthritis; pneumocystis
drug delivery system, methotrexate; methotrexate delivery system; G 301	unspecified	Dihydrofolic acid reductase inhibition; cytotoxic	psoriasis
drug delivery system, topical methotrexate; methotrexate, topical; CHX 150	unspecified	Dihydrofolic acid reductase inhibition; cytotoxic	psoriasis
psoriasis therapy	unspecified	EGF receptor inhibitor	psoriasis
ALP 242	unspecified	elastase inhibitor; proteinase inhibitor	asthma; emphysema; psoriasis
efomycines	unspecified	Endothelium mediated antiadhesive properties	psoriasis
psoriasis enzyme therapy	unspecified	enzyme	psoriasis
fibroblast growth factor antagonist	unspecified	FGF antagonist; angiogenesis inhibitor	cancer; retinopathy; psoriasis
free radical scavengers	unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
SLH 301	unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
beta-glucan antagonist	unspecified	glucan antagonist	conjunctivitis; asthma; psoriasis; ulcerative colitis

SU 5271	unspecified	growth factor modulator; signal transduction inhibitor; EGF receptor inhibitor	psoriasis
epinastine; WAL 801; WAL 801CL; ALESION	9,13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepin-3-amine	histamine antagonist; histamine H1 antagonist	allergy; asthma; psoriasis; rhinitis
psoriasis therapy	unspecified	immunomodulation	psoriasis
drug delivery system, HILT, ciclosporin; ciclosporin, HILT, psoriasis; CYCLOPS	unspecified	immunosuppressant	psoriasis
drug delivery system, liposome ciclosporin; ciclosporin liposome; LipoSPOR	unspecified	immunosuppressant	psoriasis
VX 497	unspecified	immunosuppressant	psoriasis; autoimmune disease; viral infection; hepatitis
PRO 2844	(OC-6-22)-pentaamine(4-methylpyridine)ruthenium(3+) trichloride	immunosuppressant	psoriasis; autoimmune disease; transplant rejection
SDZ 281240	unspecified	immunosuppressant; macrolide; antibiotic	psoriasis
PIC 060 analogs	unspecified	immunosuppressant; NSAID	psoriasis; dermatitis; diabetes; transplant rejection; rheumatoid arthritis
VX 10393	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
VX 10428	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
laflunimus; HR 325	(Z)-2-cyano-3-cyclopropyl-3-hydroxy-N-[3-methyl-4-(trifluoromethyl)phenyl]-2-propenamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; psoriasis

CI 972	2,6-diamino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; cancer; psoriasis
amiprilose; amiprilose hydrochloride; THN; SM 1213; KAP 690; THERAFECTIN	3-O-(3-(dimethylamino)propyl)-1,2-O-isopropylidene- $\alpha$ -D-glucopyranose hydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; psoriasis
atiprimod; atiprimod dimaleate; SKF 106615	N,N-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine	immunosuppressant; NSAID; macrophage inhibitor	rheumatoid arthritis; autoimmune disease; psoriasis
ABT 281; A 86281	unspecified	Immunosuppression like tacrolimus ; ao systemic side effects	psoriasis
MAB, ICAM-3; MAB, intracellular adhesion molecule-3; MAB, ICAM-R; ICM3	unspecified	integrin antagonist; biotechnology; cell adhesion inhibitor; immunosuppressant; monoclonal antibody	autoimmune disease; psoriasis
alphaE beta7 antagonists	unspecified	integrin antagonist; cell adhesion inhibitor	asthma; psoriasis; inflammatory bowel disease
TBC 427	unspecified	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor	ischemia; psoriasis; respiratory distress syndrome; transplant rejection; reperfusion injury
SCHAL 3	unspecified	Ion transport modulation	skin disease; cancer; psoriasis
antiproliferative agents	unspecified	Ion transport modulation; antiproliferative	Cancer; psoriasis
sumarotene; Ro 149706	(E)-1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-[1-methyl-2-[4-(methylsulfonyl)phenyl]ethenyl]naphthalene	keratolytic	psoriasis

VML 262	unspecified	Leukotriene B4 antagonist	psoriasis
SC 52798	(+)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist	psoriasis; ulcerative colitis
SC 53228; (+)-SC 51146	(S)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-[(methylamino)carbonyl]phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid	leukotriene B4 antagonist; leukotriene antagonist	psoriasis
LY 293111; VML 295	2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]2-propylphenoxy]-benzoic acid	leukotriene B4 antagonist; leukotriene antagonist	psoriasis
SM 15178	3-[[[2-[[[2-ethyl-4-(1-oxoethyl)-5-hydroxyphenyl]oxy]methyl]pyridin-6-yl]carbonyl]ethylamino]propanoic acid	leukotriene B4 antagonist; leukotriene antagonist	psoriasis; inflammatory bowel disease
SC 41930	7-[3-(-4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist	psoriasis

WF 11605	(1S,1R,4aS,6aR,8R,9R,10aS,12aS)-9-acetoxy-2-((R)-1,2dimethylpropyl)-8-(beta-D-glucopyranosyl)oxy-1,2,3,4,4a,5,6,6a,7,8,9,10,10a,11,12,12a-hexadecahydro-2,4a,7,7,10a,12a,hexamethyl-3-oxochrysene-1-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	hepatitis; inflammation; psoriasis
SB 201993	(E)-3-[[[6-(2-carboxyethenyl)-5-[[8-(4-methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	psoriasis; inflammation
ticolubant; SB 209247	(E)-3-[6-[[2,6-dichlorophenyl]thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation; psoriasis
RP 64966	2-((4-(5-(3-phenylpropyl)-2-thienyl)butyl)oxy)acetic acid (sodium salt)	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation; psoriasis; inflammatory bowel disease
SC 50605	7-[3-[2(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	psoriasis; inflammation

SC 51146	7-[3-[2(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; psoriasis; rheumatoid arthritis; inflammatory bowel disease
immunosuppressant	Monoclonal antibody	Monoclonal antibody to complement	psoriasis
MAB, interleukin-8; MAB, IL-8; ABX IL8	unspecified	monoclonal antibody; biotechnology; NSAID	respiratory distress syndrome; inflammatory bowel disease; rheumatoid arthritis; inflammation; psoriasis
IPL 400; SORTAC	unspecified	NSAID	psoriasis
IPL 576; IZP 94005	unspecified	NSAID	psoriasis; allergy; inflammation
pseudopterosin	unspecified	NSAID	arthritis; asthma; psoriasis
2-CdAP	2-chloro-2'-deoxy-5'-adenylic acid disodium salt	nucleoside analogue	psoriasis
CMI 392	trans-2-[5-(N'-methyl-N'-hydroxyureidylmethyl)-3-methoxy-4-p-chlorophenylthioethoxyphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran	PAF antagonist; leukotriene antagonist	psoriasis; dermatitis; asthma
drug delivery system, SEPA peptide T; peptide T SEPA	unspecified	peptide; TNF inhibitor	psoriasis
transglutaminase inhibitor	unspecified	peptide; transglutaminase inhibitor	psoriasis; Alzheimer disease
IC 351; GF 196960; GG 960	unspecified	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	heart failure; angina; sexual dysfunction; psoriasis

BMS 181162	(Z,E,Z,E)-3-[1-(2-carboxy-1-methylethenyl)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3,5-hexatrienyl]benzoic acid	phospholipase inhibitor	psoriasis; dermatitis
phospholipase A2 inhibitors	unspecified	phospholipase inhibitor; NSAID	asthma; rheumatoid arthritis; psoriasis; inflammatory bowel disease
BMS 188184	3-[(1Z,2Z)-3-carboxy-2-methyl-1-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)methylene]-2-propenyl]benzoic acid	phospholipase inhibitor; NSAID	psoriasis; dermatitis; inflammation
bergapten; 5-methoxypsoralen; 5-MOP; GERALEN; PSORADERM 5; GEROXALEN	unspecified	photosensitizer	psoriasis
hypericin; VIMRxyn; CYCLO-WERROL; CYCLOSAN	1,3,4,6,8,13-hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione	photosensitizer	psoriasis; cancer
aminolevulinic acid, photodynamic therapy; 5-ALA PDT; LEVULAN	unspecified	photosensitizer; contrast medium	psoriasis; skin disease; endometriosis; cancer; diagnosis
verteporfin; benzoporphyrin derivative; BPD-MA; CL 318952; BPDR; VISUDYNE	trans-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]porphine-9,13-dipropanoic acid monomethyl ester	photosensitizer; NSAID	cancer; psoriasis; arthritis; retinopathy

diethylhomospermine; DEHOP; DE 444	N,N'-bis[4-(ethylamino)butyl]-1,4-butanediamine	polyamine analogue	diarrhea; hypertension; cancer; psoriasis; ulcerative colitis
diethylnorspermine; DENSPM; CI 1006; DE 333	N1,N11-diethylnorspermine	polyamine analogue	cancer; psoriasis; Alzheimer disease
protein kinase C inhibitor, microalgal	unspecified	protein kinase inhibitor; protein kinase C inhibitor	cancer; psoriasis
safingol; safingol hydrochloride; SPC 100270; mSPC 100271; KYNAC; KYNACYTE	(2S,3S)-2-amino-1,3-octadecanediol	protein kinase inhibitor; protein kinase C inhibitor	psoriasis; dermatitis; cancer
CPR 1006	4-hydroxy-7-(1H-imidazol-1-yl)-N,N,N-trimethyl-3,5,9-trioxa-4-phosphaheptacosan-1-aminium, 4-oxide, inner salt	protein kinase inhibitor; protein kinase C inhibitor; ether lipid	psoriasis
SPC 100840	unspecified	protein kinase inhibitor; protein kinase C inhibitor; NSAID	ischemia; psoriasis; cancer; inflammation; reperfusion injury
balanol; (-)-balanol; azepinostatin; ophiocordin	(3R-trans)-4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxybenzoic acid 1-[hexahydro-3-[(4-hydroxybenzoyl)amino]-1H-azepin-4-yl] ester	protein kinase inhibitor; protein kinase C inhibitor; NSAID	cancer; inflammation; psoriasis
alpha-1-antitrypsin	unspecified	proteinase inhibitor; biotechnology	asthma; emphysema; cystic fibrosis; dermatitis; psoriasis
peldesine; BCX 34; BCX 34B	2-amino-1,5-dihydro-7-(3-pyridinylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; immunosuppressant; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection; eye disease; dermatitis; HIV infection



purine nucleoside phosphorylase inhibitors, PNP inhibitors, Chiroscience	unspecified	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection
CI 1000; PD 141955	2-amino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis
cancer therapy, retinoids	unspecified	retinoid	cancer; psoriasis
retinoids	unspecified	retinoid	psoriasis; acne
acitretin; etretin; etretinate free acid; Ro 101670; Ro 101670000; NEOTIGASON; SORIATANE	(all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid	retinoid	psoriasis
tazarotene; AGN 190168; ZORAC; TAZORAC	6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester	retinoid	acne; cancer; psoriasis
tamibarotene; AM 80	4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]carbonyl]benzoic acid	retinoid agonist	psoriasis; cancer
AM 580	4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]amino]benzoic acid	retinoid agonist	psoriasis; cancer
ER 38925	4-[5-(4,7-dimethyl-2-benzofuranyl)-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis
ER 65250	4-[5-(7-ethyl-4-methyl-2-benzofuranyl)-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis

ER 69029	4-[5-[7-fluoro-4-(trifluoromethyl)-2-benzofuranyl]-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis
bexarotene; LGD 1069; LG 100069; LG 1069; LDG 1069; TARGRETIN	4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthenyl)-1-ethenyl]-benzoic acid	retinoid agonist; retinoid; differentiation inducer; RXR agonist	cancer; diabetes; psoriasis; skin disease
AGN 4310; ALRT 4310	unspecified	retinoid antagonist	psoriasis; cancer
ALRT 1109	unspecified	retinoid antagonist; RAR antagonist	psoriasis
lanreotide; BIM 23014; DC 13116; BIM 23014C; BN 52030; SOMATULINE; ANGIOPEPTIN; DERMOPEPTIN; IPSTYL	3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2,7)-disulfide	somatostatin analogue	cancer; acromegaly; retinopathy; diabetes; psoriasis; restenosis
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
AG 85	1-[[4-[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-2-propynylamino]phenyl]sulfonyl]-1H-indole	thymidylate synthase inhibitor	psoriasis
ITF 1779	unspecified	TNF inhibitor; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease

peptide T, natural; peptide T	N-[N-[N2-[N-[N-[N- (N-L-alanyl-L-seryl)- L-threonyl]-L- threonyl]-L-threonyl]- L-asparaginy]-L- tyrosyl]-L-threonine	TNF inhibitor; peptide; NSAID	HIV infection; psoriasis; inflammation
APC 2059	unspecified	tryptase inhibitor	inflammatory bowel disease; psoriasis
oral tryptase inhibitors	unspecified	tryptase inhibitor	inflammatory bowel disease; asthma; psoriasis
tryptase inhibitors	unspecified	tryptase inhibitor; NSAID	asthma; inflammation; rhinitis; inflammatory bowel disease; psoriasis
tyrphostins	unspecified	tyrphostin	psoriasis; cancer; atherosclerosis; septic shock
AG 555	(2E)-2-cyano-3-(3,4- dihydroxyphenyl)-N- (3-phenylpropyl)-2- propenamide	tyrphostin	psoriasis; cancer; atherosclerosis
AG 213; RG 50964; tyrphostin AG 213; RG 50864 (no stereo)	(E)-2-cyano-3-(3,4- dihydroxyphenyl)-2- propenethioamide	tyrphostin	psoriasis; cancer; atherosclerosis
CHX 108	unspecified	Unspecified	psoriasis
P 53	unspecified	Unspecified	psoriasis; pruritis
SM 10193	unspecified	Unspecified	psoriasis
T 511	Azelaic acid analogue	unspecified	psoriasis
vaccine, PVAC, psoriasis; psoriasis vaccine	unspecified	vaccine	psoriasis
CPR 2005	unspecified	vitamin D analogue	psoriasis
drug delivery system, vitamin D derivatives	unspecified	vitamin D analogue	psoriasis
SH 597	unspecified	vitamin D analogue	psoriasis
calcipotriol; calcipotriene; MC 903; BMS 181161; DAIVONEX; DOVONEX; PSORCUTAN	(1 $\alpha$ ,3 $\beta$ ,5Z,7E,22 E,24S)-24- cyclopropyl-9,10- secochola- 5,7,10(19),22- tetraene-1,3,24-triol	vitamin D analogue	psoriasis

EL 715	unspecified	vitamin D2 analogue	psoriasis; osteoporosis; osteodystrophy
1-alpha-D-hydroxycholecalciferol	unspecified	vitamin D3 analogue	psoriasis
drug delivery system, polymer, ST 630; ST 630 polymer	unspecified	vitamin D3 analogue	psoriasis
tacalcitol; 1alpha,24(R)-dihydrocholecalciferol; 1,24(R)-dihydroxyvitamin D3; TV 02; BONALFA; CURATODERM	(+)-(5Z,7E,24R)9,10-secocholesta-5,7,10(19)-triene-1alpha,3beta,24-triol	vitamin D3 analogue	psoriasis
falecalcitriol; flocalcetriol; ST 630; FULSTAN; HORNEL	(1alpha,3beta,5Z,7E)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D3 analogue	osteoporosis; kidney disease; hyperparathyroidism; psoriasis
solverol; PRI 1901	(1R,3S,5Z)-4-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-1-[(1R,5E)-7-hydroxy-1,7-dimethyl-5-octenyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol	vitamin D3 analogue; differentiation inducer	cancer; psoriasis

Table 46. Current Candidate Therapeutic Interventions for the Treatment of Atherosclerosis

Product Name	Chemical Name	Action	Indication
AGR 529	N-(4-amino-4-oxobutyl)adenosine hydrochloride	A1 fat cell receptor antagonist	hypertension; hyperlipidemia
AGR 540	N-(4-amino-4-oxobutyl)adenosine 2',3',5'-tripropanoate	A1 fat cell receptor antagonist; AGR 529 prodrug	hypertension; hyperlipidemia
ACAT inhibitor	unspecified	ACAT inhibitor	hyperlipidemia
BW 2164U90; BW 2164	unspecified	ACAT inhibitor	hyperlipidemia
FR 129169	unspecified	ACAT inhibitor	hyperlipidemia

NTE 122	unspecified	ACAT inhibitor	hyperlipidemia; atherosclerosis
SKF 98016	unspecified	ACAT inhibitor	hyperlipidemia
terpendole C	unspecified	ACAT inhibitor	hyperlipidemia
terpendole D	unspecified	ACAT inhibitor	hyperlipidemia
CP 113818	(S)-(2)-(hexylthio)-N-[6-methyl-2,4-bis(methylthio)-3-pyridinyl]decanamide	ACAT inhibitor	hyperlipidemia
CP 105191	(S)-2-(hexylthio)-N-[6-(methylthio)-5-quinolinyl]decanamide	ACAT inhibitor	hyperlipidemia
CI 999	[[2,6-bis(1-methylethyl)phenoxy]sulfonyl]carbamic acid 2,6-bis(1-methylethyl)phenyl ester sodium salt	ACAT inhibitor	hyperlipidemia
gypsetin	[5aR-(5aalpha,7aalpha,8abeta,13abeta,15aalpha,16aalpha)]-5a,13a-bis(1,1-dimethyl-2-propenyl)-5a,8,8a,13,13a,15a,16a-octahydro-8a,16a-dihydroxypyrazino[1",2":1,5;4",5":1',5']dipyrrolo[2,3-b:2',3'-b']diindole-7,15(5H,7aH)-dione	ACAT inhibitor	hyperlipidemia
YM 750	1-cycloheptyl-1-(9H-fluoren-2-ylmethyl)-3-(2,4,6-trimethylphenyl) urea	ACAT inhibitor	hyperlipidemia
CI 976	2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide	ACAT inhibitor	hyperlipidemia
AS 183	2,4-dimethyl-2-hydroxy-5-(1,3,5,7-tetramethyl-nonyl)-3(2H)-fluronone	ACAT inhibitor	hyperlipidemia

RP 64477	3-(4-decylcloxybenzamido)-4-methylthio-N-methylthio-N-butylbenzamide	ACAT inhibitor	hyperlipidemia
P 06139	4-[3-[(4,5-diphenyl-1H-imidazol-2-yl)thio]-2-hydroxypropoxy]-benzoic acid 2-methylpropyl ester	ACAT inhibitor	hyperlipidemia
lateritin	4-methyl-6-(1-methylethyl)-3-phenylmethyl-1,4-perhydrooxazine-2,5-dione	ACAT inhibitor	hyperlipidemia
eldacimibe; WAY 125147; ACA 147; ANA 147; WAY-ACA 147	5-[[[3,5-bis(1,1-dimethyl-ethyl)-4-hydroxyphenyl]amino][[4-(2,2-dimethylpropyl)phenyl]methyl]hexylamino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione	ACAT inhibitor	hyperlipidemia
U 73482	7,7'-[1,2-ethanediylbis(4,1-piperidinediylmethyle ne)]-bis[4,9-dimethoxy-5H-furo[3,2-g][1]benzopyran-5-one	ACAT inhibitor	hyperlipidemia
lecimibide; DUP 128	N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea	ACAT inhibitor	hyperlipidemia
HL 004; TS 962	N-(2,6-diisopropylphenyl)-2-(tetradecylthio)acetamide	ACAT inhibitor	atherosclerosis; hyperlipidemia

YM 17E	N,N'-[1,3-phenylenebis(methylene)]bis[N-cycloheptyl-N'-[4-(dimethylamino)phenyl]urea dihydrochloride	ACAT inhibitor	hyperlipidemia
F 1394	N-[(2,2,5,5-tetramethyl-1,3-dioxan-4-yl)carbonyl]-beta-alanine, 2-[[[2,2-dimethylpropyl)nonyl amino]carbonyl]aminocyclohexyl ester	ACAT inhibitor	atherosclerosis; hyperlipidemia
avasimibe; CI 1011; PD 148515; AVASIMIBE	N-[[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-2,4,6-tris(1-methylethyl)benzeneacetamide	ACAT inhibitor	hyperlipidemia
KW 3033	N-[2,6-bis(1-methylethyl)phenyl]-2-bromo-6,11-dihydrodibenz[b,e]oxepin-11-carboxamide	ACAT inhibitor	hyperlipidemia
PD 129337	N-[2,6-bis(1-methylethyl)phenyl]-N'-[(1-phenylcyclopentyl)methyl]urea	ACAT inhibitor	hyperlipidemia
PD 1323012; PD 132301-2	N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl)methyl]urea monohydrochloride	ACAT inhibitor	hyperlipidemia
TMP 153	N-[4-(2-chlorophenyl)-6,7-dimethyl-3-quinolinyl]-N'-(2,4-difluorophenyl)urea	ACAT inhibitor	hyperlipidemia
ACAT inhibitor	N-butyl-N'-(2,4-dimethylphenyl)-N-(phenylmethyl)urea	ACAT inhibitor	hyperlipidemia

E 5324	N-butyl-N'-[2-[3-(5-ethyl-4-phenyl-1H-imidazol-1-yl)propoxy]-6-methyl-phenyl]-urea	ACAT inhibitor	hyperlipidemia
BW 447C88	N-heptyl-N'-(2(4-(2,2-dimethylpropyl)phenyl)ethyl)phenyl)urea	ACAT inhibitor	hyperlipidemia
ACAT inhibitors	unspecified	ACAT inhibitor; imidazole	hyperlipidemia
beauvericin	1,7,13-trioxa-4,10,16-triazacyclooctadecane cyclic peptide derivative	ACAT inhibitor; peptide	bacterial infection; hyperlipidemia
RPR 100579	unspecified	adenosine agonist	hypertension; heart failure; hyperlipidemia
SDZ WAG994; SDZ WAG 994	N-cyclohexyl-2'-O-methyladenosine	adenosine agonist; adenosine A1 agonist	heart failure; hyperlipidemia
SNAP 5150	N-[3-(4,4-diphenyl-1-piperidinyl)propyl]-1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinecarboxamide	alpha adrenergic antagonist; alpha1 adrenergic antagonist	benign prostate hypertrophy; hyperlipidemia; hypertension
colestilan; colestimide; MCI 196; BMS 180543; CHOLEBINE	1H-imidazole-2-methyl polymer with (chloromethyl)oxirane	anion exchange resin	hyperlipidemia
LY 335124	unspecified	antiestrogen; estrogen agonist	hyperlipidemia
raloxifene; keoxifene; LY 139481; LY 156758; EVISTA	[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone	antiestrogen; estrogen agonist	osteoporosis; hyperlipidemia; myocardial infarction; cancer
atpenin B	[S-(R*,S*)]-3-(2,4-dimethyl-1-oxohexyl)-4-hydroxy-5,6-dimethoxy-2(1H)-pyridinone	antifungal	hyperlipidemia; mycosis



probucol; DH 581; DE 3872; LORELCO; PANAVIR; SINLESTAL	4,4'- isopropylidenedithio- bis-2,6-di-t- butylphenol	antioxidant	HIV infection; hyperlipidemia; restenosis
L 551369	N,N'-diphenyl- phenylenediamine	antioxidant	hyperlipidemia
CK 3363; CK 3368	unspecified	bile acid sequestrant	hyperlipidemia
GT 102279	unspecified	bile acid sequestrant	hyperlipidemia
ICI 245991	unspecified	bile acid sequestrant	hyperlipidemia
SKF 97426	unspecified	bile acid sequestrant	hyperlipidemia
KF 17828	2-bromo-N-(2,6- diisopropylphenyl)- 6,11- dihydrodibenz(b,e)ox epin-11-carboxamide	bile acid sequestrant	hyperlipidemia
colesevelam hydrochloride; GT 31-104HB; GT 31- 104; CholestaGel	N,N,N-trimethyl-6- (2-propenylamino)-1- hexanaminium chloride polymer with (chloromethyl)oxiran e, 2-propen-1-amine and N-2-propenyl-1- decanamine hydrochloride	bile acid sequestrant	hyperlipidemia
CP 88488	N-[2-hydroxy-3- (trimethylammonio)pr opyl] chitosan chloride	bile acid sequestrant	hyperlipidemia
DMP 504	Unspecified	bile acid sequestrant	hyperlipidemia
macrophage colony stimulating factor; M- CSF; MACROLIN	unspecified	biotechnology; growth factor; hematopoietic factor; immunostimulant; cicatrizant; antifungal	mycosis; hyperlipidemia; skin ulcer; bacterial infection
BN 50394	unspecified	calcium antagonist	hyperlipidemia; hypertension
anipamil; LU 42668	alpha-dodecyl-3- methoxy-alpha-[3- [[2-(3- methoxyphenyl)ethyl] methylamino]propyl] benzeneacetonitrile	calcium antagonist	hyperlipidemia

monatepil; monatepil maleate; monasedin maleate; AJ 2615; AD 2615	(+,-)-N-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)-4-(4-fluorophenyl)-1-piperazinebutanamide	calcium antagonist; alpha adrenergic antagonist; alpha adrenergic antagonist	hypertension; angina; hyperlipidemia
BAY 194798	unspecified	CETP inhibitor	atherosclerosis; hyperlipidemia
BNP 9010	unspecified	CETP inhibitor	hyperlipidemia
cholesteryl ester transfer protein inhibitor, CETP inhibitor	unspecified	CETP inhibitor	hyperlipidemia
JTT 705	unspecified	CETP inhibitor	hyperlipidemia
atrinisitol; PP 56	D-myo-inositol 1,2,6-tris(dihydrogen phosphate)	chelating agent; NSAID	inflammation; hyperlipidemia
NIP 200	3,5-dimethyl-4,6-diphenyl-tetrahydro-2H-1,3,5-thiadiazine-2-thione	Cholesterol 7-alpha hydroxylase inhibitor	hyperlipidemia
tiqueside; beta-tigogenin cellobioside; CP 88818	(3beta,5alpha,25R)-spirostan-3-yl-4-O-beta-D-glucopyranosyl-beta-D-glucopyranoside	cholesterol absorption inhibitor	hyperlipidemia
SCH 48461	(3R-trans)-1,4-bis(4-methoxyphenyl)-3-(3-phenylpropyl)-2-azetidinone	cholesterol absorption inhibitor	hyperlipidemia
CVT 1	unspecified	cholesterol absorption inhibitor; polysaccharide sulfate	hyperlipidemia
CEB 925	unspecified	cholesterol hydrolase inhibitor	hyperlipidemia
WAY 121751	unspecified	cholesterol hydrolase inhibitor	hyperlipidemia
WAY 121898	unspecified	cholesterol hydrolase inhibitor	hyperlipidemia
policosanol; ATEROMIXOL	unspecified	Cholesterol lowering	hyperlipidemia
fatty acids, microalgal	unspecified	Cholesterol lowering agent	hyperlipidemia; Parkinson disease; Alzheimer disease; eye disease

hyperlipidemia therapy	unspecified	Cholesterol reduction	hyperlipidemia
MC 031	unspecified	cholesterol synthesis inhibitor	hyperlipidemia
MC 032	unspecified	cholesterol synthesis inhibitor	hyperlipidemia
MC 033	unspecified	cholesterol synthesis inhibitor	hyperlipidemia
MC 034	unspecified	cholesterol synthesis inhibitor	hyperlipidemia
SQ 34919	unspecified	cholesterol synthesis inhibitor	hyperlipidemia
azalanstat; azalanstat dihydrochloride; RS 21607; RS 21607-197	(2S-cis)-4-[[[2-[2-(4-chlorophenyl)ethyl]-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl]thio]benzenamine	cholesterol synthesis inhibitor	hyperlipidemia
lifibrol; K 12148	4-[4-[4-(1,1-dimethylethyl)phenyl]-2-hydroxybutoxy]benzoic acid	cholesterol synthesis inhibitor	hyperlipidemia
MEDICA 16	beta, beta-tetramethyl hexadecanedioic acid	cholesterol synthesis inhibitor	hyperlipidemia
MDL 28815	N-[(1,5,9)-trimethyldecyl]-4alpha,10dimethyl-8-aza-trans-decal-3beta-ol	cholesterol synthesis inhibitor	hyperlipidemia
acipimox; K 9321; OLBETAM; OLBEMOX; ACIPIMOX; NEDIOS	5-methylpyrazinecarboxylic acid 4-oxide	Cyclic AMP inhibition; hormone sensitive lipase inhibitor	hyperlipidemia
AHL 157	unspecified	fibrate	hyperlipidemia
drug delivery system, gemfibrozil; gemfibrozil sustained release; LOPID PUSH-PILL OROS	unspecified	fibrate	hyperlipidemia

drug delivery system; gemfibrozil; gemfibrozil sustained release; LOPID SR	unspecified	fibrate	hyperlipidemia
ciprofibrate; WIN 35833; LIPANOR; HYPERLIPEN; MODALIM; ESTAPROL	2-(p-(2,2- dichlorocyclopropyl)p henoxy)-2- methylpropionic acid	fibrate	hyperlipidemia
fenofibrate; fenofibrato; procetofene; LF 178; LIPANTHYL; LIPANTIL; LIPIDIL; LIPSIN; NORMALIP; BISTEROL; NORMOLIP; PROMERAL; LIPCOR; TRICOR	2-[4-(4- chlorobenzoyl)pheno xy]-2- methylpropanoic acid 1-methylethyl ester	fibrate	hyperlipidemia
gemfibrozil; CI 719; CS 719; LOPID; ZILOP; IPOLIPID; MARISTON; DELIPID; SCANTIPID	5-(2,5- dimethylphenoxy)- 2,2- dimethylpentanoic acid	fibrate	hyperlipidemia
F 2875	[2'-chloro-4-(1,1')- biphenyl]methyl-1- (imidazolyl)acetate	free radical scavenger	hyperlipidemia
cilmostim; macrophage colony stimulating factor; M- CSF; MACSTIM	unspecified	growth factor; hematopoietic factor; immunostimulant	hyperlipidemia; bacterial infection; cancer
high-density lipoproteins	HDL synthetic particles	HDL stimulation	hyperlipidemia; atherosclerosis
BRL 39924A	1-[3-[(3alpha,5beta)-3- hydroxy-24- oxocholan-24- yl]amino]propyl]- 1,4,4- trimethylpiperazinium diiodide	HDL stimulator	hyperlipidemia
supersulfated low molecular weight heparin; ssLMWH	unspecified	heparinoid	thrombosis; hyperlipidemia

pentosan polysulfate sodium; SP 54; PZ 68; CARTROPHEN; LASONIL; ELMIRON; LELONG MOUSSE	(1-4)-beta-D-xylan 2,3-bis(hydrogen sulfate), sodium salt	heparinoid; vasodilator; NSAID	arthritis; angina; hyperlipidemia; rheumatoid arthritis; cancer; cystitis
BAY 102987	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
BAY w 9533	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
BB 476	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
BMS 180436	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
BMV 22566	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
DMP 565	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
GR 95030	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
S 853758A	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
S 861006A	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
ZD 4522; S 4522; VISACOR	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
glenvastatin; HR 780; HOE 780	(E)-6(S)-2-[4-(fluorophenyl)-2-(2-methylethyl)-6-phenylpyridin-3-yl]ethenyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
lovastatin; mevinolin; monakolin K; MK 803; MSD 803; MB 530B; L 154803; MEVACOR; MEVLOR; LOVACOL; HIPOVASTIN; DISLIPIN; LOVASTEROL; LINCIL	(S)-2-methylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia; cancer

SQ 33600	(S)-4-[[[1-(4-fluorophenyl)-3-(1-methylethyl)-1H-indol-2-yl]ethynyl]hydroxyphosphinyl]-3-hydroxybutanoic acid	HMG CoA reductase inhibitor	hyperlipidemia
U 88156	[1alpha(E),4beta]-3-[2-(4-hydroxy-1-methylcyclohexyl)ethenyl]-alpha,alpha-dimethylbenzenepentanol	HMG CoA reductase inhibitor	hyperlipidemia
pravastatin; eptastatin; epastatin; CS 514; SQ 31000; RMS 431; LIPOSTAT; MEVALOTIN; PRAVACHOL; PRAVASTATIN; SELECTIN; LIPREVIL; PREVACOL; PRAVASIN; APLACTIN; BRISTACOL	[1S-[1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalfa]]-1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic acid	HMG CoA reductase inhibitor	hyperlipidemia; myocardial infarction
L 669262	[1S-[1alpha,7beta,8beta(2S*,4S*),8abeta]]-1,2,6,7,8,8a-hexahydro-3,7-dimethyl-6-oxo-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester of 2,2-dimethylbutanoic acid	HMG CoA reductase inhibitor	hyperlipidemia

RP 61969	[2S-[2 $\alpha$ (E),4 $\beta$ ]]-4-(4-fluorophenyl)-2-(1-methylethyl)-3-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethenyl]-1(2H)-isoquinolinone	HMG CoA reductase inhibitor	hyperlipidemia
dalvastatin; RG 12561	[4 $\alpha$ ,6 $\beta$ (E)]-(+,-)-6-[2-2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethyl-1-cyclohexen-1-yl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
nisbastatin; NK 104	[4R-[4 $\alpha$ ,6 $\beta$ (E)]]-6-[2-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
atorvastatin; atorvastatin calcium; CI 981; PD 1342 98; YM 548; LPITOR; SORTIS	[R-(R*,R*)]-2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid	HMG CoA reductase inhibitor	hyperlipidemia
CP 83101	[R*,S*-(E)]-(+,-)-3,5-dihydroxy-9,9-diphenyl-6,8-nonadienoic acid methyl ester	HMG CoA reductase inhibitor	hyperlipidemia
fluvastatin; fluindostatin; XU 62320; LESCOL; LOCOL; LOCHOL; FRACTAL	[R*,S*-(E)]-(+,-)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid	HMG CoA reductase inhibitor	hyperlipidemia

BMS 180431; BMS 18043109; BMY 21950	[R*,S*-(E)]-(+,-)-9,9-bis(4-fluorophenyl)-3,5-dihydroxy-8-(1-methyl-1H-tetrazol-5-yl)-6,8-nonadienoic acid	HMG CoA reductase inhibitor	hyperlipidemia
cerivastatin; rivastatin; BAY w 6228; LIPOBAY; BAYCOL; LIPOSTEROL; CERVASTA; VASLIP; SELTA; CERTA	[S-[R*,S*-(E)]]-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid	HMG CoA reductase inhibitor	hyperlipidemia
simvastatin analogue	2,2-dimethylbutanoic acid octahydro-3,7-dimethyl-4-hydroxy-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2yl)ethyl)-1-naphthaleny ester	HMG CoA reductase inhibitor	hyperlipidemia
pannorin	4,8,10-trihydroxy-5-methyl-2H-naphtho[1,2-b]pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
simvastatin analogue; L 679336	6(R)-(2-(8(S)-(2,2-dimethylbutyryl)oxy)-2(S),6(R)-dimethyl-5(R)-hydroxy-1,2,3,4,4a(R),5,6,7,8,8a(R)-decahydronaphthyl-1(S))ethyl)-4-(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
hypolipemic AMMCA	6-amino-1,2-dihydro-5-methyl-2-thioxo-4-pyrimidinecarboxylic acid	HMG CoA reductase inhibitor	hyperlipidemia
BAY x 2678	unspecified	HMG CoA reductase inhibitor; cholesterol synthesis inhibitor	hyperlipidemia



simvastatin; epistatin; synvinolin; velostatin; MK 733; L 654; L 644128; 590328; ZOCOR; DENAN; MEDIPO; SIMOVIL; COLEDIS	2,2-dimethylbutanoic acid [1S-[1 $\alpha$ ,3 $\alpha$ ,7 $\beta$ ,8 $\beta$ ta(2S*,4S*)8 $\alpha$ beta]]-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester	HMG CoA reductase inhibitor; osteoanagenetic	hyperlipidemia; osteoporosis
A 1233; 1233 A	unspecified	HMG CoA synthase inhibitor	hyperlipidemia
L 659699; F 244	[2R-[2 $\alpha$ (2E,4E,7R*),3 $\beta$ eta]]-11-[3-(hydroxymethyl)-4-oxo-2-oxetanyl]-3,5,7-trimethyl-2,4-undecadienoic acid	HMG CoA synthase inhibitor	hyperlipidemia
CHOLESS	unspecified	immunostimulant	hyperlipidemia
inhibitor of mevalonate incorporation into cholesterol; IMIC	unspecified	inhibitor of mevalonate incorporation into cholesterol	cancer; hyperlipidemia
DRF 2725	unspecified	insulin sensitizer	diabetes; hyperlipidemia
englitazone; englitazone sodium; CP 68722; CP 72466; CP 72467; CP 724672	(-)-5-[[2R)-2-benzyl-6-chromanyl)methyl]-2,4-thiazolidinedione	insulin sensitizer	diabetes; hyperlipidemia
TA 1801	ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate	Intestinal cholesterol absorption inhibitor	hyperlipidemia
AJ 814	unspecified	Intestinal lipid absorption inhibitor	hyperlipidemia
LF 70165c	N-methyl-N,N-bis(2-hydroxyethyl)-N-[3-[(3 $\beta$ ,5 $\alpha$ ,25R)-spirostan-3-yloxy]propyl]ammonium chloride	Intestinal lipid absorption inhibitor	hyperlipidemia
hypolipidemic, Sam II	unspecified	LDL lowering agent	hyperlipidemia

S 12340	8-[3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]propyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one	LDL peroxidation inhibition	hyperlipidemia
LY 295427	(3A,4A,5A)-4-(2-propenylcholestan-3-ol	LDL receptor upregulator	hyperlipidemia
BAY 139952	unspecified	LDL reduction	hyperlipidemia
CGP 26214	unspecified	LDL regulator	hyperlipidemia; atherosclerosis
E 5050	4-(2,6-dimethylheptyl)-N-(2-hydroxyethyl)-beta-methyl-benzenepropanamide	LDL uptake stimulator	hyperlipidemia
crilvastatin; PMD 387	5-oxo-proline, (+,-)-cis-3,3,5-trimethylcyclohexyl ester	LDL-cholesterol stimulate uptake; potent ACAT inhibition	hyperlipidemia
FL 386	trans-1-[4-(2-methylpropyl)cyclohexyl]-2-[(phenylsulfonyl)oxy]ethanone	lipase inhibitor	hyperlipidemia
K 85; OMACOR	Omega 3 fatty acids	Lipid lowering	hyperlipidemia; restenosis
apolipoprotein E	unspecified	lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
pro-apolipoprotein A1	unspecified	lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
yeast-derived dietary fiber; FIBERCEL; CHOLESTRAN; CHOLAZOL	unspecified	lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
NO 1886	[[4-[[4-bromo-2-cyanophenyl)amino]carbonyl]phenyl]methyl]-phosphonic acid, diethyl ether	lipoprotein lipase activator	hyperlipidemia

imanixil; HOE 402	4-amino-2-(4,4-dimethyl-2-oxo-1-imidazolidinyl)-alpha,alpha,alpha-trifluoro-5-pyrimidinecarboxym-tolide	lipoprotein regulator	hyperlipidemia
BMS 212122	unspecified	microsomal transfer protein inhibitor	hyperlipidemia
GW 328713; GR 328713	unspecified	microsomal transfer protein inhibitor	hyperlipidemia
JTT 722	unspecified	microsomal transfer protein inhibitor	hyperlipidemia; obesity
BMS 201038	Unspecified	microsomal transfer protein inhibitor	hyperlipidemia
MAB, LDL and Fc; bispecific antibody, low density lipoprotein	unspecified	monoclonal antibody	hyperlipidemia
drug delivery system, sustained release niacin; niacin sustained release; NIASPAN	unspecified	Niacin sustained release	hyperlipidemia
leucomyzin	unspecified	NSAID	inflammation; hyperlipidemia
orlistat; orlipastat; tetrahydrolipistatin; THL; Ro 180647; XENICAL	N-formyl-L-leucine [2S-[2alpha(R*),3beta]]-1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester	pancreatic lipase inhibitor	obesity; hyperlipidemia; diabetes
LA 230	unspecified	peptide	hypertension; hyperlipidemia
ethyl eicosapentaenoate; ethyl icosapentate; EPA-E; MND 21; EPADEL	ethyl all-cis-5,8,11,14,17-eicosapentaenoate	platelet antiaggregant	thrombosis; hyperlipidemia
AL 0671	(1S-endo)-N-(6-amino-3-pyridinyl)-N'-bicyclo[2.2.1]hept-2-yl-N''-cyanoguanidine	potassium channel activator	hyperlipidemia; hypertension

MDL 29311	4,4'-(methylenebis[thio])bis(2,6-bis[1,1-dimethylethyl]phenol	Probucol analogue antioxidant; LDL inhibitor	diabetes; hyperlipidemia
BMY 42393	2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy] acetic acid	prostaglandin agonist; platelet antiaggregant	hyperlipidemia; thrombosis
KB 5246	6-fluoro-5-(4-methyl-1-piperazinyl)-8-oxo-3H,8H-4-oxa-1-thia-9b-azacyclopenta[cd]phenalene-9-carboxylic acid monohydrochloride	quinolone; antibiotic	cancer; pruritis; hypertension; HIV infection; gastrointestinal ulcer; hyperlipidemia; bacterial infection
BIBX 245	unspecified	Squalene cyclase inhibitor	hyperlipidemia
NB 598	(E)-3-([3,3'-bithiophen]-5-ylmethoxy)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-ethyl-benzenemethanamine	squalene epoxidase inhibitor	hyperlipidemia
RPR 107393	3-hydroxy-3-[4-(quinolin-6-yl)phenyl]-1-azabicyclo[2-2-2]octane dihydrochloride	squalene synthase inhibitor	hyperlipidemia
RPR 101821	trans-2-[4-(benzoxazol-2-yl)-phenylmethoxy] amino cyclohexane HCl	squalene synthase inhibitor	hyperlipidemia
GR 105155	unspecified	squalene synthetase inhibitor	hyperlipidemia
squalestatins	unspecified	squalene synthetase inhibitor	hyperlipidemia

squalestatin 1; zaragozic acid A; L 694599	[5(2E,4S,6S),7S]-2,7- anhydro-3,4-di-C- carboxy-8,9,10,12,13- pentadeoxy-10- methylene-12- (phenylmethyl)-L- erythro-L-glycero-D- altro-7-trideculo-7,4- furanosonic acid 11- acetate 5-(4,6- dimethyl-2-octenoate)	squalene synthetase inhibitor	hyperlipidemia
BMS 188494	2,2- dimethylpropanoic acid [[4-(3- phenoxyphenyl)-1- sulfoethyl]phosphinyl idene]bis(oxyethylene) ester	squalene synthetase inhibitor	hyperlipidemia
thyroid hormone receptor beta agonist, thyroid hormone receptor beta agonist	unspecified	thyroid hormone agonist	obesity; hyperlipidemia
transcription factor regulators, antihypercholesterole mia	unspecified	transcription factor regulator	hyperlipidemia
antiatherosclerotic agents	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	atherosclerosis; hyperlipidemia
BOF 6721	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
BOF 6766	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
CDRI 80574	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia

CR 2083	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
diabetes therapy	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	diabetes; obesity; hyperlipidemia
FCP 3P1	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	atherosclerosis; hyperlipidemia
N 1197	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
SRI 62320; SRI 6230	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
CGS 23425	[[4-[4-hydroxy-3-(1-methylethyl)phenoxy]-3,5-dimethylphenyl]amino]oxoacetic acid	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
compound 10	2-acetylthio-3-[4-(phenylthio)benzoyl]propanoic acid	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
F 2833	2'-chloro-alpha,alpha-dimethyl-[1,1'-biphenyl]-4-methanol	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
LM 1554	2-chloromethyl-5,6,7,8-tetrahydrobenzo(b)thieno(2,3-d)pyrimidin-4(3H)-one	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
RP 54275	2-n-octadecylindole-5-carboxylic acid	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia

fenofibrate; BW 207U; BW 207	4'-(trifluoromethyl)-2-biphenylcarboxylic acid	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
fenofibrate; AY 25712; REDUCTOL	4,5-dihydro-5-methyl-4-oxo-5-phenyl-2-furancarboxylic acid	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
P 06103	4-[3-[(6-amino-9-beta-D-ribofuranosyl-9H-purin-8-yl)thio]-2-oxopropoxy]-benzoic acid 2-methylpropyl ester	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
MKC 121	4-tridecylpyrrole-2-carboxylic acid	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
P 0654	8-[3-[4-(2-methylpropyloxycarbonyl)phenoxy]-2-(R)-hydroxypropyl]adenosine	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
hypolipemic	8-O,N-dipivaloyl-3-(N'-(2,4,6-trimethylbenzyl)-N-piperazinyl)rifamycin S	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
CGS 24565	N,15-didehydro-11,15-dideoxy-1,15-epoxy-11-hydroxy-4-O-methyl-3-[4-[(2,4,6-trimethylphenyl)methyl]-1-piperazinyl]rifamycin 8-(2,2-dimethylpropanoate)	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia

CGP 43371	N,15-didehydro-15-deoxo-1-deoxy-1,15-epoxy-3-[4-[(2,4,6-trimethylphenyl)methyl]-1-piperazinyl]rifamycin 8-(2,2-dimethylpropanoate)	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
LS 2904	Unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
NIP 261	unspecified	VLDL catabolism stimulator; HDL synthesis stimulator	hyperlipidemia
S 2E	(S)-(+)-4-[[1-[4-(1,1-dimethylethyl)phenyl]-5-oxo-3-pyrrolidinyl]methoxy]benzoic acid	VLDL formation inhibitor	hyperlipidemia; atherosclerosis

Table 47. Current Candidate Therapeutic Interventions for the Treatment of Asthma

Product Name	Chemical Name	Action	Indication
3323W	unspecified	5 lipoxygenase inhibitor	asthma
CMI 977	Unspecified	5 lipoxygenase inhibitor	asthma
ZD 4407	(2S-trans)-1,3-dihydro-1-methyl-5-[[4-(tetrahydro-4-hydroxy-2-methyl-2H-pyran-4-yl)-2-thienyl]thio]-2H-indol-2-one	5 lipoxygenase inhibitor	asthma
WY 50295; WY 50295 tromet	(S)-alpha-methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid	5 lipoxygenase inhibitor	asthma; rhinitis
SB 202235	(S)-N-(2,3-dihydro-6-phenylmethoxy-3-benzofuranyl)urea	5 lipoxygenase inhibitor	asthma



L 739010	1,6-anhydro-3-C-[6-[[[7-cyano-5-(3-furanyl)-2-naphthalenyl]oxy]methyl]-2-pyridinyl]-2,4-dideoxy-beta-D-threo-hexopyranose	5 lipoxygenase inhibitor	asthma
FR 110302	2,2-dibutyl-1,2,3,4-tetrahydro-5-(2-quinolinylmethoxy)-1-naphthalenol	5 lipoxygenase inhibitor	asthma
bunaprolast; U 66858	2-butyl-4-methoxy-1-naphthalenol acetate	5 lipoxygenase inhibitor	asthma
TDI 41127	4-(5-methoxy-3-methyl-1H-indol-2-yl)-2,6-dimethylphenol	5 lipoxygenase inhibitor	asthma
linazolast; TMK 688; YM 257	4-[5-[[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]amino]-5-oxo-1,3-pentadienyl]-2-methoxyphenylcarbonic acid ethyl ester	5 lipoxygenase inhibitor	asthma; rhinitis
L 691816	5-[3-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]-2,2-dimethylpropyl]-1H-tetrazole	5 lipoxygenase inhibitor	asthma
docebenone; AA 861	6-(12-hydroxy-5,10-dodecadienyl)-2,3,5-trimethyl-1,4-benzoquinone	5 lipoxygenase inhibitor	asthma; heart failure
PF 5901	alpha-pentyl-3-(2-quinolinylmethoxy)-benzenemethanol	5 lipoxygenase inhibitor	asthma

BW B70C	N-[3-[3-(4-fluorophenoxy)phenyl]-1-methyl-2-propenyl]-N-hydroxyurea	5 lipoxygenase inhibitor	asthma
R 85355	Unspecified	5 lipoxygenase inhibitor	asthma; psoriasis; inflammatory bowel disease
CHF 1909	Unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma
GR 80907	Unspecified	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
SC 45662	Unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis; inflammatory bowel disease
CGS 25997	(2S)-(-)-2-[[N-(aminocarbonyl)-N-hydroxyamino]methyl]-7-(4-fluorophenoxy)-1,4-benzodioxan	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
L 663536; MK 886	1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-alfa,alfa-diethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis
L 699333	2-[2-[1-[(4-chlorophenyl)methyl]-4,5-dihydro-4-methyl-6-[(5-phenyl-2-pyridinyl)methoxy]-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
E 6080	4-[[[(6-hydroxy-4,4,7-trimethyl-2-benzothiazolyl)amino]methyl]benzenesulfonamide monohydrochloride	5 lipoxygenase inhibitor; NSAID	asthma; inflammation

L 651392	4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one	5 lipoxygenase inhibitor; NSAID	inflammation; bacterial infection; asthma
ZD 2138; ICI D2138	6-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-2(1H)-quinolinone	5 lipoxygenase inhibitor; NSAID	arthritis; asthma
ZD 7717; ICI D7717	7-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenyl]thio]-4-methyl-2H-1,4-benzoxazin-3(4H)-one	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
zileuton; A 64077; ABBOTT 64077; ZYFLO	N-(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea	5 lipoxygenase inhibitor; NSAID	inflammation; asthma
TA 270	N-[1,2-dihydro-4-hydroxy-1-methyl-3-(octyloxy)-2-oxo-7-quinolinyl]-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenamide	5-lipoxygenase inhibitor	asthma; rhinitis
GW 328267	Unspecified	adenosine antagonist; adenosine A2 antagonist	asthma
midaglizole; DG 5128	2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine	alpha adrenergic antagonist; alpha2 adrenergic antagonist	asthma; diabetes
melanocortin receptor-1 modulators, Trega Biosciences	Unspecified	analgesic; melanocortin agonist; melanocortin MC1 agonist	asthma; pain; nephritis
LA 351	5H-(1)-benzopyrano(2,3-b)pyridin-5-one	analgesic; NSAID	inflammation; pain; asthma
HP 228	N-acetyl-Nleu-Gln-His-Phe-Arg-Trp-Gly-amide	analgesic; NSAID; peptide; melanocortin agonist	pain; inflammation; asthma; cachexia
anti-inflammatory macrolide analogues, KOSAN	Unspecified	antibiotic; macrolide	asthma; inflammation

SB 226882	4-[4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-N-methyl-2-pyrimidinamine	antifungal; MAP kinase inhibitor; signal transduction inhibitor; imidazole	inflammation; asthma; rheumatoid arthritis
U 75412E	(16alpha)-21-[4-[3-(ethylamino)-2-pyridinyl]-1-piperazinyl]-16-methylpregna-1,4,9(11)-triene-3,20-dione (2Z)-2-butenedioate (1:1)	Antigen induced bronchopulmonary eosinophilia inhibition, no glucocorticoid activity	asthma
CPR 3005	Lipid analogue	Antiinflammatory	skin disease; eye disease; asthma; rheumatoid arthritis
CPR 3014	Lipid analogue	Antiinflammatory	skin disease; eye disease; asthma; rheumatoid arthritis
CT 1441	Unspecified	Antiinflammatory	asthma; allergy
CPR 3016	Lipid analogue	antiinflammatory	skin disease; eye disease; asthma; rheumatoid arthritis
synthetic catalytic scavenger analogues; SCS analogues	Unspecified	antioxidant; free radical scavenger	stroke; trauma; atherosclerosis; neurodegeneration; asthma
VANTOX	Unspecified	antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke
antisense oligonucleotide, interleukin-5; antisense oligonucleotide, IL-5	Unspecified	antisense; oligonucleotide; biotechnology	asthma
D 2522	Unspecified	beta adrenergic agonist	asthma
SL 2021	Unspecified	beta adrenergic agonist	asthma

procaterol; procaterol hydrochloride; OPC 2009; CI 888; MEPTIN; PRO-AIR; ONSUKIL; BRON NOVO; PROMAXOL; MASACIN; PROCADIL; PROPULUM	2(1H)-quinolone, 8-hydroxy-5-(1-hydroxy-2-(1-methylethylamino)butyl)-, monohydrochloride, (R*S*)(+,-)	beta adrenergic agonist	asthma
nardeterol; SOM 1122	alpha-[[[3-(1H-benzimidazol-1-yl)-1,1-dimethylpropyl]amino]methyl]-2-fluoro-4-hydroxybenzenemethanol	beta adrenergic agonist	asthma
RP 58802B	alpha-[[[3-(1H-benzimidazol-1-yl)-1-methylpropyl]amino]methyl]-4-hydroxy-3-methoxybenzenemethanol	beta adrenergic agonist	asthma
CEDO 20433	Unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
picumeterol; picumeterol fumarate; GR 114297; GR 114297 X; GR 63411	(-)-(R)-4-amino-3,5-dichloro-alpha-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzenemethanol	beta adrenergic agonist; beta2 adrenergic agonist	asthma
salmeterol, (R)-; (R)-salmeterol	(R)-4-hydroxy-alpha.1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol	beta adrenergic agonist; beta2 adrenergic agonist	asthma

formoterol; eformoterol; formoterol fumarate; YM 08316; BD 40A; CGP 25827; CGP 25827A; ATOCK; FORADIL; ASMATEC; SINASFIX; LEMOTEC; OXIS	(R*,R*)-(+,-)-N-[2- hydroxy-5-[1- hydroxy-2-[[2-(4- methoxyphenyl)-1- methylethyl]amino]et hyl]phenyl]formamid e	beta adrenergic agonist; beta2 adrenergic agonist	asthma
formoterol, (R,R); (R,R)-formoterol	[R-(R*,R*)-(+,-)-N- [2-hydroxy-5-[1- hydroxy-2-[[2-(4- methoxyphenyl)-1-m ethylethyl]amino]ethy l]phenyl]formamide	beta adrenergic agonist; beta2 adrenergic agonist	asthma
LAS 32521	Unspecified	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
salmeterol + fluticasone; fluticasone + salmeterol; SERETIDE; ADVAIR DISKUS	Unspecified	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator; corticosteroid	asthma
broxaterol; Z 1170; SUMMAIR	(+,-)-3-bromo-alpha- [(tert- butylamino)methyl]- 5-isoxazolemethanol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
levosalbutamol; levalbuterol; salbutamol, (R)-; (R)- salbutamol; (R)- albuterol; levalbuterol sulfate; XOPENEX	(R)-alpha'-[[ (1,1- dimethylethyl)amino] methyl]-4-hydroxy- 1,3- benzenedimethanol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
TA 2005	[R-(R*,R*)]-8- hydroxy-5-[1- hydroxy-2-[[2-(4- methoxyphenyl)-1- methylethyl]amino]et hyl]-2(1H)- quinolinone monohydrochloride	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma

salmeterol; salmaterol; GR 33343X; SN 408; GR 33343G; SEREVENT	4-hydroxy-alpha.1- [[[6-(4- phenylbutoxy)hexyl]a mino]methyl-1,3- benzenedimethanol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma; pulmonary obstructive disease
etanterol	5-amino-alpha-[[p- hydroxy-alpha- methylphenethyl]ami no]methyl]-m-xylene- alpha,alpha'-diol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
bambuterol; BWD 2183; BAMBEC	dimethylcarbamic acid 5-[2-[(1,1- dimethylethyl)amino] -1-hydroxyethyl]-1,3- phenylene ester	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
SM 11044	[R-(R*,S*)]-1-[3- (3,4- dihydroxypheny)-2- [[3-(4- fluorophenyl)propyl]a mino]-3-hydroxy-1- oxopropyl]pyrrolidine monohydrobromide	beta adrenergic agonist; beta3 adrenergic agonist; leukotriene antagonist; leukotriene D4 antagonist	asthma
AR C68397AA; AR- C68397AA; ARL 68397	4-hydroxy-7-[2-[[2- [[3-(2- phenylethoxy)propyl] sulfonyl]ethyl]amino] ethyl-2(3H)- benzothiazolone monohydrochloride	beta adrenergic agonist; bronchodilator	asthma; pulmonary obstructive disease; rhinitis
tulobuterol; HN 078; C 78; HSR 078A; BRELOMAX; BREMEX; ATENOS; BERACHIN; HOKUNALIN	alpha-[(tert- butylamino)methyl]- o-chlorobenzyl alcohol	beta adrenergic agonist; bronchodilator	asthma
allergy immunogen, migis epsilon, Tanox	Unspecified	Immunomodulation	allergy; asthma
allergy therapy, E coli enterotoxin B subunit-antigen fusion protein	Unspecified	Immunomodulation	rhinitis; asthma
emoctakin; interleukin-8	Unspecified	Immunomodulation	asthma

fusion protein, IL-10	Unspecified	Immunomodulation	asthma; inflammatory bowel disease
antisense oligonucleotide, adenosine A1 receptor; antisense oligonucleotide, asthma; EPI 2010; E 2010; EpiGenRx	Unspecified	antisense; oligonucleotide; mRNA translation inhibitor	asthma
interleukin-4 receptor; IL-4r; NUVANCE	Unspecified	cytokine antagonist	inflammation; asthma
soluble interleukin-5 receptor alpha; IL-5Ra	Unspecified	cytokine antagonist	asthma
interleukin-1 receptor; IL-1r; HJ 1306	Unspecified	cytokine inhibitor; immunosuppressant	asthma
anakinra; interleukin-1 receptor antagonist; IL-1ra; interleukin-1 inhibitor; ANTRIL	N2-L-methionylinterleukin 1 receptor antagonist (human isoform x reduced)	cytokine inhibitor; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; transplant rejection; asthma; septic shock
interleukin-12; IL-12; natural killer stimulatory factor; NKSF; cdodekin alfa; Ro 247472; Ro 24-7472	Unspecified	cytokine; immunostimulant	asthma
enkephalinase	Unspecified	enkephalinase; enzyme	asthma; ophthalmological
platelet-activating factor acetylhydrolase; PAF-AH; SUN Y7016; PAFASE	Unspecified	hydrolase	respiratory distress syndrome; asthma; inflammatory bowel disease
IgE receptors, soluble, CorBec	Unspecified	immunosuppressant	asthma
antisense oligonucleotide, ICAM-1; antisense oligonucleotide, intracellular adhesion molecule-1; ISIS 2302	d[(R)-P-thio](G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A) DNA	immunosuppressant; antisense; oligonucleotide; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease; asthma



lenercept; tumor necrosis factor receptor fusion protein; TNF receptor fusion protein; Ro 452081; TENEFUSE	Unspecified	immunosuppressant; NSAID	rheumatoid arthritis; asthma; septic shock; multiple sclerosis
MAB, AL 901; MAb, IgE; AL 901; CGP 51901; IGE 025A	Unspecified	monoclonal antibody	allergy; rhinitis; asthma
MAB, CD23; MAb, PRIMATIZED CD23	Unspecified	monoclonal antibody	asthma; allergy; rhinitis
MAB, IgE; MAb, E25	Unspecified	monoclonal antibody	asthma; allergy; rhinitis
MAB, interleukin-4; SB 240683	Unspecified	monoclonal antibody	asthma
MAB, interleukin-5; MAB, IL-5; SCH 55700; CDP 835	Unspecified	monoclonal antibody; immunosuppressant	asthma
MAB, macrophage migration inhibitory factor, Picower Institute for Medical Research	Unspecified	monoclonal antibody; NSAID	arthritis; asthma
MAB, VLA-4, humanized; MAB, very late antigen-4, humanized	Unspecified	monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
clenoliximab; MAB, CD4; MAB, PRIMATIZED CD4; IDEC 151; SB 217969	immunoglobulin G 4 (human-Macaca monoclonal CE9gamma4PE gamma4-chain anti-human antigen CD4), disulfide with human-Macaca monoclonal CE9gamma4PE kappa-chain, dimer	monoclonal antibody; NSAID	rheumatoid arthritis; psoriasis; asthma

keliximab; MAb, CD4; MAb, PRIMATIZED CD4; IDEC CE9.1; SB 210396	immunoglobulin G1 (human-Macaca monoclonal CE9.1.gamma.1-chain anti-human antigen CD 4), disulfide with human-Macaca monoclonal CE9.1.lambda.-chain, dimer	monoclonal antibody; NSAID	rheumatoid arthritis; asthma
neutrophil degranulation inhibitor; DGI	Unspecified	NSAID	asthma; rheumatoid arthritis
RecepTox-Fce	Unspecified	peptide; fusion toxin	asthma; allergy
lipocortin; lipomodulin; macrocortin	Unspecified	phospholipase inhibitor; NSAID	asthma; arthritis
LEX 043	Unspecified	proteinase inhibitor; serine proteinase inhibitor	inflammation; asthma
neutral endopeptidase; NEP	Unspecified	proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
ribozymes, asthma	Unspecified	ribozyme; oligonucleotide	asthma
secretory leukocyte proteinase inhibitor; serine leukocyte proteinase inhibitor; SLPI; serine proteinase inhibitor; SPI; SLPI	Unspecified	serine proteinase inhibitor; proteinase inhibitor	asthma
vaccine, TNF alpha	Unspecified	Immunomodulation, vaccine; cytokine antagonist	rheumatoid arthritis; Crohn disease; cachexia; asthma
bradykinin2 antagonists, Neurogen	Unspecified	bradykinin antagonist	asthma
NOVA 567; NPC 567	N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalaninebradykinin	bradykinin antagonist; cicatrizant; peptide; NSAID	asthma; skin ulcer; inflammation

icatibant; icatibant acetate; HOE 140	D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolincarbonyl-L-(2alpha,3abeta,7abeta)-octahydro-1H-indole-2-carbonyl-L-arginine	bradykinin antagonist; NSAID	asthma; inflammation; rhinitis; osteoarthritis
NPC 17731	N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-(trans-4-propoxy-D-proline)-8-[L-(2alpha,3abeta,7abeta)-octahydro-1H-indole-2-carboxylic acid]-bradykinin	bradykinin antagonist; NSAID	inflammation; septic shock; asthma
FR 172657	(E)-3-[6-(acetylamino)-3-pyridinyl]-N-[2-[[2,4-dichloro-3-[(2-methyl-8-quinolinyl)oxy]methyl]phenyl]methylamino]-2-oxoethyl-2-propenamide	bradykinin antagonist; NSAID; analgesic	asthma; inflammation; pain
HOE 058A	Unspecified	bronchodilator	asthma
RU 32210	Unspecified	bronchodilator	asthma
S 123701	Unspecified	bronchodilator	asthma
SC 109	Unspecified	bronchodilator	asthma; pulmonary fibrosis
SDZ MKS492	(R)-8-[[1-(3,4-dimethoxyphenyl)-2-hydroxyethyl]amino]-3,7-dihydro-7-(2-methoxyethyl)-1,3-dimethyl-1H-purine-2,6-dione	bronchodilator	asthma

F 3121	1,4-dihydro-3-amino-4-oxo-1-((3-trifluoromethyl)phenyl)pyridazine	bronchodilator	asthma
PF 904	1-ethyl-6-methyl-1H-pyrazino[2,3-c][1,2,6]thiadiazin-4-amine 2,2-dioxide	bronchodilator	asthma
LM 3339	2-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)pyridine 1-oxide	bronchodilator	asthma
KF 17625	5-phenyl-(3H)-imidazo(4,5-c) (1,8)-naphthyridin-4-(5H)-one	bronchodilator	asthma
dametralast; LA 2851	7-methylpyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine	bronchodilator	asthma
KF 15570	imidazo(4,5-c)quinoline-4-one	bronchodilator	asthma
LY 150310	1-(1,2,3,4-tetrahydro-1-naphthalenyl)-1H-imidazole mononitrate	bronchodilator; imidazole	asthma
fenspiride; KSP 193; PNEUMORAL; ESPIRAN	8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one	bronchodilator; NSAID	inflammation; asthma
Ro 251553; Ro 25-1553	N-acetyl-His-Ser-Asp-Ala-Val-Phe-Thr-Glu-Asn-Tyr-Thr-Lys-Leu-Arg-Lys-Gln-NLeu-Ala-Ala-Lys-Lys-Tyr-Leu-Asn-Asp-Leu-Lys-Lys-Gly-Gly-Thr-amide, cyclic (25->21)-peptide	bronchodilator; VIP agonist	asthma

CD 349	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-(nitrooxy)propyl 3-(nitrooxy)propyl ester	calcium antagonist; bronchodilator	hypertension; asthma; angina
RWJ 22108	4-(2-chloro-6-fluorophenyl)-1,4,6,7,8,9-hexahydro-2-methylthiépino[3,2-b]pyridine-3-carboxylic acid 5,5-dioxide 2-[methyl(phenylmethyl)amino]ethyl ester	calcium antagonist; bronchodilator	asthma
IgE regulators	Unspecified	CD23 increase expression and production	asthma; allergy
VLA4 integrin antagonist, Cytel	Unspecified	cell adhesion inhibitor; integrin antagonist; VLA 4 antagonist; NSAID	asthma; rheumatoid arthritis; multiple sclerosis
CCR3 inhibitors	Unspecified	chemokine antagonist	asthma
CCR3 receptor modulators,	Unspecified	Chemokine receptor, CCR3 modulator	asthma
chloride channel blocker, Bayer	Unspecified	chloride channel blocker	asthma; pulmonary obstructive disease
AQRA 721	N-1-azabicyclo[2.2.2]oct-3-yl-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepine-11-carboxamide	cholinergic antagonist; bronchodilator	asthma
tiotropium bromide; BA 679BR	(1-alpha,2beta,4beta,5alpha,7beta)-7-[(hydroxydi-(2-thienyl)acetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0 <sup>2,4</sup> ]nonane bromide	cholinergic antagonist; muscarinic antagonist; muscarinic M1 antagonist; muscarinic M3 antagonist; bronchodilator	asthma

rispenzepine; ulvenzepine; DF 594	6,11-dihydro-11-[(1-methyl-3-piperidiny)carbonyl]-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one	cholinergic antagonist; muscarinic antagonist; muscarinic M1 antagonist; muscarinic M3 antagonist; antispasmodic; bronchodilator	asthma; bronchitis
DAC 5889; DAC 6150	6-oxo-3-phenyl-3-piperidinecarboxylic acid 1-azabicyclo[2.2.2]oct-3-yl ester	cholinergic antagonist; muscarinic antagonist; muscarinic M1 antagonist; bronchodilator	asthma
revatropate; UK 112166	(R)-3-quinuclidyl-(2S)-2-hydroxymethyl-4-(R)-methylsulfinyl-2-phenylbutyrate	cholinergic antagonist; muscarinic M3 antagonist; muscarinic antagonist	asthma; pulmonary obstructive disease
chymase inhibitors, Axys	Unspecified	chymase inhibitor; NSAID	asthma; inflammation; rhinitis
CMI 903	Unspecified	complement inhibitor	asthma
anti-inflammatory corticosteroids, A&M University	Unspecified	corticosteroid	psoriasis; asthma
D 5272	Unspecified	corticosteroid	asthma
D 5519	Unspecified	corticosteroid	asthma
GW 215864	Unspecified	corticosteroid	asthma
GW 250495	Unspecified	corticosteroid	asthma
ST 126; TO 199	Unspecified	corticosteroid	asthma
CGP 13774; KSR 592	(+)-methyl 9alpha-chloro- -6alpha-fluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-p ropionyloxy-androsta-1,4-diene-17beta-carboxylate	corticosteroid	asthma; rhinitis

icometasone enbutate; icomethasone enbutate; icometasone acetate; isomethasone acetate; CL 09	(11.beta.,16.alpha.)- 21-(acetyloxy)-9- chloro-11-hydroxy- 16-methyl-17-(1- oxobutoxy)pregna- 1,4-diene-3,20-dione	corticosteroid	asthma; skin disease
butixocort propionate; JO 1222	(11beta)-11-hydroxy- 17-(1-oxobutoxy)-21- [(1- oxopropyl)thio]]pregn -4-ene-3,20-dione	corticosteroid	inflammation; asthma; inflammatory bowel disease
budesonide; budesonide propionate; S 1320; PREFERID; PULMICORT; RHINOCORT; ENTOCORT; NARICORT; INFLAMMIDE; BETACTIN; ELTAIR; HORACORT; RHINOCORT AQUA	(11beta,16alpha)- 16,17- [butylidenebis(oxy)]- 11,21- dihydroxypregna-1,4- diene-3,20-dione	corticosteroid	asthma; skin disease; inflammation; rhinitis; ulcerative colitis; Crohn disease
mometasone furoate; mometasone; S 2640; SCH 32088; ELOCOM; ELOCON; FULMETA; ECURAL; ERMIL; NASONEX; ASMANEX	(11beta,16alpha)- 9,21-dichloro-17-[(2- furanylcabonyl)oxy]- 11-hydroxy-16- methyl-pregna-1,4- diene-3,20-dione	corticosteroid	dermatitis; asthma; rhinitis; psoriasis; pruritis
deflazacort; azacort; L 5458; MDL 458; AZACORTID; CALCORT; LANTADIN; DEFLAN; FLANTADIN; DEZACOR; ZAMENE; ROSILIN; DEFLAMON; PRANDIN	(11beta,16beta)-21- (acetyloxy)-11- hydroxy-2'-methyl- 5'H-pregna-1,4-die no[17,16-d]oxazole- 3,20-dione	corticosteroid	rheumatoid arthritis; skin disease; asthma

fluticasone propionate; fluticasone; CCI 18781; SN 410; SN 411MD; FLOVENT; FLIXONASE; FLIXOTIDE; FLONASE; FLUTIVATE; FLUTIDE NASAL; CUTIVATE; RONTILONA; TRIALONA; FLUNASE	(6alpha,11beta,16alpha,17alpha)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-androst-1,4-diene-17-carbothioic acid, S-(fluoromethyl) ester	corticosteroid	dermatitis; rhinitis; asthma; pulmonary obstructive disease; skin disease
ciclesonide; BY 9010	[11beta,16alpha(R)]-16,17-[[cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-diene-3,20-dione	corticosteroid	asthma
drug delivery system, liposome rofleponide; rofleponide liposome; rofleponide palmitate	[6alpha,11beta,16alpha(R)] 16,17-[[butylidenebis(oxy)]6,9-difluoro-11,21-dihydroxypregn-4-ene-3,20-dione	corticosteroid	asthma; rhinitis
rofleponide; D 5522	[6alpha,11beta,16alpha(R)] 16,17-[[butylidenebis(oxy)]6,9-difluoro-11,21-dihydroxypregn-4-ene-3,20-dione	corticosteroid	asthma
RPR 106541	[6alpha,11beta,16alpha(R),17beta]-16,17-[[butylidenebis(oxy)]-6,9-difluoro-11-hydroxy-17-(methylthio)androst-4-en-3-one	corticosteroid; glucocorticoid	asthma



methylprednisolone suleptanate; U 67590A; PROMEDROL	(6alpha,11beta)-11,17- dihydroxy-6-methyl- 21-[[8-[methyl(2- sulfoethyl)amino]- 1,8- dioxooctyl]oxy]pregn- a-1,4-diene-3,20- dione monosodium salt	corticosteroid; immunosuppressant	inflammation; asthma; anaphylactic shock; transplant rejection
tepoxalin; RWJ 20485; ORF 20485	5-(4-chlorophenyl)-N- hydroxy-1-(4- methoxyphenyl)-N- methyl-1H-pyrazole- 3-propanamide	COX inhibitor; 5- lipoxigenase inhibitor; NSAID	asthma; inflammation; inflammatory bowel disease
BAY 169996	Unspecified	cytokine antagonist	asthma
cytokine trap, Regeneron	Unspecified	cytokine antagonist	cancer; asthma; rheumatoid arthritis; allergy
IL-4 antagonists, Pharmacopeia; IL-4 antagonists, Regeneron	Unspecified	cytokine antagonist	asthma
interleukin-4 signal transduction antagonists, Ligand	Unspecified	cytokine antagonist	asthma
interleukin-4 receptor inhibitors, Affymax	Unspecified	cytokine inhibitor	asthma; diabetes
interleukin-1 inhibitors, Selectide	Unspecified	cytokine inhibitor; NSAID	inflammation; asthma; inflammatory bowel disease
JTE 711	Unspecified	cytokine synthesis inhibitor	dermatitis; asthma; rhinitis
repirinast; BAY u 2372; MY 5116; ROMET	isopentyl 5,6-dihydro- 7,8-dimethyl-4,5- dioxo-4H-pyrano[3,2- c]quinoline-2- carboxylate	Degranulation inhibitor	asthma
CGP 25875	Unspecified	degranulation inhibitor	asthma
sulochrin	Unspecified	degranulation inhibitor	asthma

cromoglicate lisetil; AKY 953; KY 556; N 556	2-[[2-(ethoxycarbonyl)-4-oxo-4H-1-benzopyran-5-yl]oxy]-1-[[[2-(ethoxycarbonyl)-4-oxo-4H-1-benzopyran-5-yl]oxy]methyl]ethyl ester, L-lysine dihydrochloride	degranulation inhibitor	asthma; rhinitis; dermatitis; allergy
BN 50601	2-[4-(1,1-dimethylethyl)phenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[3,4-b]pyridin-7-ol	degranulation inhibitor	asthma
amlexanox; amoxanox; CHX 3673; AA 673; SOLFA; ELICS; APHTHASOL	2-amino-7-(1-methylethyl)-5-oxo-5H-[1]-benzopyrano[2,3-b]pyridine-3-carboxylic acid	degranulation inhibitor	asthma; psoriasis; rhinitis; mucositis; conjunctivitis; allergy
asobamast; Z 1819	2-ethoxyethyl[4-(3-methyl-5-isoxazolyl)-2-thiazolyl]oxamate	degranulation inhibitor	asthma
tetrazolast meglumine; tetrazolast; MDL 26024GO	4-(1H-tetrazol-5-yl)tetrazolo[1,5-a]quinoline with 1-deoxy-1-(methylamino)-D-glucitol	degranulation inhibitor	asthma
azelastine; A 5610; W 2979M; E 0659; AZEPTIN; ALLERGODIL; ASTELIN; RADETHAZIN; AFLUONA; AFLUON; AZEPIT; AZECOF; AZERUNART CHOS H; BIFERTIN	4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone	degranulation inhibitor	asthma; rhinitis; skin disease; conjunctivitis

quinotolast; quinotolast sodium; FK 021; FR 71021; ASLOCK	4-oxo-1-phenoxy-N- 1H-tetrazol-5-yl-4H- quinolizine-3- carboxamide	degranulation inhibitor	asthma; rhinitis; dermatitis
picumast; picumast dihydrochloride; BM 15100	7-[3-[4-(4- chlorobenzyl)-1- piperazinyl]propoxy]- 3,4-dimethylcoumarin	degranulation inhibitor	rhinitis; asthma
nedocromil; FPL 59002; FPL 59002KP; TILADE; TILARIN; TILAVIST; TILAD; NEDREL; DISVEN; IRTEN	9-ethyl-6,9-dihydro- 4,6-dioxo-10-propyl- 4H-pyrano[3,2- g]quinoline-2,8- dicarboxylic acid	degranulation inhibitor	asthma; eye disease; skin disease; rhinitis
pemirolast; pemirolast potassium; BMY 26517; DE 068; BL 5617; PEMILASTON; ALLEGYSAL	9-methyl-3-(1H- tetrazol-5-yl)-4H- pyrido[1,2- a]pyrimidin-4-one	degranulation inhibitor	asthma; conjunctivitis; rhinitis; dermatitis; restenosis
suplatast tosilate; IPD 1151T; MPD; IPD	dimethyl-2-[4-(3- ethoxy-2- hydroxypropoxy)phen- ylcarbamoyl]ethylsulf- onium-p-toluene sulfonate	degranulation inhibitor	dermatitis; asthma; allergy; rhinitis
tazanolast; WP 833; TAZANOL; TAZALEST	oxo[[3-(1H-tetrazol- 5- yl)phenyl]amino]aceti- c acid, butyl ester	degranulation inhibitor	asthma; rhinitis
CI 959	5-methoxy-3-(1- methylethoxy)-N-1H- tetrazol-5-yl- benzo[b]thiophene-2- carboxamide sodium salt	degranulation inhibitor; immunosuppressant; NSAID	rhinitis; inflammation; asthma; arthritis
AP 414	Unspecified	degranulation inhibitor; tyrosine kinase inhibitor	asthma; allergy
MDAM	N-[4-[2-(2,4-diamino- 6- pteridiny]ethyl]benzo- yl]-4-methylene-DL- glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma

ALP 242	Unspecified	elastase inhibitor; proteinase inhibitor	asthma; emphysema; psoriasis
BQ 153	cyclo(3-sulfo-D- alanyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl)	endothelin A antagonist; endothelin antagonist	asthma
endothelin antagonist	Unspecified	endothelin antagonist	kidney disease; ischemia; inflammatory bowel disease; asthma
BW 443C	L-tyrosyl-D- arginylglycyl-4-nitro- L-phenylalanyl-L- prolinamide diacetate (salt)	enkephalinase inhibitor; analgesic	asthma; pain; cough
KCA 757	4-[6-acetyl-3-[3-[(4- acetyl-3-hydroxy-2- propylphenyl)thio]pro- poxyl-2- propylphenoxy]butan- oic acid	Eosinophil inhibitory activity	asthma
VML 530; ABT 080	Unspecified	FLAP antagonist	asthma
BAY x 1005	(R)-alpha- cyclopentyl-4-(2- quinolinylmethoxy)ben- zeneacetic acid	FLAP antagonist	asthma
VB 5122	Unspecified	free radical scavenger; xanthine oxidase inhibitor	inflammation; asthma
beta-glucan antagonist	Unspecified	glucan antagonist	conjunctivitis; asthma; psoriasis; ulcerative colitis
nitrocinonide	6alpha,9-difluoro- 11beta,16alpha,17- trihydroxy-3- oxoandrost-1,4- diene-17beta- carboxylic acid, ester with ethyl(S)-1- hydroxyethyl carbonate, cyclic(R)- 16,17-acetal with butyraldehyde	glucocorticoid	asthma

glucocorticoids; Ligand	Unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation; asthma; autoimmune disease
L 0066; F 11105	Unspecified	GM-CSF inhibitor	asthma
methylhistamine, R- alpha; BP 2.94	Unspecified	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 49648	(2S-trans)-4-(2- methyl-3- pyrrolidiny)-1H- imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 50971	(3R-trans)-4-(4- methyl-3- pyrrolidiny)-1H- imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
HQL 79	Unspecified	histamine antagonist; 5HT antagonist	allergy; asthma
asthma therapy, Esteve	Unspecified	histamine antagonist; histamine H1 antagonist	asthma
F 9505A	Unspecified	histamine antagonist; histamine H1 antagonist	asthma
olopatadine; olopatadine hydrochloride; KW 4679; ALO 4943A; PATANOL	(Z)-11-[3- (dimethylamino)prop ylidene]-6,11- dihydro-dibenz[b,e] oxepin-2-acetic acid	histamine antagonist; histamine H1 antagonist	allergy; rhinitis; asthma; conjunctivitis
DF 1111301	1-(2-ethoxyethyl)- N,N-dimethyl-1H- benzimidazole-2- cthanamine dihydrochloride	histamine antagonist; histamine H1 antagonist	allergy; asthma
ebastine; LAS W090; LAS 90; EBASTEL; KESTINE; EVASTEL	1-[4-(1,1- dimethylethyl)phenyl] -4-[4- (diphenylmethoxy)-1- piperidiny]-1- butanone	histamine antagonist; histamine H1 antagonist	allergy; rhinitis; asthma
mizolastine; SL 850324; MKC 431; MIZOLLEN; ZOLIM; MISTAMINE	2-[[1-[1-[(4- fluorophenyl)methyl]- 1H-benzimidazol-2- yl]-4-piperidiny] methylamino]-4(1H)- pyrimidinone	histamine antagonist; histamine H1 antagonist	asthma; allergy; rhinitis

ZCR 2060	2-[2-[4-(diphenylmethyl)-1-piperazinyl]ethoxy]benzoic acid maleate	histamine antagonist; histamine H1 antagonist	asthma; allergy
selenotifen; BN 52256	4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo[4,5]cyclohepta[1,2-b]selenophen-10-one	histamine antagonist; histamine H1 antagonist	eye disease; asthma; arrhythmia; rhinitis
epinastine; WAL 801; WAL 801CL; ALESION	9,13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepin-3-amine	histamine antagonist; histamine H1 antagonist	allergy; asthma; psoriasis; rhinitis
FCC 13	3,4,10,14b-tetrahydrodibenzo[c,f]pyranzino[1,2-a]azepine-2(1H)carboxamide	histamine antagonist; histamine H1 antagonist; 5HT antagonist	asthma
mequitamium iodide; LG 30435	1-methyl-3-(10H-phenothiazin-10-ylmethyl)-1-azoniabicyclo[2.2.2]octane iodide	histamine antagonist; histamine H1 antagonist; muscarinic antagonist; cholinergic antagonist	asthma; rhinitis
KY 234	1-[3-(4-benzhydryl-1-piperazinyl)propyl]-3-(1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylic acid	histamine antagonist; histamine H1 antagonist; thromboxane synthetase inhibitor	asthma
pibaxizine; UCB 20028; UCB J028; J028; J 028	[2-[2-[4-(diphenylmethylene)piperidinyl]ethoxy]ethoxy]acetic acid	histamine antagonist; histamine H2 antagonist	irritable bowel syndrome; asthma
KC 11425	5,6-dihydro-2-methyl-8-(2-methylpropyl)-1-[2-[4-(4-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4H-pyrrolo[3,2,1-hi]quinoline	histamine antagonist; PAF antagonist	asthma; allergy

KC 11404	4-n-butyl-5,6-dihydro-8-hydroxy-2-methyl-1-[2-[4-(4-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4H-pyrrolo[3,2,1-ij]quinoline	histamine antagonist; PAF antagonist; 5-lipoxygenase inhibitor	asthma; allergy
batebulast; batebulast hydrochloride; NCO 650	trans-4-guanidinomethylcyclohexanecarboxylic acid p-tert-butyl-phenyl ester hydrochloride	Histamine release inhibitor	asthma
dehydroepiandrosterone sulfate; DHEAS; PB 005	Unspecified	hormone; vaccine adjuvant; corticosteroid	inflammation; infectious disease; asthma
pentigetide; IgE pentapeptide human; pentapeptide DSDPR; TA 521; PENTYDE	N2-[1-N-(N-L-alpha-aspartyl-L-seryl)-L-[alpha-aspartyl]-L-prolyl]-L-arginine	immunoglobulin	conjunctivitis; asthma; rhinitis
CL 296141	Unspecified	Immunomodulation	asthma
SRL 172	Unspecified	immunostimulant	tuberculosis; cancer; asthma; bacterial infection; leprosy; rhinitis
asthma/allergy therapy, Rigel	Unspecified	immunosuppressant	asthma; allergy
D 22557	Unspecified	immunosuppressant	allergy; asthma
D 7193	Unspecified	immunosuppressant	asthma
IgE receptor inhibitors, InKine	Unspecified	immunosuppressant	asthma
immunology/inflammation therapy, Rigel	Unspecified	immunosuppressant	inflammation; autoimmune disease; asthma
immunosuppressant, Rhone-Poulenc Rorer	Unspecified	immunosuppressant	asthma
immunosuppressants, Agouron	Unspecified	immunosuppressant	autoimmune disease; asthma
T cell modulators, Fisons	Unspecified	immunosuppressant	asthma; rhinitis; conjunctivitis; allergy
oxeclosporin; SDZ IMM 125; IMM 125	2-[O-(2-hydroxyethyl)-D-serine]-cyclosporin A	immunosuppressant	asthma
LCB 2183	Unspecified	immunosuppressant	rhinitis; dermatitis; asthma

CBP 1011	Unspecified	immunosuppressant; corticosteroid	autoimmune disease; systemic lupus erythematosus; asthma
D 22558	Unspecified	immunosuppressant; cytokine inhibitor	asthma; allergy
immunoregulators, AVANT Immunotherapeutics; immunoregulators, Repligen	Unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma
phellodendrinc; OB 5	(7S-cis)-5,8,13,13a- tetrahydro-2,11- dihydroxy-3,10- dimethoxy-7-methyl- 6H- dibenzo[a,g]quinolizi nium	immunosuppressant; NSAID	transplant rejection; inflammation; viral infection; asthma; kidney disease
antiasthma agent, s	Unspecified	Inflammatory mediator blockade,	asthma
alphaE beta7 antagonists, LeukoSite/Warner Lambert	Unspecified	integrin antagonist; cell adhesion inhibitor	asthma; psoriasis; inflammatory bowel disease
cell adhesion inhibitors, Ligand/Sankyo	Unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	asthma; rheumatoid arthritis; reperfusion injury
TBC 1269	3',3'''-(1,6- hexanediyl)bis[6'- (alpha-D- mannopyranosyloxy)- [1,1'-biphenyl]-3- acetic acid	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation; asthma
VLA-4 antagonist, Merck/Biogen	Unspecified	integrin antagonist; VLA 4 antagonist	asthma
VLA-4 antagonists, inflammatory diseases; BIO 1211	N-[[4-[[[(2- methylphenyl)amino] carbonyl]amino]phen yl]acetyl]-L-leucyl-L- alpha-aspartyl-L- valyl-L-proline	integrin antagonist; VLA 4 antagonist	asthma; multiple sclerosis
VLA4 antagonists, Celltech Therapeutics	Unspecified	integrin antagonist; VLA 4 antagonist; cell adhesion inhibitor	asthma; inflammatory bowel disease
CL 891301	Unspecified	leukotriene antagonist	asthma



CS 615	Unspecified	leukotriene antagonist	asthma
FK 011	Unspecified	leukotriene antagonist	asthma
LF 60361	Unspecified	leukotriene antagonist	asthma
RP 12525	Unspecified	leukotriene antagonist	asthma
zafirlukast; Zeneca 204219; ICI 204219; ACCOLATE; VANTICON	[3-[[2-methoxy-4- [[[(2- methylphenyl)sulfonyl] amino]carbonyl]phenyl] methyl]-1-methyl-1H-indol-5-yl] carbamic acid, cyclopentyl ester	leukotriene antagonist	asthma; rhinitis
BW A797C	acetamide, n-hydroxy-n-(3-(5,6,7,8-tetrahydro-2-naphthalenyl)-2-propenyl)-	leukotriene antagonist	asthma
BW A137C	N-hydroxy-N-[[4-(phenylmethoxy)phenyl]methyl]acetamide	leukotriene antagonist	asthma
BIIL 284	Unspecified	leukotriene antagonist; leukotriene B4 antagonist	asthma; pulmonary obstructive disease
pranlukast; dolukast; ONO 1078; RS 411; ONON; ULTAIR	N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide	leukotriene antagonist; leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene E4 antagonist	asthma; rhinitis
leukotriene D4 antagonists, Pfizer	Unspecified	leukotriene antagonist; leukotriene D4 antagonist	asthma
RG 14524	Unspecified	leukotriene antagonist; leukotriene D4 antagonist	asthma

LY 290154	(E)-7-chloro-2-[2-[3-[4-(1H-tetrazol-5-yl)-1-[7-(1H-tetrazol-5-ylmethoxy)-1H-indol-1-yl]butyl]phenyl]ethenyl]quinoline	leukotriene antagonist; leukotriene D4 antagonist	asthma
RS 601	4-[5,5,6,6,6-pentafluoro-1-[[4-(4-fluorophenyl)sulfonyl]amino]hexyl]benzenebutanoic acid	leukotriene antagonist; leukotriene D4 antagonist; thromboxane antagonist	asthma
YM 158; YM 57158	N-[5-[3-[(4-chlorophenyl)sulfonyl]propyl]-2-(1H-tetrazol-5-ylmethoxy)phenyl]-3-[[4-(1,1-dimethylethyl)-2-thiazolyl]methoxy]-benzamide	leukotriene antagonist; leukotriene D4 antagonist; thromboxane antagonist	asthma; rhinitis
ZD 3523; ICI D3523	Unspecified	leukotriene antagonist; NSAID	asthma; inflammation
ontazolast; BIRM 270	(S)-N-[2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazoline	leukotriene B4 antagonist; leukotriene antagonist	asthma
RP 69698	5-(1,1-dimethyl-5-((4,6-diphenyl-2-pyridyl)oxy)pentyl)-1H-tetrazole	leukotriene B4 antagonist; leukotriene antagonist	asthma; emphysema
LY 292728	7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo-9H-xanthene-4-propanoic acid disodium salt	leukotriene B4 antagonist; leukotriene antagonist	asthma

RG 14893	4-(2-(methyl(2-phenethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; inflammation
SC 51146	7-[3-[2(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; psoriasis; rheumatoid arthritis; inflammatory bowel disease
cinalukast; Ro 245913	(E)-4-(3-(2-(4-cyclobutyl-2-thiazolyl)ethenyl)phenylamino)-2,2-diethyl-4-oxobutanoic acid	leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene antagonist	asthma
BAY x.7195	[S-(Z)]-4-[[1-(2-carboxyethyl)-4-[4-(4-phenoxybutoxy)phenyl]-2-butenyl]thio]benzoic acid	leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene antagonist	asthma
pirodomast; SCH 37224	4-hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one	leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	rhinitis; asthma
CGP 44044A	(1R,2S)-1-hydroxy-1-(3-trifluoromethylphenyl)-8-(4-acetyl-3-hydroxy-2-propylphenoxy)-octa-3(E),5(Z)-dien-2-yl-7-thio-4-oxo-4H-1-benzopyran-2-carboxylic acid sodium salt	leukotriene D4 antagonist; leukotriene antagonist	asthma

LY 287192	(E)-2-[[5-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-2H-tetrazol-1-yl]methyl]-5-fluorobenzoic acid sodium salt	leukotriene D4 antagonist; leukotriene antagonist	asthma
LY 290324	(E)-7-chloro-2-[2-[3-[[7-[2-(1H-tetrazol-5-yl)ethyl]-1H-indol-1-yl]methyl]phenyl]ethenyl]quinoline hydrochloride	leukotriene D4 antagonist; leukotriene antagonist	asthma
SKF 106203	(S)-beta[(2-carboxyethyl)thio]-2-(8-phenyloctyl)benzenepropanoic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
YM 16638	[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]acetic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
montelukast; montelukast sodium; MK 476; MK 0476; SINGULAIR	[R-(E)]- 1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropaneacetic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
verlukast; MK 679; L 660711; MK 571; L 668019	[R-(E)]-3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propanoic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
pobilukast; pobilukast edamine; SKF 104353; SKF 104353Z2; SKF 104353Q	[R-(R*,S*)]-beta-[(2-carboxyethylthio)-alpha-hydroxy-2-(8-phenyloctyl)benzenepropanoic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma; rhinitis

ritolukast; WY 48252	1,1,1-trifluoro-alpha-2-quinolylmethanesulfonyl-m-aniside	leukotriene D4 antagonist; leukotriene antagonist	asthma
LY 203647	1-[2-hydroxy-3-propyl-4-[4-[2-[4-(1H-tetrazol-5-yl)butyl]-2H-tetrazol-5-yl]butoxy]phenyl]ethanone	leukotriene D4 antagonist; leukotriene antagonist	hypertension; asthma
RG 12525	2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]quinoline	leukotriene D4 antagonist; leukotriene antagonist	asthma
NZ 107	4-bromo-5-[[4-(3-ethoxy-4-methoxyphenyl)methyl]amino]-3(2H)-pyridazinone	leukotriene D4 antagonist; leukotriene antagonist	asthma
DS 4574	6-(2-cyclohexylethyl)-[1,3,4]thiadiazolo[3,2-a]-1,2,3-triazolo[4,5-d]pyrimidin-9(1H)-one	leukotriene D4 antagonist; leukotriene antagonist	gastrointestinal ulcer; asthma
irialukast; CGP 45715A	(1R,2S)-1-hydroxy-1-(3-(trifluoromethyl)phenyl)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-deca-3(E),5(Z)-diene-2-yl-7-thio-4-oxo-4H-1-benzopyran-2-carboxylic acid sodium salt	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
MDL 43291	(4a.alpha,7Z,8.beta,8a.beta)-[(octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio]acetic acid	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma

CGP 44826	2-ethenyloxy-N-[4-(5-cyclopentyl-carbonylamino-1-methylindol-3-ylmethyl)-3-methoxy-benzoyl]benzenesulfonylamide	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
FPL 55712	7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid monosodium salt	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
sulukast; LY 170680	5-(3-(2(R)-(carboxyethylthio)-1(S)-hydroxypentadeca-3(E),5(Z)-dienyl)phenyl)-1H-tetrazole	leukotriene E4 antagonist; leukotriene D4 antagonist; leukotriene antagonist	asthma
LDP 977	Unspecified	Leukotriene inhibitor	asthma
BAY y 1015	Unspecified	leukotriene synthesis inhibitor	asthma
CPR 7011	L-alpha-dipalmitoyl-sn-glycero-3-phosphocholine	Lung surfactant	bronchitis; cystic fibrosis; rhinitis; asthma
mast cell activation inhibitors, AstraZeneca	Unspecified	Mast cell degranulation inhibition	asthma; rhinitis
MAB, interleukin-5; MAB, IL-5; SB 240563	Unspecified	monoclonal antibody; biotechnology	asthma
MAbs, CCR3	Unspecified	monoclonal antibody; biotechnology; chemokine antagonist	asthma
MAB, CD23; GW 353430	Unspecified	monoclonal antibody; biotechnology; NSAID	rheumatoid arthritis; asthma

FK 888	trans-4-hydroxy-1- [(1-methyl-1H-indol-3-yl)carbonyl]-L-propyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide	neurokinin antagonist	asthma; migraine
lanepitant; LY 303870	(R)-N-[2-acetyl[(2-methoxyphenyl)methyl]amino]-1-(1H-indol-3-ylmethyl)ethyl]-[1,4'-bipiperidine]-1'-acetamide	neurokinin antagonist; analgesic; neurokinin 1 antagonist	asthma; pain; migraine
L 733060	(2S-cis)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID	inflammation; pain; asthma
saredutant; SR 48968	(S)-N-[4-(4-acetylamino-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl]-N-methyl-benzamide	neurokinin antagonist; analgesic; neurokinin 2 antagonist	asthma; pain; urinary incontinence
MEN 10376	Unspecified	neurokinin antagonist; bronchodilator; neurokinin 2 antagonist	asthma; anxiety
CP 99994	(2S-cis)-N-[(2-methoxyphenyl)methyl]-2-phenyl-3-piperidinamine	neurokinin antagonist; neurokinin 1 antagonist; analgesic	asthma; pain
nolpitantium besilate; SR 140333	(S) 1-[2-[3-(3,4-dichlorophenyl)-1-[[3-(1-methylethoxy)phenyl]acetyl]-3-piperidinyl]ethyl]-4-phenyl-1-azoniabicyclo[2.2.2]octane	neurokinin antagonist; neurokinin 1 antagonist; NSAID	asthma; inflammation

ZD 7944	Unspecified	neurokinin antagonist; neurokinin 2 antagonist	asthma
SR 144190	(R)-4-benzoyl-2-(3,4-difluorophenyl)-2-[2-[4-[[[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]ethyl]morpholine	neurokinin antagonist; neurokinin 2 antagonist; analgesic	asthma; urinary incontinence; asthma; pain
FK 224; FR 115224	N-[N2-[N-[N-[N-[alfa,beta-didehydro-N-methyl-N-[N-[1-oxo-3-(2-pentylphenyl)propyl]-L-threryl]tyrosyl]-L-leucyl]-D-phenylalanyl]-L-allothreonyl]-L-asparaginy]-L-serine epsilon-lactone	neurokinin antagonist; neurokinin 2 antagonist; NSAID	asthma; inflammation
NS 2073	Unspecified	nitric oxide activator; NSAID	inflammation; glaucoma; gastrointestinal ulcer; asthma
NCX 1005	(11beta,16alpha)-9-fluoro-11,17-dihydroxy-16-methyl-21-[4-(nitrooxy)-1-oxobutoxyl]pregna-1,4-diene-3,20-dione	nitric oxide donor	asthma; inflammatory bowel disease
D 21247	Unspecified	Non-steroid respiratory antiinflammatory agent	asthma; rhinitis
D 24241	Unspecified	Non-steroid respiratory antiinflammatory agent	asthma; allergy
D 43787	Unspecified	Non-steroid respiratory antiinflammatory agent	asthma; allergy



FPL 68164	Unspecified	Non-steroid respiratory antiinflammatory agent	asthma
KSU 2178	Unspecified	Non-steroid respiratory antiinflammatory agent	dermatitis; asthma
LAS 30813	Unspecified	Non-steroid respiratory antiinflammatory agent	asthma; allergy
CI 1018	(R)-N-(3,4,6,7- tetrahydro-9-methyl- 4-oxo-1- phenylpyrrolo[3,2,1- jk][1,4]benzodiazepin -3-yl)-4- pyridinecarboxamide	Non-steroid respiratory antiinflammatory agent	asthma
tetrahydrocorynanthei n	17-methoxycorynan- 16-carboxylic acid methyl ester	Non-steroid respiratory antiinflammatory agent	asthma; allergy
tranilast; MK 341; AINTERU; BESSARAL; CLANIST; LIZAMONT; RIZALAST; SYNBERNIA; TEIBLOCK; RIZABEN	2-[[3-(3,4- dimethoxyphenyl)-1- oxo-2- propenyl]amino]benz oic acid	Non-steroid respiratory antiinflammatory agent	asthma; allergy; conjunctivitis; rhinitis; restenosis
NIP 502	4-chloro-5-[[3- ethoxy-4- methoxyphenyl)meth yl]amino]-3(2H)- pyridazinone	Non-steroid respiratory antiinflammatory agent	asthma
AP 0341	5-amino-3-(4- chlorophenyl)-N- methyl-1H-1,2,4- triazole-1- carbothioamide	Non-steroid respiratory antiinflammatory agent	asthma

SCA 8801	6-bromo 8-(methylamino)-imidazo[1,2-a]pyrazine-2-carbonitrile	Non-steroid respiratory antiinflammatory agent	asthma
scopinast; KA 398	7-[3-[4-[bis(4-fluorophenyl)hydroxy methyl]-1-piperidiny]propoxy]-6-methoxy-2H-1-benzopyran-2-one	Non-steroid respiratory antiinflammatory agent	asthma; allergy
KP 136; AL 136	8-hexyloxy-3-(1H-tetrazol-5-yl)-2H-1-benzopyran-2-one	Non-steroid respiratory antiinflammatory agent	asthma
anti-inflammatory agent, North Carolina University	Unspecified	NSAID	inflammation; asthma
CD40 receptor signalling pathway inhibitor, Axiom Biotechnologies; CD40 receptor signalling pathway inhibitor, Zaiya	Unspecified	NSAID	allergy; asthma; inflammation
chemokine receptor modulators, Pharmacopeia	Unspecified	NSAID	inflammation; asthma; atherosclerosis
gene discovery, immune system disorders, AlphaGene	Unspecified	NSAID	arthritis; asthma; allergy
glucocorticoid agonists, Ligand	Unspecified	NSAID	inflammation; rheumatoid arthritis; inflammatory bowel disease; asthma
interleukin modulators, Receptron	Unspecified	NSAID	inflammation; asthma
IPL 576092	Unspecified	NSAID	asthma; respiratory disease
macrophage migration inhibitory factor inhibitors, Picower Institute for Medical Research	Unspecified	NSAID	arthritis; asthma

PKC-RACK interaction inhibitors, Telik	Unspecified	NSAID	arthritis; multiple sclerosis; asthma
pseudopterosin	Unspecified	NSAID	arthritis; asthma; psoriasis
contignasterol	(3alpha,4beta,5alpha, 6alpha,7beta,14beta,2 2S)-22,29-epoxy- 3,4,6,7,29- pentahydroxystigmast an-15-one	NSAID	asthma; respiratory disease
tioxamast; F 1865	[[4-(4- methoxyphenyl)-2- thiazolyl]amino]oxoa cetic acid ethyl ester	NSAID	asthma; inflammation; skin disease
PNU 142731; PNU 142731A	1-[(2,4-di-1- pyrrolidinyl-9H- pyrimido[4,5-b]indol- 9- yl)acetyl]pyrrolidine mono hydrochloride	NSAID	asthma
bamaquimast; F 10126; L 0042	3-[3- [[[(methylamino)carbo nyl]oxy]propyl]-1- propyl-2(1H)- quinoxalinone	NSAID	asthma
Z 1957	ethyl N-((3-methyl-5- isoxazolyl)-2- thiazolyl) oxamate	NSAID	asthma; inflammation
BTS 71321	N-[1-(4- chlorophenyl)-1- methylethyl]-1H- imidazole-1- propanamine	NSAID	asthma
andolast; CR 2039	N-4-(5-tetrazolyl)- phenyl-4-(5- tetrazolyl)-benzamide	NSAID	asthma; inflammation; allergy
VX 745	Unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation; neurological; heart failure; Crohn disease; asthma
NCX 1004	Unspecified	NSAID; nitric oxide donor	asthma

phospholipase A2 inhibitors, La Jolla	Unspecified	NSAID; phospholipase inhibitor	rheumatoid arthritis; inflammatory bowel disease; asthma
INKP 300	Unspecified	NSAID; signal transduction inhibitor	asthma
oligonucleotide, asthma	Unspecified	oligonucleotide; biotechnology; immunostimulant	asthma
sulfated oligosaccharide, Progen	Unspecified	oligosaccharide	asthma
Ro 191400	Unspecified	PAF antagonist	asthma
tulopafant; RP 59227	(+)-N-(3-benzoylphenyl)-3-(3-pyridinyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide	PAF antagonist	asthma
ginkgolide A,B,C; BN 52063	(1alpha,7beta)-1,7-dihydroxyginkgolide A mixt with ginkgolide A and (1beta)-1-hydroxyginkgolide A	PAF antagonist	asthma; rhinitis; thrombocytopenia
L 680573; MK 287	(2S-trans)-2-[[3-methoxy-2-propoxy-5-[tetrahydro-5-(3,4,5-trimethoxyphenyl)-2-furanyl]phenyl]sulfonyl]ethanol	PAF antagonist	asthma; septic shock
Ro 193704; Ro 19-3704	(R)-3-[4-[2-[(methoxycarbonyl)oxy]-3-[[[(octadecylamino)carbonyl]oxy]propoxy]butyl]thiazolium iodide	PAF antagonist	asthma

E 6123	(S)-(+)-6-(2-chlorophenyl)-3-cyclopropanecarbonyl-8,11-dimethyl,2,3,4,5-tetrahydro-8H-pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine	PAF antagonist	asthma
Ro 240238; Ro 240238; Ro 244376	[R-(E,E)]-5-(4-methoxyphenyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-2,4-decadienamide	PAF antagonist	asthma
YM 461; YM 46A	1-(3-phenylpropyl)-4-[[2-(3-pyridinyl)-4-thiazolidinyl]carbonyl]piperazine (E)-2-butenedioate (1:1)	PAF antagonist	asthma; pulmonary obstructive disease
israpafant; Y 24180; PAFNOL	4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist	asthma
bepafant; WEB 2170	4-[[6-(2-chlorophenyl)-8,9-dihydro-1-methyl-4H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazpin-8-yl]carbonyl]morpholine	PAF antagonist	asthma; rhinitis

rocepaftant; BN 50730	6-(2-chlorophenyl)-7,10-dihydro-N-(4-methoxyphenyl)-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-9(8H)-carbothioamide	PAF antagonist	hypotension; cytoprotectant; asthma
loropafant; SR 27417	N,N-dimethyl-N'-(3-pyridinylmethyl)-N'-[4-[2,4,6-tris(1-methylethyl)phenyl]-2-thiazolyl]-1,2-ethanediamine	PAF antagonist	asthma
SCH 37370	1-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine	PAF antagonist; histamine antagonist; histamine H1 antagonist	asthma; rhinitis
CMI 392	trans-2-[5-(N'-methyl-N'-hydroxyureidylmethyl)-3-methoxy-4-p-chlorophenylthioethoxyphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran	PAF antagonist; leukotriene antagonist	psoriasis; dermatitis; asthma
UR 12510	Unspecified	PAF antagonist; NSAID	inflammation; asthma
UR 12519	Unspecified	PAF antagonist; NSAID	inflammation; asthma
UR 12551	Unspecified	PAF antagonist; NSAID	inflammation; asthma
BN 52111	1-(6-((2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy)-6-oxohexyl)-pyridinium bromide	PAF antagonist; NSAID	asthma; inflammation

tiapafant; PCA 4248	1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid methyl 2-(phenylthio)ethyl ester	PAF antagonist; NSAID	asthma; inflammation
BN 52115	1-[6-[(2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy]-6-oxohexyl]quinolinium bromide	PAF antagonist; NSAID	asthma; inflammation
UR 10324	2-(2-acetyl-3,11-dioxo-4,10-dioxo-7-thia-2,12-diazanonacos-1-yl)-1-ethylpyridinium chloride	PAF antagonist; NSAID	inflammation; asthma
tetrahydrocarbazole	4-(2-chlorophenyl)-9-methyl-2-[3-(1,2,3,4-tetrahydro-9H-carbazol-9-yl)-1-propynyl]-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist; NSAID	inflammation; asthma
UR 12460	4-[[[(diphenylmethyl)amino]acetyl]-alpha-(2-methyl-3-pyridinyl)-1-piperazineacetonitrile	PAF antagonist; NSAID	inflammation; asthma
SM 10661	cis-(+,-)-3,5-dimethyl-2-(3-pyridinyl)-4-thiazolidinone monohydrochloride	PAF antagonist; NSAID	endotoxic shock; inflammation; asthma

AH 21132	cis N-(4-(1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo(c)(1,6)naphthyridin-6-yl)phenyl)-acetamide (Z)-2-butenedioate (1:2)	PAF antagonist; phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
F 1850	Unspecified	PAF antagonist; platelet antiaggregant	thrombosis; asthma
dacopafant; RP 48740	(3R)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide	PAF antagonist; platelet antiaggregant	asthma; thrombosis
YM 264	1-(3-methyl-3-phenylbutyl)-4-[[2-(3-pyridinyl)-4-thiazolidinyl]carbonyl]piperazine (E)-2-butenedioate (1:1)	PAF antagonist; platelet antiaggregant	thrombosis; asthma
SDZ 64412; SDZ 64-412	2,3-dihydro-5-[4-[2-(3,4,5-trimethoxyphenyl)ethyl]phenyl]imidazo[2,1-a]isoquinoline monohydrochloride	PAF antagonist; platelet antiaggregant	asthma; thrombosis
R 74717	3-(5-(0-(2S,3S)-(3-heptadecylcarbamoylthiotetrahydropyran-2-yl)methyl)phosphonoxy)pentylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis
R 74654	3-(6-(0-(2R,2S)-(3-heptadecylcarbamoyloxytetrahydropyran-2-yl)methyl)phosphonoxy)hexylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis



UK 74505	4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]-5-[(2-pyridinylamino)carbonyl]-3-pyridinecarboxylic acid ethyl ester	PAF antagonist; platelet antiaggregant	thrombosis; asthma
UR 12670	4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]-1-(1-oxo-3,3-diphenylpropyl)-piperidine	PAF antagonist; platelet antiaggregant	kidney disease; ischemia; asthma; pancreatitis
SR 27388	4-[2-[(2-(dimethylamino)ethyl)](3-pyridinylmethyl)amino]-4-thiazolyl]-2,6-bis(1,1-dimethylethyl)phenol	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock
apafant; WEB 2086; WEB 2086BS	4-[3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-1-oxopropylmorpholine	PAF antagonist; platelet antiaggregant	asthma; rhinitis; pancreatitis
Ro 244736; Ro 24-4736	5-[3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-2-propynyl]-6(5H)-phenanthridinone	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock

WEB 2347	6-(2-chlorophenyl)-8,9-dihydro-1-methyl-N,N-dipropyl-4H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-8-carboxamide	PAF antagonist; platelet antiaggregant	asthma; anaphylactic shock; thrombosis
ginkgolide B; BN 52021	hexacyclic trilactone	PAF antagonist; platelet antiaggregant	thrombosis; dermatitis; asthma; multiple sclerosis; septic shock
L 659989	trans-(+,-)-tetrahydro-2-[3-methoxy-5-(methylsulfonyl)-4-propoxyphenyl]-5-(3,4,5-trimethoxyphenyl)furan	PAF antagonist; platelet antiaggregant	asthma; thrombosis
SDZ 64619	(+,-)-2-[6-methoxy-2-(methylsulfonyl)-3,9-dioxo-4,8-dioxo-2,10-diazaoctacosan-1-yl]-1-methylpyridinium iodide	PAF antagonist; platelet antiaggregant; bronchodilator	thrombosis; asthma
asthma therapy, Peptide Therapeutics	Unspecified	peptide	asthma
cathepsin S inhibitors, Peptimmune	Unspecified	peptide; proteinase inhibitor; cathepsin S inhibitor	asthma
BY 217	Unspecified	phosphodiesterase inhibitor	asthma
phosphodiesterase inhibitor, Rhone-Poulenc Rorer	Unspecified	phosphodiesterase inhibitor	asthma
KP 885	Unspecified	phosphodiesterase inhibitor; bronchodilator	asthma
WY 123641; PDA 641	Unspecified	phosphodiesterase inhibitor; bronchodilator	asthma
KF 19514	1,5-dihydro-5-phenyl-4H-imidazo[4,5-c][1,8]naphthyridin-4-one	phosphodiesterase inhibitor; bronchodilator	asthma

P 1432	3-(cyclopropylmethyl)-xanthine	phosphodiesterase inhibitor; bronchodilator	asthma
LAS 31396	Unspecified	phosphodiesterase inhibitor; bronchodilator; NSAID	asthma; inflammation
arofylline; LAS 31025	3-(4-chlorophenyl)-3,7-dihydro-1-propyl-1H-purine-2,6-dione	phosphodiesterase inhibitor; bronchodilator; NSAID	asthma; inflammation
tolafentrine; BY 4070	(-)-4-(cis-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]=naphthyridin-6-yl)-p-toluenesulfonamide	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
zardaverine; B 84290	6-(4-(difluoromethoxy)-3-methoxyphenyl)-3(2H)-pyridazinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
AWD 12281	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
BAY 198004	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
DWP 205297	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
PDE-4 inhibitors, Zambon	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
YM 976	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma

CP 220629; CP 220,629	1-cyclopentyl-3-ethyl-1,4,5,6-tetrahydro-6-(2-methylphenyl)-7H-pyrazolo[3,4-c]pyridin-7-one	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
LAS 32688	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
phosphodiesterase inhibitors, Celltech/Merck & Co	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
CDP 840	(R)-4-[2-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-phenylethyl]pyridine	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; inflammation
filaminast; WAY PDA 641	1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethanone, (E)-O-(aminocarbonyl)oxime	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
piclamilast; RP 73401; RPR 73401	3-cyclopentyloxy-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; arthritis
SB 207499; ARIFLO	cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylic acid	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; pulmonary obstructive disease
D 4418	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; immunosuppressant; bronchodilator	asthma

D 22888	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; phosphodiesterase V inhibitor; bronchodilator	asthma
SKF 96231	2-(2-propoxyphenyl)-6-purinone	phosphodiesterase inhibitor; phosphodiesterase V inhibitor; bronchodilator	asthma
doxofylline; ABC 12/3; DO 309; MAXIVENT; ANSIMAR	7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione	phosphodiesterase inhibitor; xanthine	asthma
phospholipase A2 inhibitors, Fisons	Unspecified	phospholipase inhibitor; NSAID	asthma; rheumatoid arthritis; psoriasis; inflammatory bowel disease
cyclic polyamine analogue, SunPharm	Unspecified	polyamine analogue; NSAID	Crohn disease; asthma; inflammation
thymosin beta 4; Tbeta4	Thymosin beta 4 (rat clone pROS2 precursor)	Polymerization of G-actin to F-actin controlling agent	septic shock; respiratory distress syndrome; asthma
BIIX 1; RS 91309	Unspecified	potassium channel activator	asthma
CL 891902	Unspecified	potassium channel activator; bronchodilator	asthma; hypertension
BRL 55834	(3S,4R)-3,4-dihydro-2,2-dimethyl-4-(2-oxopiperidin-1-yl)-6-pentafluoroethyl-2H-1-benzopyran-3-ol	potassium channel activator; bronchodilator	asthma
SDZ PCO400	(3S-trans)-2,4-dihydro-3-hydroxy-2,2-dimethyl-4-[(3-oxo-1-cyclopenten-1-yl)oxy]-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	asthma

emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease
UR 8308	1,2-dihydro-2,2-dimethyl-4-(N-oxide-2-pyridyl)-1-oxonaphthalen-6-carbonitrile	potassium channel activator; bronchodilator	asthma
UR 8328	1,2-dihydro-2,2-dimethyl-4-(N-oxide-2-pyridyl)-6-pentafluoroethylnaphtalen-1-one	potassium channel activator; bronchodilator	asthma
UR 8225	1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence
RP 66471	1S,2R-trans-2-benzoyloxy-1-(pyrid-3-yl)cyclohexane-(N-methyl)-carbthioamide	potassium channel activator; bronchodilator	asthma
Ro 316930	2,2-dimethyl-4-(2-pyridinyl)-2H-1-benzopyran-6-carbonitrile N4-oxide	potassium channel activator; bronchodilator	hypertension; asthma
YM 934	3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-2H-1,4-benzoxazine N-oxide	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence
SR 47063	4-(2-cyanoimino-1,2-dihydropyrid-1-yl)-6-nitro-2,2-dimethyl-2H-1-benzopyran	potassium channel activator; bronchodilator	heart ischemia; asthma
potassium channel activator, Merck KGaA	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma

symakalim; EMD 57283	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; coronary artery disease; asthma
SCA 40	6-bromo-8-(methylamino)-imidazo[1,2-a]pyrazine-2-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
rilmakalim; HOE 234	(3S,4R)-3-hydroxy-2,2-dimethyl-4-(3-oxo-1-pyrrolidinyl)-6-phenylsulfonylchroman hemihydrate	potassium channel activator; vasodilator; bronchodilator	asthma
bimakalim; EMD 52692; SR 44866	2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; vasodilator; bronchodilator	coronary artery disease; asthma; peripheral vascular disease
potassium channel modulators, Phytera/NeuroSearch	Unspecified	potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes
NS 1619	1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one	potassium channel modulator; bronchodilator	stroke; asthma
protein kinase activators, SmithKline Beecham	Unspecified	protein kinase activator; protein kinase A activator	asthma; thrombosis
allergy therapy, Kinetix	Unspecified	protein kinase inhibitor	allergy; asthma
Y 27632	[4(R)-trans]-4-(1-aminoethyl)-N-4-pyridinylcyclohexane carboxamide	protein kinase inhibitor	hypertension; asthma; cancer
Syk inhibitors, Ariad	Unspecified	protein kinase inhibitor; tyrosine kinase inhibitor	asthma; allergy
Der p I inhibitor, Peptide Therapeutics	Unspecified	proteinase inhibitor	asthma

alpha-1-antitrypsin	Unspecified	proteinase inhibitor; biotechnology	asthma; emphysema; cystic fibrosis; dermatitis; psoriasis
mycophenolate mofetil; RS 61443; CellCept	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany l)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
asthma therapy, SAIK,	Unspecified	SAIK immunomodulation	asthma
NO-SOD mimetics, NitroMed; nitrosylated superoxide dismutase mimetics, NitroMed	Unspecified	SOD mimetic; nitric oxide donor	asthma; respiratory distress syndrome; ischemia; reperfusion injury
WS 9326A	Unspecified	substance P antagonist	asthma
CGP 49823	(2R-trans)-1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-N-(4-quinolinylmethyl)-4-piperidinamine	substance P antagonist	anxiety; asthma
FR 113680	N-acetyl-L-threonyl-1-formyl-D-tryptophyl-N-methyl-N-(phenylmethyl)-L-phenylalaninamide	substance P antagonist	asthma
dapitant; RPR 100893	[3aS-[2(R*),3aalpha,4beta,7aalpha]]-octahydro-4-(2-methoxyphenyl)-2-[2-(2-methoxyphenyl)-1-oxopropyl]-7,7-diphenyl-1H-isoindol-4-ol	substance P antagonist; NSAID	asthma; inflammation; migraine
MEN 10627	Unspecified	tachykinin antagonist; antispasmodic	irritable bowel syndrome; asthma



nepadutant; MEN 11420	Cyclo[3-amino-L-alanyl-L-leucyl-N-[2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]-L-asparaginy]-L-alpha-aspartyl-L-tryptophyl-L-phenylalanyl], cyclic (4->1)-peptide	tachykinin antagonist; antispasmodic	asthma; irritable bowel syndrome
Th2 modulators, AstraZeneca	Unspecified	Th2 modulation	asthma; dermatitis
seratrovast; serabenast; AA 2414; A 73001; ABT 001; BRONICA	(+,-)-zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-benzeneheptanoic acid	thromboxane antagonist	asthma; rhinitis
SKF 88046	N,N'-bis[7-93-chlorobenzene aminosulfonyl]-1,2,3,4-tetrahydroisoquinolyl]disulfonylimide	thromboxane antagonist	asthma
L 670596	(-)-6,8-difluoro-2,3,4,9-tetrahydro-9-[[4-(methylsulfonyl)phenyl]methyl]-1H-carbazole-1-acetic acid	thromboxane antagonist; platelet antiaggregant	asthma; thrombosis
domitroban; S 1452; S 145; ANBOXAN	(+,-)-[1alpha,2alpha(Z),3beta,4alpha]-7-[3-[(phenylsulfonyl)amino]bicyclo[2.2.1]hept-2-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	asthma; rhinitis; thrombosis
ramatroban; BAY u 3405; EN 13774	(R)-3-[[4-(fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid	thromboxane antagonist; platelet antiaggregant	asthma; rhinitis

SQ 33961	[1S-(exo,exo)]-2-[[3-[4-[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl)methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
ONO 8809	[1S-[1alfa,2alfa(Z),3beta,4alfa]]-6-[3-[[[(4-bromophenyl)sulfonyl]amino)methyl]bicyclo[2.2.1]hept-2-yl]-5-hexenoic acid decyl ester	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
ICI 192605	[2alfa,4alfa,5alfa(Z)]-6-[2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-4-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
ICI 185282	[2alfa,4alfa,5alfa(Z)]-7-[4-(2-hydroxyphenyl)-2-(trifluoromethyl)-1,3-dioxan-5-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
KT 2962; KT 2-962	3-[4-[[[(4-chlorophenyl)sulfonyl]amino]butyl]-6-(1-methylethyl)-1-azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis
ON 579	4-(2-(4-chlorophenylsulfonylamino)ethylthio)-2,6-difluorophenoxyacetic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma

KDI 792; FK 070; FR 12170	[2S-[2alpha,(Z),4beta]]-6-[4-[(4-chlorophenyl)sulfonylamino]-1-(3-pyridinylmethyl)-2-pyrrolidinyl]-5-hexenoic acid	thromboxane antagonist; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
E 6700	(E)-alpha-[(4-methoxy-2,5-dimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene]-3-pyridineheptanoic acid	thromboxane synthetase inhibitor	asthma
F 1322	N-[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]-3-hydroxy-5-(3-pyridinylmethoxy)-2-naphthalenecarboxamide	thromboxane synthetase inhibitor	asthma
KK 505	2-ethyl-4-(3-pyridyl)-1(2H)-phthalazinone	thromboxane synthetase inhibitor; bronchodilator	asthma
KK 562	2-methyl-4-(5-thiazolyl)-1(2H)-phthalazinone	thromboxane synthetase inhibitor; bronchodilator	asthma
ozagrel; ozagrel sodium; OKY 046; DOMENAN; CATACLOT; XANBON; VEGA	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	stroke; thrombosis; asthma; cough
Y 20811	4-(hydroxy(5-(1H-imidazol-1-yl)-2-methylphenyl)methyl)-3,5-dimethyl-benzoic acid, monosodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; asthma; stroke
imitrodast; CS 518; RS 5186	4,5-dihydro-2-(1H-imidazol-1-ylmethyl)-benzo[b]thiophene-6-carboxylic acid sodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	asthma

nafagrel; DP 1904	5,6,7,8-tetrahydro-6-(1H-imidazol-1-ylmethyl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; angina; asthma; restenosis
ZT 386	Unspecified	thromboxane synthetase inhibitor; thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
tumor necrosis factor inhibitors, Selectide	Unspecified	TNF inhibitor; NSAID	inflammation; asthma; inflammatory bowel disease
NF-kappaB inhibitor, Molecumetics	Unspecified	transcription factor regulator; NSAID	asthma; inflammation; restenosis
asthma therapy, Proteus	Unspecified	tryptase inhibitor	asthma
BAY 358535; BAY 35-8535; BAY 171998; BAY 17-1998	Unspecified	tryptase inhibitor	asthma
BAY 443428	Unspecified	tryptase inhibitor	asthma
oral tryptase inhibitors, Molecumetics	Unspecified	tryptase inhibitor	inflammatory bowel disease; asthma; psoriasis
tryptase inhibitors, Axys	Unspecified	tryptase inhibitor; NSAID	asthma; inflammation; rhinitis; inflammatory bowel disease; psoriasis
APC 366	N2-[(1-hydroxy-2-naphthalenyl)carbonyl]-L-arginyl-L-prolinamide monohydrochloride	tryptase inhibitor; peptide	asthma
allergy/asthma therapy,	Unspecified	Tyrosine kinase stimulator; blocks IgE	asthma; allergy
APO 77	Unspecified	Unspecified	asthma
ARL 68475; FPL 68475	Unspecified	Unspecified	asthma
asthma/allergy therapy,	Purified plant extracts	Unspecified	asthma; allergy
TO 190	Unspecified	Unspecified	asthma

MDL 105212	(R)-1-[2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)-3-pyrrolidinyl]ethyl]-4-phenyl-4-piperidinecarboxamide	Unspecified	asthma
doqualast; SM 857	11-oxo-11H-pyrido[2,1-b]quinazoline-2-carboxylic acid	uricosuric	asthma; gout
vaccine, asthma	Unspecified	vaccine	asthma
non-ionic surfactant vesicles; NISV	Unspecified	vaccine adjuvant; immunosuppressant	rheumatoid arthritis; asthma; inflammation
colforsin dapropate; NKH 477; ADEHL	6-[3-(dimethylamino)propionyl]forskolin	vasodilator; bronchodilator	heart failure; asthma; musculoskeletal disorder
ibudilast; KC 404; KETAS; AIVYNAL; EYEVYNIL	3-isobutyl-2-isopropylpyrazolo-(1,5 $\alpha$ )-pyridine	vasodilator; PAF antagonist	asthma; eye disease
VLA-4 inhibitors, Cytel	Unspecified	VLA 4 antagonist; integrin antagonist; cell adhesion inhibitor	asthma
nestifylline; ABC 99	7-(1,3-dithiolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione	xanthine	asthma
MX 2120	7-(2,2-dimethylpropyl)-1-methylxanthine	xanthine	asthma
isbufylline	7-isobutyltheophylline	xanthine	asthma
MPX	3,7-dihydro-1-methyl-3-(1-methylethyl)-1H-purine-2,6-dione	xanthine; bronchodilator	asthma

Table 48. Current Candidate Therapeutic Interventions for the Treatment of Inflammatory Bowel Disease

Product Name	Chemical Name	Action	Indication
E 3040	5,7-dimethyl-2-(methylamino)-4-(3-pyridinylmethyl)-6-benzothiazolol	5 lipoxigenase inhibitor; thromboxane synthase inhibitor	ulcerative colitis

FPL 64170	unspecified	Antiinflammatory	ulcerative colitis
antisense oligonucleotide, NF- kappaB p65 subunit	unspecified	antisense; oligonucleotide; immunosuppressant	Crohn disease
balazipone; OR 1364	3-(2-acetyl-3-oxo-1- butenyl)benzonitrile	chemoprotectant; cytoprotectant	Crohn disease; ulcerative colitis
sucrafate; ANTEPSIN; CARAFATE; KEAL; TUNALMIN; ULCAR; ULCERLMIN; ULCERIM; ULCOGENT; ULSANIC	sucrose octakis(hydrogen sulfate), aluminum complex	chemoprotectant; cytoprotectant	gastrointestinal ulcer; ulcerative colitis
CR 1795	(R)-5- (dipentylamino)-4- [(2- naphthalenylcarbonyl) amino-5-oxo- pentanoic acid	cholecystokinin antagonist	ulcerative colitis; pancreatitis
budesonide; budesonide propionate; S 1320; PREFERID; PULMICORT; RHINOCORT; ENTOCORT; NARICORT; INFLAMMIDE; BETACTIN; ELTAIR; HORACORT; RHINOCORT AQUA	(11beta,16alpha)- 16,17- [butylidenebis(oxy)]- 11,21- dihydroxypregna-1,4- diene-3,20-dione	corticosteroid	asthma; skin disease; inflammation; rhinitis; ulcerative colitis; Crohn disease
FPL 62064	N-(4- methoxyphenyl)-1- phenyl-1H-pyrazole- 3-amine	COX inhibitor; 5 lipoxxygenase inhibitor	inflammatory bowel disease; psoriasis
CRF1 partial agonist,	unspecified	CRF1 receptor agonist	Alzheimer disease; Crohn disease

CDC 801	unspecified	cytokine inhibitor; TNF inhibitor; phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	Crohn disease
oprelvekin; interleukin-11; IL-11; YM 294; NEUMEGA	unspecified	cytokine; immunostimulant	cancer; HIV infection; mucositis; Crohn disease
interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSIF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
IxC1-62/47	unspecified	enzyme	kidney disease; inflammatory bowel disease; Crohn disease
interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion toxin; IL-2 fusion toxin; DAB 486-IL-2; D-IL-2	unspecified	fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; cancer
WILD 20	[R-[R*,S*-(E)]]-2- amino-3-hydroxy-4- cicosenyl-O-beta-D- galactopyranosyl-(1- >3)-O-2-amino-2- deoxy-beta-D- galactopyranosyl-(1- >4)-O-[alpha- neuraminosyl-(2- >3)]-O-beta-D- galactopyranosyl-(1- >4)-beta-D- glucopyranoside	ganglioside	inflammatory bowel disease
beta-glucan antagonist	unspecified	glucan antagonist	conjunctivitis; asthma; psoriasis; ulcerative colitis

heparin binding epidermal growth factor-like factor; HB-EGF	unspecified	growth factor	respiratory distress syndrome; ulcerative colitis
glucagon-like peptide-2; GLP-2	unspecified	growth factor; peptide; hormone	inflammatory bowel disease
ALX 0600	unspecified	hormone; peptide	gastrointestinal disorder
interleukin-1 beta converting enzyme inhibitors,	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	inflammation
VX 740; HMR 3480	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	rheumatoid arthritis; osteoarthritis; inflammation
antisense oligonucleotide, ICAM-1; antisense oligonucleotide, intracellular adhesion molecule-1; ISIS 2302	d[(R)-P-thio](G-C-C- C-A-A-G-C-T-G-G- C-A-T-C-C-G-T-C- A) DNA	immunosuppressant; antisense; oligonucleotide; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease; asthma
leukocyte function associated antigen 3 T cell inhibitor protein; LFA3TIP; LFA3TIP; AMEVIVE	unspecified	immunosuppressant; NSAID	inflammation; autoimmune disease; psoriasis
alpha4 beta7 antagonists,	unspecified	integrin antagonist; alpha4 beta7 integrin antagonist; cell adhesion inhibitor	Crohn disease; inflammatory bowel disease
interferon alfa-2b; IFN alfa-2b; SCH 30500; YM 1490; INTRON A; CIBLAN; VIRAFERON	unspecified	interferon; cytokine; immunostimulant	cancer; viral infection
secretory cell inhibitors, CAMR	Clostridium botulinum toxin extract	Intracellular trafficking blockade	allergy; inflammation; respiratory disease



SC 52798	(+)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist	psoriasis; ulcerative colitis
ONO 4057; LB 457	(E)-2-(4-carboxybutoxy)-6-[[6-(4-methoxyphenyl)-5-hexenyl]oxy]benzene propanoic acid	leukotriene B4 antagonist; leukotriene antagonist	ulcerative colitis
MAB, tumor necrosis factor; MAB, TNF; SMA TNF	unspecified	monoclonal antibody	Crohn disease; cancer; septic shock
MAB, IBD1; MAB, inflammatory bowel disease; LM IBD1	unspecified	monoclonal antibody	Crohn disease
MAB, interleukin-12; MAB, IL-12	unspecified	monoclonal antibody	Crohn disease; ulcerative colitis
nerelimomab; MAB, TNF; MAB, tumor necrosis factor; BAY x 1351	immunoglobulin G1 (mouse monoclonal BAY x 1351.gamma.1-chain anti-human tumour necrosis factor.alpha.), disulfide with mouse monoclonal BAY x 1351 light chain, dimer	monoclonal antibody	Crohn disease
MAB, T cell antigen receptor; TM 29	unspecified	monoclonal antibody; immunosuppressant	cancer; Crohn disease
MAB, alpha4 beta7 integrin/mucosal adressin interaction; 86.2/96.1; LDP 02	unspecified	monoclonal antibody; integrin antagonist; alpha4 beta7 integrin antagonist; cell adhesion inhibitor	Crohn disease; inflammatory bowel disease

MAB, humanized tumor necrosis factor; MAB, humanized TNF; MAB, CDP571; CDP 571; BAY 103356; B 1351	unspecified	monoclonal antibody; NSAID	septic shock; inflammation; bacterial infection; inflammatory bowel disease; rheumatoid arthritis
MAB, VLA-4, humanized; MAB, very late antigen-4, humanized	unspecified	monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
infliximab; MAB, tumor necrosis factor alpha; MAB, TNF-alpha; cA2; TA 650; REMICADE; AVAKINE	immunoglobulin G, anti-(human tumour necrosis factor) (human-mouse monoclonal cA2 heavy chain), disulfide with human-mouse monoclonal cA2 light chain, dimer	monoclonal antibody; NSAID	rheumatoid arthritis; Crohn disease
ruthenium nitric oxide (NO) scavengers,	unspecified	nitric oxide scavenger	inflammatory bowel disease; cardiac therapy
sulfasalazine; salazosulfapyridine; azulfide; SI 88; AZULFIDINE; SALAZOPYRIN; SLAMA	2-hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid	NSAID	ulcerative colitis; rheumatoid arthritis
P 54	unspecified	NSAID; analgesic	osteoarthritis; Crohn disease; cancer
VX 745	unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation; neurological; heart failure; Crohn disease; asthma
MAB, tumor necrosis factor-alpha, human; D2E7; LU 200134	unspecified	onal antibody; NSAID	inflammation
MAB, alpha4beta1 integrin; AN 100226; ANTEGREN	unspecified	onoclonal antibody	multiple sclerosis; Crohn disease; ulcerative colitis

setipafant; BN 50727	6-(2-chlorophenyl)-7,10-dihydro-N-(4-methoxyphenyl)-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-9(8H)-carboxamide	PAF antagonist	gastrointestinal ulcer; cytoprotectant
pentapeptide	unspecified	peptide	inflammatory bowel disease
booly protection compound 15; BPC 15	HOOC-val-leu-gly-ala-asp-asp-ala-pro-lys-gly-pro-pro-pro-glu-gly-NH <sub>2</sub>	peptide	Crohn disease; ulcerative colitis
diethyldihydroxyhomospermine;	DEHOHO	polyamine analogue	ulcerative colitis
diethylhomospermine; DEHOP; DE 444	N,N'-bis[4-(ethylamino)butyl]-1,4-butanediamine	polyamine analogue	diarrhea; hypertension; cancer; psoriasis; ulcerative colitis
cyclic polyamine analogue, SunPharm	unspecified	polyamine analogue; NSAID	Crohn disease; asthma; inflammation
polyclonal antibody, tumor necrosis factor alpha; polyclonal antibody, TNFalpha; CytoTAb	unspecified	polyclonal antibody; immunoglobulin; immunosuppressant	septic shock; malaria; restenosis; Crohn disease; graft versus host disease
polyclonal antibody, tumor necrosis factor alpha; immunoglobulin, TNF-alpha lysate; PASSTNF-alpha	unspecified	polyclonal antibody; immunoglobulin; NSAID	rheumatoid arthritis; inflammatory bowel disease
ridogrel; R 68070	(E)-5-[[[3-pyridinyl[3-(trifluoromethyl)phenyl]methylenc]amino]oxy]pentanoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	ulcerative colitis; Crohn disease
etanercept; tumor necrosis factor receptor; TNFr; TNR 001; ENBREL	unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease

thalidomide; SYNOVIR; THALOMID	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection
AZM 091	unspecified	Undisclosed	ulcerative colitis
colitis therapy	Strath-1, strath-2	Undisclosed	ulcerative colitis
CPR 2015	unspecified	Undisclosed	ulcerative colitis
ulcerative colitis therapy, LecTec	unspecified	Undisclosed	ulcerative colitis
tazofelone; LY 213829	(+,-)-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-4-thiazolidinone	Undisclosed	inflammatory bowel disease
mesalazine; mesalamine; falsalamine; 5-ASA; N 5-ASA; SALOFALK; ASACOL; ROWASA; PENTASA; LIXACOL	5-amino-2-hydroxybenzoic acid	Undisclosed	inflammatory bowel disease
vaccine, TNF alpha	unspecified	vaccine; cytokine antagonist	rheumatoid arthritis; Crohn disease; cachexia; asthma

Table 49. Current Candidate Therapeutic Interventions for the Treatment of Hepatitis

Product Name	Chemical Name	Action	Indication
NP 77A	Plantain isolate	Antiviral	viral infection; hepatitis
hepatitis C therapy	unspecified	Epsilon RNA and 5'UTR binding	hepatitis
gene therapy, hepatitis B	unspecified	Hepatitis gene therapy	hepatitis
MAXAMINE	unspecified	histamine agonist; histamine H2 agonist	cancer; viral infection; hepatitis

VX 497	unspecified	immunosuppressant	psoriasis; autoimmune disease; viral infection; hepatitis
gene therapy, interferon alpha-2b; gene therapy, viral infection	unspecified	interferon gene therapy	hepatitis
tuvirumab; MAb, human hepatitis B; OST 577; PE 11; OSTAVIR	unspecified	monoclonal antibody	hepatitis
MAbs, hepatitis B; HBV-AB	unspecified	monoclonal antibody	hepatitis
oligonucleotides, hepatitis B virus	unspecified	oligonucleotide	hepatitis
gene therapy, hepatitis B ribozyme; ribozyme, hepatitis B	unspecified	oligonucleotide; ribozyme gene therapy;	hepatitis
polyclonal antibody, hepatitis B; hepatitis B immunoglobulin; H-BIG; NABI-HB	unspecified	polyclonal antibody; immunoglobulin	hepatitis
AM 86	unspecified	reverse transcriptase inhibitor	viral infection; hepatitis
lamivudine; BCH 189; GR 103665; GR 109714X; GG 714; 3TC; EPIVIR; ZEFFIX; EPIVIR- HBV; HEPTODIN; HEPTOVIR	(2R-cis)-4-amino-1- [2-(hydroxymethyl)- 1,3-oxathiolan-5-yl]- 2(1H)-pyrimidinone	reverse transcriptase inhibitor; nucleoside analogue; antimetabolite	viral infection; hepatitis; HIV infection
adefovir dipivoxil; bis POM PMEA; GS 840; PREVEON	[[[2-(6-amino-9H- purin-9- yl)ethoxy]methyl]pho sphinyldene]bis(oxy methylene)-2,2- dimethylpropanoic acid	reverse transcriptase inhibitor; nucleotide analogue	viral infection; HIV infection; hepatitis
ribozymes, hepatitis C; HEPTAZYME	unspecified	ribozyme; oligonucleotide	hepatitis
gene therapy, ribozyme, hepatitis C; ribozyme, hepatitis C	unspecified	Ribozyme; oligonucleotide gene therapy	hepatitis

gene therapy, hepatitis B, GenSet; ribozyme, hepatitis B, GenSet	unspccified	ribozyme; oligonuclotide gene therapy;	viral infection; hepatitis
tucaresol; BWA 589C; BW 589C80; BW 589C; 589C	4-[(2-formyl-3- hydroxyphenoxy)met hyl]benzoic acid	RNA helicase	sickle cell anemia; viral infection; HIV infection; cancer; hepatitis
AM 188	unspccified	undisclosed	viral infection; hepatitis
VP 31593	unspecified	Unspecified	hepatitis
vaccine, hepatitis A; hepatitis A vaccine	unspecified	vaccine	hepatitis
vaccine, hepatitis B; hepatitis B vaccine; Hepa-gene 3; HEPAGENE	unspecified	vaccine	hepatitis
vaccine, hepatitis C; hepatitis C vaccine	unspecified	vaccine	hepatitis
vaccine, hepatitis C	unspecified	vaccine	hepatitis

Table 50. Current Candidate Therapeutic Interventions for the Treatment of Diabetes

Product Name	Chemical Name	Action	Indication
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease
captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
imidapril; TA 6366; EMD 61800; EMD 63100; TANATRIL; NOVALOC; NOVAROK; TANAPRESS; NORTEN	4S-[3-[R*(R*)],4R*]-3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid	ACE inhibitor	hypertension; heart failure; diabetes
adenosine agonist	Unspecified	adenosine agonist	diabetes
SC 103a	Unspecified	aldose reductase inhibitor	diabetes; neuropathy
SC 103b	Unspecified	aldose reductase inhibitor	diabetes; sexual dysfunction
SX 3030	Unspecified	aldose reductase inhibitor	diabetes
WF 3681	(+,-)-2,5-dihydro-4-hydroxy-5-oxo-3-phenyl-2-furanpropanoic acid	aldose reductase inhibitor	diabetes; retinopathy
aldose reductase inhibitor	(2'R-cis)-6-chloro-2',3'-dihydro-2'methyl-spiro(imidazolidine-4,4'-(4H)pyrano(2,3-b)pyridine)-2,5-dione	aldose reductase inhibitor	diabetes; neuropathy; retinopathy

methosorbini; M 79175; E 0772; E 79175	(2R-cis)-6-fluoro-2,3-dihydro-2-methylspiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-diione	aldose reductase inhibitor	diabetes; retinopathy
fidarestat; SNK 860; SK 860	(2S-cis)-6-fluoro-2,3-dihydro-2',5'-dioxospiro[4H-1-benzopyran-4,4'-imidazolidine]-2-carboxamide	aldose reductase inhibitor	diabetes
isoliquiritigenin; GU 17	(E)-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one	aldose reductase inhibitor	diabetes
epalrestat; ONO 2235; KINEDAK	(Z,E)-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid	aldose reductase inhibitor	neuropathy; kidney disease; eye disease; diabetes
WP 921; TAT	[5-(3-thienyl)tetrazol-1-yl]acetic acid	aldose reductase inhibitor	diabetes; neuropathy
M 16209; MD 32	1-(3-bromobenzeno[b]furan-2-ylsulfonyl)hydantoin	aldose reductase inhibitor	diabetes; neuropathy
M 16287; MD 32	1-(3-chlorobenzeno(b)furan-2-ylsulfonyl)hydantoin	aldose reductase inhibitor	diabetes; neuropathy
aldose reductase inhibitor	1-[(5-bromo-1-naphthalenyl)sulfonyl]-2-thioxo-4-imidazolidinone	aldose reductase inhibitor	diabetes
AD 5467	2,3-dihydro-2,8-bis(1-methylethyl)-3-thioxo-4H-1,4-benzoxazine-4-acetic acid	aldose reductase inhibitor	diabetes; neuropathy
FR 62765	2,5-dihydro-4-methoxy-5-oxo-3-phenyl-2-furanpropanoic acid ethyl ester	aldose reductase inhibitor	diabetes; neuropathy; retinopathy



imirestat; AL 1576; AL 01576; HOE 843	2,7-difluoro- spiro(9H-fluorene- 9,4'-imidazolidine)- 2,5-dione	aldose reductase inhibitor	diabetes; retinopathy
minalrestat; ARI 509; WAY-ARI 509	2-[(4-bromo-2- fluorophenyl)methyl]- 6- fluorospiro[isoquinoli ne-4(1H),3'- pyrrolidine]- 1,2',3,5'(2H)-tetrone	aldose reductase inhibitor	diabetes
AS 3201	2'-[(4-bromo-2- fluorophenyl)methyl] spiro[pyrrolidine- 3,4'(1'H)-pyrrolo[1,2- a]pyrazine]- 1',2,3',5(2'H)-tetrone	aldose reductase inhibitor	diabetes; neuropathy
AL 01567	2-fluorospiro-[9H- fluorene-9,4'- imidazolidine]-2',5'- dione	aldose reductase inhibitor	diabetes
ponalrestat; MK 438; ICI 128436; PRODIAX; STATIL	3-(4-bromo-2- fluorobenzyl)-3,4- dihydro-4-oxo-1- phthalazineacetic acid	aldose reductase inhibitor	diabetes; neuropathy; retinopathy
SPR 210	3,4-dihydro-3-oxo-4- [(4,5,7-trifluoro-2- benzothiazolyl)methy l]-2H-1,4- benzothiazine-2- acetic acid	aldose reductase inhibitor	diabetes; retinopathy; neuropathy
zopolrestat; CP 73850; ALOND	3,4-dihydro-4-oxo-3- [[5-(trifluoromethyl)- 2- benzothiazolyl]methy l]-1-phthalazineacetic acid	aldose reductase inhibitor	diabetes; neuropathy; kidney disease
NZ 314	3-[(3- Nitrophenyl)methyl]- 2,4,5-trioxo-1- imidazolidineacetic acid	aldose reductase inhibitor	diabetes

zenarestat; FR 74366; FK 366	3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid	aldose reductase inhibitor	diabetes; retinopathy; neuropathy
aldose reductase inhibitor, CT 112	5-(3-thienyl)-1H-tetrazole-1-acetic acid	aldose reductase inhibitor	diabetes
	5-[3-ethoxy-4-(pentyloxy)phenyl]-2,4-thiazolidinedione	aldose reductase inhibitor	diabetes; retinopathy
ascorbyl gamolenate; ascorbyl gammalinolenic acid; SC 103; ASCORBYL-GLA	6-[(6Z,9Z,12Z)-6,9,12-octadecatrienoate] L-ascorbic acid	aldose reductase inhibitor	diabetes; neuropathy; sexual dysfunction
ophthalmological,	6'-chloro-3'-methylspiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-trione	aldose reductase inhibitor	retinopathy; diabetes
BAL ARI8	7-fluoro-2-(N-methyl-N-carboxymethyl)sulfa moyl xanthone	aldose reductase inhibitor	diabetes; retinopathy
tolrestat; AY 27773; ALREDASE; LORESTAT	N-(6-methoxythio-5-(trifluoromethyl)-1-naphthoyl)sarcosine	aldose reductase inhibitor	diabetes; neuropathy
ZD 5522; ICI D5522	N-[3,5-dimethyl-4-[(nitromethyl)sulphonyl]phenyl]-2-methylbenzeneacetamide	aldose reductase inhibitor	diabetes
moxonidine; BE 5895; BDF 5895; LY 326869; CYNT; PHYSIOTENS	4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine	alpha adrenergic agonist; alpha2 adrenergic agonist; imidazoline agonist	hypertension; heart failure; diabetes
deriglidole; SL 860715; SL 840418	(+)-1,2,4,5-tetrahydro-2-(2-imidazolin-2-yl)-2-propylpyrrolo[3,2,1-hi]indole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	diabetes

L 659066; MK 467	(2R-trans)-N-[2-(1,3,4,6,7,12b-hexahydro-2'-oxo-spiro[2H-benzofuro[2,3-a]quinolizine-2,4'-imidazolidin]-3'-yl)ethyl]methanesulfonamide	alpha adrenergic antagonist; alpha2 adrenergic antagonist	diabetes
midaglizole; DG 5128	2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine	alpha adrenergic antagonist; alpha2 adrenergic antagonist	asthma; diabetes
atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety
miglitol; BAY m 1099; DIASTABOL; GLYSET	(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol	alpha glucosidase inhibitor	diabetes
emiglitate; BAY o 1248	[2R-(2alpha,3beta,4alpha,5beta)]-4-[2-[3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]ethoxy]benzoic acid ethyl ester	alpha glucosidase inhibitor	diabetes
voglibose; AO 128; A 71100; GLUSTAT; BASEN	3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)-D-epi-inositol	alpha glucosidase inhibitor	diabetes
acarbose; BAY g 5421; GLUCOBAY; PRECOSE; GLUCOR; PRANDASE	O-4,6-dideoxy-4-[[[1S-(1alpha,4alpha,5beta,6alpha)]-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose	alpha glucosidase inhibitor	diabetes; neuropathy; retinopathy

amylin, human; human amylin; AC 001	37-L-tyrosine amylin (human clone lambda h201 reduced)	Amlintide	diabetes
AZM 016	Unspecified	amylase inhibitor	obesity; diabetes
AZM 120	Unspecified	amylase inhibitor	obesity; diabetes
AZM 127	Unspecified	amylase inhibitor	obesity; diabetes
AZM 140	Unspecified	amylase inhibitor	obesity; diabetes
amylin agonists	Unspecified	amylin agonist	diabetes
pramlintide; tripro- amylin; AC 137; SYMLIN; NORMYLIN	lys-cys-asn-thr-ala- thr-cys-ala-thr-gln- arg-leu-ala-asn-phe- leu-val-his-ser-ser- asn-asn-phe-gly-pro- ile-leu-pro-pro-thr- asn-val-gly-ser-asn- thr-tyr-NH <sub>2</sub> , cyclic (2->7)-disulphide	amylin agonist	diabetes
oral amylin receptor antagonists	Unspecified	amylin antagonist	diabetes
antam; AC 253; GI 150747A; GG 747	Unspecified	amylin antagonist; peptide	diabetes
galanin modulators	Unspecified	analgesic	obesity; diabetes; cognitive defect; pain
capsaicin; ZOSTRIX; ZOTRIX HP; THERAGEN; THERAGEN HP; CAPSIDOL; LION PLASTER	(E)-N-[(4-hydroxy-3- methoxyphenyl)meth yl]-8-methyl-6- nonenamide	analgesic	pain; neuropathy; diabetes
EXO 226	Unspecified	Antiglycation agent	diabetes; kidney disease
ALT 4000	Unspecified	Antiglycemic agent	diabetes
C 8778GO	1-butyl-4,5,6,7- tetrahydro-2,6,6- trimethyl-4-oxo-1H- indole-3-acetic acid	Antihypoglycemic agent	diabetes
C 9001GO	4,5,6,7-tetrahydro- 2,6,6-trimethyl-1-(2- methylpropyl)-4-oxo- 1H-indole-3-acetic acid	Antihypoglycemic agent	diabetes
MDL 29311	4,4'- (methylenebis[thio])b is(2,6-bis[1,1- dimethylethyl]phenol	Antioxidant	diabetes; hyperlipidemia
diabetes therapy	Unspecified	antioxidant	diabetes

phensuccinal	beta-phenylethylamide-2-hydroxysuccinanylic acid	antioxidant	diabetes; kidney disease; retinopathy
raxofelast; IRFI 016	(+,-)-5-(acetyloxy)-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic acid	antioxidant; mucolytic	atherosclerosis; diabetes
naphterpin; CL 190Y2	(4aS-cis)-3,4a,5,12b-tetrahydro-8,10-dihydroxy-2,5,5,9-tetramethyl-4H-benzo[d]naphtho[2,3-b]pyran-7,12-dione	antioxidant; NSAID	diabetes; cardiovascular disease; cancer; inflammation
NX 1838	Unspecified	aptamer; oligonucleotide; angiogenesis inhibitor	cancer; diabetes; retinopathy
BMS 194449	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BMS 201620	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
LY 362884	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BRL 35135; BRL 35135A	(R*,R*)-(+,-)-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid methyl ester	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
CL 314698	(R*,R*)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid dimethyl ester	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
ICI D7114; ZD 7114	(S)-2-[4-[2-[(2-hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]-N-(2-methoxyethyl)acetamide	beta adrenergic agonist; beta3 adrenergic agonist	diabetes

AJ 9677; AD 9677	[[3-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yl]oxy]-acetic acid	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
CL 316243; BTA 243	[R-(R*,R*)]-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid, disodium salt.	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
ZD 2079; ICI D2079	4-[2-[[2-(2-hydroxy-2-phenylethyl]amino]ethoxy]benzeneacetic acid hydrochloride	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
AZ 002	L-threo-(3,4-dihydroxyphenyl)-N-methylserine methyl ester	beta adrenergic agonist; beta3 adrenergic agonist	diabetes
BMS 196085	N-[5-[(1R)-2-[[2-(1R)-1-[4-(difluoromethoxy)phenyl]-2-phenylethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
NNC 550118	Unspecified	Beta cel selective agent	diabetes
CP 80629	Unspecified	beta3 adrenergic agonist; beta adrenergic agonist	diabetes
metformin; metformin hydrochloride; LA 6023; BMS 207150; GLUCOPHAGE	N,N-dimethylimidodicarbonylimidic diamide	biguanide	diabetes
somatomedin C; insulin-like growth factor-1; IGF-1; MKC 031; MKN 031	Unspecified	biotechnology; cicatrizant; hormone	catabolic disorder; diabetes; skin ulcer
interleukin-1; IL-1	Unspecified	biotechnology; cytokine	diabetes

calcitonin gene-related peptide (CGRP) receptor modulators,	Unspecified	calcitonin gene-related peptide (CGRP) receptor modulators	migraine; diabetes
amyloid production inhibitors	Unspecified	Carbohydrate binding mimetic	Alzheimer disease; diabetes
CMDM	meso-2,6-bis(carboxymethyl)-4,4-dimethylmorpholinium bromide	carnitine acetyltransferase inhibitor	diabetes
emeriamine; emeriamine dihydrochloride; AA 4808	(R)-2-amino-3-carboxy-N,N,N-trimethyl-1-propanaminium inner salt	Carnitine dependent oxidation of long chain fatty acids inhibitor	diabetes
SDZ CPI975; SDZ CPI 975	Unspecified	carnitine O-palmitoyltransferase inhibitor	diabetes
etomoxir; BY 754	ethyl (+)-(R)-2-[6-(p-chlorophenoxy)hexyl] glycidate	Carnitine palmitoyltransferase 1 inhibitor	diabetes
ICE inhibitor, IDUN	Unspecified	caspase inhibitor; apoptosis inhibitor; IL-1 beta converting enzyme inhibitor; immunosuppressant	transplant rejection; septic shock; rheumatoid arthritis; inflammatory bowel disease; diabetes
ORG 2766	4-(methylsulfonyl)-L-2-aminobutanoyl-L-alfa-glutamyl-L-histidyl-L-phenylalanyl-D-lysyl-L-phenylalanine	corticotropin analogue	diabetes; neuropathy
interleukin-4 receptor inhibitors	Unspecified	cytokine inhibitor	asthma; diabetes
drug delivery system, bromocriptine; bromocriptine delivery system; ERGOSET	Unspecified	dopamine agonist	diabetes; obesity; cancer
dopamine D1/D2 agonists	Unspecified	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	obesity; diabetes
NBI 6024	Unspecified	Down regulation of immune mediated process	diabetes

fructose 1,6-bisphosphatase inhibitors	Unspecified non-nucleotide, nonphosphate	fructose 1,6-bisphosphatase inhibitors	diabetes
bovine cerebral ganglioside; E 0704; CRONASSIAL	Unspecified	ganglioside	neuropathy; diabetes
gene therapy, diabetes	Unspecified	gene therapy; biotechnology	diabetes
gene therapy, insulinotropin	Unspecified	gene therapy; biotechnology	diabetes
GLP1 agonists	Unspecified	GLP1 agonists	obesity; diabetes
BAY 279955	Unspecified	glucagon antagonist	diabetes
glucagon antagonists	Unspecified	glucagon antagonist	diabetes
glucagon receptor inhibitors	Unspecified	glucagon antagonist	diabetes
glucagon antagonist	des-His(1)[Nle(9)-Ala(11)-Ala(16)]glucagon	glucagon antagonist; peptide	diabetes
drug delivery system, glucagon intranasal; glucagon, intranasal	Unspecified	Glucagon hormone	diabetes
glucagon; GLUCAGON	Unspecified	Glucagon hormone	diabetes
glucagon; glucagon G; GlucaGen	His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr	Glucagon hormone	diabetes
AZM 134	Unspecified Nonpeptide antagonist	Glucagon-like peptide mimetic	obesity; diabetes
drug delivery system, oral glucagon-like peptide-1	Unspecified	glucagon-like peptide-1	diabetes
glucagon-like peptide-1 mimetic	Unspecified	glucagon-like peptide-1 mimetic	diabetes
glucocorticoid receptor antagonists	Unspecified	glucocorticoid receptor antagonists	diabetes
MDL 25637	2,6-imino-2,6-dideoxy-7-O-(beta-D-glucopyranosyl)-D-glycero-L-gulo-heptitol	Glucohydrolase enzyme inhibitor	diabetes



BM 13677	2-[(3-phenoxypropoxy)iminio]butanoic acid	Gluconeogenesis inhibitor	diabetes
glucose-6-phosphatase inhibitors	Unspecified	glucose 6 phosphatase inhibitor	diabetes
bimoclomol; BRLP 42	N-[2-hydroxy-3-(1-piperidinyloxy)-3-pyridine-carboximidoyl chloride	GLUT4 mRNA expression stimulator	diabetes
glutamic acid decarboxylase, type 1 diabetes therapy,	Unspecified	glutamic acid decarboxylase, type 1 enzyme	diabetes
diabetes therapy	Unspecified	Glycoprotein, novel	diabetes
ALT 711	Unspecified	Glycosylation end points crosslink breaker	diabetes; cardiovascular disease
ALT 766	Unspecified	Glycosylation end points crosslink breaker	diabetes; cardiovascular disease; Alzheimer disease
pimagedine; pimagedine hydrochloride; aminoguanidine; GER 11; YM 585	aminoguanidine	Glycosylation end-product inhibitor	diabetes; kidney disease; retinopathy; atherosclerosis; neuropathy; stroke
GM 1306	Unspecified	growth factor modulator	diabetes; retinopathy; cancer
nerve growth factor; NGF; NEULEZE	Unspecified	growth factor; biotechnology; neurotrophic factor	neuropathy; diabetes
neurotrophic factor-3; NT-3; neurotrophin-3	Unspecified	growth factor; neurotrophic factor; biotechnology	neuropathy; diabetes
diabetes therapy, HNF-4 based	Unspecified	Hepatic nuclear factor 4 receptor agonist	diabetes; cardiovascular disease
diabetes therapy	Unspecified	Hexokinase II regulator	diabetes
drug delivery system, insulin secreting implant; insulin secreting implant	Unspecified	Hormone	diabetes

B 2036PEG; PEG-B 2036; TROVERT	Unspecified	Human Growth Hormone receptor antagonist; pegylated	retinopathy; acromegaly; cancer; diabetes; kidney disease
hypoglycemic	N-(4-acetylamino-phenylsulphonyl)-1,3-dioxepino[5,6-b]aziridine	Hypoglycemic	diabetes
BM 130907	5-(4-(chlorophenyl))-2-(4-methyl-phenylsulfonyl)-4-pentynoic acid	Hypoglycemic agent	diabetes
MTP 3631	7,8-dihydro-4-(3-hydroxypiperidinyl)-2-piperazinyl-6H-thiopyrano[3,2-d]pyrimidine-5,5-dioxide	Hypoglycemic agent	diabetes
hypoglycemic 2-oxiranecarboxylate derivatives	2-[6-(2-thienylmethoxy)hexyl]oxiranecarboxylic acid ethyl ester	Hypoglycemic agents	diabetes
PEPTIMER	Unspecified	immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes
fluasterone	Unspecified	immunosuppressant	cancer; diabetes; systemic lupus erythematosus
insulin-dependent diabetes therapy	Unspecified	immunosuppressant	diabetes
apoptosis-inducing antigen, diabetes; IG 2; IG2	Unspecified	immunosuppressant; apoptosis inducer	diabetes
AI 401	Unspecified	immunosuppressant; hormone	diabetes
PIC 060 analogs	Unspecified	immunosuppressant; NSAID	psoriasis; dermatitis; diabetes; transplant rejection; rheumatoid arthritis
VX 10393	Unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes

VX 10428	Unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
AI 402	Unspecified	immunosuppressant; peptide	diabetes
HOE 1423	Unspecified	insulin analogue	diabetes
insulin lispro; lys-pro insulin; insulin analogue; LY 275585; HUMALOG	28B-L-lysine-29B-L- proline insulin (human)	insulin analogue	diabetes
insulin glargine; HOE 901	human [A21-glycine, B31-arginine, B32- arginine] insulin	insulin analogue	diabetes
insulin analogue B9AspB27Glu; insulin monomeric analogue	Unspecified	insulin analogue	diabetes
LY 197535	Unspecified	insulin analogue	diabetes
insulin detemir; NN 304	Human 29B-[N6-(1- oxotetradecyl)-L- lysine]-(1A- 21A),(1B-29B)- Insulin	insulin analogue	diabetes
insulin aspart; NovoRapid	insulin (human), 28B- L-aspartic acid	insulin analogue	diabetes
drug delivery system, oral insulin; insulin oral; ORALIN; ORALGEN	Unspecified	Insulin hormone	diabetes
drug delivery system, ORASOME, insulin; insulin oral ORASOME	Unspecified	Insulin hormone	diabetes
drug delivery system, TRANSFERSOMES transdermal insulin; TRANSFERSULIN	Unspecified	Insulin hormone	diabetes
insulin, human, BioTechnology General	Unspecified	Insulin hormone	diabetes

insulin, human; HR 1799; INSUMAN	Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn (chain A) Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr (B chain)	Insulin hormone	diabetes
drug delivery system, BEODAS insulin; insulin BEODAS	Unspecified	Insulin hormone	diabetes
drug delivery system, insulin secreting implant; insulin secreting implant; EndoCRIB	Unspecified	Insulin hormone	diabetes
drug delivery system, insulin secreting implant; insulin secreting implant	Unspecified	Insulin hormone	diabetes
drug delivery system, insulin subcutaneous implant; insulin subcutaneous implant	Unspecified	Insulin hormone	diabetes
drug delivery system, MACROMOL oral insulin; insulin MACROMOL; MACRULIN	Unspecified	Insulin hormone	diabetes
drug delivery system, nasal insulin; insulin nasal formulation; NOVOLIN	Unspecified	Insulin hormone	diabetes
drug delivery system, oral copolymer insulin; insulin oral	Unspecified	Insulin hormone	diabetes
drug delivery system, oral insulin; insulin oral delivery system	Unspecified	Insulin hormone	diabetes

drug delivery system, oral insulin; insulin oral delivery system	Unspecified	Insulin hormone	diabetes
drug delivery system, oral nanosphere insulin; insulin oral	Unspecified	Insulin hormone	diabetes
drug delivery system,	Unspecified	Insulin hormone	diabetes
drug delivery system, transdermal BIPHASIX insulin; insulin transdermal	Unspecified	Insulin hormone	diabetes
drug delivery system, transdermal insulin; insulin transdermal	Unspecified	Insulin Hormone	diabetes
drug delivery system, Zot oral insulin; insulin oral	Unspecified	Insulin Hormone	diabetes
RF 1051	Unspecified	Insulin Hormone	obesity; diabetes
drug delivery system, MEDUSA insulin; insulin MEDUSA; BASULIN	Unspecified	Insulin Hormone	diabetes
insulin mimetics, oral,	Unspecified	insulin mimetic	diabetes
oral insulin mimetics,	Unspecified	insulin mimetic	diabetes
diabetes therapy,	(SP-5-21)-oxobis(1- pyrrolidinecarbodithi oato-S,S')vanadium	insulin mimetic	diabetes
L 783281	2-[2-(1,1-dimethyl-2- propenyl)-1H-indol- 3-yl]-3,6-dihydroxy- 5-[7-(3-methyl-2- butenyl)-1H-indol-3- yl]-2,5- cyclohexadiene-1,4- dione	insulin mimetic	diabetes
repaglinide; AGEE 623; AGEE 623 ZW; NN 623PRANDIN	(S)-2-ethoxy-4-[2-[[3- methyl-1-[2-(1- piperidinyl)phenyl]bu tyl]amino]-2- oxoethyl]benzoic acid	Insulin release stimulator	diabetes
Ro 34563	Unspecified	insulin secretagogue	diabetes
JTT 608	trans-4-methyl- gamma- oxocyclohexanebutan oic acid	insulin secretagogue	diabetes

nateglinide; A 4166; AY 4166; YM 026; FOX 988; DJN 608; SDZ DJN608; STARLIX; STARSIS; FASTIC	trans-N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-D-phenylalanine	insulin secretagogue	diabetes
glucagon-like peptide1; GLP 1	Unspecified	insulin secretagogue; peptide	diabetes
M&B 39890A	N-(3-imidazol-1-ylpropyl)-2-(3-trifluoromethylbenzenesulfonamido)-benzamide hydrochloride	insulin secretion inhibitor; glucagon secretion inhibitor	diabetes
exendin agonists	Unspecified	Insulin secretion stimulation	diabetes
(R)-alpha lipoic acid; (R)-thioctic acid; dextlipotam	Unspecified	insulin sensitizer	diabetes
AM 454	Unspecified	insulin sensitizer	diabetes
BM 170249	Unspecified	insulin sensitizer	diabetes
diabetes therapy	Unspecified	insulin sensitizer	diabetes
DRF 2725	Unspecified	insulin sensitizer	diabetes; hyperlipidemia
insulin potentiating factor; IPF	Unspecified	insulin sensitizer	diabetes
insulin sensitizer	Unspecified	insulin sensitizer	diabetes
insulin sensitizers	Unspecified	insulin sensitizer	diabetes
insulin sensitizers	Unspecified	insulin sensitizer	diabetes
KP 102	Unspecified	insulin sensitizer	diabetes
NN 2344; DRF 2593	Unspecified	insulin sensitizer	diabetes
PNU 106817	Unspecified	insulin sensitizer	diabetes; obesity
PNU 140975	Unspecified	insulin sensitizer	diabetes; obesity
V 411; DIAB II	Unspecified	insulin sensitizer	diabetes
YM 440	Unspecified	insulin sensitizer	diabetes
englitazone; englitazone sodium; CP 68722; CP 72466; CP 72467; CP 724672	(-)-5-[[[(2R)-2-benzyl-6-chroman-1-yl]methyl]-2,4-thiazolidinedione	insulin sensitizer	diabetes; hyperlipidemia
JTT 501	4-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-3,5-isoxazolidinedione	insulin sensitizer	diabetes

troglitazone; CS 045; CI 991; GR 92132X; NOSCAL; ReZulin; ROMOZIN; PRELAY	5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione	insulin sensitizer	diabetes; gynecological
pioglitazone; pioglitazone hydrochloride; AD 4833; U 72107; U 72107A; U 72107E; ACTOS	5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione	insulin sensitizer	diabetes
rosiglitazone; rosiglitazone maleate; BRL 49653; BRL 49653c; SB 210232; AVANDIA	5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione	insulin sensitizer	diabetes
isaglitazone; MCC 555	5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-2,4-thiazolidinedione	insulin sensitizer	diabetes
diabetes therapy	Unspecified	Insulin sensitizing agent	diabetes
insulin agonists,	Unspecified	Insulin small molecule	diabetes
insulin-associated protein tyrosine phosphatase inhibitors	Unspecified	insulin-associated protein tyrosine phosphatase inhibitors	diabetes
insulinotropin; glucagon-like peptide 1; GLP-1; NNC 901170	Unspecified	insulinotropin; glucagon-like peptide 1	diabetes
drug delivery system, insulin-producing beta cells	Unspecified	Insulin-producing beta cells	diabetes
alpha d modulator	Unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	diabetes; atherosclerosis; arthritis; inflammatory bowel disease; respiratory disease

interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion toxin; IL-2 fusion toxin; DAB 486-IL-2; D-IL-2	Unspecified	interleukin-2 diphtheria toxin chimeric protein; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; cancer
denileukin diftitox; interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion protein; DAB 389-IL- 2; LY 335348; DAB389IL2; ONTAK	1-388-toxin (Corneybacterium diphtheriae strain C7), N-L-methionyl- 387-L-histidine-388- L-alanine-, (388.fwdarw.2')- protein with 2-133- interleukin 2 (human clone pTIL2-21a)	interleukin-2 diphtheria toxin chimeric protein; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; psoriasis; cancer
islets of neogenesis- associated protein (INGAP)-based therapy	Unspecified	islets of neogenesis- associated protein (INGAP)-based therapy	diabetes
leptin receptor	Unspecified	Leptin receptor	anemia; obesity; diabetes
leptin	Unspecified	Leptin receptor analogs	obesity; diabetes
type II diabetes therapy	Oxidized lipids	Lipid oxidation pathway	diabetes
ALT 420	Unspecified	macrophage stimulator	diabetes; neuropathy; retinopathy; kidney disease
macrophage stimulators	Unspecified	macrophage stimulator	diabetes; neuropathy; retinopathy; kidney disease
NEPHROSTAT	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor	kidney disease; diabetes
ilomastat; GM 6001; CS 610; GALARDIN; GALARDIN MPI	N4-hydroxy-N1-[1- (1H-indol-3- ylmethyl)-2- (methylamino)-2- oxoethyl]-2-(2- methylpropyl)- butanediamide	matrix metalloproteinase inhibitor; proteinase inhibitor	retinopathy; diabetes; cancer



melanocortin receptor-4 modulators	Unspecified	melanocortin agonist; melanocortin MC1 agonist	obesity; diabetes
obesity therapy, diabetes therapy	Unspecified	melanocortin agonist; melanocortin MC4 agonist	obesity; diabetes
MAB, A1717; MAB A717	Unspecified	monoclonal antibody	diabetes
MAB, adrenomedullin	Unspecified	monoclonal antibody	cancer; diabetes; Alzheimer disease; diagnosis
monoclonal antibody, leptin receptor	Unspecified	monoclonal antibody; biotechnology	diabetes; anemia; obesity
MAB, VLA-4, humanized; MAB, very late antigen-4, humanized	Unspecified	monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
oxcarbazepine; CGP 47680; KIN 493; GP 47680; TRILEPTAL; TOXECAR	10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide	Na <sup>+</sup> channel modulator	epilepsy; diabetes; neuropathy
mexiletine; KO 1173; MEXITIL	1-methyl-2-(2,6-xylyloxy)ethylamine hydrochloride	Na <sup>+</sup> channel open and native open state blockade	neuropathy; arrhythmia; diabetes
MSI 1436	Steroidal compound; dog fish shark isolate	Na <sup>+</sup> /H <sup>+</sup> antiporter modulation	viral infection; restenosis; diabetes; cancer
neurotrophin-4; NT-4	Unspecified	neurotrophic factor; growth factor	neuropathy; diabetes
NS 521	Unspecified	neurotrophic factor; growth factor	Alzheimer disease; neuropathy; cancer; diabetes
NOX 100	Unspecified	nitric oxide scavenger	diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 51	Unspecified	nitric oxide scavenger	diabetes; cancer; cardiovascular disease; transplant rejection; septic shock
NOX 101	Unspecified	nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease

AXC 4047	Unspecified	Nonglucagon receptor antagonist	diabetes
acetyl-L-carnitine; acetylcarnitine, L-; ALC; ST 200; TA 803; NICETILE; BRANIGAN; ALCAR; NEUROACTIL; BRANIGEN	acetyl-L-carnitine	Nootropic, acetylcholine mimetic	Alzheimer disease; stroke; diabetes; neuropathy
autoimmune disease therapy,	Unspecified	NSAID	diabetes; rheumatoid arthritis
nucleoside mimetics,	Unspecified	nucleoside analogue	diabetes
orlistat; orlipastat; tetrahydrolipistatin; THL; Ro 180647; XENICAL	N-formyl-L-leucine [2S-[2alpha(R*),3beta]]-1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester	pancreatic lipase inhibitor	obesity; hyperlipidemia; diabetes
C-peptide analogues	Unspecified	peptide	diabetes; kidney disease
CP 95253	Unspecified	peptide	diabetes
exendin 4; exendin-4; AC 2993	Unspecified	peptide	diabetes
exendin agonists,	Unspecified	peptide	diabetes
glucagon-like peptide; GLP-1	Unspecified	peptide	diabetes
insulin B chain peptide	Unspecified	peptide	diabetes
NBI 115	Unspecified	peptide	diabetes
phosphoenol pyruvate carboxykinase modulators; PEPCK modulators	Unspecified	phosphoenol pyruvate carboxykinase modulators; PEPCK modulators	diabetes
ALFA 366	Unspecified	platelet antiaggregant	kidney disease; diabetes
ALFA 642	Unspecified	platelet antiaggregant	diabetes; kidney disease
iroplact; platelet factor 4; PF4; endostatin B; REPLISTATIN	Unspecified	Platelet factor 4	heparin neutralization; psoriasis; HIV infection; cancer; diabetes
NN 5501	Unspecified	potassium channel activator	diabetes

mitiglinide; mituglimide calcium hydrate; KAD 1229; S 21403	[2(S)-cis]-octahydro- gamma-oxo-alpha- (phenylmethyl)-2H- isoindole-2-butanoic acid, calcium salt.	potassium channel blocker; insulin secretagogue	diabetes
potassium channel modulators	Unspecified	potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes
PPAR-gamma agonist SB 219994	Unspecified	PPAR agonist	diabetes
GW 1929	N-(2-benzoylphenyl)- O-[2-(methyl-2- pyridinylamino)ethyl] -L-tyrosine	PPAR agonist	diabetes
GW 9820	Unspecified	PPAR agonist; fibrate	diabetes
GI 262570	Unspecified	PPAR agonist; retinoid agonist	diabetes
PPAR modulators, metabolic diseases	Unspecified	PPAR modulation	diabetes
S 18277	Unspecified	PPAR modulation	diabetes
SDZ PGU 693	2-[(4- chlorophenoxy)methy l]-7a-(3,4- dichlorophenyl)tetrahy dropyrrolo[2,1- b]oxazol-5(6H)-one	PPAR modulation	diabetes
prohormone convertase 2 inhibitors	Unspecified	Prohormone convertase 2 inhibitors	diabetes
beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro- 2-hydroxy-1-(3- hydroxy-4-methyl-1- octen-6-ynyl)-1H- cyclopenta[b]benzofu ran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
LY 333531	(S)-9- [(dimethylamino)met hyl]-6,7,10,11- tetrahydro-9H,18H- 5,21:12,17- dimethenodibenzo[e,k ]pyrrolo[3,4- h][1,4,13]oxadiazacyc lohexadecine- 18,20(19H)-dione	protein kinase inhibitor; protein kinase C inhibitor	diabetes; retinopathy

RAGE modulators	Unspecified	RAGE modulators	diabetes
diabetes therapy	Unspecified	retinoid	diabetes
bexarotene; LGD 1069; LG 100069; LG 1069; LDG 1069; TARGRETIN	4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthenyl)-1-ethenyl]-benzoic acid	retinoid agonist; retinoid; differentiation inducer; RXR agonist	cancer; diabetes; psoriasis; skin disease
AGN 4326	Unspecified	retinoid agonist; RXR agonist	diabetes
LGD 1324; ALRT 324	Unspecified	retinoid agonist; RXR agonist	diabetes; cancer
RXR agonist, second generation	Unspecified	retinoid agonist; RXR agonist; insulin sensitizer	diabetes
AGN 4204; ALRT 4204	Unspecified	RXR agonist; retinoid agonist	diabetes
ALRT 326	Unspecified	RXR agonist; retinoid agonist	diabetes
LGD 1268; ALRT 268	Unspecified	RXR agonist; retinoid agonist	diabetes; cancer
signal transduction inhibitor, SUGEN/ArQule	Unspecified	signal transduction inhibitor; immunosuppressant	cancer; diabetes; neurological; autoimmune disease
insulin-like growth factor-1 coupled with binding protein; IGF-BP3; SomatoKine	Unspecified	somatomedin C coupled with binding protein hormone; cicatrizant; growth factor	osteoporosis; musculoskeletal disorder; skin ulcer; diabetes
lanreotide; BIM 23014; DC 13116; BIM 23014C; BN 52030; SOMATULINE; ANGIOPEPTIN; DERMOPEPTIN; IPSTYL	3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2,7)-disulfide	somatostatin analogue	cancer; acromegaly; retinopathy; diabetes; psoriasis; restenosis
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly

drug delivery system, controlled release GEOMATRIX glibenclamide; glibenclamide GEOMATRIX	Unspecified	sulfonylurea	diabetes
drug delivery system, controlled release glibenclamide; glibenclamide controlled release; Glynase PresTab	Unspecified	sulfonylurea	diabetes
drug delivery system, GEOMATRIX controlled release glipizide; glipizide GEOMATRIX	Unspecified	sulfonylurea	diabetes
drug delivery system, GITS glipizide; glipizide GITS; GLUCOTROL XL; GLUCOTROL GITS	Unspecified	sulfonylurea	diabetes
glibenclamide cyclodextrin; cyclodextrin glibenclamide; CHF 1522	Unspecified	sulfonylurea	diabetes
glimepiride; HOE 490; AMARYL	trans-3-ethyl-2,5- dihydro-4-methyl-N- [2-[4-[[[(4- methylcyclohexyl)am ino]carbonyl]amino]s ulfonyl]phenyl]ethyl]- 2-oxo-1H-pyrrole-1- carboxamide	sulfonylurea	diabetes
ZD 9583	Unspecified	thromboxane antagonist; thromboxane synthetase inhibitor	diabetes
etanercept; tumor necrosis factor receptor; TNFr; TNF 001; ENBREL	Unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease
MNX 160	Unspecified	TNF inhibitor; NSAID	rheumatoid arthritis; diabetes; multiple sclerosis

NEURULIN	Unspecified	Topical diabetic neuropathy	diabetes; neuropathy
diabetes therapy	Unspecified	transcription activator	diabetes
insulin RTP antagonist	Unspecified	tyrosine phosphatase inhibitor	diabetes
ALT 946	Pimagedine derivative	Unspecified	diabetes; neuropathy; retinopathy; kidney disease
AR H039242XX	Unspecified	Unspecified	diabetes; atherosclerosis
BST 4001; PYRIDORIN	Vitamin B6 derivative	unspecified	diabetes; kidney disease
BTS 67587	Unspecified	Unspecified	diabetes
diabetes therapy,	Unspecified	Unspecified	diabetes
diabetes therapy	Unspecified	Unspecified	diabetes; obesity; hyperlipidemia
diabetes therapy	Unspecified	Unspecified	diabetes
diabetes therapy	Unspecified	Unspecified	diabetes
DW 391	Unspecified	Unspecified	diabetes
fagopyritols	Alpha-galactosyl-D-chiro inositols	Unspecified	diabetes
fagopyritols	Alpha-galactosyl-D-chiro inositols	Unspecified	diabetes
gammalinolenic acid; EF 4; TARABETIC	gammalinolenic acid; EF 4; Unspecified	Unspecified	diabetes; neuropathy
INS 1	Unspecified	Unspecified	diabetes; gynecological
LG 1411	Biotin derived, Unspecified	Unspecified	diabetes
metabolic disease therapy,	Unspecified	unspecified	diabetes
metabolic disorder therapy	Unspecified	Unspecified	diabetes; obesity; hyperlipidemia
metabolic disorders,	Unspecified	Unspecified	diabetes; obesity; hyperlipidemia
MGI 197	Unspecified	Unspecified	retinopathy; diabetes
MKC 542	Unspecified	Unspecified	diabetes
MXC 3255; MXC3255	Unspecified	Unspecified	diabetes
NNC 051869	Unspecified	Unspecified	neuropathy; diabetes
P 30	Unspecified	Unspecified	diabetes
PN 401	Unspecified	Unspecified	diabetes; neuropathy
SEROSET	Unspecified	Unspecified	diabetes; obesity
SP 134101	Plant extract	Unspecified	diabetes
TV 2251	Unspecified	Unspecified	diabetes

vanadeine	Vanadyl containing compound	Unspecified	diabetes
AS 6	[1R-[1 $\alpha$ -(2E,4E)-2,6-bis(2-chloro-4-formyl-5-hydroxy-3-methyl-6-[3-methyl-5-(1,2,6-trimethyl-3-oxocyclohexyl)-2,4-pentadienyl]phenoxy]acetic acid	Unspecified	diabetes
succibun	1-[4-N-butylureasulfonyl(phenyl)]pyrrolidin-2,5-dione	Unspecified	diabetes
AY 31637	5-(2-naphthalenylsulfonyl)-2,4-thiazolidine-dione	Unspecified	diabetes
maglivan	bis(2-amino-3-mercapto-N-octylpropanamido-O,S)oxovanadium	Unspecified	diabetes
BTS 67582	N,N'-dimethyl-N'-[2-(4-morpholinyl)phenyl]-guanidine, (E)-2-butenedioate	Unspecified	diabetes
U 10483	Unspecified	Unspecified NIDDM	diabetes
DiaPep 277	Unspecified	vaccine	diabetes
vaccine, diabetes type 1; diabetes type 1 vaccine	Unspecified	vaccine	diabetes
vaccine, diabetes	Unspecified	vaccine; peptide	diabetes
20-epi-1,25 dihydroxyvitamin D <sub>3</sub> ; MC 1288; IE	(1 $\alpha$ ,3 $\beta$ ,5Z,7E,20S)-9,10-secosteroid-5,7,10(19)-triene-1,3,25-triol	vitamin D <sub>3</sub> analogue; immunosuppressant	diabetes; transplant rejection; arthritis

Table 51. Current Candidate Therapeutic Interventions for the Treatment of Obesity

Product Name	Chemical Name	Action	Indication
obesity therapy	Unspecified	5HT agonist; 5HT <sub>2C</sub> agonist	obesity

sertraline; CP 51974; CP 519741; CP 5197401; LUSTRAL; ZOLOFT; ALTRULINE; TATIG; GLADEM	(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety; sexual dysfunction; obesity
Dexfenfluramine; dexfenfluramine hydrochloride; S 5614; IP 001; ISOMERIDE; ADIFAX; ARDIX; ISOLIPAN; SIRAN; OBESINE; FLURIL; DISPONDAL; REDUX	(S)-N-ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine	5HT reuptake inhibitor	obesity; depression; nicotine withdrawal
sibutramine; sibutramine hydrochloride monohydrate; BTS 54524; REDUCTIL; MERIDIA	1-(4-chlorophenyl)-N,N-dimethyl-alpha-(2-methylpropyl)cyclobutanemethanamine hydrochloride monohydrate	5HT reuptake inhibitor; noradrenalin reuptake inhibitor	obesity
sibutramine, (S)-; (S)-sibutramine	1-(4-chlorophenyl)-N,N-dimethyl-alpha-(2-methylpropyl)cyclobutanemethanamine	5HT reuptake inhibitor; noradrenalin reuptake inhibitor	obesity
Obesity therapy	Unspecified	5HT1 human neuroreceptor ligands, 5HT1 receptor pathway	obesity; anxiety; depression; migraine; drug design technology
MAb, adipocytes	Unspecified	Adipocyte monoclonal antibody	obesity
adiposin; lipotropin	Unspecified	Adiposin, lipotropin pathways	obesity; cancer
RP 55462	6-chloro-5-methyl-N-(1-methylethyl)-2-(1-piperazinyl)-4-pyrimidinamine	alpha adrenergic antagonist; alpha2 adrenergic antagonist	obesity
AZM 016	Unspecified	amylase inhibitor	obesity; diabetes
AZM 120	Unspecified	amylase inhibitor	obesity; diabetes
AZM 127	Unspecified	amylase inhibitor	obesity; diabetes
AZM 140	Unspecified	amylase inhibitor	obesity; diabetes
galanin modulators	Unspecified	analgesic	obesity; diabetes; cognitive defect; pain



galanin1 antagonists	Unspecified	analgesic	obesity; pain; cognitive defect
SNX 024	Typtoline analogue	Appetite suppressant	obesity
AZM 090	unspecified	Appetite suppressant	obesity
AZM 114	Unspecified	Appetite suppressant	obesity
AZM 115	Unspecified	Appetite suppressant	obesity
AZM 132	Unspecified	Appetite suppressant	obesity
biamine	Unspecified	Appetite suppressant	obesity
BTS 78050	Unspecified	Appetite suppressant	obesity
obesity therapy	Aminosterols	Appetite suppression	obesity
P 57	Plant extract	Appetite suppression	obesity
obesity therapy	Unspecified	Beta 3 adrenergic receptor oligonucleotide	obesity
BRL 26830A	(R,R) (+,-)methyl 4- (2-((2-hydroxy-2- phenylethyl)amino)pr opyl)benzoate	beta adrenergic agonist	obesity
BMS 194449	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BMS 201620	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BMS 210285	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity
LY 362884	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
ULTG 307	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity
BRL 35135; BRL 35135A	(R*,R*)-(+,-)-[4-[2- [[2-(3-chlorophenyl)- 2- hydroxyethyl]amino] propyl]phenoxy]aceti c acid methyl ester	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
BRL 37344	(R*,R*)-(+,-)-[4-[2- [[2-(3-chlorophenyl)- 2- hydroxyethyl]amino] propyl]phenoxy]aceti c acid	beta adrenergic agonist; beta3 adrenergic agonist	obesity

CL 314698	(R*,R*)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid dimethyl ester	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
ICI 198157	(S)-(-)-(methyl-(4-(2-((2-hydroxy-3-phenoxypropyl)amino)ethoxy)phenoxy)acetate	beta adrenergic agonist; beta3 adrenergic agonist	obesity
LY 377604	(S)-6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-3-pyridinecarboxamide monohydrochloride	beta adrenergic agonist; beta3 adrenergic agonist	obesity
AJ 9677; AD 9677	[[3-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yl]oxy]-acetic acid	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
CL 316243; BTA 243	[R-(R*,R*)]-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid, disodium salt.	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
SR 56811; SR 58611A; SR 58611; ME 3411	[R-(R*,S*)]-[[7-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]acetic acid ethyl ester hydrochloride	beta adrenergic agonist; beta3 adrenergic agonist	irritable bowel syndrome; obesity; depression
ZD 2079; ICI D2079	4-[2-[[2-(2-hydroxy-2-phenylethyl)amino]ethoxy]benzeneacetic acid hydrochloride	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity

BMS 196085	N-[5-[(1R)-2-[(1R)-1-[4-(difluoromethoxy)phenyl]-2-phenylethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
beta3 adrenergic receptor agonists	Unspecified	beta3 adrenergic agonist; beta adrenergic agonist	obesity
A 71378	N-[1-oxo-3-[4-(sulfooxy)phenyl]propyl]-L-norleucylglycyl-L-tryptophyl-L-norleucyl-N-methyl-L-alfa-aspartyl-L-phenylalanineamide	Cholecystokinin A agonist; cholecystokinin agonist; peptide	obesity
FPL 15849	Unspecified	cholecystokinin agonist; cholecystokinin A agonist	obesity
GI 248573	Unspecified	cholecystokinin agonist; cholecystokinin A agonist	obesity; cholestasis
SR 146131	Unspecified	cholecystokinin agonist; cholecystokinin A agonist	obesity
FPL 14294	(Hpa(S03H)-Met-Gly-Trp-Met-Asp-MePhe-NH2NH3	cholecystokinin agonist; cholecystokinin A agonist	obesity
A 71623	N-[(1,1-dimethylethoxy)carbonyl]-L-tryptophyl-N6-[[[(2-methylphenyl)amino]carbonyl]-L-lysyl-L-alfa-aspartyl-N-alfa-methyl-L-phenylalanineamide	cholecystokinin agonist; peptide	obesity

CMI 477	(1S-exo)-2-(6-chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane	cholinergic agonist; nicotinic agonist; analgesic	obesity; depression; Alzheimer disease; nicotine withdrawal
corticotrophin releasing factor (CRF) agonists	Unspecified	CRF receptor ligand	obesity
drug delivery system, bromocriptine; bromocriptine delivery system; ERGOSET	Unspecified	dopamine agonist	diabetes; obesity; cancer
dopamine D1/D2 agonists	Unspecified	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	obesity; diabetes
drug delivery system, dopamine; dopamine delivery system; NMI 8739; DOPREXIN	Unspecified	Dopaminergic receptor ligand	obesity; Parkinson disease
Galanin receptor modulators	Unspecified	Galanin receptor modulators	obesity
GLP1 agonists	unspecified	GLP1 agonists pathway	obesity; diabetes
AZM 134	unspecified	Glucagon-like peptide 1	obesity; diabetes
RF 1051	Unspecified	hormone	obesity; diabetes
AOD 9604	Human growth hormone analogue	Human growth hormone receptor ligand	obesity
obesity therapy, Obesys; obesity therapy, BTG	Unspecified	Immunomodulation	obesity
PNU 106817	Unspecified	insulin sensitizer	diabetes; obesity
PNU 140975	Unspecified	insulin sensitizer	diabetes; obesity
leptin	Unspecified	Leptin pathway	obesity; diabetes
leptin receptor	Unspecified	Leptin pathway	anemia; obesity; diabetes
leptin, second generation	Unspecified	Leptin pathway	obesity
obesity therapy	Unspecified	Leptin pathway	obesity
leptin agonists	Unspecified	Leptin receptor pathway	obesity
leptin expression modulators	Unspecified	Leptin receptor pathway	obesity

leptin modulator	Unspecified	Leptin receptor pathway	obesity
leptin signalling pathway modulators	Unspecified	Leptin receptor pathway	obesity
ATL 962	Unspecified	lipase inhibitor	obesity
AZM 008	Unspecified	lipase inhibitor	obesity; atherosclerosis
AZM 097	Unspecified	lipase inhibitor	obesity; atherosclerosis
AZM 108	Unspecified	lipase inhibitor	obesity; atherosclerosis
AZM 119	Unspecified	lipase inhibitor	obesity; atherosclerosis
AZM 131	Unspecified	lipase inhibitor	obesity
natural lipase inhibitor	Unspecified	lipase inhibitor	obesity; atherosclerosis
obesity therapy	Unspecified	lipase inhibitor	obesity
MCR4 modulators	Unspecified	MCR4 receptor pathway	obesity
melanocortin receptor-4 modulators	Unspecified	melanocortin agonist; melanocortin MC1 agonist	obesity; diabetes
Melanocortin-4 receptor agonist	Unspecified	melanocortin agonist; melanocortin MC4 agonist	obesity
Obesity therapy, diabetes therapy	Unspecified	melanocortin agonist; melanocortin MC4 agonist	obesity; diabetes
JTT 722	Unspecified	microsomal transfer protein inhibitor	hyperlipidemia; obesity
monoclonal antibody, leptin receptor	Unspecified	monoclonal antibody; biotechnology	diabetes; anemia; obesity
obesity therapy	Unspecified	Neuropeptide Y and galanin receptor ligands	obesity
AXC 0216	Unspecified	neuropeptide Y antagonist	obesity; hypertension
AXC 1829	Unspecified	neuropeptide Y antagonist	obesity; hypertension
neuropeptide Y antagonist	Unspecified	neuropeptide Y antagonist	obesity; hypertension
NGD 951; NGD 95-1; CP 422935	Unspecified	neuropeptide Y antagonist	obesity; eating disorder

Neuropeptide Y antagonists	Unspecified	neuropeptide Y antagonist; analgesic	obesity; cardiovascular disease; anxiety; pain
Neuropeptide Y1 antagonists	Unspecified	neuropeptide Y antagonist; neuropeptide Y1 antagonist	obesity
BIBP 3226	(R)-N-[4-[(aminoiminomethyl)amino]-1-[[[(4-hydroxyphenyl)methyl]amino]carbonyl]butyl]-alpha-phenylbenzeneacetamide	neuropeptide Y antagonist; neuropeptide Y1 antagonist	obesity
SR 120819A	[alpha R-[N[R*(cis)],alpha R*]]-N-[1-[[4-[[[(dimethylamino)methyl]cyclohexyl)methyl]amino]iminomethyl]phenyl)methyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-alpha-[(2-naphthalenylsulfonyl)amino]benzenepropanamide	neuropeptide Y antagonist; neuropeptide Y1 antagonist	hypertension; obesity; eating disorder
Neuropeptide Y antagonists	Unspecified	neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypotension; obesity; depression
Neuropeptide Y5 antagonist	Unspecified	neuropeptide Y antagonist; neuropeptide Y5 antagonist	obesity
Neuropeptide Y5 antagonists	Unspecified	neuropeptide Y antagonist; neuropeptide Y5 antagonist	obesity
Neuropeptide Y receptor modulators	Unspecified	Neuropeptide Y receptor modulation	obesity
SEROSET	Unspecified	Neurotransmitter modulating agent	diabetes; obesity

AXOKINE	Unspecified	neurotrophic growth factor	amyotrophic lateral sclerosis; obesity; eye disease
Amfebutamone; bupropion hydrochloride; bupropion; bupropin; BW 323U; WELLBUTRIN; ZYBAN	(+,-)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone	noradrenalin reuptake inhibitor	depression; nicotine withdrawal; obesity
drug delivery system, liposome oleoyl-estrone;	oleoyl-estrone liposome	Oleoyl estrone activity	obesity
LY 255582	[3R-[1(S*),3alpha,4alpha]-alpha-cyclohexyl-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinepropanol	opiate antagonist	obesity
nalmefene; nalmetrene; JF 1; INCYSTENE; ARTHENE; FENARC; CERVENE; REVEX	17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma
opioid antagonists	Unspecified	opiate antagonist; peptide; immunosuppressant	addiction; alcoholism; obesity; transplant rejection
orlistat; orlipastat; tetrahydrolipistatin; THL; Ro 180647; XENICAL	N-formyl-L-leucine [2S-[2alpha(R*),3beta]]-1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester	pancreatic lipase inhibitor	obesity; hyperlipidemia; diabetes
A 68552	Unspecified	peptide	obesity
SNAP 1156	Unspecified	peptide	anxiety; hypertension; obesity; addiction
enterostatin; D 3800	N2-[1-[N-(1-L-valyl-L-prolyl)-L-alpha-aspartyl]-L-prolyl]-L-arginine	peptide	obesity
obesity therapy	Unspecified	PPAR gamma	obesity; diabetes

butabindide; UCL 1397	[S-(R*,R*)]-1-(2-Amino-1-oxobutyl)-N-butyl-2,3-dihydro-1H-indole-2-carboxamide	proteinase inhibitor; serine proteinase inhibitor	obesity
posatirelin; RGH 2202	(S)-N-[(6-oxo-2-piperidiny)carbonyl]-L-leucyl-L-prolinamide	protirelin analogue	cognitive defect; obesity
orotirelin; CG 3509	N-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-L-prolinamide	protirelin analogue	obesity; neuropathy
PPAR modulators	Unspecified	retinoid	atherosclerosis; obesity
obesity therapy, SIDR	Plant extract	Sustained weight loss partially dissociated from a reduction in food intake	obesity
mazindol; MAZANOR; SANOREX	5-(4-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol	Sympathomimetic	obesity
thyroid hormone receptor beta agonist	Unspecified	thyroid hormone agonist	obesity; hyperlipidemia
diabetes therapy	Unspecified	Unspecified	diabetes; obesity; hyperlipidemia
FPL 69931	Unspecified	Unspecified	obesity

Table 52. Current Candidate Therapeutic Interventions for the Treatment of Contraception

Product Name	Chemical Name	Action	Indication
drug delivery system, MENT implant; MENT implant	7-alpha-methyl-19-nortestosterone	androgen	contraception; hypogonadism
testosterone buciclate; testosterone bucyclate	17[[[(4-butylcyclohexyl)carbonyl]oxy]androst-4-en-3-one	androgen; hormone replacement therapy	hypogonadism; contraception
saralasin; saralasin acetate; aralasin; P 113; P 113 (peptide); SARENIN	1-(N-methylglycine)-5-L-valine-8-L-alanineangiotensin II	angiotensin II antagonist	hypertension; contraception; diagnosis



anordrin; Pill No. 53; vacation pill; ANORDRIN; AF 45	(2beta,5alpha,17alpha)-2-ethynyl-A-norpregn-20-yne-2,17-diol dipropionate	antiestrogen	contraception
CDRI 85287	1-[2-[4-(3-phenyl-2H-1-benzopyran-2-yl)phenoxy]ethyl]piperidine	antiestrogen	contraception
CDB 2914; RTI 3021-012	(11beta)-17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione	antiprogesterone	contraception
onapristone; ZK 98299; SH 549; ZK 299	(11beta,13alpha,17alpha)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)estra-4,9-dien-3-one	antiprogesterone	cancer; contraception
mifepristone; RU 486; RU 4866; RU 38486; R 38486; MIFEGYNE	(11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one	antiprogesterone	abortion; cancer; contraception
ORG 31710	(6beta,11beta,17beta)-11-[4-(dimethylamino)phenyl]-4',5'-dihydro-6-methyl-spiro[estra-4,9-diene-17,2'(3'H)-furan]-3-one	antiprogesterone	cancer
ZK 137316	Unspecified	antiprogesterone	contraception
RTI 4587056	Unspecified	Antispermatozoicidal	contraception
male contraceptive	Sugar analogue and derivatives	B variant of N-acetyl-beta-D-glucosaminidase inhibition (only found in sperm)	contraception
vaccine, human chorionic gonadotropin; vaccine, hCG	Unspecified	biotechnology; vaccine	contraception
vaccine, zona protein A	Unspecified	biotechnology; vaccine	contraception

vaccine, zona protein B	Unspecified	biotechnology; vaccine	contraception
cypoterone + estradiol valerate; estradiol valerate + cypoterone; FEMILAR	Unspecified	estrogen	contraception
ethinylestradiol cyclodiol; SH 580; ZK 4944 + ZK 115194	Unspecified	estrogen	contraception
levormeloxifene; NNC 460020	(3R-trans)-1-[2-[4-(3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-1-benzopyran-4-yl)phenoxy]ethyl]pyrrolidine	estrogen partial agonist	osteoporosis
J 995	(17beta)-estra-1,3,5(10)-triene-3,17-diol 3-sulfamate	estrogen; hormone replacement therapy	hormone deficiency; contraception
cypoterone acetate + ethinylestradiol; ethinylestradiol + cypoterone acetate; SH 592; ZK 4944 + ZK 9471	Unspecified	estrogen; progestogen	contraception; acne
dienogest + ethinylestradiol; ethinylestradiol + dienogest; SH 659; VALETTE	Unspecified	estrogen; progestogen	contraception
drospirenone + ethinylestradiol; ethinylestradiol + drospirenone; SH 470; ZK 4944 + ZK 30595	Unspecified	estrogen; progestogen	contraception
drug delivery system, IVR estrogen + progestogen; estrogen + progestogen intravaginal ring; progestogen + estrogen intravaginal ring	Unspecified	estrogen; progestogen	contraception

drug delivery system, IVR norethisterone + ethinylestradiol; norethisterone + ethinylestradiol intravaginal ring	Unspecified	estrogen; progestogen	contraception
ethinylestradiol + gestodene; gestodene + ethinylestradiol; SH 543; ZK 4944 + ZK 67998; MELIANE	Unspecified	estrogen; progestogen	contraception
gestodene + ethinylestradiol; ethinylestradiol + gestodene; SH 575; ZK 4944 + ZK 67998	Unspecified	estrogen; progestogen	contraception
norethindrone acetate + ethinyl estradiol; ethinyl estradiol + norethindrone acetate; CI 376; ESTROSTEP	Unspecified	estrogen; progestogen	contraception
norethindrone acetate + ethinyl estradiol; CI 1001	Unspecified	estrogen; progestogen	contraception
norethindrone enanthate + estradiol valerate; estradiol valerate + norethindrone enanthate; SH 329; ZK 5410 + ZK 5104; MESIGYNA	Unspecified	estrogen; progestogen	contraception
norgestimate + ethinylestradiol; ethinylestradiol + norgestimate; CILEST; ORTHOCYCLEN	Unspecified	estrogen; progestogen	contraception
ethinylestradiol + norethisterone; ME 3501; ORTHO- NOVUM 10/11; ELLIOT	(17alpha)-19-nor- prega-1,3,5(10)-trien- 20-yne-3,17-diol and (17alpha)-17- hydroxy-19- norpregna-4-en-20- yn-3-one	estrogen; progestogen	contraception

estradiol + ORG 30659; ORG 30659 + estradiol; ORG 30659	Unspecified	estrogen; progestogen; hormone replacement therapy	contraception; osteoporosis
CaRest M3	Unspecified	Glycoprotein protective coat destruction	cancer; contraception
histrelin; ORF 17070; SUPPRELIN	6-[1-(phenylmethyl)-D-histidine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing hormone releasing factor (pig)	gonadorelin agonist	precocious puberty
leuprolide + estrogen + progesterone	Unspecified	gonadorelin agonist; estrogen; progestogen	contraception; cancer
drug delivery system, histrelin hydrogel implant; histrelin hydrogel implant	Unspecified	gonadorelin agonist; peptide	precocious puberty; cancer
drug delivery system, microcapsule SB 75; SB 75 microcapsule	Unspecified	gonadorelin antagonist	cancer; contraception
cetrorelix; SB 75; SB 075; CETROTIDE	N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide	gonadorelin antagonist	infertility; cancer; endometriosis; benign prostate hypertrophy; contraception
detirelix; RS 68439	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-Phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide	gonadorelin antagonist	contraception; cancer

deslorelin; BACHEM 9022; SOMAGARD	5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide	gonadorelin superagonist	cancer; precocious puberty
anteovine	Unspecified	Gonadotropin basal periovulatory secretion inhibitor	contraception
drug delivery system, subcutaneous gonadotropin releasing hormone; gonadotropin releasing hormone subcutaneous implant; GnRH subcutaneous implant	Unspecified	hormone	precocious puberty; endometriosis; cancer; contraception
drug delivery system, intravaginal estradiol; estradiol intravaginal	Unspecified	hormone replacement therapy; estrogen	hormone deficiency
arginine derivative,	Unspecified	nitric oxide synthase inhibitor	contraception
drug delivery system, subcutaneous norethindrone subcutaneous implant; ANNUELLE	norethindrone	Norethindrone; estrogen and progestogen	contraception
vaccine, contraceptive, IMMUCON; contraceptive vaccine, IMMUCON	Unspecified	peptide; vaccine	contraception
drug delivery system, implant etonogestrel; etonogestrel implant; drug delivery system, 3-keto-desogestrel; IMPLANON; DESOPLAN	Unspecified	progestogen	contraception
drug delivery system, IVR levonorgestrel; levonorgestrel intravaginal ring; FEMRING	Unspecified	progestogen	contraception

drug delivery system, IVR NESTORONE; NESTORONE intravaginal ring	Unspecified	progestogen	contraception
drug delivery system, IVR progesterone; progesterone intravaginal ring	Unspecified	progestogen	contraception
drug delivery system, levonorgestrel; levonorgestrel drug delivery system; NORPLANT II; NORPLANT; NORPLANT 2	Unspecified	progestogen	contraception
drug delivery system, NESTORONE subdermal implant; NESTORONE subdermal implant	Unspecified	progestogen	contraception
drug delivery system, transdermal NESTORONE; NESTORONE bracelet	Unspecified	progestogen	contraception
levonorgestrel butanoate	Unspecified	progestogen	contraception
gestrinone; R 2323; RU 2323; A 46745; DIMETROSE; NEMESTRAN; DIMETRIOSE	(17alpha)-13-ethyl- 17-hydroxy-18,19- dinorpregna-4,9,11- trien-20-yn-3-one	progestogen	endometriosis
dienogest; dienogestril; SH 660; STS 557; M 18575; MJR 35; ENDOMETRION	(17alpha)-17- hydroxy-3-oxo-19- norpregna-4,9-diene- 21-nitrile	progestogen	endometriosis; contraception
ST 1435; NESTORONE	17-(acetyloxy)-16- methylene-19- norpregn-4-ene-3,20- dione	progestogen	contraception

drospirenone; ZK 30595	[6R-(6alpha,7alpha,8beta,9alpha,10beta,13beta,14alpha,15alpha,16alpha,17beta)]-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione	progestogen; aldosterone antagonist	contraception
drug delivery system, IVR NESTORONE + ethinylestradiol; NESTORONE + estradiol intravaginal ring	Unspecified	progestogen; estrogen	contraception
drug delivery system, intrauterine levonorgestrel; IUD levonorgestrel; levonorgestrel interuterine drug delivery system; LNG 20 IUD; SH 650; LEVONOVA; MIRENA	Unspecified	progestogen; hormone replacement therapy	contraception; hormone deficiency
desogestrel; ORG 2969; DESOGEN; MARVELON; MERCILON; OVIDAL; PLANUM; ORTHO-CEPT; CERAZETTE	(17alpha)-13-ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol	progestogen; hormone replacement therapy	contraception; hormone deficiency
C 31G; SAVVY	Unspecified	spermicidal	bacterial infection; contraception; HIV infection
DK 1	Unspecified	Spermicidal, germicidal	contraception
DNM 5	Unspecified	Spermicidal, germicidal	contraception

thalidomide; SYNOVIR; THALOMID	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
USHERCELL	Cullose sulfate	Topical contraceptive	contraception; bacterial infection; HIV infection; viral infection
85/83	6,7-dimethoxy-1H-pyrazolo[3,4-b]quinolin-3-amine	Trophoblast cell development inhibitor	contraception
cucumariosid	Unspecified	Unspecified	contraception
drug delivery system, transdermal contraceptive	Unspecified	Unspecified	contraception
praneem	Unspecified	Unspecified	contraception; bacterial infection
immunocontraceptive , human chorionic gonadotropin; vaccine, hCG	Unspecified	vaccine	contraception
vaccine, antisperm	Unspecified	vaccine	contraception
vaccine, contraceptive; contraceptive vaccine	Unspecified	vaccine	contraception
vaccine, FSH; vaccine, contraceptive	Unspecified	vaccine	contraception
vaccine, gonadotropin releasing hormone; vaccine, GnRH; vaccine, contraceptive	Unspecified	vaccine	contraception
vaccine, human chorionic gonadotropin; vaccine, hCG, vaccine, contraceptive; vaccine, lung cancer	Unspecified	vaccine	contraception; cancer
vaccine, human chorionic gonadotropin; vaccine, hCG; vaccine, contraceptive	Unspecified	vaccine	contraception



vaccine, human chorionic gonadotropin beta subunit fragment	Unspecified	vaccine	contraception
vaccine, PH 20; contraceptive vaccine	Unspecified	vaccine	contraception
vaccine, oral contraceptive, IMMUCON; contraceptive vaccine, oral, IMMUCON	Unspecified	vaccine; peptide	contraception
YAL 198	Unspecified	vaccine; peptide	contraception

Table 53. Current Candidate Therapeutic Interventions for the Treatment of Osteoporosis

Product Name	Chemical Name	Action	Indication
ZM 230487; ICI 230487	1-ethyl-6-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-2(1H)-quinolinone	5 lipoxygenase inhibitor	osteoporosis
3-benzothiepin derivative, osteoporosis	(6R-trans)-[[4-[[[(5,6,8,9-tetrahydro-8-methyl-9-oxothiepine[4,5-f]-1,3-benzodioxol-6-yl)carbonyl]amino]phenyl]methyl]phosphonic acid diethyl ester	Alkaline phosphatase activity stimulator	osteoporosis; musculoskeletal disorder
androgen agonists,	Unspecified	Androgen receptor pathway	hypogonadism; osteoporosis
drug delivery system, transdermal testosterone; testosterone transdermal		androgen; hormone replacement therapy	hypogonadism; osteoporosis

drug delivery system, transdermal TheraDerm-LRS testosterone; testosterone TheraDerm-LRS; ANDRODERM; ATMOS; ANDROPATCH; TANDREXEN; ANDROCINOS; TESTOCLIM		androgen; hormone replacement therapy	hypogonadism; osteoporosis
osaterone; osaterone acetate; TZP 4238; HIPROS	17-(acetyloxy)-6-chloro-2-oxapregna-4,6-diene-3,20-dione	antiandrogen	benign prostate hypertrophy; cancer; osteoporosis
droloxifene; droloxifene citrate; 3-hydroxytamoxifen; K 21060E citrate	(E)-alpha-[p-[2-(dimethylamino)ethoxy]phenyl]-alpha-ethyl-3-stilbenol	antiestrogen	cancer; osteoporosis
estrogen receptor modulator,		antiestrogen; estrogen agonist	cancer; osteoporosis
estrogen receptor modulators		antiestrogen; estrogen agonist	cancer; osteoporosis
HMR 3339		antiestrogen; estrogen agonist	osteoporosis
HMR 3656		antiestrogen; estrogen agonist	osteoporosis
raloxifene; keoxifene; LY 139481; LY 156758; EVISTA	[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone	antiestrogen; estrogen agonist	osteoporosis; hyperlipidemia; myocardial infarction; cancer
osteoblast-specific factor; OSF		biotechnology	osteoporosis
osteopoietin; OPO		biotechnology	osteoporosis
osteoprotegerin; OPG		biotechnology	osteoporosis; cancer

drug delivery system, somatomedin C; drug delivery system, insulin-like growth factor-1; somatomedin C DepoFoam; Depo IGF-1		biotechnology; cicatrizant; hormone; NSAID; growth factor	rheumatoid arthritis; osteoporosis
gene therapy, bone growth factor; gene therapy, osteoporosis		biotechnology; gene therapy	osteoporosis
gene therapy, calcitonin; gene therapy, osteoporosis		biotechnology; gene therapy; hormone	osteoporosis
osteoblast stimulating factor; OSF		biotechnology; growth factor	osteoporosis
polyethylene glycol transforming growth factor beta2; PEG-TGF beta2; transforming growth factor beta2 macrogol		biotechnology; growth factor	osteoporosis; psoriasis; eye disease
TGF-beta growth and differentiation factors		biotechnology; growth factor; cicatrizant	skin ulcer; osteoporosis
trafermin; fibroblast growth factor, basic; basic fibroblast growth factor; bFGF; trofermin; KCB 1; CAB 2001; FIBLAST	2-155-fibroblast growth factor, basic (human clone lambda KB7/lambda HFL 1 precursor reduced)	biotechnology; growth factor; cicatrizant	skin ulcer; osteoporosis; stroke; neuropathy; peripheral vascular disease; coronary artery disease
transforming growth factor beta 2; TGF beta2; FOVALIN; BetaKine		biotechnology; growth factor; cicatrizant	retinopathy; osteoporosis; skin ulcer; multiple sclerosis

somatropin; somatotropin; human growth hormone; hGH; CB 311; GENOTROPIN; NUTROPIN; NUTROPIN AQ; CRESCORMON; GENOTONORM	somatotropin (human)	biotechnology; growth hormone	hormone deficiency; growth disorder; Turner syndrome; osteoporosis
calcitonin, human; human calcitonin; hCT; SUN 8577		biotechnology; hormone	osteoporosis
parathyroid hormone		biotechnology; hormone	osteoporosis
parathyroid hormone fragment; BM 06024		biotechnology; hormone	osteoporosis
parathyroid hormone, human; human parathyroid hormone; ALX 111; ALX 1-11		biotechnology; hormone	osteoporosis
TJN 135		biotechnology; hormone	osteoporosis
somatomedin C coupled with binding protein; insulin-like growth factor-1 coupled with binding protein; IGF-BP3;		biotechnology; hormone; cicatrizant; growth factor	osteoporosis; musculoskeletal disorder; skin ulcer; diabetes
bone inducing protein; BIP; osteogenetic protein 1; OP 1; OP 1; NOVOS		biotechnology; osteoanagenetic	musculoskeletal disorder; osteoporosis; neurological
somatomedin B; insulin-like growth factor-2; IGF-2		biotechnology; osteoanagenetic; growth factor	osteoporosis; hormone deficiency
TAK 726		biotechnology; proteinase inhibitor; cathepsin L inhibitor	osteoporosis
proteinase nexin-1; PN-1		biotechnology; proteinase inhibitor; osteoanagenetic; cicatrizant	osteoporosis; skin ulcer

alendronic acid; alendronate sodium; MK 217; G 704650; L 670452; GTH 42; FOSAMAX; DRONAL; ADRONAT; ALENDROS; BONARON; TEIROC; ONCLAST; FOSALAN; MARVIL	(4-amino-1-hydroxybutylidene)bisphosphonic acid	bisphosphonate	osteoporosis
BM 211182	[3-(1-iminoethylamino)-1-hydroxypropylidene]bisphosphonic acid	bisphosphonate	osteoporosis
clodronic acid; clodronate; CL2 MDP; KCO 692; BONEFOS; OSTAC; CLASTEON; OSSITEN; CLASTOBAN; OSSITEN; DIFOSFONAL; OSTAC; MEBONAT; LORON	(dichloromethylene)bisphosphonic acid	bisphosphonate	osteoporosis; hypercalcemia
EB 1053	[1-hydroxy-3-(1-pyrrolidiny)propylidene]bisphosphonic acid	bisphosphonate	osteoporosis
incadronic acid; incadronate disodium; YM 175; BISPHONAL	[(cycloheptylamino)methylene]bisphosphonic acid	bisphosphonate	hypercalcemia; osteoporosis
minodronic acid; YM 529; YH 529	(1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethylidene)bisphosphonic acid	bisphosphonate	osteoporosis; hypercalcemia; cancer

meridronic acid; amino-hexane diphosphonate; AHDP Na	(6-amino-1-hydroxyhexylidene)diphosphonic acid	bisphosphonate	Paget disease; osteoporosis; cancer
olpadronic acid; olpadronate	[3-(dimethylamino)-1-hydroxypropylidene]diphosphonic acid	bisphosphonate	osteoporosis
pamidronic acid; pamidronate disodium; APD; CGP 23339AE; AREDIA; OSTEOKIT	(3-amino-1-hydroxypropylidene)bisphosphonic acid	bisphosphonate	osteoporosis; cancer
risedronic acid; risedronate sodium; NE 58095; HMR 4003; ACTONEL	[1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid	bisphosphonate	osteoporosis; Paget disease
tiludronic acid; tiludronate disodium; tiludronate sodium; SR 41319; SR 41319B; SR 41319G; ME 3737; SKELID	[[4-chlorophenyl)thio]methylene]bisphosphonic acid	bisphosphonate	Paget disease; osteoporosis
WY 47766	2-[[[3-methoxyphenyl)methyl]sulfinyl]-1H-imidazo[4,5-c]pyridine	bisphosphonate	osteoporosis
ibandronic acid; ibandronate sodium; BM 210955; BONDRONAT	[1-hydroxy-3-(methylpentylamino)propylidene]bisphosphonic acid	bisphosphonate; osteoclast-inhibitory	osteoporosis; cancer; hypercalcemia
zoledronic acid; zoledronate; CGP 42446; ZOL 446	[1-hydroxy-2-(1H-imidazol-1-yl)-ethylidene]bisphosphonic acid	bisphosphonate; osteoclast-inhibitory	osteoporosis; hypercalcemia
KCA 098	dimethylcarbamic acid 5,6-dihydro-6-oxobenzofuro[3,2-c]quinoline-3,9-diyl ester	Bone resorption inhibitor	osteoporosis

menatetrenone; E 0167; KAYTWO; GLAKAY	(E,E,E)-2-methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-1,4-naphthalenedione	Bone resorption inhibitor	osteoporosis; blood clotting disorder
ranelic acid; strontium ranelate; S 12911	5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-3-thiopheneacetic acid	Bone resorption inhibitor	osteoporosis
ipriflavone; TL 80; TC 80; FL 113; OSTEOCHIN; OSTEOFIX; OSTEN; IPRIOSTEN; TEOBONE; OSTEN; IPRI OSTEN	7-isopropoxyisoflavone	Calcium influx regulated osteoclast differentiation and function	osteoporosis
PAA	polyacrylic acid	carbonate dehydratase inhibitor	osteoporosis
TAE 2		carbonate dehydratase inhibitor	osteoporosis
cathepsin K inhibitors		cathepsin K inhibitor; proteinase inhibitor	osteoporosis
cathepsin K inhibitors, osteoporosis		cathepsin K inhibitor; proteinase inhibitor	osteoporosis
SB 205123		cell adhesion inhibitor; integrin antagonist; alpha5 beta3 integrin antagonist	osteoporosis
IL-6 antagonists		cytokine antagonist	osteoporosis
estrogen agonists		estrogen agonist	osteoporosis
estrogen agonists		estrogen agonist	osteoporosis
GW 5638	(E,Z)-3-[4-(1,2-diphenyl-1-butenyl)phenyl]-2-propenoic acid	estrogen agonist; antiestrogen	osteoporosis; cancer; coronary artery disease
FC 1271	(Z)-2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]ethanol	estrogen agonist; antiestrogen; hormone replacement therapy	osteoporosis; hormone deficiency

IL-6 production inhibitors	Unspecified	Estrogen mimetic	osteoporosis; cancer
interleukin-6 production inhibitors, estrogen receptor-independent	Unspecified	Estrogen mimetic	osteoporosis
CP 336156	(5R,6S)-5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt)	estrogen partial agonist	osteoporosis; cancer
levormeloxifene; NNC 460020	(3R-trans)-1-[2-[4-(3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-1-benzopyran-4-yl)phenoxy]ethyl]pyrrolidine	estrogen partial agonist	osteoporosis
free radical scavenging estrogens		estrogen; free radical scavenger; NSAID	osteoporosis; arthritis; neurological
drug delivery system, transdermal 17beta estradiol; 17beta estradiol transdermal; FEMATRIX; FEMAPAK		estrogen; hormone replacement therapy	hormone deficiency; osteoporosis
drug delivery system, transdermal estradiol; estradiol transdermal; SH 577; ZK 5018; CLIMARA; PROGYNOVA TS; PROGYNOVA TS FORTE		estrogen; hormone replacement therapy	hormone deficiency; osteoporosis
estrogen receptor therapy		estrogen; hormone replacement therapy	hormone deficiency; contraception; cancer; osteoporosis
estradiol + ORG 30659; ORG 30659 + estradiol; ORG 30659		estrogen; progestogen; hormone replacement therapy	contraception; osteoporosis



simvastatin; epistatin; synvinolin; velostatin; MK 733; L 654; L 644128; 590328; ZOCOR; DENAN; MEDIPO; SIMOVIL; COLEDIS	2,2-dimethylbutanoic acid [1S- [[1alfa,3alfa,7beta,8beta a(2S*,4S*)8abeta]]- 1,2,3,7,8,8a- hexahydro-3,7- dimethyl-8-[2- (tetrahydro-4- hydroxy-6-oxo-2H- pyran-2-yl)ethyl]-1- naphthalenyl ester	HMG CoA reductase inhibitor; osteoclastogenesis	hyperlipidemia; osteoporosis
avicatonin; MCI 536	1-butanoic acid-2-L- alanine-3-L-serine- 26-L-aspartic acid-27- L-valine-29-L- alanine 1,7- dicarbocalcitonin (salmon)	hormone	osteoporosis
drug delivery system, calcitonin		hormone	osteoporosis
drug delivery system, calcitonin; salmon calcitonin; STH 32		hormone	osteoporosis
drug delivery system, LDS microemulsion calcitonin; calcitonin LIPID DISPERSAL SYSTEMS		hormone	osteoporosis
drug delivery system, oral calcitonin; calcitonin oral delivery system		hormone	osteoporosis
drug delivery system, oral MACROMOL calcitonin; calcitonin MACROMOL; MACRITONIN		hormone	osteoporosis
drug delivery system, oral transmucosal calcitonin; calcitonin transmucosal		hormone	osteoporosis

drug delivery system, PEPTITROL calcitonin; calcitonin PEPTITROL		hormone	osteoporosis; Paget disease; cancer
drug delivery system, salmon calcitonin;		hormone	osteoporosis
drug delivery system, salmon calcitonin; salmon calcitonin drug delivery system		hormone	osteoporosis
drug delivery system, submicron emulsion calcitonin; calcitonin SME		hormone	osteoporosis
elcatonin; HC 58I; ELCITONIN; ELCITONIN S; LASKARTON; ELCIMEN; CARBICALCIN; TURBOCALCIN; ELCITONINA; DIATIN	1-butyric acid-7(L-2-aminobutyric acid)-26-L-aspartic acid-27-L-valine-29-L-alaninecalcitonin (salmon)	hormone	osteoporosis
parathyroid hormone analogue		hormone	osteoporosis
semparatide; RS 66271	Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Glu-Lys-Leu-His-Thr-Ala-NH <sub>2</sub>	hormone	osteoporosis
drug delivery system, oral calcitonin; calcitonin delivery system; FORTICAL		hormone; biotechnology	osteoporosis
parathyroid hormone, human; human parathyroid hormone; rhPTH		hormone; biotechnology	osteoporosis

parathyroid hormone; PTH; SUN E3001		hormone; biotechnology	osteoporosis
NOF 003	Eicosapentaenoic acid	IL-6 production inhibition	osteoporosis
integrin antagonist		integrin antagonist; cell adhesion inhibitor	osteoporosis
SB 223245	(S)-7-[[[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid	integrin antagonist; cell adhesion inhibitor	osteoporosis; restenosis; cancer
vitronectin antagonist,		integrin antagonist; cell adhesion inhibitor	osteoporosis
vitronectin receptor antagonists		integrin antagonist; cell adhesion inhibitor; alpha5 beta3 integrin antagonist	osteoporosis; cancer; restenosis
WS 7528	(2S-cis)-2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-3-methyl-4H-1-benzopyran-4-one	isoflavanone	osteoporosis
anti-arthritic matrix metalloproteinase inhibitors		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis
matrix metalloproteinase inhibitor		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	periodontal disease; kidney disease; cancer; arthritis; osteoporosis
TEI 3313	5-(4,7-dihydroxy-2-heptenylidene)-4-hydroxy-2-(methylthio)-4-(4-phenoxybutyl)-2-cyclopenten-1-one	Mineralization of osteoclasts stimulator	osteoporosis
indian hedgehog gene-based therapy		NSAID	osteoporosis; osteoarthritis
HCT 1026		NSAID; nitric oxide donor	urinary incontinence; Alzheimer disease; osteoporosis

59-0145; 590145	N,N'-bis[5-(trifluoromethyl)-2-pyridinyl]-1,2-ethanediamine	osteoanagenetic	osteoporosis
S 14292		osteoanagenetic	osteoporosis
TEI 7457		osteoanagenetic	osteoporosis
ED 71	2-(3-hydroxypropoxy)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	osteoanagenetic; vitamin D3 analogue	osteoporosis
osteoclast calcimimetic	unspecified	osteoclast calcimimetic	osteoporosis
ACT 15		peptide	osteoporosis
OSA; CT 1		peptide	osteoporosis
OSB 201; CT 2		peptide	osteoporosis
peptide fragments, osteoporosis		peptide	osteoporosis
integrin-specific peptides		peptide; integrin antagonist; cell adhesion inhibitor; angiogenesis inhibitor	osteoporosis; cancer; restenosis
Src inhibitors		protein kinase inhibitor; tyrosine kinase inhibitor	osteoporosis
proteinase inhibitors		proteinase inhibitor	viral infection; osteoporosis; Chagas disease
proteinase inhibitors		proteinase inhibitor	osteoporosis
cathepsin L inhibitors		proteinase inhibitor; cathepsin L inhibitor; NSAID	osteoporosis
cathepsin O2 inhibitors		proteinase inhibitor; cathepsin O2 inhibitor	osteoporosis
K 11017		proteinase inhibitor; cathepsin O2 inhibitor	osteoporosis
BB 2983; GI 245402		proteinase inhibitor; matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis; inflammatory bowel disease
cysteine proteinase inhibitor		proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis; cancer; osteoarthritis

SB 242784		proton pump inhibitor	osteoporosis
FRK phosphatase inhibitor; fos regulating kinase phosphatase inhibitor		signal transduction inhibitor; MAP kinase inhibitor	osteoporosis; musculoskeletal disorder; periodontal disease
EF 40		triglyceride	osteoporosis
SC 116		triglyceride	osteoporosis
AP 448		tyrosine kinase inhibitor	osteoporosis
N 2749	Unspecified	Unspecified	osteoporosis
ormeloxifene; 67/20	trans-1-[2-[4-(3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-1-benzopyran-4-yl)phenoxy]ethyl]pyrrolidine	Unspecified	osteoporosis
1 alpha-hydroxyvitamin D2; 1 alpha-D2; one-alpha D2; TSA 870; HECTOROL		vitamin D2 analogue	osteoporosis; hyperparathyroidism; cancer
EL 715		vitamin D2 analogue	psoriasis; osteoporosis; osteodystrophy
alfacalcidol; ALFA D; PLATIBIT; VITAMILO ALFA; CALFINA; ANTUL; CALCITAMIN; BONDIOL; CALBONE; ALFAROL; ONEALFA	(1 alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3-diol	vitamin D3 analogue	osteomalacia; osteoporosis
falecalcitriol; flocalcitriol; ST 630; FULSTAN; HORNEL	(1 alpha,3beta,5Z,7E)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D3 analogue	osteoporosis; kidney disease; hyperparathyroidism; psoriasis
LR 108		vitamin D3 analogue	osteoporosis
NOF 002		vitamin D3 analogue	osteoporosis

secalciferol; 24,25-dihydroxycholecalciferol; KDR; Ro 215816; OSTEO D	(3beta,5Z,7E,24R)-9,10-secocholesta-5,7,10(19)-triene-3,24,25-triol	vitamin D3 analogue	osteodystrophy; osteoporosis
---	---	---------------------	------------------------------

Table 54. Current Candidate Therapeutic Interventions for the Treatment of Acne

Product Name	Chemical Name	Action	Indication
azelaic acid; AGN 191861; T 150; SH 441; SKINOREN; AZELEX; CUTACELAN; DIOLA; ARZEM	nonanedioic acid; saturated dicarboxylic acid	Topical antiacne preparation	acne; skin disease
MGI 434	Unspecified	Unspecified	acne
SH 570; SH H570; ZK 118372	Unspecified	Unspecified	acne
SYC 201G	Unspecified	unspecified	acne
topical antiacne agents,	Unspecified	unspecified	acne
epristeride; SKF 105657; ONO 9302	17beta-[[[(1,1-dimethylethyl)amino]carbonyl]androst-3,5-diene-3-carboxylic acid	5 alpha reductase inhibitor	benign prostate hypertrophy; cancer; alopecia; acne
finasteride; MK 906; MK 0906; YM 152; PROSCAR; FINASPROS; CHIBRO-PROSCAR; FINASTID; PROSTIDE; EUTIZ; PRODEL; PROPECIA	(5alpha,17beta)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide	5 alpha reductase inhibitor	cancer; benign prostate hypertrophy; alopecia; acne
I 23	Unspecified	5 alpha reductase inhibitor	cancer; acne; hirsutism
L 751788	(5alpha,7beta,16beta)-16-(4-chlorophenoxy)-4,7-dimethyl-4-azaandrost-3-one	5 alpha reductase inhibitor	acne
LY 191704	trans-8-chloro-1,4,4a,5,6,10b-hexahydro-4-methylbenzo[f]quinolin-3(2H)-one	5 alpha reductase inhibitor	benign prostate hypertrophy; acne; alopecia

MK 0434; MK 434	(5alpha, 17beta)-17-benzoyl-4-azaandrost-1-en-3-one	5 alpha reductase inhibitor	benign prostate hypertrophy; alopecia; acne
MK 386	(5alpha, 7beta)-4,7-dimethyl-4-azacholestan-3-one	5 alpha reductase inhibitor	acne; alopecia; benign prostate hypertrophy
ONO 3805	sodium (-)-4-(2-(2,3-dimethyl-4(1-(4-isobutylphenyl)ethoxy)benzoylamino)phenoxy)butyrate	5 alpha reductase inhibitor	benign prostate hypertrophy; acne; alopecia
turosteride; FCE 26073	(5alpha, 17beta)-4-methyl-N-(1-methylethyl)-N-[[[(1-methylethyl)amino]carbonyl]-3-oxo-4-azaandrostane-17-carboxamide	5 alpha reductase inhibitor	benign prostate hypertrophy; acne; alopecia
Antiandrogen; EM 250; SCH 54726	Unspecified	antiandrogen	acne; alopecia
cioterone; cyoctol; X-andron; CPC 10997; CYOCTOL; XANDRON	hexahydro-4-(5-methoxyheptyl)-2(1H)-pentalenone	antiandrogen	acne; alopecia; mycosis; hirsutism; benign prostate hypertrophy
inocoterone; inocoterone acetate; RU 882; RU 38882	[3S-(3alpha, 3aalpha, 9aalpha, 9beta)]-3-(acetyloxy)-6-ethyl-1,2,3,3a,4,5,8,9,9a,9b-decahydro-3a-methyl-7H-benz[e]inden-7-one	antiandrogen	acne; hirsutism
L 651580	(5alpha, 17beta)-4-methyl-3-oxo-4-azaandrost-1-ene-17-carboxylic acid methyl ester	antiandrogen	acne; alopecia
LGD 1331	Unspecified	antiandrogen	cancer; benign prostate hypertrophy; acne; alopecia
RU 58841	4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)-benzonitrile	antiandrogen	acne; alopecia

acne therapy	Unspecified	antibacterial; peptide	acne
drug delivery system, CRYSTALIP topical metronidazole; metronidazole CRYSTALIP	Unspecified	antibiotic	acne; bacterial infection
drug delivery system, HIT topical clindamycin; HyClinda	Unspecified	antibiotic	acne
drug delivery system, liposome clindamycin phosphate; clindamycin phosphate liposome; LipoCIN	Unspecified	antibiotic	acne
drug delivery system, liposome metronidazole; metronidazole liposome; LipoZOL	Unspecified	antibiotic	acne; dermatitis
drug delivery system, ResiDerm zinc-based clindamycin; clindamycin ResiDerm; ResiDerm A	Unspecified	antibiotic	acne
antiacne	(E)-3-Tridecen-2-one	antibiotic; antifungal	acne; mycosis
zimidoben; GBR 14095	1H-imidazole-1-ethanol benzoate (ester)	antifungal; imidazole	acne
antisense oligonucleotide, 2-5A chimeric, 5 alpha reductase	Unspecified	biotechnology; antisense; oligonucleotide	acne
cypoterone acetate + ethinylestradiol; ethinylestradiol + cypoterone acetate; SH 592; ZK 4944 + ZK 9471	Unspecified	estrogen; progestogen	contraception; acne
flurithromycin; P 0501A; P 80206; CI 932; FLURIZIC; MIZAR; RITRO	8-fluoroerythromycin	macrolide; antibiotic	bacterial infection; acne



erythromycin salnacedin; G 101; SCY Er; ACTAGEN	Erythromycin, compound with N- acetyl-L-cysteine-2- hydroxybenzoate (ester) (1:1)	macrolide; NSAID; antibiotic	acne
adelmidrol; LG 21301	N,N'-bis(2- hydroxyethyl)nonane diamide	NSAID	inflammation; acne
nadifloxacin; zinoxifloxacin; OPC 7251; ACUATIM; NADIXA	9-fluoro-6,7-dihydro- 8-(4-hydroxy-1- piperidinyl)-5- methyl-1-oxo-1 H,5H- benzo[ij]quinolizine- 2-carboxylic acid	quinolone; antibiotic	bacterial infection; acne
BMS 181163	Unspecified	retinoid	acne
BMV 30047	11-cis- (hydroxymethyl)- retinoic acid deltalactone	retinoid	acne
BMV 30123	retinoic acid 4- (acetylamino)phenyl ester	retinoid	acne
drug delivery system, MICROSPONGE tretinoin; tretinoin MICROSPONGE; RETIN A MICRO	Unspecified	retinoid	acne
retinoids	Unspecified	retinoid	psoriasis; acne
tazarotene; AGN 190168; ZORAC; TAZORAC	6-[(3,4-dihydro-4,4- dimethyl-2H-1- benzothiopyran-6- yl)ethynyl]-3-pyrid inecarboxylic acid ethyl ester	retinoid	acne; cancer; psoriasis
tretinoin; Ro 015488/115; NSC 122758; VESANOID	(all-E)-3,7-dimethyl- 9-(2,6,6-trimethyl-1- cyclohexen-1-yl)- 2,4,6,8- nonatetraenoic acid	retinoid	acne; cancer
adapalene; CD 271; DIFFERINE; DIFFERIN	6-(4-methoxy-3- tricyclo[3.3.1.1(3,7)]d ec-1-ylphenyl)-2- naphthalenecarboxylic acid	retinoid agonist; retinoid; RAR agonist; RARbeta agonist	acne; multiple sclerosis
CPR 2003	Unspecified	retinoid; ether lipid	acne

RS 10025	[S-(R*,R*)]-[2-[[[3-chloro-4,5-dihydro-5-isoxazolyl)methyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxoethyl]carbamic acid phenylmethyl ester	transglutaminase inhibitor	acne
----------	---	----------------------------	------

Table 55. Current Candidate Therapeutic Interventions for the Treatment of Alopecia

Product Name	Chemical Name	Action	Indication
L 733692	Unspecified	5 alpha reductase inhibitor	alopecia
turosteride; FCE 26073	(5alpha,17beta)-4-methyl-N-(1-methylethyl)-N-[[[1-methylethyl)amino]carbonyl]-3-oxo-4-azaandrostane-17-carboxamide	5 alpha reductase inhibitor	benign prostate hypertrophy; acne; alopecia
MK 0434; MK 434	(5alpha, 17beta)-17-benzoyl-4-azaandrost-1-en-3-one	5 alpha reductase inhibitor	benign prostate hypertrophy; alopecia; acne
finasteride; MK 906; MK 0906; YM 152; PROSCAR; FINASPROS; CHIBRO-PROSCAR; FINASTID; PROSTIDE; EUTIZ; PRODEL; PROPECIA	(5alpha,17beta)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide	5 alpha reductase inhibitor	cancer; benign prostate hypertrophy; alopecia; acne
dutasteride; GI 198745; GG 745; GI 198745X	(5alpha,17beta)-N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrost-1-ene-17-carboxamide	5 alpha reductase inhibitor	benign prostate hypertrophy; alopecia
MK 386	(5alpha,7beta)-4,7-dimethyl-4-azacholestan-3-one	5 alpha reductase inhibitor	acne; alopecia; benign prostate hypertrophy

epristeride; SKF 105657; ONO 9302	17beta-[[[(1,1-dimethylethyl)amino]carbonyl]androsta-3,5-diene-3-carboxylic acid	5 alpha reductase inhibitor	benign prostate hypertrophy; cancer; alopecia; acne
ONO 3805	sodium (-)-4-(2-(2,3-dimethyl-4(1-(4-isobutylphenyl)ethoxy)benzoylamino)phenoxy)butyrate	5 alpha reductase inhibitor	benign prostate hypertrophy; acne; alopecia
LY 191704	trans-8-chloro-1,4,4a,5,6,10b-hexahydro-4-methylbenzo[f]quinolin-3(2H)-one	5 alpha reductase inhibitor	benign prostate hypertrophy; acne; alopecia
PC 1358; TRICOMIN	Unspecified	Anagen phase activation of follicular growth	alopecia
antiandrogen, antiandrogen, EM 250; SCH 54726	Unspecified	antiandrogen	acne; alopecia
LGD 1331	Unspecified	antiandrogen	cancer; benign prostate hypertrophy; acne; alopecia
L 651580	(5alpha,17beta)-4-methyl-3-oxo-4-azaandrost-1-ene-17-carboxylic acid methyl ester	antiandrogen	acne; alopecia
RU 58841	4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)-benzonitrile	antiandrogen	acne; alopecia
cioterone; cyoctol; X-andron; CPC 10997; CYOCTOL; XANDRON	hexahydro-4-(5-methoxyheptyl)-2(1H)-pentalenone	antiandrogen	acne; alopecia; mycosis; hirsutism; benign prostate hypertrophy
keratinocyte growth factor 2; KGF 2; HG 03400	Unspecified	growth factor; cicatrizant; chemoprotectant; cytoprotectant	cancer; mucositis; skin ulcer; alopecia; kidney disease

drug delivery system, hydrogel topical insulin + growth hormone + thyroxine + MCDB 153; CARIEL; PILIEL	Unspecified	hormone	alopecia
drug delivery system, liposome minoxidil; minoxidil liposome	Unspecified	Minoxidil	alopecia
drug delivery system, minoxidil; minoxidil-SEPA	Unspecified	Minoxidil	sexual dysfunction; alopecia
antisense oligonucleotide, androgen receptor mRNA	Unspecified	mRNA translation inhibitor; antisense; oligonucleotide	alopecia
benign prostatic hypertrophy therapy, PC 1031; TRICOMIN	Unspecified	Overproliferation of cells	benign prostate hypertrophy; alopecia
PC 1332; TRICOMIN	Unspecified	peptide	alopecia
KC 516	Unspecified	peptide	alopecia
P 1075	Unspecified	potassium channel activator	alopecia
AN 10; NOVAHEME	[N-cyano-N'-(1,1-dimethylpropyl)-N"-3-pyridylguanidine]	potassium channel activator; vasodilator	alopecia
P 45	Unspecified Butyric acid derivative	Topical	sickle cell anemia; alopecia
diphencyprone; diphenylcyclopropenone	Unspecified	Unspecified	alopecia
	2,3-diphenyl-2-cyclopropen-1-one	Unspecified	alopecia

Table 56. Current Candidate Therapeutic Interventions for the Treatment of Metabolic Syndrome X (including Hypertension, Obesity, Hyperlipidemia, and Diabetes).

Product Name	Chemical Name	Action	Indication
(R)-alpha lipoic acid; (R)-thioctic acid			diabetes
20-epi-1,25 dihydroxyvitamin D3; MC 1288; IE	(1alpha,3beta,5Z,7E,20S)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D3 analogue; immunosuppressant	diabetes; transplant rejection; arthritis

5-methylurapidil; 5-MU	6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3,5-trimethyl-2,4(1H,3H)-pyrimidinedione	5HT agonist; 5HT1A agonist	hypertension
5HT2A human neuroreceptor; neuroreceptor, 5HT2A human		biotechnology	hypertension; research tool
A 1233; 1233 A		HMG CoA synthase inhibitor	hyperlipidemia
A 65317	[5S-[5R*[1R*[R*(S*)],2S*]]-N1-[2-[[1-(cyclohexylmethyl)-2-(3-ethyl-2-oxo-5-oxazolidinyl)-2-hydroxyethyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl]-N4-[2-[(2-methoxyethoxy)methoxy]ethyl]-N4-methyl-2-(phenylmethyl)butane diamide	renin inhibitor	hypertension
A 68552		peptide	obesity
A 68930	(1R,3S)-1-aminomethyl-5,6-dihydroxy-3-phenylisochroman	dopamine agonist; dopamine D1 agonist	hypertension; Parkinson disease
A 81282; ABBOTT 81282	4-[butyl[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-5-pyrimidinecarboxylic acid	angiotensin II antagonist	hypertension

acarbose; BAY g 5421; GLUCOBAY; PRECOSE; GLUCOR; PRANDASE	O-4,6-dideoxy-4- [[[1S- (1 alfa,4alfa,5beta,6alf a)]-4,5,6-trihydroxy- 3-(hydroxymethyl)-2- cyclohexen-1- yl]amino]-alfa-D- glucopyranosyl-(1-4)- O-alfa-D- glucopyranosyl-(1-4)- D-glucose	alpha glucosidase inhibitor	diabetes; neuropathy; retinopathy
acetyl-L-carnitine; acetylcarnitine, L-; ALC; ST 200; TA 803; NICETILE; BRANIGAN; ALCAR; NEUROACTIL; BRANIGEN	acetyl-L-carnitine		Alzheimer disease; stroke; diabetes; neuropathy
acipimox; K 9321; OLBETAM; OLBEMOX; ACIPIMOX; NEDIOS	5- methylpyrazinecarbox ylic acid 4-oxide		hyperlipidemia
adenosine agonist, Glaxo Wellcome		adenosine agonist	diabetes
adiposin; lipotropin		biotechnology	obesity; cancer
adrenergic alpha2 human neuroreceptors; neuroreceptors, adrenergic alpha2 human		analgesic	research tool; pain; hypertension; glaucoma
aging-related disease therapy, Chiroscience/Geron			atherosclerosis; cancer; osteoporosis; diabetes; eye disease
AGN 4204; ALRT 4204		RXR agonist; retinoid agonist	diabetes
AGN 4326		RXR agonist	diabetes

AGR 529	N-(4-amino-4-oxobutyl)adenosine hydrochloride		hypertension; hyperlipidemia
AGR 540	N-(4-amino-4-oxobutyl)adenosine 2',3',5'-tripropionate		hypertension; hyperlipidemia
AHL 157		fibrate	hyperlipidemia
AHR 12742	4-(bis(4-fluorophenylmethyl)-7-(3-(4-chlorophenoxy)propyl)piperidine (E)-2-butenedioate	calcium antagonist	hypertension
AHR 16303B	1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]phenyl]-2-methyl-1-propanone ethanedioate (1:1)	5HT antagonist; 5HT2 antagonist	hypertension; angina
AHR 16462B	4-[bis(4-fluorophenyl)methyl]-1-(2-naphthalenylmethyl)piperidine hydrochloride	calcium antagonist; vasodilator	hypertension
AI 402		immunosuppressant; biotechnology; peptide	diabetes
AIT 111			angina; arrhythmia; hypertension
AJ 9677; AD 9677	[[3-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yl]oxy]-acetic acid	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity

AL 01567	2-fluorospiro-[9H-fluorene-9,4'-imidazolidine]-2',5'-dione	aldose reductase inhibitor	diabetes
AL 0670	(+)-N-(6-amino-3-pyridyl)-N'-[(1S,2R,4R)-bicyclo[2.2.1]hept-2-yl]-N''-cyanoguanidine	potassium channel activator	hypertension
AL 0671	(1S-endo)-N-(6-amino-3-pyridinyl)-N'-bicyclo[2.2.1]hept-2-yl-N''-cyanoguanidine	potassium channel activator	hyperlipidemia; hypertension
alacepril; DU 1219; CETAPRIL	(S)-N-[1-[3-(acetylthio)-2-methyl-1-oxopropyl]-L-prolyl]-L-phenylalanine	ACE inhibitor	hypertension
aldose reductase inhibitor, Pfizer	(2'R-cis)-6-chloro-2',3'-dihydro-2'methyl-spiro(imidazolidine-4,4'-(4H)pyrano(2,3-b)pyridine)-2,5-dione	aldose reductase inhibitor	diabetes; neuropathy; retinopathy
aldose reductase inhibitor, Wakamoto; TAT	5-(3-thienyl)-1H-tetrazole-1-acetic acid	aldose reductase inhibitor	diabetes
aldose reductase inhibitor, Wyeth Ayerst	1-[(5-bromo-1-naphthalenyl)sulfonyl]-2-thioxo-4-imidazolidinone	aldose reductase inhibitor	diabetes
ALFA 366		platelet antiaggregant	kidney disease; diabetes
ALFA 642		platelet antiaggregant	diabetes; kidney disease



alfuzosin; alfuzosin hydrochloride; SL 77499; SL 7749910; ALFOTEN; XATRAL; BENESTAN; BENESTAIN; XATRAL-MAG; DILOTEX; URION; UROXATRAL	N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide	alpha adrenergic antagonist; alpha 1 adrenergic antagonist	benign prostate hypertrophy; hypertension
alpha d modulator		cell adhesion inhibitor; NSAID	diabetes; atherosclerosis; arthritis; inflammatory bowel disease; respiratory disease
alprostadiol; lipo-prostaglandin E1; lipo-PGE1; U 10136; G 511; CAVERJECT; PROSTANDIN; PROSTAVASIN; PALUX; LIPLE; APISTANDIN; PROMOSTAN; PROSTIN; VASOPROST; EDEX	(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid	prostanoid; vasodilator; cicatrizant	hepatitis; thrombosis; peripheral vascular disease; sexual dysfunction; pulmonary hypertension; skin ulcer; hearing loss
ALRT 326		RXR agonist; retinoid agonist	diabetes
ALT 4000			diabetes
ALT 711			diabetes; cardiovascular disease
ALT 946			diabetes; neuropathy; retinopathy; kidney disease
AM 454		insulin sensitizer	diabetes
AM 522		cardiac glycoside	hypertension; heart failure

AM 524		cardiac glycoside	heart failure; hypertension
amlodipine + benazepril; benazepril + amlodipine; CGP 24267A; LOTREL		calcium antagonist; ACE inhibitor	hypertension
amlodipine analogue, Pfizer	4-(2,3- dichlorophenyl)-1,4- dihydro-2-[(2- hydroxyethoxy)methyl]- 6-methyl-3,5- pyridinedicarboxylic acid 3-ethyl 5-methyl ester	calcium antagonist	hypertension
amlodipine besilate; UK 4834026; NORVASC; ISTIN	2-[(2- aminoethoxy)methyl]- 4-(2-chlorophenyl)- 1,4-dihydro-6- methyl-3,5- pyridinedicarboxylic acid, 3-ethyl 5-methyl ester monobenzenesulfonate	calcium antagonist	hypertension
amlodipine, (S)-; (S)- amlodipine; (-)- amlodipine; l- amlodipine	(S)-2-[(2- aminoethoxy)methyl]- 4-(2-chlorophenyl)- 1,4-dihydro-6- methyl-3,5- pyridinedicarboxylic acid, 3-ethyl 5-methyl ester	calcium antagonist	hypertension
amosulalol; YM 09538; LOWGAN	5-[1-hydroxy-2-[[2- (2- methoxyphenoxy)ethyl] amino]ethyl]-2- methylbenzenesulfon amide	alpha adrenergic antagonist; beta adrenergic antagonist	hypertension
amylin agonists, Amylin		amylin agonist	diabetes

amyloid production inhibitors, Neurochem			Alzheimer disease; diabetes
angiotensin II receptor antagonist, Yuhan		angiotensin II antagonist	hypertension
angiotensinogen based therapy, Myriad; AGT gene-based therapy, Myriad; hypertension therapy, Myriad			hypertension
antiatherosclerotic agents, Allelix		biotechnology	atherosclerosis; hyperlipidemia
antihypertensive, Central Drug Research Institute	1-((3-methylphenyl)piperazin-1-yl)-3-(thio(4-acetamido)phenyl)-propane		hypertension
antihypertensive, Georgia Institute of Technology			hypertension
antihypertensive, Uppsala University; ALT 462	4-amino-2,4-dihydro-5-(1-methylethyl)-3H-1,2,4-triazol-3-one hydrazone		hypertension
antihypertensive, Yamasu Shoyu	2-hexynyladenosine (2-H-Ado)	adenosine agonist; adenosine A2 agonist	hypertension
antihypertensive, Yamasu Shoyu	2-octynyladenosine (2-O-Ado)	adenosine agonist; adenosine A2 agonist	hypertension
antisense oligonucleotide, angiotensinogen		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	hypertension
AOD 9604			obesity

apoptosis-inducing antigen, diabetes; IG 2; IG2		immunosuppressant; biotechnology; apoptosis inducer	diabetes
apraclonidine; p-aminoclonidine; aplonidine; ALO 2145; NC 14; IOPIDINE	2,6-dichloro-N'-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine	alpha adrenergic agonist; alpha2 adrenergic agonist	glaucoma; hypertension
AR H039242XX			diabetes; atherosclerosis
aranidipine; MPC 1304; SAPRESTA; BEC BM; BEC MARUKO; BEC	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid, methyl 2-oxopropyl ester	calcium antagonist	hypertension
arotinolol; S 596; ALMARL; ANBROTH; ACEMAIL; ALOCHINON; AMOPSOL; AROTINOIL; ASTONIL; LISTERIA	(+,-)-5-[2-[[3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl]thio]-4-thiazolyl]-2-thiophenecarboxamide	beta adrenergic antagonist	glaucoma; hypertension
ascorbyl gamolenate; ascorbyl gammalinolenic acid; SC 103		aldose reductase inhibitor	diabetes; neuropathy; sexual dysfunction
AT 112	2,3-dihydro-2-[(4-phenyl-1-piperazinyl)methyl]imidazo[1,2-c]quinazolin-5(6H)-one	alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	thrombosis; hypertension

atorvastatin; atorvastatin calcium; CI 981; PD 1342 98; YM 548; LIPITOR; SORTIS	[R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid	HMG CoA reductase inhibitor	hyperlipidemia
atpenin B	[S-(R*,S*)]-3-(2,4-dimethyl-1-oxohexyl)-4-hydroxy-5,6-dimethoxy-2(1H)-pyridinone	antifungal	hyperlipidemia; mycosis
atrinisitol; PP 56	D-myo-inositol 1,2,6-tris(dihydrogen phosphate)	chelating agent; NSAID	inflammation; hyperlipidemia
AXC 0216		neuropeptide Y antagonist	obesity; hypertension
AXC 1829		neuropeptide Y antagonist	obesity; hypertension
AXC 4047			diabetes
AXOKINE		biotechnology; growth factor; neurotrophic factor	amyotrophic lateral sclerosis; obesity; eye disease
AY 31637	5-(2-naphthalenylsulfonyl)-2,4-thiazolidine-dione		diabetes
AZM 090			obesity
AZM 119		lipase inhibitor	obesity; atherosclerosis
AZM 131		lipase inhibitor	obesity
AZM 133			obesity; gastrointestinal disorder
AZM 134			obesity; diabetes
AZM 140		amylase inhibitor	obesity; diabetes

BAL ARI8	7-fluoro-2-(N-methyl-N-carboxymethyl)sulfa moyl xanthone	aldose reductase inhibitor	diabetes; retinopathy
barnidipine; mepirodipine; YM 09730; YM 097305; YM 730; HYPOCA; OLDECA	[S-(R*,R*)]-1,4- dihydro-2,6-dimethyl- 4-(3-nitrophenyl)-3,5- pyridinedicarboxylic acid methyl 1- (phenylmethyl)-3- pyrrolidinyl ester	calcium antagonist; vasodilator	hypertension; ischemia
BAY 102987		HMG CoA reductase inhibitor	hyperlipidemia
BAY 139952			hyperlipidemia
BAY 194798			atherosclerosis; hyperlipidemia
BAY 279955		glucagon antagonist	diabetes
BAY w 9533		HMG CoA reductase inhibitor	hyperlipidemia
BAY x 2678		HMG CoA reductase inhibitor; cholesterol synthesis inhibitor	hyperlipidemia
beauvericin	1,7,13-trioxa-4,10,16- triazacyclooctadecane cyclic peptide derivative	ACAT inhibitor; antibiotic; peptide	bacterial infection; hyperlipidemia
belfosdil; SR 7037; BMY 21891	[2-(2-phenoxyethyl)- 1,3- propanediyl]bisphosp honic acid tetrabutyl ester	calcium antagonist	hypertension
benazepril; benazepril hydrochloride; benzazepril; CGS 148247; CIBACEN; LOTENSIN; BRIEM; ZINADRIL; TENSANIL; CIBACENE	[S-(R*,R*)]-3-[[1- (ethoxycarbonyl)-3- phenylpropyl]amino]- 2,3,4,5-tetrahydro-2- oxo-1H-1- benzazepine-1-acetic acid	ACE inhibitor	hypertension

benazepril + hydrochlorothiazide; hydrochlorothiazide + benazepril; CIBADREX; LOTENSIN HCT		ACE inhibitor; diuretic	hypertension
benidipine; nakadipine; nacadipine; KW 3049; CONIEL	(R*,R*)-(+,-)-1,4- dihydro-2,6-dimethyl- 4-(3-nitrophenyl)-3,5- pyridinedicarboxylic acid methyl 1- (phenylmethyl)-3- piperidinyl ester	calcium antagonist; vasodilator	hypertension; angina
beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro- 2-hydroxy-1-(3- hydroxy-4-methyl-1- octen-6-ynyl)-1H- cyclopenta[b]benzofu ran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
beta3 adrenergic receptor agonists, Pfizer		beta3 adrenergic agonist; beta adrenergic agonist	obesity
betaxolol; betaxolol hydrochloride; SL 75212; MCI 144; ABAXON; KERLONE; BETOPTIC; KERLONG; GLAUTAXOL; BERTOCIL; OPTIPRES; BETASEL; BEOF NICOLICH; LOKREN	1-[4-[2- (cyclopropylmethoxy) ethyl]phenoxy]-3-[(1- methylethyl)amino]- 2-propanol	beta adrenergic antagonist	glaucoma; hypertension; angina
betaxolol + chlortalidone; chlortalidone + betaxolol; KERLEDEX		beta adrenergic antagonist; diuretic	hypertension

bevantolol; bevantolol hydrochloride; CL 775; NC 1400; VANTOL; CALVAN; RANESTOL	(+,-)-1-[(3,4- dimethoxyphenethyl) amino]-3-(m- tolylloxy)-2-propanol	beta adrenergic antagonist	hypertension
bexarotene; LGD 1069; LG 100069; LG 1069; LDG 1069; TARGRETIN	4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8- tetrahydro-2- naphthenyl)-1-et henyl]-benzoic acid	retinoid; differentiation inducer; RXR agonist	cancer; diabetes; psoriasis; skin disease
biamine			obesity
BIBX 245			hyperlipidemia
bisoprolol; bisoprolol fumarate; EMD 33512; CL 297939; CONCOR; EMCOR; EMCORE; MONOCOR; ISOTEN; SOPROL; DETENSIEL; MAINTATE; ISOBLOC; ZEBETA	1-[(1- methylethyl)amino]- 3-[4-[[2-(1- methylethoxy)ethoxy] methyl]phenoxy]-2- propanol	beta adrenergic antagonist	hypertension; heart failure
bisoprolol + hydrochlorothiazide; hydrochlorothiazide + bisoprolol; EMD 47378; ZIAC; CONCOR PLUS; EMCORECTIC; FONDRIL; MONOZIDE		beta adrenergic antagonist; diuretic	hypertension
BMS 188494	2,2- dimethylpropanoic acid [[4-(3- phenoxyphenyl)-1- sulfoethyl]phosphinyl idene]bis(oxymethyle ne) ester	squalene synthetase inhibitor	hyperlipidemia



BMS 189921		ACE inhibitor; matrix metalloproteinase inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
BMS 194449		beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BMS 196085	N-[5-[(1R)-2-[(1R)-1-[4-(difluoromethoxy)phenyl]-2-phenylethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BMS 201038	Unspecified	microsomal transfer protein inhibitor	hyperlipidemia
BMS 201620		beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BMS 210285		beta adrenergic agonist; beta3 adrenergic agonist	obesity
BMS 212122		microsomal transfer protein inhibitor	hyperlipidemia
BNP 9010			hyperlipidemia
BOF 6721			hyperlipidemia
BOF 6766			hyperlipidemia
bopindolol; LT 31200; SANDONORM	(+,-)-1-[(1,1-dimethylethyl)amino]-3-[(2-methoxy)-1H-indo-4-yl]oxy]-2-propanol, benzoate	beta adrenergic antagonist	hypertension
bovine cerebral ganglioside; E 0704; CRONASSIAL		ganglioside	neuropathy; diabetes

BST 4001; PYRIDORIN			diabetes; kidney disease
BTS 78050			obesity
bunazosin; bunazosin hydrochloride; E 643; DE 070; E 1015; DETANTOL; DETANTOL R; ANDANTE	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-butyrylhexahydro-1H-1,4-diazepine	alpha adrenergic antagonist; alpha 1 adrenergic antagonist	hypertension; glaucoma; benign prostate hypertrophy
butabindide; UCL 1397	[S-(R*,R*)]-1-(2-Amino-1-oxobutyl)-N-butyl-2,3-dihydro-1H-indole-2-carboxamide	serine proteinase inhibitor	obesity
C-peptide analogues		peptide	diabetes; kidney disease
calcitonin gene-related peptide (CGRP) receptor modulators, SKBeecham			migraine; diabetes
candesartan; CV 11974	2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist; imidazole	hypertension
candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMLAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease

candoxatril; UK 79300	4-[[[1-[3-[(2,3-dihydro-1H-inden-5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]-cyclohexanecarboxylic acid	atriopeptidase inhibitor	hypertension; heart failure
capsaicin; ZOSTRIX; ZOTRIX HP; THERAGEN; THERAGEN HP; CAPSIDOL; LION PLASTER	(E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide	analgesic	pain; neuropathy; diabetes
captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
cardiovascular disease therapy, Cytokinetics			hypertension; heart failure
carteolol; OPC 1085; ABBOTT 43326; ARTEOPTIC; CARTEOL; CARTROL; ENDAK; MERCATOA; MIKELAN; ORUKALOL; PALSIT; TENALET; TENALIN	5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydroquinolinone	beta adrenergic antagonist; beta adrenergic antagonist	glaucoma; hypertension

carvedilol; karvedilol; BM 14190; DQ 2466; KREDEX; COREG; DILATREND; DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC	1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol	beta adrenergic antagonist	hypertension; angina; heart failure
celiprolol; NPB 582; ST 1396; REV 5320A; SELECTOL; CELECTOL	N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethylurea	beta adrenergic antagonist; beta2 adrenergic partial antagonist; vasodilator	hypertension; nephritis
cerivastatin; rivastatin; BAY w 6228; LIPOBAY; BAYCOL; LIPOSTEROL; CERVASTA; VASLIP	[S-[R*,S*-(E)]]-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid	HMG CoA reductase inhibitor	hyperlipidemia
CGP 26214		LDL regulator	hyperlipidemia; atherosclerosis
CGP 60536B; CGS 60536	[alphaS-(alphaR*,gammaR*,deltaR*,zetaR*)]-delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)benzeneoctanamide	renin inhibitor	hypertension
CHOLESS		immunostimulant	hyperlipidemia

CI 996	2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
CI 999	[[2,6-bis(1-methylethyl)phenoxy]sulfonyl]carbamic acid 2,6-bis(1-methylethyl)phenyl ester sodium salt	ACAT inhibitor	hyperlipidemia
cicletanine; cycletanide; BN 1270; RU 270; WIN 90000; TENSTATEN; JUSTAR	3-(4-chlorophenyl)-1,3-dihydro-6-methylfuro[3,4-c]pyridin-7-ol	diuretic	hypertension
cilazapril; Ro 312848; Ro 312848 006; INHIBACE; VASCACE; DYNORM	(1S,9S)-9-[[[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid	ACE inhibitor	hypertension
cilnidipine; cinaldipine; FRC 8653; SISCARD; CINALONG; ATELEC	(E)-(+,-)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 3-phenyl-2-propenyl ester	calcium antagonist	hypertension
ciprofibrate; WIN 35833; LIPANOR; HYPERLIPEN; MODALIM; ESTAPROL	2-(p-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropionic acid	fibrate	hyperlipidemia
CK 3363; CK 3368		bile acid sequestrant	hyperlipidemia

CKD 705			hypertension
CL 314698	(R*,R*)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid dimethyl ester	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
CMDM	meso-2,6-bis(carboxymethyl)-4,4-dimethylmorpholinium bromide	carnitine acetyltransferase inhibitor	diabetes
CMI 477	(1S-exo)-2-(6-chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane	cholinergic agonist; nicotinic agonist; analgesic	obesity; depression; Alzheimer disease; nicotine withdrawal
colesevelam hydrochloride; GT 31-104HB; GT 31-104; CholestaGel	N,N,N-trimethyl-6-(2-propenylamino)-1-hexanaminium chloride polymer with (chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine hydrochloride	bile acid sequestrant	hyperlipidemia
corticotrophin releasing factor (CRF) agonists, Neurogen			obesity
CP 105191	(S)-2-(hexylthio)-N-[6-(methylthio)-5-quinolinyl]decanamide	ACAT inhibitor	hyperlipidemia
CP 113818	(S)-(2)-(hexylthio)-N-[6-methyl-2,4-bis(methylthio)-3-pyridinyl]decanamide	ACAT inhibitor	hyperlipidemia

CP 71362	[2R-(2R*,4S*,5S*)]-N-[N2-[6-cyclohexyl-5-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-4-hydroxy-2-(2-methylpropyl)-1-oxohexyl]-L-lysyl]-L-phenylalanine	renin inhibitor	hypertension
CP 80629		beta3 adrenergic agonist; beta adrenergic agonist	diabetes
CP 83101	[R*,S*-(E)]-(+,-)-3,5-dihydroxy-9,9-diphenyl-6,8-nonadienoic acid methyl ester	HMG CoA reductase inhibitor	hyperlipidemia
CP 95253		peptide	diabetes
CR 2991		alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
CV 11194; EP 425921A	2-butyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist; imidazole	hypertension
cyclazosin	Cis-1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)decahydroquinoxaline monohydrochloride	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
cyclothiazomycin	cyclothiazomycin	renin inhibitor; antibiotic	hypertension

delapril; alindapril; CV 3317; REV 6000A; ADECUT; CUPRESSIN; KEDAPRIL; DELAKET	(S)-N-(2,3-dihydro- 1H-inden-2-yl)-N-[N- [1-(ethoxycarbonyl)- 3-phenylpropyl]-L- alanyl]glycine	ACE inhibitor	hypertension
delapril + indapamide; indapamide + delapril; CHF 1513; DELAPRIDE		ACE inhibitor; diuretic	hypertension
denileukin difitox; interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion protein; DAB 389-IL- 2; LY 335348; DAB389IL2; ONTAK	1-388-toxin (Corneybacterium diphtheriae strain C7), N-L-methionyl- 387-L-histidine-388- L-alanine-, (388.fwdarw.2')- protein with 2-133- interleukin 2 (human clone pTIL2-21a)	biotechnology; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; psoriasis; cancer
dexfenfluramine; dexfenfluramine hydrochloride; S 5614; IP 001; ISOMERIDE; ADIFAX; ARDIX; ISOLIPAN; SIRAN; OBESINE; FLURIL; DISPONDAL; REDUX	(S)-N-ethyl-alfa- methyl-3- (trifluoromethyl)benz eneethanamine	5HT reuptake inhibitor	obesity; depression; nicotine withdrawal
DF 100	4-(3,5-dimethyl-1H- pyrazol-1-yl)-2,5- dihydro-1H- pyridazino[4,5- b]indol-1-one hydrazone monohydrochloride		hypertension
diabetes therapy, Allergan/Parke Davis		retinoid	diabetes



diabetes therapy, Cell Therapeutics/City of Hope National Medical Center		antioxidant	diabetes
diabetes therapy, Cornell Research Foundation			diabetes
diabetes therapy, DeveloGen		transcription activator	diabetes
diabetes therapy, Dr Reddy's Research Foundation/Novo Nordisk			diabetes; obesity; hyperlipidemia
diabetes therapy, HNF-4 based, Ligand/Lilly			diabetes; cardiovascular disease
diabetes therapy, Kyoto University	(SP-5-21)-oxobis(1-pyrrolidinecarbodiithioato-S,S')vanadium	insulin mimetic	diabetes
diabetes therapy, Lipha/Ono			diabetes
diabetes therapy, Metabolex			diabetes
diabetes therapy, Metabolix/Parke Davis			diabetes
diabetes therapy, Novo Nordisk/ACADIA			diabetes
diabetes therapy, Novo Nordisk/Takeda			diabetes
diabetes therapy, Novo Nordisk/Trega Biosciences			diabetes
diabetes therapy, OSI			diabetes

diabetes therapy, Telik/Sanwa Kagaku		insulin sensitizer	diabetes
diabetes therapy, Vita Invest			diabetes
DiavaX; IDDM-AnergiX		biotechnology	diabetes
dicentrine; d-dicentrine; (+)-dicentrine; eximine; O,N-dimethylitseferine	(S)-6,7,7a,8-tetrahydro-10,11-dimethoxy-7-methyl-5H-benzo[g]-1,3-benzodioxolo[6,5,4-de]quinoline	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
digitoxigenin-PC		cardiac glycoside	heart failure; hypertension
diltiazem analogue, Tanabe; 1058		calcium antagonist	hypertension
diltiazem malate + enalapril; enalapril + diltiazem malate; TECZEM		calcium antagonist; ACE inhibitor	hypertension
ditekiren; U 71038	[1S-[1R*,2R*,4R*(1R*,2R*)]]-1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-L-phenylalanyl-N-[2-hydroxy-5-methyl-1-(2-methylpropyl)-4-[[[2-methyl-1-[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-N-alfa-methyl-L-histidinamide	renin inhibitor	hypertension
dopamine D1/D2 agonists, Ergo Science		dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	obesity; diabetes

doxazosin; UK 33274; UK 3327427; CARDURA; CARDENALIN; SUPRESSIN; CARDURAN; DIBLOCIN; DOXABEN; NORMOTHEN; DEDRALEN; ALFADIL	1-(4-amino-6,7-dimethoxy-2-quinazoliny1)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperizine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	benign prostate hypertrophy; hypertension
DRF 2725		insulin sensitizer	diabetes; hyperlipidemia
drug delivery system, alliinase + alliin; alliinase + alliin delivery system		biotechnology	hyperlipidemia
drug delivery system, BEODAS insulin; insulin BEODAS		hormone	diabetes
drug delivery system, COER-24 oral verapamil; verapamil COER-24; OROS verapamil; COER-24 verapamil; COVERA-HS; CHRONOVERA; CRONOVERA		calcium antagonist	hypertension; angina
drug delivery system, controlled release antidiabetic; antidiabetic, GEOMATRIX			diabetes
drug delivery system, controlled release diltiazem; diltiazem controlled release; TIAZAC; VIAZEM		calcium antagonist	hypertension; angina

drug delivery system, controlled release GEOMATRIX glibenclamide; glibenclamide GEOMATRIX		sulfonylurea	diabetes
drug delivery system, controlled release glibenclamide; glibenclamide controlled release; Glynase PresTab		sulfonylurea	diabetes
drug delivery system, dopamine; dopamine delivery system; NMI 8739; DOPREXIN			obesity; Parkinson disease
drug delivery system, GEOMATRIX controlled release glipizide; glipizide GEOMATRIX		sulfonylurea	diabetes
drug delivery system, GEOMATRIX controlled release nifedipine; nifedipine GEOMATRIX		calcium antagonist	hypertension; angina
drug delivery system, GEOMATRIX controlled release verapamil; verapamil GEOMATRIX		calcium antagonist	hypertension
drug delivery system, GITS glipizide; glipizide GITS; GLUCOTROL XL; GLUCOTROL GITS		sulfonylurea	diabetes

drug delivery system, insulin secreting implant; insulin secreting implant; EndoCRIB		hormone	diabetes
drug delivery system, insulin secreting implant; insulin secreting implant		hormone	diabetes
drug delivery system, insulin subcutaneous implant; insulin subcutaneous implant		hormone	diabetes
drug delivery system, insulin-producing beta cells		hormone	diabetes
drug delivery system, liposome oleoyl- estrone; oleoyl- estrone liposome			obesity
drug delivery system, MEDUSA insulin; insulin MEDUSA; BASULIN		hormone; biotechnology	diabetes
drug delivery system, MICROPUMP oral controlled release atenolol; atenolol MICROPUMP; ATENAX		beta adrenergic antagonist	hypertension
drug delivery system, oral copolymer insulin; insulin oral		hormone	diabetes
drug delivery system, oral glucagon-like peptide-1		biotechnology; peptide	diabetes

drug delivery system, oral insulin; insulin oral delivery system		hormone	diabetes
drug delivery system, oral insulin; insulin oral; ORALIN; ORALGEN		biotechnology; hormone	diabetes
drug delivery system, oral nanosphere insulin; insulin oral		hormone	diabetes
drug delivery system, OROS oral controlled release isradipine; isradipine OROS; DynaCirc CR		calcium channel blocker	hypertension
drug delivery system, OROS prazosin; prazosin OROS; CP 122991; MINIPRESS XL; ALPRESS LP		alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
drug delivery system, OSAT nifedipine; nifedipine sustained release		calcium antagonist	hypertension; angina
drug delivery system, phospholipase A2; phospholipase A2 delivery system; drug delivery system, PLA2		enzyme	hyperlipidemia
drug delivery system, PROTEIMER insulin; insulin, PROTEIMER; PROTEIMER insulin		hormone	diabetes
drug delivery system, SODAS captopril; captopril SODAS		ACE inhibitor	heart failure; hypertension

drug delivery system, sustained release diltiazem; diltiazem sustained release; DILACOR XR		calcium antagonist	hypertension
drug delivery system, sustained release diltiazem; diltiazem sustained release; DILTELAN; CARDIZEM CD; HERBESSER R; DILZEM OD; TIAZEM SR		calcium antagonist	hypertension
drug delivery system, sustained release diltiazem malate; diltiazem malate sustained release		calcium antagonist	hypertension
drug delivery system, sustained release niacin; niacin sustained release; NIASPAN			hyperlipidemia
drug delivery system, sustained release nifedipine; nifedipine once daily; INDAS nifedipine; NIFENSAR XL; ADALAT SR; UNIDIPINE; NIFELAN; ADALAT OROS		calcium antagonist	angina; hypertension
drug delivery system, transdermal clonidine; clonidine transdermal; M 5041T		alpha adrenergic agonist	hypertension

drug delivery system, transdermal insulin; insulin transdermal		hormone	diabetes
drug delivery system, TRANSFERSOMES transdermal insulin; TRANSFERSULIN		biotechnology	diabetes
drug delivery system, Zot oral insulin; insulin oral		hormone	diabetes
drug discovery, Trega Biosciences; drug discovery, Chugai		NSAID	inflammation; diabetes; cardiovascular disease; neurological; cancer; infectious disease
DY 9708	[1R-[1 alpha,2(3S*,4R*),6al pha]]-3,4-dihydro-3- hydroxy-2,2-dimethy l-4-[(5-oxo-3,4- diazabicyclo[4.1.0]he pt-2-en-2-yl)oxy]-2H- 1-benzopyran-6- carbonitrile	potassium channel activator; vasodilator	hypertension; angina
E 4010	4-[[[(3-chloro-4- methoxyphenyl)meth y]amino]-1-(4- hydroxy-1-piperid inyl)-6- phthalazinecarbonitril e monohydrochloride	dopamine agonist; dopamine D1 agonist; phosphodiesterase inhibitor; phosphodiesterase V inhibitor	pulmonary hypertension; sexual dysfunction
efonidipine; selefodipine; NZ 105; LANDEL	5-(5,5-dimethyl- 1,3,2- dioxaphosphorinan-2- yl)-1,4-dihydro-2,6- dim ethyl-4-(3- nitrophenyl)-3- pyridine-carboxylic acid, 2- [phenyl(phenylmethyl )amino] ethyl ester, P- oxide	calcium antagonist	hypertension; angina; cerebrovascular disease



emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease
EMD 61650	2-butyl-3,5-dihydro-5-(phenylmethyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4H-imidazo[4,5-c]pyridin-4-one		hypertension
EMD 66684	2-butyl-4,5-dihydro-4-oxo-3[[2'-(1H-tetrazol-5-yl)-4-biphenyl]methyl]-3H-imidazo[4,5-C]pyridine-5-(N,N-dimethylacetamide)		hypertension
EMD 94246	N-2,1,3-benzothiadiazol-5-yl-5-(dimethylamino)-1-naphthalenesulfonamide, potassium salt	endothelin antagonist	hypertension
enalapril; MK 421; INNOVACE; COVERTEN; ENAPREN; RENITEN; VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE	(S)-1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline	ACE inhibitor	hypertension
endothelin antagonists, Novartis		endothelin antagonist	hypertension

englitazone; englitazone sodium; CP 68722; CP 72466; CP 72467; CP 724672	(-)-5-[[[(2R)-2-benzyl- 6-chromanyl]methyl]- 2,4-thiazolidinedione	insulin sensitizer	diabetes; hyperlipidemia
epalrestat; ONO 2235; KINEDAK	(Z,E)-5-(2-methyl-3- phenyl-2- propenylidene)-4- oxo-2-thioxo-3- thiazolidineacetic acid	aldose reductase inhibitor	neuropathy; kidney disease; eye disease; diabetes
epoprostenol; epoprostenol sodium; prostacyclin; prostaglandin X; prostaglandin I <sub>2</sub> ; UN 53217A; U 53217; FLOLAN; CYCLO- PROSTIN	(5Z,9 $\alpha$ ,11 $\alpha$ ,13E, 15S)-6,9-epoxy- 11,15- dihydroxyprosta- 5,13-dien-1-oic acid	platelet antiaggregant; vasodilator; prostanoid	pulmonary hypertension; thrombosis
eprosartan; eprosartan mesylate; SB 108566; SKF 108566; SKF 108566 J; TEVETEN	(E)- $\alpha$ -[[[2-butyl-1- [(4- carboxyphenyl)methyl- 1]-1H-imidazol-5- yl]methylene]-2- thiophenepropanoic acid	angiotensin II antagonist	hypertension; kidney disease; heart failure
ER 3295		ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
erythritol; NIK 242	1,2,3,4-butanetetrol		hypertension

ES 1005	[1S-[1R*(R*),2R*,4[R*(R*)]]-N-[4-[[1-[(5-amino-6-hydroxyhexyl)amino]carbonyl]-3-methylbutyl]amino]-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-alfa-[[3-(1-naphthalenyl)-2-(1-naphthalenylmethyl)-1-oxopropyl]amino]-1H-imidazole-4-propanamide dihydrochloride	renin inhibitor; peptide	hypertension
ES 8891	5-cyclohexyl-2,4,5-trideoxy-N-hexyl-4-[[N-[3-(1-naphthalenyl)-N-(4-morpholinylacetyl)-L-alanyl]-3-(4-thiazolyl)-L-alanyl]amino]-L-threo-pentonamide	renin inhibitor	hypertension
esatenolol; atenolol, (S)-; (S)-atenolol; (-)-atenolol	(S)-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide	beta adrenergic antagonist	hypertension
esmolol; ASL 8052; ASL 8123; BREVIBLOC	4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzenepropanoic acid methyl ester	beta adrenergic antagonist	hypertension; arrhythmia
ethyl eicosapentaenoate; ethyl icosapentate; EPA-E; MND 21; EPADEL	ethyl all-cis-5,8,11,14,17-eicosapentaenoate	platelet antiaggregant	thrombosis; hyperlipidemia
exendin 4; exendin-4; AC 2993		peptide	diabetes
exendin agonists, Amylin		peptide	diabetes

exendin agonists, Amylin			diabetes
EXP 3174; E 3174	2-butyl-4-chloro-1- [[[2'-(1H-tetrazol-5- yl)[1,1'-biphenyl]-4- yl]methyl]-1H- imidazole-5- carboxylic acid	angiotensin II antagonist	hypertension
F 1394	N-[(2,2,5,5- tetramethyl-1,3- dioxan-4- yl)carbonyl]-beta- alanine, 2-[[[2,2- dimethylpropyl)nonyl amino]carbonyl]amin ocyclohexyl ester	ACAT inhibitor	atherosclerosis; hyperlipidemia
fagopyritols			diabetes
fagopyritols, Cornell Research Foundation			diabetes
fatty acids, microalgal, Martek			hyperlipidemia; Parkinson disease; Alzheimer disease; eye disease
FCP 3P1			atherosclerosis; hyperlipidemia
felodipine; H 15482; HOE 869; CGH 869; HYDAC; PLENDIL; VASOPINE; SPLENDIL; MUNOBAL; FLODIL	4-(2,3- dichlorophenyl)-1,4- dihydro-2,6-dimethyl- 3,5- pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist; vasodilator; diuretic	hypertension; angina; heart failure; atherosclerosis
felodipine + enalapril; enalapril + felodipine; LEXXEL		calcium antagonist; ACE inhibitor	hypertension

felodipine + metoprolol; metoprolol + felodipine; LOGIMAX		calcium antagonist; beta adrenergic antagonist	hypertension; angina
felodipine + ramipril; ramipril + felodipine; HOE 9869; UNIMAX; TAZKO		calcium antagonist; ACE inhibitor	hypertension
fenofibrate; fenofibrato; procetofene; LF 178; LIPANTHYL; LIPANTIL; LIPIDIL; LIPSIN; NORMALIP; BISTEROL; NORMOLIP; PROMERAL; LIPCOR; TRICOR	2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methylethyl ester	fibrate	hyperlipidemia
fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM	6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenol)-1H-3-benzazepine-7,8-diol	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	hypertension; glaucoma; kidney disease; heart failure
fidarestat; SNK 860; SK 860	(2S-cis)-6-fluoro-2,3-dihydro-2',5'-dioxospiro[4H-1-benzopyran-4,4'-imidazolidine]-2-carboxamide	aldose reductase inhibitor	diabetes
fluasterone		immunosuppressant	cancer; diabetes; systemic lupus erythematosus
fluvastatin; fluidostatin; XU 62320; LESCOL; LOCOL; LOCHOL; FRACTAL	[R*,S*-(E)]-(+,-)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid	HMG CoA reductase inhibitor	hyperlipidemia

fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 prodrug; MONOPRIL; DYNACIL; FUSINORM; FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC	[1[S*(R*)],2alpha.,4b eta]-4-cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl]acetyl]-L-proline	ACE inhibitor	hypertension
fosinopril + hydrochlorothiazide; hydrochlorothiazide + fosinopril; TENSOZIDE; MONOPRIL-HCT; FOSICOMP		ACE inhibitor; diuretic	hypertension; heart failure
FPL 69931			obesity
fructose 1,6-bisphosphatase inhibitors, Ontogen			diabetes
furnidipine; CRE 319	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl (tetrahydro-2-furanyl)methyl ester	calcium antagonist	hypertension; angina; reperfusion injury
galanin modulators, Synaptic		analgesic	obesity; diabetes; cognitive defect; pain
galanin receptor modulators, Pharmacopeia			obesity
galanin1 antagonists, Neurogen		analgesic	obesity; pain; cognitive defect

gallopamil; D 600; PROCORUM; CORAPAMIL; ALGOCOR	5-[(3,4-dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile	calcium antagonist	hypertension; angina; arrhythmia
gemfibrozil; CI 719; CS 719; LOPID; ZILOP; IPOLIPID; MARISTON; DELIPID; SCANTIPID	5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid	fibrate	hyperlipidemia
gene discovery, cardiovascular disease, GenSet			hypertension
gene discovery, cardiovascular disorders, AlphaGene			heart failure; hypertension; stroke
gene discovery, connective tissue disorders			cancer; diabetes; obesity; autoimmune disease
gene discovery, diabetes			diabetes
gene discovery, diabetes, BioStratum			diabetes; kidney disease
gene discovery, diabetes, Glaxo Wellcome/Axys			diabetes
gene discovery, diabetes, LifeSpan			diabetes
gene discovery, diabetes, Lilly			diabetes
gene discovery, diabetes, Millennium/Roche			diabetes

gene discovery, insulin signalling pathway			diabetes
gene discovery, metabolic disease, deCODE genetics			diabetes
gene discovery, metabolic disorders, AlphaGene			obesity; diabetes; osteoporosis
gene discovery, noninsulin dependent diabetes (NIDDM)			diabetes
gene discovery, obesity			obesity
gene discovery, obesity and diabetes, CuraGen			obesity; diabetes
gene discovery, obesity, Amplicon			obesity
gene discovery, obesity, Axys			obesity
gene discovery, obesity, Exelixis			obesity
gene discovery, obesity, Millennium/Roche			obesity
gene discovery, obesity, Myriad; gene discovery, obesity, Bayer			obesity
gene discovery, type II diabetes, Amplicon			diabetes
gene therapy, adrenomedullin; gene therapy, hypertension		gene therapy; biotechnology	hypertension



gene therapy, antisense, AT1; antisense oligonucleotide, AT1; antisense oligonucleotide, hypertension		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide; gene therapy	hypertension
gene therapy, cytokines, Stanford University; gene therapy, autoimmune disease		biotechnology; gene therapy; cytokine; immunosuppressant	autoimmune disease; rheumatoid arthritis; diabetes; multiple sclerosis
gene therapy, diabetes		gene therapy; biotechnology	diabetes
gene therapy, diabetes, GenEra		biotechnology; gene therapy; hormone	diabetes
gene therapy, diabetes, University of California at San Francisco		biotechnology; gene therapy	diabetes
gene therapy, insulin		biotechnology; gene therapy; hormone	diabetes
gene therapy, insulinotropin		gene therapy; biotechnology	diabetes
gene therapy, LDL receptor; gene therapy, hyperlipidemia		biotechnology; gene therapy	hyperlipidemia
gene therapy, LDL receptor; gene therapy, hypercholesterolemia		biotechnology; gene therapy	hyperlipidemia
gene therapy, LDL receptor; gene therapy, hypercholesterolemia		biotechnology; gene therapy	hyperlipidemia

GI 248573		cholecystokinin A agonist	obesity; cholestasis
glimepiride; HOE 490; AMARYL	trans-3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide	sulfonylurea	diabetes
GLP1 agonists, Neurogen			obesity; diabetes
glucagon; glucagon G; GlucaGen	His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr	biotechnology; hormone	diabetes
glucagon hydrochloride; GLUCAGON		biotechnology; hormone	diabetes
glucagon receptor inhibitors		glucagon antagonist	diabetes
glucagon-like peptide; GLP-1		peptide	diabetes
glucagon-like peptide-1 mimetic			diabetes
glucagon-like peptide1; GLP 1		biotechnology; insulin secretagogue; peptide	diabetes
glucocorticoid receptor antagonists, Karo Bio			diabetes

glutamic acid decarboxylase, Genzyme; type 1 diabetes therapy, Genzyme		biotechnology; enzyme	diabetes
glycopril	N-[(2S)-3- (acetylthio)-2-(1,3- benzodioxol-5- ylmethyl)-1- oxopropyl]glycine phenylmethyl ester	ACE inhibitor; enkephalinase inhibitor	hypertension
GM 1306		growth factor modulator	diabetes; retinopathy; cancer
GR 328713		microsomal transfer protein inhibitor	hyperlipidemia
GW 1929	N-(2-benzoylphenyl)- O-[2-(methyl-2- pyridinylamino)ethyl] -L-tyrosine	PPAR agonist	diabetes
GW 9820		PPAR agonist; fibrate	diabetes
GYKI 46544	Unspecified	calcium antagonist	hypertension
gypsetin	(5aalfa,7aalfa,8abeta, 13abeta,15aalfa,16aal fa)-5a,13a-bis(1,1- dimethyl-2-propenyl)- 5a,8,8a,13,13a,15a,16 ,16a-octahydro- 8a,16a- dihydroxypyrazino[1" ,2":1,5;4",5":1',5']dipy rrolo[2,3-b:2',3'- b']diindole- 7,15(5H,7aH)-dione	ACAT inhibitor	hyperlipidemia
HL 004; TS 962	N-(2,6- diisopropylphenyl)-2- (tetradecylthio)aceta mide	ACAT inhibitor	atherosclerosis; hyperlipidemia

HOE 1423		biotechnology; insulin analogue	diabetes
HSR 175	R-(-)-5-[2[2-(5-fluoro-2-methoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; urinary incontinence
hyperlipidemia therapy, City of Hope National Medical Center			hyperlipidemia
hypoglycemic 2-oxiranecarboxylate derivatives, Seoul University	2-[6-(2-thienylmethoxy)hexyl]oxiranecarboxylic acid ethyl ester		diabetes
hypoglycemic, Pliva	N-(4-acetylaminophenylsulphonyl)-1,3-dioxepino[5,6-b]aziridine		diabetes
hypolipemic, North Carolina University; AMMCA	6-amino-1,2-dihydro-5-methyl-2-thioxo-4-pyrimidinecarboxylic acid	HMG CoA reductase inhibitor	hyperlipidemia
hypolipidemic, Sam II			hyperlipidemia
ICE inhibitor, IDUN		caspase inhibitor; apoptosis inhibitor; IL-1 beta converting enzyme inhibitor; immunosuppressant	transplant rejection; septic shock; rheumatoid arthritis; inflammatory bowel disease; diabetes
ilomastat; GM 6001; CS 610; GALARDIN; GALARDIN MPI	N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-butanediamide	matrix metalloproteinase inhibitor; proteinase inhibitor	retinopathy; diabetes; cancer

imidapril; TA 6366; EMD 61800; EMD 63100; TANATRIL; NOVALOC; NOVAROK; TANAPRESS; NORTEN	4S-[3-[R*(R*)],4R*]- 3-[2-[[1- (ethoxycarbonyl)-3- phenylpropyl]amino]- 1-oxopropyl]-1- methyl-2-oxo-4- imidazolidinecarboxy lic acid	ACE inhibitor	hypertension; heart failure; diabetes
indoramin; WY 21901; DORALESE; TILTAB; BARATOL; WYDORA; WYPRESIN; VIDORA	N-[1-[2-(1H-indol-3- yl)ethyl]-4- piperidiny]benzamid e	alpha adrenergic antagonist	hypertension; benign prostate hypertrophy
insulin agonists, Neurogen			diabetes
insulin B chain peptide, University of Colorado		peptide	diabetes
insulin glargine; HOE 901	human [A21-glycine, B31-arginine, B32- arginine] insulin	biotechnology; insulin analogue	diabetes
insulin lispro; lys-pro insulin; insulin analogue; LY 275585; HUMALOG	28B-L-lysine-29B-L- proline insulin (human)	biotechnology; insulin analogue	diabetes
insulin mimetics, oral, Biota		insulin mimetic	diabetes
insulin potentiating factor; IPF		insulin sensitizer	diabetes
insulin RTP antagonist, SUGEN		tyrosine phosphatase inhibitor	diabetes
insulin sensitizer, Recepton		insulin sensitizer	diabetes
insulin sensitizers, SmithKline Beecham		insulin sensitizer	diabetes

insulin, human; HR 1799; INSUMAN	Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn (chain A) Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr (B chain)	biotechnology; hormone	diabetes
insulin, human, BioTechnology General		biotechnology; hormone	diabetes
insulin-associated protein tyrosine phosphatase inhibitors, Ontogen			diabetes
insulin-dependent diabetes therapy, Procept		immunosuppressant	diabetes
insulinotropin; glucagon-like peptide 1; GLP-1; NNC 901170		biotechnology; hormone; peptide	diabetes
interleukin-1; IL-1		biotechnology; cytokine	diabetes
interleukin-4 receptor inhibitors, Affymax		cytokine inhibitor	asthma; diabetes
irbesartan; SR 47436; BMS 186295; APROVEL; KARVEA; AVAPRO	2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one	angiotensin II antagonist	hypertension; kidney disease; heart failure

irbesartan + hydrochlorothiazide; hydrochlorothiazide + irbesartan; AVALIDE; COAPROVEL; KARVEZIDE		angiotensin II antagonist; diuretic	hypertension; kidney disease
IRLS DR09			hypertension
IRLS DR12			hypertension
IRLS DR33			hypertension
islets of neogenesis-associated protein (INGAP)-based therapy, Lilly		biotechnology; gene	diabetes
isradipine; isradipine; PN 200110; PN 205033; PN 205034; PRESCAL; LOMIR; DynaCirc; VASCAL; ICAZ	4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester	calcium antagonist	hypertension; angina
J 104132; L 753037	[5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl-5-(1,3-benzodioxol-5-yl)-7-[(2-carboxy-propyl)-4-methoxyphenyl]-6,6-dihydro-5H-cyclopenta[b]pyridine-6-carboxylic acid	endothelin antagonist	hypertension
JMV 236	N-[(1,1-dimethylethoxy)carboxyl]-O-sulfo-L-tyrosyl-L-norleucylglycyl-L-tryptophyl-L-norleucyl-L-alpha-aspartyl-L-phenylalaninamide	cholecystokinin antagonist	hypertension

K 85; OMACOR			hyperlipidemia; restenosis
ketanserin; R 41468; SEREFREV; SUFREXAL; SEREFREX	3-[2-[4-(4-fluorobenzyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione	5HT antagonist; 5HT2 antagonist	hypertension
KP 102		insulin sensitizer	diabetes
KRN 4884	5-amino-N-[2-(2-chlorophenyl)ethyl]-N'-cyano-3-pyridinecarboximide	potassium channel activator	hypertension
KS 341; RKS 0341		adenosine antagonist	hypertension
L 159689	N-[3,4-dihydro-4-oxo-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-6-quinazolinyl]-N-pentylbenzamide	angiotensin II antagonist	hypertension
L 161177	2-ethyl-5,7-dimethyl-3-[[2'-(2-oxido-3H-1,2,3,5-oxathiadiazol-4-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazo[4,5-b]pyridine	angiotensin II antagonist	hypertension
L 162234	[[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]sulphonyl]carbamic acid 1,1-dimethylethyl ester	angiotensin II antagonist	hypertension



L 659699; F 244	[2R-[2alpha(2E,4E,7R*),3betaeta]]-11-[3-(hydroxymethyl)-4-oxo-2-oxetanyl]-3,5,7-trimethyl-2,4-undecadienoic acid	HMG CoA synthase inhibitor	hyperlipidemia
L 692429	3-amino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3(R)-yl]-butanamide	angiotensin II antagonist	hypertension
lacidipine; GR 43659; GR 43659X; SN 305; GX 1048; LACIPIL; VIAPRES; LACIREX; MOTENS; CALDINE; MIDOTENS; APONIL; ZASCAL; LACIMEN	(E)-4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester	calcium channel blocker	hypertension
laennec; human placenta hydrolysate			hypertension; liver disease
lanreotide; BIM 23014; DC 13116; BIM 23014C; BN 52030; SOMATULINE; ANGIOPEPTIN; DERMOPEPTIN; IPSTYL	3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2,7)-disulfide	somatostatin analogue	cancer; acromegaly; retinopathy; diabetes; psoriasis; restenosis
lateritin	4-methyl-6-(1-methylethyl)-3-phenylmethyl-1,4-perhydrooxazine-2,5-dione	ACAT inhibitor	hyperlipidemia
leptin agonists, Pharmacopeia; leptin agonists, Regeneron			obesity

leptin expression modulators			obesity
leptin modulator, Recepton			obesity
leptin receptor		biotechnology	anemia; obesity; diabetes
leptin signalling pathway modulators, Ligand			obesity
leptin, second generation, Amgen		biotechnology	obesity
lercanidipine; masnidipine; REC 152375; R 75; TJN 324; ZANIDIP; LERDIP; ZANEDIP; LERCADIP; CARDIOVASC; LERZAM	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic acid 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester	calcium antagonist	hypertension
leucomyzin		NSAID	inflammation; hyperlipidemia
levobunolol; W 7000A; AG 901; BETAGAN; VISTAGEN; GOTENSIN; VISTAGAN; LEVOGAN	(-)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1(2H)-naphthalenone	beta adrenergic antagonist	hypertension; glaucoma
LG 1411			diabetes
LGD 1268; ALRT 268		RXR agonist; retinoid agonist	diabetes
LGD 1324; ALRT 324		retinoid agonist; RXR agonist	diabetes

lidanserin; ZK 33839	(+,-)-4-[3-[3-[4-(p-fluorobenzoyl)piperidin-2-yl]propoxy]-4-methoxyphenyl]-2-pyrrolidinone	5HT antagonist; 5HT2 antagonist; alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease
lisinopril + hydrochlorothiazide; hydrochlorothiazide + lisinopril; PRINZIDE; PRINIVIL PLUS; CARACE; ZESTORETIC; ACECOMB; ACERCOMP		ACE inhibitor; diuretic	hypertension
LM 1554	2-chloromethyl-5,6,7,8-tetrahydrobenzo(b)thieno(2,3-d)pyrimidin-4 (3H)-one		hyperlipidemia
losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
losartan + hydrochlorothiazide; HYZAAR; LOSACOR D		angiotensin II antagonist; diuretic	hypertension

lovastatin; mevinolin; monakolin K; MK 803; MSD 803; MB 530B; L 154803; MEVACOR; MEVLOR; LOVACOL; HIPOVASTIN; DISLIPIN; LOVASTEROL; LINCIL	(S)-2-methylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia; cancer
LP 805	8-tert-butyl-6,7-dihydropyrrolo[3,2-e]-5-methylpyrazolo[1,5a]pyrimidine-3-carbonitrile	vasodilator	hypertension; angina
LR B139		angiotensin II antagonist	hypertension; angina
LY 197535		insulin analogue	diabetes
LY 203647	1-[2-hydroxy-3-propyl-4-[4-[2-[4-(1H-tetrazol-5-yl)butyl]-2H-tetrazol-5-yl]butoxy]phenyl]ethanone	leukotriene D4 antagonist; leukotriene antagonist	hypertension; asthma
LY 333531	(S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione	protein kinase inhibitor; protein kinase C inhibitor	diabetes; retinopathy
LY 335124		antiestrogen; estrogen agonist	hyperlipidemia

LY 362884		beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
MAB, A1717; MAB A717		biotechnology; monoclonal antibody	diabetes
MAB, adipocytes		biotechnology; monoclonal antibody	obesity
MAB, adrenomedullin		biotechnology; monoclonal antibody	cancer; diabetes; Alzheimer disease; diagnosis
MAB, LDL and Fc; bispecific antibody, low density lipoprotein		biotechnology; monoclonal antibody	hyperlipidemia
MAB, VLA-4, humanized; MAB, very late antigen-4, humanized		biotechnology; monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
macrophage colony stimulating factor; M-CSF; MACROLIN		biotechnology; growth factor; hematopoietic factor; immunostimulant; cicatrizant; antifungal	mycosis; hyperlipidemia; skin ulcer; bacterial infection
manidipine; manidipine hydrochloride; CV 4093; CALSLOT; MADIPINE; IPERTEN	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[4-(diphenylmethyl)-1-piperazinyl]ethyl 3,5-pyridinedicarboxylic acid methyl ester	calcium antagonist; vasodilator	hypertension
mazindol; MAZANOR; SANOREX	5-(4-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol		obesity
MCC 134	1-[4-(1H-imidazol-1-yl)benzoyl]-N-methylcyclobutanecarbothioamide	diuretic; potassium channel activator	hypertension

MCC 555	5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-2,4-thiazolidinedione	insulin sensitizer	diabetes
MCR4 modulators, Pharmacopeia			obesity
MD 31; M 17055	N-[7-chloro-2,3-dihydro-1-(2-methylbenzoyl)-4(1H)-quinolinyldene]hydroxylamine-O-sulfonic acid	diuretic	hypertension
MEDICA 16	beta, beta-tetramethylhexadecanedioic acid	cholesterol synthesis inhibitor	hyperlipidemia
melanocortin receptor-4 modulators, Trega Biosciences			obesity; diabetes
MER A2026A; Mer-A 2026A	2-(10-hydroxy-3,7,9,11,13-pentamethyl-2,5,7,11-tetradecatetraenyl)-6-methoxy-3-methyl-4-pyridinol	vasodilator	hypertension
MER A2026B; Mer-A 2026B	2-(10-hydroxy-3,7,9,11-tetramethyl-2,5,7,11-tridecatetraenyl)-6-methoxy-3-methyl-4-pyridinol	vasodilator	hypertension
metabolic disease therapy, Amylin/SIDDCO			diabetes
metabolic disorder therapy, Amylin			diabetes; obesity; hyperlipidemia
metabolic disorders, Amylin			diabetes; obesity; hyperlipidemia

metazosin; metasozin; metazocin; KENOSIN	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxy-1-oxopropyl)piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; glaucoma; benign prostate hypertrophy; heart failure
metformin; metformin hydrochloride; LA 6023; BMS 207150; GLUCOPHAGE	N,N-dimethylimidodicarbonylimidic diamide	biguanide	diabetes
metipamide	3-(aminosulfonyl)-4-chlorobenzoic acid 2-methyl-2-phenylhydrazide	vasodilator	hypertension
metoprolol, (S)-; (S)-metoprolol		beta adrenergic antagonist; beta1 adrenergic antagonist	angina; hypertension; arrhythmia
mexiletine; KO 1173; MEXITIL	1-methyl-2-(2,6-xylyloxy)ethylamine hydrochloride		neuropathy; arrhythmia; diabetes
miglitol; BAY m 1099; DIASTABOL; GLYSET	(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol	alpha glucosidase inhibitor	diabetes
millisrol; NK 843H; NK 843L; NK 843			hypertension; diagnosis
mineralocorticoid antagonists, Ligand		mineralocorticoid antagonist	hypertension
mixanpril		ACE inhibitor; neutral endopeptidase inhibitor	hypertension
MKC 121	4-tridecylpyrrole-2-carboxylic acid		hyperlipidemia

moexipril; RS 10085; SPM 925; CI 925; RS 10085197; UNIVASC; FAMPRESS; MOEX; PERDIX; FEMPRESS	[3S-[2[R*(R*),3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid	ACE inhibitor	hypertension
moexipril + hydrochlorothiazide; hydrochlorothiazide + moexipril; UNIRETIC		ACE inhibitor; diuretic	hypertension
monoclonal antibody, leptin receptor		monoclonal antibody; biotechnology	diabetes; anemia; obesity
moxonidine; BE 5895; BDF 5895; LY 326869; CYNT; PHYSIOTENS	4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine	alpha adrenergic agonist; alpha2 adrenergic agonist; imidazoline agonist	hypertension; heart failure; diabetes
MXC 3255; MXC3255			diabetes
nalmeffene; nalmetrene; JF 1; INCYSTENE; ARTHENE; FENARC; CERVENE; REVEX	17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma
naphterpin; CL 190Y2	(4aS-cis)-3,4a,5,12b-tetrahydro-8,10-dihydroxy-2,5,5,9-tetramethyl-4H-benzo[d]naphtho[2,3-b]pyran-7,12-dione	antioxidant; NSAID	diabetes; cardiovascular disease; cancer; inflammation
natural lipase inhibitor, Yakurigaku Chuo Kenkyusho		lipase inhibitor	obesity; atherosclerosis
NBI 115		peptide	diabetes
NCX 900		nitric oxide donor; NSAID	pulmonary hypertension



nebivolol; narbivolol; R 67555; R 65824; ME 3255; R 67138; R 67145; R 065824; NEBILET	[2R*[R*[R*(S*)]]]- alpha, alpha'- iminobis(methylene) bis[6-fluoro-3,4- dihydro-2H-1- benzopyran-2- methanol]	beta adrenergic antagonist; beta1 adrenergic antagonist; nitric oxide activator; vasodilator	hypertension; migraine; heart failure
NEPHROSTAT		matrix metalloproteinase inhibitor; proteinase inhibitor	kidney disease; diabetes
nerve growth factor; NGF; NEULEZE		growth factor; biotechnology; neurotrophic factor	neuropathy; diabetes
neuropeptide Y antagonist, Alanex		neuropeptide Y antagonist	obesity; hypertension
neuropeptide Y antagonists, Neurogen		neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypotension; obesity; depression
neuropeptide Y antagonists, Synaptic; neuropeptide Y antagonists, Novartis		neuropeptide Y antagonist; analgesic	obesity; cardiovascular disease; anxiety; pain
neuropeptide Y receptor modulators, Allelix			obesity
neuropeptide Y1 antagonists, Neurogen		neuropeptide Y antagonist; neuropeptide Y1 antagonist	obesity
neuropeptide Y5 antagonist, Synaptic; neuropeptide Y5 antagonist, Novartis		neuropeptide Y antagonist; neuropeptide Y5 antagonist	obesity
neuropeptide Y5 antagonists, Neurogen		neuropeptide Y antagonist; neuropeptide Y5 antagonist	obesity

neurotrophin-4; NT-4		biotechnology; neurotrophic factor; growth factor	neuropathy; diabetes
NGD 951; NGD 95-1; CP 422935		neuropeptide Y antagonist	obesity; eating disorder
nifedipine; nifedipine; FK 235; FR 34235; SKF 102362; CL 287389; NIVADIL; ESCOR	2-cyano-1,4-dihydro- 6-methyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid 3-methyl 5-(1- methylethyl) ester	calcium antagonist	hypertension; angina
nifedipine; BAY k 5552; SULAR; SYSCOR; BAYMYCARD; CORASOL; CORNEL; NISODIPEN; NISOCOR; ZADIPINA	1,4-dihydro-2,6- dimethyl-4-(2- nitrophenyl)-3,5- pyridinedicarboxylic acid methyl 2- methylpropyl ester	calcium antagonist	angina; hypertension
nitrendipine; BAY e 5009; BAYOTENSIN; BAYPRESS; NIRAPEL; NITRENDIL; NITRENDIPINA; HYPERDIPINA; HIPERTENOL; PORTIONAL; NELCONIL; RETENCAL	1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist	hypertension
nitrendipine, (S)-; (S)-nitrendipine		calcium antagonist	hypertension
NK 104	[4R- [4alpha,6beta(E)]]-6- [2-[2-cyclopropyl-4- (4-fluorophenyl)-3- quinolinyl]ethenyl]tetra- hydro-4-hydroxy- 2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
NN 2344; DRF 2593		insulin sensitizer	diabetes

NN 5501		potassium channel activator	diabetes
NNC 051869			neuropathy; diabetes
NNC 550118			diabetes
noninsulin dependent diabetes mellitus (NIDDM) therapy, MitoKor			diabetes
NOX 100		nitric oxide scavenger	diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 51		nitric oxide scavenger	diabetes; cancer; cardiovascular disease; transplant rejection; septic shock
NTE 122		ACAT inhibitor	hyperlipidemia; atherosclerosis
nucleoside mimetics, Gensia		nucleoside analogue	diabetes
NX 1838		aptamer; oligonucleotide; angiogenesis inhibitor	cancer; diabetes; retinopathy
NY 008	3-octyl-1(3H)-isobenzofuranone	vasodilator	hypertension
obesity therapy, Bristol-Myers Squibb/Garvan Institute of Medical Research			obesity
obesity therapy, Cerebrus		5HT agonist; 5HT2C agonist	obesity
obesity therapy, GelTex		lipase inhibitor	obesity
obesity therapy, Magainin			obesity

obesity therapy, Novo Nordisk/ACADIA			obesity
obesity therapy, Novo Nordisk/Boehringer Ingelheim			obesity
obesity therapy, Obesys; obesity therapy, BTG			obesity
obesity therapy, Pharmacia & Upjohn			obesity
obesity therapy, SIDR			obesity
obesity therapy, Trega/Novartis; diabetes therapy, Trega/Novartis			obesity; diabetes
obesity therapy, Tularik/Japan Tobacco			obesity; diabetes
obesity therapy, Tularik/Knoll			obesity
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic; hormone	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly

olmesartan; CS 866	4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-imidazole-5-carboxylic acid, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester	angiotensin II antagonist	hypertension
ophthalmological, Tanabe	6'-chloro-3'-methylspiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-trione	aldose reductase inhibitor	retinopathy; diabetes
opioid antagonists, NIH		opiate antagonist; peptide; immunosuppressant	addiction; alcoholism; obesity; transplant rejection
oral amylin receptor antagonists, Amylin		amylin antagonist	diabetes
oral insulin mimetics, Insulin Mimetics		insulin mimetic	diabetes
orlistat; orlipastat; tetrahydrolipistatin; THL; Ro 180647; XENICAL	N-formyl-L-leucine [2S-[2alpha(R*),3beta]]-1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester	pancreatic lipase inhibitor	obesity; hyperlipidemia
oxcarbazepine; CGP 47680; KIN 493; GP 47680; TRILEPTAL; TOXECAR	10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide		epilepsy; diabetes; neuropathy
P 06103	4-[3-[(6-amino-9-beta-D-ribofuranosyl-9H-purin-8-yl)thio]-2-oxopropoxy]-benzoic acid 2-methylpropyl ester		hyperlipidemia

P 06139	4-[3-[(4,5-diphenyl-1H-imidazol-2-yl)thio]-2-hydroxypropoxy]-benzoic acid 2-methylpropyl ester	ACAT inhibitor	hyperlipidemia
P 0654	8-[3-[4-(2-methylpropyloxycarbonyl)phenoxy]-2-(R)-hydroxypropyl]adenosine		hyperlipidemia
P 30			diabetes
P 5		calcium channel blocker	hypertension
P 57			obesity
pannorin	4,8,10-trihydroxy-5-methyl-2H-naphtho[1,2-b]pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
PD 123177; EXP 655	1-[(4-amino-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid	angiotensin II antagonist	hypertension
PD 123319	(S)-1-[[4-(dimethylamino)-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid	angiotensin II antagonist	hypertension
PD 129337	N-[2,6-bis(1-methylethyl)phenyl]-N'-[(1-phenylcyclopentyl)methyl]urea	ACAT inhibitor	hyperlipidemia

PD 132002	[1S-(1R*,2S*,3R*)]-N-(4-morpholinylsulfonyl)-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-O-methyl-3-oxo-DL-serinamide	renin inhibitor	hypertension
PD 1323012; PD 132301-2	N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea monohydrochloride	ACAT inhibitor	hyperlipidemia
PD 150304	Unspecified	angiotensin II antagonist	hypertension
PD 156707; PD 156123	alpha-[2-(4-methoxyphenyl)-2-oxo-1-[(3,4,5-trimethoxyphenyl)methyl]ethylidene]1,3-benzodioxole-5-acetic acid sodium salt	endothelin antagonist; endothelin-A antagonist	ischemia; reperfusion injury; pulmonary hypertension
pentosan polysulfate sodium; SP 54; PZ 68; CARTROPHEN; LASONIL; ELMIRON; LELONG MOUSSE	(1-4)-beta-D-xylan 2,3-bis(hydrogen sulfate), sodium salt	heparinoid; vasodilator; NSAID	arthritis; angina; hyperlipidemia; rheumatoid arthritis; cancer; cystitis
PEPTIMER		biotechnology; immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes

perindopril; perindopril erbumine; S 9490; S 94903; SED 9490; MCN A2833109; DW 7950; COVERSYL; ACEON; ACERTIL; COVERENE; COVEREX; COVERSIL	(2S,3aS,7aS)-1-[(2S)- 2-[[[(1S)-1- (ethoxycarbonyl)butyl ]amino]-1- oxopropyl]octahydro- 1-1H-indole-2- carboxylic acid	ACE inhibitor	hypertension; coronary artery disease
phensuccinal	beta- phenylethylamide-2- hydroxysuccinanylic acid	antioxidant	diabetes; kidney disease; retinopathy
phentolamine mesilate; phentolamine mesylate; VASOMAX; Z- MAX; VASOFEM	3-[[[(4,5-dihydro-1H- imidazol-2- yl)methyl](4- methylphenyl)amino] phenol	vasodilator; alpha adrenergic antagonist	sexual dysfunction; hypertension
phosphoenol pyruvate carboxykinase modulators; PEPCK modulators			diabetes
PIC 060 analogs		immunosuppressant; NSAID	psoriasis; dermatitis; diabetes; transplant rejection; rheumatoid arthritis
pimagedine; pimagedine hydrochloride; aminoguanidine; GER 11; YM 585	aminoguanidine		diabetes; kidney disease; retinopathy; atherosclerosis; neuropathy; stroke
pinacidil; P 1134; PINDACIL; PINDAL; PINDAC; THERAPRESS	N-cyano-N'-(4- pyridinyl)-N''-(1,2,2- trimethylpropyl)guani- dine	potassium channel blocker	hypertension
PNU 106817		insulin sensitizer	diabetes; obesity



PNU 140975		insulin sensitizer	diabetes; obesity
policosanol; ATEROMIXOL			hyperlipidemia
posatirelin; RGH 2202	(S)-N-[(6-oxo-2- piperidiny)carbonyl]- L-leucyl-L- prolinamide	protirelin analogue	cognitive defect; obesity
potassium channel activator, Merck KGaA	4-[(1,6-dihydro-1- methyl-6-oxo-3- pyridazinyl)oxy]-3,4- dihydro-3-hydroxy- 2,2-dimethyl-2H-1- benzopyran-6- carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
potassium channel modulators, Phytera/NeuroSearch		potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes
PPAR modulators		retinoid	atherosclerosis; obesity
PPAR modulators, metabolic diseases, Ligand/Lilly			diabetes
PPAR-gamma agonist		PPAR agonist	diabetes
pramlintide; tripro- amylin; AC 137; NORMYLIN	lys-cys-asn-thr-ala- thr-cys-ala-thr-gln- arg-leu-ala-asn-phe- leu-val-his-ser-ser- asn-asn-phe-gly-pro- ile-leu-pro-pro-thr- asn-val-gly-ser-asn- thr-tyr-NH <sub>2</sub> , cyclic (2->7)-disulphide	amylin agonist	diabetes

pravastatin; eptastatin; epastatin; CS 514; SQ 31000; RMS 431; LIPOSTAT; MEVALOTIN; PRAVACHOL; PRAVASTATIN; SELECTIN; LIPREVIL; PREVACOL; PRAVASIN; APLACTIN; BRISTACOL	[1S- [1 alfa(betaS*,deltaS* ,2alfa,6alfa,8beta(R* ,8aalfa)]- 1,2,6,7,8,8a- hexahydro- beta,delta,6- trihydroxy-2-methyl- 8-(2-methyl-1- oxobutoxy)-1- naphthaleneheptanoic acid	HMG CoA reductase inhibitor	hyperlipidemia; myocardial infarction
probucol; DH 581; DE 3872; LORELCO; PANAVIR; SINLESTAL	4,4'- isopropylidenedithio- bis-2,6-di-t- butylphenol	antioxidant	HIV infection; hyperlipidemia; restenosis
prohormone convertase 2 inhibitors			diabetes
prostanit		vasodilator; prostaglandin agonist	hypertension
PST 2238	(3beta,5beta,14beta)- 21,23-epoxy-24- norchola-20,22-diene- 3,14,17-triol		hypertension
QF 301	2-[2-(N4-O- methoxyphenyl-N1- piperaziny)ethyl]-1- tetralone	alpha adrenergic antagonist; alpha 1 adrenergic antagonist	hypertension

quinapril; quinapril hydrochloride; CI 906; PD 1094522; ACCUPRIL; CONAN; ACCUPRO; ACUITEL; ACEQUIN; ACCUZIDE; QUINAZIDE	[3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid	ACE inhibitor	hypertension
quinapril + hydrochlorothiazide; hydrochlorothiazide + quinapril; ACCURETIC; ACEQUIDE		ACE inhibitor; diuretic	hypertension
RAGE modulators			diabetes
raloxifene; keoxifene; LY 139481; LY 156758; EVISTA	[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone	antiestrogen; estrogen agonist	osteoporosis; hyperlipidemia; myocardial infarction; cancer
ramipril; HOE 498; ALTACE; TRIATEC; PRAMACE; RAMACE; TRITACE; CARASEL; ACOVIL	(2S,3aS,6aS)-1-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid 1-ethyl ester	ACE inhibitor	hypertension; heart failure
RD 211; (+-)-RD 211	(+,-)-2-(dipropylamino)-2,3-dihydro-5-methyl-1H-inden-4-ol	dopamine agonist	hypertension
renin inhibitor, Roche		renin inhibitor; proteinase inhibitor	hypertension
repaglinide; AGEE 623; AGEE 623 ZW; NN 623; NovoNorm; PRANDIN	(S)-2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid		diabetes

RES 7011; RES 701-1	Gly-Asn-Trp-His-Gly-Thr-Ala-Pro-Asp-Trp-Phe-Phe-Asn-Tyr-Tyr-Trp cyclic (9-1)-peptide		hypertension
riodipine; ryodipine; PP 1466; FORIDONE	4-[2-(difluoromethoxy)phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester	calcium antagonist	hypertension; angina
RL 6134; EQUATEN	unspecified	ACE inhibitor	hypertension
RL 6207; PRENTYL	unspecified	ACE inhibitor	hypertension
RL 6893; SYNECOR		ACE inhibitor	hypertension
Ro 34563		insulin secretagogue	diabetes
RPEP 27		renin inhibitor	hypertension
RS 5773	((2S,3S)-3-acetoxy-8-benzyl-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-1,5-benzothiazepine-4-(5H)-one hydrochloride	calcium antagonist	angina; hypertension
S 12340	8-[3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]propyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one		hyperlipidemia
S 18277			diabetes
S 2E	(S)-(+)-4-[[1-[4-(1,1-dimethylethyl)phenyl]-5-oxo-3-pyrrolidinyl]methoxy]benzoic acid		hyperlipidemia

SA 7060	[S-(R*,R*)]-alpha- [[[(3-butoxy-2-hydroxy-3-oxopropyl)(2-methylpropyl)amino]carbonyl]amino]-2-naphthalenepropanoic acid	neutral endopeptidase inhibitor; ACE inhibitor	heart failure; hypertension
SC 103a		aldose reductase inhibitor	diabetes; neuropathy
SC 103b		aldose reductase inhibitor	diabetes; sexual dysfunction
SCA 40	6-bromo-8-(methylamino)-imidazo[1,2-a]pyrazine-2-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
SCH 39370	[S-(R*,R*)]-N-[N-(1-carboxy-3-phenylpropyl)-L-phenylalanyl]-2-hydroxy-beta-alanine	neutral endopeptidase inhibitor	hypertension
SCH 59498		phosphodiesterase inhibitor; phosphodiesterase I inhibitor; phosphodiesterase V inhibitor	hypertension
screening technology, 5HT1 human neuroreceptors; neuroreceptors, 5-HT1 human		target based screening	obesity; anxiety; depression; migraine; drug design technology
SDZ PGU 693	2-[(4-chlorophenoxy)methyl]-7a-(3,4-dichlorophenyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one		diabetes

sertraline; CP 51974; CP 519741; CP 5197401; LUSTRAL; ZOLOFT; ALTRULINE; TATIG; GLADEM	(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety; sexual dysfunction; obesity
sibutramine hydrochloride monohydrate; BTS 54524; REDUCTIL; MERIDIA	1-(4-chlorophenyl)-N,N-dimethyl- $\alpha$ -(2-methylpropyl)cyclobutanemethanamine hydrochloride monohydrate	5HT reuptake inhibitor; noradrenalin reuptake inhibitor	obesity
sibutramine, (S)-; (S)-sibutramine		5HT reuptake inhibitor; noradrenalin reuptake inhibitor	obesity
signal transduction inhibitor, SUGEN/ArQule		signal transduction inhibitor; immunosuppressant	cancer; diabetes; neurological; autoimmune disease
simvastatin; epistatin; synvinolin; velostatin; MK 733; L 654; L 644128; ZOCOR; DENAN; MEDIPO; SIMOVIL; COLEDIS	2,2-dimethylbutanoic acid [1S-[1 $\alpha$ ,3 $\alpha$ ,7 $\beta$ ,8 $\beta$ ,a(2S*,4S*)8 $\beta$ ]]-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester	HMG CoA reductase inhibitor	hyperlipidemia
simvastatin analogue, Merck & Co; L 679336	6(R)-(2-(8(S)-(2,2-dimethylbutyryl)oxy)-2(S),6(R)-dimethyl-5(R)-hydroxy-1,2,3,4,4a(R),5,6,7,8,8a(R)-decahydronaphthyl-1(S))ethyl)-4-(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia

simvastatin analogue, Merck & Co	2,2-dimethylbutanoic acid octahydro-3,7-dimethyl-4-hydroxy-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2yl)ethyl)-1-naphthaleny ester	HMG CoA reductase inhibitor	hyperlipidemia
SK 1080; KR 31080	2-butyl-5-methyl-6-(1-oxido-2-pyridinyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazodo[4,5-b]pyridine	angiotensin II antagonist	hypertension
SKP 450; KR 30450	(R)-1-[2-(1,3-dioxolan-2-yl)-2-methyl-6-nitro-2H-1-benzopyran-4-yl]-2-pyrrolidinone	potassium channel activator	hypertension; heart ischemia
SL 910102		angiotensin II antagonist	hypertension
SP 134101			diabetes
spirapril; spirapril hydrochloride; SCH 33844; TI 211950; RENPRESS; SANDOPRIL; RENORMAX; CARDIOPRIL	[8S-[7[R*(R*)]]8R*]-7-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid	ACE inhibitor	hypertension
squalestatin 1; zaragozic acid A; L 694599	[5(2E,4S,6S),7S]-2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-L-erythro-L-glycero-D-altro-7-trideculo-7,4-furanosonic acid 11-acetate 5-(4,6-dimethyl-2-octenoate)	squalene synthetase inhibitor	hyperlipidemia
squalestatins, Reading University		squalene synthetase inhibitor	hyperlipidemia

SR 121463	cis-N-(1,1-dimethylethyl)-4-[[5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2'H)-yl]sulfonyl]-3-methoxy-benzamide (E)-2-butenedioate (1:1)	vasopressin antagonist; diuretic	heart failure; hypertension
SR 146131		cholecystokinin agonist; cholecystokinin A agonist	obesity
staurosporine; (+)-staurosporine; staurosporin; antibiotic 230; AM 2282	(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one	protein kinase inhibitor; protein kinase C inhibitor	hypertension
succibun	1-[4-N-butylureasulfonyl(phenyl)]pyrrolidin-2,5-dione		diabetes
supersulfated low molecular weight heparin; ssLMWH		heparinoid	thrombosis; hyperlipidemia
symakalim; EMD 57283	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; coronary artery disease; asthma
T 0115		endothelin antagonist	pulmonary hypertension



TAK 536	1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl)methyl-2-ethoxy-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist	hypertension
TAK 636		potassium channel activator	hypertension; angina
talinolol; CORDANUM	(+/-)-N-cyclohexyl-N'-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]urea	beta1 adrenergic antagonist; beta adrenergic antagonist	hypertension; myocardial infarction; cardiovascular disease
telmisartan; BIBR 277; BIBR 0277SE; MICARDIS; PRITOR	4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid	angiotensin II antagonist	hypertension
telmisartan + hydrochlorothiazide; hydrochlorothiazide + telmisartan		diuretic; angiotensin II antagonist	hypertension
temocapril; temocapril hydrochloride; CS 622; ESCOL; ACECOL; ACECOR	[2S-[2alpha,6beta(R*)]]-6-[[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic acid	ACE inhibitor	hypertension
terazosin; A 45975; MY 208; HYTRIN; HEITRIN; VASOMET; SINALFA; BLAVIN; URODIE; HYTRINEX; TERAPROST; ISONTYN	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist; vasodilator	benign prostate hypertrophy; hypertension

terlakiren; CP 80794	[R-(R*,S*)]-N-(4-morpholinylcarbonyl)-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2-hydroxy-3-(1-methylethoxy)-3-oxopropyl]-S-methyl-L-cysteineamide	renin inhibitor; peptide	hypertension
terpendole C		ACAT inhibitor	hyperlipidemia
terpendole D		ACAT inhibitor	hyperlipidemia
tertatolol; S 2395; SE 2395; ARTEX; ARTENSIL	(+,-)-1-[(3,4-dihydro-2H-1-benzothiopyran-8-yl)oxy]-3-[(1,1-dimethylethyl)amino]-2-propanol	beta adrenergic antagonist	hypertension
thyroid hormone receptor beta agonist, Karo Bio; thyroid hormone receptor beta agonist, Bristol-Myers Squibb			obesity; hyperlipidemia
tienoxolol; UP 78842	2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-5-[(2-thienylcarbonyl)amino]benzoic acid ethyl ester	beta adrenergic antagonist; diuretic	hypertension
tilisolol; N 696; DAIM; SELECAL	4-[3-[(1,1-dimethylethylamino)]-2-hydroxypropoxy]-2-methyl-1(2H)-isoquinolinone	beta adrenergic antagonist; vasodilator	hypertension
tiqueside; beta-tigogenin cellobioside; CP 88818	(3beta,5alpha,25R)-spirostan-3-yl-4-O-beta-D-glucopyranosyl-beta-D-glucopyranoside	cholesterol absorption inhibitor	hyperlipidemia

TMB 8	3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester	calcium antagonist	hypertension
TMP 153	N-[4-(2-chlorophenyl)-6,7-dimethyl-3-quinoliny]-N'-(2,4-difluorophenyl)urea	ACAT inhibitor	hyperlipidemia
TN 891	(S)-4-(2-hydroxy-3-isopropylaminopropoxy)phenylacetamide		hypertension
torasemide; torsemide; JDL 464; BM 02015; AC 4464; GJ 1090; UNAT; PRESARIL; TORREM; TOREM; ZEMIDE; DEMADEX; TORADIUR; DIURESIX; LUPRAC	N-[[[(1-methylethylamino)carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide	diuretic	hypertension; heart failure
trandolapril; CI 907; RU 44570; RU 570; ODRIK; UDRIK; GOPTEN; TRAPRIL; ODRIC; MAVIK	[2S-[1[R*(R*)],2alpha,3alpha,7abeta]]-1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid	ACE inhibitor; vasodilator	hypertension; heart failure; myocardial infarction
trandolapril + verapamil; verapamil + trandolapril; RU 44570A; TARKA; VERATRON		ACE inhibitor; calcium channel blocker	hypertension

transcription factor regulators, antihypercholesterole mia		transcription factor regulator	hyperlipidemia
troglitazone; CS 045; CI 991; GR 92132X; NOSCAL; ReZulin; ROMOZIN; PRELAY	5-[[4-[(3,4-dihydro-6- hydroxy-2,5,7,8- tetramethyl-2H-1- benzopyran-2- yl)methoxy]phenyl]m ethyl]-2,4- thiazolidinedione	insulin sensitizer	diabetes; gynecological
type II diabetes therapy, Cell Therapeutics			diabetes
U 10483			diabetes
U 37883A	N-cyclohexyl-N'- tricyclo[3.3.1.1 <sup>3,7</sup> ]de c-1-yl-4- morpholinecarboximi damide monohydrochloride	potassium channel blocker	hypertension
U 73482	7,7'-[1,2- ethanediylbis(4,1- piperidinediylmethyle ne)]-bis[4,9- dimethoxy-5H- furo[3,2- g][1]benzopyran-5- one	ACAT inhibitor	hyperlipidemia
U 86192A	2,3-dihydro-2-[[[(3- phenylpropyl)amino] methyl]-7H-1,4- dioxino[2,3-e]indole- 8-carboxylic acid methyl ester	5HT antagonist; 5HT1A antagonist	hypertension

U 88156	[1 alpha(E),4beta]-3-[2-(4-hydroxy-1-methylcyclohexyl)ethenyl]-alpha,alpha-dimethylbenzenepentanol	HMG CoA reductase inhibitor	hyperlipidemia
U 92352	N-cyano-N'-(3,4-dichlorobenzyl)-N''-(4-pyridinyl)guanidine	vasodilator	hypertension
UH 334			hypertension
ULTG 307		beta adrenergic agonist; beta3 adrenergic agonist	obesity
UP 27522	Unspecified	angiotensin II antagonist	hypertension
urapidil; B 66256; BY 05068; EBRANTIL; ALPHA DEPRESSAN	6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; benign prostate hypertrophy; dysuria
UT 15		prostanoid; vasodilator	pulmonary hypertension
UT 26		biotechnology; antisense; oligonucleotide	pulmonary hypertension
V 411; DIAB II		insulin sensitizer	diabetes
vaccine, angiotensin, Proteus; vaccine, hypertension, Proteus		vaccine	hypertension
vaccine, diabetes		vaccine; peptide	diabetes
valsartan; CGP 48933; DIOVAN	N-(1-oxopentyl)-N-[[[2'-(1H-tetrazol-5-yl)[1,1-biphenyl]-4-yl]methyl]-L-valine	angiotensin II antagonist	hypertension; heart failure

valsartan + hydrochlorothiazide; hydrochlorothiazide + valsartan; CoDiovan; CO-DIOVAN; DIOVAN HCT; CoTareg; CO- TAREG; DIOVAN-D		angiotensin II antagonist; diuretic	hypertension
vanadeine			diabetes
vasodilator, Ortho	N-(2,3-dihydro-6,7- dimethoxy-1-methyl- 3-oxo-4- isoquinoliny)-N'-2- propenyl-urea	vasodilator	hypertension
verapamil, (S)-; (S)- verapamil; levoverapamil; D 2024	(S)-alpha-[3-[[2-(3,4- dimethoxyphenyl)eth yl]methylamino]prop yl]-3,4-dimethoxy- alpha-(1- methylethyl)benzeneac etonitrile	calcium channel blocker	hypertension; arrhythmia; angina
veroxan; VUFB 18814		calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease
voglibose; AO 128; A 71100; GLUSTAT; BASEN	3,4-dideoxy-4-[[2- hydroxy-1- (hydroxymethyl)ethyl ]amino]-2-C- (hydroxymethyl)-D- epi-inositol	alpha glucosidase inhibitor	diabetes
WY 126227; WAY 126227	N-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4- yl]methyl]-2- (trifluoromethyl)-4- quinazolinamine	angiotensin II antagonist	hypertension
Y 20835		calcium antagonist	hypertension
Y 23785	unspecified	ACE inhibitor	hypertension

Y 27632	[4(R)-trans]-4-(1-aminoethyl)-N-4-pyridinylcyclohexane carboxamide	protein kinase inhibitor	hypertension; asthma; cancer
YM 161511; YM 16151-1	(+)-1,4-dihydro-4-[2-[4-[(2-hydroxy-3-phenoxypropyl)amino]butoxy]-5-nitrophenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester monohydrochloride	calcium antagonist	hypertension; angina
YM 440		insulin sensitizer	diabetes
YM 598	{potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylthioethanesulfonamide}	endothelin A antagonist	hypertension
Z 13752A		ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
Z 15040		dopamine agonist	hypertension
ZD 4522; S 4522		HMG CoA reductase inhibitor	hyperlipidemia
zenarestat; FR 74366; FK 366	3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid	aldose reductase inhibitor	diabetes; retinopathy; neuropathy
ZK 110841	[1R-[1 $\alpha$ -(Z),2 $\beta$ -(1E,3S*),3 $\alpha$ ,5 $\beta$ ]]-7-[5-chloro-2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxycyclopentyl]-5-heptenoic acid	prostanoid; platelet antiaggregant	glaucoma; hypertension; thrombosis

ZK 112566	N'-[(3beta, 8alpha)-13-amino-2,3-dihydro-2,6-dimethyl-ergolin-8-yl]-N,N-dimethylurea	dopamine agonist; dopamine D2 agonist; alpha adrenergic antagonist; alpha2 adrenergic antagonist; vasodilator	hypertension
ZK 118182	[1R-[1alpha(Z),2beta(1E,3S*),3alpha,5alpha]]-[[4-[5-chloro-2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxycyclopentyl]-2-butenyl]oxy]acetic acid	prostanoid; platelet antiaggregant	thrombosis; hypertension
zopolrestat; CP 73850; ALOND	3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid	aldose reductase inhibitor	diabetes; neuropathy; kidney disease



Table 57. Current Candidate Therapeutic Interventions for the Treatment of Anemia

Product Name	Chemical Name	Action	Indication
iron lysozyme glutarate; ABC 1020	Unspecified	Antianemic	anemia
PG 2	Tranditional Asian medicine isolate	Antianemic	anemia; cancer; leukopenia
PG 266	Tranditional Asian medicine isolate	Antianemic	anemia; cancer; leukopenia
PG 349	Tranditional Asian medicine isolate	Antianemic	cancer; anemia
PG 488	Tranditional Asian medicine isolate	Antianemic	cancer; anemia
clotrimazole; BAY 5097; CUTAMYCON; ENSCHENT; FUNGIZID; HAKUSERIN; LOTRIMIN AF; MYCO-HERMAL; MYKO CORDES; TRIGENTAX; CANESTEN; LOTRIMIN	Unspecified	antifungal; imidazole	mycosis; sickle cell anemia; cancer; diarrhea
fructose-1,6- diphosphate; CPC 111; CORDOX	1,6-bis(dihydrogen phosphate) D-fructose	anti-ischemic	heart failure; myocardial infarction; sickle cell anemia; septic shock
SCHAL 1SCA	Unspecified	Antiproliferative agent	sickle cell anemia
CT 15KG	Unspecified	Bursten pathwya inhibitor	anemia
activin	Unspecified	Enzyme antianemic	sickle cell anemia; infertility
transcription factor, erythropoietin	Unspecified	EPO and GM-CSF gene transcription	anemia
erythropoietin mimic, EPO mimic,	Unspecified	EPO mimic; Orally active	anemia
Erythropoietin receptor activators	Unspecified	EPO pathway stimulation	anemia
VG 18563	Oral prodrug of butyrate	Erythropoiesis stimulator	anemia; cancer
erythropoietin modulator	Unspecified	growth factor	anemia

hematopoietic agent, PolyMASC	Unspecified	growth factor	anemia
hematopoietic growth factor mimetics	unspecified	growth factor	cancer; bacterial infection; anemia
HP 367	Unspecified	growth factor	anemia
HP 395	Unspecified	growth factor	anemia
erythropoietin agonists	unspecified	growth factor modulator	anemia
drug delivery system, erythropoietin;	EPO	growth factor; hematopoietic factor	anemia
drug delivery system, oral MACROMOL erythropoietin; erythropoietin MACROMOL; erythropoietin oral; EPO oral	EPO	growth factor; hematopoietic factor	anemia
drug delivery system, ProLease erythropoietin; erythropoietin ProLease; drug delivery system, EPO	EPO	growth factor; hematopoietic factor	anemia
epoetin alfa; recombinant human erythropoietin; KRN 5702; KRN 5701; EPREX; EPOGEN; ERYPO; PROCRIT; ESPO; EPOADE	1-165-erythropoietin (human clone lambdaHEPOFL13 protein moiety) glycoform alpha	growth factor; hematopoietic factor	anemia
epoetin beta; recombinant human erythropoietin; BM 06019; MAROGEN; BECEUMEN; EPOGIN; RECORMON; EPOCH; NEORECORMON	1-165-erythropoietin (human clone lambdaHEPOFL13 protein moiety) glycoform beta	growth factor; hematopoietic factor	anemia
epoetin epsilon; erythropoietin (genetical recombination); SNB 5001; r HuEPO	1-165-erythropoietin (human clone lambdaHEPOFL13 protein moiety), glycoform epsilon	growth factor; hematopoietic factor	anemia

erythropoietin; GA EPO; MDL 104396; HMR 4396	EPO	growth factor; hematopoietic factor	anemia
hemoglobin 1.1; rHb1.1; OPTRO	Hemoglobin	growth factor; hematopoietic factor	anemia
PEG-hemoglobin	polyethylene glycol hemoglobin	growth factor; hematopoietic factor	cancer; anemia
; PEG-EPO; PolyMASC-EPO	polyethylene glycol- erythropoietin	growth factor; hematopoietic factor	anemia
RF 1010	Unspecified	growth factor; hematopoietic factor	anemia
RF 1012	Unspecified	growth factor; hematopoietic factor	anemia
RF 1017	Unspecified	growth factor; hematopoietic factor	anemia
epo-epo fusion protein	EPO recombinant	growth factor; hematopoietic factor; peptide	anemia
novel erythropoiesis stimulating protein; NESP	unspecified	hematopoietic factor; growth factor	anemia
erythropoietin mimic, MYELOS; EPO mimic	EPO mimic unspecified	hematopoietic factor; growth factor; peptide	anemia; neurological
VX 105	Unspecified	Hemoglobin F gene transcription activator	thalassemia; sickle cell anemia
VX 366	2-methyl- propanamide	Hemoglobin F gene transcription activator (analogue of VX105)	thalassemia; sickle cell anemia
tucarecol; BWA 589C; BW 589C80; BW 589C; 589C	4-[(2-formyl-3- hydroxyphenoxy)met hyl]benzoic acid	Hemoglobin stoichiometrically binding to produce high affinity for oxygen	sickle cell anemia; viral infection; HIV infection; cancer; hepatitis
polyclonal antibody, equine antithymocyte; immunoglobulin, equine antithymocyte; LYMPHOGLOBULI N	Unspecified	immunoglobulin; polyclonal antibody	aplastic anemia

lenograstim; granulocyte colony stimulating factor; G- CSF; pluripoietin; NEUTROGIN; GRANOCYTE; EUPROTIN; MYELOSTIM	133-[O-[O-(N-acetyl- alpha-neuraminosyl)- (2-3)-O-beta-D- galactopyranosyl-(1- 3)-2-(acetylamino)-2- deoxy-beta-D- galactopyranosyl]-L- threonine]-colony stimulating factor (human clone 1034)	immunostimulant; growth factor; hematopoietic factor	anemia; HIV infection; cancer; leukopenia
polyclonal antibody, rabbit antithymocyte; immunoglobulin, THYMOGLOBULIN	unspecified	immunosuppressant; immunoglobulin; polyclonal antibody	transplant rejection; aplastic anemia
iron proteinsuccinylate; iron succinyl-protein complex; ITF 282; PERNEXIN; LEGOFER; FERPLEX; FERLATUM; LACTOFERRINA; FERROCUR; FERXAL; HEMO Q	Iron engulfed in succinyl casein shell	Iron supplementation	anemia
ITF 1096	iron-succinyl-albumin	Iron supplementation	anemia
monoclonal antibody, leptin receptor	Unspecified	monoclonal antibody	diabetes; anemia; obesity
sickle cell anemia therapy	Unspecified	oligonucleotide	sickle cell anemia
velaresol; BW 12C79; 12C	5-(2-formyl-3- hydroxyphenoxy)- pentanoic acid	Oxyhemoglobin stabilization	cancer; sickle cell anemia
ribozyme, sickle cell anemia	Unspecified ribozyme	Ribozyme; oligonucleotide	sickle cell anemia
poloxamer 188; CRL 5861; FLOCOR; RheothRx	Unspecified	thrombolytic; fibrinolytic	thrombosis; cytoprotectant; sickle cell anemia
thrombospondin inhibitor, Allelix	Unspecified	thrombospondin inhibitor; peptide; NSAID	inflammation; cancer; sickle cell anemia
anemia therapy	Unspecified	transcription activator	anemia
AN 10; NOVAHEME	Butyric acid	Unspecified	sickle cell anemia; alopecia
EL 532	Unspecified	Unspecified	anemia; cancer

TRIFENS	Unspecified	Unspecified	diarrhea; gastrointestinal disorder; sickle cell anemia; cancer
vaccine, parvovirus B-19; MEDI 491	unspecified	vaccine	anemia
cetiedil; cetiedil citrate; INO 502; STRATENE; CELCIS	alpha-cyclohexyl-3- thiopheneacetic acid 2-(hexahydro-1H- azepin-1-yl)ethyl ester	vasodilator	sickle cell anemia

Table 58. Current Candidate Therapeutic Interventions for the Treatment of Angina

Product Name	Chemical Name	Action	Indication
BW 1139W	Unspecified	5HT antagonist; 5HT1D antagonist	angina
AHR 16303B	1-[4-[3-[4-[bis(4- fluorophenyl)hydroxy methyl]-1- piperidinyl]propoxy]p henyl]-2-methyl-1- propanone ethanedioate (1:1)	5HT antagonist; 5HT2 antagonist	hypertension; angina
LY 215840	[8beta(1S,2R)]-N-(2- hydroxycyclopentyl)- 6-methyl-1-(1- methylethyl)ergoline- 8-carboxamide	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis; angina
N 0840	N-cyclopentyl-9- methyl-9H-purin-6- amine	adenosine antagonist; adenosine A1 antagonist; diuretic	angina
N 0861	endo-(+,-)-N- bicyclo[2.2.1]hept-2- yl-9-methyl-9H- purin-6-amine	adenosine antagonist; adenosine A1 antagonist; vasodilator	arrhythmia; angina
CPC 400; CPC 402; CPC 405; CPC 406	Unspecified	adenosine regulating agent	neuropathy; angina
GP 14683	5-amino-1-(5-amino- 5-deoxy-beta-D- ribofuranosyl)imidazo le-4-N-[(4- chlorophenyl)methyl] carboxamide	adenosine regulating agent	angina

GP 1668; GP 668	5-amino-1-[beta-D-5-phosphoribofuranosyl]-imidazole-1-N-[(4-nitrophenyl)methyl]carboxamide)	adenosine regulating agent	angina; stroke
ledazerol; UCB 22061	2-hydroxy-3-(imidazol-4-ylmethyl)benzyl alcohol	alpha adrenergic agonist	angina
LR B139	Unspecified	angiotensin II antagonist	hypertension; angina
ranolazine; ranolazine hydrochloride; RS 43285; KEG 1295	(+,-)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide	anti-ischemic	angina; peripheral vascular disease
Z 4003	2-[1-[4-(2-methylpropyl)phenyl]ethyl]-4-thiazolidinecarboxylic acid	antioxidant; NSAID	angina; inflammation; emphysema
betaxolol; betaxolol hydrochloride; SL 75212; MCI 144; ABAXON; KERLONE; BETOPTIC; KERLONG; GLAUTAXOL; BERTOCIL; OPTIPRES; BETASEL; BEOF NICOLICH; LOKREN	1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist	glaucoma; hypertension; angina
carvedilol; karvedilol; BM 14190; DQ 2466; KREDEX; COREG; DILATREND; DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC	1-(9H-carbazol-4-yl)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol	beta adrenergic antagonist	hypertension; angina; heart failure

epanlol; ICI 141292; TS 704; VISACOR; VISICOR	N-[2-[[3-(2-cyanophenoxy)-2-hydroxypropyl]amino]ethyl]-4-hydroxybenzencacetamide	beta adrenergic antagonist	angina
esprolol; levo-SL 1050	Unspecified	beta adrenergic antagonist	angina
metoprolol, (S)-; (S)-metoprolol	(2S)-1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist; beta1 adrenergic antagonist	angina; hypertension; arrhythmia
cicloprolol; SL 7517710; SL 75177; SLD 177	(+,-)-1-[4-[2-(cyclopropylmethoxy)ethoxy]phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist; beta1 adrenergic partial agonist	angina; glaucoma
MAB, 7E3-F(ab')2	Unspecified	monoclonal antibody	angina
MAB, thrombosis; 12D10; CORSEVIN M	Unspecified	monoclonal antibody	thrombosis; septic shock; angina
abciximab; abcirximab; MAB, F(ab')2 fragment platelet; MAB, 7E3; c7E3 FAb; c7E3; ReoPro; CENTORX	Immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VhC.gamma.1 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3V.kappa.hc.kappa.a.light chain	platelet antiaggregant; monoclonal antibody	thrombosis; restenosis; angina; stroke; myocardial infarction
cilobradine; DKAH 269	3-((1-(2-(3,4-dimethoxyphenyl)ethyl)-3-piperidinyl)methyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one	bradycardic agent	angina
DKAH 3; DKAH 3 CL	Unspecified	bradycardic agent	angina

ivabradine; S 16257; S 16257-2	3-[3-[N-(4,5-dimethoxybenzocyclobutan-1(S)-ylmethyl)-N-methylanimo]propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one	bradycardic agent	angina; arrhythmia
zatebradine; ULFS 49	3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-benzazepin-2-one	bradycardic agent	angina; hypertension
ZD 7288; ICI D7288	N-ethyl-1,6-dihydro-1,2-dimethyl-6-(methylimino)-N-phenyl-4-pyrimidineamine monohydrochloride	bradycardic agent	angina
drug delivery system, COER-24 oral verapamil; verapamil COER-24; OROS verapamil; COER-24 verapamil; COVERA-HS; CHRONOVERA; CRONOVERA	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, controlled release diltiazem; diltiazem controlled release; TIAZAC; VIAZEM	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, GEOMATRIX controlled release nifedipine; nifedipine GEOMATRIX	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, OSAT nifedipine; nifedipine sustained release	Unspecified	calcium antagonist	hypertension; angina



drug delivery system, sustained release nifedipine; nifedipine once daily; INDAS nifedipine; NIFENSAR XL; ADALAT SR; UNIDIPINE; NIFELAN; ADALAT OROS	Unspecified	calcium antagonist	angina; hypertension
efonidipine; selefodipine; NZ 105; LANDEL	5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridine-carboxylic acid, 2-[phenyl(phenylmethyl)amino] ethyl ester, P-oxide	calcium antagonist	hypertension; angina; cerebrovascular disease
fantofarone; SR 33557; SR 33700	3,4-dimethoxy-N-methyl-N-[3-[4-[[2-(1-methylethyl)-1-indoliziny]sulfonyl]phenoxylpropyl]benzeneethanamine	calcium antagonist	angina; arrhythmia
flosatidil; SL 851016	[2-(dimethylamino)ethyl][2-[[2-(methylthio)phenyl][3-(trifluoromethyl)phenyl]methyl]amino]-2-oxoethyl]carbamic acid 2-methylpropyl ester	calcium antagonist	angina; hypertension
FPL 62129	4-[3-chloro-6-fluoro-2-(trifluoromethyl)phenyl]-2-(fluoromethyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-methyl 5-(1-methylethyl) ester	calcium antagonist	hypertension; angina

furnidipine; CRE 319	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl (tetrahydro-2-furanyl)methyl ester	calcium antagonist	hypertension; angina; reperfusion injury
gallopamil; D 600; PROCORUM; CORAPAMIL; ALGOCOR	5-[(3,4-dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile	calcium antagonist	hypertension; angina; arrhythmia
GS 386	3,4-dihydro-6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]isoquinoline	calcium antagonist	angina
iganidipine; kirenidipine hydrochloride; NKY 722	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2,2-dimethyl-3-[4-(2-propenyl)-1-piperazinyl]propyl 3,5-pyridinedicarboxylic acid methyl ester	calcium antagonist	hypertension; angina
isradipine; isrodipine; PN 200110; PN 205033; PN 205034; PRESCAL; LOMIR; DynaCirc; VASCAL; ICAZ	4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester	calcium antagonist	hypertension; angina
nilvadipine; nivadipine; FK 235; FR 34235; SKF 102362; CL 287389; NIVADIL; ESCOR	2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-methyl 5-(1-methylethyl) ester	calcium antagonist	hypertension; angina

nisoldipine; BAY k 5552; SULAR; SYSCOR; BAYMYCARD; CORASOL; CORNEL; NISODIPEN; NISOCOR; ZADIPINA	1,4-dihydro-2,6- dimethyl-4-(2- nitrophenyl)-3,5- pyridinedicarboxylic acid methyl 2- methylpropyl ester	calcium antagonist	angina; hypertension
ORG 13020	Unspecified	calcium antagonist	angina
PCA 50982	Unspecified	calcium antagonist	hypertension; angina
pranidipine; OPC 13340; ACALAS	(E)-1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid methyl 3-phenyl- 2-propenyl ester	calcium antagonist	hypertension; angina
riodipine; ryodipine; PP 1466; FORIDONE	4-[2- (difluoromethoxy)phe- nyl]-1,4-dihydro-2,6- dimethyl-3,5- pyridinedicarboxylic acid dimethyl ester	calcium antagonist	hypertension; angina
RS 5773	((2S,3S)-3-acetoxy-8- benzyl-2,3-dihydro-5- (2- (dimethylamino)ethyl )-2-(4- methoxyphenyl)-1,5- benzothiazepine-4- (5H)-one hydrochloride	calcium antagonist	angina; hypertension
siratiazem; LR A113	(2S-cis)-3- (acetyloxy)-2,3- dihydro-2-(4- methoxyphenyl)-5-[2- [methyl(1- methylethyl)amino]et hyl]-1,5- benzothiazepin- 4(5H)-one	calcium antagonist	angina; hypertension

SL 870495; SL 495	N-[2-(2-methylpropoxy)phenyl]-N-[4-[methyl[2-(3-pyridinyl)ethyl]amino]butyl]-3-(trifluoromethyl)benzamide	calcium antagonist	angina
teludipine; taludipine; GR 53992B; GR 53992X	(E)-2-[[dimethylamino)methyl]-4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid diethyl ester	calcium antagonist	hypertension; angina
UK 51656	2-((2-((4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl)methoxy)ethyl)amino)acetamide	calcium antagonist	hypertension; angina
UK 56593	2-[[[(2-amino-1,6-dihydro-6-oxo-4-pyrimidinyl)methoxy]methyl]-4-(2,3-dichlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester	calcium antagonist	angina
YM 161511; YM 16151-1	(+)-1,4-dihydro-4-[2-[4-[(2-hydroxy-3-phenoxypropyl)amino]butoxy]-5-nitrophenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester monohydrochloride	calcium antagonist	hypertension; angina

monatepil; monatepil maleate; monasedin maleate; AJ 2615; AD 2615	(+,-)-N-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)-4-(4-fluorophenyl)-1-piperazinebutanamide	calcium antagonist; alpha adrenergic antagonist; alpha adrenergic antagonist	hypertension; angina; hyperlipidemia
BMV 20014	Unspecified	calcium antagonist; alpha adrenergic antagonist; vasodilator	angina
felodipine + metoprolol; metoprolol + felodipine; LOGIMAX	Unspecified	calcium antagonist; beta adrenergic antagonist	hypertension; angina
YM 154301; YM 430	[S-(R*,R*)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinecarboxylic acid, 4-[(2-hydroxy-3-phenoxypropyl)amino]butyl methyl ester	calcium antagonist; beta adrenergic antagonist	hypertension; angina
CD 349	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-(nitrooxy)propyl 3-(nitrooxy)propyl ester	calcium antagonist; bronchodilator	hypertension; asthma; angina
dopropidil; CERM 4205; ORG 30701	1-[1-[(2-methylpropoxy)methyl]-2-[[1-(1-propynyl)cyclohexyl]oxy]ethyl]pyrrolidine	calcium antagonist; class I antiarrhythmic; class IV antiarrhythmic	angina
benidipine; nakadipine; nacadipine; KW 3049; CONIEL	(R*,R*)-(+,-)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester	calcium antagonist; vasodilator	hypertension; angina

CD 832	(-)-(4R)-2-(nicotinoylamino)ethyl 3-nitrooxypropyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine dicarboxylate	calcium antagonist; vasodilator	angina
clentiazem; clentiazem maleate; TA 3090; LOGNA	(2S-cis)-3-(acetyloxy)-8-chloro-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one	calcium antagonist; vasodilator	hypertension; angina
elgodipine; IQB 875	(+,-)-4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 2-[[4-(fluorophenyl)methyl]methylamino]ethyl 1-methylethyl ester	calcium antagonist; vasodilator	angina; hypertension; heart failure
semotiadil; semotiadil fumarate; SD 3211; DQ 4823; DS 4823	(R)-2-[2-[3-[[2-(1,3-benzodioxol-5-yloxy)ethyl]methylamino]propoxy]-5-methoxyphenyl]-4-methyl-2H-1,4-benzothiazin-3(4H)-one	calcium antagonist; vasodilator	angina; hypertension
felodipine; H 15482; HOE 869; CGH 869; HYDAC; PLENDIL; VASOPINE; SPLENDIL; MUNOBAL; FLODIL	4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist; vasodilator; diuretic	hypertension; angina; heart failure; atherosclerosis
AIT 110	Unspecified	Calcium channel	angina; arrhythmia
AIT 111	Unspecified	Calcium channel	angina; arrhythmia; hypertension

BRL 3287A	(N-(3,4-dimethoxyphenyl)-N-3-(N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino)-propyl)-N'-4-nitrobenzamide hydrochloride	Calcium channel (verapamil derivative)	angina
bepiridil; ORG 5730; CERM 1978; CORDIUM; VASCOR; BEPRICOR	1-[2-(N-benzylanilino)-1-(isobutoxymethyl)ethyl]-pyrrolidine	calcium channel blocker	angina
CP 060S	(S)-3-[3-[[2-(1,3-benzodioxol-5-yl)oxy]ethyl]methylamino]propyl]-2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-thiazolidinone (E)-2-butenedioate (1:1)	calcium channel blocker	heart ischemia; angina
verapamil, (S)-; (S)-verapamil; levoverapamil; D 2024	(S)-alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile	calcium channel blocker	hypertension; arrhythmia; angina
mibefradil; mibefradil dihydrochloride; Ro 405967; Ro 405967001; POSICOR; CERATE	methoxyacetic acid, (1S-cis)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester	calcium channel blocker; vasodilator	hypertension; angina; heart failure
bertosamil	3'-isobutyl-7'-isopropylspiro(cyclohexane-1,9'-(3,7)diazabicyclo(3.3.1)nonane)	class I antiarrhythmic; class III antiarrhythmic	arrhythmia; angina
CV 3611	2-O-octadecyl-L-ascorbic acid	free radical scavenger	angina

JTV 806	Unspecified	glycoprotein IIb/IIIa antagonist	angina; restenosis
EMD 122347; YM 028	Unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina; stroke
tirofiban; tirofiban hydrochloride; MK 383; L 700462; AGGRASTAT	N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina
ZD 2486	Unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	angina
eptifibatide; INTEGRILIN; INTEGRILIN	N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide cyclic (1->6)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; peptide	thrombosis; angina; myocardial infarction; restenosis
dalteparin sodium; low molecular weight heparin; heparin, low molecular weight; tedelparin; tedelparine; KABI 2165; K 2165; FR 860; FRAGMIN; FRAGMINE; BOXOL	heparin, sodium salt	heparinoid	thrombosis; coronary artery disease; angina
enoxaparin sodium; low molecular weight heparin; enoxaparin; enoxaparine; PK 10169; RPY 005; RP 54563; LOVENOX; CLEXAN; CLEXANE	heparin sodium salt	heparinoid	thrombosis; angina; stroke; myocardial infarction
pentosan polysulfate sodium; SP 54; PZ 68; CARTROPHEN; LASONIL; ELMIRON; LELONG MOUSSE	(1-4)-beta-D-xylan 2,3-bis(hydrogen sulfate), sodium salt	heparinoid; vasodilator; NSAID	arthritis; angina; hyperlipidemia; rheumatoid arthritis; cancer; cystitis



BM 121173	4-(2-nitroxyethyl)piperidine	nitrate	angina
BM 121179	trans-2-amino-2-methyl-N-(4-nitroxycyclohexyl)propionamide	nitrate	angina
BM 121200	trans-2-amino-2-methyl-N-(4-nitroxycyclohexylmethyl)propionamide	nitrate	angina
CEDO 8956	trans-1,4-cyclohexanedimethanol dinitrate	nitrate	angina
CRE 652	2-[2-(nitrooxy)ethyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide	nitrate	angina
drug delivery system, SODAS isosorbide mononitrate; isosorbide mononitrate SODAS	Unspecified	nitrate	angina
drug delivery system, transdermal isosorbide dinitrate; isosorbide dinitrate transdermal; CR 2471/P	Unspecified	nitrate	angina
drug delivery system, transdermal nitrate; nitrate transdermal delivery system	Unspecified	nitrate	angina
drug delivery system, transdermal nitroglycerin; nitroglycerin transdermal	Unspecified	nitrate	angina
drug delivery system, transdermal nitroglycerin; nitroglycerin transdermal	Unspecified	nitrate	angina

drug delivery system, transdermal nitroglycerin; nitroglycerin, transdermal	Unspecified	nitrate	angina
drug delivery system, transdermal nitroglycerin; nitroglycerin transdermal; OPTIZOR	Unspecified	nitrate	angina; labor inhibition
nitroglycerin TheraDerm-MTX; NITROSYLON; TRINIPATCH; TRINIPLAS; ANGIDERM	drug delivery system, transdermal TheraDerm-MTX nitroglycerin;	nitrate	angina
LA 409	Unspecified	nitrate	angina
PF 9104	Unspecified	nitrate	angina
PF 9404	Unspecified	nitrate	angina; hypertension
SPM 3672; SP/W 3672	N-[2,2-dimethyl-3- (nitrooxy)-1- oxopropyl]-L-cysteine ethyl ester	nitrate	angina
nitroglycerin; glyceryl trinitrate; trinitrin; ANOGESIC	Unspecified	nitrate; cicatrizant; analgesic	skin ulcer; angina; pain
D-isoidide dinitrate; D-IIDN	1,4:3,6-dianhydro-D- iditol dinitrate	nitrate; vasodilator	angina
E 4701	2,3-dihydro-8- hydroxy-7-nitro-1,4- benzodioxin-2- methanol alpha- nitrate	nitrate; vasodilator	angina
sinitrodil; ITF 296	2,3-dihydro-3-[2- (nitrooxy)ethyl]-4H- 1,3-benzoxazin-4-one	nitrate; vasodilator	angina
CAS 1609	Unspecified	nitric oxide donor	angina
cyclosin	Unspecified	nitric oxide donor	angina
darsidomine; marsidomine; C 873754; CAS 754	cis-5-amino-3-(2,6- dimethyl-1- piperidinyl-1,2,3- oxadiazolium inner salt	nitric oxide donor	angina

NO donors	Unspecified	nitric oxide donor	angina
ITF 1129	2,3-dihydro-6-methyl-3-[2-(nitrooxy)ethyl]-4H-1,3-benzoxazin-4-one	nitric oxide donor; nitrate	heart ischemia; angina
FK 409; FR 900409	(3E)-4-ethyl-2-hydroxyimino-5-nitro-3-hexene carboxamide	nitric oxide donor; vasodilator	angina
GEA 3175	Unspecified	nitric oxide donor; vasodilator	angina; hypertension
nitric oxide vasodilators, IVAX	Unspecified	nitric oxide donor; vasodilator	angina; heart failure
pirsidiomine; CAS 936; CAS 754	cis-3-(2,6-dimethyl-1-piperidiny)-N-(4-methoxybenzoyl)synone imine	nitric oxide donor; vasodilator	angina
SPM 5185	N-[2,2-dimethyl-3-(nitrooxy)-1-oxopropyl]-L-cysteine ethyl ester, ester with N-acetyl-L-alanine	nitric oxide donor; vasodilator	angina
THE 1869	Unspecified	nitric oxide donor; vasodilator	angina
THE CYL358; CYL 358	Unspecified	nitric oxide donor; vasodilator	angina
SPM 4744	2,2-dimethyl-3-(nitrooxy)propanoic acid	nitric oxide donor; vasodilator; nitrate	angina
SIN 1A/CD	(4-morpholinyl)nitrosoamino)acetonitrile	nitric oxide donor; vasodilator; platelet antiaggregant	angina
XR 334 series; XR 334	(Z,Z)-3-[(4-Methoxyphenyl)methylene]-6-(phenylmethylene)-2,5-piperazinedione	PAI inhibitor; thrombolytic	thrombosis; angina
phosphodiesterase I/V inhibitor	Unspecified	phosphodiesterase I inhibitor; phosphodiesterase V inhibitor; phosphodiesterase inhibitor	angina; myocardial infarction

E 4021; ER 21355	1-[4[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinazolinyl]-4-piperidinecarboxylic acid, monosodium salt	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	hypertension; angina; heart failure
IC 351; GF 196960; GG 960	Unspecified	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	heart failure; angina; sexual dysfunction; psoriasis
BMV 43351	7-(4-(4-(cyclohexylmethyl)-1-piperazinyl)-4-oxobutoxy)-1,3-dihydro-2H-imidazo(4,5-b)quinolin-2-one	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis; angina
BMS 180448	(3S-trans)-N-(4-chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-guanidine	potassium channel activator	angina
FK 336	2-methyl-N-[2-(nitrooxyethyl)-4-thiazolecarboxamide monohydrochloride	potassium channel activator	angina
KC 399	[N-(2-cyanoethyl)-2,2-bisfluoromethyl-6-nitro-2H-1-benzopyran-4-carbothioamide]	potassium channel activator	angina; stroke
TAK 636	Unspecified	potassium channel activator	hypertension; angina
Y 27152	(3S,trans)-N-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N-(phenylmethoxy)acetamide	potassium channel activator	hypertension; angina

nicorandil; SG 75; EMD 36385; U 64417; SIGMART; PERISALOL; DANCOR; IKOREL; ADANCOR; CORDONE; KALIDIL	N-[2-(nitrooxy)ethyl]- 3- pyridinecarboxamide	potassium channel activator; nitrate; vasodilator	angina; cerebrovascular disease; heart failure
DY 9708	[1R-[1 alpha,2(3S*,4R*),6al pha]]-3,4-dihydro-3- hydroxy-2,2-dimethy l-4-[(5-oxo-3,4- diazabicyclo[4.1.0]he pt-2-en-2-yl)oxy]-2H- 1-benzopyran-6- carbonitrile	potassium channel activator; vasodilator	hypertension; angina
KRN 2391	N-cyano-N'-[2- (nitrooxy)ethyl]-3- pyridinecarboximida mide monomethanesulfonat e	potassium channel activator; vasodilator	angina
RWJ 29009	(-)-trans-5,6-dihydro- 6-hydroxy-5,5- dimethyl-2-nitro-7-(2- oxopiperidin-1-yl)- 7H-thieno[3,2- b]pyran	potassium channel activator; vasodilator	angina
fasudil; fasudil hydrochloride; AT 877; HA 1077; HA 004; ERIL	hexahydro-1-(5- isoquinolylsulfonyl)- 1H-1,4-diazepine	protein kinase inhibitor; protein kinase C inhibitor; vasodilator	brain ischemia; stroke; angina; HIV infection

bivalirudin; BG 8967; HIRULOG	D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl-glycylglycylglycylglycyl-L-asparaginylglycyl-L- $\alpha$ -aspartyl-L-phenylalanyl-L- $\alpha$ -glutamyl-L- $\alpha$ -glutamyl-L-isoleucyl-L-prolyl-L- $\alpha$ -glutamyl-L- $\alpha$ -glutamyl-L-tyrosyl-L-leucine	proteinase inhibitor; hirudin analogue; thrombin inhibitor	thrombosis; angina; myocardial infarction
argatroban; argatrovan; argipidine; argopidine; alipidine; DK 7419; MCI 9038; MD 805; OM 805; GN 1600; NOVASTAN; SLONNON	(2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[[(1,2,3,4-tetrahydro-3-methyl-8-quinoliny)sulfonyl]amino]pentyl]-4-methyl-2-[piperidinecarboxylic acid	proteinase inhibitor; platelet antiaggregant; thrombin inhibitor	thrombosis; myocardial infarction; ischemia; angina; brain ischemia; thrombocytopenia
inogatran; H 31427; HA 31427	N-[(1R)-2-cyclohexyl-1-[(2S)-2-[(3-guanidinopropyl)carbamoyl]piperidino]carbonyl]ethyl]glycine	proteinase inhibitor; thrombin inhibitor; platelet antiaggregant	angina; myocardial infarction
cariporide; cariporide mesilate; HOE 642; HOE 642A	N-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)benzamide	sodium/hydrogen exchange inhibitor	arrhythmia; myocardial infarction; angina; restenosis
efegatran; efegatran sulfate; GYKI 14766; LY 294468	N-methyl-D-Phe-Pro-Arg-H	thrombin inhibitor; proteinase inhibitor; peptide	thrombosis; angina; myocardial infarction
nafagrel; DP 1904	5,6,7,8-tetrahydro-6-(1H-imidazol-1-ylmethyl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; angina; asthma; restenosis
JTV 519	Unspecified	Unspecified	reperfusion injury; angina

teopranitol; KC 046	1,4:3,6-dianhydro-2-deoxy-2-[[3-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purin-7-yl)propyl]amino]-L-iditol-5-nitrate	vasodilator	angina
CAS 754	Unspecified	vasodilator	angina
E 4080	(E)-N-[3-[[2-(3,5-dimethoxyphenyl)ethyl]methylamino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]-3-butenamide dihydrochloride	vasodilator	angina
KW 3196	5-deoxy-2-O-nitro-5-(4-(pyridin-3-yl)carbonyl piperazin-1-yl)-1,4:3,6-dianhydro-L-iditol	vasodilator	angina
LP 805	8-tert-butyl-6,7-dihydropyrrolo[3,2-e]-5-methylpyrazolo[1,5a]pyrimidine-3-carbonitrile	vasodilator	hypertension; angina
PF 8920	Unspecified	vasodilator	angina
PF 8921	Unspecified	vasodilator	angina
PF 9005	Unspecified	vasodilator	angina
vasodilator	N-(2-(N-hexylamino)ethyl)-5-isoquinolinesulfonamide	vasodilator	angina
propionylcarnitine, L-; propionyl-L-carnitine; levocarnitine propionyl; ST 261; DROMOS	L-3-carboxy-2-(1-oxopropoxy)-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt	vasodilator; cicatrizant	peripheral vascular disease; angina; heart failure; skin ulcer

JTV 506	(3S-trans)-4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)amino]-3,4-dihydro-3-hydroxy-2,2-bis(methoxymethyl)-2H-1-benzopyran-6-carbonitrile	vasodilator; potassium channel activator	angina
---------	--	--	--------

Table 59. Current Candidate Therapeutic Interventions for the Treatment of Arrhythmia

Product Name	Chemical Name	Action	Indication
draflazine; R 75231; R 70380	2-(aminocarbonyl)-N-(4-amino-2,6-dichlorophenyl)-4-[5,5-bis(4-fluorophenyl)pentyl]-1-piperazineacetamide	Adenosine uptake inhibitor	arrhythmia; schistosomiasis
CVT 429	Unspecified	adenosine A1 agonist; adenosine agonist	arrhythmia; heart failure
CVT 609	Unspecified	adenosine A1 agonist; adenosine agonist	arrhythmia; heart failure
CV 1808	2-(phenylamino)adenosine	adenosine agonist	arrhythmia
BN 063	1-cyclopropylisoguanosine	adenosine agonist; adenosine A1 agonist	arrhythmia
CVT 427	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
CVT 510	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
CVT 741	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
DTI 0009	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia
N 0723	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia



adenosine; MEDR 340; SR 96225; MEDR 640; ADENOCOR; ADENOCARD; CARIADEN; ADENOSCAN; KRENOSIN; PALLACOR	9-alpha-D-ribofuranosyl-9H-purin-6-amine	adenosine agonist; vasodilator	arrhythmia; ischemia; reperfusion injury; diagnosis
N 0861	endo-(+,-)-N-bicyclo[2.2.1]hept-2-yl-9-methyl-9H-purin-6-amine	adenosine antagonist; adenosine A1 antagonist; vasodilator	arrhythmia; angina
BW A1433U	4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)benzoic acid	adenosine antagonist; adenosine A3 antagonist	arrhythmia
abanoquil; UK 5204627; UK 52046	2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinoliny)-6,7-dimethoxy-4-quinolinamine	alpha adrenergic antagonist; alpha 1 adrenergic antagonist; vasodilator	arrhythmia
A 2545	N-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-2,5-dihydro-2,2,5,5-tetramethyl-1H-pyrrole-3-carboxamide	antiarrhythmic	arrhythmia
amidepin	2-(diethylamino)-N-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)acetamide S,S-dioxide	Antiarrhythmic	arrhythmia
amiodarone; L 3428; SKF 33134A; CORDARONE; CORDARONE X; RYTHMARONE; CARDIORONA; ARRITMIL; ANCARON; AMIORIT; ORTARON	(2-butyl-3-benzofuranyl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone	Antiarrhythmic	arrhythmia

AN 132	3-[[2-[bis(1-methylethyl)amino]ethyl]amino]-N-(2,6-dimethylphenyl)propanamide phosphate (1:2)	Antiarrhythmic	arrhythmia
antiarrhythmic, chronic	Unspecified	antiarrhythmic	arrhythmia
Antiarrhythmic chronic	Unspecified	Antiarrhythmic	arrhythmia
Antiarrhythmic	1-[[4-(3-phenoxypropyl)phenyl]methyl]pyrrolidine	Antiarrhythmic	arrhythmia
artilide; artilide fumarate; U 88943E	(R)-N-[4-[4-(dibutylamino)-1-hydroxybutyl]phenyl]methanesulfonamide	Antiarrhythmic	arrhythmia
AWD 160274	Unspecified	Antiarrhythmic	arrhythmia
AWD 23078	Unspecified	Antiarrhythmic	arrhythmia
BRB I28	7-benzyl-7-aza-3-thiabicyclo[3.3.1]nonane hydroperchlorate	Antiarrhythmic	arrhythmia
CK 4000	(S)-N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1-yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide monohydrochloride	Antiarrhythmic	arrhythmia
detajmium bitartrate; TACHMALCOR	(17R,21.alpha.)-4-[3(diethylamino)-2-hydroxypropyl]ajmalinium	Antiarrhythmic	arrhythmia
EO 4711	Unspecified	Antiarrhythmic	arrhythmia

ES 313	[1S-[1R*(R*),2R*,4(1R*,2R*)]]-N-[1-[[[2-hydroxy-4-[[1-(hydroxymethyl)-2-methylbutyl]amino]-1-(2-methylpropyl)-4-oxobutyl]amino]carbonyl]-2-methylpropyl]-alfa-(1-naphthalenylmethyl)-1-naphthalenepropanamide	Antiarrhythmic	arrhythmia
GFA	Unspecified	Antiarrhythmic	arrhythmia
GLG V13	3-[4-(1H-imidazol-1-yl)benzoyl]-7-(1-methylethyl)-3,7-diazabicyclo[3.3.1]nonane diperchlorate	Antiarrhythmic	arrhythmia
GYKI 38233; TYB 3823; B-GYKI 38233; RESTACORIN	2-(2,6-dimethylphenyl)-N,N-dimethylhydrazinecarboximide monohydrochloride	Antiarrhythmic	arrhythmia
H 34552; H 345/52	Unspecified	Antiarrhythmic	arrhythmia
L 702958	(R)-N-[1'-(6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl)-3,4-dihydro-4-oxospiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide	Antiarrhythmic	arrhythmia
L 961121	Unspecified	Antiarrhythmic	arrhythmia
LG 6102	1-[2-[2-methoxy-3-(propylamino)propoxy]phenyl]-3-phenyl-1-propanone hydrochloride	Antiarrhythmic	arrhythmia
M 14157; MD 26	Unspecified	Antiarrhythmic	arrhythmia

NC 1006	N-(azabicyclo[2,2,2]octan-2-yl)methyl, N-(2-indanyl)aniline hydrochloride	Antiarrhythmic	arrhythmia
superoxide dismutase, polyoxyethylene modified; SOD-POE	polyoxyethylene-modified superoxide dismutase	Antiarrhythmic	arrhythmia
RP 58866	1-[2-(3,4-dihydro-2H-1-benzopyran-4-yl)ethyl]-4-(3,4-dimethoxyphenyl)piperidine hydrochloride	Antiarrhythmic	arrhythmia
RS 89497	Unspecified	Antiarrhythmic	arrhythmia
S 711389; S 1389	1-(3,6-dichloro-2-(1-(1H-imidazol-1-yl)ethenyl)phenoxy)-3-(1-methylethyl)amino)-2-propanol	Antiarrhythmic	arrhythmia
SL 1112	Unspecified	Antiarrhythmic	arrhythmia; local anesthesia
solpecainol; EGIS 2936; EGYT 2936	(+,-)-[1R*,2S*(S*)]-2-[(1-methyl-2-phenoxyethyl)amino]-1-phenyl-1,3-propanediol	Antiarrhythmic	arrhythmia
tiracizine; AWD 19166; GS 015; GS 15; BONNECOR	[5-[(dimethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]carbamic acid ethyl ester	Antiarrhythmic	arrhythmia
TN 851; TMC 851	Unspecified	Antiarrhythmic	arrhythmia
Desoxoamiodarone	(2-n-butyl-3-benzofuranyl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methane	Antiarrhythmic; amiodarone derivative	arrhythmia
E 047/1	Unspecified	Antiarrhythmic; amiodarone derivative	arrhythmia

ethacizin; NIK 422	[10-[3-(diethylamino)-1-oxopropyl]-10H-phenothiazin-2-yl-carbamic acid, ethyl ester, monohydrochloride	Antiarrhythmic; chemically related to ethmozine	arrhythmia
cibenzoline; cifenline; UP 33901; Ro 227796; CIPRALAN; CIBENOL; EXACOR	2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole	Antiarrhythmic; imidazoline derivative	arrhythmia
glutapyrone	2-(2,6-dimethyl-3,5-diethoxycarbonyl-1,4-dihydropyridine-4-carboxamide)glutaric acid, disodium salt	antioxidant	arrhythmia
ACC 9369	2-[2-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzenepropanoic acid ethyl ester	beta adrenergic antagonist	arrhythmia
drug delivery system, submicron emulsion adaprolol; adaprolol SME; HGP 2; CDDD 2803	4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetic acid; 2-tricyclo[3.3.1.1sup3,7]dec-1-ylethyl ester	beta adrenergic antagonist	arrhythmia; glaucoma
esmolol; ASL 8052; ASL 8123; BREVIBLOC	4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzenepropanoic acid methyl ester	beta adrenergic antagonist	hypertension; arrhythmia
AM 140; AM 0140; D 140	Unspecified	beta adrenergic antagonist; beta1 adrenergic antagonist	glaucoma; arrhythmia
landiolol; ONO 1101; ONOACT	[S-(R*,R*)]-4-[2-hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]benzenepropanoic acid (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester	beta adrenergic antagonist; beta1 adrenergic antagonist	arrhythmia

metoprolol, (S)-; (S)-metoprolol	(2S)-1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist; beta 1 adrenergic antagonist	angina; hypertension; arrhythmia
sotalol; sotalol hydrochloride; MJ 1999; BMY 05763; SOTACOR; SOTALEX; SOTAZIDE; BETAPACE	N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]methanesulfonamide	beta adrenergic antagonist; class II antiarrhythmic; class III antiarrhythmic	arrhythmia
dexsotalol; sotalol, (d)-; (+) MJ 1999; BMY 05763	(S)-N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]methanesulfonamide	beta adrenergic antagonist; class III antiarrhythmic	arrhythmia
ivabradine; S 16257; S 16257-2	3-[3-[N-(4,5-dimethoxybenzocyclobutan-1(S)-ylmethyl)-N-methylamino]propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one	bradycardic agent	angina; arrhythmia
flapamil; AQ A39 CL; AG A 39	2-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-2,3-dihydro-5,6-dimethoxy-1H-isoindol-1-one	calcium antagonist	arrhythmia
flantofarone; SR 33557; SR 33700	3,4-dimethoxy-N-methyl-N-[3-[4-[[2-(1-methylethyl)-1-indoliziny]sulfonyl]phenoxy]propyl]benzethanamine	calcium antagonist	angina; arrhythmia
gallopamil; D 600; PROCORUM; CORAPAMIL; ALGOCOR	5-[(3,4-dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile	calcium antagonist	hypertension; angina; arrhythmia

KT 362	5-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1-oxopropyl]-2,3,4,5-tetrahydro-1,5-benzothiazepine (E)-butenedioate (1:1)	calcium antagonist	arrhythmia
Ro 236152	(+)-cis-3-(acetoxo)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-dimethylamino)ethyl-1-naphtho(1,2b)-1,4-thiazepin-4-(5H)one	calcium antagonist	arrhythmia
EGIS 3966	(E,E)-(+/-)-2-(phenylmethylene)-[3-[bis(1-methylethyl)amino]-2-hydroxypropyl]oxime cyclohexanone (E)-2-butendionate	calcium antagonist; 5HT antagonist	arrhythmia
BRL 32872	N-(3,4-dimethoxyphenyl)-N-[3[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-4-nitrobenzamide	calcium antagonist; class III antiarrhythmic; class IV antiarrhythmic	arrhythmia
AIT 110	Unspecified	Calcium channel	angina; arrhythmia
AIT 111	Unspecified	Calcium channel	angina; arrhythmia; hypertension
verapamil, (S)-; (S)-verapamil; levoverapamil; D 2024	(S)-alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile	calcium channel blocker	hypertension; arrhythmia; angina
EMD 60263	(+)-5-(1-(alpha-ethylimino-3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroquinoline-6-yl)-6-methyl-3,6-dihydro-2H-1,3,4-thiadiazine-2-one	calcium sensitizer	arrhythmia

AFDX 384	N-[2-[2- [(dipropylamino)methyl]-1- piperidinyl]ethyl]-5,6- dihydro-6-oxo-11H- pyrido[2,3- b][1,4]benzodiazepin e-11-carboxamide monomethanesulfonate	cholinergic antagonist; muscarinic antagonist; muscarinic M2 antagonist	arrhythmia; diagnosis
otenzepad; AFDX 116; AFDX 116BS	(+,-)-11-[[2- [(diethylamino)methyl]-1- piperidinyl]acetyl]- 5,11-dihydro-6H- pyrido[2,3- b][1,4]benzodiazepin e-6-one	cholinergic antagonist; muscarinic antagonist; muscarinic M2 antagonist	arrhythmia
acecainide; acecainide hydrochloride; N- acetylprocainamide; NAPA; ASL 601	4-(acetylamino)-N-(2- (diethylamino)ethyl)benzamide	class I antiarrhythmic	arrhythmia
actisomide; SC 36602	(+,-)-cis-4-[(2- diisopropylamino)ethyl]-4,4a,5,6,7,8- hexahydro-1-methyl- 4-phenyl-3H- pyrido[1,2- c]pyrimidin-3-one	class I antiarrhythmic	arrhythmia
barucainide	4-benzyl-1,3-dihydro- 7-[4- (isopropylamino)butoxy]-6-methylfuro[3,4- c]pyridine	class I antiarrhythmic	arrhythmia
berlafenone; bipranol; GK 23G	1-([1,1'-biphenyl]-2- yloxy)-3-[(1,1- dimethylethyl)amino]- 2-propanol	class I antiarrhythmic	arrhythmia
bidisomide; SC 40230	(+,-)-alpha-[2- [acetyl(1- methylethyl)amino]ethyl]-alpha-(2- chlorophenyl)-1- piperidinebutanamide	class I antiarrhythmic	arrhythmia



CV 6402	2,2'-(2-amino-ethyl)imino diethanol bis(butylcarbamate) dihydrochloride	class I antiarrhythmic	arrhythmia
diprafenone; butafenone	(+,-)-1-[2-[3-[(1,1-dimethylpropyl)amino]-2-hydroxypropoxy]phenyl]-3-phenyl-1-propanone	class I antiarrhythmic	arrhythmia
E 0747; E 747; L 29065	6-chloro-2,3-dihydro-1'-[3-(4-hydroxy-1-piperidinyl)propyl]-2,2-dimethylspiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione	class I antiarrhythmic	arrhythmia
E 0747 (-)isomer; E 747 (-)isomer	(-)-6-chloro-2,3-dihydro-1'-(3-(4-hydroxy-1-piperidinyl)propyl)-2,2-dimethylspiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione	class I antiarrhythmic	arrhythmia
encainide; MJ 9067; MJ 90671; ENKADE; ENKAID	(+,-)-4-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide	class I antiarrhythmic	arrhythmia
flecainide; flecainide acetate; R 818; E 0735; DIONDEL; TAMBOCOR; ALMARYTM; FLECAINE; APOCARD; ECRINAL	N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide	class I antiarrhythmic	arrhythmia
indecainide; recainide; LY 135837; DECABID	9-[3-(isopropylamino)propyl]fluorene-9-carboxamide	class I antiarrhythmic	arrhythmia

K 953	3-amino-5'-ethoxy-2'-(3-pyridyl)butyranilide dihydrochloride	class I antiarrhythmic	arrhythmia
LG 6101	1-[3-[2-methoxy-3-[(2-methylpropyl)amino]propoxy]-4-methyl-2-thienyl]-3-phenyl-1-propanone hydrochloride	class I antiarrhythmic	arrhythmia
LNC 834; LNC 409 sulfate	(9S)-10,11-dihydro-6'-methoxycinchonan-3,9-diol sulfate (1:1) salt	class I antiarrhythmic	arrhythmia
modecainide; MJ 14030	(+,-)-4-hydroxy-3-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide	class I antiarrhythmic	arrhythmia
moracizine; moricizine; ethmosine; ethmozin; etmozin; EN 313; ETHMAZONE; ETHMOZINE	ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate	class I antiarrhythmic	arrhythmia
NS 2	4-diisobutylamino-1,1-diphenyl-1-butanol maleate	class I antiarrhythmic	arrhythmia
ORG 7797	(16 $\alpha$ ,17 $\beta$ )-17-(methylamino)-estra-1,3,5(10)-triene-3,16-diol (Z)-butenedioate (1:1) salt	class I antiarrhythmic	arrhythmia
pilsicainide; pilsicainide hydrochloride; pilzicainide; SUN 1165; SUNRYTHM	N-(2,6-dimethylphenyl)tetrahydro-1H-pyrrolizine-7a(5H)-acetamide	class I antiarrhythmic	arrhythmia
pirmenol; pirmenol hydrochloride; CI 845; PIRMAVAR; PIMENOL	cis-(+,-)- $\alpha$ -[3-(2,6-dimethyl-1-piperidinyl)propyl]- $\alpha$ -phenyl-2-pyridinemethanol	class I antiarrhythmic	arrhythmia

quinacainol; RP 54272; PK 10139	2-(1,1-dimethylethyl)-alpha-[2-(4-piperidinyl)ethyl]-4-quinolinemethanol	class I antiarrhythmic	arrhythmia
recainam; WY 42362; WIN 42362	N-(2,6-dimethylphenyl)-N'-[3-[(1-methylethyl)amino]propyl]urea	class I antiarrhythmic	arrhythmia
bertosamil	3'-isobutyl-7'-isopropylspiro(cyclohexane-1,9'-(3,7)diazabicyclo[3.3.1]nonane)	class I antiarrhythmic; class III antiarrhythmic	arrhythmia; angina
levosemotiadil; DQ 4824; DS 4824; SD 3212; SA 3212	(S)-2-[2-[3-[[2-(1,3-benzodioxol-5-yl)oxy]ethyl]methylamino]propoxy]-5-methoxyphenyl]-4-methyl 2H-1,4-benzothiazin-3(4H)-one	class I antiarrhythmic; class III antiarrhythmic	arrhythmia
WIN 57600	Unspecified	class I antiarrhythmic; class III antiarrhythmic	arrhythmia
WIN 61773	Unspecified	class I antiarrhythmic; class III antiarrhythmic	arrhythmia
WIN 65802	Unspecified	class I antiarrhythmic; class III antiarrhythmic	arrhythmia
bisaramil; bisaramil hydrochloride; RGH 2957; YUTAC	4-chlorobenzoic acid syn-3-ethyl-7-methyl-3,7-diazabicyclo[3.3.1]non-9-yl ester	class I antiarrhythmic; class IV antiarrhythmic	arrhythmia
ersentilide; CK 3579	N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1-yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide	class II antiarrhythmic; class III antiarrhythmic	arrhythmia

ambasilide; LU 47110	3-(4-aminobenzoyl)-7-benzyl-3,7-diazabicyclo[3.3.1]nonane	class III antiarrhythmic	arrhythmia
AWD 160275	Unspecified	class III antiarrhythmic	arrhythmia
AWD 23111	unspecified	class III antiarrhythmic	arrhythmia
CK 1649C	1-[2-hydroxy-2-[4-[(methylsulfonyl)amino]phenyl]ethyl]-3-methyl-1H-imidazolium chloride	class III antiarrhythmic	arrhythmia
dronedarone; SR 33589	N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]-methanesulfonamide	class III antiarrhythmic	arrhythmia
E 4031	N-[4-[[1-[2-(6-methyl-2-pyridinyl)ethyl]-4-piperidinyl]carbonyl]phenyl]methanesulfonamide dihydrochloride	class III antiarrhythmic	arrhythmia
EGIS 7229	5-chloro-4-[[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]amino]-3(2H)-pyridazinone (E)-2-butenedioate (1:1)	class III antiarrhythmic	arrhythmia
ibutilide; ibutilide fumarate; U 70226; U 70226E; CORVERT	N-[4-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl]methanesulfonamide	class III antiarrhythmic	arrhythmia
ipazilide; ipalizide fumarate; WIN 54177; WIN 541774	N-[3-(diethylamino)propyl]-4,5-diphenyl-1H-pyrazole-1-acetamide	class III antiarrhythmic	arrhythmia

L 691121	N-[1'-[2-(5-benzofurazanyl)ethyl]-3,4-dihydro-4-oxospiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide monohydrochloride	class III antiarrhythmic	arrhythmia
L 768673	(R)_N-[2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-2,4-bis(trifluoromethyl)benzeneacetamide	class III antiarrhythmic	arrhythmia
nifekalant; MS 551	6-[[2-[(2-hydroxyethyl)[3-(4-nitrophenyl)propyl]amino]ethyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione monohydrochloride	class III antiarrhythmic	arrhythmia
ORG 20781	unspecified	class III antiarrhythmic	arrhythmia
SB 237376	N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide	class III antiarrhythmic; class IV antiarrhythmic	arrhythmia
KCB 328	1-(2-amino-4-methanesulfonamidophenoxy)-2-[N-(3,4-dimethoxyphenethyl)-N-methylamino]ethane hydrochloride	class III antiarrhythmic; potassium channel blocker	arrhythmia
ITF 1300	Unspecified	heparinoid; class III antiarrhythmic	thrombosis; arrhythmia

selenotifen; BN 52256	4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo[4,5]cyclohepta[1,2-b]selenophen-10-one	histamine antagonist; histamine H1 antagonist	eye disease; asthma; arrhythmia; rhinitis
atrial fibrillation therapy	Unspecified	Ion channel modulator	arrhythmia
ion channel modulators	Unspecified	Ion channel modulator	arrhythmia; asthma
ecdisteron; ecdisten	Unspecified	Membrane stabilization	arrhythmia
mexiletine; KO 1173; MEXITIL	1-methyl-2-(2,6-dimethoxy)ethylamine hydrochloride	Na <sup>+</sup> channel induction of native open state and first step of open channel	neuropathy; arrhythmia; diabetes
5HT4 human neuroreceptor;	Unspecified	neuroreceptor, 5HT4	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
AAP 10	6-L-tyrosinamide-retro-antiarrhythmic peptide (cattle atrium)	peptide	arrhythmia
kappa-conopeptides	Unspecified	peptide; potassium channel blocker	heart ischemia; arrhythmia; gastrointestinal disorder
cloricromen; cloricromene; AD 6; PROENDOTEL	[[8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2H-1-benzopyran-7-yl]oxy]acetic acid ethyl ester	platelet antiaggregant; vasodilator	arrhythmia; thrombosis
almokalant; H 234/09	(+,-)-p-[3-[ethyl[3-(propylsulfinyl)propyl]amino]-2-hydroxypropoxy]benz nitrile	Positive inotropic; antiarrhythmic	arrhythmia

pentisomide; penticainide; propisomide; CM 7857; ME 3202; RHYTHMATE	(+,-)-alfa-[2-[bis(1-methylethyl)amino]ethyl]-alfa-(2-methylpropyl)-2-pyridineacetamide	potassium channel activator; class I antiarrhythmic	arrhythmia
AWD 12260; AWD 122-60	6-[[3-(diethylamino)propyl]amino][3,4'bipyridine]-5-carbonitrile	potassium channel blocker	arrhythmia
HMR 1098	unspecified	potassium channel blocker	arrhythmia
HMR 1883	Unspecified	potassium channel blocker	arrhythmia
potassium channel blocker,	Unspecified	potassium channel blocker	arrhythmia
WAY 123398	N-methyl-N-[2-[methyl(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4-[(methylsulfonyl)amino]benzensulfonamide	potassium channel blocker	arrhythmia
azimilide; azimilide dihydrochloride; azilimide; NE 10064; STEDICOR	1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione	potassium channel blocker; class III antiarrhythmic	ischemia; arrhythmia
dofetilide; UK 68798; XELIDE; TIKOSYN	N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]-methanesulfonamide	potassium channel blocker; class III antiarrhythmic	arrhythmia
MK 499; L 706000	unspecified	potassium channel blocker; class III antiarrhythmic	arrhythmia
sematilide; sematilide hydrochloride; CK 1752; RU 752; SH 506; ZK 110516	N-[2-(diethylamino)ethyl]-4-[(methylsulfonyl)amino]benzamide	potassium channel blocker; class III antiarrhythmic	arrhythmia

WAY 123223	N-[4-[2-hydroxy-3-[methyl(2-quinolinylmethyl)amino]propoxy]phenyl]methanesulfonamide	potassium channel blocker; class III antiarrhythmic	arrhythmia
WAY 125971	N-(2-((methyl(3-(4-((methylsulfonyl)amino)phenoxy)propyl)amino)methyl)-6-quinolinyl)methanesulfonamide	potassium channel blocker; class III antiarrhythmic	arrhythmia
KW 3407	5-[[[(2-diethylamino)ethyl]amino]-5,11-dihydro-7-methoxy-(1)-benzoxepino-[3,4-b]pyridine fumarate (2:3)	sodium channel blocker	arrhythmia
antiarrhythmic, acute,	unspecified	sodium channel blocker; potassium channel blocker	arrhythmia
cariporide; cariporide mesilate; HOE 642; HOE 642A	N-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)benzamide	sodium/hydrogen exchange inhibitor	arrhythmia; myocardial infarction; angina; restenosis
KBR 9032; KB-R 9032	N-(aminoiminomethyl)-3,4-dihydro-2,2-dimethyl-4-(1-methylethyl)-3-oxo-2H-1,4-benzoxazine-6-carboxamide monomethanesulfonate	sodium/hydrogen exchange inhibitor; anti-ischemic	arrhythmia; heart ischemia; reperfusion injury
KB 130015	unspecified	thyroid hormone antagonist	arrhythmia
thyroid hormone receptor alpha antagonists	unspecified	thyroid hormone antagonist	arrhythmia



RS 2135	(3aR,12R,12aR,12bS)-12-amino-2,3,3a,4,11,12,12a,12b-octahydro-10-hydroxyisoquino[2,1,8-lma]carbazol-5(1H)-one hydrochloride 1:5 hydrate	vasodilator	arrhythmia
milacainide; xilacainide; Ro 229194	(R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridinyl)propyl]propanamide [S-(R*,R*)]-2,3-dihydroxybutanedioate	vasodilator; sodium channel blocker; class I antiarrhythmic	arrhythmia

Table 60. Current Candidate Therapeutic Interventions for the Treatment of Hypertension

Product Name	Chemical Name	Action	Indication
5-methylurapidil; 5-MU	6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3,5-trimethyl-2,4(1H,3H)-pyrimidinedione	5HT agonist; 5HT1A agonist	hypertension
A 74283	Unspecified	5HT agonist; 5HT1A agonist; vasodilator	hypertension
U 86192A	2,3-dihydro-2-[[[3-(phenylpropyl)amino]methyl]-7H-1,4-dioxino[2,3-e]indole-8-carboxylic acid methyl ester	5HT antagonist; 5HT1A antagonist	hypertension
AHR 16303B	1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]phenyl]-2-methyl-1-propanone ethanedioate (1:1)	5HT antagonist; 5HT2 antagonist	hypertension; angina

ketanserin; R 41468; SEREFREV; SUFREXAL; SEREFREX	3-[2-[4-(4-fluorobenzyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolin-6(1H)-one	5HT antagonist; 5HT2 antagonist	hypertension
lidanserin; ZK 33839	(+,-)-4-[3-[3-[4-(p-fluorobenzoyl)piperidin-1-yl]propoxy]-4-methoxyphenyl]-2-pyrrolidinone	5HT antagonist; 5HT2 antagonist; alpha adrenergic antagonist; alpha 1 adrenergic antagonist	hypertension
SUN 9221	2-(4-chlorophenyl)-1,4-dihydro-3-[1-benzothiopyrano[4,3-c]pyrazol-3(2H)-one 5-oxide	5HT antagonist; 5HT2 antagonist; alpha adrenergic antagonist; alpha 1 adrenergic antagonist; platelet antiaggregant	hypertension
AB 47	(S)-1-[N-(8-amino-1-carboxy-octyl)-L-alanyl]-L-proline	ACE inhibitor	hypertension
ACE inhibitor	1-(2-((1-carboxy-6-(4-piperidinyl)hexyl)amino)-1-oxopropyl)octahydro-1H-indole-2-carboxylic acid	ACE inhibitor	hypertension
alacepril; DU 1219; CETAPRIL	(S)-N-[1-[3-(acetylthio)-2-methyl-1-oxopropyl]-L-prolyl]-L-phenylalanine	ACE inhibitor	hypertension
benazepril; benazepril hydrochloride; benazepril; CGS 148247; CIBACEN; LOTENSIN; BRIEM; ZINADRIL; TENSANIL; CIBACENE	[S-(R*,R*)]-3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid	ACE inhibitor	hypertension

captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
ceronapril; ceranapril; SQ 29852	(S)-1-[6-amino-2-[[[hydroxy(4-phenylbutyl)phospinyloxy]-1-oxohexyl]-L-proline	ACE inhibitor	cognitive defect; hypertension; anxiety
cilazapril; Ro 312848; Ro 312848-006; INHIBACE; VASCACE; DYNORM	(1S,9S)-9-[[[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid	ACE inhibitor	hypertension
CV 5975	(R)-3-[(S)-1-carboxy-5-(4-piperidyl)pentyl]amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-acetic acid	ACE inhibitor	hypertension
delapril; alindapril; CV 3317; REV 6000A; ADECUT; CUPRESSIN; KEDAPRIL; DELAKET	(S)-N-(2,3-dihydro-1H-inden-2-yl)-N-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]glycine	ACE inhibitor	hypertension
drug delivery system, controlled release captopril; captopril	Unspecified	ACE inhibitor	hypertension
drug delivery system, SODAS captopril; captopril SODAS	Unspecified	ACE inhibitor	heart failure; hypertension

DU 1777	(2S,3aS,7aS)-1-(N2-nicotinoyl-L-lysyl-alpha-D-glutamyoctahydro-1H-indole-2-carboxylic acid	ACE inhibitor	hypertension
enalapril; MK 421; INNOVACE; COVERTEN; ENAPREN; RENITEN; VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE	(S)-1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline	ACE inhibitor	hypertension
fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 produg; MONOPRIL; DYNACIL; FUSINORM; FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC	[1[S*(R*)],2alpha.,4b eta]-4-cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl]acetyl]-L-proline	ACE inhibitor	hypertension
fosinoprilat; fosfenopril; fosinoprilic acid; SQ 27519	trans-4-cyclohexyl-1-[[[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-L-proline	ACE inhibitor	hypertension
FPL 66564	(R)-2-(3-mercapto-2(S)-methyl-1-oxopropoxy)-3-(methylthio)-propanoic acid	ACE inhibitor	hypertension
hidrapril; LG 32001	(1S,2R)-2-(((hydroxycarbamoyl)methyl)methylcarbamoyl)cyclohexane carboxylic acid	ACE inhibitor	hypertension

imidapril; TA 6366; EMD 61800; EMD 63100; TANATRIL; NOVALOC; NOVAROK; TANAPRESS; NORTEN	4S-[3-[R*(R*)],4R*]- 3-[2-[[1- (ethoxycarbonyl)-3- phenylpropyl]amino]- 1-oxopropyl]-1- methyl-2-oxo-4- imidazolidinecarboxy lic acid	ACE inhibitor	hypertension; heart failure; diabetes
libenzapril; CGS 16617	[S-(R*,R*)]-3-[(5- amino-1- carboxypentyl)amino] -2,3,4,5-tetrahydro-2- oxo-1H-1- benzazepine-1-acetic acid	ACE inhibitor	hypertension
lisinopril; MK 521; L 154826; MK 522; PRINTVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1- carboxy-3- phenylpropyl)-L- lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease
moexipril; RS 10085; L SPM 925; CI 925; RS 10085197; UNIVASC; FAMPRESS; MOEX; PERDIX; FEMPRESS; PRIMOXIL; FEMPRESS; FEMPRES	[3S-[2[R*(R*),3R*]]- 2-[2-[[1- (ethoxycarbonyl)-3- phenylpropyl]amino]- 1-oxopropyl]-1,2,3,4- tetrahydro-6,7- dimethoxy-3- isoquinolinecarboxyli c acid	ACE inhibitor	hypertension
perindopril; perindopril erbumine; S 9490; S 94903; SED 9490; MCN A2833109; DW 7950; COVERSYL; ACEON; ACERTIL; COVERENE; COVEREX; COVERSIL	(2S,3aS,7aS)-1-[(2S)- 2-[[[(1S)-1- (ethoxycarbonyl)butyl ]amino]-1- oxopropyl]octahydro- 1-1H-indole-2- carboxylic acid	ACE inhibitor	hypertension; coronary artery disease; heart failure

perindoprilat; S 9780; S 9490 diacid	[2S-[1[R(R*)],2alfa,3abeta,7abeta]]-1-[2-[(1-carboxybutyl)amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid	ACE inhibitor	hypertension
quinapril; quinapril hydrochloride; CI 906; PD 1094522; ACCUPRIL; CONAN; ACCUPRO; ACUITEL; ACEQUIN; ACCUZIDE; QUINAZIDE	[3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid	ACE inhibitor	hypertension
ramipril; HOE 498; ALTACE; TRIATEC; PRAMACE; RAMACE; TRITACE; CARASEL; ACOVIL	(2S,3aS,6aS)-1-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid 1-ethyl ester	ACE inhibitor	hypertension; heart failure
RL 6134; EQUATEN	unspecified	ACE inhibitor	hypertension
RL 6207; PRENTYL	unspecified	ACE inhibitor	hypertension
RL 6893; SYNECOR	Unspecified	ACE inhibitor	hypertension
spirapril; spirapril hydrochloride; SCH 33844; TI 211950; RENPRESS; SANDOPRIL; RENORMAX; CARDIOPRIL	[8S-[7[R*(R*)]]8R*]-7-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid	ACE inhibitor	hypertension
temocapril; temocapril hydrochloride; CS 622; ESCOL; ACECOL; ACECOR	[2S-[2alfa,6beta(R*)]]-6-[[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic acid	ACE inhibitor	hypertension

temocaprilat; temocapril diacid; RS 5139	[2S- [2alpha,6beta(R*)]]- 6-[(1-carboxy-3- phenylpropyl)amino]t etrahydro-5-oxo-2-(2- thienyl)-1,4- thiazepine-4(5H)- acetic acid	ACE inhibitor	hypertension
utibapril; FPL 63547	(S)-2-tert-butyl-4- [(S)-N-[(S)-1- carboxy-3- phenylpropyl]alanyl]- delta2-1,3,4- thiadiazoline-5- carboxylic acid, 4- ethyl ester	ACE inhibitor	hypertension; heart failure
WY 44655	(2S- (1(R*(R*)),2R*))1- (2-(1- (ethoxycarbonyl)-3- phenylpropyl)amino)- 1-oxopropyl)-2,3- dihydro-1H-indole-2- carboxylic acid	ACE inhibitor	hypertension
Y 23785	unspecified	ACE inhibitor	hypertension
zofenopril; SQ 26991; ZOPRACE	[(R*),2alfa,4alfa]-1- [3-(benzoylthio)-2- methyl-1-oxopropyl]- 4-(phenylthio)-L- proline	ACE inhibitor	hypertension; myocardial infarction
zofenoprilat; SQ 26333	(4S)-1-((S)-3- mercapto-2- methylpropionyl)-4- (phenylthio)-L- proline	ACE inhibitor	hypertension
quinapril + diltiazem; diltiazem + quinapril; CI 975	Unspecified	ACE inhibitor; calcium antagonist	hypertension
spirapril + isradipine; isradipine + spirapril; ISPRI	Unspecified	ACE inhibitor; calcium antagonist	hypertension
delapril + manidipine; manidipine + delapril; CHF 1521	Unspecified	ACE inhibitor; calcium channel blocker	hypertension

trandolapril + verapamil; verapamil + trandolapril; RU 44570A; TARKA; VERATRON	Unspecified	ACE inhibitor; calcium channel blocker	hypertension
telmisartan+lacidipine ; lacidipine+telmisartan	Unspecified	ACE inhibitor; calcium channel blocker; angiotensin II antagonist	hypertension
benazepril + hydrochlorothiazide; hydrochlorothiazide + benazepril; CIBADREX; LOTENSIN HCT	Unspecified	ACE inhibitor; diuretic	hypertension
delapril + indapamide; indapamide + delapril; CHF 1513; DELAPRIDE	Unspecified	ACE inhibitor; diuretic	hypertension
fosinopril + hydrochlorothiazide; hydrochlorothiazide + fosinopril; TENSOZIDE; MONOPRIL-HCT; FOSICOMP	Unspecified	ACE inhibitor; diuretic	hypertension; heart failure
lisinopril + hydrochlorothiazide; hydrochlorothiazide + lisinopril; PRINZIDE; PRINTIVIL PLUS; CARACE; ZESTORETIC; ACECOMB; ACERCOMP	Unspecified	ACE inhibitor; diuretic	hypertension
moexipril + hydrochlorothiazide; hydrochlorothiazide + moexipril; UNIRETIC; FEMPRESS PLUS	Unspecified	ACE inhibitor; diuretic	hypertension



quinapril + hydrochlorothiazide; hydrochlorothiazide + quinapril; ACCURETIC; ACEQUIDE	Unspecified	ACE inhibitor; diuretic	hypertension
fasidotril; valadotril; alatriopril; BP 1.137	(S)-N-[3-(acetylthio)- 2-(1,3-benzodioxol-5- ylmethyl)-1- oxopropyl]-L-alanine phenylmethyl ester	ACE inhibitor; enkephalinase inhibitor	hypertension
glycopril	N-[(2S)-3- (acetylthio)-2-(1,3- benzodioxol-5- ylmethyl)-1- oxopropyl]glycine phenylmethyl ester	ACE inhibitor; enkephalinase inhibitor	hypertension
BMS 189921	[S-(R*,R*)]- hexahydro-6-[(2- mercapto-1-oxo-3- phenylpropyl)amino]- 2,2-dimethyl-7-oxo- 1H-azepine	ACE inhibitor; matrix metalloproteinase inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
BMS 182657	(S,S)-2-[3-(2- mercapto-3- phenylpropionamide)- 2-oxo-2,3,4,5- tetrahydro-1H-1- benzazepin-1- yl]acetic acid	ACE inhibitor; neutral endopeptidase inhibitor	hypertension
ER 3295	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
mixanpril	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension
sampatrilat; UK 81252	2-[[1-[[[1-carboxy-2- (4- hydroxyphenyl)ethyl] amino]carbonyl]cyclo pentyl]methyl]-N- [N2-(methylsulfonyl)- L-lysyl]-beta-alanine [S-(R*,R*)]-	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure

Z 13752A	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
MDL 100240; MDL 100173 pro	[4S- [4alpha,7alpha(R*),1 2bbeta]]-7-[[2- (acetylthio)-1-oxo-3- phenylpropyl]amino]- 1,2,3,4,6,7,8,12b- octahydro-6-oxo- pyrido[2,1- a][2]benzazepine-4- carboxylic acid	ACE inhibitor; neutral endopeptidase inhibitor; diuretic	heart failure; hypertension
C 111	Gly-Val-Tyr-Pro-His- Lys	ACE inhibitor; peptide	hypertension
C 112	Ile-Arg-Pro-Val-Gln	ACE inhibitor; peptide	hypertension
moveltipril; altiopril calcium; MC 838; LOWPRES	[R-(R*,S*)]-1-[3-[[2- [(cyclohexycarbonyl) amino]-1- oxopropyl]thio]-2- methyl-1-oxopropyl]- L-proline	ACE inhibitor; vasodilator	hypertension
spiraprilat; SCH 33861	(8S)-7-[(S)-N-[(S)-1- carboxy-3- phenylpropyl]alanyl]- 1,4-dithia-7- azaspiro[4.4]nonane- 8-carboxylic acid	ACE inhibitor; vasodilator	hypertension; glaucoma
trandolapril; CI 907; RU 44570; RU 570; ODRIK; UDRIK; GOPTEN; TRAPRIL; ODRIC; MAVIK	[2S- [1[R*(R*)],2alpha,3a alpha,7abeta]]-1-[2- [[1-(ethoxycarbonyl)- 3- phenylpropyl]amino]- 1- oxopropyl]octahydro- 1H-indole-2- carboxylic acid	ACE inhibitor; vasodilator	hypertension; heart failure; myocardial infarction
AGR 529	N-(4-amino-4- oxobutyl)adenosine hydrochloride	Adenosine A1 receptors in fat cells	hypertension; hyperlipidemia
AGR 540	N-(4-amino-4- oxobutyl)adenosine 2',3',5'-tripropanoate	Adenosine A1 receptors in fat cells	hypertension; hyperlipidemia

RPR 100579	Unspecified	adenosine agonist	hypertension; heart failure; hyperlipidemia
antihypertensive	2-hexynyladenosine (2-H-Ado)	adenosine agonist; adenosine A2 agonist	hypertension
antihypertensive	2-octynyladenosine (2-O-Ado)	adenosine agonist; adenosine A2 agonist	hypertension
CGS 21680	4-[2-[[6-amino-9-(N-ethyl-beta-D-ribofuranuronamidoyl)-9H-purin-2-yl]amino]ethyl]benzenepropanoic acid	adenosine agonist; adenosine A2 agonist; adenosine A3 agonist	hypertension
CGS 22492	2-[(2-cyclohexylethyl)amino]adenosine	adenosine agonist; vasodilator	hypertension
YT 146	2-(1-octynyl)adenosine	adenosine agonist; vasodilator	hypertension
KS 341; RKS 0341	Unspecified	adenosine antagonist	hypertension
FK 453; FR 113453	[R-(E)]-1-[1-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propenyl]-2-piperidineethanol	adenosine antagonist; adenosine A1 antagonist	hypertension
FK 838	6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazine butyric acid	adenosine antagonist; adenosine A1 antagonist; diuretic	hypertension
CVT 124; BG 9719; ADENTRI	3,7-dihydro-8-(3-oxatricyclo[3.2.1.0 <sup>2,4</sup> ]oct-6-yl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; diuretic; adenosine A1 antagonist	heart failure; hypertension
eplerenone; epoxymexrenone; CGP 30083; SC 66110	(7.alpha.,11.alpha.,17.alpha.)-9,11-epoxy-17-hydroxy-3-oxopregn-4-ene-7,21-dicarboxylic acid .gamma.-lactone methyl ester	aldosterone antagonist	heart failure; hypertension

drug delivery system, transdermal clonidine; clonidine transdermal; M 5041T	Unspecified	alpha adrenergic agonist	hypertension
apraclonidine; p-aminoclonidine; aplonidine; ALO 2145; NC 14; IOPIDINE	2,6-dichloro-N'-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine	alpha adrenergic agonist; alpha2 adrenergic agonist	glaucoma; hypertension
moxonidine; BE 5895; BDF 5895; LY 326869; CYNT; PHYSIOTENS	4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine	alpha adrenergic agonist; alpha2 adrenergic agonist; imidazoline agonist	hypertension; heart failure; diabetes
indoramin; WY 21901; DORALESE; TILTAB; BARATOL; WYDORA; WYPRESIN; VIDORA	N-[1-[2-(1H-indol-3-yl)ethyl]-4-piperidinyl]benzamide	alpha adrenergic antagonist	hypertension; benign prostate hypertrophy
CL 870801	2-methyl-4-chloro-5-(((2-(4-(2-methoxyphenyl)piperazinyl-1)ethyl)amino)-3(2H)-pyridazinone hydrochloride	alpha adrenergic antagonist; 5HT agonist; vasodilator	hypertension
alfuzosin; alfuzosin hydrochloride; SL 77499; SL 7749910; ALFOTEN; XATRAL; BENESTAN; BENESTAIN; XATRAL-MAG; DILOTEX; URION; UROXATRAL	N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide	alpha adrenergic antagonist; alpha1 adrenergic antagonist	benign prostate hypertrophy; hypertension
bunazosin; bunazosin hydrochloride; E 643; DE 070; E 1015; DETANTOL; DETANTOL R; ANDANTE	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-butyrylhexahydro-1H-1,4-diazepine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; glaucoma; benign prostate hypertrophy

CR 2991	Unspecified	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
cyclazosin	Cis-1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)decahydroquinoxaline monohydrochloride	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
dicentrine; d-dicentrine; (+)-dicentrine; eximine; O,N-dimethylitseferine	(S)-6,7,7a,8-tetrahydro-10,11-dimethoxy-7-methyl-5H-benzo[g]-1,3-benzodioxolo[6,5,4-de]quinoline	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
doxazosin; UK 33274; UK 3327427; CARDURA; CARDENALIN; SUPRESSIN; CARDURAN; DIBLOCIN; DOXABEN; NORMOTHEN; DEDRALEN; ALFADIL	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	benign prostate hypertrophy; hypertension
drug delivery system, OROS prazosin; prazosin OROS; CP 122991; MINIPRESS XL; ALPRESS LP	Unspecified	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
HSR 175	R-(-)-5-[2[2-(5-fluoro-2-methoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; urinary incontinence
metazosin; metasozin; metazocin; KENOSIN	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxy-1-oxopropyl)piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; glaucoma; benign prostate hypertrophy; heart failure

QF 301	2-[2-(N4-O-methoxyphenyl-N1-piperazinyl)ethyl]-1-tetralone	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
SGB 1534	3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-2,4(1H,3H)-quinazolinedione monohydrochloride	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
SNAP 5150	N-[3-(4,4-diphenyl-1-piperidinyl)propyl]-1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinecarboxamide	alpha adrenergic antagonist; alpha1 adrenergic antagonist	benign prostate hypertrophy; hyperlipidemia; hypertension
urapidil; B 66256; BY 05068; EBRANTIL; ALPHA DEPRESSAN	6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; benign prostate hypertrophy; dysuria
AT 112	2,3-dihydro-2-[(4-phenyl-1-piperazinyl)methyl]imidazo[1,2-c]quinazolin-5(6H)-one	alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	thrombosis; hypertension
terazosin; A 45975; MY 208; HYTRIN; HEITRIN; VASOMET; SINALFA; BLAVIN; URODIE; HYTRINEX; TERAPROST; ISONTYN	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist; vasodilator	benign prostate hypertrophy; hypertension
A 65265	Unspecified	alpha adrenergic antagonist; alpha2 adrenergic antagonist	hypertension

amosulalol; YM 09538; LOWGAN	5-[1-hydroxy-2-[[2-(2-methoxyphenoxy)ethyl]amino]ethyl]-2-methylbenzenesulfonamide	alpha adrenergic antagonist; beta adrenergic antagonist	hypertension
brefonalol; BDF 8186	(+,-)-6-[2-[(1,1-dimethyl-3-phenylpropyl)amino]-1-hydroxyethyl]-3,4-dihydrocarbostyrl	alpha adrenergic antagonist; beta adrenergic antagonist	hypertension
N 1518	4-[2-hydroxy-3-[[2-(2-methoxyphenoxy)-1-methylethyl]amino]propoxy]-1(2H)-isoquinolinone	alpha adrenergic antagonist; beta adrenergic antagonist	hypertension
AC 625	Unspecified	amylin antagonist; peptide	hypertension
adrenergic alpha2 human neuroreceptors; neuroreceptors, adrenergic alpha2 human	Unspecified	analgesic	research tool; pain; hypertension; glaucoma
EMD 61650	2-butyl-3,5-dihydro-5-(phenylmethyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4H-imidazo[4,5-c]pyridin-4-one	Angiotensin II	hypertension
EMD 66684	2-butyl-4,5-dihydro-4-oxo-3[[2'-(1H-tetrazol-5-yl)-4-biphenyl]methyl]-3H-imidazo[4,5-C]pyridine-5-(N,N-dimethylacetamide)	Angiotensin II	hypertension
A 81282; ABBOTT 81282	4-[butyl[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-5-pyrimidinecarboxylic acid	angiotensin II antagonist	hypertension

A 81988	Unspecified	angiotensin II antagonist	hypertension
angiotensin II receptor antagonist	Unspecified	angiotensin II antagonist	hypertension
BIBR 363	Unspecified	angiotensin II antagonist	hypertension
BIBS 222	2-[[[4-[[2-butyl-6-[[[(methylamino)carbonyl]pentylamino]-1H-benzimidazol-1-yl]methyl]phenyl]amino]carbonyl]-3,6-dichlorobenzoic acid	angiotensin II antagonist	hypertension
BIBS 39	4'-[[[(2-n-butyl-6-cyclohexylaminocarbonylamino-benzimidazole-1-yl)methyl]biphenyl]-2-carboxylic acid	angiotensin II antagonist	hypertension
BMS 180560	2-butyl-4-chloro-1-[[[1-[2-(1H-tetrazol-5-yl)phenyl]-1H-indol-4-yl]methyl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMIAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
CI 996	2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
DA 2079	Unspecified	angiotensin II antagonist	hypertension



DUP 532	4-(pentafluoroethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
E 4177	4'-[(2-cyclopropyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid	angiotensin II antagonist	hypertension
embusartan; BAY 106734	6-butyl-1-[[3-fluoro-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1,2-dihydro-2-oxo-4-pyridinecarboxylic acid methyl ester	angiotensin II antagonist	hypertension
EMD 66397	Unspecified	angiotensin II antagonist	hypertension
eprosartan; eprosartan mesylate; SB 108566; SKF 108566; SKF 108566 J; TEVETEN	(E)-alfa-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl)methylene]-2-thiophenepropanoic acid	angiotensin II antagonist	hypertension
EXP 3174; E 3174	2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
EXP 6155	2-butyl-1-[(4-carboxyphenyl)methyl]-4-chloro-1H-imidazole-5-acetic acid disodium salt	angiotensin II antagonist	hypertension

EXP 6803	2-butyl-1-[[4-[(2-carboxybenzoyl)amino]phenyl]methyl]-4-chloro-1H-imidazole-5-acetic acid alfa-methyl ester monosodium salt	angiotensin II antagonist	hypertension
FK 739; FR 130739	Unspecified	angiotensin II antagonist	hypertension
forasartan; SC 52458	5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(1H-tetrazol-5-ylphenyl)]pyridine	angiotensin II antagonist	hypertension
GA 0056	2-[6-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-quinolinyl]benzoic acid	angiotensin II antagonist	hypertension
HN 65021	2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid 1-(ethoxycarbamoyl)ethyl ester potassium salt	angiotensin II antagonist	hypertension
HR 720; HOE 720	2-butyl-4-(methylthio)-1-[[2'-[[[(propyl)amino]sulfonyl](1,1'-biphenyl)-4-yl]methyl]-1H-imidazole-5-carboxylic acid dipotassium salt	angiotensin II antagonist	hypertension
ICI D6888	Unspecified	angiotensin II antagonist	hypertension
ICI D7155	Unspecified	angiotensin II antagonist	hypertension

ICI D8731	2-ethyl-4-((2'-(1H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl)-methoxy)quinoline hydrochloride	angiotensin II antagonist	hypertension
irbesartan; SR 47436; BMS 186295; APROVEL; KARVEA; AVAPRO	2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one	angiotensin II antagonist	hypertension; kidney disease; heart failure
KRH 594	2-[[[5-ethyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1,3,4-thiadiazol-2(3H)-ylidene]amino]carbonyl]-1-cyclopentene-1-carboxylic acid dipotassium salt	angiotensin II antagonist	hypertension
KT 3671; DA 727; KT 3-671	5,6,7,8-tetrahydro-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4(3H)-cycloheptimidazole	angiotensin II antagonist	hypertension
KW 3433	Unspecified	angiotensin II antagonist	hypertension
L 158978	Unspecified	angiotensin II antagonist	hypertension
L 159282; MK 996	N-[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]-benzamide	angiotensin II antagonist	hypertension
L 159689	N-[3,4-dihydro-4-oxo-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-6-quinazolinyl]-N-pentylbenzamide	angiotensin II antagonist	hypertension

L 161177	2-ethyl-5,7-dimethyl-3-[[2'-(2-oxido-3H-1,2,3,5-oxathiadiazol-4-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazo[4,5-b]pyridine	angiotensin II antagonist	hypertension
L 162154	N-[[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]-3-chloro-2-thiophenecarboxamide	angiotensin II antagonist	hypertension
L 162234	[[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]sulphonyl]carbamic acid 1,1-dimethylethyl ester	angiotensin II antagonist	hypertension
L 163017	6-[benzoylamino]-7-methyl-2-propyl-3-[[2'-(N-(3-methyl-1-butoxy)carbonylaminosulfonyl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazo[4,5-b]pyridine	angiotensin II antagonist	hypertension
L 692429	3-amino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3(R)-yl]-butanamide	angiotensin II antagonist	hypertension

losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
LR B139	Unspecified	angiotensin II antagonist	hypertension; angina
LY 235656	Unspecified	angiotensin II antagonist	hypertension
LY 285434	Unspecified	angiotensin II antagonist	hypertension
LY 301875	(4S)-4-[4-(carboxymethyl)phenoxy]-1-[(2R)-1-oxo-2-[4-[(2-sulfonyl)amino]-1H-imidazol-1-yl]octyl]-L-proline	angiotensin II antagonist	hypertension
LY 302289	Unspecified	angiotensin II antagonist	hypertension
LY 315995	Unspecified	angiotensin II antagonist	hypertension
ME 3221	3-methoxy-2,6-dimethyl-4-[[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl]-4-yl]methoxy]pyridine	angiotensin II antagonist	hypertension
milfasartan; LR B081; LRB 081	2-[[[4-butyl-2-methyl-6-oxo-5-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1(6H)-pyrimidinyl]methyl]-3-thiophenecarboxylic acid methyl ester	angiotensin II antagonist	hypertension

olmesartan; CS 866	4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester	angiotensin II antagonist	hypertension
PD 123177; EXP 655	1-[(4-amino-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid	angiotensin II antagonist	hypertension
PD 123319	(S)-1-[[4-(dimethylamino)-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid	angiotensin II antagonist	hypertension
PD 150304	(Z)-4-[[2-butyl-5-[[1-butyl-3-[(5-methyl-3-thienyl)methyl]-2,5-dioxo-4-imidazolidinylidene]methyl]-1H-imidazol-1-yl]methyl]benzoic acid	angiotensin II antagonist	hypertension
tipisartan; UP 2696	5-methyl-7-propyl-8-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-[1,2,4-triazolo[1,5-c]pyrimidin-2(3H)-one	angiotensin II antagonist	hypertension

RWJ 46458	2-carbethoxymethyliden e-4-methyl-4-ethyl-2- [4-(2'-tetrazolo)- phenyl]benzylpiperidi n-6-one	angiotensin II antagonist	hypertension
saprisartan; saprisartan potassium; GR 138950; GR 138950X; GR 138950C	1-[3-bromo-2-[2- (trifluoromethylsulfon ylamino)phenyl]benz o[b]furan-5- ylmethyl]-4- cyclopropyl-2-ethyl- 1H-imidazole-5- carboxamide	angiotensin II antagonist	hypertension
saralasin; saralasin acetate; aralasin; P 113; P 113 (peptide); SARENIN	1-(N-methylglycine)- 5-L-valine-8-L- alanineangiotensin II	angiotensin II antagonist	hypertension; contraception; diagnosis
SC 51316	2,5-dibutyl-2,4- dihydro-4-[[2'-(1H- tetrazol-5-yl)[1,1'- biphenyl]-4- yl]methyl]-3H-1,2,4- triazol-3-one	angiotensin II antagonist	hypertension
SK 1080; KR 31080	2-butyl-5-methyl-6- (1-oxido-2-pyridinyl)- 3-[[2'-(1H-tetrazol-5- yl)[1,1'-biphenyl]-4- yl]methyl]-3H- imidazodo[4,5- b]pyridine	angiotensin II antagonist	hypertension
SL 910102	Unspecified	angiotensin II antagonist	hypertension
TAK 536	1-[[2'-(2,5-dihydro-5- oxo-1,2,4-oxadiazol- 3-yl)[1,1'-biphenyl]- 4-yl]methyl-2- ethoxy-1H- benzimidazole-7- carboxylic acid	angiotensin II antagonist	hypertension

tasosartan; ANA 756; WAY ANA 756; VERDLA	5,8-dihydro-2,4-dimethyl-8-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-pyrido[2,3-d]pyrimidin-7(6H)-one	angiotensin II antagonist	hypertension
telmisartan; BIBR 277; BIBR 0277SE; MICARDIS; PRITOR	4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid	angiotensin II antagonist	hypertension
U 97018	2-butyl-3,6,7,8,9,11-hexahydro-6,9-dimethyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-6,9-ethano-4H-imidazo[4,5-d]pyridazino[1,2-a]pyridazin-4-one	angiotensin II antagonist	hypertension
UP 27522	5-propyl-6-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol	angiotensin II antagonist	hypertension
UR 7247	3-(1-methylethyl)-1-propyl-5-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazole-4-carboxylic acid	angiotensin II antagonist	hypertension; heart failure
UR 7280	3-(1,1-dimethylethyl)-1-propyl-5-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazole-4-carboxylic acid	angiotensin II antagonist	hypertension



valsartan; CGP 48933; DIOVAN	N-(1-oxopentyl)-N-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine	angiotensin II antagonist	hypertension; heart failure
WK 1360	Unspecified	angiotensin II antagonist	hypertension
WY 126227; WAY 126227	N-[[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-2-(trifluoromethyl)-4-quinazolinamine	angiotensin II antagonist	hypertension
YM 31472	Unspecified	angiotensin II antagonist	hypertension
YM 358	2,7-diethyl-5-[(2'-(5-tetrazoyl)biphenyl-4-yl)methyl]-5H-pyrazolo[1,5-b][1,2,4]triazole	angiotensin II antagonist	hypertension; heart failure
irbesartan + hydrochlorothiazide; hydrochlorothiazide + irbesartan; AVALIDE; COAPROVEL; KARVEZIDE	Unspecified	angiotensin II antagonist; diuretic	hypertension; kidney disease
losartan + hydrochlorothiazide; HYZAAR; LOSACOR D	Unspecified	angiotensin II antagonist; diuretic	hypertension
tasosartan + hydrochlorothiazide; hydrochlorothiazide + tasosartan; VERDIA/HCTZ	Unspecified	angiotensin II antagonist; diuretic	hypertension
valsartan + hydrochlorothiazide; hydrochlorothiazide + valsartan; CoDiovan; CO-DIOVAN; DIOVAN HCT; CoTareg; CO-TAREG; DIOVAN-D	Unspecified	angiotensin II antagonist; diuretic	hypertension

candesartan; CV 11974	2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist; imidazole	hypertension
CV 11194; EP 425921A	2-butyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist; imidazole	hypertension
LR B087; LRB 087	Unspecified	angiotensin II antagonist; imidazole	hypertension
zolasartan; GR 117289; GR 117289C	1-[[3-bromo-2-[2-(1H-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-2-butyl-4-chloro-1H-imidazole-5-carboxylic acid	angiotensin II antagonist; vasodilator	hypertension
LA 360	Unspecified	anion transport inhibitor	hypertension
AP 539	1-(2-naphthoxyacetyl)piperidin-4-carbonyl-Nalfo-L-arginyl-Nalfo-L-isoleuciny-Nalfo-L-aspartyl-Nalfo-L-arginyl-Nalfo-L-isoleucinyamide	ANP antagonist	hypertension
antihypertensive	Unspecified	Antihypertensive	hypertension
antihypertensive, ALT 462	4-amino-2,4-dihydro-5-(1-methylethyl)-3H-1,2,4-triazol-3-one hydrazone	Antihypertensive	hypertension
BR 9201	Unspecified	Antihypertensive	hypertension
BW 1045U85	Unspecified	Antihypertensive	hypertension
CKD 705	Unspecified	Antihypertensive	hypertension
erythritol; NIK 242	1,2,3,4-butanetetrol	Antihypertensive	hypertension
IRLS DR09	Unspecified	Antihypertensive	hypertension
IRLS DR12	Unspecified	Antihypertensive	hypertension
IRLS DR33	Unspecified	Antihypertensive	hypertension

LCB 2601	Unspecified	Antihypertensive	hypertension
millisrol; NK 843H; NK 843L; NK 843	Unspecified	Antihypertensive	hypertension; diagnosis
MYD 37	Unspecified	Antihypertensive	hypertension
PST 2238	(3beta,5beta,14beta)- 21,23-epoxy-24- norchola-20,22-diene- 3,14,17-triol	Antihypertensive	hypertension
RES 7011; RES 701- 1	Gly-Asn-Trp-His- Gly-Thr-Ala-Pro- Asp-Trp-Phe-Phe- Asn-Tyr-Tyr-Trp cyclic (9-1)-peptide	Antihypertensive	hypertension
RS 89769	Unspecified	Antihypertensive	hypertension
TN 891	(S)-4-(2-hydroxy-3- isopropylaminopropo xy)phenylacetamide	Antihypertensive	hypertension
UH 334	Unspecified	Antihypertensive	hypertension
antihypertensive	1-((3- methylphenyl)piperaz in-1-yl)-3-(thio(4- acetamido)phenyl)-pr opane	Antihypertensive; central site	hypertension
APCI	Unspecified	atrial peptide clearance receptor inhibitor	hypertension
candoxatril; UK 79300	4-[[[1-[3-[(2,3- dihydro-1H-inden-5- yl)oxy]-2-[(2- methoxyethoxy)meth yl]-3- oxopropyl]cyclopenty l]carbonyl]amino]- cyclohexanecarboxyli c acid	atriopeptidase inhibitor	hypertension; heart failure
candoxatrilat; UK 73967	(alfa,S)-1-[(cis-4- carboxycyclohexyl)ca rbamoyl]-alfa-[(2- methoxyethoxy)meth yl]cyclopentanepropio nic acid	atriopeptidase inhibitor	hypertension
SCH 42945	Unspecified	atriopeptidase inhibitor	hypertension

adimolol; imidolol; MEN 935	1,3-dihydro-1-[3-[[2-hydroxy-3-(1-naphthalenyloxy)propyl]amino]-3-methylbutyl]-2H-benzimidazol-2-one	beta adrenergic antagonist	hypertension
arotinolol; S 596; ALMARL; ANBROTH; ACEMAIL; ALOCHINON; AMOPSOL; AROTINOIL; ASTONIL; LISTERIA	(+,-)-5-[2-[[3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl]thio]-4-thiazolyl]-2-thiophenecarboxamide	beta adrenergic antagonist	glaucoma; hypertension
betaxolol; betaxolol hydrochloride; SL 75212; MCI 144; ABAXON; KERLONE; BETOPTIC; KERLONG; GLAUTAXOL; BERTOCIL; OPTIPRES; BETASEL; BEOF NICOLICH; LOKREN	1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist	glaucoma; hypertension; angina
bevantolol; bevantolol hydrochloride; CL 775; NC 1400; VANTOL; CALVAN; RANESTOL	(+,-)-1-[(3,4-dimethoxyphenethyl)amino]-3-(m-tolyloxy)-2-propanol	beta adrenergic antagonist	hypertension
bisoprolol; bisoprolol fumarate; EMD 33512; CL 297939; CONCOR; EMCOR; EMCORE; MONOCOR; ISOTEN; SOPROL; DETENSIEL; MAINTATE; ISOBLOC; ZEBETA	1-[(1-methylethyl)amino]-3-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-2-propanol	beta adrenergic antagonist	hypertension; heart failure

bopindolol; LT 31200; SANDONORM	(+,-)-1-[(1,1,-dimethylethyl)amino]-3-[(2-methoxy)-1H-indo-4-yl]oxy]-2-propanol, benzoate	beta adrenergic antagonist	hypertension
carvedilol; karvedilol; BM 14190; DQ 2466; KREDEX; COREG; DILATREND; DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC	1-(9H-carbazol-4-yl)oxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol	beta adrenergic antagonist	hypertension; angina; heart failure
cetamolol; ICI 72222; AY 27303; AI 27303; BETACOR	2-[2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenoxy]-N-methylacetamide	beta adrenergic antagonist	hypertension
drug delivery system, HALO labetalol; labetalol HALO	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, HALO metoprolol; metoprolol HALO	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, HALO oxprenolol; oxprenolol HALO	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, HALO timolol; timolol HALO	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, MICROPUMP oral controlled release atenolol; atenolol MICROPUMP; ATENAX	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, transdermal mepindolol; transdermal soft disc, mepindolol; mepindolol B10 TSD	Unspecified	beta adrenergic antagonist	hypertension

esatenolol; atenolol; (S)-; (S)-atenolol; (-)- atenolol	(S)-4-[2-hydroxy-3- [(1- methylethyl)amino]pro- poxylbenzeneacetam- ide	beta adrenergic antagonist	hypertension
esmolol; ASL 8052; ASL 8123; BREVIBLOC	4-[2-hydroxy-3-[(1- methylethyl)amino]pro- poxylbenzenepropan- oic acid methyl ester	beta adrenergic antagonist	hypertension; arrhythmia
levobunolol; W 7000A; AG 901; BETAGAN; VISTAGEN; GOTENSIN; VISTAGAN; LEVOGAN	(-)-5-[3-(tert- butylamino)-2- hydroxypropoxyl-3,4- dihydro-1(2H)- naphthalenone	beta adrenergic antagonist	hypertension; glaucoma
ridazolol; CAS 413	4-chloro-5-[[2-[[3-(2- chlorophenoxy)-2- hydroxypropyl]amino] ethyl]amino]-3(2H)- pyridazinone	beta adrenergic antagonist	hypertension
tertatolol; S 2395; SE 2395; ARTEX; ARTENSIL	(+,-)-1-[(3,4-dihydro- 2H-1-benzothiopyran- 8-yl)oxy]-3-[(1,1- dimethylethyl)amino] -2-propanol	beta adrenergic antagonist	hypertension
atenolol + lisinopril; lisinopril + atenolol	Unspecified	beta adrenergic antagonist; ACE inhibitor	hypertension
EXP 063	4-[[[4-[2-hydroxy-3- [(1- methylethyl)amino]pro- poxyl-1H-indol-2- yl]carbonyl]amino]m- ethyl]-2-propyl-1-[[2'- (1H-tetrazol-5- yl)[1,1'-biphenyl]-4- yl]methyl]-1H- imidazole-5- carboxylic acid	beta adrenergic antagonist; angiotensin II antagonist	hypertension

carteolol; OPC 1085; ABBOTT 43326; A 43326; ARTEOPTIC; CARTEOL; CARTROL; ENDAK; MERCATOA; MIKELAN; ORUKALOL; PALSIT; TENALET; TENALIN	5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydroquinolinone	beta adrenergic antagonist; beta adrenergic antagonist	glaucoma; hypertension
metoprolol, (S)-; (S)-metoprolol	(2S)-1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist; beta1 adrenergic antagonist	angina; hypertension; arrhythmia
nebivolol; narbivolol; R 67555; R 65824; ME 3255; R 67138; R 67145; R 065824; NEBILET; LOBIVON	[2R*[R*[R*(S*)]]]-alpha,alpha'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]	beta adrenergic antagonist; beta1 adrenergic antagonist; nitric oxide activator; vasodilator	hypertension; migraine; heart failure
drug delivery system, HALO sustained release propranolol; propranolol HALO sustained release	Unspecified	beta adrenergic antagonist; beta2 adrenergic antagonist	hypertension
celiprolol; NPB 582; ST 1396; REV 5320A; SELECTOL; CELECTOL	N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethylurea	beta adrenergic antagonist; beta2 adrenergic partial antagonist; vasodilator	hypertension; nephritis
betaxolol + chlortalidone; chlortalidone + betaxolol; KERLEDEX	Unspecified	beta adrenergic antagonist; diuretic	hypertension

bisoprolol + hydrochlorothiazide; hydrochlorothiazide + bisoprolol; EMD 47378; ZIAC; CONCOR PLUS; EMCORECTIC; FONDRIL; MONOZIDE	Unspecified	beta adrenergic antagonist; diuretic	hypertension
tenoxolol; UP 78842	2-[3-[(1,1- dimethylethyl)amino]- 2-hydroxypropoxy]- 5-[(2- thienylcarbonyl)amino] benzoic acid ethyl ester	beta adrenergic antagonist; diuretic	hypertension
bendacalol; bendacalol; CGS 10078B	[2R*[S*[R*(S*)]]]- alpha, alpha- [iminobis(methylene)] bis[2,3-dihydro-1,4- benzodioxin-2- methanol]	beta adrenergic antagonist; vasodilator	hypertension
tilisolol; N 696; DAIM; SELECAL	4-[3-[(1,1- dimethylethylamino)]- 2-hydroxypropoxy]-2- methyl-1(2H)- isoquinolinone	beta adrenergic antagonist; vasodilator	hypertension
TS 702	Unspecified	beta adrenergic antagonist; vasodilator	hypertension
talinolol; CORDANUM	(+/-)-N-cyclohexyl- N'-[4-[3-[(1,1- dimethylethyl)amino]- 2- hydroxypropoxy]phenyl] urea	beta adrenergic antagonist; beta adrenergic antagonist	hypertension; myocardial infarction; cardiovascular disease
UT 26	Unspecified	biotechnology; antisense; oligonucleotide	pulmonary hypertension
nesiritide; nesiritide citrate; brain natriuretic peptide; BNP; NATRECOR	Brain natriuretic peptide-32	biotechnology; hormone; peptide	heart failure; hypertension



antisense oligonucleotide, angiotensinogen	Unspecified	biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	hypertension
zatebradine; ULFS 49	3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-benzazepin-2-one	bradycardic agent	angina; hypertension
WIN 64338	(S)-[[4-[[2-[[[bis(cyclohexylamino)methylene]amino]-3-(2-naphthalenyl)-1-oxopropyl]amino]phenyl]methyl]tributylphosphonium chloride	bradykinin antagonist	hypertension
CP 0364	Unspecified	bradykinin antagonist; NSAID	hypertension; inflammation
AHR 12742	4-(bis(4-fluorophenylmethyl)-7-(3-(4-chlorophenoxy)propyl)piperidine (E)-2-butenedioate	calcium antagonist	hypertension
amlodipine analogue	4-(2,3-dichlorophenyl)-1,4-dihydro-2-[(2-hydroxyethoxy)methyl]-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester	calcium antagonist	hypertension
amlodipine besilate; UK 4834026; NORVASC; ISTIN	2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid, 3-ethyl 5-methyl ester monobenzenesulfonate	calcium antagonist	hypertension

amlodipine, (S)-; (S)-amlodipine; (-)-amlodipine; l-amlodipine	(S)-2-[(2-aminoocthoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid, 3-ethyl 5-methyl ester	calcium antagonist	hypertension
antihypertensive, Kanebo	ethyl isopropyl 4-(benzothiazol-2-yl)benzylphosphonate	calcium antagonist	hypertension
aranidipine; MPC 1304; SAPRESTA; BEC BM; BEC MARUKO; BEC	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid, methyl 2-oxopropyl ester	calcium antagonist	hypertension
azelnidipine; CS 905; RS 9054	(+,-)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-[1-(diphenylmethyl)-3-azetidiny] 5-(1-methylethyl) ester	calcium antagonist	hypertension
belfosdil; SR 7037; BMY 21891	[2-(2-phenoxyethyl)-1,3-propanediyl]bisphosphonic acid tetrabutyl ester	calcium antagonist	hypertension
BN 50394	Unspecified	calcium antagonist	hyperlipidemia; hypertension
calcium antagonist	(6R)-1-(aminocarbonyl)-1,2,3,6-tetrahydro-4-methyl-6-(3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester	calcium antagonist	hypertension

calcium antagonist, Suntory	5-isopropoxyloxy carbonyl -2-chloro-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine	calcium antagonist	hypertension
CGP 28861	Unspecified	calcium antagonist	hypertension
CHF 1978	Unspecified	calcium antagonist	hypertension
cilnidipine; cinaldipine; FRC 8653; SISCARD; CINALONG; ATELEC	(E)-(+,-)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 3-phenyl-2-propenyl ester	calcium antagonist	hypertension
clevidipine	4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl (1-oxobutoxy)methyl ester	calcium antagonist	hypertension
cronidipine; LF 20254	[8-(4-chlorophenyl)-1,4-dioxo-8-azaspiro[4.5]dec-2-yl]methyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate	calcium antagonist	hypertension
darodipine; dazodipine; PY 108068; PY 108; PY 10868; PLIMO	4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester	calcium antagonist	hypertension
diltiazem analogue	Unspecified	calcium antagonist	hypertension

drug delivery system, COER-24 oral verapamil; verapamil COER-24; OROS verapamil; COER-24 verapamil; COVERA-HS; CHRONOVERA; CRONOVERA	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, controlled release diltiazem; diltiazem controlled release; TIAZAC; VIAZEM	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, controlled release nifedipine; nifedipine	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, controlled release verapamil; verapamil	Unspecified	calcium antagonist	hypertension
drug delivery system, HALO nicardipine; nicardipine HALO	Unspecified	calcium antagonist	hypertension
drug delivery system, HALO nifedipine; nifedipine HALO	Unspecified	calcium antagonist	hypertension
drug delivery system, HALO sustained release diltiazem; diltiazem HALO sustained release	Unspecified	calcium antagonist	hypertension
drug delivery system, HALO verapamil; verapamil HALO	Unspecified	calcium antagonist	hypertension
drug delivery system, OSAT nifedipine; nifedipine sustained release	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, sustained release diltiazem malate; diltiazem malate sustained release	Unspecified	calcium antagonist	hypertension

drug delivery system, sustained release diltiazem; diltiazem sustained release; DILACOR XR	Unspecified	calcium antagonist	hypertension
drug delivery system, sustained release diltiazem; diltiazem sustained release; DILTELAN; CARDIZEM CD; HERBESSER R; DILZEM OD; TIAZEM SR	Unspecified	calcium antagonist	hypertension
drug delivery system, sustained release nifedipine; nifedipine once daily; INDAS nifedipine; NIFENSAR XL; ADALAT SR; UNIDIPINE; NIFELAN; ADALAT OROS	Unspecified	calcium antagonist	angina; hypertension
efonidipine; selefodipine; NZ 105; LANDEL	5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridine-carboxylic acid, 2-[phenyl(phenylmethyl)amino] ethyl ester, P-oxide	calcium antagonist	hypertension; angina; cerebrovascular disease
flosatidil; SL 851016	[2-(dimethylamino)ethyl][2-[[2-(methylthio)phenyl][3-(trifluoromethyl)phenyl]methyl]amino]-2-oxoethyl]carbamic acid 2-methylpropyl ester	calcium antagonist	angina; hypertension

FPL 62129	4-[3-chloro-6-fluoro-2-(trifluoromethyl)phenyl]-2-(fluoromethyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-methyl 5-(1-methylethyl) ester	calcium antagonist	hypertension; angina
furidipine; CRE 319	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl (tetrahydro-2-furanyl)methyl ester	calcium antagonist	hypertension; angina; reperfusion injury
gallopamil; D 600; PROCORUM; CORAPAMIL; ALGOCOR	5-[(3,4-dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile	calcium antagonist	hypertension; angina; arrhythmia
GOE 6070; PD 406070	(+)-2-(N-methyl-N-phenylmethylamino)-ethyl 1,4-dihydro-5-isopropoxy-2-methyl-4-(2-trifluoromethylphenyl)-1,6-naphthyridine-3-carboxylate	calcium antagonist	hypertension
GYKI 46544	Unspecified	calcium antagonist	hypertension
HP 406	1'-[4,4-bis(3-fluorophenyl)butyl]-7-fluoro-2-methylspiro[(2H)-1,4-benzodioxepin-3(5H),4'-piperidine] hydrochloride	calcium antagonist	hypertension

flunaridipine; flunaridipine hydrochloride; NKY 722	1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-2,2- dimethyl-3-[4-(2- propenyl)-1- piperazinyl]propyl 3,5- pyridinedicarboxylic acid methyl ester	calcium antagonist	hypertension; angina
flunaridipine; isradipine; PN 200110; PN 205033; PN 205034; PRESCAL; LOMIR; DynaCirc; VASCAL; ICAZ	4-(4-benzofurazanyl)- 1,4-dihydro-2,6- dimethyl-3,5- pyridinedicarboxylic acid methyl 1- methylethyl ester	calcium antagonist	hypertension; angina
LCB 2514	Unspecified	calcium antagonist	hypertension
flunaridipine; flunaridipine; REC 152375; R 75; TJN 324; ZANIDIP; LERDIP; ZANEDIP; LERCADIP; CARDIOVASC; LERZAM	1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)pyridine- 3,5-dicarboxylic acid 2-[(3,3- diphenylpropyl)methy lamino]-1,1- dimethylethyl methyl ester	calcium antagonist	hypertension
flunaridipine	cyclo(beta-alanyl-4- methyl-2- hydroxypentanoyl)leuc yl-4-methyl-2- hydroxypentanoyl-N- methylphenylalanyl)	calcium antagonist	hypertension
flunaridipine; flunaridipine; FK 235; FR 34235; SKF 102362; CL 287389; NIVADIL; ESCOR	2-cyano-1,4-dihydro- 6-methyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid 3-methyl 5-(1- methylethyl) ester	calcium antagonist	hypertension; angina

nisoldipine; BAY k 5552; SULAR; SYSCOR; BAYMYCARD; CORASOL; CORNEL; NISODIPEN; NISOCOR; ZADIPINA	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 2-methylpropyl ester	calcium antagonist	angina; hypertension
nitrendipine, (S)-; (S)-nitrendipine	(4S)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist	hypertension
nitrendipine; BAY e 5009; BAYOTENSIN; BAYPRESS; NIRAPEL; NITRENDIL; NITRENDIPINA; HYPERDIPINA; HIPERTENOL; PORTIONAL; NELCONIL; RETENCAL	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist	hypertension
NPK 1868	2-[[[(aminocarbonyl)oxy]methyl]-4-(2,3-dichlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid dimethyl ester	calcium antagonist	hypertension
olradipine; S 11568; S 12968	(+,-)-2-[[2-(2-aminoethoxy)ethoxy]methyl]-4-(2,3-dichlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester	calcium antagonist	hypertension



OPC 8490	3,4-dihydro-6-[4-(4-oxo-4-phenylbutyl)-1-piperazinyl carbonyl]-2(1H)-quinolinone	calcium antagonist	hypertension
oxodipine; IQB 837	ethyl methyl 1,4-dihydro-2,6-dimethyl-4-[2,3-(methylenedioxy)phenyl]-3,5-pyridinedicarboxylate	calcium antagonist	hypertension
palonidipine; TC 81	(+,-)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate	calcium antagonist	hypertension
PCA 50982	Unspecified	calcium antagonist	hypertension; angina
pranidipine; OPC 13340; ACALAS	(E)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 3-phenyl-2-propenyl ester	calcium antagonist	hypertension; angina
riodipine; ryodipine; PP 1466; FORIDONE	4-[2-(difluoromethoxy)phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester	calcium antagonist	hypertension; angina
RS 5773	((2S,3S)-3-acetoxy-8-benzyl-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-1,5-benzothiazepine-4-(5H)-one hydrochloride	calcium antagonist	angina; hypertension

S 12967	(+)-2-[[2-(2-aminoethoxy)ethoxy]methyl]-4-(2,3-dichlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinecarboxylic acid 3-ethyl 5-methyl ester	calcium antagonist	hypertension
siratazem; LR A113	(2S-cis)-3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-[2-[methyl(1-methylethyl)amino]ethyl]-1,5-benzothiazepin-4(5H)-one	calcium antagonist	angina; hypertension
SM 6586	1,4-dihydro-2,6-dimethyl-5-[3-[[methyl(phenylmethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-4-(3-nitrophenyl)-3-pyridinecarboxylic acid methyl ester	calcium antagonist	hypertension
teludipine; taludipine; GR 53992B; GR 53992X	(E)-2-[(dimethylamino)methyl]-4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid diethyl ester	calcium antagonist	hypertension; angina
TMB 8	3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester	calcium antagonist	hypertension

UK 51656	2-((2-((4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl)methoxy)ethyl)amino)acetamide	calcium antagonist	hypertension; angina
vatanidipine; watanidipine; AE 0047; GJ 0956; CALBREN	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid, 2-[4-[4-(diphenylmethyl)-1-piperazinyl]phenyl]ethyl methyl ester	calcium antagonist	hypertension
Y 20835	Unspecified	calcium antagonist	hypertension
YM 161511; YM 16151-1	(+)-1,4-dihydro-4-[2-[4-[(2-hydroxy-3-phenoxypropyl)amino]butoxy]-5-nitrophenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester monohydrochloride	calcium antagonist	hypertension; angina
LU 49938	(2S)-5-[N-methyl-N-(n-hexyl)]amino-2-(3,4,5-trimethoxyphenyl)-2-isopropylvaleronitrile hydrochloride	calcium antagonist; 5HT antagonist	hypertension
amlodipine + benazepril; benazepril + amlodipine; CGP 24267A; LOTREL	Unspecified	calcium antagonist; ACE inhibitor	hypertension
diltiazem malate + enalapril; enalapril + diltiazem malate; TECZEM	Unspecified	calcium antagonist; ACE inhibitor	hypertension
felodipine + enalapril; enalapril + felodipine; LEXCEL	Unspecified	calcium antagonist; ACE inhibitor	hypertension

felodipine + ramipril; ramipril + felodipine; HOE 9869; UNIMAX; TAZKO	Unspecified	calcium antagonist; ACE inhibitor	hypertension
monatepil; monatepil maleate; monasedin maleate; AJ 2615; AD 2615	(+,-)-N-(6,11- dihydrodibenzo[b,c]th iepin-11-yl)-4-(4- fluorophenyl)-1- piperazinebutanamide	calcium antagonist; alpha adrenergic antagonist; alpha 1 adrenergic antagonist	hypertension; angina; hyperlipidemia
felodipine + metoprolol; metoprolol + felodipine; LOGIMAX	Unspecified	calcium antagonist; beta adrenergic antagonist	hypertension; angina
YM 154301; YM 430	[S-(R*,R*)]-1,4- dihydro-2,6-dimethyl- 4-(3-nitrophenyl)-3,5- pyridinecarboxylic acid, 4-[(2-hydroxy-3- phenoxypropyl)amino ]butyl methyl ester	calcium antagonist; beta adrenergic antagonist	hypertension; angina
CD 349	1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid 2- (nitrooxy)propyl 3- (nitrooxy)propyl ester	calcium antagonist; bronchodilator	hypertension; asthma; angina
AHR 16462B	4-[bis(4- fluorophenyl)methyl]- 1-(2- naphthalenylmethyl)p iperidine hydrochloride	calcium antagonist; vasodilator	hypertension
barnidipine; mepirodipine; YM 09730; YM 097305; YM 730; HYPOCA; OLDECA	[S-(R*,R*)]-1,4- dihydro-2,6-dimethyl- 4-(3-nitrophenyl)-3,5- pyridinedicarboxylic acid methyl 1- (phenylmethyl)-3- pyrrolidinyl ester	calcium antagonist; vasodilator	hypertension; ischemia

benidipine; nakadipine; nacadipine; KW 3049; CONIEL	(R*,R*)-(+,-)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester	calcium antagonist; vasodilator	hypertension; angina
clentiazem; clentiazem maleate; TA 3090; LOGNA	(2S-cis)-3-(acetyloxy)-8-chloro-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one	calcium antagonist; vasodilator	hypertension; angina
elgodipine; IQB 875	(+,-)-4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 2-[[4-(fluorophenyl)methyl]methylamino]ethyl 1-methylethyl ester	calcium antagonist; vasodilator	angina; hypertension; heart failure
lomerizine; KB 2796; TERRANAS TAB; MIGSIS	1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine	calcium antagonist; vasodilator	hypertension; migraine
manidipine; manidipine hydrochloride; CV 4093; CALSLOT; MADIPINE; IPERTEN	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[4-(diphenylmethyl)-1-piperazinyl]ethyl 3,5-pyridinedicarboxylic acid methyl ester	calcium antagonist; vasodilator	hypertension
McN 5691	N-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-N,alfa-dimethyl-2-(phenylethynyl)benzenepropanamine	calcium antagonist; vasodilator	hypertension

P 1268	2-(1,2,3,4-tetrahydroisoquinoline-2-yl)ethyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-methoxycarbonylpyridine-3-carboxylate, monohydrochloride	calcium antagonist; vasodilator	hypertension
semotiadil; semotiadil fumarate; SD 3211; DQ 4823; DS 4823	(R)-2-[2-[3-[[2-(1,3-benzodioxol-5-yl)oxy]ethyl]methylamino]propoxy]-5-methoxyphenyl]-4-methyl-2H-1,4-benzothiazin-3(4H)-one	calcium antagonist; vasodilator	angina; hypertension
TJN 220	(1beta)-7-ethoxy-6,6',12-trimethoxy-2,2'-dimethylberbaman	calcium antagonist; vasodilator	hypertension
felodipine; H 15482; HOE 869; CGH 869; HYDAC; PLENDIL; VASOPINE; SPLENDIL; MUNOBAL; FLODIL	4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist; vasodilator; diuretic	hypertension; angina; heart failure; atherosclerosis
drug delivery system, OROS oral controlled release isradipine; isradipine OROS; DynaCirc CR	Unspecified	calcium channel blocker	hypertension
lacidipine; GR 43659; GR 43659X; SN 305; GX 1048; LACIPIL; VIAPRES; LACIREX; MOTENS; CALDINE; MIDOTENS; APONIL; ZASCAL; LACIMEN	(E)-4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester	calcium channel blocker	hypertension
P 5	Unspecified	calcium channel blocker	hypertension

RWJ 22726	N-benzyl-N-methyl-aminoethyl 10-(2,3-dichlorophenyl)-3,4,5,6,7,10-hexahydro-8-methyl-1,1-dioxo-2H-thiacycloocteno(3,2-b)pyridine-carboxylate	calcium channel blocker	hypertension
verapamil, (S)-; (S)-verapamil; levoverapamil; D 2024	(S)-alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile	calcium channel blocker	hypertension; arrhythmia; angina
Z 6568	Unspecified	calcium channel blocker	hypertension
meoxan	Unspecified	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease
S 2150	(+)-cis-3-acetoxy-8-chloro-2,3-dihydro-2-(4-methoxyphenyl)-5-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-1,5-benzothiazepin-4(5H)-one citrate	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
veroxan; VUFB 18814	Unspecified	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease

ZM 224832	3,5-diamino-N-[2-[[2-[[[(6-bromo-2,3-dihydro-5-hydroxy-1,1-dimethyl-1H-inden-4-yl)methyl]amino]ethyl]methylamino]ethyl]-6-chloropyrazinecarboxamide	calcium channel blocker; diuretic	hypertension
LAS 30538	1-[2-(2,6-dimethylphenoxy)ethyl-alpha,alpha-bis(4-fluorophenyl)-4-piperidinemethanol	calcium channel blocker; vasodilator	hypertension
mibefradil; mibefradil dihydrochloride; Ro 405967; Ro 405967001; POSICOR; CERATE	methoxyacetic acid, (1S-cis)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester	calcium channel blocker; vasodilator	hypertension; angina; heart failure
SQ 33351	[3R-[1(S*),3alfa,4alfa]]-3-(acetyloxy)-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-1-(2-pyrrolidinylmethyl)-6-(trifluoromethyl)-2H-1-benzazepin-2-one monohydrochloride	calcium channel blocker; vasodilator	hypertension
SQ 33537	[3R-[1(S*),3alfa,4alfa]]-1,3,4,5-tetrahydro-3-hydroxy-4-(4-methoxyphenyl)-1-(2-pyrrolidinylmethyl)-6-(trifluoromethyl)-2H-1-benzazepin-2-one monohydrochloride	calcium channel blocker; vasodilator	hypertension



DF 100	4-(3,5-dimethyl-1H-pyrazol-1-yl)-2,5-dihydro-1H-pyridazino[4,5-b]indol-1-one hydrazone monohydrochloride	Calcium influx modulator	hypertension
AM 522	Unspecified	cardiac glycoside	hypertension; heart failure
AM 524	Unspecified	cardiac glycoside	heart failure; hypertension
digitoxigenin-PC	Unspecified	cardiac glycoside	heart failure; hypertension
antihypertensive	Unspecified	Catecholamine metabolism	hypertension
JMV 236	N-[(1,1-dimethylethoxy)carboxyl]-O-sulfo-L-tyrosyl-L-norleucylglycyl-L-tryptophyl-L-norleucyl-L-alpha-aspartyl-L-phenylalaninamide	cholecystokinin agonist	hypertension
besulpamide; E 3050	1-(4-chloro-3-sulfamoylbenzamido)-2,4,5-trimethylpyridinium hydroxide	diuretic	hypertension
cicletanine; cycletanide; BN 1270; RU 270; WIN 90000; TENSTATEN; JUSTAR	3-(4-chlorophenyl)-1,3-dihydro-6-methylfuro[3,4-c]pyridin-7-ol	diuretic	hypertension
drug delivery system, furosemide; furosemide delivery system; HYAL DI4151	Unspecified	diuretic	hypertension
hattalin	2,3-dibenzylbutane-1,4-diol	diuretic	hypertension

ICI 181037	(R*,R*)-(+,-)-2-[2-[2-(dimethylamino)-1-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-1-hydroxypropyl]phenoxy]acetamide	diuretic	hypertension
ICI 206970	3,5-diamino-N-[2-[N-[2-(3-bromo-5-tert-butyl-2-hydroxybenzylamino)ethyl]-N-methylamino]ethyl]-6-chloropyrazine-2-carboxamide	diuretic	hypertension
ICI 207828	N-(2-(3-bromo-5-tert-butyl-2-hydroxybenzylamino)ethyl)-3-(N-2-(3,5-diamino-6-chloropyrazin-2-ylcarboxamido)ethyl)-N-methylamino)propionamide	diuretic	hypertension
MD 31; M 17055	N-[7-chloro-2,3-dihydro-1-(2-methylbenzoyl)-4(1H)-quinolinyldene]hydroxylamine-O-sulfonic acid potassium salt	diuretic	hypertension
PF 886	Unspecified	diuretic	hypertension
SC 46279	1-(5-amino-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidine-8-yl)-1,2-ethanediol	diuretic	hypertension

torasemide; torsemide; JDL 464; BM 02015; AC 4464; GJ 1090; UNAT; PRESARIL; TORREM; TOREM; ZEMIDE; DEMADEX; TORADIUR; DIURESIX; LUPRAC	N-[[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide	diuretic	hypertension; heart failure
telmisartan + hydrochlorothiazide; hydrochlorothiazide + telmisartan	Unspecified	diuretic; angiotensin II antagonist	hypertension
MCC 134	1-[4-(1H-imidazol-1-yl)benzoyl]-N-methylcyclobutanecarbothioamide	diuretic; potassium channel activator	hypertension
quinelorane; quinelorane hydrochloride; LY 163502	(5aR-trans)-5,5a,6,7,8,9,9a,10-octahydro-6-propylpyrido[2,3-g]quinazolin-2-amine	dopamine agonist	Parkinson disease; hyperprolactinemia; hypertension
RD 211; (+-)-RD 211	2-(dipropylamino)-2,3-dihydro-5-methyl-1H-inden-4-ol	dopamine agonist	hypertension
Z 15040	Unspecified	dopamine agonist	hypertension
A 68930	(1R,3S)-1-aminomethyl-5,6-dihydroxy-3-phenylisochroman	dopamine agonist; dopamine D1 agonist	hypertension; Parkinson disease
SKF-R 106114	ethylcarbamic acid, (R)-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepin-7,8-diyl ester monohydrochloride	dopamine agonist; dopamine D1 agonist	hypertension
Z 1046	((S)-6[[[6[[2-(methoxyphenoxy)ethyl]amino]propylamino]5,6,7,8-tetrahydro-1,2-naphthalenediol dihydrochloride	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist; vasodilator	hypertension

E 4010	4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-1-(4-hydroxy-1-piperidinyl)-6-phthalazinecarbonitrile monohydrochloride	dopamine agonist; dopamine D1 agonist; phosphodiesterase inhibitor; phosphodiesterase V inhibitor	pulmonary hypertension; sexual dysfunction
fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM	6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenyl)-1H-3-benzazepine-7,8-diol	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	hypertension; glaucoma; kidney disease; heart failure
carboxirole; EMD 45609	3-[4-[3,6-dihydro-4-phenyl-1(2H)-pyridinyl]butyl]-1H-indole-5-carboxylic acid	dopamine agonist; dopamine D2 agonist	hypertension
ZK 112566	N'-[(3beta, 8alpha)-13-amino-2,3-dihydro-2,6-dimethyl-ergolin-8-yl]-N,N-dimethylurea	dopamine agonist; dopamine D2 agonist; alpha adrenergic antagonist; alpha2 adrenergic antagonist; vasodilator	hypertension
fosopamine; SIM 2055; Z 2055	4-[2-(methylamino)ethyl]-1,2-benzenediol 1-(dihydrogenphosphate)	dopamine agonist; vasodilator	hypertension
MDL 43925	Unspecified	dopamine beta monooxygenase inhibitor	hypertension
endothelin A antagonist	Unspecified	endothelin A antagonist; endothelin antagonist	hypertension; kidney disease
FR 139317; FK 139317	N-[N-[N-[(hexahydro-1H-azepin-1-yl)carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-D-alanine	endothelin A antagonist; endothelin antagonist	hypertension; ischemia

SB 209670	(+)-(1S,2R,3S)-3[2-(carboxymethoxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-propoxyindane-2-carboxylic acid	endothelin A antagonist; endothelin antagonist	kidney disease; hypertension
TAK 044	cyclo[4-oxo-4 (4-phenyl-1-piperazinyl)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D-alpha-aspartyl] disodium salt	endothelin A antagonist; endothelin B antagonist; endothelin antagonist; peptide	hypertension; kidney disease; myocardial infarction; brain ischemia
BMS 182874	5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide	endothelin antagonist	hypertension
EMD 94246	N-2,1,3-benzothiadiazol-5-yl-5-(dimethylamino)-1-naphthalenesulfonamide, potassium salt	endothelin antagonist	hypertension
endothelin antagonists	Unspecified	endothelin antagonist	hypertension
J 104132; L 753037	[5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl-5-(1,3-benzeodioxol-5-yl)-7-[(2-carboxypropyl)-4-methoxyphenyl]-6,-dihydro-5H-cyclopenta[b]pyrindine-6-carboxylic acid	endothelin antagonist	hypertension
T 0115	Unspecified	endothelin antagonist	pulmonary hypertension

PD 156707; PD 156123	alpha-[2-(4-methoxyphenyl)-2-oxo-1-[(3,4,5-trimethoxyphenyl)methyl]ethylidene]1,3-benzodioxole-5-acetic acid sodium salt	endothelin antagonist; endothelin A antagonist	ischemia; reperfusion injury; pulmonary hypertension
SB 247083	Unspecified	endothelin antagonist; endothelin A antagonist	pulmonary hypertension
YM 598	potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]-2-phenylthioethanesulfonamide	endothelin antagonist; endothelin A antagonist	hypertension
ecadotril; sinorphan; BP 1.02; BAY y 7432; S 049; BP 102	(S)-N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]glycine phenyl methyl ester	enkephalinase inhibitor	hypertension; heart failure; cirrhosis
LY 203647	1-[2-hydroxy-3-propyl-4-[4-[2-[4-(1H-tetrazol-5-yl)butyl]-2H-tetrazol-5-yl]butoxy]phenyl]ethanone	leukotriene D4 antagonist; leukotriene antagonist	hypertension; asthma
omapatrilat; BMS 186716	[4S-[4alpha(R*),7alpha,10beta]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid	matrix metalloproteinase inhibitor; ACE inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
mineralocorticoid antagonists	Unspecified	mineralocorticoid antagonist	hypertension
cardiovascular disease therapy	Unspecified	Myosin motor filaments; actin filaments	hypertension; heart failure
AXC 0216	Unspecified	neuropeptide Y antagonist	obesity; hypertension

AXC 1829	Unspecified	neuropeptide Y antagonist	obesity; hypertension
neuropeptide Y antagonist, Alanex SR 120819A	Unspecified	neuropeptide Y antagonist	obesity; hypertension
	[alpha R-[N[R*(cis)],alpha R*]]-N-[1-[[4-[[[4-[(dimethylamino)methyl]cyclohexyl)methyl]amino]iminomethyl]phenyl]methyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-alpha-[(2-naphthalenylsulfonyl)amino]benzenepropanamide	neuropeptide Y antagonist; neuropeptide Y1 antagonist	hypertension; obesity; eating disorder
SC 3117	N,N'-bis-[2-N-(o-2,6-dichlorobenzyl-L-tyrosyl)aminoethylguanidyl]cystamine	neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypertension
drug delivery system, TheraDerm-MTX transdermal clonidine; clonidine TheraDerm-MTX	Unspecified	Neurotransmitter modulation	hypertension
CGS 24128	N-[3-[1,1'-biphenyl]-4-yl-N-(phosphonomethyl)alaninyl]beta-alanine	neutral endopeptidase inhibitor	hypertension
CGS 24592	N-[3-[1,1'-biphenyl]-4-yl-N-(phosphonomethyl)-L-alanyl]beta-alanine	neutral endopeptidase inhibitor	hypertension
CGS 25155	[2S-[2R*(trans),9S*]]-1-[[9-[(acetylthio)methyl]decahydro-10-oxo-2-azecynyl]carbonyl]-4-hydroxy-L-proline phenylmethyl ester	neutral endopeptidase inhibitor	hypertension

CGS 25462	N-[3-[1,1'-biphenyl]-4-yl-N-[(diphenoxyphosphinyl)methyl]-L-alanyl]-beta-alanine	neutral endopeptidase inhibitor	hypertension
SCH 39370	[S-(R*,R*)]-N-[N-(1-carboxy-3-phenylpropyl)-L-phenylalanyl]-2-hydroxy-beta-alanine	neutral endopeptidase inhibitor	hypertension
SCH 42495	N-[2(S)-acetylthiomethyl-3-(2-methylphenyl)-propanoyl-L-methionine ethyl ester	neutral endopeptidase inhibitor	hypertension
SQ 29072	7-[[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]amino]heptanoic acid	neutral endopeptidase inhibitor	hypertension
SA 7060	[S-(R*,R*)]-alpha-[[[(3-butoxy-2-hydroxy-3-oxopropyl)(2-methylpropyl)amino]carbonyl]amino]-2-naphthalenepropanoic acid	neutral endopeptidase inhibitor; ACE inhibitor	heart failure; hypertension
SCH 50690	Unspecified	neutral endopeptidase inhibitor; ACE inhibitor	hypertension; heart failure
SQ 28603	N-[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]-beta-alanine	neutral endopeptidase inhibitor; diuretic	hypertension
PF 9404	Unspecified	nitrate	angina; hypertension
NCX 900	Unspecified	nitric oxide donor; NSAID	pulmonary hypertension
GEA 3175	Unspecified	nitric oxide donor; vasodilator	angina; hypertension
antihypertensive agent	Unspecified	Noradrenergic release inhibitor	hypertension
LA 213	Unspecified	PAF antagonist; peptide; platelet antiaggregant	hypertension; thrombosis



LA 228	Unspecified	peptide	hypertension
LA 230	Unspecified	peptide	hypertension; hyperlipidemia
LA 231	Unspecified	peptide	hypertension
SNAP 1156	Unspecified	peptide	anxiety; hypertension; obesity; addiction
CGS 19281A	Unspecified	phenylethanolamine N methyl transferase inhibitor	hypertension
KT 2734	2-phenyl-8- ethoxycycloheptimida zole	phosphodiesterase inhibitor	hypertension
SCH 59498	Unspecified	phosphodiesterase inhibitor; phosphodiesterase I inhibitor; phosphodiesterase V inhibitor	hypertension
E 4021; ER 21355	1-[4[(1,3- benzodioxol-5- ylmethyl)amino]-6- chloro-2- quinazolinyl]-4- piperidinecarboxylic acid, monosodium salt	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	hypertension; angina; heart failure
BF 385; GP 385; BF/GP 385; ONO BF11301; ONO 1505	Unspecified	phosphodiesterase inhibitor; phosphodiesterase V inhibitor; thromboxane synthetase inhibitor; platelet antiaggregant	hypertension; thrombosis
epoprostenol; epoprostenol sodium; prostacyclin; prostaglandin X; prostaglandin I <sub>2</sub> ; vasocyclin; UN 53217A; U 53217; FLOLAN; CYCLO- PROSTIN	(5Z,9α,11α,13E,15S)-6,9-epoxy- 11,15- dihydroxyprosta-5,13- dien-1-oic acid	platelet antiaggregant; vasodilator; prostanoid	pulmonary hypertension; thrombosis

diethylhomospermine; DEHOP; DE 444	N,N'-bis[4-(ethylamino)butyl]-1,4-butanediamine	polyamine analogue	diarrhea; hypertension; cancer; psoriasis; ulcerative colitis
AL 0670	(+)-N-(6-amino-3-pyridyl)-N'-[(1S,2R,4R)-bicyclo[2.2.1]hept-2-yl]-N"-cyanoguanidine	potassium channel activator	hypertension
AL 0671	(1S-endo)-N-(6-amino-3-pyridinyl)-N'-bicyclo[2.2.1]hept-2-yl-N"-cyanoguanidine	potassium channel activator	hyperlipidemia; hypertension
KC 515	N-(2-cyanoethyl)-2,2-bis(fluoromethyl)-6-(pentafluoroethyl)-2H-1-benzopyran-4-carboxamide.	potassium channel activator	hypertension
KP 403	6-cyano-2,2-dimethyl-4-[(N-cyano-acetoimidoyl)amino]-2H-benzo[b]p yran	potassium channel activator	hypertension
KP 4603	Unspecified	potassium channel activator	hypertension
KRN 4884	5-amino-N-[2-(2-chlorophenyl)ethyl]-N'-cyano-3-pyridinecarboximide	potassium channel activator	hypertension
levcromakalim; lemakalim; cromakalim, (-); BRL 38227; BRL 34915; BRL 38226; LEVANEX	(3S,4R)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator	hypertension
NIP 121	trans-(+)-1-(7,8-dihydro-7-hydroxy-6,6-dimethyl-6H-pyrano[2,3-f]-2,1,3-benzoxadiazol-8-yl)-2-piperidinone	potassium channel activator	hypertension

RP 49356	tetrahydro-N-methyl-2-(3-pyridinyl)-2H-thiopyran-2-carbothioamide 1-oxide	potassium channel activator	hypertension
RWJ 26629	trans-(+,-)-1-(6,7-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-5H-thieno[3,2-b]pyran-7-yl)-2-piperidinone	potassium channel activator	hypertension
SKP 450; KR 30450	(R)-1-[2-(1,3-dioxolan-2-yl)-2-methyl-6-nitro-2H-1-benzopyran-4-yl]-2-pyrrolidinone	potassium channel activator	hypertension; heart ischemia
TAK 636	Unspecified	potassium channel activator	hypertension; angina
TCV 295	2-(6-bromo-7-chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine N-oxide	potassium channel activator	hypertension
UR 8218	Unspecified	potassium channel activator	hypertension
UR 8267	Unspecified	potassium channel activator	hypertension
Y 27152	(3S,trans)-N-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N-(phenylmethoxy)acetamide	potassium channel activator	hypertension; angina
CL 891902	Unspecified	potassium channel activator; bronchodilator	asthma; hypertension
emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease

potassium channel activator	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
Ro 316930	2,2-dimethyl-4-(2-pyridinyl)-2H-1-benzopyran-6-carbonitrile N4-oxide	potassium channel activator; bronchodilator	hypertension; asthma
SCA 40	6-bromo-8-(methylamino)-imidazo[1,2-a]pyrazine-2-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
symakalim; EMD 57283	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; coronary artery disease; asthma
UR 8225	1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence
YM 934	3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-2H-1,4-benzoxazine N-oxide	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence
celikalim; WAY 120491	(3S-trans)-2-[3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(trifluoromethoxy)-2H-1-benzopyran-4-yl]-2,3-dihydro-1H-isoindol-1-one	potassium channel activator; vasodilator	hypertension

DY 9708	[1R-[1 alpha,2(3S*,4R*),6al pha]]-3,4-dihydro-3- hydroxy-2,2-dimethy l-4-[(5-oxo-3,4- diazabicyclo[4.1.0]he pt-2-en-2-yl)oxy]-2H- 1-benzopyran-6- carbonitrile	potassium channel activator; vasodilator	hypertension; angina
pinacidil; P 1134; PINDACIL; PINDAL; PINDAC; THERAPRESS	N-cyano-N'-(4- pyridinyl)-N''-(1,2,2- trimethylpropyl)guani dine	potassium channel blocker	hypertension
U 37883A	N-cyclohexyl-N'- tricyclo[3.3.1.1 <sup>3,7</sup> ]de c-1-yl-4- morpholinecarboximi damide monohydrochloride	potassium channel blocker	hypertension
CL 115999	(9alfa,11alfa,13E)- 6,9-epoxy-16-ethenyl- 11,16-dihydroxy-5- iodoprost-13-en-1-oic acid methyl ester	prostanoid	hypertension
beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro- 2-hydroxy-1-(3- hydroxy-4-methyl-1- octen-6-ynyl)-1H- cyclopenta[b]benzofu ran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
ZK 110841	[1R- [1alfa(Z),2beta(1E,3S *),3alfa,5beta]]-7-[5- chloro-2-(3- cyclohexyl-3- hydroxy-1-propenyl)- 3- hydroxycyclopenyl]- 5-heptenoic acid	prostanoid; platelet antiaggregant	glaucoma; hypertension; thrombosis

ZK 118182	[1R-[1alpha(Z),2beta(1E,3S*),3alpha,5alpha]]-[[4-[5-chloro-2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxycyclopentyl]-2-butenyl]oxy]acetic acid	prostanoid; platelet antiaggregant	thrombosis; hypertension
UT 15	Unspecified	prostanoid; vasodilator	pulmonary hypertension
alprostadi; lipo-prostaglandin E1; lipo-PGE1; U 10136; PGE1; CAVERJECT; PALUX; LIPL; PROSTIN; EDEX; MUSE	(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid	prostanoid; vasodilator; cicatrizant	hepatitis; thrombosis; peripheral vascular disease; sexual dysfunction; pulmonary hypertension; skin ulcer; hearing loss
Y 27632	[4(R)-trans]-4-(1-aminoethyl)-N-4-pyridinylcyclohexane carboxamide	protein kinase inhibitor	hypertension; asthma; cancer
staurosporine; (+)-staurosporine; staurosporin; antibiotic 230; AM 2282	(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one	protein kinase inhibitor; protein kinase C inhibitor	hypertension
SCH 34826	N-[N-[2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-oxo-1-(phenylmethyl)ethyl]-L-phenylalanyl]-beta-alanine	proteinase inhibitor; analgesic	pain; hypertension

A 62198	5-azido-1-cyclohexyl-1,2,5-trideoxy-2-[[[N[N-(2-methyl-1-oxopropyl)-L-phenylalanyl]-L-histidyl]amino-L-arabinitol	proteinase inhibitor; renin inhibitor	hypertension
A 65317	[5S-[5R*[1R*[R*(S*)],2S*]]-N1-[2-[[1-(cyclohexylmethyl)-2-(3-ethyl-2-oxo-5-oxazolidinyl)-2-hydroxyethyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl]-N4-[2-[(2-methoxyethoxy)methoxy]ethyl]-N4-methyl-2-(phenylmethyl)butane diamide	proteinase inhibitor; renin inhibitor	hypertension
A 74273	[alphaS-[alphaR*,gammaR*,deltaR*[R*(R*)]]]-gamma-hydroxy-delta-[[2-[2-[4-(methoxymethoxy)-1-piperidinyl]-2-oxo-1-(phenylmethyl)ethoxy]-1-oxohexyl]amino]-alpha-(1-methylethyl)-N-[3-(4-morpholinyl)propyl]cyclohexanhexanamide	proteinase inhibitor; renin inhibitor	hypertension
BW B633C	N-((2Rs,3S)-3-(L-histidyl-L-prolyl-L-phenylalanyl-L-histidyl)-amino-2-hydroxy-5-methylhexyl)-L-valyl-L-isoleucyl-L-phenylalanine methyl ester hemiacetate	proteinase inhibitor; renin inhibitor	hypertension

CG 38560	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
CGP 60536B; CGS 60536	[alphaS-(alphaR*,gammaR*,deltaR*,zetaR*)]-delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)benzeneoetanamide	proteinase inhibitor; renin inhibitor	hypertension
CI 992; PD 134672	[1S-(1R*,2S*,3R*)]-N-(4-morpholinylsulfonyl)-L-phenylalanyl-3-(2-amino-4-thiazolyl)-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-L-alaninamide	proteinase inhibitor; renin inhibitor	hypertension
ciprokiren; Ro 449375	[1S-[1R*[R*(R*)],2S*,3R*]]-N-[1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-.alpha.-[[2-[[[1,1-dimethyl-2-(4-morpholinyl)-2-oxoethyl]sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-1H-imidazole-4-propanamide	proteinase inhibitor; renin inhibitor	hypertension



CP 71362	[2R-(2R*,4S*,5S*)]-N-[N2-[6-cyclohexyl-5-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-4-hydroxy-2-(2-methylpropyl)-1-oxohexyl]-L-lysyl]-L-phenylalanine	proteinase inhibitor; renin inhibitor	hypertension
ditckiren; U 71038	[1S-[1R*,2R*,4R*(1R*,2R*)]]-1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-L-phenylalanyl-N-[2-hydroxy-5-methyl-1-(2-methylpropyl)-4-[[[2-methyl-1-[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-Nalpha-methyl-L-histidinamide	proteinase inhibitor; renin inhibitor	hypertension
EMD 56133	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
enalalalren; A 64662	[1S-(1R*,2S*,3R*)]-N-(3-amino-3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-L-histidinamide	proteinase inhibitor; renin inhibitor	hypertension; glaucoma

ES 6864	[S-(R*,S*)]-5-cyclohexyl-2,4,5-trideoxy-N-[2-(4-morpholinyl)ethyl]-4-[[2-[[4-(4-morpholinyl)-2-(1-naphthalenylmethyl)-1,4-dioxobutyl]amino]-1-oxo-3-(4-thiazolyl)propyl]amino]-L-threo-pentonamide	proteinase inhibitor; renin inhibitor	hypertension
ES 8891	5-cyclohexyl-2,4,5-trideoxy-N-hexyl-4-[[N-[3-(1-naphthalenyl)-N-(4-morpholinylacetyl)-L-alanyl]-3-(4-thiazolyl)-L-alanyl]amino]-L-threo-pentonamide	proteinase inhibitor; renin inhibitor	hypertension
FK 906; FR 115906	N-methyl-N-[2(S)-[N-methyl-N-[2-[N-methyl-N-(morpholinocarbonyl)amino]ethyl]carbamoyloxy]-3-phenylpropionyl]-L-histidine 1(S)-(cyclohexylmethyl)-2(S)-hydroxy-5-methylhexylamide hydrochloride	proteinase inhibitor; renin inhibitor	hypertension
ICI 213878	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
ICI 219623	Unspecified	proteinase inhibitor; renin inhibitor	hypertension

KRI 1314	[alfaR-[alfaR*,betaS*[S*(R*)]]]-alfa-hydroxy-beta-[[3-(1H-imidazol-4-yl)-2-[[4-(4-morpholinyl)-2-(1-naphthalenylmethyl)-1,4-dioxobutyl]amino]-1-oxopropyl]amino]cyclohexanebutanoic acid 1-methylethyl ester	proteinase inhibitor; renin inhibitor	hypertension
PD 132002	[1S-(1R*,2S*,3R*)]-N-(4-morpholinylsulfonyl)-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-O-methyl-3-oxo-DL-serinamide	proteinase inhibitor; renin inhibitor	hypertension
remikiren; Ro 425892	[1S-[1R*[R*(R*)],2S*,3R*)]-N-[1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-alfa-[[2-[[[(1,1-dimethylethyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-1H-imidazole-4-propanamide	proteinase inhibitor; renin inhibitor	hypertension

renin inhibitor	[1S-[1R*,2S*,4S*(1R*,2R*)]]-[4-[[[1-(cyclohexylmethyl)-2-hydroxy-4-[[2-methylpropyl)amino]carbonyl]-4-pentenyl]amino]carbonyl]-2-hydroxy-1-(phenylmethyl)-nonenyl]-carbamic acid, 1,1-dimethylethyl ester.	proteinase inhibitor; renin inhibitor	hypertension
renin inhibitor	isopropyl (2R,3S)-3-((N-((2R)-3-(morpholino-carbonyl)-2-(1-naphthylmethyl)propionyl)-L-histidyl)-amino)-4-cyclohexyl-2-hydroxybutyrate	proteinase inhibitor; renin inhibitor	hypertension
RPEP 27	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
S 2864	N-[N-(3-(4-amino-1-piperidinyl-carbonyl)-2(R)-benzylpropionyl)-L-histidinyl)-(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6(2-pyridyl)-2-hexylamide-acetate	proteinase inhibitor; renin inhibitor	hypertension
SC 45075	[R-(R*,S*)]-N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxypropyl]-L-leucinamide	proteinase inhibitor; renin inhibitor	hypertension

SC 46944	4-morpholinecarboxylic acid, [1S-[1R*[R*(R*)],2S*,3R*]]-2-[[1-[[[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]amino]carbonyl]-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl ester	proteinase inhibitor; renin inhibitor	hypertension
SC 56525	N2-[2(S)-benzyl-3-(4-methylpiperazin-1-ylsulfonyl)propionyl]-N1-[1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]-2(S)-(2-propynyl)glycinamide	proteinase inhibitor; renin inhibitor	hypertension
SQ 33800	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
SQ 34017	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
U 70714E	(S)-N-[2-[[N-[N-[1-(N-acetyl-1-formyl-L-tryptophyl)-L-prolyl]-L-phenylalanyl]-L-histidyl]amino]-3-phenylpropyl]-L-phenylalanyl-L-valyl-L-tyrosinamide	proteinase inhibitor; renin inhibitor	hypertension

zankiren; zankiren hydrochloride; A 72517;	[1S-[1R*[R*(R*)],2S*,3R*]]-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-alfa-[[2-[[[(4-methyl-1-piperazinyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-4-thiazolepropanamide	proteinase inhibitor; renin inhibitor	hypertension
cyclothiazomycin	cyclothiazomycin	proteinase inhibitor; renin inhibitor; antibiotic	hypertension
ES 1005	[1S-[1R*(R*),2R*,4[R*(R*)]]-N-[4-[[1-[(5-amino-6-hydroxyhexyl)amino]carbonyl]-3-methylbutyl]amino]-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-alfa-[[3-(1-naphthalenyl)-2-(1-naphthalenylmethyl)-1-oxopropyl]amino]-1H-imidazole-4-propanamide dihydrochloride	proteinase inhibitor; renin inhibitor; peptide	hypertension
terlakiren; CP 80794	[R-(R*,S*)]-N-(4-morpholinylcarbonyl)-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2-hydroxy-3-(1-methylethoxy)-3-oxopropyl]-S-methyl-L-cysteineamide	proteinase inhibitor; renin inhibitor; peptide	hypertension

KB 5246	6-fluoro-5-(4-methyl-1-piperazinyl)-8-oxo-3H,8H-4-oxa-1-thia-9b-azacyclopenta[cd]phenalene-9-carboxylic acid monohydrochloride	quinolone; antibiotic	cancer; pruritis; hypertension; HIV infection; gastrointestinal ulcer; hyperlipidemia; bacterial infection
renin inhibitor	Unspecified	renin inhibitor; proteinase inhibitor	hypertension
U 75875	(1(1S,2S),5(S))-6-cyclohexyl-2,5,6-trideoxy-5-((3-(1H-imidazol-4-yl)-2-((1-naphthalenyloxy)acetyl)amino)-1-oxopropyl)amino)-2-(1-methylethyl)-N-(2-methyl-1-((1-pyridinylmethyl)amino)carbonyl)butyl,-L-idonamide	renin inhibitor; proteinase inhibitor; HIV proteinase inhibitor	hypertension; HIV infection
BIBU 308; DTTX 30	cis-2-[[[2-(hydroxyamino)-2-oxoethyl]methylamino]carbonyl]cyclohexanecarboxylic acid	thromboxane antagonist; platelet antiaggregant	pulmonary hypertension; peripheral vascular disease
terbogrel; BIBV 308 SE	(5E)-6-[3-[[[(cyanoamino)[(1,1-dimethylethyl)amino]methylene]amino]phenyl]-6-(3-pyridinyl)-5-hexenoic acid	thromboxane antagonist; thromboxane synthase inhibitor	pulmonary hypertension; peripheral vascular disease
AIT 111	unspecified	Unspecified	angina; arrhythmia; hypertension
laennec	human placenta hydrolysate	Unspecified	hypertension; liver disease
S 8666	6,7-dichloro-5-[[[(dimethylamino)sulfonyl]-2,3-dihydro-2-benzofurancarboxylic acid	uricosuric; diuretic	hypertension; gout
vaccine, angiotensin, vaccine, hypertension	Unspecified	vaccine	hypertension

LP 805	8-tert-butyl-6,7-dihydropyrrolo[3,2-e]-5-methylpyrazolo[1,5a]pyrimidine-3-carbonitrile	vasodilator	hypertension; angina
MER A2026A; Mer-A 2026A	2-(10-hydroxy-3,7,9,11,13-pentamethyl-2,5,7,11-tetradecatetraenyl)-6-methoxy-3-methyl-4-pyridinol	vasodilator	hypertension
MER A2026B; Mer-A 2026B	2-(10-hydroxy-3,7,9,11-tetramethyl-2,5,7,11-tridecatetraenyl)-6-methoxy-3-methyl-4-pyridinol	vasodilator	hypertension
metipamide	3-(aminosulfonyl)-4-chlorobenzoic acid 2-methyl-2-phenylhydrazide	vasodilator	hypertension
NY 008	3-octyl-1(3H)-isobenzofuranone	vasodilator	hypertension
U 92352	N-cyano-N'-(3,4-dichlorobenzyl)-N''-(4-pyridinyl)guanidine	vasodilator	hypertension
vasodilator	N-(2,3-dihydro-6,7-dimethoxy-1-methyl-3-oxo-4-isoquinolinyl)-N'-2-propenyl-urea	vasodilator	hypertension
phentolamine mesilate; phentolamine mesylate; VASOMAX; Z-MAX; VASOFEM	3-[[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol	vasodilator; alpha adrenergic antagonist; muscle relaxant	sexual dysfunction; hypertension
prostanit	Unspecified	vasodilator; prostaglandin agonist	hypertension



SKF 105494	O-ethyl-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginy-5-[1-(carboxymethyl)cyclohexyl]-L-norvalyl-L-arginyl-D-argininamide cyclic (5->1)peptide	vasopressin antagonist	hypertension
OPC 21268	1-[1-[4-(3-acetylamino-propoxy)benzoyl]-4-piperidyl]-3,4-dihydro-2(1H)-quinolinone	vasopressin antagonist; diuretic	hypertension; heart failure
SR 121463	cis-N-(1,1-dimethylethyl)-4-[[5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2'H)-yl]sulfonyl]-3-methoxy-benzamide (E)-2-butenedioate (1:1)	vasopressin antagonist; diuretic	heart failure; hypertension
SR 49059	[2R-[2alpha(S*),3beta]]-1-[[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide	vasopressin antagonist; diuretic	gynecological; cancer; hypertension; heart failure; emesis

Table 61. Current Candidate Therapeutic Interventions for the Treatment of Hypotension

Product Name	Chemical Name	Action	Indication
ICI D4398; ZM 241385	4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol	adenosine antagonist; adenosine A2 antagonist	peripheral vascular disease; hypotension

midodrine; midodrine hydrochloride; A 4020 LINZ; St Peter 224; St 1085; METLIGENE; MIDON; GUTRON; AMATINE; MIDAMINE; ProAmatine; HYPERTAN; MIDRON; NATILDINE; SHUPRASE OHARA M 6434	(+,-)-2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide	alpha adrenergic agonist	hypotension; urinary incontinence; sexual dysfunction
	2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole	alpha adrenergic agonist; alpha 1 adrenergic agonist; imidazole	anaphylactic shock; hypotension
atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole	alpha adrenergic antagonist; alpha 2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety
PCA 50941	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)ethyl(tetrahydro-2H-pyran-2-yl)methyl ester	calcium agonist	hypotension; anaphylactic shock
FPL 64176	2,5-dimethyl-4-[2-(phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylic acid methyl ester	Calcium channel activator	hypotension
arginase	Arginase	enzyme depletion of arginine leading to reduction of NO leading to increase in BP	hypotension

neuropeptide Y antagonists	unspecified	neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypotension; obesity; depression
hemoglobin-based scavenger; ENDOGLOBIN-HT; ENDOGLOBIN-CT	unspecified	nitric oxide scavenger	hypotension; cancer
hemoglobin-based therapy	unspecified	nitric oxide scavenger	cancer; hypotension; septic shock
pyridoxylated hemoglobin polyoxyethylene conjugate; PHP-HT; PHP-CT	pyridoxylated hemoglobin	nitric oxide scavenger	cancer; hypotension; septic shock
nitric oxide modulators	unspecified	NSAID	hypotension; cancer; rheumatoid arthritis
BN 50739	6-(2-chlorophenyl)-9-[2-[(3,4-dimethoxyphenyl)thio]-1-thioxoethyl]-7,8,9,10-tetrahydro-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist	hypotension; septic shock; stroke
rocepaftant; BN 50730	6-(2-chlorophenyl)-7,10-dihydro-N-(4-methoxyphenyl)-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-9(8H)-carbothioamide	PAF antagonist	hypotension; cytoprotectant; asthma
ARGINON-HT	Arginine-free amino acid product	Peptide induced increase of blood pressure	hypotension

amezinium methanesulfate; amezinium methanesulfate; LU 1631; RISUMIC; REGULTON; TENFORTAN; CROVARIL; SUPRATONIN	4-amino-6-methoxy- 1-phenylpyridinium methyl sulfate	Sympathomimetic	hypotension
INO 4743	unspecified	sympathomimetic	hypotension
INO 5042	unspecified	sympathomimetic	hypotension

Table 62. Current Candidate Therapeutic Interventions for the Treatment of Myocardial Ischemia

Product Name	Chemical Name	Action	Indication
CM 57493	3,6-dihydro-4-[3-(trifluoromethyl)phenyl]-1(2H)-pyridinepropanenitrile	5HT agonist; 5HT1 agonist	ischemia
ITF 1570	Salicylester	5HT1A and bradykinin receptor ligands	peripheral vascular disease; cerebrovascular disease; heart ischemia
adenosine A3 agonists	unspecified	adenosine A3 agonist; anti-ischemic; adenosine agonist	ischemia; myocardial infarction
adenosine agonists	unspecified	adenosine agonist	ischemia
GP 3521	unspecified	adenosine regulating agent	ischemia
adenosine regulating agents, ischemia	unspecified	adenosine regulating agent; anti-ischemic	ischemia
GP 531	5-amino-1-[5-deoxy-5-[phenylmethyl]amino]-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide	adenosine regulating agent; anti-ischemic	ischemia; thrombosis
acadesine; AICA-riboside; AR 100; GP 1110; GP 11100; ARASINE; PROTARA	5-amino-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide	adenosine regulating agent; platelet antiaggregant; anti-ischemic	cardiovascular disease; thrombosis; ischemia

mivazerol; UCB 22073	2-hydroxy-3-(1H-imidazol-4-ylmethyl)benzamide	alpha adrenergic agonist; alpha2 adrenergic agonist	ischemia
LY 293558	[3S-(3alpha,4aalpha,6beta,8aalpha)]-decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-3-isoquinolinecarboxylic acid	AMPA antagonist; glutamate antagonist	heart ischemia; epilepsy
prasterone; dehydroepiandrosterone; DHEA; GL 701; NBI 106; PB 007; ASTENILE; DEANDROS; DIANDRON	(3beta)-3-hydroxyandrost-5-en-17-one	androgen; vaccine adjuvant; hormone replacement therapy; corticosteroid	systemic lupus erythematosus; hormone deficiency; Alzheimer disease; reperfusion injury; ischemia
vascular endothelial growth factor B; AM 133	unspecified	angiogenesis inducer	coronary artery disease; ischemia
Del-1 angiogenic protein based therapies	unspecified	angiogenesis inhibitor; angiogenesis inducer	cancer; ischemia; restenosis
hypoxia therapy	unspecified	antihypoxic	heart ischemia; stroke
AMP deaminase inhibitors	unspecified	anti-ischemic	ischemia
FR 76830	2-methyl-N-(2-(4-morpholinyl)ethyl)-4-(3-nitrophenyl)-6-phenyl-3-pyridinecarboxamide	anti-ischemic	ischemia
TEI 2306	gamma-L-glutamyl-L-cysteine ethyl ester	anti-ischemic	heart ischemia; reperfusion injury
ST 520	(R)-N,N,N-trimethyl-4-oxo-2-(1-oxopropoxy)-4-[(2-sulfoethyl)amino]-1-butanaminium inner salt	Antis ischemic agent	ischemia
SM 20550	N-(aminoiminomethyl)-1,4-dimethyl-1H-indole-2-carboxamide monomethanesulfonate	anti-ischemic; sodium/hydrogen exchange inhibitor	heart ischemia; reperfusion injury

delphinidin; ephdine; delphinidol; delphinidol; delphinidine; delphinidin chloride; IDB 1056	3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyrilium chloride	antioxidant; free radical scavenger	ischemia
LXR 015; LXR 015-2; ELIREX	Unspecified	apoptosis inhibitor	reperfusion injury; heart ischemia; ischemia
LXR 017	unspecified	apoptosis inhibitor	heart ischemia
LXR 1035	unspecified	apoptosis inhibitor	ischemia; heart ischemia
bak; cell death inhibitor-1; Cdi-1	unspecified	apoptosis inhibitor; chemoprotectant; cytoprotectant; gene	heart ischemia; ischemia; reperfusion injury
MAb, C5 single chain; MAb, complement C5; 5G1.1-SC	unspecified	biotechnology; complement inhibitor; monoclonal antibody; NSAID	inflammation; myocardial infarction; stroke; ischemia
superoxide dismutase; superoxide dismutase copper zinc complex; CuZnSOD; OxSODrol	N-acetylsuperoxide dismutase (human clone pS 61-10 copper-zinc subunit protein moiety reduced)	biotechnology; free radical scavenger; NSAID	respiratory disease; ischemia; rheumatoid arthritis; inflammation
F 3226	3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-2,3-dihydro-6,7-dimethoxy-4H-1,3-benzoxazin-4-one	calcium antagonist	ischemia
K 201	2,3,4,5-tetrahydro-7-methoxy-4-[1-oxo-3-[4-(phenylmethyl)-1-piperidinyl]propyl]-1,4-benzothiazepine	calcium antagonist	ischemia
KP 840	diethyl 1,4-dihydro 2,6-dimethyl-4-(3-ethynyl phenyl)-3,5-pyridine-dicarboxylic acid	calcium antagonist	ischemia; depression

R 56865	N-[1-[4-(4-fluorophenoxy)-butyl]-4-piperidinyl]-N-methyl-2-benzothiazolamine	calcium antagonist	ischemia
SQ 31486	(3R-cis)-3-(acetyloxy)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-7-(trifluoromethyl)-2H-1-benzazepin-2-one monohydrochloride	calcium antagonist	ischemia
barnidipine; mepirodipine; YM 09730; YM 097305; YM 730; HYPOCA; OLDECA	[S-(R*,R*)]-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 1-(phenylmethyl)-3-pyrrolidinyl ester	calcium antagonist; vasodilator	hypertension; ischemia
CP 060S	(S)-3-[3-[[2-(1,3-benzodioxol-5-yl)oxy]ethyl]methylamino]propyl]-2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-thiazolidinone (E)-2-butenedioate (1:1)	calcium channel blocker	heart ischemia; angina
DP 16	Acylglycerol derivative of BAPTA	Calcium chelator	epilepsy; stroke; heart ischemia
thiazohalostatin	4,5-dihydro-2-[8-hydroxy-1,3,5-trimethyl-6-oxo-8-(3,4,5-trichloro-1H-pyrrol-2-yl)-7-octenyl]-4-methyl-4-thiazolecarboxylic acid	Calcium overload-induced death inhibition	ischemia
FCE 24265	diethyl-1-,4-dihydro-2,6-dimethyl-4-(3-(1H-imidazol-1-yl)-phenyl)-pyridine-3,5-dicarboxylate	calcium synthetase inhibitor; thromboxane synthetase inhibitor	ischemia

LNF 209	(3beta,5beta,14beta,17beta)-14-amino-3-[[6-deoxy-alfa-L-mannopyranosyl)oxy]androstand-17-carboxylic acid methyl ester hydrochloride	cardiac glycoside	ischemia
R 59494	N-methyl-N-(1-(4-phenoxybutyl)-3-pyrrolidinyl)-2-benzothiazolamine	cardiac glycoside	ischemia
PERFUSOL; MYOSOL	unspecified	chelating agent	trauma; ischemia; reperfusion injury
LY 178002	5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-4-thiazolidinone	COX inhibitor; 5-lipoxygenase inhibitor; NSAID	inflammation; ischemia
FR 139317; FK 139317	N-[N-[N-[(hexahydro-1H-azepin-1-yl)carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-D-alanine	endothelin A antagonist; endothelin antagonist	hypertension; ischemia
L 749329	4-[1-(1,3-benzodioxol-5-yl)-2-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-oxoethoxy]-3-propylbenzoic acid	endothelin A antagonist; endothelin antagonist	ischemia; reperfusion injury
PD 159433	unspecified	endothelin A antagonist; endothelin antagonist	cardiovascular disease; brain ischemia
TAK 044	cyclo[4-oxo-4 (4-phenyl-1-piperazinyl)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D-alpha-aspartyl]disodium salt	endothelin A antagonist; endothelin B antagonist; endothelin antagonist; peptide	hypertension; kidney disease; myocardial infarction; brain ischemia



endothelin antagonist	unspecified	endothelin antagonist	kidney disease; ischemia; inflammatory bowel disease; asthma
PD 156707; PD 156123	alpha-[2-(4-methoxyphenyl)-2-oxo-1-[(3,4,5-trimethoxyphenyl)methyl]ethylidene]1,3-benzodioxole-5-acetic acid sodium salt	endothelin antagonist; endothelin A antagonist	ischemia; reperfusion injury; pulmonary hypertension
TBC 11251; IPI 1251	N-(4-chloro-3-methyl-5-isoxazolyl)-2-[(6-methyl-1,3-benzodioxol-5-yl)acetyl]-3-thiophenesulfonamide	endothelin antagonist; endothelin A antagonist	heart failure; pulmonary obstructive disease; brain ischemia
DCC 9364	unspecified	free radical scavenger	ischemia
disulfiram; CPC 501; ANTABUSE	bis(diethylthiocarbamoyl)disulfide	free radical scavenger	alcoholism; heart ischemia
MDL 73404	3,4-dihydro-6-hydroxy-N,N,N,2,5,7,8-heptamethyl-2H-1-benzopyran-2-ethanaminium 4-methylbenzenesulfonate	free radical scavenger	ischemia
MDL 74270	6-(acetyloxy)-3,4-dihydro-N,N,N,2,5,7,8-heptamethyl-2H-1-benzopyran-2-ethanaminium 4-methylbenzenesulfonate	free radical scavenger	ischemia
pegorgotein; polyethylene glycol superoxide dismutase; PEG-SOD; superoxide dismutase macrogol; WIN 22118; PEG-SOD; DISMUTEC	unspecified	free radical scavenger	ischemia; reperfusion injury

superoxide dismutase, human; hSOD	unspecified	free radical scavenger	heart ischemia; reperfusion injury
YM 21170; Q 1047H-A; Q 1047H-A-A; Q 1047H-A-B	11-hydroxy-4,6,8,10-tetramethyl-2-azabicyclo[10.3.1]hexadeca-8,12,15-triene-3,5,14,16-tetrone stereoisomer	free radical scavenger	heart ischemia
superoxide dismutase B, manganese complex; Mn-SOD-B	unspecified	free radical scavenger; NSAID	ischemia; arthritis
superoxide dismutase manganese complex; hMNSOD	unspecified	free radical scavenger; NSAID; immunosuppressant	ischemia; rheumatoid arthritis; inflammation; reperfusion injury
glycoprotein IIb/IIIa antagonist, P246	unspecified	glycoprotein IIb/IIIa antagonist; peptide; platelet antiaggregant	thrombosis; heart ischemia; stroke
JP 7	unspecified	Hemoglobin allosteric modifier	cancer; surgery; heart ischemia; stroke
ribose; MGI 330	D-ribose	Hemoglobin allosteric modifier	heart ischemia; diagnosis
RSR 13	2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin allosteric modifier	surgery; heart ischemia; stroke
RSR 4	2-[4-[2-[(3,5-dichlorophenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin allosteric modifier	cancer; surgery; heart ischemia; stroke
RSR 46	2-[4-[2-[(2,3-dihydro-1H-inden-5-yl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin allosteric modifier	cancer; surgery; heart ischemia; stroke

monophosphoryl lipid A; TLC 3; RDE; MPL; MPL-C; MPL-S	2-deoxy-6-O-[2-deoxy-2-[[1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-3-O-[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-4-O-phosphono-beta-D-glucopyranosyl]-2-[(3-hydroxy-1-oxotetradecyl)amino]-alpha-D-glucopyranose 3-(3-hydroxytetradecanoate)	immunostimulant; vaccine adjuvant	heart ischemia; bacterial infection; infectious disease; reperfusion injury
soluble complement receptor type 1; sCR1; TP 10; TP 10HD; BRL 55730; YM 55730	unspecified	immunosuppressant; complement inhibitor	respiratory distress syndrome; heart ischemia; transplant rejection
MAB, E/P-selectin, humanized; MAB, SMART E/P-selectin	unspecified	integrin antagonist; biotechnology; monoclonal antibody; E selectin antagonist; P selectin antagonist; cell adhesion inhibitor	respiratory distress syndrome; ischemia; reperfusion injury
GM 1998	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; respiratory distress syndrome; heart ischemia; reperfusion injury
CEN 100	unspecified	integrin antagonist; peptide; P selectin antagonist; cell adhesion inhibitor; NSAID	ischemia; inflammation; reperfusion injury
TBC 427	unspecified	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor	ischemia; psoriasis; respiratory distress syndrome; transplant rejection; reperfusion injury

tirilazad; tirilazad mesylate; trilazad; U 74006F; FREEDOX	21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-alpha-methyl-pregn-1,4,9-(11)-triene-3,20-dione	lazaroid	brain ischemia; stroke; trauma; heart ischemia; kidney disease
H 29051; H 290/51	cis-7-methyl-9-methoxy-5,5a,b,10b-tetrahydroindeno(2,1-6 indole	Lipid peroxidation inhibitor	heart ischemia; reperfusion injury
MAB, 60-3; MAB, CD18/CD11	unspecified	Monoclonal antibody	septic shock; heart ischemia; reperfusion injury
MAB, CD18; R15.7	unspecified	monoclonal antibody	ischemia
MAB, beta2 integrin; LDP 01	unspecified	monoclonal antibody; biotechnology; integrin antagonist; cell adhesion inhibitor	ischemia; reperfusion injury
MAB, P-selectin; CY 1748; CY 1747	unspecified	monoclonal antibody; integrin antagonist; P selectin antagonist; cell adhesion inhibitor	reperfusion injury; ischemia
MAB, CD11b; MAB, m60.1; m60.1; LY 303932	unspecified	monoclonal antibody; NSAID	inflammation; heart ischemia; reperfusion injury
ITF 1129	2,3-dihydro-6-methyl-3-[2-(nitrooxy)ethyl]-4H-1,3-benzoxazin-4-one	nitric oxide donor; nitrate	heart ischemia; angina
ITF 1697	Unspecified	NSAID; peptide	septic shock; inflammation; heart ischemia; inflammatory bowel disease
recombinant PSGL 1, PSGL 1	unspecified	P selectin antagonist; E selectin antagonist; L selectin antagonist; selectin antagonist; NSAID	inflammation; transplant rejection; ischemia; reperfusion injury

BN 50726	6-(2-chlorophenyl)-9-(hexadecylsulfonyl)-7,8,9,10-tetrahydro-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist	ischemia; cytoprotectant
nupafant; nupafant hydrochloride; BB 960; BB 2113	(S)-N-[1-(ethoxymethyl)-3-methylbutyl]-4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]benzenesulfonamide	PAF antagonist	ischemia; reperfusion injury
UR 12670	4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]-1-(1-oxo-3,3-diphenylpropyl)-piperidine	PAF antagonist; platelet antiaggregant	kidney disease; ischemia; asthma; pancreatitis
CEN 294	unspecified	peptide; NSAID	inflammation; ischemia; reperfusion injury
kappa-conopeptides	unspecified	peptide; potassium channel blocker	heart ischemia; arrhythmia; gastrointestinal disorder
ER 3826	N-(1-benzyl-4-piperidinyl)-4-(N-methyl-N-((E)-3-(4-(methylsulfonyl)phenyl)-2-propenoyl)amino)benzenesulfonamide	phospholipase inhibitor	ischemia
EF 12	unspecified	platelet antiaggregant; antiproliferative agent	heart ischemia; thrombosis; restenosis
aprikalim; RP 52891; APRIM	tetrahydro-N-methyl-2-(3-pyridinyl)-2H-thiopyran-2-carbothioamide 1-oxide	potassium channel activator	heart ischemia

BMS 191095	(3R-trans)-4-[(4-chlorophenyl)(1H-imidazo-2-ylmethyl)amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator	ischemia
NS 004; NS 4	1-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-5-(trifluoromethyl)-2H-benzimidazol-2-one	potassium channel activator	ischemia
SKP 450; KR 30450	(R)-1-[2-(1,3-dioxolan-2-yl)-2-methyl-6-nitro-2H-1-benzopyran-4-yl]-2-pyrrolidinone	potassium channel activator	hypertension; heart ischemia
U 89232	trans-N-cyano-N'-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N''-(1,1-dimethylpropyl)-guanidine	potassium channel activator	ischemia
SR 47063	4-(2-cyanoimino-1,2-dihydropyrid-1-yl)-6-nitro-2,2-dimethyl-2H-1-benzopyran	potassium channel activator; bronchodilator	heart ischemia; asthma
azimilide; azimilide dihydrochloride; azilimide; NE 10064; STEDICOR	1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione	potassium channel blocker; class III antiarrhythmic	ischemia; arrhythmia
tedisamil; KC 8857	3',7'-bis(cyclopropylmethyl)spiro[cyclopentane-1,9'-[3,7]diazabicyclo[3.3.1]nonane]	potassium channel blocker; class III antiarrhythmic	heart ischemia

beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
SPC 100271	unspecified	protein kinase inhibitor; protein kinase C inhibitor	ischemia; reperfusion injury
SPC 101591	unspecified	protein kinase inhibitor; protein kinase C inhibitor	cancer; ischemia; reperfusion injury
SPC 100270	unspecified	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant	ischemia; transplant rejection; reperfusion injury
SPC 100840	unspecified	protein kinase inhibitor; protein kinase C inhibitor; NSAID	ischemia; psoriasis; cancer; inflammation; reperfusion injury
argatroban; argatrovan; argipidine; argopidine; alipidine; DK 7419; MCI 9038; MD 805; OM 805; GN 1600; NOVASTAN; SLONNON	(2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[[(1,2,3,4-tetrahydro-3-methyl-8-quinoliny]sulfonyl]amino]pentyl]-4-methyl-2-[piperidinecarboxylic acid	proteinase inhibitor; platelet antiaggregant; thrombin inhibitor	thrombosis; myocardial infarction; ischemia; angina; brain ischemia; thrombocytopenia
Recombinant hemoglobin mutant	unspecified	Recombinant hemoglobin mutant	ischemia
p-38-2 inhibitor	unspecified	signal transduction inhibitor; NSAID	inflammation; ischemia
superoxide dismutase mimetics, SOD mimetics,	unspecified	SOD mimetic	ischemia; reperfusion injury
NO-SOD mimetics, nitrosylated superoxide dismutase mimetics	unspecified	SOD mimetic; nitric oxide donor	asthma; respiratory distress syndrome; ischemia; reperfusion injury
FR 183998	unspecified	sodium/hydrogen exchange inhibitor	heart ischemia

HOE 694	N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(1-piperidiny)benzamide mesilate	sodium/hydrogen exchange inhibitor	heart ischemia; reperfusion injury
KBR 9032; KB-R 9032	N-(aminoiminomethyl)-3,4-dihydro-2,2-dimethyl-4-(1-methylethyl)-3-oxo-2H-1,4-benzoxazine-6-carboxamide monomethanesulfonate	sodium/hydrogen exchange inhibitor; anti-ischemic	arrhythmia; heart ischemia; reperfusion injury
transforming growth factor beta;	unspecified	TGFbeta receptor pathway; growth factor	brain ischemia; trauma; stroke; neurodegeneration
NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	inflammation; ischemia; cancer; autoimmune disease
hemorrhagic shock therapy	Unspecified	unspecified	cardiovascular disease; ischemia; reperfusion injury
PKH 135	Lipid-colchicine conjugate	Unspecified	cancer; ischemia; reperfusion injury
vascular endothelial growth factor; VEGF; rhVEGF165	unspecified	VEGF, growth factor; cicatrizant	coronary artery disease; ischemia; restenosis; skin ulcer
Ro 315460	4-hydroxy-9H-pyrido[3,4-b]indole-1-carboxaldehyde	xanthine oxidase inhibitor	ischemia; reperfusion injury
torbafylline; HWA 448	7-ethoxymethyl-1-(5-hydroxy-5-methylhexyl)-3-methylxanthine	xanthine; vasodilator	ischemia

Table 63. Current Candidate Therapeutic Interventions for the Treatment of Heart Failure

Product Name	Chemical Name	Action	Indication
docebenone; AA 861	6-(12-hydroxy-5,10-dodecadiynyl)-2,3,5-trimethyl-1,4-benzoquinone	5 lipoxygenase inhibitor	asthma; heart failure



captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
drug delivery system, SODAS captopril; captopril SODAS	Unspecified	ACE inhibitor	heart failure; hypertension
imidapril; TA 6366; EMD 61800; EMD 63100; TANATRIL; NOVALOC; NOVAROK; TANAPRESS; NORTEN	4S-[3-[R*(R*)],4R*]-3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid	ACE inhibitor	hypertension; heart failure; diabetes
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease
perindopril; perindopril erbumine; S 9490; S 94903; SED 9490; MCN A2833109; DW 7950; COVERSYL; ACEON; ACERTIL; COVERENE; COVEREX; COVERSIL	(2S,3aS,7aS)-1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid	ACE inhibitor	hypertension; coronary artery disease; heart failure

ramipril; HOE 498; ALTACE; TRIATEC; PRAMACE; RAMACE; TRITACE; CARASEL; ACOVIL	(2S,3aS,6aS)-1-[(S)- N-[(S)-1-carboxy-3- phenylpropyl]alanyl]o ctahydrocyclopenta[b] pyrrole-2-carboxylic acid 1-ethyl ester	ACE inhibitor	hypertension; heart failure
utibapril; FPL 63547	(S)-2-tert-butyl-4- [(S)-N-[(S)-1- carboxy-3- phenylpropyl]alanyl]- delta2-1,3,4- thiadiazoline-5- carboxylic acid, 4- ethyl ester	ACE inhibitor	hypertension; heart failure
fosinopril + hydrochlorothiazide; hydrochlorothiazide + fosinopril; TENSOZIDE; MONOPRIL-HCT; FOSICOMP	Unspecified	ACE inhibitor; diuretic	hypertension; heart failure
BMS 189921	[S-(R*,R*)]- hexahydro-6-[(2- mercapto-1-oxo-3- phenylpropyl)amino]- 2,2-dimethyl-7-oxo- 1H-azepine	ACE inhibitor; matrix metalloproteinase inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
ER 3295	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
sampatrilat; UK 81252	2-[[[1-[[[1-carboxy-2- (4- hydroxyphenyl)ethyl] amino]carbonyl]cyclo pentyl]methyl]-N- [N2-(methylsulfonyl)- L-lysyl]-beta-alanine [S-(R*,R*)]-	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
Z 13752A	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure

MDL 100240; MDL 100173 pro	[4S-[4alpha,7alpha(R*),12bbeta]]-7-[[2-(acetylthio)-1-oxo-3-phenylpropyl]amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1-a][2]benzazepine-4-carboxylic acid	ACE inhibitor; neutral endopeptidase inhibitor; diuretic	heart failure; hypertension
trandolapril; CI 907; RU 44570; RU 570; ODRIK; UDRIK; GOPTEN; TRAPRIL; ODRIC; MAVIK	[2S-[1[R*(R*)],2alpha,3alpha,7abeta]]-1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid	ACE inhibitor; vasodilator	hypertension; heart failure; myocardial infarction
CVT 429	Unspecified	adenosine A1 agonist; adenosine agonist	arrhythmia; heart failure
CVT 609	Unspecified	adenosine A1 agonist; adenosine agonist	arrhythmia; heart failure
adenosine A1 antagonists	Unspecified	adenosine A1 antagonist; diuretic; adenosine antagonist	heart failure
adenosine A2a agonists	Unspecified	adenosine A2 agonist; adenosine agonist	heart failure
RPR 100579	Unspecified	adenosine agonist	hypertension; heart failure; hyperlipidemia
CVT 427	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
CVT 510	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
CVT 741	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
SDZ WAG994; SDZ WAG 994	N-cyclohexyl-2'-0-methyladenosine	adenosine agonist; adenosine A1 agonist	heart failure; hyperlipidemia
WRC 0342	Unspecified	adenosine antagonist	heart failure
WRC 0571	Unspecified	adenosine antagonist	heart failure
HMR 4902	Unspecified	adenosine antagonist; adenosine A1 antagonist	heart failure; kidney disease

KW 3902	8-(noradamantyl-3-yl)-1,3-dipropylxanthine	adenosine antagonist; adenosine A1 antagonist; diuretic	heart failure
CVT 124; BG 9719; ADENTRI	3,7-dihydro-8-(3-oxatricyclo[3.2.1.0 <sup>2,4</sup> ]oct-6-yl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; diuretic; adenosine A1 antagonist	heart failure; hypertension
FR 113453	[R-(E)]-4-hydroxy-1-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-5-(1-piperidinyl)-1-penten-3-one	adenosine antagonist; vasodilator; diuretic	heart failure
eplerenone; epoxymexrenone; CGP 30083; SC 66110	(7.alpha.,11.alpha.,17.alpha.)-9,11-epoxy-17-hydroxy-3-oxopregn-4-ene-7,21-dicarboxylic acid .gamma.-lactone methyl ester	aldosterone antagonist	heart failure; hypertension
moxonidine; BE 5895; BDF 5895; LY 326869; CYNT; PHYSIOTENS	4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine	alpha adrenergic agonist; alpha2 adrenergic agonist; imidazoline agonist	hypertension; heart failure; diabetes
metazosin; metasozin; metazocin; KENOSIN	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxy-1-oxopropyl)piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; glaucoma; benign prostate hypertrophy; heart failure
XB 513	2-amino-1,4-dihydro-4-[2-[[4-[4-(2-methoxyphenyl)-1-piperazinyl]-butyl]sulfinyl]phenyl]-6-methyl-5-nitro-3-pyridinecarboxylic acid methyl ester	alpha adrenergic antagonist; alpha1 adrenergic antagonist; calcium agonist	heart failure

candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMIAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
irbesartan; SR 47436; BMS 186295; APROVEL; KARVEA; AVAPRO	2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one	angiotensin II antagonist	hypertension; kidney disease; heart failure
losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
UR 7247	3-(1-methylethyl)-1-propyl-5-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-pyrazole-4-carboxylic acid	angiotensin II antagonist	hypertension; heart failure
valsartan; CGP 48933; DIOVAN	N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine	angiotensin II antagonist	hypertension; heart failure
YM 358	2,7-diethyl-5-[(2'-(5-tetrazoyl)biphenyl-4-yl]methyl]-5H-pyrazolo[1,5-b][1,2,4]triazole	angiotensin II antagonist	hypertension; heart failure
fructose-1,6-diphosphate; CPC 111; CORDOX	1,6-bis(dihydrogen phosphate) D-fructose	anti-ischemic	heart failure; myocardial infarction; sickle cell anemia; septic shock
apoptosis inhibitors	Unspecified	apoptosis inhibitor	neuropathy; HIV infection; heart failure

cardiovascular disease therapy	Unspecified	apoptosis inhibitor; caspase inhibitor	cardiovascular disease; myocardial infarction; heart failure
OPC 31260	N-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzapin-1-yl]carbonyl]phenyl]-2-methylbenzamide	aquaretic; vasopressin antagonist	heart failure
candoxatril; UK 79300	4-[[[1-[3-[(2,3-dihydro-1H-inden-5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]-cyclohexanecarboxylic acid	atriopeptidase inhibitor	hypertension; heart failure
T 0509	(R)-4-[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1-hydroxyethyl]-1,2-benzenediol	beta adrenergic agonist; beta1 adrenergic agonist	heart failure
xamoterol; ICI 118587; CORWIN; SEPAN	(+,-)-N-[2-[[2-hydroxy-3-(p-hydroxyphenoxy)propyl]amino]ethyl]-4-morpholinecarboxamide	beta adrenergic agonist; beta1 adrenergic agonist; beta adrenergic partial antagonist; beta1 adrenergic partial antagonist	heart failure
BIB 16S	Unspecified	beta adrenergic antagonist	heart failure
bisoprolol; bisoprolol fumarate; EMD 33512; CL 297939; CONCOR; EMCOR; EMCORE; MONOCOR; ISOTEN; SOPROL; DETENSIEL; MAINTATE; ISOBLOC; ZEBETA	1-[(1-methylethyl)amino]-3-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-2-propanol	beta adrenergic antagonist	hypertension; heart failure

carvedilol; karvedilol; BM 14190; DQ 2466; KREDEX; COREG; DILATREND; DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC	1-(9H-carbazol-4- yloxy)-3-[[2-(2- methoxyphenoxy)ethy l]amino]-2-propanol	beta adrenergic antagonist	hypertension; angina; heart failure
nebivolol; narbivolol; R 67555; R 65824; ME 3255; R 67138; R 67145; R 065824; NEBILET; LOBIVON	[2R*[R*[R*(S*)]]]- alpha,alpha'- [iminobis(methylene) ]bis[6-fluoro-3,4- dihydro-2H-1- benzopyran-2- methanol]	beta adrenergic antagonist; beta1 adrenergic antagonist; nitric oxide activator; vasodilator	hypertension; migraine; heart failure
GI 104313	(S)-2-[2-chloro-4- (1,4,5,6-tetrahydro-6- oxo-3- pyridazinyl)phenoxy]- N-[2-[[3-(2- cyanophenoxy)-2- hydroxypropyl]amino ]-2- methylpropyl]acetami de	beta adrenergic antagonist; phosphodiesterase inhibitor	heart failure
bucindolol; bucindolol hydrochloride; MJ 131051; BEXTRA	2-[2-hydroxy-3-[[2- (1H-indol-3-yl)-1,1- dimethylethyl]amino] propoxy]benzonitrile	beta adrenergic antagonist; vasodilator	heart failure; myocardial infarction
drug delivery system, controlled release GEOMATRIX bucindolol; bucindolol GEOMATRIX	Unspecified	beta adrenergic antagonist; vasodilator	heart failure
nesiritide; nesiritide citrate; brain natriuretic peptide; BNP; NATRECOR	Brain natriuretic peptide-32	biotechnology; hormone; peptide	heart failure; hypertension

carperitide; human atrial natriuretic peptide; ANP; HANP; atriopeptin-28 (human); SUN 4936; HANP	1-de-L-leucine-2-de-L-alanine-3-deglycine-4-de-L-proline-5-de-L-arginine-17-L-methionine-atrioneptin-33 (rat)	biotechnology; hormone; peptide; diuretic	heart failure
etanercept; tumor necrosis factor receptor; TNFr; TNF001; ENBREL	Unspecified	biotechnology; TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease
BAY y 5959	(-)-2-amino-5-cyano-1,4-dihydro-6-methyl-4-(3-phenyl-5-quinolinyl)-3-pyridinecarboxylic acid 1-methylethyl ester	calcium agonist	heart failure
LY 249933	(R)-1,4-dihydro,2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-3-pyridinecarboxylic acid, 1-phenylethyl ester	calcium antagonist	heart failure
SIM 6080	N-[3,3-bis(4-fluorophenyl)propyl]-N,N'-dimethyl-N'-[(3,4,5-trimethoxyphenyl)methyl]-1,2-ethanediamine	calcium antagonist	heart failure
SR 33805	Unspecified	calcium antagonist	heart failure; atherosclerosis
Y 22516	isopropyl 7-(2,6-difluorophenyl)-5-methyl-4,7-dihydropyrazolo-(1,5-a)pyrimidine-6-carboxylate	calcium antagonist	heart failure



elgodipinc; IQB 875	(+,-)-4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 2-[[[4-fluorophenyl)methyl]methylamino]ethyl 1-methylethyl ester	calcium antagonist; vasodilator	angina; hypertension; heart failure
felodipine; H 15482; HOE 869; CGH 869; HYDAC; PLENDIL; VASOPINE; SPLENDIL; MUNOBAL; FLODIL	4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist; vasodilator; diuretic	hypertension; angina; heart failure; atherosclerosis
mibefradil; mibefradil dihydrochloride; Ro 405967; Ro 405967001; POSICOR; CERATE	methoxyacetic acid, (1S-cis)-2-[2-[[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester	calcium channel blocker; vasodilator	hypertension; angina; heart failure
MCI 154	6-(4-(4-pyridinylamino)phenyl)-4,5-dihydro-3(2H)-pyridazinone monohydrochloride	calcium sensitizer	heart failure
AM 522	Unspecified	cardiac glycoside	hypertension; heart failure
AM 524	Unspecified	cardiac glycoside	heart failure; hypertension
digitalis-like compound 1; DLC-CL3	Unspecified	cardiac glycoside	heart failure
digitoxigenin-PC	Unspecified	cardiac glycoside	heart failure; hypertension
NE 11040	Unspecified	cardiac glycoside	heart failure
acrihellin; D 12316	(3beta,5beta)-5,14-dihydroxy-3-[(3-methyl-1-oxo-2-butenyl)oxy]-19-oxobufa-20,22-dienolide	Cardiac glycoside activity; cardiosteroid	heart failure

acetamide	Unspecified	Cardiac stimulant	heart failure
mildronate; MET 88	2-(2-carboxyethyl)- 1,1,1-trimethyl- hydrazinium, inner salt	Cardiostimulation	heart failure
DAC 7684	Unspecified	cardiotonic	heart failure
P 877692	Unspecified	Cardiotonic	heart failure
UP 10023	Unspecified	Cardiotonic	heart failure
VA 5	6-(2,5- dimethoxyphenyl)- 2,3- dihydroimidazo[2,1- b]thiazole	Cardiotonic	heart failure; cancer
GP 2128	1-(3,4- dihydroxyphenyl)-2- [3-(4- carbamoylphenyl)-1- methylpropylamino]et hanol	catecholamine	heart failure
dexrazoxane; razoxane (+), (S); ICRF 187; NSC 169780; ADR529; ICI 59118; CARDIOXANE; EUCARDION; RAZOXIN; ZINECORE; ZINECARD; ANTRAGARD	(+)-(S)-4,4'- propylenedi-2,6- piperazinedione	chemoprotectant; cytoprotectant	cancer; heart failure
ICRF 197	Unspecified	chemoprotectant; cytoprotectant	cancer; heart failure
AQRA 741	11-[[4-[4- (diethylamino)butyl]- 1-piperidinyl]acetyl]- 5,11-dihydro-6H- pyrido[2,3- b][1,4]benzodiazepin- 6-one	cholinergic antagonist; muscarinic antagonist; muscarinic M2 antagonist	heart failure
MCC 135	5-methyl-2-(1- piperazinyl)- benzenesulfonic acid monohydrate	Contractile dysfunction amelioration	heart failure; myocardial infarction

azosemide; PLE 1053; SK 110; LURET; DIART; URETIN	2-chloro-5-(1H-tetrazol-5-yl)-4-[(2-thienylmethyl)amino]benzenesulfonamide	diuretic	heart failure
C 2921	4-(bicyclo[2.2.1]hept-1-ylamino)-N-[(1-methylethyl)amino]carbonyl]-3-pyridinesulfonamide	diuretic	heart failure
JDL 961	4-(cyclooctylamino)-N-[(ethylamino)carbonyl]-3-pyridinesulfonamide	diuretic	heart failure
piretanide; HOE 118; S 734118; ARELIX; ARLIX; TAULIZ; EURELIX; PIRENEX	3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)benzoic acid	diuretic	heart failure
torasemide; torsemide; JDL 464; BM 02015; AC 4464; GJ 1090; UNAT; PRESARIL; TORREM; TOREM; ZEMIDE; DEMADEx; TORADIUR; DIURESIX; LUPRAC	N-[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide	diuretic	hypertension; heart failure
niravoline; niravolin; RU 51599	(1S-trans)-N-[2,3-dihydro-2-(1-pyrrolidinyl)-1H-inden-1-yl]-N-methyl-3-nitrobenzeneacetamide	diuretic; opiate agonist; kappa agonist	trauma; heart failure; cirrhosis
AY 31906	exo-2-amino-4-(bicyclo[2.2.1]hept-2-ylamino)-N-[(1-methylethyl)amino]carbonyl]-5-pyrimidinesulfonamide	diuretic; sulfonyleurea	heart failure

PNU 80873A	Unspecified	diuretic; vasopressin antagonist	heart failure
dopexamine; FPL 60278; FPL 60278AR; CARDURA; DOPACARD	4-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]-1,2-benzenediol	dopamine agonist; beta adrenergic agonist; beta2 adrenergic agonist; vasodilator	heart failure
ibopamine; SB 7506; AF 3104; SKF 100168; INOPAMIL; SCANDINE; ESCANDINE; ERFOLGAN; TRAZYL	2-methylpropanoic acid 4-[2-(methylamino)ethyl]-1,2-phenylene ester	dopamine agonist; dopamine D1 agonist; vasodilator	heart failure; eye disease
fenoldopam prodrug	Unspecified	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	heart failure
fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM	6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenyl)-1H-3-benzazepine-7,8-diol	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	hypertension; glaucoma; kidney disease; heart failure
CHF 1035	2-methylpropanoic acid 5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyl ester hydrochloride	dopamine agonist; dopamine D2 agonist; alpha adrenergic agonist; alpha2 adrenergic agonist; vasodilator	heart failure
CHF 1255	Unspecified	dopamine agonist; vasodilator	heart failure
docarpamine; TA 8704; TA 870; TANADOPA	carbonic acid (S)-4-[2-[[2-(acetylamino)-4-(methylthio)-1-oxobutyl]amino]ethyl]-1,2-phenylene diethyl ester	dopamine agonist; vasodilator	heart failure
YM 435	(S)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-7,8-isoquinolinediol hydrochloride	dopamine antagonist; dopamine D1 antagonist	heart failure
BMS 193884	Unspecified	endothelin antagonist	heart failure
BMS 207940	Unspecified	endothelin antagonist	heart failure

bosentan; Ro 470203; Ro 470203/039	4-(1,1-dimethylethyl)- N-[6-(2- hydroxyethoxy)-5-(2- methoxyphenoxy)[2,2- '-bipyrimidin]-4- yl]benzenesulfonamid e	endothelin antagonist	heart failure
TA 0201	(N-(6-(2-(5- bromopyrimidin-2- yloxy)ethoxy)-5-(4- methylphenyl)pyrimid in-4-yl)-4-(2- hydroxy-1,1- dimethyl)benzensulfo nide sodium salt)	endothelin antagonist	heart failure; myocardial infarction
ZD 1611	Unspecified	endothelin antagonist	heart failure
ZD 2574	Unspecified	endothelin antagonist	heart failure
ZD 4054	Unspecified	endothelin antagonist	heart failure
Ro 485695	2-pyridinyl-carbamic acid, 2-[[5-(2- methoxyphenoxy)-6- [[[4-(1- methylethyl)phenyl]s ulfonyl]amino]-2-(4- morpholinyl)-4- pyrimidinyl]oxy]ethyl ester	endothelin antagonist; endothelin A antagonist	heart failure
TBC 11251; IPI 1251	N-(4-chloro-3- methyl-5-isoxazolyl)- 2-[(6-methyl-1,3- benzodioxol-5- yl)acetyl]-3- thiophenesulfonamide	endothelin antagonist; endothelin A antagonist	heart failure; pulmonary obstructive disease; brain ischemia
ecadotril; sinorphan; BP 1.02; BAY y 7432; S 049; BP 102	(S)-N-[2- [(acetylthio)methyl]- 1-oxo-3- phenylpropyl]glycine phenyl methyl ester	enkephalinase inhibitor	hypertension; heart failure; cirrhosis
ThGRF 129; H 9506; ThGRF 1-29	N-(2-aminoethyl)-1,2- ethanediamine	growth hormone releasing factor analogue	heart failure; hormone deficiency

BU E75; BU-E 75	N-[3-(3,4-difluorophenyl)-3-(2-pyridinyl)propyl]-N'-[3-(1H-imidazol-4-yl)propyl]guanidine	histamine agonist; histamine H2 agonist	heart failure
BU E76; BU-E 76	N-[3-(3,5-difluorophenyl)-3-(2-pyridinyl)propyl]-N'-[3-(1H-imidazol-4-yl)propyl]guanidine	histamine agonist; histamine H2 agonist	heart failure
HE 30582	N-(3-(1H-imidazol-4-yl)propyl)-4-(2 nitro-4-(1,4,5,6- tetrahydro-4-methyl-6-oxo-2-pyridiziny)phenyl)-1-piperazine carboximidamide	histamine agonist; histamine H2 agonist	heart failure
anaritide; atrial natriuretic factor 4-28; ANF 4-28; atrial natriuretic peptide; anaritide acetate; WY 47663; AURICULIN	N-L-arginyl-8-L-methioninc-21a-L-phenylalanine-21b-L-arginine-21c-L-tyrosine-atrioneptin-21 (rat)	hormone; ANP agonist; peptide	heart failure; kidney disease
BM 500430	4,5-dihydro-5-methyl-6-[2-(pyridin-4-yl)-1H-indol-5-yl]-pyridazin-3(2H)-one	Inotropic agent	heart failure
CL 284027	Unspecified	Inotropic agent	heart failure
digitalis-like steroids	Unspecified	Inotropic agent	heart failure
DLC-CL3	digitalis-like compound 2;	Inotropic agent	heart failure
DLC-CL3	digitalis-like compound 3	Inotropic agent	heart failure
GYKI 12735	2-methyl-4-((2-4-morpholinyl)ethyl)amino-1H-pyrimido(5,4-6)-(1,4) oxazin-7(6H)-one	Inotropic agent	heart failure
KF 15832	6-(4-benzylamino-7-quinazolinyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone hydrochloride	Inotropic agent	heart failure
LAS 31180	Unspecified	Inotropic agent	heart failure
LAS 31270	Unspecified	Inotropic agent	heart failure

RG 12152	6-(3'-cyano-6'-methyl-2'-oxo-(1H)-pyridin-5'-yl)-1-methyl-2H-pyrido (3,2-b)-1,4-oxazin-3(4H)-one	Inotropic agent	heart failure
RWJ 24517	6-[1-[1-bis(4-fluorophenyl)methyl]piperazin-4-yl]-2-hydroxy-3-propylthiopurine	Inotropic agent	heart failure
UK 66838	6-(4-acetyl-2-methyl-1H-imidazol-1-yl)-8-methyl-2(1H)-quinolinone	Inotropic agent	heart failure
vasotrope	Unspecified	Inotropic agent	heart failure
meribendan; EMD 49931	4,5-dihydro-5-methyl-6-(2-pyrazol-3-yl-5-benzimidazolyl)-3(2H)-pyridazinone	Inotropic agent; cardiotonic	heart failure
omapatrilat; BMS 186716	[4S-[4alpha(R*),7alpha,10abeta]]-octahydro-4-[[2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid	matrix metalloproteinase inhibitor; ACE inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
matrix metalloproteinase inhibitor, coronary heart failure	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor	heart failure
cardiovascular disease therapy	Unspecified	Myosin motor and actin filaments modulation	hypertension; heart failure
SA 7060	[S-(R*,R*)]-alpha-[[[(3-butoxy-2-hydroxy-3-oxopropyl)(2-methylpropyl)amino]carbonyl]amino]-2-naphthalenepropanoic acid	neutral endopeptidase inhibitor; ACE inhibitor	heart failure; hypertension

SCH 50690	Unspecified	neutral endopeptidase inhibitor; ACE inhibitor	hypertension; heart failure
SLV 306	[S-(R*,S*)]-3-[[[1-[2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-acetic acid	neutral endopeptidase inhibitor; diuretic	heart failure
nitric oxide vasodilators	Unspecified	nitric oxide donor; vasodilator	angina; heart failure
VX 745	Unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation; neurological; heart failure; Crohn disease; asthma
BRL 52656	S(-)-2-(1-pyrrolidinylmethyl)-1-(4-(trifluoromethylphenyl)acetyl)piperidine hydrochloride	opiate agonist; kappa agonist; diuretic	heart failure
BRL 53114	(-)-1-(4-(trifluoromethylphenyl)acetyl)-2-(1-pyrrolidinyl)-3,3-dimethylpiperidine hydrochloride	opiate agonist; kappa agonist; diuretic	heart failure
oxytocin antagonist	Unspecified	oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
amrinone; WIN 40680; YM 10310; INOCOR; WINCORAN; VESISTOL; AMCORAL; CARTONIC	5-amino-[3,4'-bipyridin]-6(1H)-one	phosphodiesterase inhibitor	heart failure
BRL 40696	Unspecified	phosphodiesterase inhibitor	heart failure



EMD 53998	6-(3,6-dihydro-6-methyl-2-oxo-2H-1,3,4-thiadiazin-5-yl)-1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydroquinoline	phosphodiesterase inhibitor	heart failure
indolidan; LY 195115	1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one	phosphodiesterase inhibitor	heart failure
N 3601	2-[[[(4,6-dimethylpyridin-2-yl)methylamino]carboxy]-3-[2-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]ethyl]-3-aza-2,3-dihydro-1H-indole	phosphodiesterase inhibitor	heart failure
olprinone; loprinone; E 1020; CORETEC	1,2-dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3-pyridinecarbonitrile	phosphodiesterase inhibitor	heart failure
TZC 5665	4-chloro-2-[3-[[1,1-dimethyl-2[[4(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]amino]ethyl]amino]-2-hydroxypropoxy]benz onitrile, compd. with (Z)-2-butenedioic acid, monoethyl ester, (1:1)	phosphodiesterase inhibitor	heart failure
ZSY 39	4-methyl-5-(4-pyridinyl)-2-thiazolecarboxamide	phosphodiesterase inhibitor	heart failure

EMD 57033; (+)- EMD 53998	(+)-6-(3,6-dihydro-6-methyl-2-oxo-2H-1,3,4-thiadiazin-5-yl)-1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydroquinoline	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
isomazole; LY 175326; EMD 52750	2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
NSP 804	4,5-dihydro-6-[4-[(2-methyl-3-oxo-1-cyclopentenyl)amino]phenyl]-3(2H)-pyridazinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
NSP 805; TZN 01	4,5-dihydro-5-methyl-6-[4-[(2-methyl-3-oxo-1-cyclopentenyl)amino]phenyl]-3(2H)-pyridazinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
revizinone; R 801222	(E)-N-cyclohexyl-N-methyl-2-[[[phenyl(1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazolin-7-yl)methylene]amino]oxy]acetamide	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
KF 15232	4,5-dihydro-5-methyl-6-[4-[(phenylmethyl)amino]-7-quinazolinyl]-3(2H)-pyridazinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase V inhibitor; vasodilator	heart failure
ORG 10325	N-hydroxy-5,6-dimethoxy-1H-indene-2-carboximidamide monohydrochloride	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor	heart failure

ORG 30029	N-hydroxy-5,6-dimethoxy-benzo[b]thiophene-2-carboximidamide	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor	heart failure
ORG 9731	4-fluoro-N-hydroxy-5,6-dimethoxy-benzo(b)thiophene-2-carboximidamine methyl sulfonic acid	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor	heart failure
E 4021; ER 21355	1-[4[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinazolinyl]-4-piperidinecarboxylic acid, monosodium salt	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	hypertension; angina; heart failure
IC 351; GF 196960; GG 960	Unspecified	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	heart failure; angina; sexual dysfunction; psoriasis
SKF 95654	4,5-dihydro-6-(4-(1,4-dihydro-4-oxopyridin-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis; heart failure
pimobendan; UDCG 115; UDCG 115A; UDCG 115BS; ACARDI	4,5-dihydro-6-(2-(p-methoxyphenyl)-5-benzimidazolyl)-5-methyl-3-(2H)-pyridazinone	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator	thrombosis; heart failure
simendan	[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator	heart failure; thrombosis

levosimendan; OR 1259; SIMDAX	[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator; calcium sensitizer	heart failure; thrombosis
toborinone; OPC 18790	(+,-)-6-[3-[[3,4-dimethoxyphenyl)methyl]amino]-2-hydroxypropoxy ] 2(1H)-quinolinone	phosphodiesterase inhibitor; potassium channel blocker	heart failure
vesnarinone; piperanometozine; OPC 8212; ARKIN-Z; ARKIN	1-(1,2,3,4-tetrahydro-2-oxo-6-quinolyl)-4-veratroylpiperazine	phosphodiesterase inhibitor; potassium channel blocker	heart failure; HIV infection
bemoradan; ORF 22867	7-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2H-1,4-benzoxazin-3(4H)-one	phosphodiesterase inhibitor; vasodilator	heart failure
BW 349U85	6-(1-piperidinyl)-2(1H)-quinolinone monohydrochloride	phosphodiesterase inhibitor; vasodilator	heart failure
enoximone; fenoximone; phenoximone; MDL 17043; RMI 17043; PERFAN; PERFLAN; PERFANE	1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-one	phosphodiesterase inhibitor; vasodilator	heart failure
milrinone; WIN 47203; WIN 472032; YM 018; CORATROPE; PRIMACOR; MILRILA	1,6-dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile	phosphodiesterase inhibitor; vasodilator	heart failure
MS 857	4-acetyl-1-methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3(2H)-isoquinolinone	phosphodiesterase inhibitor; vasodilator	heart failure

saterinone; BDF 8634	(+,-)-1,2-dihydro-5-[4-[2-hydroxy-3-[4-(2-methoxy-phenyl)-1-piperazinyl]propoxy]phenyl]-6-methyl-2-oxo-3-pyridinecarbonitrile	phosphodiesterase inhibitor; vasodilator	heart failure
16alpha-gitoxin; gitoxin	Unspecified	Positive inotropic action	heart failure
emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease
nicorandil; SG 75; EMD 36385; U 64417; SIGMART; PERISALOL; DANCOR; IKOREL; ADANCOR; CORDONE; KALIDIL	N-[2-(nitrooxy)ethyl]-3-pyridinecarboxamide	potassium channel activator; nitrate; vasodilator	angina; cerebrovascular disease; heart failure
BW 15AU81; BW 15AU; U 62840; 15AU81	[1R-[1alpha(S*),2beta,3alpha,9alpha]]-[2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-(3-hydroxyoctyl)-1H-benz[f]inden-5-yl]oxy]acetic acid	prostanoid; vasodilator	heart failure
EMD 52297	N-(tert-butoxycarbonyl)-L-phenylalanyl-L-histidyl-(4S-amino-3S-hydroxy-5-cyclohexyl)-pentanecarbonyl)-L-isoleucyl-(2-amidomethyl)-tetrazol	proteinase inhibitor; renin inhibitor	heart failure

BDF 9148	4-[3'-(1-benzhydryl-azetidin-3-oxy)-2'-hydroxypropoxy]-1H-indole-2-carbonitrile	sodium channel activator	heart failure
BM 20	N-[[4-(cyclooctylamino)pyridin-3-yl]sulfonyl]-N'-ethylthiourea	sulfonylthiourea; diuretic	heart failure
daltroban; BM 13505; SKF 96148	4-[2-[[4-(4-chlorophenyl)sulfonyl]amino]ethyl]benzeneacetic acid	thromboxane antagonist; platelet antiaggregant	heart failure; thrombosis
BW A746C	Unspecified	Unspecified	heart failure
CM 3	Unspecified	Unspecified	heart failure
congestive heart failure therapy	Unspecified	Unspecified	heart failure
CK 2289	4-ethyl-1,3-dihydro-5-[4-(1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one	vasodilator	heart failure
FK 664	6-(3,4-dimethoxyphenyl)-1-ethyl-3,4-dihydro-3-methyl-4-[(2,4,6-trimethylphenyl)imino]-2(1H)-pyrimidinone	vasodilator	heart failure
flosequinan; BTS 49465; MANOPLAX	7-fluoro-1-methyl-3-(methylsulfinyl)-4(1H)-quinolinone	vasodilator	heart failure
HN 10200	2-((3-methoxy-5-methylsulfinyl)-2-thienyl)-1-H-imidazo(4,5-c)pyridine hydrochloride	vasodilator	heart failure
nanterinone; UK 61260; UK 6126027	6-(2,4-dimethyl-1H-imidazol-1-yl)-8-methyl-2(1H)-quinolinone	vasodilator	heart failure
piroximone; MDL 19205	4-ethyl-5-isonicotinoyl-4-imidazolin-2-one	vasodilator	heart failure

prinoxodan; RGW 2938; RG 2938	3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2-(1H)-quinazolinone	vasodilator	heart failure
colforsin dapropate; NKH 477; ADEHL	6-[3-(dimethylamino)propionyl]forskolin	vasodilator; bronchodilator	heart failure; asthma; musculoskeletal disorder
propionylcarnitine, L-; propionyl-L-carnitine; levocarnitine propionyl; ST 261; DROMOS	L-3-carboxy-2-(1-oxopropoxy)-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt	vasodilator; cicatrizant	peripheral vascular disease; angina; heart failure; skin ulcer
VPA 985	N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methylbenzamide	vasopressin antagonist; aquaretic	heart failure
WAY 140288	Unspecified	vasopressin antagonist; aquaretic	heart failure
OPC 21268	1-[1-[4-(3-acetylaminopropoxy)benzoyl]-4-piperidyl]-3,4-dihydro-2(1H)-quinolinone	vasopressin antagonist; diuretic	hypertension; heart failure
SR 121463	cis-N-(1,1-dimethylethyl)-4-[[5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2'H)-yl]sulfonyl]-3-methoxy-benzamide (E)-2-butenedioate (1:1)	vasopressin antagonist; diuretic	heart failure; hypertension

SR 49059	[2R-[2alfa(S*),3beta]]-1-[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide	vasopressin antagonist; diuretic	gynecological; cancer; hypertension; heart failure; emesis
vasopressin antagonist	Unspecified	vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
YM 087	N-[1,1'-biphenyl]-2-yl-4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]-benzamide	vasopressin antagonist; diuretic	heart failure
YM 471	(Z)-N-[4-[[5-[2-[4-(dimethylamino)-1-piperidinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-[1,1'biphenyl]-2-carboxamide, monohydrochloride	vasopressin antagonist; diuretic	heart failure

Table 64. Current Candidate Therapeutic Interventions for the Treatment of Thrombosis

Product Name	Chemical Name	Action	Indication
DV 7028	3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-6,7,8,9-tetrahydro-2H-pyrido[1,2-a]-1,3,5-triazine-2,4(3H)-dione maleate	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis



eplivanserin; SR 46349; SR 46349B	(1Z,2E)-1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-2-propen-1-one (2E)-2-butenedioate (2:1) salt	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	schizophrenia; insomnia; thrombosis
LY 215840	[8beta(1S,2R)]-N-(2-hydroxycyclopentyl)-6-methyl-1-(1-methylethyl)ergoline-8-carboxamide	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis; angina
MDL 28133A	N-[4-[[1-[2-(4-fluorophenyl)-2-oxoethyl]-4-piperidinyl]carbonyl]phenyl]methanesulfonamide monohydrochloride	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis
S 14280	3-[2-[3-[2-(4-fluorophenyl)-2-oxoethyl]pyrrolidin-1-yl]ethyl]-2,4(1H,3H)-quinazolinedione	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis
sarpogrelate; sarpogrelate hydrochloride; MCI 9042; ANPLAG	butanedioic acid mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis
AT 1015	unspecified	5HT antagonist; 5HT2A antagonist; platelet antiaggregant	thrombosis
GP 531	5-amino-1-[5-deoxy-5-[phenylmethyl]amino]-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide	adenosine regulating agent; anti-ischemic	ischemia; thrombosis
acadesine; AICA-riboside; AR 100; GP 1110; GP 11100; ARASINE; PROTARA	5-amino-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide	adenosine regulating agent; platelet antiaggregant; anti-ischemic	cardiovascular disease; thrombosis; ischemia

AT 112	2,3-dihydro-2-[(4-phenyl-1-piperazinyl)methyl]imidazo[1,2-c]quinazolin-5(6H)-one	alpha adrenergic antagonist; alpha 1 adrenergic antagonist; platelet antiaggregant	thrombosis; hypertension
thrombospondin 1 inhibitor, TSP-1 inhibitor,	unspecified	angiogenesis inhibitor; platelet antiaggregant; radiodiagnostic; contrast medium	cancer; diagnosis; thrombosis
avidinorubicin	unspecified	antibiotic; anthracycline; platelet antiaggregant	thrombosis
placetin A	unspecified	antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
placetin B	unspecified	antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
RP 12986; RG 12986	Recombinant von Willebrand factor fragment	anticoagulant	thrombosis
staphylokinase	Recombinant staphylokinase	anticoagulant	thrombosis
thrombomodulin; MR 33; MB 015	unspecified	Anticoagulant	thrombosis
vascular anticoagulant, natural; VAC, natural	Protein isolated from human placenta	anticoagulant	thrombosis
hirudin, natural	unspecified	antithrombin	thrombosis
polyethylene glycol hirudin; PEG-hirudin; hirudin macrogol	unspecified	antithrombin; platelet antiaggregant	thrombosis
FK 633	N-[4-[4-(aminoiminomethyl)phenoxy]-1-oxobutyl]-L-alpha-aspartyl-L-valine	Antithrombotic	thrombosis
LF 060377	unspecified	antithrombotic	thrombosis
LF 337	unspecified	antithrombotic	thrombosis
LU 208791	unspecified	antithrombotic	thrombosis

M 19791; U 68215	[1R-[1alpha(R*),2beta,3alpha,9alpha]]-[[1-(3-cyclohexyl-3-hydroxypropyl)-2,3,3a,4,9a-hexahydro-2-hydroxy-1H-benz[f]inden-5-yl]oxy]-acetic acid	antithrombotic	thrombosis
protein C	unspecified	antithrombotic	thrombosis
protein C natural, activated; activated protein C, natural; APC	unspecified	antithrombotic	thrombosis
protein C; CTC 111	unspecified	antithrombotic	thrombosis
thrombin receptor inhibitors	unspecified	antithrombotic	thrombosis
thrombomodulin; ART 123	Recombinant Thrombomodulin	antithrombotic	thrombosis
thrombosis therapy	unspecified	antithrombotic	thrombosis
TMD 1105	Deletion mutant of recombinant thrombomodulin	antithrombotic	thrombosis
V 20R	unspecified	antithrombotic	thrombosis
V 21	unspecified	antithrombotic	thrombosis
GS 522	GGTTGGTGTGGTTGG	aptamer; thrombin inhibitor; proteinase inhibitor	thrombosis
nematode anticoagulant protein c2, recombinant; NAPc2; AcAPc2; rNAPc2	unspecified	biotechnology; blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
tick-derived anticoagulant peptide; TAP	unspecified	biotechnology; blood clotting factor Xa inhibitor; peptide; proteinase inhibitor	thrombosis
antistatin; ATS; ghilanten	unspecified	biotechnology; blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis

factor Xa inhibitor, leech; FACTOREX	unspecified	biotechnology; blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
nematode anticoagulant protein 5, recombinant; rNAP5; NAP5	unspecified	biotechnology; blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
TP 9201	N-acetyl-L-cysteinyl- L-asparaginyl-L- prolyl-L- arginylglycyl-L- alpha-aspartyl-O- methyl-L-tyrosyl-L- arginyl-L- cysteinamide cyclic (1-9)-disulfide	biotechnology; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
CX 397	unspecified	biotechnology; hirudin analogue	thrombosis
MAB, AP-1	unspecified	biotechnology; monoclonal antibody	thrombosis
MAB, fibrin beta chain plus hirudin; HAF	unspecified	biotechnology; monoclonal antibody	thrombosis
MAB, platelet receptor IIb/IIIa + hirudin; HAP; HAP	unspecified	biotechnology; monoclonal antibody	thrombosis
MAB, RWR; MAB, alpha2-plasmin	unspecified	biotechnology; monoclonal antibody	thrombosis
MAB, thrombosis; 12D10; CORSEVIN M	unspecified	biotechnology; monoclonal antibody	thrombosis; septic shock; angina
MAB, factor IX; MAB, BC 2; SB 249417	unspecified	biotechnology; monoclonal antibody; blood clotting factor IXa inhibitor	thrombosis
MAB, Fab, 7E3	unspecified	biotechnology; monoclonal antibody; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

MAB, glycoprotein IIb/IIIa; MAB, GP IIb/IIIa	unspecified	biotechnology; monoclonal antibody; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
MAB, glycoprotein IIb/IIIa; YM 337	unspecified	biotechnology; monoclonal antibody; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
MAB, AJvW2; MAB, von Willebrand factor; AJvW2; humanized AJvW2	unspecified	biotechnology; monoclonal antibody; platelet antiaggregant	thrombosis
MAB, M735 and P14G11 urokinase conjugate; bispecific antibody, platelet antiaggregant; ATC 3; ATC (3)	unspecified	biotechnology; monoclonal antibody; platelet antiaggregant	thrombosis
MAB, platelet, humanized; SMART anti-platelet	unspecified	biotechnology; monoclonal antibody; platelet antiaggregant	cardiovascular disease; thrombosis
AAMP-1 derived peptides; cell adhesion peptides	unspecified	biotechnology; peptide	thrombosis
KPI Xa	unspecified	biotechnology; peptide; proteinase inhibitor; thrombolytic; fibrinolytic; serine proteinase inhibitor	thrombosis
D K2P	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis
FK2P; U 84793	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis
hybrid B; plasminogen activator	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis

monteplase; tissue plasminogen activator, second generation; tPA second generation; E 6010; CLEACTOR	84-L-serineplasminogen activator (human tissue-type protein moiety reduced)	biotechnology; plasminogen activator; thrombolytic	thrombosis
reteplase; tissue plasminogen activator; tPA; BM 06022; RAPILYSIN; RETAVASE; RETEVASE; ECOKINASE	173-L-serine-174-L-tyrosine-175-L-glutamine-173-527-plasminogen activator (human tissue type)	biotechnology; plasminogen activator; thrombolytic	thrombosis; myocardial infarction
tissue plasminogen activator variants; tPA variants	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis
tissue plasminogen activator, FK(2)P24; tPA second generation; FK (2)P24	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis
BIO-LASE	unspecified	biotechnology; platelet antiaggregant	thrombosis; kidney disease; eye disease
calen; calin; EMD 66800	unspecified	biotechnology; platelet antiaggregant	thrombosis
human von Willebrand fragment	unspecified	biotechnology; platelet antiaggregant	thrombosis
protein C activator	unspecified	biotechnology; platelet antiaggregant	thrombosis
tifacogin; tissue factor pathway inhibitor	N-L-alanyl- blood coagulation factor LACI (human clone lambdaP9 protein moiety reduced)	biotechnology; platelet antiaggregant	thrombosis; septic shock
ectoapyrases	unspecified	biotechnology; platelet antiaggregant; enzyme	thrombosis

abciximab; abcirximab; MAb, F(ab') <sub>2</sub> fragment platelet; MAb, 7E3; c7E3 FAb; c7E3; ReoPro; CENTORX	immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhC.gamma.1 Fab fragment anti- human glycoprotein IIb/IIIa receptor), disulfide with human- mouse monoclonal c7E3 clone p7E3V.kappa.hc.kapp a.light chain	biotechnology; platelet antiaggregant; monoclonal antibody	thrombosis; restenosis; angina; stroke; myocardial infarction
antithrombin III		biotechnology; proteinase inhibitor	thrombosis
KPI 185	unspecified	biotechnology; proteinase inhibitor; peptide; serine proteinase inhibitor; thrombolytic; fibrinolytic	thrombosis
LEX 026	unspecified	biotechnology; proteinase inhibitor; serine proteinase inhibitor	thrombosis; inflammation
lepirudin; HBW 023; REFLUDAN	1-L-leucine-2-L- threonine-63-desulfo- hirudin (hirudo medicinalis isoform HV1)	biotechnology; thrombin inhibitor; proteinase inhibitor	thrombosis; restenosis
BB 10153	unspecified	biotechnology; thrombolytic	thrombosis
hirudin, recombinant	hirudin, recombinant	biotechnology; thrombolytic	thrombosis
hirudin; rHV2-Lys47; rt HV2	unspecified	biotechnology; thrombolytic	thrombosis
LU 52369	unspecified	biotechnology; thrombolytic	thrombosis
plasminogen mutants	unspecified	biotechnology; thrombolytic	thrombosis
hementin; EMD 66777	unspecified	biotechnology; thrombolytic; fibrinolytic; peptide	thrombosis

MAB, bispecific F(ab') <sub>2</sub> fibrin and u-PA + scu-PA; scu-PA/MA-FUI-74F(ab') <sub>2</sub>	unspecified	biotechnology; thrombolytic; monoclonal antibody	thrombosis
MAB, bispecific fibrin tissue plasminogen; MAB, bispecific tPA fibrin	unspecified	biotechnology; thrombolytic; monoclonal antibody	thrombosis
MAB, chimeric plasminogen activator; K12G2S32	unspecified	biotechnology; thrombolytic; monoclonal antibody	thrombosis
MAB, D3-ATF; MAB, thrombosis; MAB, human tissue factor	unspecified	biotechnology; thrombolytic; monoclonal antibody	thrombosis
DSPA; alpha-DSPA; rDSPAalpha1; ZK 152387; SH 576	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
duteplase; tPA; tissue plasminogen activator; SM 9527; PROLYSIS; TIPLAGEN; SOLCLOT	245-L-methionine plasminogen activator (human tissue-type 2-chain form protein moiety)	biotechnology; thrombolytic; plasminogen activator	thrombosis
lanoteplase; novel plasminogen activator; nPA; SUN 9216; BMS 200980	N-[N2-(N-glycyl-L-alanyl)-L-arginyl]-117-L-glutamine-245-L-methionine-(1-5)-(87-527)-plasminogen activator (human tissue-type protein moiety)	biotechnology; thrombolytic; plasminogen activator	thrombosis
LY 210825	Unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
nateplase; tissue plasminogen activator; tPA; MMR 701; MILYZER; TEPASE	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
pamiteplase; YM 866; SOLINASE	(1-126)-(209-562)-plasminogen activator [310-glutamic acid] (human tissue-type precursor reduced)	biotechnology; thrombolytic; plasminogen activator	thrombosis



prourokinase; PUK; FCE 26177	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
prourokinase; PUK; rProUK; A 74187; PROLYSE	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis; stroke
saruplase; CG 4509	prouro-(human clone pUK4/pUK18) kinase (enzyme activating)	biotechnology; thrombolytic; plasminogen activator	thrombosis
alteplase; tissue plasminogen activator; tPA; TD 2061; DR 3200; PLASMINER	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
tissue plasminogen activator	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
tissue plasminogen activator, K2tuPA; tPA, K2tuPA	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
tissue plasminogen activator, unglycosylated; rtPA; BM 06021	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
tPA analogue	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis; myocardial infarction
alteplase; tissue plasminogen activator; tPA; ACTIVASE; ACTILYSE; ACTIVACIN; GRTPA	Unspecified	biotechnology; thrombolytic; plasminogen activator; cicatrizant	thrombosis; skin ulcer; stroke
draculin	unspecified	blood clotting factor IXa inhibitor; blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
VM 201	unspecified	blood clotting factor IXa inhibitor; proteinase inhibitor	thrombosis; stroke
factor VIIa inhibitor	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis

factor VIIa inhibitor, injectable; CORSEVIN AS	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
factor VIIa inhibitor, oral, Corvas; CORSEVIN AS	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
factor VIIa inhibitors	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
factor VIIa inhibitors	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
antithrombotic agents	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
DPC 423	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
DX 9065a	[S-(R*,R*)]-7- (aminoiminomethyl)- alpha-[4-[[1-(1- iminomethyl)-3- pyrrolidinyl]oxy]phen yl]-2- naphthalenepropanoic acid monohydrochloride, pentahydrate	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitor	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitor	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitor	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis; stroke; myocardial infarction
factor Xa inhibitor, injectable; CORDECIN AS	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitor; CORDECIN AS	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis

factor Xa inhibitors	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitors	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitors	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa/thrombin inhibitors	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
JTV 803	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	stroke; myocardial infarction; thrombosis
KFA 1411	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
SH 544; SH 630	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
YM 60828	[[[7-( (aminoiminomethyl)- 2- naphthalenyl)methyl]]- 4-[[1-(1-iminoethyl)- 4- piperidinyloxy]phenyl amino]sulfonyl]acetic acid dihydrochloride	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
ZD 4927	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
SR 34006	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor; oligosaccharide	thrombosis

TA 993	cis-(-)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-1,5-benzothiazepin-4(5H)-one	calcium antagonist; platelet antiaggregant	thrombosis
meoxan	unspecified	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease
veroxan; VUFB 18814	unspecified	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease
clinprost; lipoisocarbacyclin; isocarbacyclin methyl ester; TEI 9090	[3aS-[3aalpha,5beta,6alpha(1E,3R*),6aalpha]]-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-2-pentalenepentanoic acid methyl ester	cicatrizant; prostanoid; platelet antiaggregant	thrombosis; skin ulcer; peripheral vascular disease
MRX 408	unspecified	contrast medium; echo contrast medium; thrombolytic	diagnosis; thrombosis
FR 122047	1-[(4,5-bis(4-methoxyphenyl)-2-thiazoyl)carbonyl]-4-methylpiperazine hydrochloride	COX inhibitor; platelet antiaggregant	thrombosis
itazigrel; U 53059	4,5-bis(4-methoxyphenyl)-2-(trifluoromethyl)thiazole	COX inhibitor; platelet antiaggregant	thrombosis

KC 764	(2-methylpyrazolo[1,5-a]pyridin-3-yl)(1,4,5,6-tetrahydro-3-pyridinyl)methanone	COX inhibitor; platelet antiaggregant	thrombosis
trifenagrel; BW 325U	2-[2-(4,5-diphenyl-1H-imidazole-2-yl)phenoxy]-N,N-dimethylethanamine	COX inhibitor; platelet antiaggregant; NSAID	inflammation; thrombosis
ST 681	N-(2-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine mononitrate	COX inhibitor; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
pamigogrel; KBT 3022; KB 3022; TO 192	2-[4,5-bis(4-methoxyphenyl)-2-thiazolyl]-1H-pyrrole-1-acetic acid ethyl ester	COX inhibitor; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease
Ro 462005	4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(3-methoxyphenoxy)-4-pyrimidinyl]-benzenesulphonamide	endothelin A antagonist; endothelin B antagonist; endothelin antagonist; platelet antiaggregant	thrombosis
AC 610612; Ro 610612	unspecified	endothelin antagonist; platelet antiaggregant	thrombosis
PD 145065	(2R)-N-acetyl-2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)glycyl-L-leucyl-L-alpha-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophan disodium salt	endothelin antagonist; platelet antiaggregant	thrombosis
RPR 109891; KLerval	Unspecified	fibrinogen antagonist; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

GR 144053	4-[4-[4-(aminoiminomethyl)p-phenyl]-1-piperazinyl]-1-piperidineacetic acid monohydrochloride	fibrinogen antagonist; platelet antiaggregant	thrombosis
GR 233548	Unspecified	fibrinogen antagonist; platelet antiaggregant	thrombosis
UR 12947	unspecified	fibrinogen antagonist; platelet antiaggregant	thrombosis
GR 83895	N-[(6S-amino-5-oxo-8aR-hexahydro-5H-thiazolo[3,2-a]pyridin-3R-yl)-carbonyl]-L-arginyl-L-glycyl-L-aspartyl-L-phenylalanine, cyclic(4--->1)-peptide, monotrifluoroacetate	fibrinogen antagonist; platelet antiaggregant; peptide	thrombosis
bitistatin	unspecified	fibrinogen antagonist; venom; platelet antiaggregant	thrombosis
fibrolase	Agkistrodon conortrix venom metalloproteinase	fibrinolytic; thrombolytic; venom	thrombosis
M4	unspecified	fibrinolytic; thrombolytic; venom	thrombosis
glycoprotein IIb/IIIa antagonist; P246	unspecified	glycoprotein IIb/IIIa antagonist; peptide; platelet antiaggregant	thrombosis; heart ischemia; stroke
C 6822	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
CGH 400	7-amino heptanoyl Gly Asp Phe	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
cromafiban	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke

DMP 728	N-[3-(aminomethyl)benzoyl]-D-2-aminobutanoyl-N2-methyl-L-arginylglycyl-L-aspartic acid cyclic (41->1)-peptide monomethanesulfonate	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
DMP 802	3-[[[(5R)-3-[4-(aminoiminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl]acetyl]amino]-N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-L-alanine	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
EMD 122347; YM 028	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina; stroke
glycoprotein IIb/IIIa antagonist	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
glycoprotein IIb/IIIa inhibitors	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
lamifiban; Ro 449883	(S)-[[1-[2-[[4-(aminoiminomethyl)benzoyl]amino]-3-(4-hydroxyphenyl)-1-oxopropyl]-4-piperidinyl]oxy]acetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
lotrafiban; SB 214857	(S)-7-([4,4'-bipiperidin]-1-ylcarbonyl)-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

ME 3277	2,2'-[[4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bisacetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
MK 852; L 367073	N-acetyl-L-cysteinyl-L-asparaginy-(4R)-5,5-dimethyl-4-thiazolidinecarbonyl-4-(aminomethyl)-L-phenylalanylglycyl-L-alpha-aspartyl-L-cysteine, cyclic (1-7)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	stroke; thrombosis
Ro 435054	N-[N-[N-[4-(aminoiminomethyl)benzoyl]-beta-alanyl]-L-alfa-aspartyl]-L-phenylalanine mono(trifluoroacetate)	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
Ro 438857; Ro 43-8857	2,2'-[[4-[[[4-(aminoiminomethyl)benzoyl]methylamino]acetyl]-1,2-phenylene]bis(oxy)]bisacetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
roxifiban; DMP 754	(R)-3-[[[3-[4-(aminoiminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl]acetyl]amino]-N-(butoxycarbonyl)-L-alanine methyl ester monoacetate	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
RPR 110173	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis



SB 208651	(+,-)-8-[[[4-(aminoiminomethyl)phenyl]methylamino]carbonyl]-2,3,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)-1H-1,4-benzodiazepine-2-acetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SC 47643	(S)-3-[[8-[[[aminoiminomethyl]amino]-1-oxooctyl]amino]-4-[[2-(4-methoxyphenyl)ethyl]amino]-4-oxobutanoic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SC 49992	8-guanadino-octanoyl-Asp-Phe	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SC 52012A	N-[N-[5-[4-(aminoiminomethyl)phenyl]-1-oxopentyl]-L-alpha-aspartyl]-L-phenylalanine	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SC 54701	(S)-3-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SDZ GPI562	Unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke
sibrafiban; Ro 483657; RO 483657001; XUBIX; ZUBIX	[S-(Z)]-[[1-[2-[[4-[amino(hydroxyimino)methyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]acetic acid ethyl ester	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

SR 121787	4-[[[4-[4- [[[(ethoxycarbonyl)amino]iminomethyl]phenyl]-2-thiazolyl] (3-ethoxy-3-oxopropyl)amino]-1-piperidineacetic acid, ethyl ester	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
T 250	(-)-4-[3-(4-(aminoiminomethyl)phenoxy)propyl]-2,3-dioxo-beta-3-pyridinyl-1-piperazinepropanoic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
TAK 029	4-[[[4-(aminoiminomethyl)benzoyl]amino]acetyl]-2-oxo-1,3-piperazinediacetic acid alpha3-methyl ester	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
tirofiban; tirofiban hydrochloride; MK 383; L 700462; AGGRASTAT	N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina
TRM 147	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
xemilofiban; SC 54684A; SC 54684; CS 551	ethyl 3-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoate	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
contortrostatin; CN	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; biotechnology	cancer; thrombosis

eptifibatide; INTEGRILIN; INTEGRELIN	N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide cyclic (1->6)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; peptide	thrombosis; angina; myocardial infarction; restenosis
G 4120	N-(mercaptoacetyl)-D-tyrosyl-L-arginylglycyl-L-alpha-aspartyl-L-cysteine cyclic (1-5)-sulfide S-oxide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; peptide	thrombosis
kistrin	kistrin (Agkistrodon rhodostoma reduced)	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; venom	thrombosis
aprosulate sodium; LW 10082	N,N'-1,3-propanediylbis[4-O-(2,3,4,6-tetra-O-sulfo-beta-D-galactopyranosyl)-D-gluconamide], 2,2',3,3',5,5',6,6'-octakis(hydrogen sulfate) hexadecasodium salt	Heparin cofactor; serine proteases	thrombosis
dermatan sulfate; chondroitin sulfate B; chondroitinsulfuric acid B; MF 701; DS 435	dermatan, hydrogen sulfate (ester)	heparin cofactor II activator	thrombosis
alpha idosone	unspecified	heparinoid	thrombosis
ardeparin sodium; WY 90493; NORMIFLO	unspecified	heparinoid	thrombosis
bemiparin sodium; HIBOR	unspecified	heparinoid	thrombosis
BF 611	unspecified	heparinoid	thrombosis
C4 CY 216	unspecified	heparinoid	thrombosis
certoparin sodium; ALPHAPARIN	unspecified	heparinoid	thrombosis

dalteparin sodium; low molecular weight heparin; heparin, low molecular weight; tedelparin; tedelparine; KABI 2165; K 2165; FR 860; FRAGMIN; FRAGMINE; BOXOL	heparin, sodium salt	heparinoid	thrombosis; coronary artery disease; angina
danaparoid sodium; danaparoid; glycosamino glycan; ORG 10172; KB 101; ORGARAN; LOMOPARAN; RESTART	unspecified	heparinoid	thrombosis; thrombocytopenia
drug delivery system, BEODAS heparin; heparin BEODAS	unspecified	heparinoid	thrombosis
drug delivery system, LDS microemulsion low molecular weight heparin; heparin, low molecular weight, LDS microemulsion	unspecified	heparinoid	thrombosis
drug delivery system, nanosphere oral heparin; heparin oral; HEPORAL	unspecified	heparinoid	thrombosis
drug delivery system, oral low molecular weight heparin; heparin delivery system	unspecified	heparinoid	thrombosis
drug delivery system, submicron emulsion low molecular weight heparin; low molecular weight heparin SME	unspecified	heparinoid	thrombosis

drug delivery system, transmucosal low molecular weight heparin; heparin, low molecular weight, transmucosal	unspecified	heparinoid	thrombosis
enoxaparin sodium; low molecular weight heparin; enoxaparin; enoxaparine; PK 10169; RPY 005; RP 54563; LOVENOX; CLEXAN; CLEXANE	heparin sodium salt	heparinoid	thrombosis; angina; stroke; myocardial infarction
GM 2000	unspecified	heparinoid	thrombosis; restenosis
heparin sulfate analogue; HHS 5	unspecified	heparinoid	thrombosis
ITF 1331	heparin compound with bis[4- (dibutylamino)butyl] carbonate	heparinoid	thrombosis
ML 009723; CIRICIN	unspecified	heparinoid	thrombosis
nadroparin calcium; low molecular weight heparin; heparin, low molecular weight; CY 216; FRAXIPARIN; FRAXIPARINE; FRAXIPARINA; SELEPARIN	unspecified	heparinoid	thrombosis
naroparil; LF 90055	p-(p-((5-thio-beta-D- xylopyranosyl)thio)be nzoyl)benzonitrile	heparinoid	thrombosis
namaparin sodium; namaparin; low molecular weight heparin; heparin, low molecular weight; LHG 500; FLUXUM; MINIDALTON; LOHEPA	heparin	heparinoid	thrombosis

reviparin sodium; reviparin; low molecular weight heparin; heparin, low molecular weight; LU 47311; CLIVARIN	unspecified	heparinoid	thrombosis
S 5	unspecified	heparinoid	thrombosis
supersulfated low molecular weight heparin; ssLMWH	unspecified	heparinoid	thrombosis; hyperlipidemia
tinzaparin sodium; tinzaparin; low molecular weight heparin; heparin, low molecular weight; LHN 1; LOGIPARIN; INNOHEP	unspecified	heparinoid	thrombosis
ultra low molecular weight heparin; heparin, ultra low molecular weight; CY 222	unspecified	heparinoid	thrombosis
ZYN-LINKER conjugated heparin	unspecified	heparinoid	restenosis; thrombosis
fondaparin sodium; SR 90107; ORG 31540; SR 90107A	methyl O-2-deoxy-6- O-sulfo-2- (sulfoamino)-alfa-D- glucopyranosyl-(1-4)- O-beta-D- glucopyranuronosyl- (1-4)-O-2-deoxy-3,6- di-O-sulfo-2- (sulfoamino)-alfa-D- glucopyranosyl-(1-4)- O-2-O-sulfo-alfa-L- idopyranuronosyl-(1- 4)-2-deoxy-2- (sulfoamino)-alfa-D- glucopyranoside 6- (hydrogen sulfate)	heparinoid; blood clotting factor Xa inhibitor; proteinase inhibitor; oligosaccharide	thrombosis; peripheral vascular disease

SanOrg 32701; SR 32701	methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-alpha-L-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-alpha-D-glucopyranoside 3,6-bis(hydrogen sulfate) undecasodium salt	heparinoid; blood clotting factor Xa inhibitor; proteinase inhibitor; oligosaccharide	thrombosis
ITF 1300	Unspecified	heparinoid; class III antiarrhythmic	thrombosis; arrhythmia
GM 1077; ASTENOSE	unspecified	heparinoid; platelet antiaggregant	thrombosis; restenosis
MDL 28050	N-[N-[N-[N-[N-[1-[N-[1-[N-[N-(3-carboxy-1-oxopropyl)-L-tyrosyl]-L-alfa-glutamyl]-L-prolyl]-L-isoleucyl]-L-prolyl]-L-alfa-glutamyl]-L-alfs-glutamyl]-L-alanyl]-3-D-glutamic acid	hirudin analogue	thrombosis
hirudin peptide analogue; P 79	unspecified	hirudin analogue; peptide; thrombin inhibitor; proteinase inhibitor	thrombosis
antibody-mediated stroke inhibitor	unspecified	immunosuppressant; biotechnology	gynecological; stroke; thrombosis; myocardial infarction
drug delivery system, ANCHOR platelet inhibitor	unspecified	integrin antagonist; cell adhesion inhibitor	thrombosis

PKSI 527	[1(S)-trans]-4-[[2-[[[4-(aminomethyl)cyclohexyl]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]benzeneacetic acid monohydrochloride	kallikrein inhibitor; NSAID	septic shock; inflammation; thrombosis
linsidomine; SIN 1; CORVASAL; CORVATON	3-(4-morpholinyl)sydnone imine	nitric oxide donor; platelet antiaggregant	thrombosis
NCX 4016	2-(acetyloxy)benzoic acid, 2-[[nitrooxy)methyl]phenylester	NSAID; nitric oxide donor; platelet antiaggregant; analgesic	thrombosis; pain
OP 2000	unspecified	oligosaccharide	inflammatory bowel disease; thrombosis
ORG 31550; SR 80027	unspecified	oligosaccharide	thrombosis
SR 123781	unspecified	oligosaccharide	thrombosis
VASOFLUX	unspecified	oligosaccharide; thrombin inhibitor; proteinase inhibitor	thrombosis; myocardial infarction
lexipafant; BB 882; DO 6; GR 167089; ZACUTEX	N-methyl-N[[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]-L-leucine ethyl ester	PAF antagonist	thrombosis; endotoxic shock; pancreatitis; eye disease; multiple sclerosis
LA 213	unspecified	PAF antagonist; peptide; platelet antiaggregant	hypertension; thrombosis
dacopafant; RP 48740	(3R)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide	PAF antagonist; platelet antiaggregant	asthma; thrombosis
epiyangambin	(1R,3aR,4S,6aR)-tetrahydro-1,4-bis(3,4,5-trimethoxyphenyl)-1H,3H-furo[3,4-c]furan	PAF antagonist; platelet antiaggregant	thrombosis
F 1850	unspecified	PAF antagonist; platelet antiaggregant	thrombosis; asthma



ginkgolide B; BN 52021	hexacyclic trilactone	PAF antagonist; platelet antiaggregant	thrombosis; dermatitis; asthma; multiple sclerosis; septic shock
KO 286011	N-[1-(9-ethoxy-6-hydroxy-6-oxido-5,7,11-trioxa-6-phosphaheptacos-1-yl)-4(1H)-pyridinylidene]-N-methylmethanaminium inner salt	PAF antagonist; platelet antiaggregant	thrombosis
L 659989	trans-(+,-)-tetrahydro-2-[3-methoxy-5-(methylsulfonyl)-4-propoxyphenyl]-5-(3,4,5-trimethoxyphenyl)furan	PAF antagonist; platelet antiaggregant	asthma; thrombosis
minopafant; E 5880	(R)-1-ethyl-2-[[[2-methoxybenzoyl][2-methoxy-3-[[[4-[[[octadecylamino)carbonyl]oxy]-1-piperidinyl]carbonyl]oxy]propoxy]carbonyl]amino]methyl]pyridinium chloride	PAF antagonist; platelet antiaggregant	thrombosis
R 74654	3-(6-(0-(2R,2S)-(3-heptadecylcarbamoyloxytetrahydropyran-2-yl)methyl)phosphonoxy)hexylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis
R 74717	3-(5-(0-(2S,3S)-(3-heptadecylcarbamoylthiotetrahydropyran-2-yl)methyl)phosphonoxy)pentylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis

Ro 244736; Ro 24-4736	5-[3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-2-propynyl]-6(5H)-phenanthridinone	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock
SDZ 64412; SDZ 64-412	2,3-dihydro-5-[4-[2-(3,4,5-trimethoxyphenyl)ethyl]phenyl]imidazo[2,1-a]isoquinoline monohydrochloride	PAF antagonist; platelet antiaggregant	asthma; thrombosis
SM 12502	(2R-cis)-3,5-dimethyl-2-(3-pyridinyl)-4-thiazolidinone, monohydrochloride	PAF antagonist; platelet antiaggregant	thrombosis
SR 27388	4-[2-[[2-(dimethylamino)ethyl](3-pyridinylmethyl)amino]-4-thiazolyl]-2,6-bis(1,1-dimethylethyl)phenol	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock
UK 74505	4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]-5-[(2-pyridinylamino)carbonyl]-3-pyridinecarboxylic acid ethyl ester	PAF antagonist; platelet antiaggregant	thrombosis; asthma
WEB 2347	6-(2-chlorophenyl)-8,9-dihydro-1-methyl-N,N-dipropyl-4H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-8-carboxamide	PAF antagonist; platelet antiaggregant	asthma; anaphylactic shock; thrombosis

YM 264	1-(3-methyl-3-phenylbutyl)-4-[[2-(3-pyridinyl)-4-thiazolidinyl]carbonyl]piperazine (E)-2-butenedioate (1:1)	PAF antagonist; platelet antiaggregant	thrombosis; asthma
SDZ 64619	(+,-)-2-[6-methoxy-2-(methylsulfonyl)-3,9-dioxo-4,8-dioxo-2,10-diazaoctacosan-1-yl)-1-methylpyridinium iodide	PAF antagonist; platelet antiaggregant; bronchodilator	thrombosis; asthma
CV 6209	2-(2-acetyl-6-methoxy-3,9-dioxo-4,8-dioxo-2,10-diazaoctacos-1-yl)-1-ethylpyridinium chloride	PAF antagonist; platelet antiaggregant; NSAID	thrombosis; inflammation
UR 11353	2-[[[acetyl[[[tetrahydro-5-(octadecyloxy)-3-furanyl]methoxy]carbonyl]amino]methyl]-1-ethylpyridinium chloride	PAF antagonist; platelet antiaggregant; NSAID	thrombosis; inflammation
XR 334 series; XR 334	(Z,Z)-3-[(4-Methoxyphenyl)methylene]-6-(phenylmethylene)-2,5-piperazinedione	PAI inhibitor; thrombolytic	thrombosis; angina
XR 5118	(Z,Z)-3-[[5-[[2-(dimethylamino)ethyl]thio]-2-thienyl]methylene]-6-(phenylmethylene)-2,5-piperazinedione monohydrochloride	PAI inhibitor; thrombolytic	thrombosis
anticoagulant, Erfurt Medical Academy	D-phenylalanyl-L-prolyl-L-arginine nitrile	peptide	thrombosis
antithrombotic peptides	unspecified	peptide	thrombosis

fibrolase and thrombus targeting peptides; fibrolase and P734	unspecified	peptide	thrombosis
LU 58463	unspecified	peptide	thrombosis
AS 101; METASCAN	unspecified	peptide; contrast medium; radiodiagnostic	diagnosis; thrombosis
GPIIb/IIIa peptide antagonist	unspecified	peptide; platelet antiaggregant	thrombosis
MOL 144	unspecified	peptide; thrombin inhibitor; proteinase inhibitor	thrombosis
MOL 171	unspecified	peptide; thrombin inhibitor; proteinase inhibitor	thrombosis
triflusal; UR 1501; DISGREN; TECNOSAL; TRIFLUX; AFLEN	unspecified	phosphodiesterase inhibitor; COX inhibitor; platelet antiaggregant	thrombosis
NM 702	4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]-3(2H)-pyridazinone monohydrochloride	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase V inhibitor; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
cilostazol; OPC 13013; PLETAL; PLETAAL	6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; platelet antiaggregant; vasodilator	thrombosis
BF 385; GP 385; BF/GP 385; ONO BF11301; ONO 1505	unspecified	phosphodiesterase inhibitor; phosphodiesterase V inhibitor; thromboxane synthetase inhibitor; platelet antiaggregant	hypertension; thrombosis

AY 31390	5-bromo-6-[[[(5-bromo-3-pyridinyl)methyl]amino]-2-methyl-4(1H)-pyrimidinone monohydrobromide	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis
BMV 21190	7-[4-(cyclohexylamino)butoxy]-1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis
BMV 21638	1,3-dihydro-7-[4-(phenylsulfonyl)butoxy]-2H-imidazo[4,5-b]quinolin-2-one	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis
BMV 43351	7-(4-(4-(cyclohexylmethyl)-1-piperazinyl)-4-oxobutoxy)-1,3-dihydro-2H-imidazo(4,5-b)quinolin-2-one	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis; angina
R 69082	unspecified	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis
SKF 95654	4,5-dihydro-6-(4-(1,4-dihydro-4-oxopyridin-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis; heart failure
pimobendan; UDCG 115; UDCG 115A; UDCG 115BS; ACARDI	4,5-dihydro-6-(z-(p-methoxyphenyl)-5-benzimidazolyl)-5-methyl-3-(2H)-pyridazinone	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator	thrombosis; heart failure
simendan	[[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator	heart failure; thrombosis

levosimendan; OR 1259; SIMDAX	[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazone]propanedinitrile	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator; calcium sensitizer	heart failure; thrombosis
U 73122	1-[6-[[[(17 beta)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]	phospholipase inhibitor; platelet antiaggregant; NSAID	inflammation; thrombosis
tenecteplase; TNK-tPA; TNK	plasminogen activator (human tissue type), 103-L-asn-117-L-gln-296-L-ala-297-L-ala-298-L-ala-299-L-ala-	plasminogen activator; biotechnology; thrombolytic	thrombosis; myocardial infarction
fu-PA	unspecified	plasminogen activator; thrombolytic	thrombosis
anagrelide; anagrelide hydrochloride; BL 4162A; AGRYLIN; AGRELIN	6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one	platelet antiaggregant	thrombosis; cancer
antiaggregant, Kanebo	4,5-bis(4-methoxyphenyl)-2-(1,5-dimethyl-2-pyrrolyl)thiazole	platelet antiaggregant	thrombosis
anticoagulant	hexadecasodium N,N'-dimethylethylenebis(4-O-beta-D-galactopyranosyl-D-gluconoylamino octasulfate)	platelet antiaggregant	thrombosis
anticoagulant	hexadecasodium trimethylenebis (4-O-beta-galactopyranosyl-D-gluconoylamino octasulfate)	platelet antiaggregant	thrombosis
ARL 67085; FPL 67085; FPL 67085XX	2-(propylthio)-5'-adenylic acid monoanhydride with (dichloromethylene)bis[phosphonic acid]	platelet antiaggregant	thrombosis

aspalatone; asparatone; BK 111	2-(acetyloxy)benzoic acid 2-methyl-4-oxo- 4H-pyran-3-yl ester	platelet antiaggregant	thrombosis
BIBU 251	unspecified	platelet antiaggregant	thrombosis
BIS-TMPP	2,2'-(1-propene-1,3- diyl)bis[3,5,6- trimethylpyrazine]	platelet antiaggregant	thrombosis
BMY 21259	methyl-4-((2,3- dihydro-2-oxo-1H- imidazo(4,5- b)quinolin-7-yl)-oxy) butanoate	platelet antiaggregant	thrombosis
BMY 21260	4-[(2,3-dihydro-2- oxo-1H-imidazo[4,5- b]quinolin-7- yl)oxy]butyric acid	platelet antiaggregant	thrombosis
BP 16	potassium 6-chloro- alpha- cyanopyrazineacetic acid ethyl ester ion(1- )	platelet antiaggregant	thrombosis
C 894095	5-amino-3-(3,3- dimethyl-1,1-dioxido- 4-thiomorpholinyl)- 1,2,3-oxadiazolium chloride	platelet antiaggregant	thrombosis
CK 53	2-[[4-(2- chlorophenyl)-1- piperazinyl]methyl]- 2,6- dihydroimidazo[1,2- c]quinazolin-5(3H)- one	platelet antiaggregant	thrombosis
clopidogrel; clopidogrel bisulfate; SR 25990; SR 25990C; DV 7314; PCR 4099; SR 25990B; SR 25990A; SR 25990D; SR 25990E; PLAVIX; ISCOVER	(S)-alfa-(2- chlorophenyl)-6,7- dihydrothieno[3,2- c]pyridine-5(4H)- acetic acid methyl ester	platelet antiaggregant	thrombosis; stroke; ischemia
CS 747	unspecified	platelet antiaggregant	thrombosis
DHG 1	unspecified	platelet antiaggregant	thrombosis

dicranin	9,12,15-octadecatrien-6-ynoic acid	platelet antiaggregant	thrombosis
drug delivery system, argatroban; argatroban drug delivery system	unspecified	platelet antiaggregant	thrombosis; myocardial infarction
drug delivery system, oral heparin; heparin, oral delivery system	unspecified	platelet antiaggregant	thrombosis
drug delivery system, oral low molecular weight heparin; low molecular weight heparin oral	unspecified	platelet antiaggregant	thrombosis
echicetin	unspecified	platelet antiaggregant	thrombosis
ethyl eicosapentaenoate; ethyl icosapentate; EPA-E; MND 21; EPADEL	ethyl all-cis-5,8,11,14,17-eicosapentaenoate	platelet antiaggregant	thrombosis; hyperlipidemia
fradafiban; BIBU 52	(3S,5S)-5-[(4'-amidino-4-biphenyl)oxymethyl]-2-oxo-3-pyrrolidineacetic acid	platelet antiaggregant	thrombosis
G 619	4-methoxy-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide	platelet antiaggregant	thrombosis
glaucocalyxin A	(7 $\alpha$ ,14R)-7,14-dihydroxy-kaur-16-ene-3,15-dione	platelet antiaggregant	thrombosis
GM 1115	unspecified	platelet antiaggregant	thrombosis; restenosis
GM 1445	unspecified	platelet antiaggregant	thrombosis
GM 9005	unspecified	platelet antiaggregant	thrombosis
GT 12	alpha, alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene dihydrobromide	platelet antiaggregant	thrombosis
IBI P05006; IBI-P 05006	2-amino-6-hexylcyclohexaneheptanoic acid	platelet antiaggregant	thrombosis



indobufen; K 3920; IBUSTRIN	(+,-)-2-[p-(1-oxo-2- isoindolinyl)phenyl]b utyric acid	platelet antiaggregant	thrombosis
KK 117	2-hydroxy-1,2,3,3- tetrahydro-3H- pyrano(3,2- f)quinoline-8(7H)-one	platelet antiaggregant	thrombosis
L 367073; MK 0852	N-acetyl-L-cysteinyl- L-asparaginyl-5,5- dimethyl-L-4- thiazolidinecarbonyl- 4-(aminomethyl)-L- phenylalanylglycyl-L- alfa-aspartyl-L- cysteine cyclic (1-7)- disulfide	platelet antiaggregant	thrombosis
L 703014	unspecified	platelet antiaggregant	thrombosis
LF 1351	4-[hydroxy(4- nitrophenyl)methyl]p henyl-beta-D- xylopyranoside	platelet antiaggregant	thrombosis
ME 3229	unspecified	platelet antiaggregant	thrombosis
mycololide B	unspecified	platelet antiaggregant	thrombosis
P1	H-Phe-Gln-Val-Val- Cys(3-nitro-2- pyridinesulphenyl)- Gly-NH <sub>2</sub>	platelet antiaggregant	thrombosis
PI 200	unspecified	platelet antiaggregant	thrombosis
PI 201	unspecified	platelet antiaggregant	thrombosis
RC 3911	2-(diethylamino)-7- hydroxy-4H-1- benzopyran-4-one	platelet antiaggregant	thrombosis
RGDY	unspecified	platelet antiaggregant	thrombosis
SC 52905	unspecified	platelet antiaggregant	thrombosis
SKF 106760	N-acetyl-L-cysteinyl- N <sup>2</sup> -methyl-L- arginylglycyl-L- alpha-aspartyl-3- mercapto-L- valinamide cyclic (1- 5)-disulfide	platelet antiaggregant	thrombosis

thiofedrine	3-[(2-hydroxy-1-methyl-2-phenylethyl)amino]-1-(thien-2-yl)-1-propanone	platelet antiaggregant	thrombosis
trombodipine; thrombodipine; PCA 4230	1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid ethyl 2-(3-oxo-1,2-benzisothiazol-2(3H)-yl)ethyl ester S,S-dioxide	platelet antiaggregant	thrombosis
TY 11223	[1S-[1alpha(R*),2beta,3alpha,7alpha]]-[2-[2,3,3a,6,7,7a-hexahydro]e-hydroxy-1-(3-hydroxy-4,4-dimethyl-1,6-nonadiynyl)-1H-inden-5-yl]ethoxy]acetic acid	platelet antiaggregant	thrombosis
V 20	unspecified	platelet antiaggregant	thrombosis
EF 12	unspecified	platelet antiaggregant; antiproliferative agent	heart ischemia; thrombosis; restenosis
ticlopidine; ticlopidine hydrochloride; 5332 C; 4 C 32; PCR 5332; PICLODIN; PICLONADINE; PROPACALL; TICLID; PANALDINE; ROBETARL; RONDORIN	5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine	platelet antiaggregant; calcium antagonist	stroke; thrombosis
L 734217	[R-(R*,R*)]-3-[[[2-oxo-3-[2-(4-piperidiny)ethyl]-1-piperidiny]acetyl]amino-butanoic acid	platelet antiaggregant; fibrinogen antagonist	thrombosis

lefradafiban; BIBU 104; BIBU 104XX	(3S-trans)-5-[[[4'-[imino[(methoxycarbonyl)amino]methyl][1,1'-biphenyl]-4-yl]oxy]methyl]-2-oxo-3-pyrrolidineacetic acid methyl ester	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
MS 180	3,4-dihydro-6-[[4-(imino-4-morpholinylmethyl)benzoyl]amino]-2H-1-benzopyran-3-acetic acid ethyl ester monohydrochloride	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
orbofiban; SC 57099B; CS 511	(S)-N-[[[1-[4-(aminoiminomethyl)phenyl]-2-oxo-3-pyrrolidinyl]amino]carbonyl]-beta-alanine ethyl ester	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
RWJ 53308	[S-(R*,S*)]-beta-[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
SC 46749	unspecified	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
SR 121566	4-[[4-[4-(aminoiminomethyl)phenyl]-2-thiazolyl](2-carboxyethyl)amino]-1-piperidineacetic acid trihydrochloride	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
platelet adhesion inhibitors	unspecified	platelet antiaggregant; platelet antiaggregant	thrombosis
S 18886	unspecified	platelet antiaggregant; thromboxane antagonist	thrombosis

drug delivery system, MICROPUMP oral controlled release aspirin; aspirin MICROPUMP; ASACARD	unspecified	platelet antiaggregant; thromboxane synthetase inhibitor; analgesic; NSAID	thrombosis; pain; inflammation
cloricromen; cloricromene; AD 6; PROENDOTEL	[[8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2H-1-benzopyran-7-yl]oxy]acetic acid ethyl ester	platelet antiaggregant; vasodilator	arrhythmia; thrombosis
vintoperoxol; RGH 2981	(3 $\alpha$ ,16 $\alpha$ )-21-nor-1,14-secoeburnamein-20-ol	platelet antiaggregant; vasodilator; antioxidant	peripheral vascular disease; thrombosis
epoprostenol; epoprostenol sodium; prostacyclin; prostaglandin X; prostaglandin I <sub>2</sub> ; vasocyclin; UN 53217A; U 53217; FLOLAN; CYCLO-PROSTIN	(5Z,9 $\alpha$ ,11 $\alpha$ ,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid	platelet antiaggregant; vasodilator; prostanoid	pulmonary hypertension; thrombosis
triflavin	triflavin (trimeresurus flavoviridis reduced)	platelet antiaggregant; venom	thrombosis
albolabrin	unspecified	platelet antiaggregant; venom; peptide	thrombosis
echistatin	unspecified	platelet antiaggregant; venom; peptide	thrombosis
BMV 42393	2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy] acetic acid	prostaglandin agonist; platelet antiaggregant	hyperlipidemia; thrombosis
SQ 27986	[1S-[1 $\alpha$ ,2 $\beta$ (Z),3 $\alpha$ (1E,3R*),4 $\alpha$ ]]-7-[3-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid	prostaglandin agonist; platelet antiaggregant	thrombosis

BW 192C86; 192C86	5-(3-carboxypropylthio)-1-(2-cyclohexyl-2-hydroxyethylideneamino)-3-ethyl-hexahydrocyclopenta-(d) imidazol-2(1H)-one	prostaglandin partial agonist; platelet antiaggregant	thrombosis
ataprost; tepoprostenol; ONO 41483; OP 41483	[3aS-[2E,3aalfa,4alfa(1E,3R*),5beta,6aalfa]]-5-[4-(3-cyclopentyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2(1H)-pentalenylidene]penta noic acid	prostanoid; platelet antiaggregant	thrombosis
beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
BMV 45778	unspecified	prostanoid; platelet antiaggregant	thrombosis
ciprostene; ciprostone calcium; U 61431F	[3aS-[2Z,3aalfa,5beta,6alfa(1E,3R*),6aalfa]]-5-[hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-3a-methyl-2(1H)-pentalenylidene]penta noic acid	prostanoid; platelet antiaggregant	thrombosis; restenosis
drug delivery system, lipid microsphere, clinprost; clinprost lipid microsphere; TTC 909; ARTEON	[3aS-[3aalpha,5beta,6alpha(1E,3R*),6aalpha]]-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-2-pentalenepentanoic acid methyl ester	prostanoid; platelet antiaggregant	thrombosis; stroke

maxaprostene; CG 4305	[3aS-[2E,3aalfa,4alfa(1E,3R*),5beta,6aalfa]]-3-[[4-(3-cyclohexyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2(1H)-pentalenylidene]methyl]benzoic acid	prostanoid; platelet antiaggregant	thrombosis
ONO NT012	5(Z)-7-[(1S,2S,3S,5R)-3-(trans-beta-styren)sulfonamido-6,6-dimethylbicyclo[3.1.1]hept-2-yl]-5-heptenoic acid	prostanoid; platelet antiaggregant	thrombosis
ZK 110841	[1R-[1alfa(Z),2beta(1E,3S*),3alfa,5beta]]-7-[5-chloro-2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxycyclopentyl]-5-heptenoic acid	prostanoid; platelet antiaggregant	glaucoma; hypertension; thrombosis
ZK 118182	[1R-[1alfa(Z),2beta(1E,3S*),3alfa,5alfa]]-[[4-[5-chloro-2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxycyclopentyl]-2-butenyl]oxy]acetic acid	prostanoid; platelet antiaggregant	thrombosis; hypertension

KP 10614	[3aS-[2(Z),3aalfa,5beta,6alfa(1E,3R*,4R*),6aalfa]-5-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-4-methyl-1-nonen-6-ynyl)-2-pentalenyl]-4-pentenoic acid	prostanoid; platelet antiaggregant; vasodilator	thrombosis; peripheral vascular disease
taprostene; CG 4203	alpha-((2Z,3aR,4R,5R,6aS)-4-((1E,3S)-3-cyclohexyl-3-hydroxypropenyl)hexahydro-5-hydroxy-2H-cyclopenta(beta)furan-2-ylidene)-meta-toluic acid	prostanoid; platelet antiaggregant; vasodilator	peripheral vascular disease; thrombosis
iloprost; ciloprost; ZK 36374; E 1030; SH 401; ILOMED; ENDOPROST; ILOMEDIN; AIPRO	5-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene]pentanoic acid	prostanoid; platelet antiaggregant; vasodilator; NSAID	peripheral vascular disease; thrombosis; thrombocytopenia; rheumatoid arthritis
alprostadiol; lipo-prostaglandin E1; lipo-PGE1; U 10136; PGE1; CAVERJECT; PALUX; LIPLE; PROSTIN; EDEX; MUSE	(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid	prostanoid; vasodilator; cicatrizant	hepatitis; thrombosis; peripheral vascular disease; sexual dysfunction; pulmonary hypertension; skin ulcer; hearing loss
cicaprost; cicaprost clathrate; ZK 114923; SH 574; SH 490	[3aS-[2E,3aalpha,4alpha(3R*,4R*),5beta,6aalpha]-[2-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nonadiynyl)-2(1H)-pentalenylidene]ethoxy]acetic acid	prostanoid; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease; cancer

protein kinase activators	unspecified	protein kinase activator; protein kinase A activator	asthma; thrombosis
ONO 3307	4-[(aminoiminomethyl)amino]benzoic acid 4-(aminosulfonyl)phenyl ester monomethanesulfonate	proteinase inhibitor	thrombosis
proteinase inhibitors	unspecified	proteinase inhibitor	thrombosis
HMR 2906	unspecified	proteinase inhibitor; blood clotting factor Xa inhibitor	thrombosis
ZK 807191	N-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-N-methylglycine	proteinase inhibitor; blood clotting factor Xa inhibitor	thrombosis
bivalirudin; BG 8967; HIRULOG	D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha.-aspartyl-L-phenylalanyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-isoleucyl-L-prolyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-tyrosyl-L-leucine	proteinase inhibitor; hirudin analogue; thrombin inhibitor	thrombosis; angina; myocardial infarction
GL 522	unspecified	proteinase inhibitor; platelet antiaggregant	thrombosis
nafamostat; nafamostat mesylate; nafamostat mesilate; FUT 175; FUTHAN TORII; FUTHAN BANYU	6-amidino-2-naphthyl p-guanidinobenzoate	proteinase inhibitor; platelet antiaggregant	thrombosis; pancreatitis; allergy; anaphylactic shock



SDZ 217766; SDZ 217-766	[3aS-[2(S*),3aalpha,4beta,6beta,7aalpha]]N-[(1,1-dimethylethoxy)carbonyl]-3-(trimethylsilyl)-L-alanyl-N-[4-[(aminoiminomethyl)amino]-1-(hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl)butyl]-L-prolinamide	proteinase inhibitor; platelet antiaggregant; peptide	thrombosis
argatroban; argatrovan; argipidine; argopidine; alipidine; DK 7419; MCI 9038; MD 805; OM 805; GN 1600; NOVASTAN; SLONNON	(2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[[(1,2,3,4-tetrahydro-3-methyl-8-quinoliny)sulfonyl]amino]pentyl]-4-methyl-2-[piperidinecarboxylic acid	proteinase inhibitor; platelet antiaggregant; thrombin inhibitor	thrombosis; myocardial infarction; ischemia; angina; brain ischemia; thrombocytopenia
proteinase inhibitors, SDR	unspecified	proteinase inhibitor; serine proteinase inhibitor; peptide	thrombosis
BCH 2763	unspecified	proteinase inhibitor; thrombin inhibitor	thrombosis
CCI 1004	unspecified	proteinase inhibitor; thrombin inhibitor	thrombosis
CL 03135	unspecified	proteinase inhibitor; thrombin inhibitor	thrombosis
ORG 37940	N-(carboxymethyl)-3-cyclohexyl-D-alanyl-N-[5-amino-1-(carboxycarbonyl)pentyl]-L-prolinamide	proteinase inhibitor; thrombin inhibitor	thrombosis
PPACK	D-Phe-Pro-Arg-chloromethyl ketone	proteinase inhibitor; thrombin inhibitor	thrombosis
thrombin inhibitor	unspecified	proteinase inhibitor; thrombin inhibitor	thrombosis

SDZ 216744	unspecified	proteinase inhibitor; thrombin inhibitor; platelet antiaggregant	thrombosis
thrombin receptor inhibitors, oral	unspecified	proteinase inhibitor; thrombin inhibitor; platelet antiaggregant	thrombosis
thrombin receptor inhibitors, parenteral	unspecified	proteinase inhibitor; thrombin inhibitor; platelet antiaggregant	thrombosis
AR 69931; AR C69931MX	N-[2- (methylthio)ethyl]-2- [(3,3,3- trifluoropropyl)thio]- 5'-adenylic acid monoanhydride with (dichlorophosphonom ethyl)phosphonic acid	purinoceptor antagonist; platelet antiaggregant	thrombosis; myocardial infarction
purinoceptor 2T antagonists	unspecified	purinoceptor antagonist; platelet antiaggregant	thrombosis
Buthus Martensii Karsch venom; BMK venom; scorpion venom	unspecified	scorpion venom; thrombolytic	thrombosis
ACITIC	[3-[(7-amino-4- chloro-1-oxo-1H-2- benzopyran-3- yl)oxy]propyl]thiourea	serine proteinase inhibitor; proteinase inhibitor	thrombosis
LEX 026 analogues	unspecified	serine proteinase inhibitor; proteinase inhibitor	thrombosis
BIBR 1048	unspecified	thrombin inhibitor	thrombosis
desirudin; desulfatohirudin; hirudindesulfato; hirudin; CGP 39393; REVASC; HIRUDIN	63-desulfohirudin (hirudo medicinalis isoform HV1)	thrombin inhibitor; biotechnology; proteinase inhibitor	thrombosis

CVS 995	N-(1-oxo-2-propylpentyl)-L-alpha-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-tyrosyl-L-leucine	thrombin inhibitor; peptide; proteinase inhibitor	thrombosis
DUP 714	(S)-N-acetyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)amino]-1-boronobutyl]-L-prolinamide	thrombin inhibitor; peptide; proteinase inhibitor	thrombosis
P 8714	N-acetyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)amino]-1-boronobutyl]-L-prolinamide	thrombin inhibitor; peptide; proteinase inhibitor	thrombosis
S 18326	Ac-D-Phe-N-cyclopentylglycine-boroArg	thrombin inhibitor; peptide; proteinase inhibitor	thrombosis
napsagatran; Ro 466240	(S)-N-[N4-[[1-(aminoiminomethyl)-3-piperidinyl]methyl]-N2-(2-naphthalenylsulfonyl)-L-asparaginy]-N-cyclopropylglycine	thrombin inhibitor; platelet antiaggregant; proteinase inhibitor	thrombosis
BDP 4026	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis

BMS 180742	N2-[N-[N-[N-[N-[1-[N-[1-[N-[N-(3-carboxy-1-oxopropyl)-L-phenylalanyl]-L-alpha-glutamyl]-L-prolyl]-L-isoleucyl]-L-prolyl]-L-alpha-glutamyl]-L-alpha-glutamyl]-L-tyrosyl]-3-cyclohexyl-L-alanyl]-L-glutamine	thrombin inhibitor; proteinase inhibitor	thrombosis
BMV 44621	[S-(R*,R*)]-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-1-(1-oxo-3-phenylpropyl)-2-pyrrolidinecarboxamide	thrombin inhibitor; proteinase inhibitor	thrombosis
CORTROMBIN	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
CRC 220; CRC 200	[S-(R*,S*)]-4-[[1-[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidiny)ethyl]amino]-3-[[[4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-4-oxobutanoic acid	thrombin inhibitor; proteinase inhibitor	thrombosis
CVS 1123	N-(1-oxo-2-propylpentyl)-L-alpha-aspartyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]-L-prolinamide methyl ester	thrombin inhibitor; proteinase inhibitor	thrombosis
H 376; H 37695; H 376/95	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis

L 374087	N-[(6-amino-2-methyl-3-pyridinyl)methyl]-6-methyl-2-oxo-3-[[[(phenylmethyl)sulfonyl]amino]-1(2H)-pyridineacetamide	thrombin inhibitor; proteinase inhibitor	thrombosis
L 375378	N-[(6-amino-2-methyl-3-pyridinyl)methyl]-6-methyl-2-oxo-3-[(2-phenylethyl)amino]-1(2H)-pyrazineacetamide dihydrochloride	thrombin inhibitor; proteinase inhibitor	thrombosis
LB 30057	(S)-4-[3-(cyclopentylmethylamino)-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl]-benzenecarboximide acid hydrazide	thrombin inhibitor; proteinase inhibitor	thrombosis
LY 294291	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
LY 303496	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
MDL 73756	D-Phe-Pro-Arg-CF3	thrombin inhibitor; proteinase inhibitor	thrombosis
melagatran; H 31968	[S-(R*,S*)]-N-[2-[2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidiny]-1-cyclohexyl-2-oxoethyl]glycine	thrombin inhibitor; proteinase inhibitor	thrombosis
MOL 127	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
MOL 376	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis

Ro 091679; Ro 09-1679	[S-(E)]-N2-(3-carboxy-1-oxo-2-propenyl)-L-arginyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-L-leucinamide	thrombin inhibitor; proteinase inhibitor	thrombosis
SDZ MTH958; MTH 958	Boc-D-trimethylsilylalanine-Pro-borolysine	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor, injectable; CORTHTROMBIN	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor, systemic	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitors	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
V 19	Unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
efegatran; efegatran sulfate; GYKI 14766; LY 294468	N-methyl-D-Phe-Pro-Arg-H	thrombin inhibitor; proteinase inhibitor; peptide	thrombosis; angina; myocardial infarction
S 17436	Ac-D-Phe-perhydroindole-boroArg	thrombin inhibitor; proteinase inhibitor; peptide	thrombosis
drug delivery system, ANCHOR direct thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor; serine proteinase inhibitor	thrombosis

UK 156406	[S-(R*,S*)]-1-[3-[3-(aminoiminomethyl)phenyl]-1-oxo-2-[[[(1,2,3,4-tetrahydro-2-methyl-7-isoquinoliny]sulfonyl]amino]propyl]-1,2,3,6-tetrahydro-4-methyl-2-pyridinecarboxylic acid	thrombin inhibitor; proteinase inhibitor; serine proteinase inhibitor	thrombosis
A 76120	unspecified	thrombolytic	thrombosis; myocardial infarction
anistreplase; acetylated plasminogen streptokinase complex; APSAC; apsaplast; BRL 26921; EMINASE	anisoylated (human) lys-plasminogen streptokinase	thrombolytic	thrombosis
antithrombotic agents, Actinova	unspecified	thrombolytic	thrombosis
BBNT 12	unspecified	thrombolytic	thrombosis
BRL 54912	unspecified	thrombolytic	thrombosis
drug delivery system, MACROMOL urokinase oral; urokinase MACROMOL urokinase	unspecified	thrombolytic	thrombosis
eliparcil; LF 40212	unspecified	thrombolytic	thrombosis
factor Xa/prothrombinase inhibitors	unspecified	thrombolytic	thrombosis
factor Xai; factor Xa	unspecified	thrombolytic	thrombosis
GM 11001	unspecified	thrombolytic	thrombosis
anasaruplast; anasaruplast, natural; prourokinase; plasminogen pro-activator; proUK; GE 0943; THROMBOLYSE; TOMIZE	unspecified	thrombolytic	thrombosis
nefiparcil; LF 50030	unspecified	thrombolytic	thrombosis

oral factor Xa inhibitors, Cor	unspecified	thrombolytic	thrombosis
RWJ 27755	D-Phe-Pro-Arg-chloromethyl ketone (PPACK)	thrombolytic	thrombosis
saruplase, natural; single chain urokinase plasminogen activator; SCU-PA; SANDOLASE	unspecified	thrombolytic	thrombosis
Thrombosis therapy	unspecified	thrombolytic	thrombosis
tisokinase; tissue plasminogen activator, natural; tPA, natural; AK 124; PLASVATA; HAPASE	unspecified	thrombolytic	thrombosis; stroke
dermatan sulfate, low molecular weight; low molecular weight dermatan sulfate; low molecular weight chondroitin sulfate B; low molecular weight chondroitinsulfuric acid type B; DESMIN 370; DS 435	dermatan, hydrogen sulfate (ester)	thrombolytic; fibrinolytic	thrombosis; restenosis
nattokinase	unspecified	thrombolytic; fibrinolytic	thrombosis
poloxamer 188; CRL 5861; FLOCOR; RheothRx	unspecified	thrombolytic; fibrinolytic	thrombosis; cytoprotectant; sickle cell anemia
hementerin	unspecified	thrombolytic; fibrinolytic; biotechnology	thrombosis
OS 396	(1(S)-trans]-N-(4-acetylphenyl)-alpha-[[[4-(aminomethyl)cyclohexyl]carbonyl]amino]-4-(2-pyridinylmethoxy)benzenepropanamide	thrombolytic; proteinase inhibitor; fibrinolytic	thrombosis



coprinin	2-methoxy-5-methyl-1,4-benzoquinone	thromboxane antagonist; platelet antiaggregant	thrombosis
daltroban; BM 13505; SKF 96148	4-[2-[[[4-chlorophenyl)sulfonyl]amino]ethyl]benzene acetic acid	thromboxane antagonist; platelet antiaggregant	heart failure; thrombosis
domitroban; S 1452; S 145; ANBOXAN	(+,-)-[1 $\alpha$ ,2 $\alpha$ (Z),3 $\beta$ ,4 $\alpha$ ]-7-[3-[(phenylsulfonyl)amino]bicyclo[2.2.1]hept-2-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	asthma; rhinitis; thrombosis
F 10171; L 0051	unspecified	thromboxane antagonist; platelet antiaggregant	thrombosis
FR 106881	6-(2S,4R)-1-(4-chlorophenylsulfonyl)-4-(4-chlorophenylsulfonylamino)-pyrrolidine-2-yl-(Z)-5-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
HA 29	2-[(3-methoxyphenyl)methyl]-3,4-dimethylpyrano[2,3-c]pyrazol-6(2H)-one	thromboxane antagonist; platelet antiaggregant	thrombosis
ICI 185282	[2 $\alpha$ ,4 $\alpha$ ,5 $\alpha$ (Z)]-7-[4-(2-hydroxyphenyl)-2-(trifluoromethyl)-1,3-dioxan-5-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
ICI 192605	[2 $\alpha$ ,4 $\alpha$ ,5 $\alpha$ (Z)]-6-[2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-4-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma

KT 2962; KT 2-962	3-[4-[[[4-chlorophenyl)sulfonyl]amino]butyl]-6-(1-methylethyl)-1-azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis
KW 3635	(E)-11-(2-(5,6-dimethyl-1-benzimidazolyl)ethylidene)-6,11-dihydrodibenz(b,e)oxepine-2-carboxylic acid sodium salt	thromboxane antagonist; platelet antiaggregant	thrombosis
L 670596	(-)-6,8-difluoro-2,3,4,9-tetrahydro-9-[[[4-(methylsulfonyl)phenyl]methyl]-1H-carbazole-1-acetic acid	thromboxane antagonist; platelet antiaggregant	asthma; thrombosis
LCB 2853	4-[[[1-[[[4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl]methyl]benzene acetic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	thrombosis
linotroban; HN 11500; CL 871501	[[[5-(2-benzenesulfonamidophenyl)-2-thienyl]oxy]acetic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
mipitroban; UP 11677	6-chloro-3-[(4-chlorophenyl)methyl]-.beta.,.beta.-dimethyl-3H-imidazo[4,5-b]pyridine-2-butanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
ON 579	4-(2-(4-chlorophenyl)sulfonylamino)ethylthio)-2,6-difluorophenoxyacetic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma

ONO 8809	[1S-[1alpha,2alpha(Z),3beta,4alpha]]-6-[3-[[[(4-bromophenyl)sulfonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-5-hexenoic acid decyl ester	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
S 17732	unspecified	thromboxane antagonist; platelet antiaggregant	thrombosis
S 17733	unspecified	thromboxane antagonist; platelet antiaggregant	thrombosis
S 19167	6-[[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-3-methyl-1-naphthalenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
SQ 30741	[1S-[1alpha,2alpha(Z),3alpha,4alpha]]-7-[3[[[(1-oxoheptyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
SQ 33261	[1S-[1alpha,2alpha(Z),3alpha,4alpha]]-6-[3-[[[(phenylamino)carbonyl]hydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis

SQ 33552	[1S-[1alfa,2alfa(Z),3alfa,4alfa]]-6-[3-[[[(4-chlorophenyl)amino]carbonyl]hydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
SQ 33961	[1S-(exo,exo)]-2-[[3-[4-[[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
SQ 35091	[1S-[1alfa,2alfa,3alfa(E),4alfa]]-2-[[3-[[[(phenylamino)carbonyl]hydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
sulotroban; BM 13177; SKF 95587	4-[2-(benzenesulfonamido)ethyl]phenoxyacetic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
vapiprost; GR 32191; GR 32191B; SN 309	[1R-[1alfa(Z),2beta,3beta,5alfa]]-7-[5-([1,1'-biphenyl]-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; kidney disease

ZK 151847	(5Z)-(8R,9S,12S)-9-(p-Phenylbenzyloxy)-11-desoxy-12-(p-fluorobenzene sulfonylamino)-13,14,15,16,17,18,19,20-octanor-prost-5-enoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
ifetroban; ifetroban sodium; BMS 18029102; BMS 180291A; BMS 180291	[1S-(1 $\alpha$ ,2 $\alpha$ ,3 $\alpha$ ,4 $\alpha$ )]-2-[[3-[4-(n-pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant; cicatrizant	thrombosis; skin ulcer
CGS 22652	(+,-)-gamma-[4-[[4-chlorophenyl)sulfonyl]amino]butyl]-3-pyridineheptanoic acid	thromboxane antagonist; synthase inhibitor; platelet antiaggregant	thrombosis
GR 85305	(E)-6-[3-[2-[[4-iodophenyl)sulfonyl]amino]ethyl]phenyl]-6-(3-pyridinyl)-5-hexenoic acid	thromboxane antagonist; synthase inhibitor; platelet antiaggregant	thrombosis
ICI D1542; ZD 1542	[2S-[2 $\alpha$ ,4 $\alpha$ ,5 $\alpha$ (Z)]]-6-[2-[1-methyl-1-(4-methyl-2-nitrophenoxy)ethyl]-4-(3-pyridinyl)-1,3-dioxan-5-yl]-4-hexenoic acid	thromboxane antagonist; synthetase inhibitor; platelet antiaggregant	thrombosis
thromboxane A2/prostaglandin H2 antagonist; thromboxane A2 synthetase inhibitor, Pfizer.	3-[2-[[4-chlorophenyl)sulfonyl]amino]ethyl]-5-(3-pyridinylmethyl)benzenepropanoic acid	thromboxane antagonist; synthetase inhibitor; prostaglandin antagonist; platelet antiaggregant	thrombosis; restenosis

KDI 792; FK 070; FR 12170	[2S-[2alpha,(Z),4beta]]-6-[4-[(4-chlorophenyl)sulfonyl]amino]-1-(3-pyridinylmethyl)-2-pyrrolidinyl]-5-hexenoic acid	thromboxane antagonist; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
TER 930180	4-[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]-4-(3-pyridinyl)butyl]benzenepropanoic acid	thromboxane antagonist; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
ONO 1301; AP 50002; ONO AP 50002	[[[7,8-dihydro-5-[2-[[[(phenyl-3-pyridinylmethylene)amino]oxy]ethyl]1-naphthalenyl]oxy]acetic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
aplaggin	unspecified	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
camonagrel; DEFIBROTIDE	(+,-)-5-(2-imidazol-1-ylethoxy)-1-indancarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
FCE 27262	(E)-5-[[[1-cyclohexyl-2-(1H-imidazol-1-yl)-3-phenylpropylidene]amino]oxypentanoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
isbogrel; CV 4151; A 66900; ANTEXAN	(E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; stroke
KY 063	5-n-hexyloxy-3-(2-(1H-imidazol-1-yl)ethyl indoline-1-propionic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
nafagrel; DP 1904	5,6,7,8-tetrahydro-6-(1H-imidazol-1-ylmethyl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; angina; asthma; restenosis

ozagrel; ozagrel sodium; OKY 046; DOMENAN; CATACLOT; XANBON; VEGA	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	stroke; thrombosis; asthma; cough
platelet antiaggregant	N-((1H-pyrazol-1-yl)butyl)benzoylamide	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
rolafagrel; FCE 22178	5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; kidney disease
TEI 5178	[1R-[1[alpha,2B(1E,3S*),3alpha]]-6-[[2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxy-5-oxocyclopentyl]thio]hexanoic acid, methylester	thromboxane synthetase inhibitor; platelet antiaggregant	nephritis; thrombosis
Y 20811	4-(hydroxy(5-(1H-imidazol-1-yl)-2-methylphenyl)methyl)-3,5-dimethyl-benzoic acid, monosodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; asthma; stroke
satigrel; E 5510	4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid	thromboxane synthetase inhibitor; prostaglandin endoperoxidase inhibitor; platelet antiaggregant	thrombosis
ZT 386	unspecified	thromboxane synthetase inhibitor; thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
tricaprilin; tricaprylin; NOF 005	Octanoic acid, 1,2,3-propanetriyl ester	triglyceride; platelet antiaggregant	thrombosis
vascular anticoagulant; VAC	unspecified	vascular anticoagulant	thrombosis

drotaverine acephyllinate; DEPOGEN	1,2,3,6-tetrahydro- 1,3-dimethyl-2,6- dioxo-7H-purine-7- acetic acid cmpd. with 1-[(3,4- diethoxyphenyl)meth ylene]-6,7-diethoxy- 1,2,3,4- tetrahydroisoquinolin e (1:1)	vasodilator; antispasmodic	thrombosis; peripheral vascular disease
eptaloprost; eptaprost; ZK 97959	3aS- [2E,3aalfa,4alfa(3R*, 4R*)5beta,6aalfa]-4- (2-hexahydro-5- hydroxy-4-(3- hydroxy-4-methyl- 1,6-nonadiynyl- 2(1H)- pentalenylidene)ethox y-butanedioic acid	vasodilator; prostanoid	thrombosis; peripheral vascular disease; cancer

Table 65. Current Candidate Therapeutic Interventions for the Treatment of Renal Disease, Disorder, or Dysfunction

Product Name	Chemical Name	Action	Indication
captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	1-(3-mercapto-2- methyl-1-oxopropyl)- L-proline	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1- carboxy-3- phenylpropyl)-L- lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease



FK 352	[R-(E)]-1-[1-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propenyl]-2-piperidineacetic acid	adenosine antagonist; adenosine A1 antagonist	kidney disease
HMR 4902	Unspecified	adenosine antagonist; adenosine A1 antagonist	heart failure; kidney disease
midaxifylline; IRFI 117	8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect; depression; kidney disease
ALT 946	Pimagedine derivative	Advanced glycosylated end-products formation inhibitor	diabetes; neuropathy; retinopathy; kidney disease
BST 4001; PYRIDORIN	Vitamin B6 derivative	Advanced glycosylated end-products formation inhibitor	diabetes; kidney disease
pimagedine; pimagedine hydrochloride; aminoguanidine; GER 11; YM 585	Aminoguanidine	Advanced glycosylation end-products inhibition	diabetes; kidney disease; retinopathy; atherosclerosis; neuropathy; stroke
epalrestat; ONO 2235; KINEDAK	(Z,E)-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid	aldose reductase inhibitor	neuropathy; kidney disease; eye disease; diabetes
zopolrestat; CP 73850; ALOND	3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid	aldose reductase inhibitor	diabetes; neuropathy; kidney disease

candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMIAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
irbesartan; SR 47436; BMS 186295; APROVEL; KARVEA; AVAPRO	2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one	angiotensin II antagonist	hypertension; kidney disease; heart failure
irbesartan + hydrochlorothiazide; hydrochlorothiazide + irbesartan; AVALIDE; COAPROVEL; KARVEZIDE	Unspecified	angiotensin II antagonist; diuretic	hypertension; kidney disease
A 68828	L-arginyl-L-cysteinyl-3-cyclohexyl-L-alanylglycylglycyl-L-arginyl-L-isoleucyl-L-alfa-aspartyl-L-arginyl-L-isoleucyl-L-phenylalanyl-L-arginyl-L-cysteinamide cyclic (2-13)-disulfide	ANP agonist	kidney disease
EXO 226	Unspecified	Antiglycation agent	diabetes; kidney disease
phensuccinal	beta-phenylethylamide-2-hydroxysuccinanylic acid	antioxidant	diabetes; kidney disease; retinopathy
levocarnitine; carnitine, L-; L-carnitine; ST 198; LEVOCARNIL; CARNITENE; CARNITOR	(R)-3-carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide inner salt	Carnitine	cardiovascular disease; kidney disease; septic shock

FPL 63012AR	3-[2-(3-hydroxyphenyl)ethyl]-4-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]-1,2-benzenediol dihydrochloride	dopamine agonist; dopamine D1 agonist	kidney disease
fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM	6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenol)-1H-3-benzazepine-7,8-diol	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	hypertension; glaucoma; kidney disease; heart failure
endothelin A antagonist	Unspecified	endothelin A antagonist; endothelin antagonist	hypertension; kidney disease
SB 209670	(+)-(1S,2R,3S)-3[2-(carboxymethoxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-propoxyindane-2-carboxylic acid	endothelin A antagonist; endothelin antagonist	kidney disease; hypertension
BQ 123	cyclo(D-alpha-aspartyl-L-prolyl-D-valyl-L-leucyl-D-tryptophyl)	endothelin A antagonist; endothelin antagonist; peptide	kidney disease
TAK 044	cyclo[4-oxo-4 (4-phenyl-1-piperazinyl)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D-alpha-aspartyl] disodium salt	endothelin A antagonist; endothelin B antagonist; endothelin antagonist; peptide	hypertension; kidney disease; myocardial infarction; brain ischemia
endothelin antagonist	unspecified	endothelin antagonist	kidney disease
endothelin antagonist	Unspecified	endothelin antagonist	kidney disease; ischemia; inflammatory bowel disease; asthma
SB 234551	Unspecified	endothelin antagonist	kidney disease
VML 588; Ro 611790	Unspecified	endothelin antagonist; endothelin A antagonist	kidney disease; brain ischemia

IxC1-62/47	Unspecified	enzyme degradation of oxalate, reduction in the formation of kidney stones	kidney disease; inflammatory bowel disease; Crohn disease
OPC 15161; NF 1616904	6-(1H-indol-3-ylmethyl)-5-methoxy-3-(2-methylpropyl)-2-(1H)-pyrazinone, 4-oxide	free radical scavenger; NSAID	inflammation; kidney disease
keratinocyte growth factor 2; KGF 2; HG 03400	Protein	growth factor; cicatrizant; chemoprotectant; cytoprotectant	cancer; mucositis; skin ulcer; alopecia; kidney disease
somatropin; human growth hormone; hGH; SJ 0011; SAIZEN; SEROSTIM	Somatotropin (human)	growth hormone	hormone deficiency; Turner syndrome; growth disorder; cachexia; kidney disease
anaritide; atrial natriuretic factor 4-28; ANF 4-28; atrial natriuretic peptide; anaritide acetate; WY 47663; AURICULIN	N-L-arginyl-8-L-methionine-21a-L-phenylalanine-21b-L-arginine-21c-L-tyrosine-atriopeptin-21 (rat)	hormone; ANP agonist; peptide	heart failure; kidney disease
mecasermin; insulin-like growth factor-1; IGF-1; CGP 35126; CEP 079; KW 6151; IGF-1; CEP 151; MYOTROPHIN	Human insulin-like growth factor I	Hormone; growth factor	amyotrophic lateral sclerosis; neuropathy; kidney disease; osteoarthritis
B 2036PEG; PEG-B 2036; TROVERT	Unspecified	Human recombinant growth hormone antagonist	retinopathy; acromegaly; cancer; diabetes; kidney disease
recombinant alpha3 collagen chain; BST 3002	Alpha 3 collagen chain	immunosuppressant	kidney disease
mizoribine; HE 69; BREDININ	5-hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; kidney disease

phellodendrine; OB 5	(7S-cis)-5,8,13,13a-tetrahydro-2,11-dihydroxy-3,10-dimethoxy-7-methyl-6H-dibenzo[a,g]quinolizinium	immunosuppressant; NSAID	transplant rejection; inflammation; viral infection; asthma; kidney disease
recombinant alpha3 collagen chain; BST 3003	Alpha 3 collagen chain	Imunosuppressant	kidney disease; systemic lupus erythematosus
tirilazad; tirilazad mesylate; trilazad; U 74006F; FREDOX	21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-alpha-methyl-pregn-1,4,9-(11)-triene-3,20-dione	lazaroid	brain ischemia; stroke; trauma; heart ischemia; kidney disease
ALT 420	Unspecified	macrophage stimulator	diabetes; neuropathy; retinopathy; kidney disease
macrophage stimulators	Unspecified	macrophage stimulator	diabetes; neuropathy; retinopathy; kidney disease
NEPHROSTAT	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor	kidney disease; diabetes
matrix metalloproteinase inhibitor	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	periodontal disease; kidney disease; cancer; arthritis; osteoporosis
MAB, migis-mIgA; Mab, B cell	unspecified	monoclonal antibody	kidney disease
targinine; 546C88; BW 546C88	N5-[imino(methylamino)methyl]-L-ornithine	nitric oxide synthase inhibitor; NSAID	septic shock; arthritis; kidney disease
UR 12670	4-[(2-methyl-1H-imidazo [4,5-c] pyridin-1-yl)methyl]-1-(1-oxo-3,3-diphenylpropyl)-piperidine	PAF antagonist; platelet antiaggregant	kidney disease; ischemia; asthma; pancreatitis
C-peptide analogues		peptide	diabetes; kidney disease

ularitide; urodilatin; urodilatin (human)	l-threonyl-l-alanyl-l-prolyl-l-arginyl-l-seryl-l-leucyl-l-arginyl-l-arginyl-l-seryl-l-seryl-l-cysteinyl-l-phenylalanylglycylglycyl-l-arginyl-l-methionyl-l-aspartyl-l-arginyl-l-isoleucylglycyl-l-alanyl-l-glutaminyll-serylglycyl-l-leucylglycyl-l-cysteinyl-l-asparaginyll-seryl-l-phenylalanyl-l-arginyl-l-tyrosine cyclic (11-27) disulfide	peptide	kidney disease
lanthanum carbonate; LAMBDA	Lanthanum carbonate	Phosphate binding	kidney disease
VML 252	High molecular weight, insoluble, polymeric resin	Phosphate binding	kidney disease
sevelamer; GT16-026A; PB 94; RenaGel	2-propen-1-amine, polymer with (chloromethyl)oxirane	Phosphate binding resin	kidney disease
BIO-LASE	unspecified	platelet antiaggregant	thrombosis; kidney disease; eye disease
ALFA 366	Unspecified	platelet antiaggregant	kidney disease; diabetes
ALFA 642	Unspecified	platelet antiaggregant	diabetes; kidney disease
TFC 612; TFC 6122	[1R-[1alpha,2beta(1E,3S*,5R*),3alpha]]-6-[[3-hydroxy-2-(3-hydroxy-5-methyl-1-nonenyl)-5-oxocyclopentyl]thio]-hexanoic acid methyl ester	prostanoid	liver disease; kidney disease

mycophenolate mofetil; RS 61443	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany l)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
LSL 90202	L-lysine monoeicosapentaenoate (1:1)	Renal function improvement in nephrotoxicity associated with cyclosporine	kidney disease
KT 2962; KT 2-962	3-[4-[(4-chlorophenyl)sulfonyl]amino]butyl]-6-(1-methylethyl)-1-azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis
vapiprost; GR 32191; GR 32191B; SN 309	[1R-[1alfa(Z),2beta,3beta,5alfa]]-7-[5-([1,1'-biphenyl]-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; kidney disease
rolafagrel; FCE 22178	5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; kidney disease
TJ 8117	Unspecified	Unspecified	kidney disease
uteroglobin; CC 10	Unspecified	Uteroglobin	respiratory disease; kidney disease
CGP 22979	N-acetyl-L-glutamic acid 5-[2-(5-butyl-2-pyridinyl)hydrazide]	vasodilator	kidney disease
efalcitriol; efalcitriol; ST 630; FULSTAN; HORNEL	(1alfa,3beta,5Z,7E)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D3 analogue	osteoporosis; kidney disease; hyperparathyroidism; psoriasis

Table 66. Current Candidate Therapeutic Interventions for the Treatment of Nephritis

Product Name	Chemical Name	Action	Indication
melanocortin receptor-1 modulators, Trega Biosciences	unspecified	analgesic; melanocortin agonist; melanocortin MC1 agonist	asthma; pain; nephritis
candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMLAS; KENZEN	(+,-)-2-ethoxy-1-[[2'- (1H-tetrazol-5- yl)[1,1'-biphenyl]-4- yl]methyl]-1-H- benzimidazole-7- carboxylic acid 1- [[[(cyclohexyloxy)carb onyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
celiprolol; NPB 582; ST 1396; REV 5320A; SELECTOL; CELECTOL	N'-[3-acetyl-4-[3- [(1,1- dimethylethyl)amino] -2- hydroxypropoxy]phen yl]-N,N-diethylurea	beta adrenergic antagonist; beta2 adrenergic partial antagonist; vasodilator	hypertension; nephritis
recombinant alpha3 collagen chain; BST 3003	unspecified	biotechnology; immunosuppressant	kidney disease; systemic lupus erythematosus
decorin	unspecified	cicatrizant	nephritis; scleroderma
K 76 monocarboxylic acid; K 76C00H; MX 1	6-formyl- 3',4',4a',5',6',7',8',8a'- octahydro-4,6',7'- trihydroxy-2',5',5',8a'- tetramethylspiro[benz ofuran-2(3H),1'(2'H)- naphthalene]-7- carboxylic acid	complement inhibitor; cicatrizant	atherosclerosis; inflammatory bowel disease
MAb, C5; MAb, complement C5; 5G1.1	unspecified	complement inhibitor; monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus
interleukin-1 antagonist, ImmunoPharmaceutic s	unspecified	cytokine antagonist; NSAID	inflammation
actarit; MS 932; MOVER; ORCL	4- (acetylamino)phenyla cetic acid	DMARD; immunosuppressant; NSAID	rheumatoid arthritis



SKF-R 105058	ethylcarbamic acid, (R)-6-chloro-1-[4-[[[(ethylamino)carbon yl]oxy]ph enyl]-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diyl ester	dopamine agonist; dopamine D1 agonist; vasodilator	nephritis
OPC 15161; NF 1616904	6-(1H-indol-3-ylmethyl)-5-methoxy-3-(2-methylpropyl)-2-(1H)-pyrazinone, 4-oxide	free radical scavenger; NSAID	inflammation; kidney disease
LJP 394	unspecified	immunosuppressant	systemic lupus erythematosus
MAB, CD40 ligand; 5C8; ANTOVA	unspecified	immunosuppressant; NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
SKF 105685	N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dihydrochloride	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis; HIV infection
bindarit; AF 2838	2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy]-propanoic acid	MCP-1 production inhibition; reduction of mRNA expression	rheumatoid arthritis; nephritis
MAB, gamma interferon, humanized; SMART anti-gamma interferon	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus; multiple sclerosis
zolimomab aritox; MAB, H65 RTA; MAB, bone marrow-ricin A conjugate; CD5-T lymphocyte immunotoxin; MAB, CD5; XMMLY H65 RTA; XOMAZYME H65; XOMAZYME CD5+; ORTHOZYME CD5+; CD5 Plus	unspecified	monoclonal antibody; immunotoxin; immunosuppressant	transplant rejection

TFC 612; TFC 6122	[1R-[1alpha,2beta(1E,3S*,5R*),3alpha]]-6-[[3-hydroxy-2-(3-hydroxy-5-methyl-1-nonenyl)-5-oxocyclopentyl]thio]-hexanoic acid methyl ester	prostanoid	liver disease; kidney disease
mycophenolate mofetil; RS 61443; CellCept	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany 1)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
CV 6504	2,3,5-trimethyl-6-(3-pyridinylmethyl)-2,5-cyclohexadiene-1,4-dione	thromboxane antagonist; 5-lipoxygenase inhibitor	cancer
TEI 5178	[1R-[1alfa,2B(1E,3S*),3alfa]]-6-[[2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxy-5-oxocyclopentyl]thio]hexanoic acid, methylester	thromboxane synthetase inhibitor; platelet antiaggregant	nephritis; thrombosis
rolafagrel; FCE 22178	5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; kidney disease
TJ 8014	Lyophilized extracts of 8 Japanese herbal agents	unspecified	nephritis
vaccine, Streptococcus pyogenes; rheumatic fever vaccine	unspecified	vaccine	bacterial infection
MAb, 3E10; vaccine, nephritis	unspecified	vaccine; monoclonal antibody	nephritis

Table 67. Current Candidate Therapeutic Interventions for the Treatment of Restenosis

Product Name	Chemical Name	Action	Indication
Del-1 angiogenic protein based therapies	unspecified	angiogenesis inhibitor; angiogenesis inducer	cancer; ischemia; restenosis
RG 13577	(4-hydroxyphenoxy)acetic acid, polymer with formaldehyde monoammoniate	angiogenesis inhibitor; FGF antagonist	restenosis; multiple sclerosis
antiangiogenesis agent	Unspecified	angiogenesis inhibitor; peptide	cancer; restenosis
candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMLAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
PN 271; PN 27,1; AndroCar	unspecified	antibiotic; terpene	cancer; restenosis
CPG 603	unspecified	antioxidant	restenosis
probucol; DH 581; DE 3872; LORELCO; PANA VIR; SINLESTAL	4,4'-isopropylidenedithio-bis-2,6-di- <i>t</i> -butylphenol	antioxidant	HIV infection; hyperlipidemia; restenosis
CT 8	unspecified	antiproliferative agent	restenosis
CVT 313	2,2'-[[6-[[[(4-methoxyphenyl)methyl]amino]-9-(1-methylethyl)-9H-purin-2-yl]imino]bisethanol	antiproliferative agent; cyclin dependent kinase inhibitor	restenosis
antisense oligonucleotide, restenosis	unspecified	antisense; oligonucleotide	restenosis
antisense oligonucleotide, restenosis; TBC 395	unspecified	antisense; oligonucleotide	restenosis

antisense oligonucleotide, smooth muscle cell proliferation; antisense oligonucleotide, SMC proliferation	unspecified	antisense; oligonucleotide	restenosis
drug delivery system, HVJ liposome; drug delivery system, PCNA and cdc2 kinase antisense oligonucleotides	unspecified	antisense; oligonucleotide	restenosis
INX 3280; LR 3280; BW 4003W94; TA 3280	unspecified	antisense; oligonucleotide	restenosis
E2F inhibitors	unspecified	apoptosis inducer; antiproliferative agent	cancer; psoriasis; viral infection; restenosis
RESTENEX	unspecified	calpastatin	restenosis
calpeptin	Benzyloxycarbonyl-leu-norleucinal	calpastatin; peptide	restenosis
inhibitor 1	acetyl-leu-leu-norleucinal	calpastatin; peptide	restenosis
CT 1	Sulfated beta dextran monomer	Cationic growth factor binding and inactivator	restenosis
heparinase III; IBT 9302	unspecified	cicatrizant; enzyme	reperfusion injury; restenosis; skin ulcer
fibroblast growth factor, acidic; aFGF	unspecified	cicatrizant; growth factor	skin ulcer; restenosis
pemirolast; pemirolast potassium; BMY 26517; DE 068; BL 5617; PEMILASTON; ALLEGYSAL	9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one	degranulation inhibitor	asthma; conjunctivitis; rhinitis; dermatitis; restenosis
antisense oligonucleotide, platelet derived growth factor; triple helix oligonucleotide, PDGF	unspecified	DNA transcription inhibitor; antisense; oligonucleotide	restenosis

LU 135252; LU 127043; HMR 4005	(S)-alpha-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-beta-methoxy-beta-phenyl benzenepropanoic acid	endothelin A antagonist; endothelin antagonist	restenosis
AZT 1993	1-[1-(3-ethoxyphenyl)propyl]-4,5-dihydro-7-(5-pyrimidinylmethoxy)-1H-benz[g]indazole-3-carboxylic acid sodium salt	endothelin antagonist	restenosis
ABT 627; A 127722; A 147627	[2S-(2alpha,3beta,4alpha)]-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid	endothelin antagonist; endothelin A antagonist	cancer; restenosis; myocardial infarction
fibroblast growth factor receptor inhibitor; FGF receptor inhibitor	unspecified	FGF antagonist; angiogenesis inhibitor	restenosis; cancer
TBC 2573	unspecified	FGF antagonist; NSAID	restenosis; rheumatoid arthritis; retinopathy
epidermal growth factor diphtheria toxin chimeric protein; EGF diphtheria toxin chimeric protein; EGF fusion protein; DAB 389-EGF; DAB 389-EGF	unspecified	fusion toxin	cancer; restenosis; psoriasis
mitotoxin fibroblast growth factor-saporin; mitotoxin, FGF-saporin; PANTARIN	unspecified	fusion toxin	cancer; restenosis; eye disease
cytochalasin B; BioStent	Cytochalasin	G(s)/adenylyl cyclase stimulation	restenosis

JTV 806	unspecified	glycoprotein IIb/IIIa antagonist	angina; restenosis
eptifibatide; INTEGRILIN; INTEGRELIN	N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide cyclic (1->6)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; peptide	thrombosis; angina; myocardial infarction; restenosis
platelet derived growth factor; PDGF	unspecified	growth factor	restenosis
vascular endothelial growth factor; VEGF; rhVEGF165	unspecified	growth factor; cicatrizant	coronary artery disease; ischemia; restenosis; skin ulcer
Tie-2 ligands, Regeneron; angiogenesis ligands, Regeneron	unspecified	growth factor; hematopoietic factor; cicatrizant; angiogenesis inhibitor; angiogenesis inducer	cancer; restenosis; retinopathy; skin ulcer; atherosclerosis; peripheral vascular disease
CL 03405	unspecified	heparinoid	restenosis
GM 1702	unspecified	heparinoid	restenosis
GM 2000	unspecified	heparinoid	thrombosis; restenosis
ZYN-LINKER conjugated heparin	unspecified	heparinoid	restenosis; thrombosis
GM 1077; ASTENOSE	unspecified	heparinoid; platelet antiaggregant	thrombosis; restenosis
tranilast; MK 341; AINTERU; BESSARAL; CLANIST; LIZAMONT; RIZALAST; SYNBERNIA; TEIBLOCK; RIZABEN	2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]benzoic acid	Histamine and leukotriene release inhibitor	asthma; allergy; conjunctivitis; rhinitis; restenosis
K 85; OMACOR	Unspecified	Hypolipemic	hyperlipidemia; restenosis
insulin-like growth factor-1 receptor inhibitor; IGF-1 JB3	unspecified	IGF-1 receptor inhibitor; peptide	restenosis; cancer

SB 223245	(S)-7-[[[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid	integrin antagonist; cell adhesion inhibitor	osteoporosis; restenosis; cancer
vitronectin receptor antagonists	unspecified	integrin antagonist; cell adhesion inhibitor; alpha5 beta3 integrin antagonist	osteoporosis; cancer; restenosis
integrin-specific peptides, Integra LifeSciences	unspecified	integrin antagonist; cell adhesion inhibitor; angiogenesis inhibitor	osteoporosis; cancer; restenosis
NE 1405	unspecified	integrin antagonist; oligosaccharide; P selectin antagonist; cell adhesion inhibitor	restenosis; reperfusion injury
antiproliferative agents	Unspecified	Ion transport antiproliferative agent	cancer; restenosis; psoriasis; atherosclerosis
sirolimus; rapamycin; NSC 226080; AY 22989; RAPAMUNE	(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[[[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacycloheptatriacontine-1,5,11,28,29(4H,6H,31H)-pentone	macrolide; immunosuppressant; antibiotic	transplant rejection; autoimmune disease; restenosis

MAB, thrombin receptor; MAB, restenosis	unspecified	monoclonal antibody	restenosis
MAB, platelet derived growth factor/basic fibroblast growth factor; MAB PDGF/bFGF; SMA PDGF/bFGF	unspecified	monoclonal antibody; biotechnology	cancer; restenosis
MAB, platelet-derived growth factor beta receptor; MAB, PDGFr beta; CDP 860	unspecified	monoclonal antibody; platelet antiaggregant	restenosis
leishmania lipophosphoglycan	leishmania lipophosphoglycan	Monocyte recruitment and infiltration blockade	inflammation; restenosis
MSI 1436	Steroidal compound form dogfish shark	Na <sup>+</sup> /H <sup>+</sup> antiporter modulation	viral infection; restenosis; diabetes; cancer
TAS 301	Unspecified	Neointimal hyperlasia and late vascular constrictive remodeling inhibition	restenosis
drug delivery system, vascular stent NMI 393; NMI 393 vascular stent	unspecified	nitric oxide donor	restenosis
NMI 220	unspecified	nitric oxide donor	restenosis
oligonucleotide inhibitor, human non-muscle myosin IIB	unspecified	oligonucleotide	restenosis
AVI 2221; Resten-NG	unspecified	oligonucleotide; antisense	restenosis
CT 2	Sulfated beta cyclodextran polymer	PDGF, IL-1, bFGF inhibition	restenosis
CT 15A3MG	Unspecified	PDGF, IL-1, bFGF inhibition	restenosis; reperfusion injury
CT 2534	Unspecified	PDGF, IL-1. BFGF inhibition	restenosis; reperfusion injury
somatoprim; PTR 3046	cyclo(Phe-N2-Tyr-D-Trp-Lys-Val-Phe-C3)Thr-NH2	peptide	pancreatitis; cancer; restenosis
GM 1115	unspecified	platelet antiaggregant	thrombosis; restenosis



EF 12	unspecified	platelet antiaggregant; antiproliferative agent	heart ischemia; thrombosis; restenosis
abciximab; abcirximab; MAb, F(ab') <sub>2</sub> fragment platelet; MAb, 7E3; c7E3 FAB; c7E3; ReoPro; CENTORX	Immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhC.gamma.1 Fab fragment anti- human glycoprotein IIb/IIIa receptor), disulfide with human- mouse monoclonal c7E3 clone p7E3V.kappa.hc.kapp a.light chain	platelet antiaggregant; monoclonal antibody	thrombosis; restenosis; angina; stroke; myocardial infarction
polyclonal antibody, tumor necrosis factor alpha; polyclonal antibody, TNFalpha; CytoTab	unspecified	polyclonal antibody; immunoglobulin; immunosuppressant	septic shock; malaria; restenosis; Crohn disease; graft versus host disease
ciprostene; ciprostone calcium; U 61431F	[3aS- [2Z,3aalfa,5beta,6alfa (1E,3R*),6aalfa]]-5- [hexahydro-5- hydroxy-6-(3- hydroxy-1-octenyl)- 3a-methyl-2(1H)- pentalenylidene]penta noic acid	prostanoid; platelet antiaggregant	thrombosis; restenosis
SERP 1	unspecified	proteinase inhibitor; serine proteinase inhibitor	restenosis
mycophenolate mofetil; RS 61443; CellCept	(E)-6-(1,3-dihydro-4- hydroxy-6-methoxy- 7-methyl-3-oxo-5- isobenzofurany 1)-4- methyl-4-hexenoic acid 2-(4- morpholiny)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
ribozymes, restenosis, Immusol; RestenASE	unspecified	ribozyme; oligonucleotide	restenosis
ribozymes, restenosis	unspecified	ribozyme; oligonucleotide	restenosis

cariporide; cariporide mesilate; HOE 642; HOE 642A	N-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)benzamide	sodium/hydrogen exchange inhibitor	arrhythmia; myocardial infarction; angina; restenosis
lanreotide; BIM 23014; DC 13116; BIM 23014C; BN 52030; SOMATULINE; ANGIOPEPTIN; DERMOPEPTIN; IPSTYL	3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2,7)-disulfide	somatostatin analogue	cancer; acromegaly; retinopathy; diabetes; psoriasis; restenosis
drug delivery system, vascular stent paclitaxel; paclitaxel vascular stent	unspecified	taxane; microtubule assembly promoter	restenosis; cancer
ZYN-LINKER conjugated paclitaxel	unspecified	taxane; microtubule assembly promoter	restenosis; cancer
lepirudin; HBW 023; REFLUDAN	1-L-leucine-2-L-threonine-63-desulfohirudin (hirudo medicinalis isoform HV1)	thrombin inhibitor; proteinase inhibitor	thrombosis; restenosis
dermatan sulfate, low molecular weight; low molecular weight dermatan sulfate; low molecular weight chondroitin sulfate B; low molecular weight chondroitinsulfuric acid type B; DESMIN 370; DS 435	dermatan, hydrogen sulfate (ester)	thrombolytic; fibrinolytic	thrombosis; restenosis
thromboxane A2/prostaglandin H2 antagonist; thromboxane A2 synthetase inhibitor, Pfizer.	3-[2-[[[4-chlorophenyl)sulfonyl]amino]ethyl]-5-(3-pyridinylmethyl)benzenepropanoic acid	thromboxane antagonist; synthetase inhibitor; prostaglandin antagonist; platelet antiaggregant	thrombosis; restenosis
nafagrel; DP 1904	5,6,7,8-tetrahydro-6-(1H-imidazol-1-ylmethyl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; angina; asthma; restenosis

NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	asthma; inflammation; restenosis
AG 1296	6,7-dimethoxy-2-phenyl-quinoxaline	tyrosine kinase inhibitor	restenosis
PD 164199	6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
PD 164771	6-(2,6-dichlorophenyl)-8-methyl-2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
PD 166285	6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
KN 1022	4-(6,7-dimethoxy-4-quinazolinyl)-N-(4-nitrophenyl)-1-piperazinecarboxamide	tyrosine kinase inhibitor; PDGF inhibitor	restenosis
CT 3501	Unspecified	Unspecified	cancer; restenosis
PC 1122	Unspecified	Unspecified	restenosis; reperfusion injury

Table 68. Current Candidate Therapeutic Interventions for the Treatment of Peripheral Vascular Disease

Product Name	Chemical Name	Action	Indication
AHR 16303B	1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]phenyl]-2-methyl-1-propanone ethanedioate (1:1)	5HT antagonist; 5HT2 antagonist	hypertension; angina

ITF 1570	Salicylester derivative	5HT1A and bradykinin antagonist	peripheral vascular disease; cerebrovascular disease; heart ischemia
ICI D4398; ZM 241385	4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol	adenosine antagonist; adenosine A2 antagonist	peripheral vascular disease; hypotension
ZD 9255	Unspecified	adenosine antagonist; adenosine A2 antagonist	peripheral vascular disease
S 170891; S 18149	1,3',4',5-tetrahydro-7'-methyl-spiro[4H-imidazole-4,2'(1'H)-naphthalene]	alpha adrenergic agonist; alpha1 adrenergic agonist; alpha2 adrenergic agonist	peripheral vascular disease
angiopoietin 1	Angiopoietin 1	angiogenesis inducer; growth factor	coronary artery disease; peripheral vascular disease
ranolazine; ranolazine hydrochloride; RS 43285; KEG 1295	(+,-)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide	anti-ischemic	angina; peripheral vascular disease
antisense oligonucleotide, bcl-x	Bcl-x oligonucleotide, Unspecified	antisense oligonucleotide	Peripheral vascular disease
alifedrine; D 13625	[R-(R*,S*)]-1-cyclohexyl-3-[(2-hydroxy-1-methyl-2-phenylethyl)amino]-1-propanone	beta adrenergic agonist; vasodilator	peripheral vascular disease
trafermin; fibroblast growth factor, basic; basic fibroblast growth factor; bFGF; trofermin; KCB 1; CAB 2001; FIBLAST	2-155-fibroblast growth factor, basic (human clone lambda KB7/lambda HFL 1 precursor reduced)	biotechnology; growth factor; cicatrizant	skin ulcer; osteoporosis; stroke; neuropathy; peripheral vascular disease; coronary artery disease

flunarizine; R 14950; FLUZINA; SIBELIUM; ZINASEN; SESNARBO; RIZENA; SINAZINE; HEADACHE; FLORIRATO; DIESPRUDEL	Unspecified	calcium antagonist; vasodilator	peripheral vascular disease; cerebrovascular disease; migraine; epilepsy
elziverine; Ro 224839	1-[(3,4- dimethoxyphenyl)meth- yl]-6,7-dimethoxy-4- [[4-(2- methoxyphenyl)-1- piperazinyl]methyl]is- oquinoline	calmodulin antagonist; vasodilator	peripheral vascular disease; cognitive defect
clinprost; lipoisocarbacyclin; isocarbacyclin methyl ester; TEI 9090	[3aS- [3aalpha,5beta,6alpha (1E,3R*),6aalpha]]- 1,3a,4,5,6,6a- hexahydro-5- hydroxy-6-(3- hydroxy-1-octenyl)-2- pentalenepentanoic acid methyl ester	cicatrizant; prostanoid; platelet antiaggregant	thrombosis; skin ulcer; peripheral vascular disease
pamigocrel; KBT 3022; KB 3022; TO 192	2-[4,5-bis(4- methoxyphenyl)-2- thiazolyl]-1H-pyrrole- 1-acetic acid ethyl ester	COX inhibitor; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease
ZD 0892	N-(4- methoxybenzoyl)-L- valyl-N-[(1S)-3,3,3- trifluoro-1-(1- methylethyl)-2- oxopropyl]-L- prolinamide	elastase inhibitor; proteinase inhibitor	peripheral vascular disease
Tie-2 ligands, angiogenesis ligands,	Unspecified	hematopoietic factor; cicatrizant; growth factor; angiogenesis inhibitor; angiogenesis inducer	cancer; restenosis; retinopathy; skin ulcer; atherosclerosis; peripheral vascular disease

fondaparin sodium; SR 90107; ORG 31540; SR 90107A	methyl O-2-deoxy-6- O-sulfo-2- (sulfoamino)-alfa-D- glucopyranosyl-(1-4)- O-beta-D- glucopyranuronosyl- (1-4)-O-2-deoxy-3,6- di-O-sulfo-2- (sulfoamino)-alfa-D- glucopyranosyl-(1-4)- O-2-O-sulfo-alfa-L- idopyranuronosyl-(1- 4)-2-deoxy-2- (sulfoamino)-alfa-D- glucopyranoside 6- (hydrogen sulfate)	heparinoid; blood clotting factor Xa inhibitor; proteinase inhibitor; oligosaccharide	thrombosis; peripheral vascular disease
BAY w 9798	Unspecified	leukocyte adhesion inhibitor; vasodilator	peripheral vascular disease
MAB; AFS 98; AFS 98	Unspecified	monoclonal antibody	peripheral vascular disease
cilostazol; OPC 13013; PLETAL; PLETAAL	6-[4-(1-cyclohexyl- 1H-tetrazol-5- yl)butoxy]-3,4- dihydro-2(1H)- quinolinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; platelet antiaggregant; vasodilator	thrombosis
indobufen; K 3920; IBUSTRIN	(+,-)-2-[p-(1-oxo-2- isoindolinyl)phenyl]b utyric acid	platelet antiaggregant	thrombosis
ticlopidine; ticlopidine hydrochloride; 5332 C; 4 C 32; PCR 5332; PICLODIN; PICLONADINE; PROPACALL; TICLID; PANALDINE; ROBETARL; RONDORIN	5-[(2- chlorophenyl)methyl] -4,5,6,7- tetrahydrothieno[3,2- c]pyridine	platelet antiaggregant; calcium antagonist	stroke; thrombosis
vintoperol; RGH 2981	(3alpha,16alpha)-21- nor-1,14- secoeburnamein-20-ol	platelet antiaggregant; vasodilator; antioxidant	peripheral vascular disease; thrombosis

BMS 180448	(3S-trans)-N-(4-chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-guanidine	potassium channel activator	angina
emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease
bimakalim; EMD 52692; SR 44866	2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; vasodilator; bronchodilator	coronary artery disease; asthma; peripheral vascular disease
drug delivery system, transdermal alprostadil; alprostadil transdermal; prostaglandin E1 transdermal; OT 1404	Unspecified	prostaglandin	peripheral vascular disease
AS 013	(11alpha,13E,15S)-11,15-dihydroxy-9-(1-oxobutoxy)prosta-8,13-dien-1-oic acid butyl ester	prostanoid	peripheral vascular disease
ICI 199456	Unspecified	prostanoid	peripheral vascular disease
ONO 1608	Unspecified	prostanoid	peripheral vascular disease
SI 1702	Unspecified	prostanoid	peripheral vascular disease
limaprost; limeprost; limaprost alfadex; OP 1206; ONO 1206; OPALMON; PRORENAL	(E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl]-2-heptenoic acid	prostanoid; analgesic	cardiovascular disease; pain

beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
ciprostene; ciprostone calcium; U 61431F	[3aS-[2Z,3aalfa,5beta,6alfa(1E,3R*),6aalfa]]-5-[hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-3a-methyl-2(1H)-pentalenylidene]pentanoic acid	prostanoid; platelet antiaggregant	thrombosis; restenosis
KP 10614	[3aS-[2(Z),3aalfa,5beta,6alfa(1E,3R*,4R*),6aalfa]]-5-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-4-methyl-1-nonen-6-ynyl)-2-pentalenyl]-4-pentenoic acid	prostanoid; platelet antiaggregant; vasodilator	thrombosis; peripheral vascular disease
taprostene; CG 4203	alpha-((2Z,3aR,4R,5R,6aS)-4-((1E,3S)-3-cyclohexyl-3-hydroxypropenyl)hexahydro-5-hydroxy-2H-cyclopenta(beta)furan-2-ylidene)-meta-toluic acid	prostanoid; platelet antiaggregant; vasodilator	peripheral vascular disease; thrombosis
iloprost; ciloprost; ZK 36374; E 1030; SH 401; ILOMED; ENDOPROST; ILOMEDIN; AIPRO	5-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene]pentanoic acid	prostanoid; platelet antiaggregant; vasodilator; NSAID	peripheral vascular disease; thrombosis; thrombocytopenia; rheumatoid arthritis



alprostadi; lipo-prostaglandin E1; lipo-PGE1; U 10136; PGE1; CAVERJECT; PALUX; LIPL; PROSTIN; EDEX; MUSE	(11 $\alpha$ ,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid	prostanoid; vasodilator; cicatrizant	hepatitis; thrombosis; peripheral vascular disease; sexual dysfunction; pulmonary hypertension; skin ulcer; hearing loss
cicaprost; cicaprost clathrate; ZK 114923; SH 574; SH 490	[3 $\alpha$ S-[2E,3 $\alpha$ ,4 $\alpha$ (3R*,4R*),5 $\beta$ ,6 $\alpha$ ph a]]-[2-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nonadiynyl)-2(1H)-pentalenylidene]ethoxy]acetic acid	prostanoid; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease; cancer
BIBU 308; DTTX 30	cis-2-[[[2-(hydroxyamino)-2-oxoethyl]methylamino]carbonyl]cyclohexanecarboxylic acid	thromboxane antagonist; platelet antiaggregant	pulmonary hypertension; peripheral vascular disease
SQ 33961	[1S-(exo,exo)]-2-[[[3-[4-[[[4-cyclohexylbutyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
terbogrel; BIBV 308 SE	(5E)-6-[3-[[[(cyanoamino)[(1,1-dimethylethyl)amino]methylene]amino]phenyl]-6-(3-pyridinyl)-5-hexenoic acid	thromboxane antagonist; thromboxane synthase inhibitor	pulmonary hypertension; peripheral vascular disease
KDI 792; FK 070; FR 12170	[2S-[2 $\alpha$ , (Z),4 $\beta$ ]]-6-[4-[[[4-chlorophenyl]sulfonyl]amino]-1-(3-pyridinylmethyl)-2-pyrrolidinyl]-5-hexenoic acid	thromboxane antagonist; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma

vinpocetine; AY-27255; CAVINTON; CERACTON; AIRPACIL; MEDICHILL; NAIKINOL TEISAN; NAIKINOL IWAKI	(3 $\alpha$ ,16 $\alpha$ )-eburnamenine-14-carboxylic acid ethyl ester	vasodilator	peripheral vascular disease; cognitive defect
drotaverine acephyllinate; DEPOGEN	1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purine-7-acetic acid cmpd. with 1-[(3,4-diethoxyphenyl)methylene]-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline (1:1)	vasodilator; antispasmodic	thrombosis; peripheral vascular disease
propionylcarnitine, L-; propionyl-L-carnitine; levocarnitine propionyl; ST 261; DROMOS	L-3-carboxy-2-(1-oxopropoxy)-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt	vasodilator; cicatrizant	peripheral vascular disease; angina; heart failure; skin ulcer
calcitonin gene related peptide, $\alpha$ ; CGRP, $\alpha$ ; CGRP, human $\alpha$	H-ala-cys-asp-thr-ala-thr-cys-val-thr-his-arg-leu-ala-gly-leu-leu-ser-arg-ser-gly-gly-val-val-lys-asn-asn-phe-val-pro-thr-asn-val-gly-ser-lys-ala-phe-NH <sub>2</sub>	vasodilator; peptide hormone	peripheral vascular disease; cerebrovascular disease
eptaloprost; eptaprost; ZK 97959	3 $\alpha$ S-[2E,3 $\alpha$ alfa,4 $\alpha$ alfa(3R*,4R*)5beta,6 $\alpha$ alfa]-4-(2-hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nonadiynyl-2(1H)-pentalenylidene)ethoxy)-butanedioic acid	vasodilator; prostanoid	thrombosis; peripheral vascular disease; cancer

pimilprost; SM 10902; SKIPRON	[2R- [2.alpha.,3a.alpha.,4.alpha. [2.alpha.(1E,3S*,5S*),5.b cta.,6a.alpha.]]-[2- [octahydro-5- hydroxy-4-(3- hydroxy-5-methyl-1- nonenyl)-2- pentalenyl]ethoxy]ace tic acid methyl ester	vasodilator; prostanoid; cicatrizant	peripheral vascular disease; skin ulcer
pentoxifylline; oxpentifylline; EBISANIN; SEVSTAN; TRENTAL; TORENTAL	3,7-dimethyl-1-(5- oxo-hexyl)xanthine	xanthine; vasodilator	peripheral vascular disease; stroke; atherosclerosis

Claims

What is claimed is:

1. A method for selecting a treatment for a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune  
5 disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, disorder, or condition, comprising

determining whether cells of said patient contain at least one variance in a gene from a Table herein, wherein the presence or the absence of said at least one variance in said gene is indicative of the effectiveness of said treatment for said  
10 disease, disorder, or condition.

2. The method of claim 1, wherein disease, disorder, or condition is listed in an example or Table herein.

3. The method of claim 1, wherein the presence of said at least one variance is  
15 indicative that said treatment will be effective for said patient.

4. The method of claim 1, wherein the presence of said variance is indicative that said treatment will be ineffective or contra-indicated for said patient.

- 20 5. The method of claim 1, wherein said at least one variance comprises a plurality of variances.

6. The method of claim 5, wherein said plurality of variances comprise a haplotype or haplotypes.

- 25 7. The method of claim 1, wherein said selecting a treatment further comprises identifying a compound differentially active in a patient bearing a form of said gene containing said at least one variance.

8. The method of claim 7, wherein said compound is a compound listed in a  
30 Table herein or that belongs to the same chemical class as a compound listed in a said Table.

9. The method of claim 1, wherein said selecting a treatment further comprises  
35 excluding or eliminating a treatment, wherein said presence or absence of said at least one variance is indicative that said treatment will be ineffective or contra-indicated.

10. The method of claim 1, wherein said treatment comprises a first treatment and a second treatment, said method comprising the steps of:

identifying a said first treatment effective to treat said disease, disorder, or condition; and

identifying a said second treatment which reduces a deleterious effect or promotes efficacy of said first treatment.

11. The method of claim 1, wherein said selecting a treatment further comprises selecting a method of administration of a compound effective to treat said disease in a patient, disorder or condition, wherein said presence or absence of said at least one variance is indicative of the appropriate method of administration for said compound.

12. The method of claim 11, wherein said selecting the method of administration comprises selecting a suitable dosage level or frequency of administration of a compound.

13. The method of claim 1, further comprising determining the level of expression of said gene or the level of activity of a protein containing a polypeptide expressed from said gene,

wherein the combination of the determination of the presence or absence of said at least one variance and the determination of the level of activity or the level of expression provides a further indication of the effectiveness of said treatment.

14. The method of claim 1, further comprising determining the at least one of sex, age, racial origin, ethnic origin, and geographic origin of said patient,

wherein the combination of the determination of the presence or absence of said at least one variance and the determination of the sex, age, racial origin, ethnic origin, and geographic origin of said patient provides a further indication of the effectiveness of said treatment.

15. The method of claim 1, wherein said disease, disorder, or condition is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central

nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

16. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises amplifying a segment of nucleic acid including at least one of said variances.

17. The method of claim 16, wherein said segment of nucleic acid is 500 nucleotides or less in length.

18. The method of claim 16, wherein said segment of nucleic acid is 100 nucleotides or less in length.

19. The method of claim 16, wherein said segment of nucleic acid is 45 nucleotides or less in length.

20. The method of claim 16, wherein said segment includes a plurality of variances.

21. The method of claim 17, wherein amplification preferentially occurs from one of the two strands of a chromosome.

22. The method of claim 17, wherein said segment of nucleic acid is at least 500 nucleotides in length.

23. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises contacting nucleic acid comprising a variance site with at least one nucleic acid probe, wherein said at least one probe preferentially hybridizes with a nucleic acid sequence including said variance site and containing a complementary base at said variance site under selective hybridization conditions.

24. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises sequencing at least one nucleic acid sequence.

5 25. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises mass spectrometric determination of at least one nucleic acid sequence.

10 26. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises determining the haplotype of a plurality of variances in a gene.

27. A method for selecting a method of treatment, comprising  
comparing at least one variance in at least one gene from Tables 1-6, 12-17,  
15 and 18-23 in a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition with a list of variances or haplotypes in said at least one gene indicative of the effectiveness of at least one method of treatment.

20 28. The method of claim 27, wherein said list comprises at least 5 variances.

29. The method of claim 27, wherein said at least one variance comprises a plurality of variances.

25 30. The method of claim 27, wherein said list of variances comprises a plurality of variances.

30 31. The method of claim 27, wherein at least one said method of treatment comprises the administration of a compound effective against said disease or condition to a patient.

32. The method of claim 31, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics,  
35 or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.

33. The method of claim 27, wherein the presence or absence of at least one variance or haplotype in said gene is indicative that said treatment will be effective in said patient.

5 34. The method of claim 27, wherein the presence or absence of at least one variance in said gene is indicative that said treatment will be ineffective or contra-indicated.

10 35. The method of claim 27, wherein said treatment is a first treatment and the presence or absence of at least one variance in said gene is indicative that a second treatment will be beneficial to reduce a deleterious effect or promotes efficacy of said first treatment.

15 36. The method of claim 27, wherein said at least one method of treatment is a plurality of methods of treatment.

20 37. The method of claim 36, wherein said selecting comprises determining whether any of said plurality of methods of treatment will be more effective than at least one other of said plurality of methods of treatment.

25 38. The method of claim 27, wherein said disease is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis,  
30 atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis,  
35 renal disease, restenosis, and peripheral vascular disease.

39. A method for selecting a method of administration to a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation



or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition for a compound or compounds effective to treat said condition or disease, comprising

determining whether at least one variance in a gene from Tables 1-6, 12-17,  
5 and 18-23 is present or absent in cells of said patient, wherein said presence or absence of said at least one variance is indicative of an appropriate method of administration for said compound.

40. The method of claim 39, wherein said neurological or psychiatric disease,  
10 drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition is a disease or condition listed in the Detailed Description, an Example, or a Table herein.

41. The method of claim 39, wherein said selecting a method of administration  
15 comprises selecting a dosage level or frequency or frequency of administration of said compound.

42. The method of claim 39, wherein said compound is selected from the group  
20 consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics, or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.

43. The method of claim 39, wherein said disease is selected from the group  
25 consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood  
30 dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes  
35 mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia,

angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

44. A method for selecting a patient for administration of a treatment,  
5 comprising

comparing the presence or absence of at least one variance or haplotype in a gene from Tables 1-6, 12-17, and 18-23 in cells of a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease,  
10 or proliferative disease or condition with a list of variances or haplotypes in said at least one gene, wherein the presence or absence of said at least one variance or haplotype in said cells is indicative that said treatment will be effective, more effective, less effective, ineffective, or contra-indicated in said patient; and

determining whether said patient will receive said treatment based on the  
15 presence or absence of said at least one variance in said cells.

45. The method of claim 44, wherein said list comprises at least 5 variances.

46. The method of claim 44, wherein said method of treatment comprises  
20 administration of a compound effective against said disease or condition.

47. The method of claim 46, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics,  
25 or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.

48. A method for identifying the presence or absence of at least one form of a gene from Tables 1-6, 12-17, and 18-23 in cells of an individual, comprising:

30 determining the presence or absence of at least one variance in said gene in said cells.

49. The method of claim 48, wherein said said at least one variance is a plurality of variances.

50. The method of claim 49, wherein said plurality of variances comprises a  
35 haplotype.

51. The method of claim 50, wherein said individual suffers from a disease or condition.

52. The method of claim 50, wherein the presence or absence of said at least one variance is indicative of the effectiveness of a therapeutic treatment in a patient having cells containing said at least one variance.

53. The method of claim 50, wherein said determining comprises amplifying a segment of nucleic acid including a site of at least one variance.

54. The method of claim 50, wherein said determining comprises contacting a nucleic acid sequence containing a variance site corresponding to a said variance with a probe which specifically binds under selective binding conditions to a nucleic acid sequence comprising at least one said variance.

55. The method of claim 50, wherein the detection of the presence or absence of said at least one variance comprises sequencing at least one nucleic acid sequence.

56. The method of claim 50, wherein the detection of the presence or absence of said at least one variance comprises mass spectrometric determination of at least one nucleic acid sequence.

57. The method of claim 50, wherein the detection of the presence or absence of said at least one variance comprises determining the haplotype of a plurality of variances in a gene.

58. A pharmaceutical composition comprising  
a compound which has a differential effect in patients having at least one copy of a particular form of an identified gene from Tables 1-6, 12-17, and 18-23; and

a pharmaceutically acceptable carrier or excipient or diluent,  
wherein said composition is preferentially effective to treat a patient with cells comprising a form of said gene comprising at least one variance.

59. The method of claim 58, wherein said composition is adapted to be preferentially effective based on the unit dosage, presence of additional active components, complexing of said compound with stabilizing components, or inclusion of components enhancing delivery or slowing excretion of said compound.

60. The composition of claim 58, wherein said compound is deleterious to patients having said at least one copy or in patients not having said at least one copy, but not in both.

5 61. The composition of claim 58, wherein said patient suffers from a disease or condition selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease,  
10 schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation,  
15 psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis,  
20 renal disease, restenosis, and peripheral vascular disease.

25 62. The pharmaceutical composition of claim 58, wherein said composition is subject to a regulatory restriction or recommendation for use of a diagnostic test determining the presence or absence of at least one variance or haplotype in said gene.

30 63. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is subject to a regulatory limitation or recommendation restricting or recommending restriction of the use of said pharmaceutical composition to patients having at least one copy of a form of a gene comprising at least one variance.

35 64. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is subject to a regulatory limitation or recommendation indicating said pharmaceutical composition is not to be used in patients having at least one copy of a form of a gene comprising at least one variance.

65. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is packaged, and the packaging includes a label or insert restricting or

recommending the restriction of the use of said pharmaceutical composition to patients having at least one copy of a form of a gene comprising at least one variance or haplotype.

5        66.     The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is packaged, and said packaging includes a label or insert requiring or recommending the use of a test to determine the presence or absence of at least one variance in cells of a said patient.

10       67.     A nucleic acid probe comprising a nucleic acid sequence 7 to 200 nucleotide bases in length that specifically binds under selective binding conditions to a nucleic acid sequence comprising at least one variance in a gene from Tables 1-6, 12-17, and 18-23, or a sequence complementary thereto or an RNA equivalent.

15       68.     The probe of claim 67, wherein said probe comprises a nucleic acid sequence 500 nucleotide bases or fewer in length.

69.     The probe of claim 67, wherein said nucleic acid sequence is 100 or fewer nucleotide bases in length.

20       70.     The probe of claim 67, wherein said nucleic acid sequence is 25 or fewer nucleotide bases in length.

71.     The probe of claim 67, wherein said probe comprises DNA.

25       72.     The probe of claim 67, wherein said probe comprises DNA and at least one nucleic acid analog.

73.     The probe of claim 67, wherein said probe comprises peptide nucleic acid (PNA).

30       74.     The probe of claim 67, further comprising a detectable label.

75.     The probe of claim 74, wherein said detectable label is a fluorescent label.

35       76.     A method for determining a genotype of an individual, comprising analyzing at least one nucleic acid sequence from cells of said individual using mass spectrometric analysis,

wherein said nucleic acid sequence is a portion of a gene from Tables 1-6, 12-17, and 18-23 or a sequence complementary thereto.

5 77. The method of claim 76, wherein said analyzing a nucleic acid sequence comprises determining the presence or absence of a variance in said gene.

78. The method of claim 76, wherein said analyzing a nucleic acid sequence comprises determining the nucleotide sequence of said at least one nucleic acid sequence.

10

79. The method of claim 76, wherein said at least one nucleic acid sequence is 500 nucleotides or less in length.

15 80. The method of claim 76, wherein said at least one nucleic acid sequence comprises at least one variance site in said gene.

81. An isolated, purified or enriched nucleic acid sequence of 15 to 500 nucleotides in length, comprising at least one variance site, wherein said sequence has the base sequence of a portion of an allele of a gene from Tables 1-6, 12-17, and 18-23.

20

82. The nucleic acid sequence of claim 81, wherein said nucleic acid sequence is 15 to 100 nucleotide bases in length.

25 83. The nucleic acid sequence of claim 81, wherein said nucleic acid sequence is 15 to 25 nucleotide bases in length.

84. A method for determining whether a compound has differential effects on cells containing at least one different form of a gene from Tables 1-6, 12-17, and 18-23, comprising:

30 contacting a first cell and a second cell with said compound, wherein said first cell and said second cell differ in the presence or absence of at least one variance in said gene; and

determining whether the responses of said first cell and said second cell to said compound differ, wherein the difference in said response is due to the presence or absence of said at least one variance.

35

85. The method of claim 84, wherein said at least one variance comprises a haplotype.

5 86. The method of claim 84, wherein at least one of said first cell and said second cell are contacted *in vivo*.

87. The method of claim 85, wherein at least one of said first cell and said second cell are contacted *in vitro*.

10 88. The method of claim 87, wherein at least one of said first cell and said second cell is contacted *in vivo* in a plurality of patients suffering from a disease or condition.

15 89. A method of treating a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition, comprising:

20 a) determining whether cells of said patient contain a form of a gene from Tables 1-6, 12-17, and 18-23 which comprises at least one variance, wherein the presence or absence of said at least one variance is indicative that a treatment will be effective in said patient; and

b) administering said treatment to said patient.

25 90. The method of claim 89, wherein said gene is listed in Table 1 or is a gene in a pathway listed in Table 1 herein.

30 91. The method of claim 89, wherein said disease or condition is a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition listed in the Detailed Description, Examples, or Tables herein.

35 92. The method of claim 89, wherein said disease is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system

toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

93. The method of claim 89, wherein the presence of said at least one variance is indicative that said treatment will be effective in said patient.

94. The method of claim 93, wherein said treatment comprises the administration of a compound preferentially active for said condition or disease in a said patient having said at least one variance in said gene.

95. The method of claim 94, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics, or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.

96. The method of claim 89, wherein the presence of said at least one variance in said gene is indicative of an appropriate dosage or frequency of administration of a compound in said treatment.

97. A method of treating a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition, comprising:

a) comparing the presence or absence of at least one variance in a gene from Tables 1-6, 12-17, and 18-23 in cells of a patient suffering from said disease or condition with a list of variances in said gene indicative of the effectiveness of at least one method of treatment;

b) selecting a method of treatment from said at least one method of treatment, wherein the presence or absence of at least one of said at least one



variance is indicative that said method of treatment will be effective in said patient;  
and

c) administering said method of treatment to said patient.

5 98. The method of claim 97, wherein said at least one gene comprises a gene listed in Table 1 or comprises a gene in a pathway listed in Table 1 herein.

99. The method of claim 97, wherein said condition or disease is a condition or disease listed in the Detailed Description, Examples, or Tables herein.

10

100. The method of claim 97, further comprising determining the presence or absence of said at least one variance in cells of said patient.

15

101. The method of claim 97, wherein said at least one variance comprises a plurality of variances.

102. The method of claim 97, wherein said list of variances comprises a plurality of variances.

20

103. The method of claim 102, wherein said plurality of variances comprises a haplotype or haplotypes.

104. The method of claim 97, wherein said method of treatment comprises the administration of a compound effective against said disease or condition.

25

105. The method of claim 97, wherein said treatment is a first treatment and the presence or absence of at least one variance in said gene is indicative that a second treatment will be beneficial to reduce a deleterious effect or promotes efficacy of said first treatment.

30

106. The method of claim 97, wherein said at least one method of treatment is a plurality of methods of treatment.

35

107. The method of claim 97, wherein said disease or condition is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of

blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis,  
5 atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis,  
10 renal disease, restenosis, and peripheral vascular disease.

108. A method of treating a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative  
15 disease or condition, comprising:

a) comparing the presence or absence of at least one variance in a gene from Tables 1-6, 12-17, and 18-23 in cells of a patient suffering from said disease or condition with a list of variances in said gene indicative of the effectiveness of at least one method of treatment;

20 b) eliminating a method of treatment from said at least one method of treatment, wherein the presence or absence of at least one of said at least one variance is indicative that said method of treatment will be ineffective or contra-indicated in said patient;

25 c) selecting an alternative method of treatment effective to treat said neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition; and

e. administering said alternative method of treatment to said patient.

30 109. The method of claim 108, further comprising determining the presence or absence of said at least one variance in cells of said patient.

35 110. The method of claim 108, wherein said at least one gene comprises a gene in the acetylcholine pathway; the CNS lipid transport/membrane repair pathway; the prostaglandin, prostacylin and thromboxane pathway, or is a gene involved in Alzheimer's disease neurofibrillary plaque formation or in susceptibility to Alzheimer's disease.

111. The method of claim 108, wherein said disease or condition is a disease or condition listed in the Detailed Description, Examples, or Tables herein.

112. A method for producing a pharmaceutical composition, comprising:

5 a) identifying a compound which has differential activity against a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition in patients having at least one variance in a gene from Tables 1-6, 12-17, and 18-23;

10 b) compounding said pharmaceutical composition by combining said compound and a pharmaceutically acceptable carrier or excipient or diluent in a manner adapted to be preferentially effective in patients having said at least one variance.

113. A method for producing a pharmaceutical agent, comprising:

15 a) identifying a compound which has differential activity against a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition in patients having at least one variance in a gene from Tables 1-6, 12-17, and 18-23; and

20 b) synthesizing said compound in an amount sufficient to provide a pharmaceutical effect in a patient suffering from said neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition.

25 114. A method for determining whether a variance in a gene from Tables 1-6, 12-17, and 18-23 provides variable patient response to a method of treatment for a disease or condition, comprising:

30 determining whether the response of a first patient or set of patients suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition differs from the response of a second patient or set of patients suffering from said disease or condition;

35 determining whether the presence or absence of at least one variance in said gene differs between said first patient or set of patient and said second patient or set of patients;

wherein correlation of said presence or absence of at least one variance and the response of said patient to said treatment is indicative that said at least one variance provides variable patient response.

5 115. The method of claim 114, further comprising identifying at least one variance in a said gene.

116. The method of claim 114, wherein a plurality of pairwise comparisons of treatment response and the presence or absence of at least one variance are performed for a plurality of patients.

10 117. The method of claim 114, wherein said determining whether the presence or absence of at least one variance in at least one gene comprises comparing the response of at least one patient homozygous for said at least one variance with at least one patient homozygous for the alternative form of said at least one variance.

15 118. The method of claim 114, wherein said determining whether the presence or absence of said at least one variance in at least one gene comprises comparing the response of at least one patient heterozygous for said at least one variance with the response of at least one patient homozygous for said at least one variance.

20 119. The method of claim 114, wherein it is previously known that patient response to said method of treatment is variable.

120. The method of claim 114, wherein said disease or condition is a disease or condition listed in the Detailed Description, Examples, or Tables herein.

25 121. The method of claim 114, wherein said disease or condition is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of  
30 blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis,  
35 atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia,

adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

5 122. The method of claim 114, wherein said method of treatment comprises administration of a compound effective to treat said disease or condition.

123. A method of treating a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease,  
10 cardiovascular or renal disease, or proliferative disease or condition in a patient, comprising

a) selecting a patient whose cells comprise an allele of a gene from Tables 1-6, 12-17, and 18-23, wherein said allele comprises at least one variance correlated with more effective treatment of said neurological or psychiatric disease, drug-  
15 induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition; and

b) altering the level of activity in cells of said patient of a product said allele, wherein said altering provides a therapeutic effect.

20 124. A method for determining a method of treatment effective to treat a disease or condition in a sub-population of patients, comprising

altering the level of activity of a product of an allele of a gene from Tables 1-6, 12-17, and 18-23; and

25 determining whether said alteration provides a differential effect related to reducing or alleviating a disease or condition as compared to at least one alternative allele, wherein the presence of a said differential effect is indicative that said altering the level of activity comprises an effective treatment for said disease or condition in said sub-population.

30 125. A method for performing a clinical trial or study, comprising

selecting or stratifying subjects using a variance or variances or haplotypes from one or more genes specified in Tables 1-6, 12-17, and 18-23.

35 126. The method of claim 125, wherein differential efficacy, tolerance, or safety of a treatment in a subset of patients who have a particular variance, variances, or haplotype in a gene or genes from Tables 1-6, 12-17, and 18-23, comprising

conducting a clinical trial and using a statistical test to assess whether a relationship exists between efficacy, tolerance, or safety with the presence or absence of any of said variances or haplotype in one or more of said genes,

5 wherein results of said clinical trial or study are indicative whether a higher or lower efficacy, tolerance, or safety of said treatment in said subset of patients is associated with any of said variance or variances or haplotype in one or more of said gene.

10 127. The method of claim 125 wherein normal subjects or patients are prospectively stratified by genotype in different genotype-defined groups, including the use of genotype as a enrollment criterion, using a variance, variances or haplotypes from Tables 1-6, 12-17, and 18-23, and subsequently a biological or clinical response variable is compared between the different genotype-defined groups.

15 128. The method of claim 125 wherein the normal subjects or patients in a clinical trial or study are stratified by a biological or clinical response variable in different biologically or clinically-defined groups, and subsequently the frequency of a variance, variances or haplotypes from Tables 1-6, 12-17, and 18-23 is measured in  
20 the different biologically or clinically defined groups.

25 129. The method of claim 127 or 128 where the normal subjects or patients in a clinical trial or study are stratified by at least one demographic characteristic selected from the groups consisting of sex, age, racial origin, ethnic origin, or geographic origin.

130. The method of claim 125, wherein said determining comprises assigning said patient to a group to receive said method of treatment or to a control group.

30 131. A method for determining whether a variance in a gene provides variable patient response to a method of treatment for a disease or condition, comprising:  
determining whether the response of a first patient or set of patients suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or

renal disease, or proliferative disease or condition differs from the response of a second patient or set of patients suffering from said disease or condition;

determining whether the presence or absence of at least one variance in a gene from Tables 1-6, 12-17, and 18-23 differs between said first patient or set of patient and said second patient or set of patients;

wherein correlation of said presence or absence of at least one variance and the response of said patient to said treatment is indicative that said at least one variance provides variable patient response.

132. A method for treating a patient at risk for a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or diagnosed with a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising

identifying a said patient and determining the patient's genotype allele status for a gene from Tables 1-6, 12-17, and 18-23;

determining a treatment protocol using the patient's genotype status to provide a prediction of the efficacy and safety of a therapy in light of a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or an associated pathological condition.

133. A method for identifying a patient for participation in a clinical trial of a therapy for the treatment of neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or disorder, comprising

identifying a patient with a disease risk and determining the patient's genotype, allele status for an identified gene from Tables 1-6, 12-17, and 18-23.

134. The method of claim 133, further comprising

determining the patient's allele status and selecting those patients having at least one wild type allele of said gene as candidates likely to develop a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease.

135. A method for treating a patient at risk for a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising

5 identifying a patient with a risk for said disease;  
determining the genotypic allele status of the patient for at least one gene from Tables 1-6, 12-17, and 18-23; and

10 converting the genotypic allele status into a treatment protocol that comprises a comparison of the genotypic allele status determination with the allele frequency of a control population, thereby allowing a statistical calculation of the patient's risk for having a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease.

15 136. A method for treating a patient at risk for or diagnosed with having a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising

20 identifying a said patient;  
determining the gene allele load status of the patient for at least one gene from Tables 1-6, 12-17, and 18-23 and converting the gene allele load status into a treatment protocol that includes a comparison of the allele status determinations with the allele frequency of a control population, thereby allowing a statistical calculation of the patient's risk for having having a neurological or psychiatric disease, drug-  
25 induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease.

30 137. A method for improving the safety of candidate therapies associated with having a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising

35 comparing the relative safety of the candidate therapeutic intervention in patients having different alleles in one or more than one of the genes listed in Tables 1-6, 12-17, and 18-23, thereby identifying subsets of patients with differing safety of the candidate therapeutic intervention.

138. A kit for determination of the presence or absence of at least one sequence variance in a gene identified in any of Tables 1-6, 12-17, and 18-23, comprising



at least one probe that preferentially hybridizes with a nucleic acid sequence corresponding to a portion of said gene or at least one primer comprising a nucleic acid sequence corresponding to a portion of said gene or a sequence complementary thereto or both said at least one probe and said at least one primer.

5  
139. A method for determining whether there is a genetic component to intersubject variation in a surrogate treatment response, comprising:

10 a. administering said treatment to a group of related normal subjects and a group of unrelated normal subjects;

b. measuring a surrogate pharmacodynamic or pharmacokinetic drug response variable in said subjects;

15 c. performing a statistical test measuring the variation in response in said group of related normal subjects and, separately in said group or unrelated normal subjects;

20 d. comparing the magnitude or pattern of variation in response or both between said groups to determine if the responses of said groups are different, using a predetermined statistical measure of difference,

wherein a difference in response between said groups is indicative that there is a genetic component to intersubject variation in said surrogate treatment response.

25 140. The method of claim 129, wherein the size of the related and unrelated groups is set in order to achieve a predetermined degree of statistical power.

141. A method for evaluating the combined contribution of two or more variances to a surrogate drug response phenotype in subjects, comprising:

30 a. genotyping a set of unrelated subjects participating in a clinical trial or study of a compound for two or more variances to identify subjects with specific genotypes, wherein said two or more specific genotypes define two or more genotype-defined groups;

35 b. administering a drug to subjects with two or more of said specific genotypes;

- c. measuring a surrogate pharmacodynamic or pharmacokinetic drug response variable in said subjects;
- d. performing statistical tests to measure response in said groups separately, wherein said statistical tests provide a measurement of variation in response with each said group;
- e. comparing the magnitude or pattern of variation in response or both between said groups to determine if said groups are different using a predetermined statistical measure of difference.

142. The method of claim 141, wherein said clinical trial or study is a Phase I clinical trial or study.

143. The method of claim 141, wherein said specific genotypes are homozygous genotypes for two variances.

144. The method of claim 141, wherein the comparison is between groups of subjects differing in three or more variances.

145. A method for providing contract research services to a client, comprising:

- a. enrolling subjects in a clinical drug trial or study unit for the purpose of genotyping said subjects in order to assess the contribution of one or more variances or haplotypes to variation in drug response;
- b. genotyping said subjects to determine the status of one or more variances in said subjects;
- c. administering a compound to said subjects and measuring a surrogate drug response variable;
- d. comparing responses between two or more genotype-defined groups of said subjects to determine whether there is a genetic component to the interperson variability in response to said compound; and
- e. reporting the results of said clinical drug trial or study unit to a contracting entity.

146. The method of claim 145, wherein said clinical drug trial or study unit is a Phase I drug trial or study unit.

147. The method of claim 145, wherein at least some of the subjects have disclosed that they are related to each other and said comparing includes comparison of groups of related individuals.

148. The method of claim 147, wherein the related individuals are encouraged to participate by compensation in proportion to the number of their relatives participating.

149. A method for recruiting a clinical trial or study population for studies of the influence of one or more variances or haplotypes on drug response, comprising soliciting subjects to participate in said clinical trial or study;

obtaining consent of said subjects for participation in said clinical trial or study;

obtaining additional related subjects for participation in said clinical trial by compensating one or more of the related subjects for said participation at a level based on the number of related subjects participating or based on participation of at least a minimum specified number of related subjects.

from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease